0001766400-21-000037.txt : 20210224 0001766400-21-000037.hdr.sgml : 20210224 20210224163007 ACCESSION NUMBER: 0001766400-21-000037 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 94 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210224 DATE AS OF CHANGE: 20210224 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pennant Group, Inc. CENTRAL INDEX KEY: 0001766400 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HEALTH SERVICES [8000] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38900 FILM NUMBER: 21673743 BUSINESS ADDRESS: STREET 1: 1675 E. RIVERSIDE DRIVE, SUITE 150 CITY: EAGLE STATE: ID ZIP: 83616 BUSINESS PHONE: 2089576025 MAIL ADDRESS: STREET 1: 1675 E. RIVERSIDE DRIVE, SUITE 150 CITY: EAGLE STATE: ID ZIP: 83616 10-K 1 pntg-20201231.htm 10-K pntg-20201231
00017664002020FYfalse.50P3Y0M0DP1Y0M0D.50us-gaap:AccountingStandardsUpdate201409MemberP3YP5Y00017664002020-01-012020-12-31xbrli:shares00017664002021-02-24iso4217:USD00017664002020-06-3000017664002020-12-3100017664002019-12-31iso4217:USDxbrli:shares00017664002019-01-012019-12-3100017664002018-01-012018-12-310001766400us-gaap:CommonStockMember2017-12-310001766400us-gaap:AdditionalPaidInCapitalMember2017-12-310001766400us-gaap:RetainedEarningsMember2017-12-310001766400us-gaap:TreasuryStockMember2017-12-310001766400us-gaap:ParentMember2017-12-310001766400us-gaap:NoncontrollingInterestMember2017-12-3100017664002017-12-310001766400us-gaap:ParentMember2018-01-012018-12-310001766400us-gaap:NoncontrollingInterestMember2018-01-012018-12-310001766400us-gaap:CommonStockMember2018-12-310001766400us-gaap:AdditionalPaidInCapitalMember2018-12-310001766400us-gaap:RetainedEarningsMember2018-12-310001766400us-gaap:TreasuryStockMember2018-12-310001766400us-gaap:ParentMember2018-12-310001766400us-gaap:NoncontrollingInterestMember2018-12-3100017664002018-12-310001766400us-gaap:ParentMember2019-01-012019-12-310001766400us-gaap:NoncontrollingInterestMember2019-01-012019-12-310001766400us-gaap:RetainedEarningsMember2019-01-012019-12-310001766400us-gaap:AdditionalPaidInCapitalMember2019-01-012019-12-310001766400us-gaap:CommonStockMember2019-01-012019-12-310001766400us-gaap:CommonStockMember2019-12-310001766400us-gaap:AdditionalPaidInCapitalMember2019-12-310001766400us-gaap:RetainedEarningsMember2019-12-310001766400us-gaap:TreasuryStockMember2019-12-310001766400us-gaap:ParentMember2019-12-310001766400us-gaap:NoncontrollingInterestMember2019-12-310001766400us-gaap:NoncontrollingInterestMember2020-01-012020-12-310001766400us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310001766400us-gaap:RetainedEarningsMember2020-01-012020-12-310001766400us-gaap:CommonStockMember2020-01-012020-12-310001766400us-gaap:TreasuryStockMember2020-01-012020-12-310001766400us-gaap:CommonStockMember2020-12-310001766400us-gaap:AdditionalPaidInCapitalMember2020-12-310001766400us-gaap:RetainedEarningsMember2020-12-310001766400us-gaap:TreasuryStockMember2020-12-310001766400us-gaap:ParentMember2020-12-310001766400us-gaap:NoncontrollingInterestMember2020-12-31pntg:agency0001766400pntg:HomeHealthAndHospiceServicesSegmentMember2020-12-31pntg:facility0001766400pntg:SeniorLivingServicesSegmentMember2020-12-31xbrli:pure00017664002019-10-010001766400us-gaap:OtherNoncurrentLiabilitiesMember2020-12-310001766400srt:MinimumMember2020-01-012020-12-310001766400srt:MaximumMember2020-01-012020-12-310001766400srt:MinimumMemberus-gaap:CustomerContractsMember2020-01-012020-12-310001766400srt:MaximumMemberus-gaap:CustomerContractsMember2020-01-012020-12-310001766400srt:MinimumMemberus-gaap:CustomerRelationshipsMember2020-01-012020-12-310001766400srt:MaximumMemberus-gaap:CustomerRelationshipsMember2020-01-012020-12-310001766400us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-12-310001766400us-gaap:GeneralAndAdministrativeExpenseMember2019-01-012019-12-310001766400us-gaap:GeneralAndAdministrativeExpenseMember2018-01-012018-12-3100017664002019-01-012019-10-010001766400us-gaap:CommonStockMember2019-10-012019-10-01pntg:property0001766400srt:AffiliatedEntityMemberpntg:SeniorLivingServicesSegmentMember2020-12-310001766400srt:AffiliatedEntityMemberpntg:SeniorLivingServicesSegmentMembersrt:MinimumMember2020-12-310001766400srt:AffiliatedEntityMemberpntg:SeniorLivingServicesSegmentMembersrt:MaximumMember2020-12-310001766400pntg:OperatingLeaseRentExpenseMembersrt:AffiliatedEntityMember2020-01-012020-12-310001766400pntg:OperatingLeaseRentExpenseMembersrt:AffiliatedEntityMember2019-01-012019-12-310001766400pntg:OperatingLeaseRentExpenseMembersrt:AffiliatedEntityMember2018-01-012018-12-310001766400srt:AffiliatedEntityMember2020-01-012020-12-310001766400srt:AffiliatedEntityMember2019-01-012019-12-310001766400srt:AffiliatedEntityMember2018-01-012018-12-310001766400srt:AffiliatedEntityMemberpntg:TransitionServicesAgreementMember2020-01-012020-12-310001766400srt:AffiliatedEntityMemberpntg:TransitionServicesAgreementMember2019-01-012019-12-310001766400pntg:RecognitionOfTaxBenefitsRelatedToTaxMattersAgreementMember2020-01-012020-12-310001766400pntg:RecognitionOfTaxBenefitsRelatedToTaxMattersAgreementMember2019-01-012019-12-310001766400us-gaap:CommonStockMemberpntg:NoncontrollingInterestHoldersMember2019-10-012019-10-010001766400us-gaap:RevenueFromContractWithCustomerMemberpntg:MedicareAndMedicaidMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001766400us-gaap:RevenueFromContractWithCustomerMemberpntg:MedicareAndMedicaidMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-12-310001766400us-gaap:RevenueFromContractWithCustomerMemberpntg:MedicareAndMedicaidMemberus-gaap:CustomerConcentrationRiskMember2018-01-012018-12-310001766400pntg:SeniorLivingServicesSegmentMember2020-01-012020-12-310001766400pntg:HomeHealthSubsegmentMemberpntg:MedicareMemberpntg:HomeHealthAndHospiceServicesSegmentMember2020-01-012020-12-310001766400pntg:MedicareMemberpntg:HomeHealthAndHospiceServicesSegmentMemberpntg:HospiceSubsegmentMember2020-01-012020-12-310001766400pntg:MedicareMemberpntg:SeniorLivingServicesSegmentMember2020-01-012020-12-310001766400pntg:MedicareMember2020-01-012020-12-310001766400us-gaap:RevenueFromContractWithCustomerMemberpntg:MedicareMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001766400pntg:HomeHealthSubsegmentMemberpntg:MedicaidMemberpntg:HomeHealthAndHospiceServicesSegmentMember2020-01-012020-12-310001766400pntg:MedicaidMemberpntg:HomeHealthAndHospiceServicesSegmentMemberpntg:HospiceSubsegmentMember2020-01-012020-12-310001766400pntg:MedicaidMemberpntg:SeniorLivingServicesSegmentMember2020-01-012020-12-310001766400pntg:MedicaidMember2020-01-012020-12-310001766400us-gaap:RevenueFromContractWithCustomerMemberpntg:MedicaidMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001766400pntg:HomeHealthSubsegmentMemberpntg:HomeHealthAndHospiceServicesSegmentMemberpntg:MedicareAndMedicaidMember2020-01-012020-12-310001766400pntg:HomeHealthAndHospiceServicesSegmentMemberpntg:MedicareAndMedicaidMemberpntg:HospiceSubsegmentMember2020-01-012020-12-310001766400pntg:SeniorLivingServicesSegmentMemberpntg:MedicareAndMedicaidMember2020-01-012020-12-310001766400pntg:MedicareAndMedicaidMember2020-01-012020-12-310001766400pntg:HomeHealthSubsegmentMemberpntg:HomeHealthAndHospiceServicesSegmentMemberpntg:ManagedCareMember2020-01-012020-12-310001766400pntg:HomeHealthAndHospiceServicesSegmentMemberpntg:ManagedCareMemberpntg:HospiceSubsegmentMember2020-01-012020-12-310001766400pntg:SeniorLivingServicesSegmentMemberpntg:ManagedCareMember2020-01-012020-12-310001766400pntg:ManagedCareMember2020-01-012020-12-310001766400us-gaap:RevenueFromContractWithCustomerMemberpntg:ManagedCareMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001766400pntg:HomeHealthSubsegmentMemberpntg:PrivateAndOtherMemberpntg:HomeHealthAndHospiceServicesSegmentMember2020-01-012020-12-310001766400pntg:PrivateAndOtherMemberpntg:HomeHealthAndHospiceServicesSegmentMemberpntg:HospiceSubsegmentMember2020-01-012020-12-310001766400pntg:PrivateAndOtherMemberpntg:SeniorLivingServicesSegmentMember2020-01-012020-12-310001766400pntg:PrivateAndOtherMember2020-01-012020-12-310001766400us-gaap:RevenueFromContractWithCustomerMemberpntg:PrivateAndOtherMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001766400pntg:HomeHealthSubsegmentMemberpntg:HomeHealthAndHospiceServicesSegmentMember2020-01-012020-12-310001766400pntg:HomeHealthAndHospiceServicesSegmentMemberpntg:HospiceSubsegmentMember2020-01-012020-12-310001766400us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001766400pntg:HomeHealthSubsegmentMemberpntg:MedicareMemberpntg:HomeHealthAndHospiceServicesSegmentMember2019-01-012019-12-310001766400pntg:MedicareMemberpntg:HomeHealthAndHospiceServicesSegmentMemberpntg:HospiceSubsegmentMember2019-01-012019-12-310001766400pntg:MedicareMemberpntg:SeniorLivingServicesSegmentMember2019-01-012019-12-310001766400pntg:MedicareMember2019-01-012019-12-310001766400us-gaap:RevenueFromContractWithCustomerMemberpntg:MedicareMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-12-310001766400pntg:HomeHealthSubsegmentMemberpntg:MedicaidMemberpntg:HomeHealthAndHospiceServicesSegmentMember2019-01-012019-12-310001766400pntg:MedicaidMemberpntg:HomeHealthAndHospiceServicesSegmentMemberpntg:HospiceSubsegmentMember2019-01-012019-12-310001766400pntg:MedicaidMemberpntg:SeniorLivingServicesSegmentMember2019-01-012019-12-310001766400pntg:MedicaidMember2019-01-012019-12-310001766400us-gaap:RevenueFromContractWithCustomerMemberpntg:MedicaidMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-12-310001766400pntg:HomeHealthSubsegmentMemberpntg:HomeHealthAndHospiceServicesSegmentMemberpntg:MedicareAndMedicaidMember2019-01-012019-12-310001766400pntg:HomeHealthAndHospiceServicesSegmentMemberpntg:MedicareAndMedicaidMemberpntg:HospiceSubsegmentMember2019-01-012019-12-310001766400pntg:SeniorLivingServicesSegmentMemberpntg:MedicareAndMedicaidMember2019-01-012019-12-310001766400pntg:MedicareAndMedicaidMember2019-01-012019-12-310001766400pntg:HomeHealthSubsegmentMemberpntg:HomeHealthAndHospiceServicesSegmentMemberpntg:ManagedCareMember2019-01-012019-12-310001766400pntg:HomeHealthAndHospiceServicesSegmentMemberpntg:ManagedCareMemberpntg:HospiceSubsegmentMember2019-01-012019-12-310001766400pntg:SeniorLivingServicesSegmentMemberpntg:ManagedCareMember2019-01-012019-12-310001766400pntg:ManagedCareMember2019-01-012019-12-310001766400us-gaap:RevenueFromContractWithCustomerMemberpntg:ManagedCareMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-12-310001766400pntg:HomeHealthSubsegmentMemberpntg:PrivateAndOtherMemberpntg:HomeHealthAndHospiceServicesSegmentMember2019-01-012019-12-310001766400pntg:PrivateAndOtherMemberpntg:HomeHealthAndHospiceServicesSegmentMemberpntg:HospiceSubsegmentMember2019-01-012019-12-310001766400pntg:PrivateAndOtherMemberpntg:SeniorLivingServicesSegmentMember2019-01-012019-12-310001766400pntg:PrivateAndOtherMember2019-01-012019-12-310001766400us-gaap:RevenueFromContractWithCustomerMemberpntg:PrivateAndOtherMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-12-310001766400pntg:HomeHealthSubsegmentMemberpntg:HomeHealthAndHospiceServicesSegmentMember2019-01-012019-12-310001766400pntg:HomeHealthAndHospiceServicesSegmentMemberpntg:HospiceSubsegmentMember2019-01-012019-12-310001766400pntg:SeniorLivingServicesSegmentMember2019-01-012019-12-310001766400us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-12-310001766400pntg:HomeHealthSubsegmentMemberpntg:MedicareMemberpntg:HomeHealthAndHospiceServicesSegmentMember2018-01-012018-12-310001766400pntg:MedicareMemberpntg:HomeHealthAndHospiceServicesSegmentMemberpntg:HospiceSubsegmentMember2018-01-012018-12-310001766400pntg:MedicareMemberpntg:SeniorLivingServicesSegmentMember2018-01-012018-12-310001766400pntg:MedicareMember2018-01-012018-12-310001766400us-gaap:RevenueFromContractWithCustomerMemberpntg:MedicareMemberus-gaap:CustomerConcentrationRiskMember2018-01-012018-12-310001766400pntg:HomeHealthSubsegmentMemberpntg:MedicaidMemberpntg:HomeHealthAndHospiceServicesSegmentMember2018-01-012018-12-310001766400pntg:MedicaidMemberpntg:HomeHealthAndHospiceServicesSegmentMemberpntg:HospiceSubsegmentMember2018-01-012018-12-310001766400pntg:MedicaidMemberpntg:SeniorLivingServicesSegmentMember2018-01-012018-12-310001766400pntg:MedicaidMember2018-01-012018-12-310001766400us-gaap:RevenueFromContractWithCustomerMemberpntg:MedicaidMemberus-gaap:CustomerConcentrationRiskMember2018-01-012018-12-310001766400pntg:HomeHealthSubsegmentMemberpntg:HomeHealthAndHospiceServicesSegmentMemberpntg:MedicareAndMedicaidMember2018-01-012018-12-310001766400pntg:HomeHealthAndHospiceServicesSegmentMemberpntg:MedicareAndMedicaidMemberpntg:HospiceSubsegmentMember2018-01-012018-12-310001766400pntg:SeniorLivingServicesSegmentMemberpntg:MedicareAndMedicaidMember2018-01-012018-12-310001766400pntg:MedicareAndMedicaidMember2018-01-012018-12-310001766400pntg:HomeHealthSubsegmentMemberpntg:HomeHealthAndHospiceServicesSegmentMemberpntg:ManagedCareMember2018-01-012018-12-310001766400pntg:HomeHealthAndHospiceServicesSegmentMemberpntg:ManagedCareMemberpntg:HospiceSubsegmentMember2018-01-012018-12-310001766400pntg:SeniorLivingServicesSegmentMemberpntg:ManagedCareMember2018-01-012018-12-310001766400pntg:ManagedCareMember2018-01-012018-12-310001766400us-gaap:RevenueFromContractWithCustomerMemberpntg:ManagedCareMemberus-gaap:CustomerConcentrationRiskMember2018-01-012018-12-310001766400pntg:HomeHealthSubsegmentMemberpntg:PrivateAndOtherMemberpntg:HomeHealthAndHospiceServicesSegmentMember2018-01-012018-12-310001766400pntg:PrivateAndOtherMemberpntg:HomeHealthAndHospiceServicesSegmentMemberpntg:HospiceSubsegmentMember2018-01-012018-12-310001766400pntg:PrivateAndOtherMemberpntg:SeniorLivingServicesSegmentMember2018-01-012018-12-310001766400pntg:PrivateAndOtherMember2018-01-012018-12-310001766400us-gaap:RevenueFromContractWithCustomerMemberpntg:PrivateAndOtherMemberus-gaap:CustomerConcentrationRiskMember2018-01-012018-12-310001766400pntg:HomeHealthSubsegmentMemberpntg:HomeHealthAndHospiceServicesSegmentMember2018-01-012018-12-310001766400pntg:HomeHealthAndHospiceServicesSegmentMemberpntg:HospiceSubsegmentMember2018-01-012018-12-310001766400pntg:SeniorLivingServicesSegmentMember2018-01-012018-12-310001766400us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2018-01-012018-12-310001766400pntg:MedicareMember2020-12-310001766400pntg:MedicareMember2019-12-310001766400pntg:MedicaidMember2020-12-310001766400pntg:MedicaidMember2019-12-310001766400pntg:ManagedCareMember2020-12-310001766400pntg:ManagedCareMember2019-12-310001766400pntg:PrivateAndOtherMember2020-12-310001766400pntg:PrivateAndOtherMember2019-12-310001766400srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember2019-12-310001766400srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember2018-12-310001766400srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember2017-12-310001766400us-gaap:OperatingSegmentsMemberpntg:HomeHealthAndHospiceServicesSegmentMember2020-01-012020-12-310001766400us-gaap:OperatingSegmentsMemberpntg:SeniorLivingServicesSegmentMember2020-01-012020-12-310001766400us-gaap:CorporateNonSegmentMember2020-01-012020-12-310001766400us-gaap:OperatingSegmentsMemberpntg:HomeHealthAndHospiceServicesSegmentMember2019-01-012019-12-310001766400us-gaap:OperatingSegmentsMemberpntg:SeniorLivingServicesSegmentMember2019-01-012019-12-310001766400us-gaap:CorporateNonSegmentMember2019-01-012019-12-310001766400us-gaap:OperatingSegmentsMemberpntg:HomeHealthAndHospiceServicesSegmentMember2018-01-012018-12-310001766400us-gaap:OperatingSegmentsMemberpntg:SeniorLivingServicesSegmentMember2018-01-012018-12-310001766400us-gaap:CorporateNonSegmentMember2018-01-012018-12-3100017664002020-03-3100017664002020-09-30pntg:home_health_agencypntg:hospice_agencypntg:stand-alone_senior_living_operation0001766400pntg:AssetAcquisitions2020Memberpntg:SeniorLivingServicesSegmentMember2020-01-012020-12-310001766400us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2020-12-31pntg:senior_living_unit0001766400pntg:ScrippsHealthMember2020-10-012020-10-310001766400pntg:ScrippsHealthMemberpntg:HomeHealthJointVentureMember2020-10-310001766400pntg:HospiceJoinVentureMemberpntg:ScrippsHealthMember2020-10-310001766400pntg:ScrippsHealthMember2020-10-310001766400pntg:HomeHealthSubsegmentMemberpntg:HomeHealthAndHospiceServicesSegmentMemberpntg:BusinessAcquisitions2019Member2019-01-012019-12-310001766400pntg:HomeHealthAndHospiceServicesSegmentMemberpntg:BusinessAcquisitions2019Memberpntg:HospiceSubsegmentMember2019-01-012019-12-31pntg:home_care_agency0001766400pntg:HomeHealthAndHospiceServicesSegmentMemberpntg:BusinessAcquisitions2019Memberpntg:HomeCareSubsegmentMember2019-01-012019-12-310001766400pntg:SeniorLivingServicesSegmentMemberpntg:AssetAcquisitions2019Member2019-01-012019-12-310001766400pntg:SeniorLivingServicesSegmentMember2019-12-310001766400pntg:BusinessAcquisitions2019Member2019-01-012019-12-310001766400pntg:HomeHealthAndHospiceServicesSegmentMemberpntg:AssetAcquisitions2018Memberpntg:HomeCareSubsegmentMember2018-01-012018-12-310001766400pntg:SeniorLivingServicesSegmentMember2018-12-310001766400us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2019-12-310001766400us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2018-12-310001766400pntg:HomeHealthSubsegmentMemberus-gaap:SubsequentEventMember2021-01-012021-02-230001766400us-gaap:SubsequentEventMemberpntg:HospiceSubsegmentMember2021-01-012021-02-230001766400us-gaap:SubsequentEventMember2021-01-012021-02-230001766400us-gaap:LeaseholdImprovementsMember2020-12-310001766400us-gaap:LeaseholdImprovementsMember2019-12-310001766400us-gaap:EquipmentMember2020-12-310001766400us-gaap:EquipmentMember2019-12-310001766400us-gaap:FurnitureAndFixturesMember2020-12-310001766400us-gaap:FurnitureAndFixturesMember2019-12-310001766400pntg:HomeHealthAndHospiceServicesSegmentMember2018-12-310001766400pntg:HomeHealthAndHospiceServicesSegmentMember2019-01-012019-12-310001766400pntg:HomeHealthAndHospiceServicesSegmentMember2019-12-310001766400pntg:HomeHealthAndHospiceServicesSegmentMember2020-01-012020-12-310001766400us-gaap:TradeNamesMember2020-12-310001766400us-gaap:TradeNamesMember2019-12-310001766400us-gaap:LicensingAgreementsMember2020-12-310001766400us-gaap:LicensingAgreementsMember2019-12-310001766400srt:RestatementAdjustmentMember2020-10-310001766400us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2020-12-310001766400us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2019-12-310001766400us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2019-10-010001766400srt:MinimumMemberus-gaap:LondonInterbankOfferedRateLIBORMember2019-10-012019-10-010001766400srt:MaximumMemberus-gaap:LondonInterbankOfferedRateLIBORMember2019-10-012019-10-010001766400srt:MinimumMemberus-gaap:BaseRateMember2019-10-012019-10-010001766400srt:MaximumMemberus-gaap:BaseRateMember2019-10-012019-10-010001766400us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2019-01-012019-10-010001766400us-gaap:LetterOfCreditMemberus-gaap:LineOfCreditMember2020-12-310001766400us-gaap:SubsequentEventMember2021-02-230001766400srt:MinimumMemberus-gaap:SubsequentEventMemberus-gaap:LondonInterbankOfferedRateLIBORMember2021-02-232021-02-230001766400srt:MaximumMemberus-gaap:SubsequentEventMemberus-gaap:LondonInterbankOfferedRateLIBORMember2021-02-232021-02-230001766400srt:MinimumMemberus-gaap:SubsequentEventMemberus-gaap:BaseRateMember2021-02-232021-02-230001766400srt:MaximumMemberus-gaap:SubsequentEventMemberus-gaap:BaseRateMember2021-02-232021-02-230001766400us-gaap:EmployeeStockOptionMember2020-01-012020-12-310001766400us-gaap:EmployeeStockOptionMember2019-01-012019-12-310001766400us-gaap:EmployeeStockOptionMember2018-01-012018-12-310001766400us-gaap:RestrictedStockMember2020-01-012020-12-310001766400us-gaap:RestrictedStockMember2019-01-012019-12-310001766400us-gaap:RestrictedStockMember2018-01-012018-12-310001766400srt:DirectorMemberus-gaap:RestrictedStockMember2020-01-012020-12-310001766400srt:DirectorMemberus-gaap:RestrictedStockMember2019-01-012019-12-310001766400srt:DirectorMemberus-gaap:RestrictedStockMember2018-01-012018-12-310001766400pntg:TheEnsignPlansMemberus-gaap:EmployeeStockOptionMember2020-12-310001766400pntg:TheEnsignPlansMemberus-gaap:EmployeeStockOptionMember2020-01-012020-12-310001766400pntg:TheEnsignPlansMemberus-gaap:RestrictedStockMember2020-12-310001766400pntg:TheEnsignPlansMemberus-gaap:RestrictedStockMember2020-01-012020-12-310001766400pntg:TheEnsignPlansMember2020-12-310001766400pntg:GrantYear2020Memberpntg:TheEnsignPlansMember2020-01-012020-12-310001766400pntg:TheEnsignPlansMemberpntg:GrantYear2020Memberus-gaap:EmployeeStockOptionMember2020-01-012020-12-310001766400pntg:GrantYear2019Memberpntg:TheEnsignPlansMember2019-01-012019-12-310001766400pntg:GrantYear2019Memberpntg:TheEnsignPlansMemberus-gaap:EmployeeStockOptionMember2019-01-012019-12-310001766400pntg:TheEnsignPlansMember2019-12-310001766400pntg:TheEnsignPlansMember2020-01-012020-12-310001766400srt:MinimumMemberus-gaap:RestrictedStockMember2020-01-012020-12-310001766400srt:MaximumMemberus-gaap:RestrictedStockMember2020-01-012020-12-310001766400pntg:TheEnsignPlansMemberus-gaap:RestrictedStockMember2019-12-310001766400pntg:SeniorLivingServicesSegmentMembersrt:MinimumMember2020-12-310001766400pntg:SeniorLivingServicesSegmentMembersrt:MaximumMember2020-12-31pntg:arrangement0001766400us-gaap:CostOfSalesMemberpntg:FacilityMember2020-01-012020-12-310001766400us-gaap:CostOfSalesMemberpntg:FacilityMember2019-01-012019-12-310001766400us-gaap:CostOfSalesMembersrt:OfficeBuildingMember2020-01-012020-12-310001766400us-gaap:CostOfSalesMembersrt:OfficeBuildingMember2019-01-012019-12-310001766400us-gaap:CostOfSalesMember2020-01-012020-12-310001766400us-gaap:CostOfSalesMember2019-01-012019-12-310001766400us-gaap:CostOfSalesMember2018-01-012018-12-3100017664002019-10-012019-10-010001766400us-gaap:DomesticCountryMember2020-12-31pntg:review0001766400us-gaap:AccountsReceivableMemberpntg:MedicareAndMedicaidMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001766400us-gaap:AccountsReceivableMemberpntg:MedicareAndMedicaidMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-12-31


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________________________________________________________________________________________________________________
FORM 10-K
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
For the fiscal year ended December 31, 2020.
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
For the transition period from                      to                     .
Commission file number: 001-38900
_________________________________________________________
THE PENNANT GROUP, INC.

(Exact Name of Registrant as Specified in Its Charter)
Delaware83-3349931
(State or Other Jurisdiction of(I.R.S. Employer
Incorporation or Organization)Identification No.)
1675 East Riverside Drive, Suite 150, Eagle, ID 83616
(Address of Principal Executive Offices and Zip Code)
(208) 506-6100
(Registrant’s Telephone Number, Including Area Code)
_________________________________________________________________________________________________________________________________
Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per sharePNTGNasdaq Global Select Market
Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act, or the Act.  Yes No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.   Yes No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
Large accelerated filerAccelerated filerNon-accelerated filerSmaller reporting companyEmerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

Indicate by a check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of February 24, 2021, 28,262,407 shares of the registrant’s common stock were outstanding. The aggregate market value of the shares of common stock held by non-affiliates of the registrant on the last business day of the registrant's most recently completed second fiscal quarter (June 30, 2020) was approximately $603,746,000 based upon the closing price of the common stock on such date. For purposes of this calculation, the registrant has excluded the market value of all common stock beneficially owned by all executive officers and directors of the registrant.




Note on Incorporation by Reference

Part III of this Form 10-K incorporates information by reference from the Registrant's definitive proxy statement on Schedule 14A for the Registrant's 2021 Annual Meeting of Stockholders to be filed within 120 days after the close of the fiscal year covered by this annual report.

2


THE PENNANT GROUP, INC.
ANNUAL REPORT ON FORM 10-K
FOR THE FISCAL YEAR ENDED DECEMBER 31, 2020
TABLE OF CONTENTS
Part I.
Part II.
Part III.
Part IV.



Cautionary Note Regarding Forward-Looking Statements

Our reports, filings and other public announcements, including this Annual Report on Form 10-K may from time to time contain statements that do not directly or exclusively relate to historical facts. Such statements are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and typically include, but are not limited to, our expected future financial position, results of operations, cash flows, financing plans, business strategy, budgets, capital expenditures, competitive positions, growth opportunities and plans and objectives of management. Forward-looking statements can often be identified by words such as “anticipate,” “expect,” “intend,” “plan,” “predict,” “believe,” “seek,” “estimate,” “may,” “will,” “should,” “would,” “could,” “potential,” “continue,” “ongoing,” similar expressions, and variations or negatives of these words. Additionally, many of these risks and uncertainties are currently amplified by and will continue to be amplified by, or in the future may be amplified by, continued outbreaks of the virus that causes the disease COVID-19 (“COVID-19”). The developments with respect to COVID-19 and its impacts have occurred rapidly, and because of the unprecedented nature of the COVID-19 pandemic we are unable to predict the extent and duration of the adverse financial impact of COVID-19 on our business, financial condition and results of operations. These statements are subject to the safe harbors created under the Securities Act of 1933, as amended (the “Securities Act”), and the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors, some of which are listed in Part I, Item 1A., Risk Factors, of this Annual Report on Form 10-K for the year ended December 31, 2020. Accordingly, you should not rely upon forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this Annual Report, and are based on our current expectations, estimates and projections about our industry and business, management's beliefs, and certain assumptions made by us, all of which are subject to change. We undertake no obligation to revise or update publicly any forward-looking statement for any reason, except as otherwise required by law.

As used in this Annual Report on Form 10-K, the words, “Pennant,” “Company,” “we,” “our” and “us” refer to The Pennant Group, Inc. and its consolidated subsidiaries. All of our independent operating subsidiaries, and the Service Center (defined below) are operated by separate, wholly-owned, independent subsidiaries that have their own management, employees and assets. References herein to the consolidated “Company” and “its” assets and activities, as well as the use of the terms “we,” “us,” “our” and similar terms in this Annual Report are not meant to imply, nor should it be construed as meaning, that The Pennant Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries are operated by The Pennant Group, Inc.
 
The Pennant Group, Inc. is a holding company with no direct operating assets, employees or revenues. In addition, certain of our wholly-owned independent subsidiaries, collectively referred to as the “Service Center,” provide centralized accounting, payroll, human resources, information technology, legal, risk management, compliance oversight and other centralized services to the other independent operating subsidiaries through contractual relationships with such subsidiaries.

We were incorporated in 2019 in Delaware. The address of our headquarters is 1675 East Riverside Drive, Suite 150, Eagle, ID 83616, and our telephone number is (208) 506-6100. Our corporate website is located at www.pennantgroup.com. The information contained in, or that can be accessed through, our website does not constitute a part of this Annual Report on form 10-K.







1

Part I.
Item 1.    Business

Overview

The Pennant Group, Inc. is a leading provider of high-quality healthcare services to patients or residents of all ages, including the growing senior population, in the United States. Through our innovative operating model, we strive to be the provider-of-choice in the communities we serve. On October 1, 2019, we completed a spin-off from The Ensign Group, Inc. (“Ensign”) (NASDAQ: ENSG), our former parent company, which transferred all of its home health and hospice agencies and substantially all of its senior living businesses to us.

As of December 31, 2020, we operate multiple lines of business, including home health, hospice and senior living, throughout Arizona, California, Colorado, Idaho, Iowa, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin and Wyoming. We provide home health and hospice services through 76 agencies, and senior living services at 54 communities with 4,127 total units in our assisted living, independent living and memory care business. We derive revenue from a diversified blend of payors including Medicare and Medicaid programs, private pay patients and residents and managed care payors.

We believe our key differentiators are our (1) innovative operating model that focuses on empowering and developing strong local leaders, (2) disciplined growth strategy, and (3) ability to achieve quality care outcomes in cost effective settings. In our experience, healthcare is a local endeavor, largely dependent upon personal and professional relationships, community reputation and an ability to adapt to the changing needs of patients, residents, partners and communities. As our operational leaders build strong relationships with key partners in their local communities, they are empowered to make informed and critical operational decisions that produce quality care outcomes and more effectively meet the needs of our patients and residents.

We believe our home health and hospice businesses are able to achieve quality outcomes—as measured by multiple industry and value-based metrics (such as hospital readmission rates)—in cost effective settings. We believe our senior living business is able to offer our residents a safe and tailored quality-of-life at an affordable cost, thus appealing to a broad population. With our platform of diversified service offerings, we believe that we are well-positioned to take advantage of favorable demographic shifts as well as industry trends that reward providers offering quality care in lower cost settings.

Our Innovative Operating Model

Our innovative operating model is the foundation of our superior performance and success. Our operating model is founded on two core principles: (1) healthcare is a local business where providers are most successful when key operational decision-making meets local community needs and occurs close to patients or residents and employees, and (2) peer accountability from operational and resource partners is more effective at driving excellent clinical and financial results than traditional hierarchical or “top-down” accountability structures.

Our model is innovative because each operation has been and will continue to be an independent operating subsidiary that functions under the direction of local clinical and operational leaders, each of whom are empowered to make decisions based on the unique needs of the patients or residents, partners and communities they serve. This is in contrast to typical models where control and key decision-making is centralized at the corporate level. Moreover, we utilize a “cluster model,” where every operation is part of a defined “cluster,” which is a group of geographically proximate operations working together to allow leaders to communicate and provide support and accountability to each other. Clusters create incentives for leaders to share best practices and real-time data and benchmark clinical and financial performance with their cluster partners. We believe this locally-driven data-sharing and peer accountability model is unique among healthcare and senior living providers and has proven effective in improving clinical care, enhancing patient and resident satisfaction and promoting operational efficiencies. This “cluster” operating model is the same model used by local leaders prior to our spin-off from Ensign in 2019 (further discussed below under Company History) and will be key to the success of our future operations.

Our organizational structure empowers our highly-dedicated leaders and staff at the local level to make key decisions and creates a sense of ownership over operational and clinical results and the overall employee experience. Each operation’s leader and his or her staff are encouraged to make their operations the “provider of choice” in the communities they serve. To accomplish this goal, our leaders work closely with their clinical staff and our expert resources to identify unique patient and resident needs and priorities in their communities and to create superior service offerings tailored to those needs. We believe that our localized approach to program development and care leads prospective patients or residents and referral sources to choose or recommend our operations to others. Similarly, our emphasis on empowering local decision-makers encourages
1

leaders to strive to become the “employer of choice” in the communities they serve. One of our core values is the principle that the best patient care is provided by employees who experience significant work satisfaction because they are valued as individuals. Our leaders work hard to embody this core value and to attract, train and retain outstanding clinical staff by creating a work environment that fosters critical thinking, measurement, and relevance. Our local teams are motivated and empowered to quickly and proactively meet the needs of those they serve, without waiting for permission to act or being bound to a “one-size-fits-all” corporate strategy. In many markets, we attribute census growth and excellent clinical and financial outcomes to a healthy organizational culture built on these principles. With strong employee satisfaction across the organization, we believe we can continue to attract and retain the best talent in our industries.

Lastly, while our teams are local, they are also supported by cutting-edge systems and our “Service Center”, which is staffed with teams of subject-matter experts who advise regarding their respective fields of expertise, including information technology, compliance, human resources, accounting, payroll, legal, risk management, education and other services. The partnership and peer accountability that exists between our local leaders and Service Center resources allows each operation to improve while benefiting from the technical expertise, systems and accountability provided by our Service Center.

Partner of Choice in Local Healthcare Communities

We view healthcare services primarily as a local business, driven by personal relationships, reputation and the ability to identify and address unmet community needs. We believe our success is largely driven by our ability to build strong relationships with key stakeholders within the local healthcare communities, leveraging our reputation for providing superior care.

We believe we are a partner of choice to payors, providers, patients, residents and employees in the healthcare communities we serve. As a partner, we focus on improving care outcomes and the quality of life of our patients and residents in their home. Our local leadership approach facilitates the development of strong professional relationships within communities, which allows us to better understand and meet the needs of our partners. We believe our emphasis on working closely with other providers, payors, residents and patients yields unique, customized solutions and programs that meet local market needs and improve clinical outcomes, which in turn accelerates revenue growth and profitability.

We are a trusted partner to, and work closely with, payors and other acute and post-acute providers to deliver innovative healthcare solutions in lower cost settings. In the markets we serve, we have developed formal and informal preferred provider relationships with key referral sources and transitional care programs that result in better coordination within the care continuum. These partnerships have resulted in significant benefits to payors, patients, residents and other providers, including reduced hospital readmission rates, appropriate transitions within the care continuum, overall cost savings, increased patient satisfaction and improved quality outcomes. Positive, repeated interactions and data sharing result in strong local relationships and encourage referrals from our acute and post-acute care partners. As we continue to strengthen these formal and informal relationships and expand our referral base, we believe we will continue to drive revenue growth and operational results.

Company History

The Pennant Group, Inc. was incorporated as a Delaware corporation on January 24, 2019, for the purpose of holding the home health and hospice agencies and substantially all of the senior living businesses of Ensign, which was formed in 1999 with the goal of establishing a new level of quality care within the skilled nursing industry. The name “Ensign” is synonymous with a “flag” or a “standard,” and refers to Ensign’s goal of setting the standard by which all others in its industry are measured. The name “Pennant” draws on similar imagery and themes to represent our mission of becoming the “Ensign” to the home health, hospice and senior living industries. We believe that, through our innovative operating model, we can foster a new level of patient care and professional competence at our independent operating subsidiaries and set new industry standards for quality home health and hospice and senior living services.

On October 1, 2019, Ensign completed the spin-off of Pennant from Ensign effected through a tax-free distribution (except as to cash received in lieu of fractional shares) of substantially all of Pennant’s issued and outstanding common stock to the stockholders of Ensign, as a result of which Pennant became an independent, publicly-traded company (the “Spin-Off”). Following the Spin-Off, Ensign had no continuing ownership interest in Pennant. As part of and prior to effecting the Spin-Off, Ensign executed an internal reorganization to align the appropriate businesses within each of Pennant and Ensign whereby, among other things (1) the assets and liabilities associated with Ensign’s home health and hospice agencies and substantially all of its senior living businesses were transferred to Pennant, and (2) all other assets and liabilities of Ensign were retained by Ensign.
2


Our independent operating subsidiaries are organized into industry-specific portfolio companies, which we believe has enabled us to maintain a local, field-driven organizational structure, to attract qualified leaders and expert resources, and to effectively identify, acquire, and improve operations. Each of our portfolio companies has its own leader. These experienced and proven leaders are generally taken from the ranks of our operational leaders to serve as resources to independent operating subsidiaries within their own portfolio companies and have the primary responsibility for recruiting qualified talent, finding potential acquisition targets, and identifying other strategic and organic growth opportunities. We believe this decentralized organizational structure will continue to improve the quality of our recruiting and facilitate successful acquisitions.

We have two reportable segments: (1) home health and hospice services, which includes our home health, hospice and home care businesses; and (2) senior living services, which includes our assisted living, independent living and memory care communities. We also report an “all other” category that includes general and administrative expense. Our reporting segments are business units that offer different services and that are managed separately to provide greater visibility into those operations. For more information about our operating segments, as well as financial information, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Note 6, Business Segments, to the Consolidated and Combined Financial Statements.

Services

Home Health and Hospice. As of December 31, 2020, we provided home health and hospice services through 76 agencies. Our home health services consist of providing a combination of clinical services including nursing, speech, occupational and physical therapy, medical social work and home health aide services within a patient's home. Home health is often a cost-effective solution for patients and can also increase their quality of life by allowing them to receive excellent clinical services in the comfort and convenience of the patient's home. Our hospice services focus on the physical, spiritual and psychosocial needs of terminally ill patients and their families and consist primarily of clinical care, education and counseling. During the years ended December 31, 2020, 2019 and 2018, we generated approximately 70.3%, 68.6% and 68.6%, respectively, of our home health and hospice revenue from Medicare.

Senior Living. As of December 31, 2020, we provided assisted living, independent living and memory care services in 54 communities with 4,127 total units or rooms. Our senior living operations provide a variety of services tailored to our residents’ needs, including residential accommodations, activities, meals, housekeeping and assistance in the activities of daily living to seniors who are independent or who require some support not at the level of clinical care provided in a skilled nursing facility. We generate revenue in these communities primarily from private pay sources, with a portion earned from Medicaid or other state-specific programs. During years ended December 31, 2020, 2019 and 2018, approximately 73.2%, 77.4% and 79.8% respectively, of our senior living revenue was derived from private pay sources.

Our Growth Strategy

We believe that the following strategies are primarily responsible for our growth to date and will continue to drive the growth of our business:

Grow Talent Base and Develop Future Leaders. Our growth strategy is focused on expanding our talent base and developing future leaders. A key component of our organizational culture is our belief that strong local leadership is a primary ingredient to operational success. We use a multi-faceted strategy to identify and recruit proven business leaders from various industries and backgrounds. To develop these leaders, we have a rigorous “CEO-in-Training Program” that includes significant in-person instruction on leadership, clinical and operational topics as well as extensive on-the-ground training and active learning with key leaders from across the organization. After placement in a local operation, our leaders continue to receive training and regular feedback and support from operational, clinical and Service Center peers. We believe our model of empowering local leaders and providing them a platform of support from expert resources and systems will continue to attract and retain highly talented and entrepreneurial leaders.

Focus on Organic Growth. We believe that we have a significant opportunity to drive organic growth within our current portfolio, including recently acquired operations. As we improve clinical outcomes, quality of care and operational results at each of our existing and newly acquired operations, we believe we will become a provider of choice in the communities we serve, which leads to census growth. Through this census growth, and as we continue to expand our service areas and offerings, we believe we will continue to translate revenue growth into bottom line success with rigorous adherence to our core operating principles. By effectively using data systems and analytics and embracing a culture of transparency and accountability, we tend to see our local leaders steadily improving operational results. We believe our unique operating model will continue to cultivate steady and consistent organic growth in the future.
3


Pursue Disciplined Acquisition Strategy. The disciplined acquisition and integration of strategic and underperforming operations is a key element of our past success and is integral to our future growth plans. We have historically successfully transitioned both turnaround and stable target businesses, transforming them into top-quality operations preferred by referral sources. We plan to continue to take advantage of the fragmented home health, hospice and senior living industries by acquiring strategic and underperforming operations within both our existing and new geographic markets. With experienced leaders in place at the local level and demonstrated success in improving operating conditions at acquired businesses, we believe we are well positioned to continue expanding our footprint through disciplined acquisitions.

Leverage Our Operational Capabilities to Expand Partnerships. Our local leadership approach enables us to adapt to and efficiently meet the needs of our partners in the communities we serve. Our clinical and data analytics capabilities foster solutions and allow us to optimize clinical outcomes. We use this data to communicate with key partners in an effort to reduce overall cost of care and drive improved clinical outcomes. We will continue to expand formal and informal partnerships across the healthcare continuum by strategically investing in programs and data analytics that help us and our partners improve care transitions, achieve better outcomes and reduce costs.

Strategically Invest in and Integrate Other Post-Acute Healthcare Businesses. Another important element to our growth strategy is the in-house development and acquisition of other post-acute care businesses that are adjacent to our existing service offerings. These businesses either directly or indirectly benefit our patients and residents, help us collaborate more effectively with our partners, and allow us to compete more effectively in the rapidly changing healthcare environment. Our leadership development programs facilitate these investments, and we have supported local leaders in exploring new business opportunities. We expect to continue to selectively incubate ancillary solutions in a disciplined manner that incentivizes our local leaders and bolsters the depth and breadth of services we offer within the post-acute care continuum.

Growth and Acquisition History

Much of our historical growth can be attributed to our expertise in acquiring strategic and underperforming operations and transforming them into market leaders in clinical quality, staff competency and financial performance. Our local leaders are trained to identify these opportunities for long-term organic growth as we strive to become the provider of choice in our local communities. Accordingly, we plan to continue to drive organic growth and acquire additional operations in existing and new markets in a disciplined manner.
 
4

From 2013 to 2020, we grew our home health and hospice services and senior living services revenue by 487.9% or a compounded annual growth rate of 28.8%.
pntg-20201231_g1.jpg
From 2013 to December 31, 2020, we grew the number of our home health and hospice agencies and senior living units by 375.0% and 228.6%, respectively.


Agency and Unit Growth Since 2013
pntg-20201231_g2.jpgpntg-20201231_g3.jpg

5

December 31,
20132014201520162017201820192020
Home health and hospice agencies16 25 32 39 46 54 63 76 
Senior living communities12 15 36 36 43 50 52 54 
Senior living units1,256 1,587 3,184 3,184 3,434 3,820 3,963 4,127 
Total number of home health, hospice, and senior living operations28 40 68 75 89 104 115 130 

We aim to continue to grow our revenue and earnings by expanding our existing operations and acquiring additional operations in existing and new markets.

Industry Trends

The healthcare sector is one of the largest and fastest-growing sectors of the U.S. economy. According to CMS, national healthcare spending increased from 8.9% of U.S. GDP, or $253 billion, in 1980 to an estimated 17.7% of GDP, or $3.8 trillion, in 2019. CMS projects national healthcare spending will grow by an average of 5.4% annually from 2019 through 2028, accounting for approximately 19.7% of U.S. GDP, or approximately $6.2 trillion, in 2028.

The home health and hospice segment is growing within the overall healthcare landscape in the United States. The home health market is estimated at approximately $103 billion and is growing at an estimated CAGR of 7%. The hospice industry is estimated at approximately $28 billion and is projected to grow at an estimated CAGR of 8.3%. The senior living market is estimated at approximately $83 billion and, in the years preceding 2020 which was significantly impacted by the COVID-19 pandemic, was growing at an estimated CAGR of 5.3%. We believe that the industries in which we operate will continue to benefit from several macroeconomic and regulatory trends highlighted below:

Increased Demand Driven by Aging Populations. As seniors account for an increasing percentage of the total U.S. population, we believe demand for home health and hospice will continue to increase and demand for senior living services will improve as operating conditions impacted by the COVID-19 pandemic return to normal. According to the U.S. Census Bureau in 2019, between 2016 and 2030, the number of individuals over 65 years old is projected to be one of the fastest growing segments of the United States population, growing from 15% to 21%. The Bureau expects this segment to increase nearly 57% to 77 million by 2034 (from 2016) as compared to the total U.S. population which is projected to increase by 14% over that time period. Furthermore, the generation currently retiring has access to less post-retirement benefits and accumulated less savings than in the past, creating demand for more affordable senior housing and in-home care options. As a high-quality provider in lower cost settings, we believe we are well-positioned to benefit from this trend.

Shift of Patient Care to Lower Cost Alternatives. The growth of the senior population in the U.S. continues to increase healthcare costs, often at a rate faster than the available funding from government-sponsored healthcare programs. In response, government payors have adopted measures that encourage the treatment of patients in their homes and other cost-effective settings where the staffing requirements and associated costs are often significantly lower than the alternatives. With our emphasis on the home health, hospice and senior living industries, which are among the lowest cost settings within the post-acute care continuum, we expect this shift to continue to drive our growth.

Transition to Value-Based Payment Models. In response to rising healthcare spending, certain markets’ commercial, government and other payors are shifting away from fee-for-service payment models toward value-based models, including risk-based payment models that tie financial incentives to quality, efficiency and coordination of care. We believe that payors will continue to emphasize reimbursement models driven by value and that our clinical outcomes combined with our services in cost effective settings will be increasingly rewarded. Many of our home health agencies already receive value-based payments, and we are well-positioned to capitalize on this trend as it unfolds across the markets we serve.

Significant Acquisition and Consolidation Opportunities. The home health, hospice and senior living industries are highly fragmented markets with thousands of small and regional providers and only a handful of large national players. There are over 12,300 Medicare-certified home health agencies, with the top ten largest operators accounting for about 26% of the market. There are approximately 4,500 hospice agencies in the U.S. with the top ten largest operators accounting for about 18% of the total market share. As with the home health and hospice industries, there is significant fragmentation in the senior housing industry, with the top 25 operators controlling only a quarter of the market. We believe that our strategy of acquiring strategic and underperforming operations in these highly fragmented markets will be an instrumental piece of our future growth.

6

Changing Regulatory Framework. Regulations and reimbursement change frequently in our industries. Our model is designed to successfully navigate these regulatory and reimbursement changes. For example, effective January 1, 2020, CMS enacted additional changes to the Medicare home health prospective payment system (“HH PPS”) with the implementation of the Patient Driven Groupings Model (“PDGM”). As discussed in greater detail below under Government Regulation, this new reimbursement structure involved case mix calculation methodology refinements, changes to low-utilization payment adjustment (“LUPA”) thresholds, the elimination of therapy thresholds, a change to the unit of payment from a 60-day episode to a 30-day period of care, and reduction in fiscal year 2020 and full elimination in fiscal year 2021 of requests for anticipated payments (“RAPs”). Just as we have navigated other major reimbursement and regulatory changes, we believe that our unique operating model positions us well to thrive under PDGM as local operations and clinical leaders, supported by our expert resources, effectively adapt to the new reimbursement environment.

Payor Sources

We derive revenue primarily from the Medicare and Medicaid programs, private pay and managed care payors.

Medicare. Medicare is a federal program that provides healthcare benefits to individuals who are 65 years of age or older or are disabled. The Medicare home health benefit is available both for patients who need care following discharge from an inpatient facility and patients who suffer from chronic conditions that require ongoing but intermittent care. The Medicare hospice benefit is also available to Medicare-eligible patients with terminal illnesses, certified by a physician, where life expectancy is six months or less.

Medicaid. Medicaid is a program financed by state funds and matching federal funds administered by state agencies or managed care organizations on their behalf. Medicaid programs generally provide health benefits for qualifying individuals and may supplement Medicare benefits for the disabled and for persons aged 65 and older meeting financial eligibility requirements. Medicaid reimbursement formulas are established by each state with the approval of the federal government in accordance with federal guidelines.

Medicaid reimbursement varies from state to state and is based upon a number of different methodologies, including cost-based, prospective payment, case mixed adjusted payments, and negotiated rates. Rates are subject to a state’s annual budgetary requirements and funding, statutory and regulatory changes and interpretations and rulings by individual state agencies and State Plan Amendments approved by CMS.

Managed Care and Private Insurance. Managed care patients consist of individuals who are insured by certain third-party entities, or who are Medicare beneficiaries who have assigned their Medicare benefits to a managed care organization plan. Another type of insurance, long-term care insurance, is also becoming more widely available to consumers and is not expected to contribute significantly to industry revenues in the near term.

Private and Other Payors. Private and other payors consist primarily of individuals, family members or other third parties who directly pay for the services we provide.

The following table sets forth our total revenue by payor source as a percent of revenue generated by each of our reportable segments and as a percentage of total revenue for the year ended December 31, 2020:

Year Ended December 31, 2020
Home Health and Hospice Services
Home Health ServicesHospice ServicesSenior Living ServicesTotal Revenue
Medicare48.8 %89.4 %— %45.6 %
Medicaid6.4 9.3 26.8 14.5 
Subtotal55.2 98.7 26.8 60.1 
Managed care26.4 1.2 — 8.5 
Private and other(a)
18.4 0.1 73.2 31.4 
Total revenue100.0 %100.0 %100.0 %100.0 %

(a)
Private and other payors in our home health and hospice services segment includes revenue from all payors generated in our home care operations.

Reimbursement for Specific Services
7

Historically, adjustments to reimbursement under Medicare and Medicaid have had a significant effect on our revenue and results of operations. Recently enacted, pending and proposed legislation and administrative rulemaking at the federal and state levels could have similar effects on our business. Efforts to impose reduced reimbursement rates, greater discounts and more stringent cost controls by government and other payors are expected to continue for the foreseeable future and could adversely affect our business, financial condition and results of operations. Additionally, any delay or default by the federal or state governments in making Medicare and/or Medicaid reimbursement payments could materially and adversely affect our business, financial condition and results of operations.

Reimbursement for Home Health Services. Our home health business derives substantially all of its revenue from Medicare, managed care, and private pay sources, which may vary in the markets we serve. Our home health services generally consist of providing some combination of the services of registered nurses, speech, occupational and physical therapists, medical social workers and certified home health aides. Home health is often a cost-effective solution for patients and can also increase their quality of life and allow them to receive quality medical care in the comfort and convenience of a familiar setting.

Reimbursement for Hospice Services. Hospice revenues are primarily derived from Medicare. We receive one of four predetermined rate categories based on four different levels of care provided: routine home care, continuous home care, inpatient respite care and general inpatient care. This payment structure is designed to include all of the services needed to manage a beneficiary’s care, consisting primarily of clinical care, education and counseling. These rates are subject to annual adjustments based on inflation and geographic wage considerations.

Reimbursement for Senior Living Services. Assisted living, independent living and memory care community revenue is primarily derived from private pay residents at rates we establish based upon the services we provide and market conditions in the area of operation. In addition, Medicaid or other state-specific programs in some states where we operate supplement payments for board and care services provided in assisted living and memory care communities.

Competition

The post-acute care industry is highly competitive, and we expect that the industry will become increasingly competitive in the future. The industry is highly fragmented and characterized by numerous local and regional providers, in addition to large national providers that have achieved geographic diversity and economies of scale. Some of our independent operating subsidiaries also compete with skilled nursing facilities, inpatient rehabilitation facilities and long-term acute care hospitals. Competitiveness may vary significantly from location to location, depending upon factors such as the number of competing operations, availability of services, expertise of staff, and the physical appearance and amenities of senior living communities. We believe that the primary competitive factors in the post-acute care industry are:

ability to attract and to retain qualified leaders and caregivers;
reputation and achievements of quality healthcare outcomes and patient and resident satisfaction;
attractiveness and location of senior living communities and other physical assets;
the expertise and commitment of operational leaders and employees; and
private equity and other firms with greater financial resources and/or lower costs of capital with similar asset acquisition objections.

We seek to compete effectively in each market by establishing a reputation within the local community as the “operation of choice.” This means that the operation leaders are generally free to discern and address the unique needs and priorities of healthcare professionals, customers and other stakeholders in the local community or market, and then create superior service offerings for that particular community or market that are calculated to encourage prospective customers and referral sources to choose or recommend the operation.

Increased competition could limit our ability to attract and retain patients and residents, maintain or increase rates or to expand our business. Some of our competitors have greater financial and other resources than we have, may have greater brand recognition and may be more established in their respective communities than we are. Competing companies may also offer newer communities or different programs or services than we offer and may, therefore, attract individuals who are currently patients of our operations, potential residents of our facilities, or who are otherwise receiving our healthcare services. Other competitors may have lower expenses or other competitive advantages than us and, therefore, provide services at lower prices than we offer.

There are few barriers to entry in the home health and hospice business in jurisdictions that do not require certificates of need or permits of approval. Our primary competition in these jurisdictions comes from local privately and publicly owned
8

and hospital-owned healthcare providers. We compete based on the availability of personnel, the quality of services, expertise of visiting staff, and, in certain instances, on the price of our services. In addition, we compete with a number of non-profit organizations that finance acquisitions and capital expenditures on a tax-exempt basis and charity-funded programs that may have strong ties to their local medical communities and receive charitable contributions that are unavailable to us.

Our senior living services also compete with local, regional and national companies. The primary competitive factors in these businesses include reputation, cost of services, quality of clinical services, responsiveness to patient/resident needs, location and the ability to provide support in other areas such as third-party reimbursement, information management and patient recordkeeping. The market for acquiring and/or operating senior living communities is highly competitive, and some of our present and potential senior living competitors have, or may obtain, greater financial resources than us and may have a lower cost of capital.

Our Competitive Strengths

We believe that we are well positioned to benefit from the ongoing regulatory, reimbursement and demographic changes within the home health, hospice and senior living industries. We believe that we will achieve clinical, financial and cultural success as a direct result of the following key competitive strengths:

Innovative Operating Model. We believe healthcare should be operated primarily as a local business. Our local leadership-centered operating model encourages our leaders to make key operational decisions that meet the individualized needs of their patients, residents and community partners. Recognizing the local nature of our business, our leaders develop each operation’s reputation at the local level, rather than being bound by a traditional organization-wide branding strategy. In addition, our local leaders work closely with their cluster partners to share data and improve clinical and financial outcomes. Moreover, we do not maintain a traditional corporate headquarters, rather we operate our Service Center which supports operational results through world-class systems and by providing ancillary expertise in fields such as information technology, compliance, human resources, accounting, legal and education. This enables individual operations to function with the strength, synergies and economies of scale found in larger organizations, without the disadvantages of a top-down management structure or corporate hierarchy. We believe this approach is unique within our industries and allows us to preserve the “one-operation-at-a-time” focus and culture that has contributed to our success.

Proven Track Record of Successful Acquisitions. We adhere to a disciplined acquisition strategy focused on sourcing and selectively acquiring operations within our target markets. Local leaders are heavily involved in the acquisition process and are recognized and rewarded as these acquired operations become the provider of choice in the communities they serve. Through our innovative operating model and disciplined approach to strategic growth, we have completed and successfully transitioned dozens of value-add operations. Our expertise in acquiring and transforming strategic and underperforming operations allows us to consider a broad range of potential acquisition targets and will be a key element of our future success.

Superior Clinical Outcomes and Quality Care. We will continue to achieve success by delivering high quality home health, hospice and senior living services. Using the Centers for Medicare and Medicaid Services (“CMS”) five-star quality rating criteria, our home health agencies achieved an average of 4.1 out of 5 stars across all agencies, compared to the industry average of 3.0 stars (see Government Regulation below for further discussion on the five-star quality rating system). Our locally-driven, patient-centered approach to clinical care allows us to meet the unique needs of our patients, resulting in improved clinical outcomes, including reduced hospital readmission rates. These improved outcomes are driven by both our talented local clinicians and our data-driven analytical approach to patient care and risk stratification. We believe that our achievement of high-quality clinical outcomes positions us as a solution for patients, residents and referral sources, leading to census growth and improved profitability.

Diversified Portfolio by Payor and Services. As of December 31, 2020, we operated 76 home health and hospice agencies and 54 senior living communities across 14 states. Because of this diversified portfolio, our blended payor mix was 45.6% Medicare, 14.5% Medicaid, 8.5% managed care and 31.4% private pay for the year ended December 31, 2020. Our balanced payor mix can provide greater business stability through economic cycles and mitigates volatility arising from government-driven reimbursement changes. For the year ended December 31, 2020, we generated 64.9% of our revenue from home health and hospice services and 35.1% of our revenue from senior living services. Our diversified service portfolio allows us to opportunistically execute on our acquisition strategy as valuations fluctuate over industry cycles.

Effective Talent Recruitment, Development and Retention. We believe we have been successful in attracting, developing and retaining outstanding business and clinical leaders to lead our independent operating subsidiaries. Our unique operating model, which emphasizes local decision making and team building, supported by our platform of expert resources and best-in-class systems, attracts a highly talented and entrepreneurial group of leaders. Our operational leaders are committed
9

to ongoing training and participation in regular leadership development and educational programs. We believe that our commitment to professional development strengthens the quality of our operational leaders and staff and will continue to differentiate us from our competitors.

Human Capital

The operation of our home health and hospice operations and senior living communities requires a large number of highly skilled healthcare professionals and support staff. As of December 31, 2020, we had 5,223 employees who were employed by our independent operating subsidiaries or our Service Center. None of those employees is subject to a collective bargaining agreement relating to our operations.

Our ability to attract and retain future leaders is critical to our ongoing success. Therefore, we are dedicated to continuously recruiting and developing a diverse group of capable leaders. As described in Item 1. Grow Talent Base and Develop Future Leaders, our CEO-in-Training program provides significant in-person instruction and extensive training with key leaders from across the organization to empower local leaders.

For the year ended December 31, 2020, 55.0% of our total expenses were payroll related for our operations. Periodically, market forces, which vary by region, require that we increase wages in excess of general inflation or in excess of increases in reimbursement rates we receive. We believe that we staff appropriately, focusing primarily on the acuity level and day-to-day needs of our patients and residents. We seek to manage our labor costs by improving staff retention, improving operating efficiencies, maintaining competitive wage rates and benefits and reducing reliance on overtime compensation and temporary nursing agency services.

The healthcare industry as a whole has been experiencing shortages of qualified professional clinical staff. We believe that our ability to attract and retain qualified professional clinical staff stems from our ability to offer attractive wage and benefits packages, a high level of employee training, a culture that provides incentives for individual efforts and a quality work environment.

Government Regulation

General. The laws and statutes affecting the regulatory landscape of the home health, hospice and senior living industries continue to expand. In addition to this changing regulatory environment, federal, state and local officials are increasingly focusing their efforts on the enforcement of these laws. In order to operate our businesses, we must comply with federal, state and local laws relating to, among other things, licensure, delivery and adequacy of medical care, distribution of pharmaceuticals, equipment, personnel, operating policies, fire prevention, immigration, employment, rate-setting, billing and reimbursement, building codes and environmental protection. Additionally, we must also adhere to anti-kickback statutes, physician referral laws, and safety and health standards set by the Occupational Safety and Health Administration (“OSHA”). Changes in the law or new interpretations of existing laws may have an adverse impact on our methods and costs of doing business.

Our independent operating subsidiaries are also subject to various regulations and licensing requirements promulgated by state and local health and social service agencies and other regulatory authorities. Requirements vary from state to state and these requirements can affect, among other things, personnel education and training, patient and personnel records, services, staffing levels, monitoring of patient wellness, patient furnishings, housekeeping services, dietary requirements, emergency plans and procedures, certification and licensing of staff prior to beginning employment, and patient rights. These laws and regulations could limit our ability to expand into new markets and to expand our services and facilities in existing markets.

Medicare. All providers are subject to compliance with various federal, state and local statues and regulations in the U.S. and receive periodic inspection by state licensing agencies to review standards of medical care, equipment and safety.

Conditions of Participation. Our home health and hospice operations must comply with regulations promulgated by the United States Department of Health and Human Services (“HHS”) and CMS in order to participate in the Medicare program and receive Medicare payments. Among other things, these conditions of participation (the “CoPs”), relate to the type of operation, its personnel and its standards of medical care, as well as its compliance with state and local laws and regulations. In 2018 CMS made significant revisions to the CoPs, including (1) adding new CoPs related to quality assurance and performance improvement programs and infection control and (2) expanding or revising requirements related to patient rights, comprehensive evaluations, coordination and care planning, home health aide training and supervision, and discharge and transfer summary and time frames.

10

Home Health Quality Reporting Requirements. The CoPs require home health agencies to submit quality reporting data through Outcome and Assessment Information Set (“OASIS”) assessments within 30 days of completing the assessment of the Medicare and Medicaid beneficiary as a condition of payment and for quality measurement purposes. If the OASIS assessment is not found in CMS's quality system upon receipt of a final claim for a home health episode and the receipt date of the claim is more than 30 days after the assessment completion date, CMS will deny the claim. Home health agencies that do not submit quality measure data to CMS incur a 2% reduction in their annual home health payment update. Under the rule, all home health agencies are required to timely submit both a Start of Care or Resumption of Care OASIS assessment and a Transfer or Discharge OASIS assessment for a minimum of 90% of all episodes.

In addition, CMS requires that all Medicare certified home health and hospice agencies participate in the Consumer Assessment of Healthcare Providers and Systems (“CAHPS”). Home Health Survey or Hospice Survey, respectively. CAHPS surveys are designed to produce comparable data on the perspective of patients and their caregivers that allows meaningful and objective comparisons between agencies. Home health and hospice agencies that do not submit the required data incur a 2% reduction in their annual base rate payment update.

Home Health Star Rating. As a consumer tool for selecting a home health provider, CMS has used a five-star rating model to rate home health agencies since 2015. This Quality of Patient Care Star Rating is a summary measure of a home health agency’s performance based upon how well it provides patient care. CMS uses eight measurements indicating quality, including how often the agency initiated care in a timely manner, how often patients demonstrated improvements in ambulation, bed transferring, bathing, oral medication administration, decreased pain with activity, less shortness of breath, and decreased need for acute care hospitalization. According to CMS, a 3-star rating means the agency provides good quality of care. Using CMS’s star rating criteria, our home health agencies have achieved an average of 4.1 out of 5 stars across all agencies compared to the industry average of 3.0 stars.

Home Health Reimbursement, including HH PPS and PDGM. To qualify for home health services, Medicare CoPs require that beneficiaries (1) be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort); (2) require intermittent skilled nursing, physical therapy or speech therapy services; (3) have a face to face encounter that (a) has occurred no more than 90 days prior to the start of care or within 30 days after the start of care, (b) was related to the primary reason the patient requires home health services, and (c) was performed by a physician or allowed non-physician provider; and (4) receive treatment under a plan of care established and periodically reviewed by a physician.

Historically, under the Medicare HH PPS, Medicare pays home health agencies a predetermined base payment adjusted for case-mix (the health condition and care needs of the beneficiary), as well as geographic differences in wages for home health agencies across the country. There are also outlier payments to account for beneficiaries who incur unusually large costs. For patients who require four or fewer visits during their episode of care, HH PPS uses a low-utilization payment adjustment (“LUPA”). Until January 1, 2020, HH PPS provided home health agencies with payments for each 60-day episode of care for each beneficiary. There are no limits to the number of episodes an eligible beneficiary can receive.

In October 2019, CMS issued a final rule implementing PDGM. The PDGM reimbursement structure involves case mix calculation methodology refinements, changes to LUPA thresholds, the elimination of therapy thresholds, a change to the unit of payment from a 60-day episode to a 30-day payment period, and the reduction in fiscal year 2020 and full elimination in fiscal year 2021 of the RAP. Effective January 1, 2020, under PDGM the initial certification of patient eligibility, plan of care, and comprehensive assessment remains valid for 60-day episodes of care and payments for home health services are made based upon 30-day periods. During 2020, we received 20% of the estimated payment for a patient’s initial or subsequent period of care up-front (after the initial assessment is completed and upon initial billing) and the remaining 80% upon submission of the final claim following the 30-day period of care. Beginning January 1, 2021, the anticipated payment is completely phased out, and if the RAP is not submitted within five days following the start of care, home health agencies will receive a reduction in the payment that is equal to a 1/30th reduction to the wage and case-mix adjusted 30-day payment period for each day from the start of care. CMS implemented PDGM in a budget neutral manner, and CMS assumed home health agencies would adjust documentation and coding practices to maximize reimbursement and LUPA avoidance, including a negative 4.4% behavioral change assumption adjustment in order to calculate the 30-day payment rate. Therefore, PDGM’s ultimate impact will vary by provider based on factors including case-mix, admission source, and providers’ ability to adapt to the new reimbursement model's coding and therapy thresholds.

11

Home Health Value Based Purchasing (HH VBP). On January 1, 2016, CMS implemented Home Health Value-Based Purchasing (“HH VBP”). The HH VBP model was designed to give Medicare-certified home health agencies incentives or penalties, through payment bonuses, to drive higher quality and more efficient care. HH VBP was rolled out to nine pilot states: Arizona, Florida, Iowa, Maryland, Massachusetts, Nebraska, North Carolina, Tennessee and Washington, in three of which Pennant currently has home health operations. Bonuses and penalties began in 2018 with the maximum of plus or minus 3% growing to plus or minus 8% by 2022. Payment adjustments are calculated based on an agency’s improved performance in 20 measures, including hospital utilization (claims-based measures), quality of care (OASIS-based measures), patient satisfaction measured by Consumer Assessment of Healthcare Providers and Systems (“CAHPS”) measures, and three new measures that agencies self-report. The purpose of the HH VBP model is to improve the quality of care delivery through (1) providing incentives for better quality care with greater efficiency, (2) studying new potential quality and efficiency measures for appropriateness in the home health setting and (3) enhancing the current public reporting process. Once the changes are implemented, Medicare home health payments will no longer be based on the number of visits provided, but rather the patient’s medical condition and care needs.

Home Health Pre-Claim Review Demonstration. On June 8, 2016, CMS announced the implementation of a three-year Medicare pre-claim review ("PCR") demonstration for home health services provided to beneficiaries in the states of Florida, Illinois, Massachusetts, Michigan and Texas. PCR is a process by which a request for provisional affirmation of coverage is submitted for review before a final claim is submitted for payment.

On May 31, 2018, CMS issued a notice indicating its intention to re-launch a PCR demonstration project called Review Choice Demonstration (“RCD”) which gives home health agencies in the demonstration states three options: pre-claim review of all claims, post-payment review of all claims, or minimal post-payment review with a 25% payment reduction for all home health services. RCD initially will apply to home health agencies in Florida, Illinois, North Carolina, Ohio, and Texas, with the option to expand after five years to other states in the Medicare Administrative Contractor Jurisdiction M (Palmetto). Our home health agencies in Texas, which comprise less than 20% of our home health revenue, began participating in RCD on March 2, 2020.

Hospice Reimbursement and Cap Amounts. Payments are based on daily rates for each day a beneficiary is enrolled in the hospice benefit and are subject to two annual caps. Rates are set based on specific levels of care, are adjusted by a wage index to reflect healthcare labor costs across the country and are established annually through federal legislation. The following are the four levels of care provided under the hospice benefit:

Routine Home Care (“RHC”). Care that is not classified under any of the other levels of care, such as the work of nurses, social workers or home health aides.
General Inpatient Care. Pain control or acute or chronic symptom management that cannot be managed in a setting other than an inpatient Medicare-certified facility, such as a hospital, skilled nursing facility or hospice inpatient facility.
Continuous Home Care. Care for patients experiencing a medical crisis that requires nursing services to achieve palliation and symptom control, if the agency provides a minimum of eight hours of care within a 24-hour period.
Inpatient Respite Care. Short-term, inpatient care to give temporary relief to the caregiver who regularly provides care to the patient.

CMS has established a two-tiered payment system for RHC. Hospices are reimbursed at a higher rate for RHC services provided from days of service one through 60 and then a lower rate for all subsequent days of service. CMS also provided for a Service Intensity Add-On, which increases payments for certain RHC services provided by registered nurses and social workers to hospice patients during the final seven days of life.

Medicare payments are subject to two fixed annual caps, which are assessed on a provider number basis, and are broken into an inpatient cap amount and an overall payment cap. These cap amounts are calculated and published by the Medicare fiscal intermediary on an annual basis covering the period from October 1 through September 30. The inpatient cap limits hospice care provided on an inpatient basis. This cap limits the number of days that are paid at the higher inpatient care rate to 20.0% of the total number of days of hospice care that are provided to all Medicare beneficiaries served by a provider. The daily rate for all days exceeding the cap is the standard RHC daily rate, and the provider must reimburse Medicare for any payments received in excess of that amount. The overall payment cap is calculated by the Medicare fiscal intermediary at the end of each hospice cap period to determine the maximum allowable payments to a hospice provider during the period. We estimate our potential cap exposure by using available
12

information to compare our actual reimbursement for all hospice services provided during the period to the number of beneficiaries we served multiplied by the statutory per beneficiary cap amount. If payments received by any one of our hospice provider numbers exceeds either of these caps, we are required to reimburse Medicare for payments received in excess of the cap amounts. The fiscal year 2020 and 2021 caps are $29,964.78 and $30,683.93, respectively, per beneficiary.

Improving Medicare Post-Acute Care Transformation Act of 2014 (“IMPACT Act”). The IMPACT Act requires the submission of standardized assessment data for quality improvement, payment and discharge planning purposes across the spectrum of post-acute care providers (“PACs”), including home health agencies. The IMPACT Act requires PACs to report: (1) standardized patient assessment data at admission and discharge; (2) new quality measures, including functional status, skin integrity, medication reconciliation, incidence of major falls, and patient preference regarding treatment and discharge; and (3) resource use measures, including Medicare spending per beneficiary, discharge to community, and hospitalization rates of potentially preventable readmissions for home health agencies. Failure to report such data when required would subject a PAC to a 2% reduction in market basket prices then in effect.

The IMPACT Act also included provisions impacting Medicare-certified hospices, including (1) increasing survey frequency for Medicare-certified hospices to once every 36 months, (2) imposing a medical review process for operations with a high percentage of stays in excess of 180 days, and (3) updating the annual aggregate Medicare payment cap.

Hospice Quality Reporting Requirements (“HQRP”). HQRP, mandated by the ACA, requires hospice agencies to submit required quality data for inclusion on the public facing Hospice Compare website hosted by CMS. Hospices that fail to meet quality reporting requirements receive a 2.0% reduction to the annual market basket update for the year. This reduction penalty will be increased to 4.0% beginning in October 2021.

Licensure and Certificates of Need (“CON”). Home health, hospice and most senior living communities operate under licenses granted by the health authorities of their respective states. Some states require healthcare providers (including home health, hospice and most senior living providers) to obtain prior state approval for the purchase, construction or expansion of healthcare operations, or changes in services. Certain states, including a number in which we operate, carefully restrict new entrants into the market based on demographic and/or demonstrative usage of additional providers. These states limit the entry of new providers or services and the expansion of existing providers or services in their markets through a Certificate of Need CON process, which is periodically evaluated and updated as required by applicable state law. For those states that require a CON, we must also complete a separate application process establishing a location and must receive required approvals. Washington and Montana are the only CON state in which we operate home health or hospice agencies.

Patient Protection and Affordable Care Act (“ACA”). Various healthcare reform provisions became law upon enactment of the ACA in 2010. The reforms contained in the ACA have affected our independent operating subsidiaries in some manner and are directed in large part at increased quality and cost reductions. These reforms include modifications to the conditions of qualification for payment, bundling of payments to cover both acute and post-acute care and the imposition of enrollment limitations on new providers. The recent congressional and presidential elections in the United States and changing policies and regulations initiated by a new presidential administration and new congressional control may result in significant changes in legislation, regulation, and implementation of Medicare, Medicaid, and government policy, along with potential changes to tax rates and other tax treatment of our operations. We continually monitor these developments so we can respond to the changing regulatory environment impacting our business.

Civil and Criminal Fraud and Abuse Laws and Enforcement. Various complex federal and state laws exist which govern a wide array of referrals, relationships and arrangements, and prohibit fraud by healthcare providers. Governmental agencies are devoting increasing attention and resources to such anti-fraud efforts. The Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), and the Balanced Budget Act of 1997 (“BBA”) expanded the penalties for healthcare fraud. Additionally, in connection with our involvement with federal healthcare reimbursement programs, the government or those acting on its behalf may bring an action under the False Claims Act (“FCA”), alleging that a healthcare provider has defrauded the government by submitting a claim for items or services not rendered as claimed, which may include coding errors, billing for services not provided, and submitting false or erroneous cost reports. The Fraud Enforcement and Recovery Act of 2009 (“FERA”) expanded the scope of the FCA by, among other things, creating liability for knowingly and improperly avoiding repayment of an overpayment received from the government and broadening protections for whistleblowers. The FCA clarifies that if an item or service is provided in violation of the Anti-Kickback Statute, the claim submitted for those items or services is a false claim that may be prosecuted under the FCA as a false claim. Civil monetary penalties (“CMPs”) under the FCA range from approximately $11,600 to $23,000 and are adjusted annually for inflation. Under the qui tam or
13

“whistleblower” provisions of the FCA, a private individual with knowledge of fraud may bring a claim on behalf of the federal government and receive a percentage of the federal government’s recovery. Due to these whistleblower incentives, lawsuits have become more frequent. Many states also have a false claim prohibition that mirrors or tracks the federal FCA. Federal law also provides that the Office of the Inspector General for HHS (“OIG”) has the authority to exclude individuals and entities from federally funded health care programs on a number of grounds, including, but not limited to, certain types of criminal offenses, licensure revocations or suspensions, and exclusion from state or other federal healthcare programs. In addition, CMS can recover overpayments from health care providers up to five years following the year in which payment was made.

Monitoring Compliance in our Operations. As a healthcare provider, we have a compliance program to help us comply with various requirements of federal, state and private healthcare programs. Our compliance program includes, among other things, (1) policies and procedures modeled after applicable laws, regulations, government manuals and industry practices and customs that govern the clinical, reimbursement and operational aspects of our subsidiaries; (2) training about our compliance process for the employees of our independent operating subsidiaries, our directors and officers; (3) training about Medicare and Medicaid laws, fraud and abuse prevention, clinical standards and practices, and claim submission and reimbursement policies and procedures for appropriate employees; and (4) internal controls that monitor, for example, the accuracy of claims, reimbursement submissions, cost reports and source documents, provision of patient care, services, and supplies as required by applicable standards and laws, accuracy of clinical assessment and treatment documentation, and implementation of judicial and regulatory requirements (e.g., background checks, licensing and training).

Additionally, governmental agencies and other authorities periodically inspect our operations to assess our compliance with various standards, rules and regulations. The robust regulatory and enforcement environment continues to impact healthcare providers, especially in connection with responses to any alleged noncompliance identified in periodic surveys and other inspections by governmental authorities. Unannounced surveys or inspections generally occur at least annually at our independent operating subsidiaries and may also follow a government agency's receipt of a complaint about an operation. We are also subject to regulatory reviews relating to Medicare services, billings and potential overpayments resulting from the Recovery Audit Contractors, Zone Program Integrity Contractors, Program Safeguard Contractors, Unified Program Integrity Contractors, Supplemental Medical Review Contractors and Medicaid Integrity Contributors programs in which third party firms engaged by CMS conduct extensive reviews of claims data and medical and other records to identify potential improper payments under the Medicare programs. We must pass these inspections to maintain our licensure under state law, to obtain or maintain certification under the Medicare and Medicaid programs, to continue participation in the Veterans Administration (VA) program at some operations, and/or to comply with our provider contracts with managed care clients at many operations. From time to time, we, like others in the healthcare industry, may receive notices from federal and state regulatory agencies alleging that we failed to substantially comply with applicable standards, rules or regulations. These notices may require us to take corrective action, may impose CMPs for noncompliance, and may threaten or impose other operating restrictions. If our operations fail to comply with these directives or otherwise fail to comply substantially with licensure and certification laws, rules and regulations, we could lose our certification as a Medicare or Medicaid provider, lose our state licenses to operate and be subject to imposed fines and penalties.

Healthcare operations in our industries with otherwise acceptable regulatory histories are generally given an opportunity to correct deficiencies and continue their participation in the Medicare and Medicaid programs by a certain date, usually within nine months, although where denial of payment or similar remedies are asserted, such interim remedies go into effect much sooner. Operations with poor regulatory histories continue to be classified by CMS as poor performing operations notwithstanding any intervening change in ownership, unless the new owner obtains a new Medicare provider agreement instead of assuming the operation's existing agreement. However, new owners (including us, historically) nearly always assume the existing Medicare provider agreement due to the difficulty and time delays generally associated with obtaining new Medicare certifications, especially in previously-certified locations with sub-par operating histories. Accordingly, operations that have poor regulatory histories before we acquire them may be more likely to have sanctions imposed upon them by CMS or state regulators.

CMS has undertaken several initiatives to increase or intensify Medicaid and Medicare survey and enforcement activities, including federal oversight of state actions. CMS is taking steps to focus more survey and enforcement efforts on operations with findings of substandard care or repeat violations of Medicaid and Medicare standards, and to identify regional or national providers with patterns of noncompliance. In addition, HHS has adopted a rule that requires CMS to charge user fees to healthcare operations cited during regular certification, recertification or substantiated complaint surveys for deficiencies, which require a revisit to assure that corrections have been made. CMS is also increasing its oversight of state survey agencies and requiring state agencies to use enforcement sanctions and remedies more promptly when substandard care or repeat violations of CMS standards are identified, to investigate complaints more promptly, and to survey facilities more consistently.

14

Regulations Regarding Financial Arrangements. We are also generally subject to federal and state laws that regulate financial arrangements by healthcare providers, such as the federal and state anti-kickback laws, the Stark laws, and various state anti-referral laws.

The Anti-Kickback Statute, Section 1128B of the Social Security Act (the “Anti-Kickback Statute”) prohibits the knowing and willful offer, payment, solicitation, or receipt of any remuneration, directly or indirectly, overtly or covertly, in cash or in-kind, to induce the referral of an individual, in return for recommending, or to arrange for, the referral of an individual for any item or service payable under any federal healthcare program, including Medicare or Medicaid. The OIG has issued regulations that create “safe harbors” for certain conduct and business relationships that are deemed protected under the Anti-Kickback Statute. In order to receive safe harbor protection, all of the requirements of a safe harbor must be met. The fact that a given business arrangement does not fall within one of these safe harbors, however, does not render the arrangement per se illegal. Business arrangements of healthcare service providers that fail to satisfy the applicable safe harbor criteria, if investigated, will be evaluated based upon all facts and circumstances and risk increased scrutiny and possible sanctions by enforcement authorities.

Violations of the Anti-Kickback Statute can result in criminal penalties of up to $100,000 and ten years’ imprisonment. Violations of the Anti-Kickback Statute can also result in CMPs of over $100,000 per violation (adjusted annually for inflation) and an assessment of up to three times the total amount of remuneration offered, paid, solicited, or received. Violation of the Anti-Kickback Statute may also result in an individual’s or organization’s exclusion from future participation in Medicare, Medicaid and other state and federal healthcare programs. State Medicaid programs are required to enact an anti-kickback statute. Many states in which we operate have adopted or are considering similar legislative proposals, some of which extend beyond the Medicaid program, to prohibit the payment or receipt of remuneration for the referral of patients regardless of the source of payment for the care. We believe that business practices of providers and financial relationships between providers have become subject to increased scrutiny as healthcare reform efforts continue at the federal and state levels.

In addition to these regulations, we may face adverse consequences if we violate the federal Stark laws related to certain Medicare physician referrals. Section 1877 of the Social Security Act, commonly known as the “Stark Law,” provides that a physician may not refer a Medicare or Medicaid patient for a “designated health service” to an entity with which the physician or an immediate family member has a financial relationship unless the financial arrangement meets an exception under the Stark Law or its regulations. Designated health services include inpatient and outpatient hospital services, PT, OT, SLP, durable medical equipment, prosthetics, orthotics and supplies, diagnostic imaging, enteral and parenteral feeding and supplies, home health services, and clinical laboratory services. Under the Stark Law, a “financial relationship” is defined as an ownership or investment interest or a compensation arrangement. If such a financial relationship exists and does not meet a Stark Law exception, the entity is prohibited from submitting or claiming payment under the Medicare or Medicaid programs or from collecting from the patient or other payor. Many of the compensation arrangements exceptions permit referrals if, among other things, the arrangement is set forth in a written agreement signed by the parties, the compensation to be paid is set in advance, is consistent with fair market value and is not determined in a manner that takes into account the volume or value of any referrals or other business generated between the parties. Exceptions may have other requirements. Any funds collected for an item or service resulting from a referral that violates the Stark Law must be repaid to Medicare or Medicaid, any other third-party payor, and the patient. In addition, CMPs, which are adjusted for annual inflation, and treble damages may be imposed for presenting or causing to be presented, a claim for a service rendered in violation of the Stark Law. These CMPs include a penalty of over $25,000 per prohibited claim, and over $170,000 for knowingly entering into certain prohibited cross-referral schemes (adjusted annually for inflation), and potential exclusion from Medicare for any person who presents or causes to be presented a bill or claim the person knows or should know is submitted in violation of the Stark laws. Many states have enacted healthcare provider referral laws that go beyond physician self-referrals or apply to a greater range of services than just the designated health services under the Stark Law.

Regulations Regarding Patient Record Confidentiality. We are also subject to laws and regulations enacted to protect the confidentiality of patient health information. For example, HHS has issued rules pursuant to HIPAA as amended by the Health Information Technology for Economic and Clinical Health (“HITECH”) Act, which relate to the privacy of certain patient information and provide patients with the right of access to their health information. These rules govern our use and disclosure of protected health information. We have established policies and procedures to comply with HIPAA privacy, security and breach notification requirements at our facilities and operations subject to HIPAA. We maintain a company-wide HIPAA compliance plan, which we believe complies with the HIPAA regulations. The HIPAA regulations have and will continue to impose significant costs on our facilities in order to comply with these standards. Our operations are also subject to any federal or state privacy-related laws that are more restrictive than the privacy regulations issued under HIPAA. These laws vary and could impose additional penalties for privacy and security breaches.

15

Antitrust Laws. We are also subject to federal and state antitrust laws. Enforcement of the antitrust laws against healthcare providers is common, and antitrust liability may arise in a wide variety of circumstances, including third party contracting, physician relations, joint venture, merger, affiliation and acquisition activities. In some respects, the application of federal and state antitrust laws to healthcare is still evolving, and enforcement activity by federal and state agencies appears to be increasing. At various times, healthcare providers and insurance and managed care organizations may be subject to an investigation by a governmental agency charged with the enforcement of antitrust laws or may be subject to administrative or judicial action by a federal or state agency or a private party. Violators of the antitrust laws could be subject to criminal and civil enforcement by federal and state agencies, as well as by private litigants.

Regulations Specific to Senior Living Communities. Senior living services revenue is primarily derived from private pay residents at rates we establish based upon the needs of the resident, the amount of services we provide the resident, and market conditions in the area of operation. In addition, Medicaid or other state-specific programs may supplement payments for board and care services provided in senior living communities. A majority of states provide, or are approved to provide, Medicaid payments for personal care and medical services to some residents in licensed senior living communities under waivers granted by or under Medicaid state plans approved by CMS. State Medicaid programs control costs for assisted living and other home- and community-based services by various means such as restrictive financial and functional eligibility standards, enrollment limits and waiting lists. States that administer Medicaid programs for services in senior living communities are responsible for monitoring the services at, and physical conditions of, the participating communities. As a result of the growth of assisted living in recent years, states have adopted licensing standards applicable to assisted living communities. Most state licensing standards apply to assisted living communities regardless of whether they accept Medicaid funding.

Since 2003, CMS has commenced a series of actions to increase its oversight of state quality assurance programs for assisted living communities and has provided guidance and technical assistance to states to improve their ability to monitor and improve the quality of services paid for through Medicaid waiver programs. CMS is encouraging state Medicaid programs to expand their use of home- and community-based services as alternatives to institutional services, pursuant to provisions of the ACA, the 2014 Home and Community Based Services regulation and related guidance to state Medicaid directors, and other periodic action.

Our senior living segment is subject to a variety of federal, state and local environmental laws and regulations. As a senior living services provider, we face regulatory requirements in areas of air and water quality control, medical and low-level radioactive waste management and disposal, asbestos management, response to mold and lead-based paint in our facilities and employee safety.

As an operator of our communities, we also may be required to investigate and remediate hazardous substances that are located on and/or under the property, including any such substances that may have migrated off, or may have been discharged or transported from the property. Part of our operations involves the handling, use, storage, transportation, disposal and discharge of medical, biological, infectious, toxic, flammable and other hazardous materials, wastes, pollutants or contaminants. In addition, we are sometimes unable to determine with certainty whether prior uses of our communities and properties or surrounding properties may have produced continuing environmental contamination or noncompliance, particularly where the timing or cost of making such determinations is not deemed cost-effective. These activities, as well as the possible presence of such materials in, on and under our properties, may result in damage to individuals, property or the environment; may interrupt operations or increase costs; may result in legal liability, damages, injunctions or fines; may result in investigations, administrative proceedings, penalties or other governmental agency actions. Associated costs may not be covered by insurance.

AVAILABLE INFORMATION

We are subject to the reporting requirements under the Securities Exchange Act of 1934, as amended (the Exchange Act). Consequently, we are required to file reports and information with the Securities and Exchange Commission (“SEC”), including reports on the following forms: annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. These reports and other information concerning our company may be accessed through the SEC’s website at http://www.sec.gov.

You may also find on our website at www.pennantgroup.com electronic copies of our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. Such filings are placed on our website as soon as reasonably possible after they are filed with the SEC. All such filings are available free of charge. Information contained in our website is not deemed to be a part of this Annual Report on Form 10-K.
16


Item 1A. Risk Factors -

Based on the information currently known to us, we believe that the following information identifies material risk factors affecting our company. However, the risks and uncertainties we face are not limited to those described below. Additional risks and uncertainties may also adversely affect our business. If any of the following risks and uncertainties develops into actual events, these events could have a material adverse effect on our business, financial condition or results of operations. In such case, the trading price of our common stock could decline.

Risks Related to Our Business and Industry

Our revenue could be impacted by federal changes to reimbursement and other aspects of Medicare. We derived 45.6% of our revenue from the Medicare program for the year ended December 31, 2020, which is typical. In addition, other payors may use published Medicare rates as a basis for reimbursements. The Medicare program and its reimbursement rates, caps, deductibles and rules are subject to frequent change for a variety of reasons and Medicare home health reimbursement is undergoing a significant change with the implementation of PDGM, each of which is discussed in Item 1., Government Regulation. Budget pressures also frequently lead the federal government to reduce or limit reimbursement rates under Medicare. Additionally, Medicare payments can be delayed or declined (including retroactively) due to determinations that certain costs, services or providers are not covered. Accordingly, if Medicare reimbursement rates are reduced or fail to increase as quickly as our costs, or if there are changes in the way these programs pay for services or what services or providers are covered, our business and results of operations would be adversely affected. CMS has also introduced in the past, and will likely introduce in the future, new payment models, such as value-based arrangements, in markets in which we operate. Those models may depend on the formation of preferred provider relationships among payors and providers. Our operations may not successfully implement or adapt to these changes and our operations could be materially impacted.

Reductions in Medicaid reimbursement rates or changes in the rules governing the Medicaid program could have a material, adverse effect on our revenues, financial condition and results of operations. We derived 14.5% of our revenue from Medicaid programs for the year ended December 31, 2020, which is typical. Medicaid is a state-administered program financed by both state funds and matching federal funds and its reimbursement rates and rules are subject to frequent change (including retroactively) at both the federal and state level, as discussed in Item 1., Government Regulation. Any budget reductions or funding restrictions, discontinuance or reduction of federal matching, change in payment methodology or delays in states in which we operate could adversely affect our net patient service revenue and profitability. We can expect continuing cost containment pressures on Medicaid outlays for our services.

Reforms to the U.S. healthcare system continue to impose new requirements upon us and may lower our reimbursements. The ACA included sweeping changes to how healthcare is paid for and furnished in the United States. The ACA continues to face legal challenges and calls for repeal or amendment. We cannot predict what effect these challenges, or other legislative or regulatory changes (including, for instance, proposals for Medicare for All), will have on our business, including the demand for our services or the amount of reimbursement available for those services. It is possible new laws may lower reimbursement or increase the cost of doing business and adversely affect our business.

We are subject to various government reviews, audits and investigations that could adversely affect our business, including an obligation to refund amounts previously paid to us, potential criminal charges, the imposition of fines, and/or the loss of our right to participate in Medicare and Medicaid programs. As discussed in greater detail in Item 1., Government Regulation, as a result of our participation in the Medicaid and Medicare programs, we are frequently subject to various governmental reviews, audits and investigations to verify our compliance with these programs. Private pay sources also reserve the right to conduct audits. Disagreements about billing and reimbursement are common in our industry due in part to the subjectivity inherent in patient diagnosis and care, record keeping, claims processing and other aspects of the patient service and reimbursement processes. An adverse review, audit or investigation could result in (1) an obligation to refund amounts previously paid to us by payors in amounts that could vastly exceed the revenue derived from claims actually reviewed in the audit, and could be material to our business; (2) state or federal agencies imposing fines, penalties and other sanctions on us; (3) loss of our right to participate in the Medicare or Medicaid programs or one or more private payor networks; (4) an increase in private litigation against us; and (5) damage to our reputation in various markets.

In cases where claim and documentation review by any CMS contractor results in repeated poor performance, an operation can be subjected to protracted oversight, and sustained failure to demonstrate improvement towards meeting all claim filing and documentation requirements could ultimately lead to Medicare decertification. Additionally, both federal and state government agencies have heightened and coordinated civil and criminal enforcement efforts as part of numerous ongoing investigations of healthcare companies. The focus of these investigations includes, among other things: cost reporting and billing practices;
17

quality of care; financial relationships with referral sources; and medical necessity of services provided. If any of our affiliated operations is decertified, loses its licenses, or is subject to criminal charges or civil claims, administrative sanctions or penalties, our revenue, financial condition or results of operations would be adversely affected. We or some of the key personnel of our independent operating subsidiaries could also be temporarily or permanently excluded from future participation in state and federal healthcare reimbursement programs such as Medicaid and Medicare. In addition, the report of such issues at any of our affiliated operations could harm our reputation for quality care and could cause us to be in default under some of our agreements, including agreements governing outstanding indebtedness. Responding to audits, litigation or enforcement efforts diverts material time, resources and attention, and could have a materially detrimental impact on our results of operations during and after any such investigation or proceedings, regardless of whether we prevail.

If we do not operate in compliance with the extensive laws and regulations to which we are subject, or if these laws and regulations change, we could be required to make significant expenditures or change our operations in order to bring our operations into compliance. We, like other companies in the healthcare industry, are required to comply with extensive and complex laws and regulations at the federal, state and local government levels as discussed in greater detail in Item 1., Government Regulation. These laws and regulations are subject to frequent and unpredictable change. If we fail to comply with these applicable laws and regulations, we could suffer civil or criminal penalties and other detrimental consequences, including denial of reimbursement, imposition of fines, temporary suspension of admission of new patients, suspension or decertification from the Medicaid and Medicare programs, restrictions on our ability to acquire new operations or expand or operate existing operations, the loss of our licenses to operate and the loss of our ability to participate in federal and state reimbursement programs. These laws and regulations are complex, and we do not always have the benefit of significant regulatory or judicial interpretation of these laws and regulations. Changing interpretations or enforcement of these laws and regulations could subject our current or past practices to allegations of impropriety or illegality or could require us to change our operations, equipment, personnel, services, capital expenditure programs and operating expenses.

Public and government calls for increased survey and enforcement efforts toward our industries could result in increased scrutiny and potential sanctions or costly remedies. Government authorities have increased the scope or number of inspections or surveys and the severity of consequent citations for alleged failure to comply with regulatory requirements. As discussed in Item 1., Government Regulation, from time to time in the ordinary course of business, we receive deficiency reports from state and federal regulatory bodies resulting from such inspections or surveys. Although most inspection deficiencies are resolved through an agreed-upon plan of corrective action, the reviewing agency typically has the authority to take further action against a licensed or certified operation, which could result in the imposition of fines, imposition of a provisional or conditional license, suspension or revocation of a license, suspension of new admission or bed holds, loss of certification as a provider under state or federal healthcare programs, or imposition of other sanctions, including criminal penalties. Furthermore, in some states, citations in one operation can impact other operations in the state. Revocation of a license or decertification at a given operation could therefore impair our ability to obtain new licenses or to renew existing licenses at other operations, which may also trigger defaults or cross-defaults under our leases and our credit arrangements, or adversely affect our ability to operate in the future. If state or federal regulators were to determine, formally or otherwise, that one operation’s regulatory history ought to impact another of our existing or prospective communities, this could also increase costs, result in increased scrutiny by state and federal survey agencies, and impact our expansion plans. In addition, from time to time, we may opt to voluntarily stop accepting new patients pending completion of a new state survey, in order to avoid straining staff and other resources while retraining staff, upgrading operating systems or making other operational improvements, all of which can impact our financial results.

Future cost containment initiatives undertaken by payors may limit our future revenue and profitability. Our Managed Care revenue and profitability may be affected by continuing efforts of third-party payors to maintain or reduce costs of healthcare by lowering payment rates, narrowing the scope of covered services and network providers, increasing case management review of services and negotiating pricing. In addition, sustained unfavorable economic conditions may affect the number of patients enrolled in managed care programs and the profitability of managed care companies, which could result in reduced revenue. There can be no assurance that third-party payors will make timely payments for our services, or that we will continue to maintain our current payor or revenue mix. We are continuing our efforts to develop our private pay sources of revenue. Any changes in payment levels from current or future third-party payors could have a material adverse effect on our business and combined financial condition, results of operations and cash flows.

Increased competition for, or a shortage of, nurses and other skilled personnel could increase our staffing and labor costs and subject us to fines. Our success depends upon our ability to retain and attract nurses, certified nurse assistants, social workers and speech, physical and occupational therapists, as well as skilled personnel who are responsible for the day-to-day operations of each of our affiliated operations. If we fail to attract and retain qualified and skilled personnel, or if the associated costs increase, our independent operating subsidiaries’ ability to conduct their business operations effectively could be harmed.

18

We depend on our management team and local leaders, and the loss of their services could harm our business. We believe that our success depends in part on the continued services of our executive management and local leadership teams. The loss of, or failure to recruit, such key personnel could have a material adverse effect on our business and could adversely affect our strategic relationships and impede our ability to execute our business strategies. The market for qualified individuals is highly competitive and finding and recruiting suitable replacements for our leaders may be difficult, time consuming and costly.

Our hospice independent operating subsidiaries are subject to annual Medicare caps calculated by Medicare. With respect to our hospice independent operating subsidiaries, overall payments made by Medicare for each Medicare beneficiary are subject to caps calculated by Medicare, as discussed in greater detail in Item 1., Government Regulation. If payments received by any one of our hospice provider numbers exceeds the caps for the beneficiary, we are required to reimburse Medicare for payments received in excess of the caps, which could have a material adverse effect on our business.

Security breaches and other cyber-security incidents could subject us to significant liability. Our business is dependent on the proper functioning and availability of our computer systems and networks. Our safety and security measures designed to protect our information systems, data and patient health information and disaster recovery plan may not prevent damage, interruption, or breach of our information systems and operations. In addition, hardware, software or applications we develop or procure from third parties may contain defects in design or manufacture or other problems that could unexpectedly compromise the security of our information systems. Unauthorized parties may attempt to gain access to our systems or operations, or those of third parties with whom we do business, through fraud or other forms of deceiving our employees or contractors. In addition, costs and potential problems and interruptions associated with the implementation of new or upgraded systems and technology or with maintenance or adequate support of existing systems also could disrupt or reduce the efficiency of our operations. If a cyber-security attack or other unauthorized attempt to access our systems or operations were to be successful, it could result in the theft, destruction, loss, misappropriation or release of confidential information or intellectual property, and could cause operational or business delays or disruptions that may materially impact our ability to provide various healthcare services. Any successful cyber-security attack or other unauthorized attempt to access our systems or operations also could result in negative publicity which could damage our reputation or brand with our patients, referral sources, payors or other third parties and could subject us to substantial regulatory, civil or criminal penalties, fines, investigations and enforcement actions, including under HIPAA and other federal and state privacy laws, including, for example, the California Consumer Privacy Act, which includes a private right of action that may expose us to private litigation regarding our privacy practices and significant damages awards or settlements in civil litigation.

State efforts to regulate or deregulate the healthcare services industry or the construction or expansion of the number of home health, hospice or senior living operations could impair our ability to expand or result in increased competition. As discussed in greater detail in Item 1., Government Regulation, our ability to acquire or establish new home health, hospice or senior living operations or expand or provide new services at existing operations would be adversely affected if we are unable to obtain the necessary approvals, if there are changes in the standards applicable to those approvals, or if we experience delays and increased expenses associated with obtaining those approvals. We may not be able to obtain licensure, CON approval, Medicare or Medicaid certification, Attorney General approval or other necessary approvals for future expansion projects. Conversely, and specific to the highly competitive senior living industry, the elimination or reduction of state regulations that limit the construction, expansion or renovation of new or existing communities could result in increased competition to us. In general, regulatory and other barriers to entry in the senior living industry are not prohibitive. Over the last several years, there has been a significant increase in the construction of new senior living communities, including in the markets where we provide services. This has resulted in increased competition in many of our markets. Such new competition may limit our ability to attract new residents, raise rents or otherwise expand our senior living business, which could have a material adverse effect on our revenues, results of operations and cash flow.

Changes in federal and state employment-related laws and regulations could increase our cost of doing business. Our independent operating subsidiaries are subject to a variety of federal and state employment-related laws and regulations, including, but not limited to, the U.S. Fair Labor Standards Act which governs such matters as minimum wages, overtime and other working conditions, the Americans with Disabilities Act (the “ADA”) and similar state laws that provide civil rights protections to individuals with disabilities in the context of employment, public accommodations and other areas, the National Labor Relations Act, regulations of the Equal Employment Opportunity Commission, regulations of the Office of Civil Rights, regulations of state Attorneys General, family leave mandates and a variety of similar laws. Because labor represents a large portion of our operating costs, changes in federal and state employment-related laws and regulations could increase our cost of doing business. We also may be subject to employee-related claims such as wrongful discharge, discrimination or violation of equal employment law. Employment claims, such as wage and hour claims, frequently are the subject of class action lawsuits in many states in which our independent affiliates operate, including, for example, California.

19

Required regulatory approvals could delay or prohibit transfers of our healthcare operations, which could result in periods in which we are unable to receive reimbursement for such properties. Our independent operating subsidiaries must be licensed under applicable state law and, depending upon the type of operation, certified or approved as providers under the Medicare and/or Medicaid programs. In the process of acquiring or transferring operating assets, our operations must receive change of ownership approvals from state licensing agencies, Medicare and Medicaid, and third party payors. If there are any delays in receiving regulatory approvals from the applicable federal, state or local government agencies, or the inability to receive such approvals, such delays could result in delayed or lost reimbursement related to periods of service prior to the receipt of such approvals.

Compliance with federal and state fair housing, fire, safety and other regulations may require us to make unanticipated expenditures, which could be costly to us. We must incur the expense of complying with the federal Fair Housing Act and similar state laws, and applicable fire and safety regulations, building codes and other land use regulations and food licensing or certification requirements as they may be adopted by governmental agencies and bodies from time to time and the expense may be substantial. Changes to these laws may require us to close operations, limit occupancy, or make other costly changes.

Our revenue, financial condition and results of operations could be negatively impacted by any changes in the acuity mix of patients in our affiliated operations as well as payor mix and payment methodologies. Our revenue is determined in part by the acuity of home health and hospice patients and senior living residents. Changes in the acuity level of patients we attract, as well as our payor mix among Medicare, Medicaid, managed care organizations and private payors, significantly affect our profitability because we generally receive higher reimbursement rates for high acuity patients and because the payors reimburse us at different rates. For the year ended December 31, 2020, 60.1% of our revenue was provided by government payors that reimburse us at predetermined rates, which is typical. If we fail to maintain our proportion of high acuity patients or if there is any significant increase in the percentage of the patients of our independent operating subsidiaries for whom we receive Medicaid reimbursement, our results of operations may be adversely affected. Among other initiatives, these payors attempt to control healthcare costs by contracting with healthcare providers to obtain services on a discounted basis. We believe that this trend will continue and may limit reimbursements for healthcare services. If insurers or managed care companies from whom we receive substantial payments were to reduce the amounts they pay for services, we may lose patients if we choose not to renew our contracts with these insurers at lower rates.

We are subject to litigation that could result in significant legal costs and large settlement amounts or damage awards. Our business involves a significant risk of liability given the age and health of the patients and residents of our independent operating subsidiaries and the services we provide. The frequency and severity of litigation in the healthcare industry has increased, due in part to large verdicts and punitive damage awards. Claims are filed based upon a wide variety of assertions and theories, including deficiencies in conditions of participation under certain state and federal healthcare programs and wage and hour class actions. Plaintiffs’ attorneys have become increasingly aggressive in their pursuit of claims against healthcare providers, including home health, hospice and senior living providers, employing a wide variety of advertising and solicitation activities to generate more claims. The defense of lawsuits may result in significant legal costs, regardless of the outcome. Additionally, such litigation may result in increased liability insurance premiums and/or a decline in available insurance coverage levels, which could materially and adversely affect our business, financial condition and results of operations.

Instances of noncompliance can decrease our revenue. As discussed under Item 1., Monitoring Compliance in our Operations, we have internal compliance policies and procedures, including ongoing monitoring and controls, pursuant to which we have identified, and may in the future identify, deficiencies in the assessment of and recordkeeping for patients and residents. We must accrue liabilities for claim costs and interest and repay any amounts due in normal course and failure to refund overpayments within required time frames (as described in greater detail under Item 1., Government Regulation) could result in FCA liability. If future investigations ultimately result in findings of significant billing and reimbursement noncompliance, which require us to record significant additional provisions or remit payments, our business, financial condition and results of operations could be materially and adversely affected.

We may be unable to complete future acquisitions at attractive prices or at all, which may adversely affect our revenue growth. To date, our revenue growth has been significantly accelerated by our acquisition of new operations. Subject to general market conditions and the availability of essential resources and leadership within our company, we continue to seek home health, hospice and senior living acquisition opportunities that are consistent with our geographic, financial and operating objectives. We face competition for the acquisition of operations and businesses and expect this competition to increase. Based upon factors such as our ability to identify suitable acquisition candidates, the purchase price of the operations, prevailing market conditions, the availability of leadership to manage new operations and our own willingness to take on new operations, the rate at which we have historically acquired home health, hospice and senior living operations has fluctuated and we anticipate similar fluctuation in the future. Further, acquisitions may require financing, which may not be available to us or may be available to us only on terms that are not favorable. If funds are raised through the issuance of additional equity securities,
20

the percentage ownership of our stockholders would be diluted, and any newly issued equity securities may have rights, preferences or privileges senior to those of our common stock. We may acquire operations that prove to be non-strategic or less desirable, and we may consider disposing of such operations or exchanging them for operations which are more desirable.

We may not be able to successfully integrate acquired operations, and we may not achieve the benefits we expect from our acquisitions. We may not be able to successfully or efficiently integrate new acquisitions with our existing independent operating subsidiaries, culture and systems. We also may determine that renovations of acquired operations and changes in staff and operating management personnel are necessary to successfully integrate those acquisitions into our existing operations. We may not be able to recover the costs incurred to reposition or renovate newly independent operating subsidiaries. The financial benefits we expect to realize from many of our acquisitions are largely dependent upon our ability to improve clinical performance, overcome regulatory deficiencies, rehabilitate or improve the reputation of the operations in the community, increase and maintain census, control costs, and in some cases change the patient acuity mix. Growth also places significant demands on our leaders and operational, financial and management information systems. If we are unable to accomplish any of these objectives at the independent operating subsidiaries we acquire, we will not realize the anticipated benefits and we may experience lower than anticipated profits, or even losses.

In undertaking acquisitions, we may be impacted by costs, liabilities and regulatory issues that may adversely affect our operations. In undertaking acquisitions, we also may be adversely impacted by unforeseen liabilities attributable to the prior providers who operated the acquired operations, against whom we may have little or no recourse. Many operations we have historically acquired were underperforming prior to the acquisition. Even where operations have been improved, we still may face post-acquisition regulatory issues related to pre-acquisition events. These may include, without limitation, payment recoupment related to our predecessors’ prior noncompliance, the imposition of fines, penalties, operational restrictions or special regulatory status. Further, we may incur post-acquisition compliance risk due to the difficulty or impossibility of immediately or quickly bringing non-compliant operations into full compliance. Diligence materials pertaining to acquisition targets, especially the underperforming operations that often represent the greatest opportunity for return, are often inadequate, inaccurate or impossible to obtain, sometimes requiring us to make acquisition decisions with incomplete information. Operations that we have acquired or may acquire in the future may generate unexpectedly low returns, may cause us to incur substantial losses, may require unexpected levels of management time, expenditures or other resources, or may otherwise not meet a risk profile that our investors find acceptable. We also incur regulatory risk in acquiring certain operations due to the licensing, certification and other regulatory requirements affecting our right to operate the acquired operations, which are frequently obtained post-closing. If we were denied licensure or certification for any reason, we might not realize the expected benefits of the acquisition and would likely incur unanticipated costs and other challenges which could cause our business to suffer.

If our referral sources fail to view us as an attractive provider, or if our referral sources otherwise refer fewer patients or residents, our patient or resident base may decrease. We rely on appropriate referrals from physicians, hospitals and other healthcare providers in the communities we serve to attract appropriate residents and patients to our affiliated operations. Our referral sources are not obligated to refer business to us and may refer business to other healthcare providers. If we lose, or fail to maintain, existing relationships with our referral resources, fail to develop new relationships, or if we are perceived by our referral sources as not providing high quality patient care, our census could decline and our patient mix could change. In addition, if any of our referral sources have a reduction in patients whom they can refer due to a decrease in their business, our census could decline and patient mix could change.

If we do not achieve and maintain competitive quality of care ratings from CMS and private organizations engaged in similar monitoring activities, our business may be negatively affected. Providing quality patient care is the cornerstone of our business. We believe that referral sources, residents and patients select us in large part because of our reputation for delivering quality care. If we should fail to attain our goals regarding acute care hospitalization readmission rates and other quality metrics, we expect our ability to generate referrals would be adversely impacted, which could have a material adverse effect upon our business and combined financial condition, results of operations and cash flows.

If we are unable to obtain insurance, or if insurance becomes more costly for us to obtain, our business may be adversely affected. It may become more difficult and costly for us to obtain coverage for patient care liabilities and other risks, including property and casualty insurance. Our claims history, asset mix, or other factors may adversely affect our ability to obtain insurance at favorable rates. Our insurance carriers may require us to pay substantially higher premiums for the same or reduced coverage for insurance, including workers compensation, property and casualty, automobile, employment practices liability, directors and officers liability, employee healthcare and general and professional liability coverages. Further, many claims and other risks we face are not insurable. Attributable to the COVID-19 pandemic, insurers may increase their exclusions of infectious diseases or raise costs of coverage significantly affecting our ability to obtain insurance coverage.

21

We retain certain risks related to our insurance coverage. Under its insurance policies, the Company bares the risk of loss up to specified deductible limits, which may be substantial if there is a surge in the volume of claims subject to the deductible. The Company recognizes obligations associated with these costs in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. These costs generally are estimated based on our historical claims experience. Projections of self-insured retention losses are estimates that are subject to significant variability, and as a result, actual losses and expenses may be more or less than recorded liabilities.

The unionization of our workers may adversely affect our revenue and profitability. To date, our employees have chosen not to unionize. If they decide to unionize, our cost of doing business could increase, our operations could experience disruption, and affected operations may no longer be economical to continue operating.

Because we lease all of our affiliated senior living communities, we could experience risks associated with leased property, including risks relating to lease termination, lease extensions and special charges, which could adversely affect our business, financial position or results of operations. As of December 31, 2020, we leased all of our senior living communities and administrative offices. Most of our leases are triple-net leases, which means that, in addition to rent, we are required to pay for the costs related to the property (including property taxes, insurance, and maintenance and repair costs). Under certain master leases, a breach at a single community could subject one or more of the other communities covered by the same master lease to the same default risk. Failure to comply with provider requirements is a default under several of the leases and master lease agreements. In addition, lease defaults could trigger cross-default provisions in our outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.

A housing downturn could decrease demand for assisted living services. Seniors often use the proceeds of home sales to fund their admission to assisted living communities. A downturn in the housing markets could adversely affect seniors’ ability to afford our resident fees and entrance fees. If national or local housing markets enter a persistent decline, our occupancy rates, revenues, results of operations and cash flow could be negatively impacted.

Failure to generate sufficient cash flow to cover required payments or meet operating covenants under our long-term debt and operating leases could result in defaults under such agreements and cross-defaults under other debt or operating lease arrangements, which could harm our independent operating subsidiaries and cause us to lose operations or experience foreclosures. We have significant future operating lease obligations. We intend to continue financing operations through long-term operating leases, mortgage financing and other types of financing, including borrowings under our future credit facilities we may obtain. We may not generate sufficient cash flow from operations to cover required interest, principal and lease payments. If we are unable to generate sufficient cash flow from operations in the future to service our debt or to make lease payments on our operating leases, we may be required, among other things, to seek additional financing in the debt or equity markets, refinance or restructure all or a portion of our indebtedness, sell selected assets, reduce or delay planned capital expenditures or delay or abandon desirable acquisitions. Such measures might not be sufficient to enable us to service our debt or to make lease payments on our operating leases. The failure to make required payments on our debt or operating leases or the delay or abandonment of our planned growth strategy could result in an adverse effect on our future ability to generate revenue and sustain profitability and subject us to foreclosure. In addition, any such financing, refinancing or sale of assets might not be available on terms that are economically favorable to us, or at all. Our financing arrangements contain restrictions, covenants and events of default that, among other things, could limit our ability to respond to market conditions, provide for capital investment needs or take advantage of business opportunities by restricting our ability to incur or guarantee additional indebtedness or requiring us to offer to repurchase such indebtedness in the event of a change of control or a change of control triggering event; pay dividends or make distributions; make investments or acquisitions; sell, transfer or otherwise dispose of certain assets; create liens; consolidate or merge; enter into transactions with affiliates; and prepay and repurchase or redeem certain indebtedness.

The condition of the financial markets, including volatility and deterioration in the capital and credit markets, could limit the availability of debt and equity financing sources to fund the capital and liquidity requirements of our business, as well as negatively impact or impair the value of our future portfolio of cash, cash equivalents and investments. Credit markets are cyclical. Volatility in financial and credit markets may reduce the availability of certain types of debt financing and restrict the availability of credit. Further, we anticipate that our future cash, cash equivalents and investments may be held in a variety of interest-bearing instruments. As a result of the uncertain domestic and global political, credit and financial market conditions, investments in these types of instruments pose risks arising from liquidity and credit concerns.

Delays in reimbursement may cause liquidity problems. If we experience problems with our billing information systems or if issues arise with Medicare, Medicaid or other payors, we may encounter delays in our payment cycle. From time to time, we have experienced such delays as a result of government payors instituting planned reimbursement delays for budget balancing
22

purposes or as a result of prepayment reviews. Some states in which we operate are operating with budget deficits or could have a budget deficit in the future, which may delay reimbursement in a manner that would adversely affect our liquidity. In addition, from time to time, procedural issues require us to resubmit claims before payment is remitted, which contributes to our aged receivables. Unanticipated delays in receiving reimbursement from state programs due to changes in their policies or billing or audit procedures may adversely impact our liquidity and working capital. As discussed in Item 1., Government Regulation, with the reduction in fiscal year 2020 and elimination in fiscal year 2021 of RAPs, we may experience higher receivables and reduced cash flows as collections are delayed upon implementation.

Compliance with the regulations of the Department of Housing and Urban Development (“HUD”) may require us to make unanticipated expenditures which could increase our costs. Seventeen of our affiliated senior living communities are currently subject to regulatory agreements with HUD that give the Commissioner of HUD broad authority to require us to be replaced as the operator of those communities in the event that the Commissioner determines there are operational deficiencies at such communities under HUD regulations. Compliance with HUD’s requirements can often be difficult because these requirements are not always consistent with the requirements of other federal and state agencies and, in some instances, may require us to make additional capital expenditures to meet HUD’s heightened requirements. Appealing a failed inspection can be costly and time-consuming and, if we do not successfully remediate the failed inspection, we could be precluded from obtaining HUD financing in the future or we may encounter limitations or prohibitions on our operation of HUD-insured communities.

Failure to comply with existing environmental laws could result in increased expenditures, litigation and potential loss to our business and in our asset value. Our independent operating subsidiaries are subject to regulations under various federal, state and local environmental laws, primarily those relating to the handling, storage, transportation, treatment and disposal of medical waste; the identification and warning of the presence of asbestos-containing materials in buildings, as well as the encapsulation or removal of such materials; and the presence of other substances in the environment. The presence of such materials may be unknown and could result in remediation costs, fines, damages and other material harm to our business.

We are a holding company with no operations and rely upon our independent operating subsidiaries to provide us with the funds necessary to meet our financial obligations. We are a holding company with no direct operating assets, employees or revenues. Each of our affiliated operations is operated through a separate, independent subsidiary, which has its own management, employees and assets. Our principal assets are the equity interests we directly or indirectly hold in our independent operating subsidiaries. As a result, we are dependent upon distributions from our subsidiaries to generate the funds necessary to meet our financial obligations. Our subsidiaries are legally distinct from us and have no obligation to make funds available to us. The ability of our subsidiaries to make distributions to us will depend substantially on their respective operating results and will be subject to restrictions under, among other things, the laws of their jurisdiction of organization, which may limit the amount of funds available for distribution to investors or stockholders, agreements of those subsidiaries, the terms of our financing arrangements and the terms of any future financing arrangements of our subsidiaries.

Risks Related to the Spin-Off

We have little operating history as a separate public company; our historical financial information is not necessarily representative of the results we would have achieved as a separate publicly traded company and may not be a reliable indicator of our future results. Prior to the Spin-Off, Ensign performed various corporate functions for us, including executive management, accounting, human resources, information technology, legal, payroll, insurance, tax, treasury, and other general and administrative items. Our historical financial results reflect allocations of corporate expenses from Ensign for these and similar functions that may be less than the comparable expenses we would have incurred had we operated as a separate publicly traded company. Prior to the Spin-Off, we shared economies of scope and scale in costs, employees, vendor relationships and relationships with our partners. While we have entered into short-term transition agreements and certain other longer-term agreements that govern certain commercial and other relationships between us and Ensign, those arrangements may not capture the benefits our business has enjoyed as a result of being integrated with the other affiliates of Ensign.

One of our directors continues to serve as a director on the Ensign board of directors, and ownership of shares of Ensign common stock or equity awards of Ensign by our directors and executive officers may create conflicts of interest or the appearance of conflicts of interest. One of our directors continues to serve on the Ensign board of directors and substantially all of our executive officers and some of our non-employee directors own shares of Ensign common stock. This could create, or appear to create, potential conflicts of interest when our or Ensign’s management or directors face decisions that could have different implications for us and Ensign, including the resolution of any dispute regarding the terms of the agreements governing the Spin-Off and the relationship between us and Ensign after the Spin-Off, any commercial agreements entered into in the future between us and Ensign and the allocation of such directors’ time between us and Ensign.

23

We may not be able to engage in desirable strategic transactions and equity issuances following the Spin-Off because of certain restrictions related to preserving the tax-free treatment of the Spin-Off. In addition, we could be liable for adverse tax consequences resulting from engaging in significant strategic or capital-raising transactions. Our ability to engage in significant strategic transactions and equity issuances may temporarily be limited or restricted in order to preserve, for U.S. federal income tax purposes, the tax-free nature of the Spin-Off. Even if the Spin-Off otherwise qualifies for tax-free treatment under Sections 368(a)(1)(D) and 355 of the Code, it may result in corporate level taxable gain to Ensign (and potential liability to us under our agreements with Ensign) under Section 355(e) of the Code if 50.0% or more, by vote or value, of shares of our stock or Ensign’s stock are acquired or issued as part of a plan or series of related transactions that includes the Spin-Off. The process for determining whether an acquisition or issuance triggering these provisions has occurred is complex, inherently factual and subject to interpretation of the facts and circumstances of a particular case. Any acquisitions or issuances of our stock or Ensign stock within a two-year period after the Spin-Off generally are presumed to be part of such a plan, although we or Ensign, as applicable, may be able to rebut that presumption. Under the tax matters agreement that we entered into with Ensign, we also are generally responsible for any taxes imposed on Ensign that arise from the failure of the Spin-Off to qualify as tax-free for U.S. federal income tax purposes, within the meaning of Sections 368(a)(1)(D) and 355 of the Code, to the extent such failure to qualify is attributable to actions, events or transactions relating to our stock, assets or business, or a breach of the relevant representations or any covenants made by us in the tax matters agreement or the representation letter provided to counsel in connection with the tax opinion of Kirkland & Ellis LLP.

Risks Related to Ownership of Our Common Stock

Anti-takeover provisions in our organizational documents and Delaware law might discourage or delay acquisition attempts for us that you might consider favorable.
Our amended and restated certificate of incorporation and amended and restated bylaws may make the merger or acquisition of our company more difficult without the approval of our board of directors. Among other things, these provisions: allow us to authorize the issuance of undesignated preferred stock, the terms of which may be established and the shares of which may be issued without stockholder approval, and which may include super voting, special approval, dividend, or other rights or preferences superior to the rights of the holders of common stock; establish advance notice requirements for nominations for elections to our board or for proposing matters that can be acted upon by stockholders at stockholder meetings; create a classified board of directors whose members serve staggered three-year terms; and limit the ability of our stockholders to call and bring business before special meetings. Further, as a Delaware corporation, we are also subject to provisions of Delaware law, which may impair a takeover attempt that our stockholders may find beneficial. These provisions could discourage, delay or prevent a transaction involving a change in control of our company, including actions that our stockholders may deem advantageous, or negatively affect the trading price of our common stock. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing and to cause us to take other corporate actions you desire.

Risks Related to COVID-19

COVID-19 has created new regulatory risks that impact our operations. COVID-19 has generated, and will likely continue to generate, dramatic and rapid changes in the laws affecting our operations. U.S. Federal, state, and local regulators have implemented new laws, rules, regulations, and orders, or waived or modified existing laws, rules and regulations for the duration of the COVID-19 public health emergency. Most of these changes have been made without following typical regulatory or legislative processes and procedures and have been announced via website postings or fact sheets with limited notice and without full regulations or guidance in place. While many of the changes are beneficial in that they reduce or eliminate statutory or regulatory requirements for healthcare providers during the COVID-19 public health emergency, we remain subject to the risk of inadvertent non-compliance due to the quantity, ambiguity and frequency of changes. The regulatory changes may also have an adverse effect on our operations through increased legal and operational costs related to compliance with changes and monitoring for future changes. Further, the resumption of pre-COVID-19 regulatory requirements at the conclusion of the public health emergency may require significant operational changes on short notice.

COVID-19 and related risks have affected and could materially affect our results of operations, financial position and/or liquidity. The global spread of COVID-19 and the various attempts to contain it have created significant volatility, uncertainty and economic disruption. See “Part I—Item 2—Management’s Discussion and Analysis of Financial Condition and Results of Operations—COVID-19” herein. All of the direct and indirect consequences of COVID-19 on our business are not yet known. Risks presented by the ongoing effects of COVID-19 include the following:

Decreased home health and hospice volumes and senior living occupancy, which has led to decreased revenue.
24

Increased costs and staffing requirements related to implementation of COVID-19 infection prevention protocols, including increased utilization of personal protective equipment (“PPE”), COVID-19 diagnostic testing and vaccination for staff and residents, and additional labor and cleaning supplies to frequently sterilize equipment and surfaces.
Increased labor costs due to increased overtime or premium pay, paid leave, and the increased need for temporary labor to supplement our existing staffing as our front-line employees may become unable to work while awaiting the results of COVID-19 tests or as they recover from a COVID-19 infection.
Increased scrutiny by regulators of infection control and prevention measures, including imposition of new COVID-19 disease and mortality reporting requirements, and increased enforcement of resident rights’ violations related to visitation.
Disruptions to supply chains which could negatively impact consistent and reliable delivery of PPE, sanitizing supplies, food, pharmaceuticals, and other goods.
COVID-19 related illnesses in staff, which could lead to temporary staffing shortages or reliance on less experienced personnel.
Employee concerns related to workplace safety, including potential for increase in workers’ compensation claims.
Potential increase in insurance premiums and COVID-19 related claims.
Inconsistent application or interpretation of modifications to regulatory requirements by surveyors.
Potential for inflation resulting from changes in economic conditions and steps taken by the federal government and the Federal Reserve in response to COVID-19, which could lead to higher inflation rates than we anticipated, which could in turn lead to an increase in rent expense under our triple net leases. All of the triple net leases in our senior living business contain annual rent escalators tied to year-over-year increases in various consumer price indices. While these leases contain provisions capping the increased rent expense each year, increased inflation could cause our rent expense in our senior living business to increase at a greater rate than in prior years.

COVID-19 could lead to future litigation. COVID-19 has affected virtually all businesses in the country, and healthcare providers have been acutely impacted due to direct involvement with the virus. The challenges of dealing with a global pandemic have been amplified by supply shortages, lack of available tests, and constantly evolving information. A significant portion of senior living communities in certain states have multiple confirmed cases of COVID-19 in their buildings. Home health, hospice and home care providers also frequently come into direct contact with suspected or confirmed COVID-19 positive patients. It is likely that healthcare companies, including those in the post-acute care and senior living industries in which we operate, could become targets of plaintiffs’ litigation, alleging negligence, wrongful death, and similar claims resulting from COVID-19. If we or our operations are subject to litigation of this nature, such litigation may result in legal fees, damages, fines or settlements in amounts that could be material.

Item 1B. Unresolved Staff Comments

None.

Item 2. Properties

Service Center

We lease two office locations to accommodate our Service Center. We lease approximately 14,287 square feet of office space located at 1675 East Riverside Drive, Suite 150, Eagle, ID 83616, pursuant to a lease that expires March 31, 2025. Our principal executive offices are located at the Service Center in Eagle, Idaho. We have two options to extend our lease term at this location for an additional five-year term for each option. In addition, we currently lease 6,101 rentable square feet of office space located at 1600 West Broadway Road, Suite 100, Tempe, Arizona 85282, pursuant to a lease that expires September 30, 2021. We have one option to extend our lease term at this location for one additional five-year term.

Home Health and Hospice Agencies and Senior Living Communities

As of December 31, 2020, we operated 76 home health, hospice and home care agencies in Arizona, California, Colorado, Idaho, Iowa, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin and Wyoming. Office space is leased within geographies served by our agencies.
25


As of December 31, 2020, we operated 54 affiliated senior living communities in Arizona, California, Nevada, Texas, Washington and Wisconsin, with 4,127 Senior Living units. We lease all of our communities through long-term, triple-net lease arrangements.

The following table provides summary information regarding the locations of our home health and hospice agencies and our senior living communities and operational units as of December 31, 2020:

StateHome Health Agencies Hospice AgenciesSenior Living CommunitiesSenior Living Units
Arizona1,249 
California761 
Colorado— — 
Idaho164 
Iowa— — 
Montana— — — 
Nevada385 
Oklahoma— — 
Oregon— — 
Texas12 712 
Utah— — 
Washington98 
Wisconsin19 758 
Wyoming— — 
Total41 35 54 4,127 


Item 3.    Legal Proceedings

We are involved in various claims and lawsuits arising in the ordinary course of business, none of which, in the opinion of management, is expected to have a material adverse effect on our results of operations or financial condition. However, the results of such matters cannot be predicted with certainty and we cannot assure you that the ultimate resolution of any legal or administrative proceeding or dispute will not have a material adverse effect on our business, financial condition, results of operations and cash flows. See Note 15, Commitments and Contingencies, to the Audited Consolidated and Combined Financial Statements for a description of claims and legal actions arising in the ordinary course of our business.

Item 4.    Mine Safety Disclosures

None.

Part II.

Item 5.     Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Market Information

Our Common stock has traded under the symbol “PNTG” on the NASDAQ Global Select Market since our Spin-Off on October 1, 2019. Prior to that date we were a subsidiary of Ensign, which trades under the ticker “ENSG” on the NASDAQ Global Select Market. As of February 24, 2021, there were approximately 60 holders of record of our stock.

Dividend Policy

We do not intend to pay dividends on our common stock for the foreseeable future. Instead, we anticipate that all of our future earnings will be retained to support our operations and to finance the growth and development of our business.
26

Item 6.     Selected Financial Data

Pennant early adopted the final rule as issued on January 21, 2021 by the SEC related to amendments to modernize, simplify, and enhance certain financial disclosure requirements in Regulation S-K. Specifically, the requirement for Item 301 of Regulation S-K, which was required by Item 6 of this Form 10-K, has been eliminated.

Item 7.     Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with the consolidated and combined financial statements and accompanying notes, which appear elsewhere in this Annual Report. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed below and elsewhere in this Annual Report. See Item 1A., Risk Factors and Cautionary Note Regarding Forward-Looking Statements.

Overview

We are a leading provider of high-quality healthcare services to patients and residents of all ages, including the growing senior population, in the United States. We strive to be the provider of choice in the communities we serve through our innovative operating model. We operate in multiple lines of businesses including home health, hospice and senior living services across Arizona, California, Colorado, Idaho, Iowa, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin and Wyoming. As of December 31, 2020, our home health and hospice business provided home health, hospice and home care services from 76 agencies operating across 14 states, and our senior living business operated 54 senior living communities throughout seven states.

The following table summarizes our affiliated home health and hospice agencies and senior living communities as of:

December 31,
20132014201520162017201820192020
Home health and hospice agencies16 25 32 39 46 54 63 76 
Senior living communities12 15 36 36 43 50 52 54 
Senior living units1,256 1,587 3,184 3,184 3,434 3,820 3,963 4,127 
Total number of home health, hospice, and senior living operations28 40 68 75 89 104 115 130 

COVID-19

Since its discovery in late 2019, a new strain of coronavirus, which causes the viral disease COVID-19, has spread around the globe. The outbreak has been declared to be a pandemic by the World Health Organization, and the United States Health and Human Services Secretary has declared a public health emergency in the United States in response to the outbreak. Additionally, the United States Centers for Disease Control and Prevention (“CDC”) has stated that older adults are at a higher risk for serious illness from COVID-19. As a result of the COVID-19 outbreak, we have taken necessary precautions to prevent and/or minimize spread of the virus to our patients and our residents.

We have been, and we expect to continue to be, impacted by several factors that may cause actual results to differ from our historical results or current expectations. Due to the COVID-19 pandemic, the results presented in this report are not necessarily indicative of future operating results. The situation surrounding COVID-19 remains fluid. We are actively managing our response in collaboration with government officials, staff and business partners and assessing potential impacts to our financial position and operating results, as well as adverse developments in our business.

Operational Response

During the second half of March 2020, we began experiencing a decrease in census at our home health agencies and a slight decrease in occupancy at our senior living communities, while our hospice census remained relatively flat through the month. Beginning in April 2020, we experienced a more significant decrease in census at our home health agencies, which was driven in large part by the suspension or postponement of elective medical procedures that require in-home care after the procedure. In May we began to see those businesses stabilize and improve, which trend continued throughout June. During the third and fourth quarters we experienced increases in all metrics related to our home health and hospice businesses as compared to the prior year period (see Key Performance Indicators below). In our senior living communities, we have experienced a
27

continued decline in occupancy since the outset of the pandemic due to a greater number of move outs net of move ins. While we experienced declines in our senior living occupancy, we did not experience material disruptions during the year ended December 31, 2020. We cannot be sure when the occupancy levels in our senior living communities will stabilize or improve over multiple measurement periods.

COVID-19 continues to impact all aspects of our business and geographies, including impacts on our patients, residents, staff, vendors and business partners. With current COVID-19 outbreaks continuing across the United States, it is difficult to predict the full extent of the impact that COVID-19 will have on our future financial position and operating results due to numerous uncertainties. These uncertainties include the severity of the virus, the duration of the outbreak, effectiveness of vaccination efforts, mutation of the virus, and governmental, business or other actions to contain the virus or treat its impact (which could include limitations on our operations or mandates to provide services to our patients and communities). Further, the impacts of a potential worsening of global economic conditions and disruptions to, and volatility in, the credit and financial markets, as well as other unanticipated consequences remain unknown.

We have experienced and expect to continue to see increased labor costs due to increased overtime and premium pay and the increased need for temporary labor to supplement our existing staffing. Furthermore, we experienced and expect to continue to see increased expenses for medical supplies due to the need for more PPE as part of our strict infection control procedures, along with additional COVID-19 testing expenses. To counteract the aforementioned increased costs, beginning in the second quarter we reduced spending, non-essential supplies, travel costs and all other discretionary items, and we delayed non-essential capital expenditure projects. We are monitoring the ongoing impact of these actions to our revenue and expenses. However, the extent to which COVID-19 will continue to impact our operations will depend on future developments, which remain uncertain and cannot be predicted with confidence, including the duration of the outbreak, new information that may emerge concerning the severity of the coronavirus and the actions taken to contain the coronavirus or treat its impact, among others.

As a result of COVID-19, we have enhanced our infection control procedures in accordance with guidance from Centers for Medicare & Medicaid Services (“CMS”) along with other state and federal agencies to protect our patients, residents, and staff. The infection control guidance from CMS and other agencies continues to evolve. We frequently update our infection control procedures and share best practices across our organization. Our operating subsidiaries have followed guidelines from CMS, the CDC and other federal or state agencies regarding infection control, including recommended screening and isolation protocols, increased PPE usage and systems for addressing local needs related to supplies, staffing and communication with families, patients and residents and local health agencies.

Financial Response

In light of the uncertainty surrounding the COVID-19, we implemented several precautionary measures to limit the financial impact to our operations and provide additional financial flexibility. In connection with the receipt of the Medicare advance payments of $28.0 million, and the deferral of employer-paid FICA of $8.4 million, and strengthening of our operations, we paid down the balance of our Revolving Credit Facility, allowing us to continue with a reduced debt load, a lighter interest burden, and significant availability on our line of credit. During the year we received approximately $9.9 million in Provider Relief Funds (“PRF”). As of December 31, 2020, we have returned all such funds we received related to this distribution. The CARES Act temporarily suspended the automatic 2% reduction of Medicare claim reimbursements for the period of May 1, 2020 through March 31, 2021. The suspension of the Medicare sequestration increased our revenue by approximately $2.8 million for the year ended December 31, 2020. We also implemented cost control measures such as reduced spending on non-essential supplies, travel costs and all other discretionary items, and we have delayed non-essential capital expenditure projects. For further discussion on our financial response, please see Liquidity and Capital Resources below. We believe we have adequately adjusted our operations to maintain the financial health of our business based on current revenue and expenses.

The Spin-Off Transactions

On October 1, 2019, Ensign completed the Spin-Off, which was effected through a tax free distribution to Ensign’s stockholders of substantially all of the outstanding shares of Pennant common stock. Each Ensign stockholder received a distribution of one share of Pennant common stock for every two shares of Ensign's common stock, plus cash in lieu of fractional shares. As a result of the Spin-Off on October 1, 2019, Pennant began trading as an independent publicly traded company on the NASDAQ under the symbol “PNTG.”

We expect to benefit from a continuing relationship with Ensign, which continues to be a holding company comprised of various healthcare service providers across the post-acute care continuum.
28

In connection with the Spin-Off, we entered a transition services agreement with Ensign (the “Transition Services Agreement”) with a two-year term, subject to extension upon the mutual agreement of the parties. Pursuant to the Transition Services Agreement, Ensign and Pennant agree to provide certain transition services to each other, including finance, information technology, human resources, employee benefits and other services to ensure an orderly transition following the distribution.

See “Certain Relationships and Related Party Transactions—Agreements with Ensign Related to the Spin-Off,” contained within the Information Statement as well as the Form 8-K filed with the SEC on October 3, 2019 for further discussion of the agreements entered into in connection with the Spin-Off.

Recent Activities

Acquisitions. During 2020, we expanded our operations through the acquisition of two senior living operations, six home health agencies, and six hospice agencies. The addition of these operations added a total of 164 senior living units to be operated by our independent operating subsidiaries. We entered into a separate operations transfer agreement with the prior operator as part of each transaction. The aggregate value for these acquisitions was $39.2 million. For further discussion of our acquisitions, see Note 7, Acquisitions, in the Notes to the consolidated and combined financial statements.

Amended Credit Facility. On February 23, 2021, we amended our existing revolving credit facility to increase our aggregate principal amount available from $75.0 million to $150.0 million.

Trends

As discussed more above under COVID-19, for the year ended December 31, 2020 we experienced an increase in all of our key metrics in our home health and hospice businesses. Since the pandemic began, we have experienced a decline in senior living occupancy as move-ins declined relative to move-outs due to the pandemic. We cannot be sure when the occupancy levels in our senior living communities will stabilize or improve over consecutive measurement periods. As uncertainty regarding the COVID-19 pandemic persists, and if cases continue to rise, we could see a more prolonged recovery. For further discussion of trends related to COVID-19, see COVID-19 above.

When we acquire turnaround or start-up operations, we expect that our combined metrics may be impacted. We expect these metrics to vary from period to period based upon the maturity of the operations within our portfolio. We have generally experienced lower occupancy rates at our senior living communities and lower census at our home health and hospice agencies for recently acquired operations; as a result, we generally anticipate lower consolidated and segment margins during years of acquisition growth. We established two start-up hospice agencies in California and Washington during the year ended December 31, 2020.

Regulation

In response to the COVID-19 pandemic, a variety relief bills have been passed to provide cash payments and other resources to help individuals, small businesses, state and local governments, hospitals and other healthcare providers affected by COVID-19. The first such bill was the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) enacted on March 27, 2020. The CARES Act and subsequent legislation, including the Paycheck Protection Program and Health Care Enhancement Act, called for congressional appropriations totaling $178 billion to be used as Provider Relief Funds (“PRF”) for hospitals and other healthcare providers on the front lines of the COVID-19 response. This funding is being used to support healthcare-related expenses or lost revenue attributable to COVID-19 and to ensure uninsured Americans can get testing and treatment for COVID-19. Providers who receive funds from the general distribution have to sign an attestation confirming receipt of funds and agree to the terms and conditions of payment. We did not apply for any relief funding under the CARES Act. During the second quarter of 2020 we received automatic PRF payments in the amount of $9.9 million, and during the second quarter of 2020 the Company returned the full amount of payments received.

The CARES Act also contains provisions for accelerated or advance Medicare payments under the Accelerated and Advanced Payments (“AAP”) Program to provide supporting cash flow to providers and suppliers combating the effects of the COVID-19 pandemic. We applied for and received $28.0 million. These funds are subject to automatic recoupment through offsets to new claims beginning one year after payment were issued beginning in April, 2021, at which time Medicare will automatically recoup 25 percent of Medicare payments for 11 months. At the end of the 11 months and assuming full repayment has not occurred, recoupment will increase to 50 percent for another six months. Any balance outstanding after these
29

two recoupment periods will be subject to repayment at a four percent interest rate. We anticipate completing repayment of the AAP within the allotted recoupment periods.

The CARES Act temporarily suspends the 2% sequestration payment adjustment on Medicare fee-for-service payment beginning May 1, 2020 until March 31, 2021. The CARES Act payroll tax deferral program allows employers to defer the deposit and payment of the employer’s portion of social security taxes that otherwise would be due between March 27, 2020, and December 31, 2020. The CARES Act permits employers to deposit half of these deferred payments by the end of 2021 and the other half by the end of 2022. We recognized $2.8 million in revenue related to the suspension of sequestration for the year ended December 31, 2020. Further, we are deferring employer social security taxes that we would normally pay with each payroll. As of December 31, 2020 we deferred $8.4 million, with $4.2 million in other long-term liabilities.

The Families First Coronavirus Response Act (“FFCRA”) enacted April 1, 2020, provided certain employees with paid sick leave or expanded family and medical leave for specified reasons related to COVID-19. While the sick and family leave provisions of the FFCRA expired on December 31, 2020, the FFCRA tax credit provisions, which reimburses employers for the cost of providing FFCRA leave, was extended through March 31, 2021. Thus, employers are no longer required to provide FFCRA leave, but may benefit from voluntarily doing so. Certain health care workers, including those who provide direct patient care, and those whose services are integrated with and necessary to the provision of patient care, are exempt from the Act.

On July 31, 2020, CMS released the final FY 2021 hospice payment rule. The national hospice payment rates, subject to geographical application, and the hospice CAP will increase by 2.4% over the current payment rates. Hospices that fail to meet quality reporting requirements receive a 2.0% reduction to the annual market basket update for the year. Further, the finalized hospice cap amount for the fiscal year 2021 cap year will be $30,683.93, which is equal to the fiscal year 2020 cap amount of $29,964.78, updated by the proposed fiscal year 2021 hospice payment increase percentage of 2.4%. In addition to payment updates, the rule finalizes the proposal to adopt the most recent Office of Management and Budget (“OMB”) statistical area delineations and apply a 5.0% cap on wage index decreases.

On October 29, 2020, CMS released the final rule updating the Medicare HH PPS rates and wage index for calendar year 2021. The final rule increases payments in the aggregate of 2.0%, reduced by an estimated 0.1% due to the rural add-on percentages mandated by the Bipartisan Budget Act of 2018. Home health agencies that fail to meet quality reporting requirements will receive a 2.0% reduction to the home health payment update percentage for the year. The final rule adopts the most recent OMB statistical area delineations and applies a 5.0% cap on wage index decreases to account for the transition. The final rule also implements Medicare enrollment requirements for qualified home infusion therapy suppliers, excluding home infusion therapy services from coverage under the Medicare home health benefit beginning in calendar year 2021. Finally, this rule finalizes the changes to the home health regulations regarding the use of technology in providing services under the Medicare home health benefit as described in the March 30, 2020 Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency Interim Final Rule.

Segments

We have two reportable segments: (1) home health and hospice services, which includes our home health, home care and hospice businesses; and (2) senior living services, which includes the operation of assisted living, independent living and memory care communities. Our Chief Executive Officer, who is our Chief Operating Decision Maker (“CODM”), reviews financial information at the operating segment level using segment adjusted EBITDAR from operations. We also report an “all other” category that includes general and administrative expense from our Service Center.

Key Performance Indicators

We manage the fiscal aspects of our business by monitoring key performance indicators that affect our financial performance. These indicators and their definitions include the following:

Home Health and Hospice Services

Total home health admissions. The total admissions of home health patients, including new acquisitions, new admissions and readmissions.
Total Medicare home health admissions. Total admissions of home health patients, who are receiving care under Medicare reimbursement programs, including new acquisitions, new admissions and readmissions.
30

Average Medicare revenue per completed 60-day home health episode. The average amount of revenue for each completed 60-day home health episode generated from patients who are receiving care under Medicare reimbursement programs.
Total hospice admissions. Total admissions of hospice patients, including new acquisitions, new admissions and recertifications.
Average hospice daily census. The average number of patients who are receiving hospice care during any measurement period divided by the number of days during such measurement period.
Hospice Medicare revenue per day. The average daily Medicare revenue recorded during any measurement period for services provided to hospice patients.
The following table summarizes our overall home health and hospice statistics for the periods indicated:
Year Ended December 31,
20202019
Home health services:
Total home health admissions26,670 22,637 
Total Medicare home health admissions12,974 10,656 
Average Medicare revenue per 60-day completed episode$3,320 $3,018 
Hospice services:
Total hospice admissions8,186 6,196 
Average hospice daily census2,083 1,680 
Hospice Medicare revenue per day$166 $164 

Senior Living Services

Occupancy. The ratio of actual number of days our units are occupied during any measurement period to the number of units available for occupancy during such measurement period.
Average monthly revenue per occupied unit. The revenue for senior living services during any measurement period divided by actual occupied senior living units for such measurement period divided by the number of months for such measurement period.
The following table summarizes our senior living statistics for the periods indicated:

Year Ended December 31,
20202019
Occupancy77.7 %80.2 %
Average monthly revenue per occupied unit$3,188 $3,120 

Revenue Sources

Home Health and Hospice Services

Home Health. We derive the majority of our home health revenue from Medicare and managed care. The Medicare payment is adjusted for differences between estimated and actual payment amounts, an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. For Medicare episodes that began prior to January 1, 2020, home health agencies were reimbursed under the Medicare HH PPS, while Medicare periods of care that began on or after that date are reimbursed under the PDGM methodology. Under PDGM, Medicare provides agencies with payments for each 30-day period of care provided to beneficiaries. If a beneficiary is still eligible for care after the end of the first 30-day payment period, a second 30-day payment period can begin. There are no limits to the number of periods of care a beneficiary who remains eligible for the home health benefit can receive. While payment for each 30-day period of care is adjusted to reflect the beneficiary’s health condition and needs, a special outlier provision exists to ensure appropriate payment for those beneficiaries that have the most expensive care needs. The payment under the Medicare program is also adjusted for certain variables including, but not limited to: (a) a low utilization payment adjustment if the number of visits is below an established threshold that varies based on the diagnosis of a beneficiary; (b) a partial payment if the patient transferred
31

to another provider or the Company received a patient from another provider before completing the period of care; (c) adjustment to the admission source of claim if it is determined that the patient had a qualifying stay in a post-acute care setting within 14 days prior to the start of a 30-day payment period; (d) the timing of the 30-day payment period provided to a patient in relation to the admission date, regardless of whether the same home health provider provided care for the entire series of episodes; (e) changes to the acuity of the patient during the previous 30-day period of care; (f) changes in the base payments established by the Medicare program; (g) adjustments to the base payments for case mix and geographic wages; and (h) recoveries of overpayments.

Hospice. We derive the majority of our hospice business revenue from our hospice business from Medicare reimbursement. The estimated payment rates are calculated as daily rates for each of the levels of care we deliver. Rates are set based on specific levels of care, are adjusted by a wage index to reflect healthcare labor costs across the country and are established annually through federal legislation. The following are the four levels of care provided under the hospice benefit:

Routine Home Care (“RHC”). Care that is not classified under any of the other levels of care, such as the work of nurses, social workers or home health aides.
General Inpatient Care. Pain control or acute or chronic symptom management that cannot be managed in a setting other than an inpatient Medicare-certified facility, such as a hospital, skilled nursing facility or hospice inpatient facility.
Continuous Home Care. Care for patients experiencing a medical crisis that requires nursing services to achieve palliation and symptom control, if the agency provides a minimum of eight hours of care within a 24-hour period.
Inpatient Respite Care. Short-term, inpatient care to give temporary relief to the caregiver who regularly provides care to the patient.

CMS has established a two-tiered payment system for RHC. Hospices are reimbursed at a higher rate for RHC services provided from days of service 1 through 60 and a lower rate for all subsequent days of service. CMS also provided for a Service Intensity Add-On, which increases payments for certain RHC services provided by registered nurses and social workers to hospice patients during the final seven days of life.

Medicare reimbursement is adjusted for an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. Additionally, as Medicare hospice revenue is subject to an inpatient cap limit and an overall payment cap, we monitor our provider numbers and based upon empirical experience estimate amounts due back to Medicare to the extent that the cap has been exceeded.

Senior Living Services . As of December 31, 2020, we provided assisted living, independent living and memory care services at 54 communities. Within our senior living operations, we generate revenue primarily from private pay sources, with a portion earned from Medicaid or other state-specific programs.

Primary Components of Expense

Cost of Services (excluding rent, general and administrative expense and depreciation and amortization). Our cost of services represents the costs of operating our independent operating subsidiaries, which primarily consists of payroll and related benefits, supplies, purchased services, and ancillary expenses such as the cost of pharmacy and therapy services provided to patients or residents. Cost of services also includes the cost of general and professional liability insurance and other general cost of services specifically attributable to our operations.
 
Rent—Cost of Services. Rent—cost of services consists solely of base minimum rent amounts payable under lease agreements to our landlords. Our subsidiaries lease and operate but do not own the underlying real estate at our operations, and these amounts do not include taxes, insurance, impounds, capital reserves or other charges payable under the applicable lease agreements.

General and Administrative Expense. General and administrative expense consists primarily of payroll and related benefits and travel expenses for our Service Center personnel, including training and other operational support. General and administrative expense also includes professional fees (including accounting and legal fees), costs relating to our information systems, share-based compensation and rent for our Service Center offices.
 
Depreciation and Amortization. Property and equipment are recorded at their original historical cost. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three to 15
32

years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.
 
Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based on our consolidated and combined financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The preparation of these financial statements and related disclosures requires us to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. On an ongoing basis we review our judgments and estimates, including but not limited to those related to revenue, cost allocations, leases, intangible assets, goodwill, and income taxes. We base our estimates and judgments upon our historical experience, knowledge of current conditions and our belief of what could occur in the future considering available information, including assumptions that we believe to be reasonable under the circumstances. By their nature, these estimates and judgments are subject to an inherent degree of uncertainty, and actual results could differ materially from the amounts reported. While we believe that our estimates, assumptions, and judgments are reasonable, they are based on information available when the estimate was made. Refer to Note 2, Basis of Presentation and Summary of Significant Accounting Policies, within the Consolidated and Combined Financial Statements for further information on our critical accounting estimates and policies, which are as follows:

Revenue recognition - The amounts owed by private pay individuals for services and estimate of variable considerations to arrive at the transaction price, including methods and assumptions used to determine settlements with Medicare and Medicaid adjustments due to audits and reviews;
Cost allocation - The Consolidated and Combined Financial Statements include allocations of costs for certain shared services provided to the Company by Ensign subsidiaries prior to the spin-off on October 1, 2019. These costs were allocated to the Company on a basis of revenue, location, employee count, or other measures;
Leases - We use our estimated incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments;
Acquisition accounting - The assumptions used to allocate the purchase price paid for assets acquired and liabilities assumed in connection with our acquisitions;
Self-insurance reserves - The valuation methods and assumptions used in estimating costs to settle open claims of insureds, as well as an estimate of the cost of insured claims up to retention amounts that have been incurred but not reported; and
Income taxes - The estimation of valuation allowance or the need for and magnitude of liabilities for uncertain tax position.

Recent Accounting Pronouncements

    Information concerning recently issued accounting pronouncements which are not yet effective is included in Note 2, Basis of Presentation and Summary of Significant Accounting Policies in the Consolidated and Combined Financial Statements. As of December 31, 2020, there were no recently issued accounting pronouncements that were expected to have an impact on the Company.

33

Results of Operations

The following table sets forth details of our expenses and earnings as a percentage of total revenue for the periods indicated:

Year Ended December 31,
202020192018
Total revenue100.0 %100.0 %100.0 %
Expense:
Cost of services75.9 76.5 74.3 
Rent—cost of services10.1 10.3 10.9 
General and administrative expense8.0 10.4 6.6 
Depreciation and amortization1.2 1.1 1.0 
Total expenses95.2 98.3 92.8 
Income from operations4.8 1.7 7.2 
Other income (expense):
Other income0.1 — — 
Interest expense, net(0.3)(0.1)— 
Other income (expense), net(0.2)(0.1)— 
Income before provision for income taxes4.6 1.6 7.2 
Provision for income taxes0.6 0.6 1.5 
Net income4.0 1.0 5.7 
Less: net income/ (loss) attributable to noncontrolling interest(a)
— 0.2 0.2 
Net income attributable to Pennant4.0 %0.8 %5.5 %

(a)
Net loss attributable to noncontrolling interest for the year ended December 31, 2020 was less than .1% and thus not meaningful as a percentage of total revenue.

Year Ended December 31,
202020192018
(In thousands)
Consolidated and Combined GAAP Financial Measures:
Total revenue$390,953 $338,531 $286,058 
Total expenses$372,036 $332,861 $265,427 
Income from operations$18,917 $5,670 $20,631 

34

The following table presents certain financial information regarding our reportable segments. General and administrative expenses are not allocated to the reportable segments and are included in “All Other”:

Home Health and Hospice ServicesSenior Living ServicesAll OtherTotal
(In thousands)
Segment GAAP Financial Measures:
Year Ended December 31, 2020
Revenue$253,659 $137,294 $— $390,953 
Segment Adjusted EBITDAR from Operations$49,501 $48,309 $(22,762)$75,048 
Year Ended December 31, 2019
Revenue$206,624 $131,907 $— $338,531 
Segment Adjusted EBITDAR from Operations$33,354 $47,344 $(18,591)$62,107 
Year Ended December 31, 2018
Revenue$169,037 $117,021 $— $286,058 
Segment Adjusted EBITDAR from Operations$26,427 $47,230 $(16,191)$57,466 

The table below provides a reconciliation of Segment Adjusted EBITDAR from Operations above to income from operations:
Year Ended December 31,
202020192018
(In thousands)
Segment Adjusted EBITDAR from Operations(a)
$75,048 $62,107 $57,466 
Less: Depreciation and amortization4,675 3,810 2,964 
Rent—cost of services39,191 34,975 31,199 
Other income225 — — 
Adjustments to Segment EBITDAR from Operations:
Less: Costs at start-up operations(b)
1,787 483 129 
Share-based compensation expense(c)
8,335 3,382 2,382 
Acquisition related costs(d)
99 665 — 
Spin-Off related transaction costs(e)
— 13,219 756 
Transition services costs(f)
1,181 532 — 
COVID-19 related costs and supplies(g)
447  — 
Add: Net income/ (loss) attributable to noncontrolling interest(191)629 595 
Income from operations$18,917 $5,670 $20,631 

(a)
Segment Adjusted EBITDAR from Operations is net income/ (loss) attributable to the Company's reportable segments excluding interest expense, provision for income taxes, depreciation and amortization expense, rent, and, in order to view the operations performance on a comparable basis from period to period, certain adjustments including: (1) costs at start-up operations, (2) share-based compensation, (3) acquisition related costs, (4) Spin-Off transaction costs, (5) redundant and nonrecurring costs associated with the transition services agreement, (6) net income/ (loss) attributable to noncontrolling interest, and (7) net COVID-19 related costs. General and administrative expenses are not allocated to the reportable segments, and are included as “All Other”, accordingly the segment earnings measure reported is before allocation of corporate general and administrative expenses. The Company's segment measures may be different from the calculation methods used by other companies and, therefore, comparability may be limited.
(b)Represents results related to start-up operations. This amount excludes rent and depreciation and amortization expense related to such operations.
(c)Share-based compensation expense incurred which is included in cost of services and general and administrative expense.
(d)Acquisition related costs that are not capitalizable.
(e)Costs incurred related to the Spin-Off are included in general and administrative expense.
(f)A portion of the costs incurred under the Transition Services Agreement (as defined in Note 3, Related Party Transactions and Net Parent Investment) identified as redundant or nonrecurring that are included in general and administrative expense. Transition service costs includes $446 of duplicative software expense for the year ended December 31, 2020, of which $333 pertains to the first three quarters of the fiscal year and were not included as adjustments in previous interim periods. Fees incurred under the Transition Services agreement, net of the Company’s payroll reimbursement, were $5,536, $2,982, and zero for the years ended December 31, 2020, 2019 and 2018, respectively.
(g)Represents incremental costs incurred as part of the Company's response to COVID-19 including direct medical supplies, labor, and other expenses, net of $2,765 in increased revenue related to the 2% payment increase in Medicare reimbursements for sequestration relief for the year ended December 31, 2020.
35


Performance and Valuation Measures:

Year Ended December 31,
202020192018
(In thousands)
Consolidated and Combined Non-GAAP Financial Measures:
Performance Metrics
Consolidated and Combined EBITDA$24,008 $8,851 $23,000 
Consolidated and Combined Adjusted EBITDA$36,080 $27,157 $26,927 
Valuation Metric
Consolidated and Combined Adjusted EBITDAR$75,048 

Year Ended December 31,
202020192018
(In thousands)
Segment Non-GAAP Measures:(a)
Segment Adjusted EBITDA from Operations
Home health and hospice services$46,015 $30,415 $24,716 
Senior living services$12,827 $15,333 $18,312 

(a)
General and administrative expenses are not allocated to any segment for purposes of determining segment profit or loss.

The table below reconciles Consolidated and Combined Net Income to Consolidated and Combined EBITDA, Consolidated and Combined Adjusted EBITDA and Consolidated and Combined Adjusted EBITDAR for the periods presented:
Year Ended December 31,
202020192018
(In thousands)
Consolidated and Combined Net income$15,553 $3,175 $16,279 
Less: Net income/ (loss) attributable to noncontrolling interest(191)629 595 
Add: Provision for income taxes (benefit)2,350 2,085 4,352 
Net interest expense1,239 410 — 
Depreciation and amortization4,675 3,810 2,964 
Consolidated and Combined EBITDA24,008 8,851 23,000 
Adjustments to Consolidated and Combined EBITDA
Add: Costs at start-up operations(a)
1,787 483 129 
Share-based compensation expense(b)
8,335 3,382 2,382 
Acquisition related costs(c)
99 665 — 
Spin-Off related transaction costs(d)
— 13,219 756 
Transition services costs(e)
1,181 532 — 
Net COVID-19 related costs(f)
447 — — 
Rent related to items (a) above223 25 30 
Consolidated and Combined Adjusted EBITDA36,080 27,157 26,297 
Rent—cost of services39,191 34,975 31,199 
Rent related to items (a) above(223)(25)(30)
Adjusted rent—cost of services38,968 34,950 31,169 
Consolidated and Combined Adjusted EBITDAR$75,048 

36

(a)Represents results related to start-up operations. This amount excludes rent and depreciation and amortization expense related to such operations.
(b)Share-based compensation expense incurred which is included in cost of services and general and administrative expense.
(c)Acquisition related costs that are not capitalizable.
(d)Costs incurred related to the Spin-Off are included in general and administrative expense.
(e)A portion of the costs incurred under the Transition Services Agreement (as defined in Note 3, Related Party Transactions and Net Parent Investment) identified as redundant or nonrecurring that are included in general and administrative expense. Transition service costs includes $446 of duplicative software expense for the year ended December 31, 2020, of which $333 pertains to the first three quarters of the fiscal year and were not included as adjustments in previous interim periods. Fees incurred under the Transition Services agreement, net of the Company’s payroll reimbursement, were $5,536, $2,982, and zero for the years ended December 31, 2020, 2019 and 2018, respectively.
(f)Represents incremental costs incurred as part of the Company's response to COVID-19 including direct medical supplies, labor, and other expenses, net of $2,765 in increased revenue related to the 2% payment increase in Medicare reimbursements for sequestration relief for the year ended December 31, 2020.

The table below reconciles Segment Adjusted EBITDAR from Operations to Segment Adjusted EBITDA from Operations for the periods presented:
Year Ended December 31,
Home Health and HospiceSenior Living
202020192018202020192018
(In thousands)
Segment Adjusted EBITDAR from Operations$49,501 $33,354 $26,427 $48,309 $47,344 $47,230 
Less: Rent—cost of services3,629 2,964 2,281 35,562 32,011 28,918 
Rent related to start-up operations(143)(25)(30)(80)— — 
Segment Adjusted EBITDA from Operations$46,015 $30,415 $24,176 $12,827 $15,333 $18,312 

The following discussion includes references to certain performance and valuation measures, which are non-GAAP financial measures, including Consolidated and Combined EBITDA, Consolidated and Combined Adjusted EBITDA, Segment Adjusted EBITDA from Operations, and Consolidated Adjusted EBITDAR (collectively, “Non-GAAP Financial Measures”). Non-GAAP Financial Measures are used in addition to, and in conjunction with, results presented in accordance with GAAP and should not be relied upon to the exclusion of GAAP financial measures. Non-GAAP Financial Measures reflect an additional way of viewing aspects of our operations and company that, when viewed with our GAAP results and the accompanying reconciliations to corresponding GAAP financial measures, we believe can provide a more comprehensive understanding of factors and trends affecting our business.

We believe these Non-GAAP Financial Measures are useful to investors and other external users of our financial statements regarding our results of operations because:

they are widely used by investors and analysts in our industry as a supplemental measure to evaluate the overall performance of companies in our industry without regard to items such as interest expense, rent expense and depreciation and amortization, which can vary substantially from company to company depending on the book value of assets, the method by which assets were acquired, and differences in capital structures;
they help investors evaluate and compare the results of our operations from period to period by removing the impact of our asset base and capital structure from our operating results; and
Consolidated and Combined Adjusted EBITDAR is used by investors and analysts in our industry to value the companies in our industry without regard to capital structures.

We use Non-GAAP Financial Measures:

as measurements of our operating performance to assist us in comparing our operating performance on a consistent basis from period to period;
to allocate resources to enhance the financial performance of our business;
to assess the value of a potential acquisition;
to assess the value of a transformed operation’s performance;
to evaluate the effectiveness of our operational strategies; and
to compare our operating performance to that of our competitors.
37


We typically use Non-GAAP Financial Measures to compare the operating performance of each operation from period to period. We find that Non-GAAP Financial Measures are useful for this purpose because they do not include such costs as interest expense, income taxes, depreciation and amortization expense, which may vary from period-to-period depending upon various factors, including the method used to finance operations, the date of acquisition of a community or business, and the tax law of the state in which a business unit operates.

We also establish compensation programs and bonuses for our leaders that are partially based upon the achievement of Consolidated and Combined Adjusted EBITDAR targets.

Non-GAAP Financial Measures have no standardized meaning defined by GAAP. Therefore, our Non-GAAP Financial Measures have limitations as analytical tools, and they should not be considered in isolation, or as a substitute for analysis of our results as reported in accordance with GAAP. Some of these limitations are:

they do not reflect our current or future cash requirements for capital expenditures or contractual commitments;
they do not reflect changes in, or cash requirements for, our working capital needs;
they do not reflect the net interest expense, or the cash requirements necessary to service interest or principal payments, on our debt;
in the case of Consolidated and Combined Adjusted EBITDAR, it does not reflect rent expenses, which are normal and recurring operating expenses that are necessary to operate our leased operations;
they do not reflect any income tax payments we may be required to make;
although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and these non-cash charges do not reflect any cash requirements for such replacements; and
other companies in our industry may calculate the same Non-GAAP Financial Measures differently than we do, which may limit their usefulness as comparative measures.

We compensate for these limitations by using Non-GAAP Financial Measures only to supplement net income on a basis prepared in accordance with GAAP in order to provide a more complete understanding of the factors and trends affecting our business.

We strongly encourage investors to review our Consolidated and Combined Financial Statements, included in this report in their entirety and to not rely on any single financial measure. Because these Non-GAAP Financial Measures are not standardized, it may not be possible to compare these financial measures with other companies’ Non-GAAP financial measures having the same or similar names. These Non-GAAP Financial Measures should not be considered a substitute for, nor superior to, financial results and measures determined or calculated in accordance with GAAP. We strongly urge you to review the reconciliation of income from operations to the Non-GAAP Financial Measures in the table presented above, along with our Financial Statements and related notes included elsewhere in this report.

We believe the following Non-GAAP Financial Measures are useful to investors as key operating performance measures and valuation measures:

Performance Measures:

Consolidated and Combined EBITDA

We believe Consolidated and Combined EBITDA is useful to investors in evaluating our operating performance because it helps investors evaluate and compare the results of our operations from period to period by removing the impact of our asset base (depreciation and amortization expense) from our operating results.

We calculate Consolidated and Combined EBITDA as net income, adjusted for net income/ (loss) attributable to noncontrolling interest prior to the Spin-Off, before (a) interest expense (b) provision for income taxes and (c) depreciation and amortization.

Consolidated and Combined Adjusted EBITDA

We adjust Consolidated and Combined EBITDA when evaluating our performance because we believe that the exclusion of certain additional items described below provides useful supplemental information to investors regarding our
38

ongoing operating performance. We believe that the presentation of Consolidated and Combined Adjusted EBITDA, when considered with Consolidated and Combined EBITDA and GAAP net income is beneficial to an investor’s complete understanding of our operating performance. 

We calculate Consolidated and Combined Adjusted EBITDA by adjusting Consolidated and Combined EBITDA to exclude the effects of non-core business items, which for the reported periods includes, to the extent applicable:

costs at start-up operations;
share-based compensation expense;
acquisition related costs;
Spin-Off related transaction costs;
redundant or nonrecurring costs incurred as part of the Transition Services Agreement (as defined in Note 3, Related Party Transactions and Net Parent Investment); and
COVID-19 related costs and supplies.

Segment Adjusted EBITDA from Operations

We calculate Segment Adjusted EBITDA from Operations by adjusting Segment Adjusted EBITDAR from Operations to include rent-cost of services. We believe that the inclusion of rent-cost of services provides useful supplemental information to investors regarding our ongoing operating performance for each segment.

Valuation Measure:

Consolidated and Combined Adjusted EBITDAR

We use Consolidated and Combined Adjusted EBITDAR as one measure in determining the value of prospective acquisitions. It is also a measure commonly used by us, research analysts and investors to compare the enterprise value of different companies in the healthcare industry, without regard to differences in capital structures. Additionally, we believe the use of Consolidated and Combined Adjusted EBITDAR allows us, research analysts and investors to compare operational results of companies with operating and finance leases. A significant portion of finance lease expenditures are recorded in interest, whereas operating lease expenditures are recorded in rent expense.

This measure is not displayed as a performance measure as it excludes rent expense, which is a normal and recurring operating expense and, as such, does not reflect our cash requirements for leasing commitments. Our presentation of Consolidated and Combined Adjusted EBITDAR should not be construed as a financial performance measure.

The adjustments made and previously described in the computation of Consolidated and Combined Adjusted EBITDA are also made when computing Consolidated and Combined Adjusted EBITDAR. We calculate Consolidated and Combined Adjusted EBITDAR by excluding rent-cost of services and rent related to start up operations from Consolidated and Combined Adjusted EBITDA.

39

Year Ended December 31, 2020 Compared to the Year Ended December 31, 2019
Revenue
Year Ended December 31,
20202019
Revenue DollarsRevenue PercentageRevenue DollarsRevenue Percentage
(In thousands)
Home health and hospice services
Home health$98,267 25.1 %$83,330 24.6 %
Hospice134,075 34.3 105,682 31.2 
Home care and other(a)
21,317 5.5 17,612 5.2 
Total home health and hospice services253,659 64.9 206,624 61.0 
Senior living services137,294 35.1 131,907 39.0 
Total revenue$390,953 100.0 %$338,531 100.0 %

(a)
Home care and other revenue is included with home health revenue in other disclosures in this report.

Our consolidated and combined revenue increased $52.4 million, or 15.5% driven by organic growth of existing operations of $33.2 million or 9.8% as well as increased revenue from acquired operations of $19.2 million or 5.7% during the year ended December 31, 2020.

Home Health and Hospice Services
Year Ended December 31,
20202019Change% Change
(In thousands)
Home health and hospice revenue
Home health services$98,267 $83,330 $14,937 17.9 %
Hospice services134,075 105,682 28,393 26.9 
Home care and other21,317 17,612 3,705 21.0 
Total home health and hospice revenue$253,659 $206,624 $47,035 22.8 %
Year Ended December 31,
20202019Change% Change
Home health services:
Total home health admissions26,670 22,637 4,033 17.8 %
Total Medicare home health admissions12,974 10,656 2,318 21.8 
Average Medicare revenue per 60-day completed episode$3,320 $3,018 $302 10.0 
Hospice services:
Total hospice admissions8,186 6,196 1,990 32.1 
Average daily census2,083 1,680 403 24.0 
Hospice Medicare revenue per day$166 $164 $1.2 
Number of home health and hospice agencies at period end76 63 13 20.6 %

Home health and hospice revenue increased $47.0 million, or 22.8%. Revenue grew due to an increase in all key performance indicators including an increase in total home health admissions of 17.8%, including an increase in Medicare home health admissions of 21.8%, an increase in average Medicare revenue per 60-day completed episode of 10.0%, an increase of 32.1% in total hospice admissions, and an increase of 24.0% in hospice average daily census. Growth was partially driven by the acquisition of 12 home health, hospice and home care operations between December 31, 2019 and December 31, 2020,
40

resulting in an increase of $17.2 million or 8.3% overall, as well as additional revenue of $2.8 million due to the sequestration suspension in the current year.

Senior Living Services
Year Ended December 31,
20202019Change% Change
Revenue (in thousands)$137,294 $131,907 $5,387 4.1 %
Number of communities at period end54 52 3.8 %
Occupancy77.7 %80.2 %(2.5)%
Average monthly revenue per occupied unit$3,188 $3,120 $68 2.2 %

Senior living revenue increased $5.4 million, or 4.1%, for the year ended December 31, 2020 when compared to the same period in the prior year due to an increase in average monthly revenue per occupied unit and an increase of $2.0 million or 1.5% in revenue from the addition of two senior living communities between December 31, 2019 and December 31, 2020.

Cost of Services

The following table sets forth total cost of services by each of our reportable segments for the periods indicated:
Year Ended December 31,
20202019Change% Change
(In thousands)
Home Health and Hospice$206,094 $174,037 $32,057 18.4 %
Senior Living90,780 84,904 5,876 6.9 
Total cost of services$296,874 $258,941 $37,933 14.6 %

Consolidated and Combined cost of services increased $37.9 million or 14.6%. The increase in cost of services was driven by the increase in revenue, new acquisitions in the current year, and additional costs related to the COVID-19 pandemic. Cost of services as a percentage of revenue decreased by 0.6% from 76.5% to 75.9% for the year ended December 31, 2020 as the increase in revenue outpaced the increase in costs.

Home Health and Hospice Services
Year Ended December 31,
20202019Change% Change
(In thousands)
Cost of service $206,094 $174,037 $32,057 18.4 %
Cost of services as a percentage of revenue81.2 %84.2 %(3.0)%

Cost of services related to our home health and hospice services segment increased $32.1 million, or 18.4%, primarily due to increased volume of services provided. Cost of services as a percentage of revenue for the year ended December 31, 2020 decreased 3.0% compared to the year ended December 31, 2019, from focusing on managing labor and services and additional revenue due to the sequestration suspension in the current year.

41

Senior Living Services

Year Ended December 31,
20202019Change% Change
(In thousands)
Cost of service $90,780 $84,904 $5,876 6.9 %
Cost of services as a percentage of revenue66.1 %64.4 %1.7 %

Cost of services related to our senior living services segment increased $5.9 million, or 6.9%. As a percentage of revenue, costs of service increased by 1.7% as a result of a decrease in occupancy and COVID-19 related costs.

Rent—Cost of Services. Actual rent increased from $35.0 million in the year ended December 31, 2019 to $39.2 million in the year ended December 31, 2020, primarily as a result of a full year of expense for leases modified in the fourth quarter of 2019 in connection with the Spin-Off. Rent as a percentage of total revenue decreased from 10.3% to 10.1% in the year ended December 31, 2020, as the growth in revenue outpaced the increase in rent expense.

General and Administrative Expense. Our general and administrative expense decreased by $3.8 million from $35.1 million to $31.3 million and as a percent of revenue from 10.4% to 8.0%. The primary driver for the decrease in general and administrative costs was due to the no transaction costs related to the Spin-Off. The reduction of $13.2 million in transaction related costs were partially offset by $8.3 million in share-based compensation in the current year.

Depreciation and Amortization. Depreciation and amortization expense remained relatively flat as a percentage of total revenue.

Provision for Income Taxes. Our effective tax rate for the year ended December 31, 2020 was 13.1% of earnings before income taxes. Our effective tax rate decreased from our statutory tax rate by approximately 10.6 percentage points, which was driven by an excess tax benefit from share-based compensation of 10.8 percentage points offset by approximately 0.4 percentage points of non-deductible expenses. Our effective tax rate for the year ended December 31, 2019 was 39.6% of earnings before income taxes. As of the completion of the Spin-Off, approximately $10.3 million of transaction costs became nondeductible, having a one-time impact of increasing our effective tax rate. This was offset by a decrease to our effective tax rate resulting from a tax benefit of share-based compensation. See Note 14, Income Taxes, to the Consolidated and Combined Financial Statements included elsewhere in this report filed on Form 10-K for further discussion.

Comparison of Prior Year Information

For a comparison of our results of operations of the fiscal year ended December 31, 2019 as compared to the year ended December 31, 2018 refer to Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operation on Form 10-K filed with the SEC on March 4, 2020.

Liquidity and Capital Resources

Our primary sources of liquidity are net cash provided by operating activities, including advance payments under the CARES Act, and borrowings under our revolving credit facility.

Revolving Credit Facility    

On October 1, 2019, Pennant entered into a credit agreement (the “Credit Agreement”), which provided for a revolving credit facility with a syndicate of banks with a borrowing capacity of $75.0 million.

Amended Credit Facility

On February 23, 2021, Pennant entered into an amendment to the Credit Agreement (the “Amended Credit Agreement”), which provides for an increased revolving credit facility with a syndicate of banks with a borrowing capacity of $150.0 million (the “Revolving Credit Facility”). The Revolving Credit Facility is not subject to interim amortization and the Company will not be required to repay any loans under the Revolving Credit Facility prior to maturity in 2026. The Company is permitted to prepay all or any portion of the loans under the Revolving Credit Facility prior to maturity without premium or penalty, subject to reimbursement of any LIBOR breakage costs of the lenders.

42

The Amended Credit Agreement contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its independent operating subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend certain material agreements and pay certain dividends and other restricted payments. Financial covenants require compliance with certain levels of leverage ratios that impact the amount of interest. As of December 31, 2020, the Company was in compliance with all covenants.

The CARES Act and COVID-19 Capital Considerations

The CARES Act expanded CMS’s ability to provide accelerated/advance payments intended to increase the cash flow of healthcare providers and suppliers impacted by COVID-19. During the year, the Company applied for and received $28.0 million as an advance payment. These funds are subject to automatic recoupment through offsets to new claims beginning one year after payments were issued beginning in April 2021, at which time, Medicare will automatically recoup 25 percent of Medicare payments for 11 months. At the end of the 11 months and assuming full repayment has not occurred, recoupment will increase to 50 percent for another six months. Any balance outstanding after these two recoupment periods will be subject to repayment at a four percent interest rate. We anticipate completing repayment of the AAP within the allotted recoupment periods. The CARES Act also temporarily suspends the 2% sequestration payment adjustment on Medicare fee-for-service payment, meaning a 2% payment increase on Medicare claims with dates of service from May 1, 2020 through December 31, 2020. Through December 31, 2020, we have earned $2.8 million due to the suspension of the sequestration adjustment. Further, the CARES Act allows for the deferral of FICA taxes owed from March - December 31, 2020 with 50% payment due on December 31, 2021 and the remainder due on December 31, 2022. As of December 31, 2020 we deferred $8.4 million, with $4.2 million in other long-term liabilities.

In addition to relief provided by the CARES Act and other legislative and regulatory assistance, we have implemented cost control measures such as reduced spending, non-essential supplies, travel costs and all other discretionary items, and we have delayed non-essential capital expenditure projects. The continued impact of COVID-19 on our liquidity and financial resources is uncertain. We are monitoring the ongoing impact of these actions to our revenue and expenses. The extent to which COVID-19 impacts our operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak, new information that may emerge concerning the severity of the coronavirus and the actions taken to contain the coronavirus or treat its impact, among others.

We believe that our existing cash, cash generated through operations and our access to financing facilities, together with funding through third-party sources such as commercial banks, will be sufficient to fund our operating activities and growth needs, and provide adequate liquidity for the next twelve months.

The following table presents selected data from our combined statement of cash flows for the periods presented:
Year Ended December 31,
20202019
(In thousands)
Net cash provided by operating activities$50,204 $9,554 
Net cash used in investing activities(41,616)(26,465)
Net cash (used in)/ provided by financing activities(8,947)17,272 
Net change in cash(359)361 
Cash at beginning of year402 41 
Cash at end of year$43 $402 

Year Ended December 31, 2020 Compared to the Year Ended December 31, 2019
    
Our net cash provided by operating activities for the year ended December 31, 2020 increased by $40.7 million. The increase was primarily due to an increase in net income of $12.4 million and the receipt of $28.0 million related to Advance Payments received from the CARES Act.

Our net cash used in investing activities for the year ended December 31, 2020 increased by $15.2 million compared to the year ended December 31, 2019. This use of cash is primarily attributable to an increase in acquisitions of $14.4 million and an increase in capital expenditures of $0.5 million in support of establishing post Spin-Off stand-alone systems.

43

    Our net cash used in financing activities decreased by approximately $26.2 million for the year ended December 31, 2020 when compared to the year ended December 31, 2019 primarily due to an increase in payments on our revolving credit facility in the current year, offset by net cash proceeds from our revolving credit facility in the prior year.

Contractual Obligations, Commitments and Contingencies

20212022202320242025ThereafterTotal
(In thousands)
Operating lease obligation(a)
$38,393 $37,730 $37,038 $36,230 $35,349 $356,838 $541,578 
Long-term debt(b)
— — — 9,500 — — 9,500 
Interest payments on long-term debt(c)
935 935 935 702 — — 3,507 
Total$39,328 $38,665 $37,973 $46,432 $35,349 $356,838 $554,585 

(a)
Lease amounts include minimum rental payments under our non-cancelable operating leases. The amounts presented are consistent with contractual terms and are not expected to differ significantly from actual results under our existing leases. In connection with the Spin-Off, we amended our master lease agreements with Ensign and certain other landlords.
(b)Assumes all long-term debt under the current credit facility is outstanding until scheduled maturity in 2024. Under the Amended Credit Facility the Company will not be required to repay any loans prior to maturity in 2026.
(c)
Interest payments on long-term debt are projected for future periods using the outstanding long-term debt and the interest rates in effect as of December 31, 2020. Interest payments may differ in the future based on changes in market interest rates and borrowings.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

Interest Rate Risk. We are exposed to risks associated with market changes in interest rates. Our Revolving Credit Facility exposes us to variability in interest payments due to changes in LIBOR. A 1.0% interest rate change would cause interest expense to change by approximately $0.1 million annually based upon our outstanding long-term debt as of December 31, 2020. We manage our exposure to this market risk by monitoring available financing alternatives.

LIBOR Phase-Out. LIBOR is currently expected to be phased out in 2021. We are required to pay interest on borrowings under our Credit Facility at floating rates based on LIBOR. Future debt that we may incur may also require that we pay interest based upon LIBOR. We currently expect that the determination of interest under our credit agreement would be revised as provided under the agreement or amended as necessary to provide for an interest rate that approximates the existing interest rate as calculated in accordance with LIBOR for similar types of loans. Despite our current expectations, we cannot be sure that, if LIBOR is phased out or transitioned, the changes to the determination of interest under our agreement would approximate the current calculation in accordance with LIBOR. We do not know what standard, if any, will replace LIBOR if it is phased out or transitioned.

Item 8.    Financial Statements and Supplementary Data

The consolidated and combined financial statements and accompanying notes listed in Part IV, Item 15(a)(1) of this Annual Report on Form 10-K are included elsewhere in this report.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

None.

Item 9A. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that these disclosure controls and procedures were effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management,
44

including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Management’s Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Management conducted an assessment of the effectiveness of our internal control over financial reporting as of December 31, 2020 based on the criteria set forth in “Internal Control-Integrated Framework” (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on this assessment, management has concluded that our internal control over financial reporting was effective as of December 31, 2020 based on those criteria.

This annual report on Form 10-K does not include an attestation report of our registered public accounting firm due to our Emerging Growth Company (“EGC”) status and exemption from the auditor attestation requirement of Section 404(b) of the Sarbanes-Oxley Act.

Changes in Internal Control over Financial Reporting

During the fiscal quarter ended December 31, 2020, there were no material changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Item 9B. Other Information

None.

Part III.

Item 10.     Directors, Executive Officers and Corporate Governance

The information required by this Item is hereby incorporated by reference to our definitive proxy statement on Form 14A for the 2021 Annual Meeting of Stockholders.

Item 11. Executive Compensation

The information required by this Item is hereby incorporated by reference to our definitive proxy statement on Form 14A for the 2021 Annual Meeting of Stockholders.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholders

The information required by this Item is hereby incorporated by reference to our definitive proxy statement on Form 14A for the 2021 Annual Meeting of Stockholders.

Item 13.     Certain Relationships and Related Transactions and Director Independence

The information required by this Item is hereby incorporated by reference to our definitive proxy statement on Form 14A for the 2021 Annual Meeting of Stockholders.

Item 14.     Principal Accountant Fees and Services

The information required by this Item is hereby incorporated by reference to our definitive proxy statement on Form 14A for the 2021 Annual Meeting of Stockholders.

45

Part IV.

Item 15. Exhibits, Financial Statements and Schedules

The following documents are filed as a part of this report:
 
(a)(1) Financial Statements:

The following Consolidated and Combined Financial Statements of the Company are included in Part II, Item 8 of this Annual Report on Form 10-K.

Report of Independent Registered Public Accounting Firm
Consolidated Balance Sheets as of December 31, 2020 and 2019
Consolidated and Combined Statements of Income for the Years Ended December 31, 2020, 2019 and 2018
Consolidated and Combined Statements of Changes in Shareholders' Equity and Net Parent Investment for the Three Years Ended December 31, 2020, 2019 and 2018
Consolidated and Combined Statements of Cash Flows for the Years Ended December 31, 2020, 2019 and 2018
Notes to the Consolidated and Combined Financial Statements

(a)(2) Financial Statement Schedules:

There are no financial schedules included in this Report as they are either not applicable or included in the financial statements.
 
(a) (3) Exhibits:  The following exhibits are filed with this Report or incorporated by reference:

Exhibits
Exhibit No.Exhibit Description
Master Separation Agreement, dated as of October 1, 2019, by and between The Ensign Group, Inc. and The Pennant Group, Inc. (incorporated by reference to Exhibit 2.1 to The Pennant Group, Inc.’s Current Report on Form 8-K (File No. 001-38900) filed with the SEC on October 3, 2019).
Amended and Restated Certificate of Incorporation of The Pennant Group, Inc., effective as of September 27, 2019 (incorporated by reference to Exhibit 3.1 to The Pennant Group, Inc.’s Current Report on Form 8-K (File No. 001-38900) filed with the SEC on October 3, 2019).
Amended and Restated By-laws of The Pennant Group, Inc. (incorporated by reference to Exhibit 3.2 to The Pennant Group, Inc.’s Current Report on Form 8-K (File No. 001-38900) filed with the SEC on October 3, 2019).
Description of Securities of The Pennant Group, Inc. (incorporated by reference to Exhibit 4.1 to The Pennant Group, Inc.’s Annual Report on Form 10-K (File No. 001-389000) filed with the SEC on March 4, 2020).
Transition Services Agreement, dated as of October 1, 2019, by and between The Ensign Group, Inc. and The Pennant Group, Inc. (incorporated by reference to Exhibit 10.1 to The Pennant Group, Inc.’s Current Report on Form 8-K (File No. 001-38900) filed with the SEC on October 3, 2019).
Tax Matters Agreement, dated as of October 1, 2019, by and between The Ensign Group, Inc. and The Pennant Group, Inc. (incorporated by reference to Exhibit 10.2 to The Pennant Group, Inc.’s Current Report on Form 8-K (File No. 001-38900) filed with the SEC on October 3, 2019).
Employee Matters Agreement, dated as of October 1, 2019, by and between The Ensign Group, Inc. and The Pennant Group, Inc. (incorporated by reference to Exhibit 10.3 to The Pennant Group, Inc.’s Current Report on Form 8-K (File No. 001-38900) filed with the SEC on October 3, 2019).
Form of Lease Agreement by and among subsidiaries of The Ensign Group, Inc. and subsidiaries of The Pennant Group, Inc. (incorporated by reference to Exhibit 10.4 to The Pennant Group, Inc.’s Amendment No. 2 to the Registration Statement on Form 10 (File No. 001-38900) filed with the SEC on August 19, 2019).
46

The Pennant Group, Inc. 2019 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.12 to The Pennant Group, Inc.’s Current Report on Form 8-K (File No. 001-38900) filed with the SEC on October 3, 2019).
Form of Options Granted Under The Pennant Group, Inc. 2019 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.6 to The Pennant Group, Inc.’s Amendment No. 2 to the Registration Statement on Form 10 (File No. 001-38900) filed with the SEC on August 19, 2019).
Form of RSUs Granted Under The Pennant Group, Inc. 2019 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.7 to The Pennant Group, Inc.’s Amendment No. 2 to the Registration Statement on Form 10 (File No. 001-38900) filed with the SEC on August 19, 2019).
Form of RS Granted Under The Pennant Group, Inc. 2019 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.8 to The Pennant Group, Inc.’s Amendment No. 2 to the Registration Statement on Form 10 (File No. 001-38900) filed with the SEC on August 19, 2019).
The Pennant Group, Inc. 2019 Long Term Incentive Plan (incorporated by reference to Exhibit 10.11 to The Pennant Group, Inc.’s Current Report on Form 8-K (File No. 001-38900) filed with the SEC on October 3, 2019).
Form of LTIP RS Granted Under The Pennant Group, Inc. 2019 Long Term Incentive Plan (incorporated by reference to Exhibit 10.10 to The Pennant Group, Inc.’s Amendment No. 2 to the Registration Statement on Form 10 (File No. 001-38900) filed with the SEC on August 19, 2019).
Form of Indemnification Agreement to be entered into between The Pennant Group, Inc. and each of its directors and executive officers (incorporated by reference to Exhibit 10.11 to The Pennant Group, Inc.’s Amendment No. 2 to the Registration Statement on Form 10 (File No. 001-38900) filed with the SEC on August 19, 2019).
Credit Agreement, dated February 23, 2021, by and among the Company and certain of its subsidiaries, the lenders named therein, and Truist Bank (successor by merger to SunTrust Bank), as administrative agent for the lenders (incorporated by reference to Exhibit 10.1 to The Pennant Group, Inc.’s Current Report on Form 8-K (File No. 001-38900) filed with the SEC on February 24, 2021).
Cornerstone Healthcare, Inc. 2016 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.13 to The Pennant Group, Inc.’s Amendment No. 3 to the Registration Statement on Form 10 (File No. 001-38900) filed with the SEC on September 3, 2019).
The Ensign Group, Inc. 2017 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.14 to The Pennant Group, Inc.’s Amendment No. 3 to the Registration Statement on Form 10 (File No. 001-38900) filed with the SEC on September 3, 2019).
Subsidiaries of The Pennant Group, Inc.
Consent of Deloitte & Touche LLP.
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
Certification of Chief Financial Officer pursuant 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH*Inline XBRL Taxonomy Extension Schema Document.
101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104*Cover Page Interactive Data File – the cover page XBRL tags are embedded within the Inline XBRL document.
47

* Filed with this report.
** Furnished with this report.
+ Exhibit constitutes a management contract or compensatory plan or agreement.
# Schedules omitted pursuant to Item 601(b)(2) of Regulation S-K. The Pennant Group Inc. agrees to furnish a supplemental copy of any omitted schedule to the SEC upon request.

Item 16.     Form 10-K Summary

Not applicable.
48

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 The Pennant Group, Inc.
Dated: February 24, 2021
BY: /s/ JENNIFER L. FREEMAN  
  Jennifer L. Freeman
  Chief Financial Officer (Principal Financial Officer, Principal Accounting Officer and Duly Authorized Officer)




Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.


SignatureTitleDate
/s/ DANIEL H WALKERChairman and Chief Executive Officer (Principal Executive Officer)February 24, 2021
Daniel H Walker
/s/ JENNIFER L. FREEMANChief Financial Officer (Principal Financial Officer, Principal Accounting Officer and Duly Authorized Officer)February 24, 2021
Jennifer L. Freeman
/s/ CHRISTOPER R. CHRISTENSEN DirectorFebruary 24, 2021
Christopher R. Christensen
/s/ JOHN G. NACKEL, Ph.D.DirectorFebruary 24, 2021
John G. Nackel, Ph.D.
 /s/ STEPHEN M. R. COVEYDirectorFebruary 24, 2021
Stephen M. R. Covey
/s/ JOANNE STRINGFIELD DirectorFebruary 24, 2021
JoAnne Stringfield
/s/ SCOTT E. LAMBDirectorFebruary 24, 2021
Scott E. Lamb
/s/ RODERIC W. LEWISDirectorFebruary 24, 2021
Roderic W. Lewis

49

THE PENNANT GROUP, INC.
INDEX TO THE CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS
AND FINANCIAL STATEMENT SCHEDULE






50

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the shareholders and the Board of Directors of The Pennant Group, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of The Pennant Group, Inc. (the "Company") as of December 31, 2020 and 2019, the related consolidated and combined statements of income, stockholders' equity and net parent investment, and cash flows for each of the three years in the period ended December 31, 2020, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019 and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ DELOITTE & TOUCHE LLP

Boise, Idaho
February 24, 2021

We have served as the Company's auditor since 2019.
51

THE PENNANT GROUP, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except par value)

December 31, 2020December 31, 2019
Assets
Current assets:
Cash $43 $402 
Accounts receivable—less allowance for doubtful accounts of $643 and $677, respectively
47,221 32,183 
Prepaid expenses and other current assets12,335 6,098 
Total current assets59,599 38,683 
Property and equipment, net17,884 14,644 
Operating lease right-of-use assets308,650 316,328 
Escrow deposits525 1,400 
Deferred tax assets2,097  
Restricted and other assets4,289 2,000 
Goodwill66,444 41,233 
Other indefinite-lived intangibles47,488 33,462 
Total assets$506,976 $447,750 
Liabilities and equity
Current liabilities:
Accounts payable$9,761 $8,653 
Accrued wages and related liabilities26,873 16,343 
Operating lease liabilities—current14,106 12,285 
Other accrued liabilities38,275 13,911 
Total current liabilities89,015 51,192 
Operating lease liabilities—long-term 296,615 304,044 
Other long-term liabilities11,897 2,877 
Long-term debt, net8,277 18,526 
Total liabilities405,804 376,639 
Commitments and contingencies
Equity:
Common stock, $0.001 par value; 100,000 shares authorized; 28,696 and 28,243 shares issued and outstanding at December 31, 2020, respectively, and 28,435 and 27,853 shares issued and outstanding at December 31, 2019, respectively.
28 28 
Additional paid-in capital84,671 74,882 
Retained earnings (accumulated deficit)11,945 (3,799)
Treasury stock, at cost, 3 shares at December 31, 2020
(65) 
Total Pennant Group, Inc. stockholders' equity96,579 71,111 
Noncontrolling interest4,593  
Total equity101,172 71,111 
Total liabilities and equity$506,976 $447,750 
See accompanying notes to consolidated and combined financial statements.

52

THE PENNANT GROUP, INC.
CONSOLIDATED AND COMBINED STATEMENTS OF INCOME
(In thousands, except for per-share amounts)


Year Ended December 31,
202020192018
Revenue$390,953 $338,531 $286,058 
Expense:
Cost of services296,874 258,941 212,421 
Rent—cost of services39,191 34,975 31,199 
General and administrative expense31,296 35,135 18,843 
Depreciation and amortization4,675 3,810 2,964 
Total expenses372,036 332,861 265,427 
Income from operations18,917 5,670 20,631 
Other income (expense):
Other income225   
Interest expense, net(1,239)(410) 
Other income (expense), net(1,014)(410) 
Income before provision for income taxes17,903 5,260 20,631 
Provision for income taxes2,350 2,085 4,352 
Net income15,553 3,175 16,279 
Less: net (loss)/ income attributable to noncontrolling interest(191)629 595 
Net income and other comprehensive income attributable to The Pennant Group, Inc. $15,744 $2,546 $15,684 
Earnings per share (Note 4):
Basic$0.56 $0.11 $0.58 
Diluted$0.52 $0.11 $0.58 
Weighted average common shares outstanding:
Basic28,029 27,838 27,834 
Diluted30,228 29,586 27,834 
See accompanying notes to consolidated and combined financial statements.

53

THE PENNANT GROUP, INC.
CONSOLIDATED AND COMBINED STATEMENTS OF STOCKHOLDERS' EQUITY
AND NET PARENT INVESTMENT
(In thousands)
Common StockAdditional Paid-In CapitalRetained Earnings/ (Accumulated Deficit)Treasury StockNon-Controlling Interest
SharesAmountSharesAmountNet Parent InvestmentTotal
Balance at December 31, 2017 $ $ $  $ $54,996 $4,920 $59,916 
Noncontrolling interest attributable to subsidiary equity— — — — — — (2,539)3,917 1,378 
Net income attributable to noncontrolling interest— — — — — — — 595 595 
Net transfer from parent— — — — — — (12,285)— (12,285)
Net income attributable to The Pennant Group, Inc.— — — — — — 15,684 — 15,684 
Balance at December 31, 2018      55,856 9,432 65,288 
Noncontrolling interest attributable to subsidiary equity plan— — — — — — (2,991)3,585 594 
Share repurchase related to subsidiary equity plan— — — — — — — (394)(394)
Net income attributable to noncontrolling interest— — — — — — — 629 629 
Net transfer from parent— — — — — — 11,894 — 11,894 
Net income attributable to The Pennant Group, Inc.— — — (3,799)— — 6,345 — 2,546 
Cash Dividend to Parent— — — — — — (11,600)(11,600)
Reclassification of Invested Equity— — 72,893 — — (59,504)(13,252)137 
Issuance of Common Stock after spin-off27,834 28 (28)— — — — —  
Share-based Compensation after spin-off— — 1,987 — — — — — 1,987 
Exercise of Stock Options, issuance of other awards after spin-off601 — 30 — — — — — 30 
Balance at December 31, 201928,435 28 74,882 (3,799)    71,111 
Noncontrolling interests assumed related to acquisitions— — — — — — — 4,646 4,646 
Sale of noncontrolling interests, net of tax— — 313 — — — — 138 451 
Net loss attributable to Non-Controlling Interests— — — — — — — (191)(191)
Net income attributable to The Pennant Group, Inc.— — — 15,744 — — — — 15,744 
Share-based compensation— — 8,335 — — — — — 8,335 
Issuance of common stock from the exercise of stock options238 — 1,141 — — — — — 1,141 
Issuance/ (cancellation) of restricted stock26 — — — — — — —  
Shares of common stock withheld to satisfy tax withholding obligations(3)— — — 3 (65)— — (65)
Balance at December 31, 202028,696 $28 $84,671 $11,945 3 $(65)$ $4,593 $101,172 

See accompanying notes to consolidated and combined financial statements.
54

THE PENNANT GROUP, INC.
CONSOLIDATED AND COMBINED STATEMENTS OF CASH FLOWS
(In thousands)
Year Ended December 31,
202020192018
Cash flows from operating activities:
Net income$15,553 $3,175 $16,279 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization4,675 3,810 2,964 
Amortization of deferred financing fees330 78  
Provision for doubtful accounts560 858 346 
Share-based compensation8,335 3,382 2,382 
Deferred income taxes(2,201)79  
Change in operating assets and liabilities:
Accounts receivable(15,712)(8,571)(2,569)
Prepaid expenses and other assets(7,435)(2,746)(210)
Operating lease obligations2,068 (1,861) 
Accounts payable993 4,069 1,373 
Accrued wages and related liabilities10,538 3,376 1,583 
Other accrued liabilities2,427 1,720 398 
Advance payments27,997   
Other long-term liabilities2,076 2,185 729 
Net cash provided by operating activities50,204 9,554 23,275 
Cash flows from investing activities:
Purchase of property and equipment(7,253)(6,714)(3,603)
Cash payments for business acquisitions(33,193)(18,760)(4,725)
Cash payments for asset acquisitions (20)(593)
Escrow deposits(525)(1,400) 
Restricted and other assets(645)429 (556)
Net cash used in investing activities(41,616)(26,465)(9,477)
Cash flows from financing activities:
Proceeds from sale of subsidiary shares 2,293 1,972 
Repurchase of subsidiary shares  (2,687)(1,972)
Net investment from/(to) parent 10,788 (13,793)
Cash distribution to parent in connection with Spin-Off  (11,600) 
Sale of noncontrolling interest555   
Proceeds from revolver agreement52,700 42,500  
Payments on revolver agreement(63,200)(22,500) 
Repurchase of shares of common stock to satisfy tax withholding obligations(65)  
Payments for deferred financing costs(78)(1,552) 
Issuance of common stock upon the exercise of options1,141 30  
Net cash provided by/(used in) financing activities(8,947)17,272 (13,793)
Net (decrease)/ increase in cash (359)361 5 
Cash beginning of period402 41 36 
Cash end of period$43 $402 $41 
See accompanying notes to consolidated and combined financial statements.

55

THE PENNANT GROUP, INC.
CONSOLIDATED AND COMBINED STATEMENTS OF CASH FLOWS - (Continued)
(In Thousands)
Year Ended December 31,
202020192018
Supplemental disclosures of cash flow information:
Cash paid during the period for:
Interest$1,116 $156 $ 
Income taxes$7,865 $120 $ 
Operating lease liabilities$35,853 $37,088 $ 
Right-of-use assets obtained in exchange for new operating lease obligations$5,451 $9,059 $ 
Net non-cash adjustment to right-of-use assets and lease liabilities from lease modifications$1,939 $77,462 $ 
Non-cash investing activity:
Capital expenditures$560 $946 $717 
See accompanying notes to consolidated and combined financial statements.

56

THE PENNANT GROUP INC.
NOTES TO THE CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS
(Dollars in thousands, except per share data and operational senior living units)
1. DESCRIPTION OF BUSINESS

The Pennant Group, Inc. (herein referred to as “Pennant,” the “Company,” “it,” or “its”), is a holding company with no direct operating assets, employees or revenue. The Company, through its independent operating subsidiaries, provides healthcare services across the post-acute care continuum. As of December 31, 2020, the Company’s subsidiaries operated 76 home health, hospice and home care agencies and 54 senior living communities located in Arizona, California, Colorado, Idaho, Iowa, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin and Wyoming.

On October 1, 2019, The Ensign Group, Inc. (NASDAQ: ENSG) (“Ensign” or the “Parent”) completed the separation of Pennant from Ensign through a tax-free distribution (except as to cash received in lieu of fractional shares) of substantially all of Pennant’s issued and outstanding common stock to the stockholders of Ensign (the “Spin-Off”). To accomplish the Spin-Off, Ensign contributed the Company’s assets and liabilities into Pennant and each Ensign stockholder received a distribution of one share of Pennant common stock for every two shares of Ensign’s common stock, plus cash in lieu of fractional shares. Additionally, the noncontrolling interest was converted into shares of Pennant at the established conversion ratio. As a result of the Spin-Off on October 1, 2019, Pennant began trading as an independent company on the NASDAQ under the symbol “PNTG.”
Certain of the Company’s subsidiaries, collectively referred to as the Service Center, provide accounting, payroll, human resources, information technology, legal, risk management, and other services to the operations through contractual relationships.
Each of the Company’s affiliated operations are operated by separate, independent subsidiaries that have their own management, employees and assets. References herein to the consolidated “Company” and “its” assets and activities is not meant to imply, nor should it be construed as meaning, that Pennant has direct operating assets, employees or revenue, or that any of the subsidiaries, are operated by Pennant.

2. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation - The accompanying consolidated and combined financial statements of the Company (the “Financial Statements”) reflect the Company’s financial position, results of operations and cash flows as the business was operated as part of Ensign prior to the Spin-Off, and have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and pursuant to the regulations of the Securities and Exchange Commission (“SEC”). Prior to the Spin-Off, the combined financial statements were prepared on a stand-alone basis and derived from the consolidated financial statements and accounting records of Ensign. Management believes that the Financial Statements reflect, in all material respects, all adjustments which are of a normal and recurring nature necessary to present fairly the Company’s financial position, results of operations, and cash flows for the periods presented in conformity with GAAP applicable to the annual period.

All intercompany transactions and balances between the various legal entities comprising the Company have been eliminated in consolidation. The consolidated and combined statements of income reflect income that is attributable to the Company and the noncontrolling interest.

The Company consists of various limited liability companies and corporations established to operate home health, hospice, home care, and senior living operations. The Financial Statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest. Revenue was derived from transactional information specific to the Company’s services provided. The costs in the consolidated and combined statements of income reflect direct costs and allocated costs prior to the Spin-Off.

Estimates and Assumptions - The preparation of the Financial Statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Financial Statements relate to revenue, cost allocations from prior to the Spin-Off, intangible assets and goodwill, right-of-use assets and lease liabilities for leases greater than 12 months, self-insurance reserves, and income taxes. Actual results could differ from those estimates.

57

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

Revenue Recognition - Revenues are recognized when services are provided to the patients at the amount that reflects the consideration to which the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net service revenue in the period such variances become known. See Note 5, Revenue and Accounts Receivable.

CARES Act: The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted on March 27, 2020 in the United States. During the second quarter of 2020 the Company applied for and received $27,997 in funds under the Accelerated and Advance Payment (“AAP”) Program. The CARES Act allows for deferred payment of the employer-paid portion of social security taxes through the end of 2020, with 50% due on December 31, 2021 and the remainder due on December 31, 2022. For the year ended December 31, 2020, the Company deferred approximately $8,358 of the employer-paid portion of social security taxes, of which $4,179 is included in other long-term liabilities and the current portion of $4,179 in accrued wages and related liabilities. The CARES Act temporarily suspended the automatic 2% reduction of Medicare claim reimbursements for the period of May 1, 2020 through March 31, 2021. The suspension of the Medicare sequestration increased our revenue by approximately $2,765 for the year ended December 31, 2020. The Company will continue to assess the effect of the CARES Act and ongoing other government legislation related to the COVID-19 pandemic that may be issued.

Cash - Cash consists of petty cash and bank term deposits and therefore approximates fair value. The Company places its cash with high credit quality financial institutions. Prior to the Spin-off the Company participated in a cash management program with Ensign where net cash activity was included in the net parent investment.

Accounts Receivable and Allowance for Doubtful Accounts - Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration. Subsequent to our adoption of ASU 2016-13, as noted below, the allowance for doubtful accounts is the Company’s best estimate of current expected credit losses in the accounts receivable balance.

Property and Equipment - Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three to 15 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.

Impairment of Long-Lived Assets - The Company reviews the carrying value of long-lived assets that are held and used in the independent operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiary to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. Management has evaluated its long-lived assets and the Company did not identify any asset impairment during the years ended December 31, 2020, 2019 and 2018.

Intangible Assets and Goodwill - Definite-lived intangible assets consist primarily of patient base and customer relationships. Patient base is amortized over a period of four months to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition when acquired. Customer relationships are amortized between one to seven years depending on the significance of the relationships.

The Company’s indefinite-lived intangible assets consist of trade names and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable. The Company did not identify any asset impairment during the years ended December 31, 2020, 2019 and 2018.
58

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)


Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to annual test for impairment as of the beginning of the fourth quarter or more frequently if events or changes indicate that the Company's goodwill might be impaired. The Company assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company determines it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then it is required to perform a quantitative impairment test by comparing the fair value with the carrying amount of the reporting unit. If the carrying amount of a reporting unit exceeds its fair value, then the Company records an impairment of goodwill equal to the amount that the carrying amount of a reporting unit exceeds its fair value.

As of December 31, 2020, we evaluated potential triggering events that might be indicators that our goodwill and indefinite lived intangibles were impaired. No goodwill or intangible asset impairments were recorded during the years ended December 31, 2020, 2019 and 2018. See further discussion at Note 9, Goodwill and Intangible Assets, Net.

Insurance - The Company retains risk for a substantial portion of potential claims for general and professional liability and workers’ compensation. The Company does not retain risk related to its employee health plans.

The Company recognizes obligations associated with these costs, up to specified deductible limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. As of December 31, 2020 the general and professional liability insurance has a retention limit of $150 per claim with a $500 corridor as an additional out-of-pocket retention we must satisfy for claims within the policy year before the carrier will reimburse losses. The workers’ compensation insurance has a retention limit of $250 per claim, except for policies held in Texas and Washington which are subject to state insurance and possess their own limits.

These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis. Additionally, the Company has partially indemnified Ensign for general and professional liabilities incurred prior to the Spin-off but not reported until after that date and included that amount in its accrual below.

The following table presents details of the Company's insurance programs, including amounts accrued for the periods indicated in other accrued liabilities and other long-term liabilities in our accompanying balance sheets. The amounts accrued below represent the total estimated liability for individual claims that are less than our noted insurance coverage amounts, which includes outstanding claims and claims incurred but not reported. The amounts are reported gross of reinsurance receivable of $704 and zero included in restricted and other assets for the years ended December 31, 2020 and 2019, respectively.

Year Ended December 31,
20202019
Type of Insurance
General and professional liability $1,063 $521 
Workers’ compensation2,783 433 
Total estimated liability3,846 954 
Less: long-term portion, included in other long-term liabilities(2,492)(774)
Current portion of estimated liability, included in other accrued liabilities$1,354 $180 

Fair Value of Financial Instruments - The Company’s financial instruments consist principally of cash, accounts receivable, accounts payable and accrued liabilities. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations. The Company determines fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.

Income Taxes - Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences
59

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized.

In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.

Noncontrolling Interest - The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income/ (loss) attributable to The Pennant Group, Inc. in its consolidated and combined statements of income. Net income per share is calculated based on net income/ (loss) attributable to The Pennant Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest.

Share-Based Compensation -The Company measures and recognizes compensation expense for all share-based payment awards, including employee stock options, made to employees and Pennant’s directors based on estimated fair values, ratably over the requisite service period of the award. The Company accounts for forfeitures as they occur. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables. The total amount of share-based compensation was $8,335, $3,382, and $2,382 for the years ended December 31, 2020, 2019 and 2018, respectively, of which $7,222, $2,769 and $1,900, respectively, was recorded in general and administrative expense. For further discussion see Note 12, Options and Awards.

Prior to Spin-Off

Cost Allocation - The Financial Statements include allocations of costs for certain shared services provided to the Company by Ensign subsidiaries prior to the Spin-Off on October 1, 2019. Such allocations include, but are not limited to, executive management, accounting, human resources, information technology, compliance, legal, payroll, insurance, tax, treasury, and other general and administrative items. These costs were allocated to the Company on a basis of revenue, location, employee count, or other measures. These cost allocations are reflected within general and administrative expense in the consolidated and combined statements of income, including for share-based compensation expenses disclosed in Note 12, Options and Awards. The amount of general and administrative costs allocated from January 1, 2019 to October 1, 2019, the date of the Spin-Off, inclusive of share-based compensation expense, was $23,710. Management believes the basis on which the expenses were allocated to be a reasonable reflection of the services provided to the Company during the periods.

Insurance - Prior to the Spin-Off Ensign was partially self-insured for healthcare, general and professional liability, and workers’ compensation, and historically allocated premium expense to all subsidiaries of Ensign in its accounting records. To reflect all of the insurance costs, quarterly actuary determined adjustments were allocated to the Company based on the proportional historical premium expense. No self-insurance accruals were allocated to the Company as these accruals represent the obligations of Ensign. In connection with the Spin-Off, the Company purchased insurance through a third-party to replace the coverage provided by Ensign’s self-insured policies.

Debt - Ensign’s external debt and related interest expense were not allocated to the Company for any of the periods presented as no portion of the borrowings were assumed by the Company as part of the Spin-Off. All interest incurred by the Company was subsequent to the Spin-Off.

Income Taxes - Prior to the date of the Spin-off, the Company’s operations have been included in Ensign’s U.S. federal and state income tax returns and all income taxes have been paid by subsidiaries of Ensign. Also prior to the date of the Spin-off, income tax expense and other income tax related information contained in these Financial Statements were presented using a separate tax return approach. Under this approach, the provision for income taxes represents income tax paid or payable for the current year plus the change in deferred taxes during the year calculated as if the Company was a stand-alone taxpayer filing hypothetical income tax returns. Management believes that the assumptions and estimates used to determine these tax amounts are reasonable. However, the Company’s Financial Statements may not necessarily reflect its income tax expense or tax
60

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

payments in the future, or what tax amounts would have been if the Company had been a stand-alone company for the entire period presented.

Invested Capital - The net parent investment on the consolidated balance sheets represents Ensign’s historical investment in the Company, the net effect of transactions with, and allocations from, Ensign and the Company’s accumulated earnings. Invested capital was reclassified into additional paid-in-capital at the date of the Spin-Off.

Noncontrolling Interest - Prior to the Spin-Off, the Company presented the noncontrolling interest and the amount of consolidated net income/ (loss) attributable to the Company in its Financial Statements. The carrying amount of the noncontrolling interest was adjusted by an allocation of subsidiary earnings based on ownership interest prior to the Spin-Off. The noncontrolling subsidiary interest included in the Financial Statements was converted into common shares of Pennant concurrent with the distribution to Ensign stockholders at the date of the Spin-Off and thus, will no longer be allocated a portion of earnings.

Share-based compensation - Prior to the Spin-Off, employees of the Company’s subsidiaries participated in Ensign’s equity-based incentive plans (the “Ensign Plans”) and the Cornerstone Subsidiary Equity plan (the “Subsidiary Equity Plan”). Share-based compensation includes the expense attributable to employees of the Company’s subsidiaries who participated in the Ensign Plans, as well as the allocated cost related to Ensign subsidiaries’ employees that participated in the Ensign Plans. Share-based compensation related to Ensign subsidiaries’ employees that participated in the Ensign Plans were allocated on the basis of revenue. All share-based compensation related to the Subsidiary Equity Plan was recognized in the Financial Statements and, therefore, no cost allocation was necessary.

Prior to the Spin-Off, share-based compensation costs associated with the Subsidiary Equity Plan awards was initially measured at fair value at the grant date and was expensed as non-cash compensation over the vesting term. Historically, these awards were granted once per year and the fair value has been determined by an independent valuation of the subsidiary shares. The valuation incorporated a discounted cash flow analysis combined with a market-based approach to determine the fair value of the subsidiary equity.

Earnings Per Share - For the year ended December 31, 2018, the earnings per share included on the accompanying Consolidated and Combined Statements of Income was calculated based on the 27,834 shares of Pennant common stock distributed on October 1, 2019 in conjunction with the Spin-Off, including shares related to the conversion of the noncontrolling interest. Prior to October 1, 2019, Pennant did not have any issued and outstanding common stock. The same number of shares was used to calculate basic and diluted earnings per share since no Pennant employee equity awards were outstanding prior to the Spin-Off. In connection with the Spin-Off, shares of existing equity awards were replaced with shares under the new Pennant awards and are reflected in basic and diluted net income per share for the years ended December 31, 2020 and 2019, respectively. For further discussion see Note 4, Computation of Net Income Per Common Share

Recent Accounting Standards Adopted by the Company

Except for rules and interpretive releases of the SEC under authority of federal securities laws and a limited number of grandfathered standards, the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management and certain standards are under consideration.

FASB Accounting Standards Update, or ASU, ASU 2020-04 “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” or ASU 2020-4 - In March 2020, the FASB concluded its reference rate reform project and issued this ASU. The amendments in this ASU provide optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in this ASU apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The optional expedients and exceptions are available for all entities as of March 12, 2020, through December 31, 2022. The Company has adopted ASU 2020-04, effective March 12, 2020. The impact of this ASU will be determined based on terms of any future contract modification related to a change in reference rate, including future modifications to the Company’s Revolving Credit Facility described in further detail in Note 11, Debt.
61

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)


FASB ASU, 2018-15, “Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract” or ASU 2018-15. The update helps entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement (hosting arrangement), by providing guidance in determining when the arrangement includes a software license. It requires entities to account for such costs consistent with the guidance on capitalizing costs associated with developing or obtaining internal-use software. The Company has adopted ASU 2018-15, effective January 1, 2020. There was no material impact to the Company’s Financial Statements or disclosures.

FASB ASU, 2018-13 “Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement” or ASU 2018-13 - In August 2018, the FASB issued amended guidance to simplify fair value measurement disclosure requirements. The new provisions eliminate the requirements to disclose (1) transfers between Level 1 and Level 2 of the fair value hierarchy, (2) policies related to valuation processes and the timing of transfers between levels of the fair value hierarchy, and (3) net asset value disclosure of estimates of timing of future liquidity events. The FASB also modified disclosure requirements of Level 3 fair value measurements. The Company adopted ASU 2018-13 as of January 1, 2020. There was no material impact to the Company’s Financial Statements or disclosures.

FASB ASU, 2017-04 “Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” or ASU 2017-04 - In January 2017, the FASB issued amended authoritative guidance to simplify and reduce the cost and complexity of the goodwill impairment test. The new guidance eliminates “Step 2” from the traditional two-step goodwill impairment test and redefines the concept of impairment from a measure of loss when comparing the implied fair value of goodwill to its carrying amount, to a measure comparing the fair value of a reporting unit with its carrying amount. The FASB also eliminated the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment or “Step 2” of the goodwill impairment test. The new guidance does not amend the optional qualitative assessment of goodwill impairment. The Company adopted ASU 2017-04 as of January 1, 2020. There was no material impact to the Company’s Financial Statements or disclosures.

FASB ASU 2016-13 “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” or ASU 2016-13 - In June 2016, the FASB issued ASU 2016-13, which replaced the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected to be collected. The Company adopted ASU 2016-13 as of January 1, 2020. There was no material impact to the Company’s Financial Statements or related disclosures.

3. RELATED PARTY TRANSACTIONS AND NET PARENT INVESTMENT
The Financial Statements include a combination of stand-alone and combined business functions between Ensign and the Company’s subsidiaries prior to the Spin-Off. The Company leases 31 of its senior living communities from subsidiaries of Ensign, each of the leases have a term of between 14 and 20 years from the lease commencement date. The total amount of rent expense included in Rent - cost of services paid to subsidiaries of Ensign was $12,536, $11,292, and $10,363 for the years ended December 31, 2020, 2019 and 2018, respectively.

Certain related party activity occurred as the Company’s subsidiaries received services from Ensign’s subsidiaries. Services included in cost of services were $4,205, $3,166, and $2,996 for the years ended December 31, 2020, 2019 and 2018, respectively.

The consolidated balance sheets of the Company include Ensign assets and liabilities that are specifically identifiable or otherwise attributable to the Company and were transferred to the Company in connection with the Spin-Off. Transactions that have occurred between subsidiaries of the Company and subsidiaries of Ensign are considered to be effectively settled at the time the transaction is recorded. The net effect of these transactions, including the cash management, is included in the consolidated and combined statements of cash flows as “Net investment from/(to) Parent”.

Other related party activity with Ensign
On October 1, 2019, in connection with the Spin-Off, Pennant entered into several agreements with Ensign that set forth the principal actions taken or to be taken in connection with the Spin-Off and govern the relationship of the parties following the Spin-Off.
62

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

The Company has incurred $5,536 and $2,982 in costs related to the Transitions Services Agreement for the years ended December 31, 2020 and 2019, respectively. Additionally, the Company has recognized $578 and $291 in tax benefits related to the Tax Matters Agreement for the years ended December 31, 2020 and 2019, respectively, and has recorded a payable to Ensign in connection with any unpaid portion of these amounts. See “Certain Relationships and Related Party Transactions—Agreements with Ensign Related to the Spin-Off,” contained within the Information Statement as well as the Form 8-K filed with the SEC on October 3, 2019 for further discussion of the agreements entered into in connection with the Spin-Off.

4. COMPUTATION OF NET INCOME PER COMMON SHARE
Basic and diluted net income per share are computed by dividing net income by the weighted average number of outstanding common shares during the period. In the basic and diluted earnings per share calculations, net income is equal to net income attributable to The Pennant Group, Inc.

Prior to Spin-Off

Net income attributable to the noncontrolling interest has been included in the numerator for the years ended December 31, 2019 and 2018, respectively, as the non-controlling subsidiary interest that existed prior to the Spin-Off was converted into common shares of Pennant concurrent with the distribution to Ensign stockholders at the date of the Spin-Off.

The following table sets forth the computation of basic and diluted net income per share for the periods presented:


Year Ended December 31,
 202020192018
Numerator:
Net income$15,553 $3,175 $16,279 
Add: net (loss)/ income attributable to noncontrolling interests(191)629 595 
Net income attributable to The Pennant Group, Inc.$15,744 $2,546 $15,684 
Denominator:
Weighted average shares outstanding for basic net income per share(a)
28,029 27,838 27,834 
Plus: incremental shares from assumed conversion(b)
2,199 1,748  
Adjusted weighted average common shares outstanding for diluted income per share30,228 29,586 27,834 
Earnings Per Share:
Basic net income per common share(c)
$0.56 $0.11 $0.58 
Diluted net income per common share(c)
$0.52 $0.11 $0.58 

(a)
Concurrent with the Spin-Off the noncontrolling subsidiary interest converted into 1,160 shares of Pennant. The total number of common shares distributed on October 1, 2019 of 27,834 was utilized in the denominator for the calculation of basic and diluted earnings per share for the year ended December 31, 2018 , as no common stock was outstanding prior to the date of the Spin-Off.
(b)
The calculation of dilutive shares outstanding excludes out-of-the-money stock options (i.e., such options’ exercise prices were greater than the average market price of our common shares for the period) because their inclusion would have been antidilutive. Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were 93 and 15 for the years ended December 31, 2020 and 2019, respectively.
(c)
For the years ended December 31, 2019 and 2018 basic and diluted earnings per share were calculated based on net income as the numerator, which included the conversion of the noncontrolling interest in connection with the Spin-Off. For the year ended December 31, 2020, basic and diluted earnings per share was calculated based on net income attributable to The Pennant Group, Inc. as the numerator, . See Note 7, Acquisitions, for further information on our acquisitions for the year ended December 31, 2020.


5. REVENUE AND ACCOUNTS RECEIVABLE
Revenues are recognized when services are provided to the patients or residents at the amount that reflects the consideration to which the Company expects to be entitled from patients, residents and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care or senior living residence. The healthcare services in home health and hospice patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as
63

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct within the context of the contract. Additionally, there may be ancillary services which are not included in the rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered.

Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net service revenue in the period such variances become known.

Revenue from the Medicare and Medicaid programs accounted for 60.1%, 55.6%, and 53.1% of the Company’s revenue for the years ended December 31, 2020, 2019 and 2018, respectively. The Company records revenue from these governmental and managed care programs as services are performed at their expected net realizable amounts under these programs. The Company’s revenue from governmental and managed care programs is subject to audit and retroactive adjustment by governmental and third-party agencies. Consistent with healthcare industry accounting practices, any changes to these governmental revenue estimates are recorded in the period the change or adjustment becomes known based on final settlement.

Disaggregation of Revenue

The Company disaggregates revenue from contracts with its patients or residents by reportable operating segments and payors. The Company has determined that disaggregating revenue into these categories achieves the disclosure objectives to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. A reconciliation of disaggregated revenue to segment revenue as well as revenue by payor is provided in below.

The Company’s service specific revenue recognition policies are as follows:

Home Health Revenue

Medicare Revenue

For Medicare episodes that began after January 1, 2020, net service revenue is recognized in accordance with the Patient Driven Groupings Model (“PDGM”). This new reimbursement structure involves case mix calculation methodology refinements, changes to low-utilization payment adjustment (“LUPA”) thresholds, the elimination of therapy thresholds, a change to the unit of payment from a 60-day episode to a 30-day payment period, and reduction of requests for anticipated payments (“RAPs”) to 20% of the estimated payment for a patient’s initial or subsequent period of care up-front (after the initial assessment is completed and upon initial billing). The RAPs will be completely phased out effective January 1, 2021. Under PDGM, Medicare provides agencies with payments for each 30-day payment period provided to beneficiaries. If a beneficiary is still eligible for care after the end of the first 30-day payment period, a second 30-day payment period can begin. There are no limits to the number of periods of care a beneficiary who remains eligible for the home health benefit can receive. While payment for each 30-day payment period is adjusted to reflect the beneficiary’s health condition and needs, a special outlier provision exists to ensure appropriate payment for those beneficiaries that have the most expensive care needs. The payment under the Medicare program is also adjusted for certain variables including, but not limited to: (a) a LUPA if the number of visits is below an established threshold that varies based on the diagnosis of a beneficiary; (b) a partial payment if the patient transferred to another provider or the Company received a patient from another provider before completing the period of care; (c) adjustment to the admission source of claim if it is determined that the patient had a qualifying stay in a post-acute care setting within 14 days prior to the start of a 30-day payment period; (d) the timing of the 30-day payment period provided to a patient in relation to the admission date, regardless of whether the same home health provider provided care for the entire series of episodes; (e) changes to the acuity of the patient during the previous 30-day payment period; (f) changes in the base payments established by the Medicare program; (g) adjustments to the base payments for case mix and geographic wages; and (h) recoveries of overpayments.

64

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

For all episodes that began prior to January 1, 2020, net service revenue was recorded under the Medicare prospective payment system based on a 60-day episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a) an outlier payment if the patient’s care was unusually costly; (b) a LUPA if the number of visits was fewer than five; (c) a partial payment if the patient transferred to another provider or transferred from another provider before completing the episode; (d) a payment adjustment based upon the level of covered therapy services; (e) the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (f) changes in the base episode payments established by the Medicare program; (g) adjustments to the base episode payments for case mix and geographic wages; and (h) recoveries of overpayments.

The Company adjusts Medicare revenue on completed episodes to reflect differences between estimated and actual payment amounts, an inability to obtain appropriate billing documentation and other reasons unrelated to credit risk. Therefore, the Company believes that its reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered.

In addition to revenue recognized on completed episodes and periods, the Company also recognizes a portion of revenue associated with episodes and periods in progress. Episodes in progress are 30-day payment periods, if the episode started after January 1, 2020, or 60-day episodes of care, if the episode started prior to January 1, 2020, that begin during the reporting period but were not completed as of the end of the period. As such, the Company estimates revenue and recognizes it on a daily basis. The primary factors underlying this estimate are the number of episodes in progress at the end of the reporting period, expected Medicare revenue per period of care or episode of care and the Company’s estimate of the average percentage complete based on the scheduled end of period and end of episode dates.

Non-Medicare Revenue

Episodic Based Revenue - The Company recognizes revenue in a similar manner as it recognizes Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms.

Non-episodic Based Revenue - Revenue is recognized on an accrual basis based upon the date of service at amounts equal to its established or estimated per visit rates, as applicable.

Hospice Revenue

Revenue is recognized on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are calculated as daily rates for each of the levels of care the Company delivers. Revenue is adjusted for an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. Additionally, as Medicare hospice revenue is subject to an inpatient cap and an overall payment cap, the Company monitors its provider numbers and estimates amounts due back to Medicare if a cap has been exceeded. The Company regularly evaluates and records these adjustments as a reduction to revenue and an increase to other accrued liabilities.

Senior Living Revenue

The Company has elected the lessor practical expedient within ASC Topic 842, Leases (“ASC 842”) and therefore recognizes, measures, presents, and discloses the revenue for services rendered under the Company’s senior living residency agreements based upon the predominant component, either the lease or non-lease component, of the contracts. The Company has determined that the services included under the Company’s senior living residency agreements each have the same timing and pattern of transfer. The Company recognizes revenue under ASC Topic 606, Revenue from Contracts with Customers for its senior residency agreements, for which it has determined that the non-lease components of such residency agreements are the predominant component of each such contract.

The Company’s senior living revenue consists of fees for basic housing and assisted living care. Accordingly, we record revenue when services are rendered on the date services are provided at amounts billable to individual residents. Residency agreements are generally for a term of 30 days, with resident fees billed monthly in advance. For residents under reimbursement arrangements with Medicaid, revenue is recorded based on contractually agreed-upon amounts or rates on a per resident, daily basis or as services are rendered.

65

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

Revenue by payor for the years ended December 31, 2020, 2019 and 2018, is summarized in the following tables:

Year Ended December 31, 2020
Home Health and Hospice Services
Home Health ServicesHospice ServicesSenior Living ServicesTotal RevenueRevenue %
Medicare$58,399 $119,873 $ $178,272 45.6 %
Medicaid7,645 12,462 36,780 56,887 14.5 
Subtotal66,044 132,335 36,780 235,159 60.1 
Managed care31,572 1,546  33,118 8.5 
Private and other(a)
21,968 194 100,514 122,676 31.4 
Total revenue$119,584 $134,075 $137,294 $390,953 100.0 %

(a)Private and other payors in our home health and hospice services segment includes revenue from all payors generated in our home care operations.


Year Ended December 31, 2019
Home Health and Hospice Services
Home Health ServicesHospice ServicesSenior Living ServicesTotal RevenueRevenue %
Medicare$47,819 $93,933 $ $141,752 41.9 %
Medicaid6,575 10,061 29,819 46,455 13.7 
Subtotal54,394 103,994 29,819 188,207 55.6 
Managed care27,711 1,536  29,247 8.6 
Private and other(a)
18,837 152 102,088 121,077 35.8 
Total revenue$100,942 $105,682 $131,907 $338,531 100.0 %

(a)Private and other payors in our home health and hospice services segment includes revenue from all payors generated in our home care operations.

Year Ended December 31, 2018
Home Health and Hospice Services
Home Health ServicesHospice ServicesSenior Living ServicesTotal RevenueRevenue %
Medicare$42,091 $73,906 $ $115,997 40.5 %
Medicaid4,680 7,729 23,624 36,033 12.6 
Subtotal46,771 81,635 23,624 152,030 53.1 
Managed care23,541 918  24,459 8.6 
Private and other(a)
16,067 105 93,397 109,569 38.3 
Total revenue$86,379 $82,658 $117,021 $286,058 100.0 %

(a)Private and other payors in our home health and hospice services segment includes revenue from all payors generated in our home care operations.

Balance Sheet Impact

Included in the Company’s consolidated balance sheets are contract assets, comprised of billed accounts receivable and unbilled receivables, which are the result of the timing of revenue recognition, billings and cash collections, as well as, contract liabilities, which primarily represent payments the Company receives in advance of services provided. As of December 31, 2020, the Company had contract liabilities in the amount of $27,997 related to Advance Payments received in connection with the CARES Act. As further discussed in Note 10, Other Accrued Liabilities, the repayment terms for Medicare advance payments were modified through the passage of the Continuing Appropriations Act, 2021 and Other Extensions Act on October 1, 2020.

66

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

Accounts receivable as of December 31, 2020 and December 31, 2019 is summarized in the following table:

December 31, 2020December 31, 2019
Medicare$28,569 $17,822 
Medicaid7,669 6,579 
Managed care7,590 4,380 
Private and other4,036 4,079 
Accounts receivable, gross47,864 32,860 
Less: allowance for doubtful accounts(643)(677)
Accounts receivable, net$47,221 $32,183 

The following table summarizes the activity for our allowance for doubtful accounts for the years ended years ended December 31, 2020, 2019 and 2018:

Year Ended December 31,
202020192018
Balance at beginning of period$677 $616 $5,058 
Impact of ASC 606 Adoption(a)
  (4,590)
Additions to bad debt expense560 858 346 
Write-offs of uncollectible accounts(594)(797)(198)
Balance at end of period$643 $677 $616 

(a)
Subsequent to the adoption of ASC 606, the majority of what was previously presented as allowance for doubtful accounts related to bad debt expense has been incorporated as an implicit price concession factored into net revenue and accounts receivable. Allowance for doubtful accounts as of December 31, 2020 represents the Company’s best estimate of probable losses inherent in the accounts receivable balance based on known troubled accounts and other currently available evidence.


Practical Expedients and Exemptions

As the Company’s contracts have an original duration of one year or less, the Company uses the practical expedient applicable to its contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of the end of each reporting period or when the Company expects to recognize this revenue. In addition, the Company has applied the practical expedient provided by ASC 340, Other Assets and Deferred Costs (“ASC 340”), and all incremental customer contract acquisition costs are expensed as they are incurred because the amortization period would have been one year or less.

6. BUSINESS SEGMENTS
The Company classifies its operations into the following reportable operating segments: (1) home health and hospice services, which includes the Company’s home health, hospice and home care businesses; and (2) senior living services, which includes the operation of assisted living, independent living and memory care communities. The reporting segments are business units that offer different services and are managed separately to provide greater visibility into those operations. Our Chief Executive Officer and President, who is our Chief Operating Decision Maker “CODM”, reviews financial information at the operating segment level. We also report an “all other” category that includes general and administrative expense from our Service Center.

As of December 31, 2020, the Company provided services through 76 affiliated home health, hospice and home care agencies, and 54 affiliated senior living operations. The Company evaluates performance and allocates capital resources to each segment based on an operating model that is designed to maximize the quality of care provided and profitability. The Company’s Service Center provides various services to all lines of business. The Company does not review assets by segment and therefore assets by segment are not disclosed below.

Beginning in the third quarter of 2019, in anticipation of the Spin-Off, the GAAP segment measure of profit and loss was changed from Segment Income (Loss) Before Provision for Income Taxes to Adjusted Segment EBITDAR from Operations. Prior period presentation has been revised to reflect the new measurement.
67

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)


The CODM uses Segment Adjusted EBITDAR from Operations as the primary measure of profit and loss for the Company's reportable segments and to compare the performance of its operations with those of its competitors. Segment Adjusted EBITDAR from Operations is net income/ (loss) attributable to the Company's reportable segments excluding interest expense, provision for income taxes, depreciation and amortization expense, rent, and, in order to view the operations performance on a comparable basis from period to period, certain adjustments including: (1) costs at start-up operations, (2) share-based compensation, (3) acquisition related costs, (4) Spin-Off transaction costs, (5) redundant and nonrecurring costs associated with the transition services agreement, (6) net income/ (loss) attributable to noncontrolling interest, and (7) net COVID-19 related costs. General and administrative expenses are not allocated to the reportable segments, and are included as “All Other”, accordingly the segment earnings measure reported is before allocation of corporate general and administrative expenses. The Company's segment measures may be different from the calculation methods used by other companies and, therefore, comparability may be limited.

The following table presents certain financial information regarding our reportable segments, general and administrative expenses are not allocated to the reportable segments and are included in “All Other” for the years ended December 31, 2020, 2019 and 2018:
Home Health and Hospice ServicesSenior Living ServicesAll OtherTotal
Year Ended December 31, 2020
Revenue$253,659 $137,294 $ $390,953 
Segment Adjusted EBITDAR from Operations$49,501 $48,309 $(22,762)$75,048 
Year Ended December 31, 2019
Revenue$206,624 $131,907 $ $338,531 
Segment Adjusted EBITDAR from Operations$33,354 $47,344 $(18,591)$62,107 
Year Ended December 31, 2018
Revenue$169,037 $117,021 $ $286,058 
Segment Adjusted EBITDAR from Operations$26,427 $47,230 $(16,191)$57,466 

The table below provides a reconciliation of Segment Adjusted EBITDAR from Operations above to income from operations:

Year Ended December 31,
202020192018
Segment Adjusted EBITDAR from Operations$75,048 $62,107 $57,466 
Less: Depreciation and amortization4,675 3,810 2,964 
Rent—cost of services39,191 34,975 31,199 
Other income225   
Adjustments to Segment EBITDAR from Operations:
Less: Costs at start-up operations(a)
1,787 483 129 
Share-based compensation expense(b)
8,335 3,382 2,382 
Acquisition related costs(c)
99 665  
Spin-off related transaction costs(d)
 13,219 756 
Transition services costs(e)
1,181 532  
COVID-19 Related costs and supplies(f)
447   
Add: Net income/ (loss) attributable to noncontrolling interest(191)629 595 
Consolidated and Combined Income from operations$18,917 $5,670 $20,631 

(a)Represents results related to start-up operations. This amount excludes rent and depreciation and amortization expense related to such operations.
(b)Share-based compensation expense incurred which is included in cost of services and general and administrative expense.
(c)Acquisition related costs that are not capitalizable.
68

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

(d)Costs incurred related to the Spin-Off are included in general and administrative expense.
(e)
A portion of the costs incurred under the Transition Services Agreement (as defined in Note 3, Related Party Transactions and Net Parent Investment) identified as redundant or nonrecurring that are included in general and administrative expense. Transition service costs includes $446 of duplicative software expense for the year ended December 31, 2020, of which $333 pertains to the first three quarters of the fiscal year and were not included as adjustments in previous interim periods. Fees incurred under the Transition Services agreement, net of the Company’s payroll reimbursement, were $5,536, $2,982, and zero for the years ended December 31, 2020, 2019 and 2018, respectively.
(f)
Represents incremental costs incurred as part of the Company's response to COVID-19 including direct medical supplies, labor, and other expenses, net of $2,765 in increased revenue related to the 2% payment increase in Medicare reimbursements for sequestration relief for the year ended December 31, 2020.


7. ACQUISITIONS
The Company’s acquisition focus is to purchase or lease operations that are complementary to the Company’s current businesses, accretive to the Company’s business or otherwise advance the Company’s strategy. The results of all the Company’s independent operating subsidiaries are included in the Financial Statements subsequent to the date of acquisition. Acquisitions are accounted for using the acquisition method of accounting.

2020 Acquisitions

During the year ended December 31, 2020, the Company expanded its operations with the addition of six home health agency, six hospice agencies, and two senior living communities. The aggregate purchase price for these acquisitions was $39,239. In connection with the addition of the senior living communities, the Company entered into a new long-term “triple-net” lease with a subsidiary of Ensign. The addition of these operations added a total of 164 operational senior living units to be operated by the Company’s independent operating subsidiaries. A subsidiary of the Company entered into a separate operations transfer agreement with the prior operator of each acquired operation as part of each transaction. The goodwill was primarily attributable intangible assets that do not qualify for separate recognition and to synergies the Company expects to achieve related to the acquisition and was allocated to the Company's operating segments which are its reporting units. The Company anticipates that the total goodwill recognized will be fully deductible for tax purposes. Acquisition costs related to the business combinations of home health, hospice, and home care acquisitions of $99 were expensed related to the business combinations during the year ended December 31, 2020.

In October 2020, the Company announced it closed on a home health joint venture and hospice joint venture with Scripps Health (“Scripps”), a leading nonprofit integrated health system based in San Diego, California. The closing was effective October 1, 2020. The resulting joint ventures, which combined certain assets and the operations of Scripps’ home health business and the assets and operations of the local Pennant-affiliated home health and hospice agencies, are majority-owned and managed by an independent operating subsidiary of the Company and provide home health and hospice services to patients throughout San Diego County. The fair value of assets contributed by Scripps to the home health joint venture were included in the total value of assets acquired as described above and in the summary table below. The Company paid Scripps $6,200 in cash and contributed assets from the local Pennant-affiliated home health agency with a net book value of $614. The Company acquired 60.0% ownership interest in the joint venture. The contributions of assets by Scripps to the joint venture, resulted in the Company recording a noncontrolling interest with a fair value of $4,646. The fair value of the noncontrolling interest was determined using discounted cash flow models. As part of the transaction with Scripps, the Company contributed the assets of the local Pennant-affiliated hospice agency to another joint venture. The Company sold Scripps a noncontrolling interest in the hospice joint venture for $555 in cash. The company retained an 80.0% ownership interest in the hospice joint venture. The transaction resulted in the Company recognizing a noncontrolling interest of $138 and a contribution to additional paid in capital of $313, net of $104 of the income tax effect.

2019 Acquisitions

During the year ended December 31, 2019, the Company expanded its operations with the addition of two home health agencies, five hospice agencies, two home care agencies and two senior living operations. In connection with the acquisitions of one of the senior living communities, the Company entered into a new long-term “triple-net” lease with a subsidiary of Ensign. The Company did not acquire any material assets or assume any liabilities. A subsidiary of the Company entered into a separate operations transfer agreement with the prior operator of each acquired operation as part of each transaction. The addition of these operations added a total of 143 operational senior living units to be operated by the Company’s independent operating subsidiaries. The aggregate purchase price for these acquisitions was $18,780. Acquisition costs related to the business combinations of home health, hospice, and home care was $611 during the year ended December 31, 2019.

69

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

2018 Acquisitions

During the year ended December 31, 2018, the Company expanded its operations with the addition of four home health agencies, two hospice agencies, two home care agencies and seven senior living operations. The Company did not acquire any material assets or assume any liabilities other than the tenant’s post-assumption rights and obligations under the senior living long-term leases. The aggregate purchase price for these acquisitions during the year ended December 31, 2018 was $5,318. The addition of these operations added a total of 386 operational senior living units to be operated by the Company’s independent operating subsidiaries. Typically, subsidiaries of the Company entered into a separate operations transfer agreement with the prior operator as part of each transaction. The Company did not incur acquisition costs related to business combinations during the year ended December 31, 2018.

The fair value of assets for home health and hospice acquisitions was mostly concentrated in goodwill and as such, these transactions were classified as business combinations in accordance with ASC Topic 805, Business Combinations (“ASC 805”). The table below presents the allocation of the purchase price for the operations acquired in business combinations during the years ended December 31, 2020, 2019 and 2018 as noted above:

Year Ended December 31,
202020192018
Equipment, furniture, and fixtures$174 $91 $15 
Goodwill25,211 10,341 2,872 
Other indefinite-lived intangible assets14,026 8,326 1,838 
Other Assets 2  
Liabilities Assumed(172)  
    Total acquisitions$39,239 $18,760 $4,725 
Less: noncontrolling interest and additional paid in capital(a)
(4,646)  
Total cash paid for acquisitions(b)
$34,593 $18,760 $4,725 

(a)Consists of the of noncontrolling interest related to Scripps contribution of assets to the joint venture.
(b)
Total cash paid for acquisitions for the year ended December 31, 2020 includes $1,400 that was recorded as an escrow deposit at December 31, 2019.

Unaudited Pro Forma Financial Information

The Company’s acquisition strategy has been focused on identifying both opportunistic and strategic acquisitions within its target markets that offer strong opportunities for return. The independent operating subsidiaries acquired by the Company are frequently underperforming financially and can have regulatory and clinical challenges to overcome. From time to time, these acquisitions are more strategic in nature that may or may not have positive operational results. Financial information, especially with underperforming independent operating subsidiaries, is often inadequate, inaccurate or unavailable. Consequently, the Company believes that prior operating results are not a meaningful representation of the Company’s current operating results or indicative of the integration potential of its newly acquired independent operating subsidiaries. Revenue and income before tax included in the consolidated and combined statement of income relating to the business combinations was $17,676 and $750, respectively, during the year ended December 31, 2020.

The following tables represent unaudited pro forma results of consolidated and combined operations as if the business combinations in fiscal year 2020 had occurred at the beginning of 2019, after giving effect to certain adjustments. The unaudited pro forma information is not indicative of what the results of operations would have been if the acquisitions had actually occurred at the beginning of the periods presented and is not intended as a projection of future results or trends.

70

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

Unaudited Pro Forma Data

Years Ended December 31,
20202019
Revenue$424,805 $396,468 
Net income attributable to The Pennant Group, Inc.(a)
13,784 1,277 

(a)
Net income attributable to The Pennant Group, Inc. for the year ended December 31, 2020 and 2019 includes a tax impact of 25.0% and 25.2%, which are the respective statutory tax rates.

The unaudited pro forma financial information has been included for the businesses combinations during the year ended December 31, 2020. The acquisitions during the year ended December 31, 2020 have been included in the December 31, 2020 consolidated balance sheets of the Company, and the operating results have been included in the consolidated and combined statements of income of the Company since the dates the Company gained effective control.

Revenues and operating costs were based on actual results from the prior operator or from regulatory filings where available. If actual results were not available, revenues and operating costs were estimated based on available partial operating results of the prior operator of the operation, or if no information was available, estimates were derived from the Company’s post-acquisition operating results for that particular operation.

The unaudited pro forma information is not indicative of what the results of operations would have been if the business combinations had actually occurred at the beginning of the periods presented and is not intended as a projection of future results or trends.

Subsequent Events

Subsequent to December 31, 2020, the Company acquired two home health agencies and two hospice agencies. The aggregate purchase price for these acquisitions was $3,625. As of the date of this report, the preliminary allocation of the purchase price for the acquisitions acquired subsequent to December 31, 2020 were not completed as necessary valuation information was not yet available. As such, the determination whether these acquisitions should be classified as business combinations or asset acquisitions under ASC 805 will be determined upon completion of the allocation of the purchase price.


8. PROPERTY AND EQUIPMENT—NET
Property and equipment, net consist of the following:

Year Ended December 31,
20202019
Leasehold improvements$9,984 $6,621 
Equipment22,420 18,930 
Furniture and fixtures1,186 877 
33,590 26,428 
Less: accumulated depreciation(15,706)(11,784)
Property and equipment, net$17,884 $14,644 

Depreciation expense was $4,661, $3,757 and $2,863 for the years ended December 31, 2020, 2019 and 2018, respectively.

9. GOODWILL AND INTANGIBLE ASSETS—NET
The Company tests goodwill during the fourth quarter of each year and also if events or changes in circumstances indicate the occurrence of a triggering event which might indicate there may be impairment. The Company performs its goodwill impairment analysis for each reporting unit that constitutes a component for which (1) discrete financial information is available and (2) segment management regularly reviews the operating results of that component, in accordance with the provisions of ASC Topic 350, Intangibles-Goodwill and Other (“ASC 350”).
71

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)


The Company reviews goodwill for impairment by initially considering qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill, as a basis for determining whether it is necessary to perform a quantitative analysis. If it is determined that it is more likely than not that the fair value of reporting unit is less than its carrying amount, a quantitative analysis is performed to identify goodwill impairment. If it is determined that it is not more likely than not that the fair value of the reporting unit is less than its carrying amount, it is unnecessary to perform a quantitative analysis. The Company may elect to bypass the qualitative assessment and proceed directly to performing a quantitative analysis. Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value. An impairment loss is recognized for the amount that the carrying amount of the reporting unit, including goodwill, exceeds its fair value, limited to the total amount of goodwill allocated to that reporting unit. The Company did not identify any impairment charge during the years ended December 31, 2020, 2019 and 2018.

The following table represents activity in goodwill by segment as of and for the year ended December 31, 2020:

Home Health and Hospice ServicesSenior Living ServicesTotal
December 31, 2018$27,250 $3,642 $30,892 
Additions10,341  10,341 
December 31, 201937,591 3,642 41,233 
Additions25,211  25,211 
December 31, 2020$62,802 $3,642 $66,444 

Other indefinite-lived intangible assets consist of the following:

Year Ended December 31,
20202019
Trade name$1,355 $355 
Medicare and Medicaid licenses46,133 33,107 
Total$47,488 $33,462 

10. OTHER ACCRUED LIABILITIES
Other accrued liabilities consist of the following:

December 31, 2020December 31, 2019
Refunds payable$2,664 $2,152 
Deferred revenue1,271 1,937 
Resident deposits5,647 6,292 
Contract Liabilities (CARES Act advance payments)22,771  
Property taxes982 1,130 
Accrued insurance retention - current portion1,354  
Other3,586 2,400 
Other accrued liabilities$38,275 $13,911 

Refunds payable includes payables related to overpayments, duplicate payments and credit balances from various payor sources. Deferred revenue occurs when the Company receives payments in advance of services provided. Resident deposits include refundable deposits to residents and a small portion consists of non-refundable deposits recognized into revenue over a period of time. The CARES Act also expanded the Centers for Medicare & Medicaid Services’ (“CMS”) ability to provide accelerated/advance payments intended to increase the cash flow of healthcare providers and suppliers impacted by COVID-19. During the second quarter the Company applied for and received $27,997 in funds under the AAP Program. On October 1, 2020, the Continuing Appropriations Act, 2021 and Other Extensions Act (the “CA Act”) was signed into law.
72

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

Among other things, the CA Act significantly changed the repayment terms for AAP. These funds are subject to automatic recoupment through offsets to new claims beginning one year after funds were issued beginning in April 2021, at which time, Medicare will automatically recoup 25 percent of Medicare payments for 11 months. At the end of the 11 months and assuming full repayment has not occurred, recoupment will increase to 50 percent for another six months. Any balance outstanding after these two recoupment periods will be subject to repayment at a four percent interest rate. The Company anticipates completing repayment of the AAP within the allotted recoupment periods. As a result of the recoupment guidance, the Company reclassified $5,226 of the AAP to other long-term liabilities.

11. DEBT
Long-term debt, net consists of the following:
Year Ended December 31,
20202019
Revolving Credit Facility$9,500 $20,000 
Less: unamortized debt issuance costs(1,223)(1,474)
Long-term debt, net$8,277 $18,526 

On October 1, 2019, Pennant entered into a credit agreement (the “Credit Agreement”), which provided for a revolving credit facility (the “2019 Revolving Credit Facility”) with a syndicate of banks with a borrowing capacity of $75,000. The interest rates applicable to loans under the 2019 Revolving Credit Facility were, at the Company’s election, either (i) Adjusted LIBOR (as defined in the Credit Agreement) plus a margin ranging from 2.5% to 3.5% per annum or (ii) Base Rate plus a margin ranging from 1.5% to 2.5% per annum, in each case based on the ratio of Consolidated Total Net Debt to Consolidated EBITDA (each, as defined in the Credit Agreement). In addition, Pennant paid a commitment fee on the undrawn portion of the commitments under the 2019 Revolving Credit Facility that of approximately 0.6% per annum. The Company is not required to repay any loans under the Credit Agreement prior to maturity in 2024, other than to the extent the outstanding borrowings exceed the aggregate commitments under the Credit Agreement. As of December 31, 2020, the Company’s weighted average interest rate on its outstanding debt was 4.75%. As of December 31, 2020, we had availability on the 2019 Revolving Credit Facility of $62,164, which is net of outstanding letters of credit of $3,336.

The fair value of the 2019 Revolving Credit Facility approximates carrying value, due to the short-term nature and variable interest rates. The fair value of this debt is categorized within Level 2 of the fair value hierarchy based on the observable market borrowing rates.

The Credit Agreement is guaranteed, jointly and severally, by certain of the Company’s wholly owned subsidiaries, and is secured by a pledge of stock of the Company's material independent operating subsidiaries as well as a first lien on substantially all of each material operating subsidiary's personal property. The Credit Agreement contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its independent operating subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend certain material agreements and pay certain dividends and other restricted payments. Financial covenants require compliance with certain levels of leverage ratios that impact the amount of interest. As of December 31, 2020, the Company was compliant with all covenants.

Subsequent Events

On February 23, 2021, Pennant entered into an amendment to the Credit Agreement (the “Amended Credit Agreement”), which provides for a revolving credit facility (the “2021 Revolving Credit Facility”) with a syndicate of banks with a borrowing capacity of $150,000. The interest rates applicable to loans under the 2021 Revolving Credit Facility are, at the Company’s election, either (i) Adjusted LIBOR (as defined in the Amended Credit Agreement) plus a margin ranging from 2.3% to 3.3% per annum or (ii) Base Rate plus a margin ranging from 1.3% to 2.3% per annum, in each case based on the ratio of Consolidated Total Net Debt to Consolidated EBITDA (each, as defined in the Amended Credit Agreement). In addition, Pennant will pay a commitment fee on the undrawn portion of the commitments under the Revolving Credit Facility that will range from 0.35% to 0.50% per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio of the Company and its subsidiaries. The Company is not required to repay any loans under the Amended Credit Agreement prior to maturity in 2026.


73

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

12. OPTIONS AND AWARDS

For all periods prior to the Spin-Off, employees of the Company participated in Ensign's share-based compensation plans. The compensation expense recorded by the Company included the expense associated with these employees, as well as an allocation of share-based compensation of certain Ensign employees who provided general and administrative services on our behalf.

Outstanding options held by employees of the Company under the Ensign stock plans (collectively the “Ensign Plans”) and outstanding options and restricted stock awards under the Company Subsidiary Equity Plan (together with the Ensign Plans the “Pre-Spin Plans”) were modified and replaced with Pennant awards under the Pennant Plans at the Spin-Off date. Additionally, in connection with the Spin-Off, the Company issued new options and restricted stock awards to Pennant and Ensign employees under the 2019 Omnibus Incentive Plan (the OIP) and Long-Term Incentive Plan (the LTIP”, together referred to as the “Pennant Plans”).

Under the Ensign Plans and the Pennant Plans, share-based payment awards, including employee stock options, restricted stock awards (“RSA”), and restricted stock units (“RSU” and together with RSA, “Restricted Stock”) are issued based on estimated fair value. The following disclosures represent share-based compensation expense relating to the Ensign and Pennant Plans, including awards to employees of the Company’s subsidiaries and an allocation of costs from employees in the Service Center prior to the Spin-Off, and total share-based compensation after the Spin-Off.

Total share-based compensation expense for all of the Plans for the years ended December 31, 2020, 2019 and 2018:

Year Ended December 31,
202020192018
Prior to the Spin-Off:
Total share-based compensation$— $1,395 $2,382 
Following the Spin-Off:
Share-based compensation expense related to stock options1,660 315  
Share-based compensation expense related to Restricted Stock6,200 1,589  
Share-based compensation expense related to Restricted Stock to non-employee directors475 83  
Total share-based compensation$8,335 $3,382 $2,382 

In future periods, the Company estimates it will recognize the following share-based compensation expense for unvested stock options and unvested Restricted Stock, which were unvested as of December 31, 2020:

Unrecognized Compensation ExpenseWeighted Average Recognition Period (in years)
Unvested stock options$10,055 4.3
Unvested Restricted Stock10,956 1.8
Total unrecognized share-based compensation expense$21,011 

Stock Options

Under the Pennant Plans, options granted to employees of the subsidiaries of Pennant generally vest over five years at 20% per year on the anniversary of the grant date. Options expire ten years after the date of grant.

The Company uses the Black-Scholes option-pricing model to recognize the value of share-based compensation expense for share-based payment awards under the Plans. Determining the appropriate fair-value model and calculating the fair value of share-based awards at the grant date requires considerable judgment, including estimating stock price volatility and
74

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

expected option life. The Company develops estimates based on historical data and market information, which can change significantly over time.

The fair value of each option is estimated on the grant date using a Black-Scholes option-pricing model with the following weighted average assumptions for stock options granted after the Spin-Off:

Grant YearOptions GrantedRisk-Free Interest Rate
Expected Life(a)
Expected Volatility(b)
Dividend YieldWeighted Average Fair Value of Options
2020693 0.5 %6.535.9 % %$11.05 
2019667 1.6 %6.534.6 % %$5.70 

(a)
Under the midpoint method, the expected option life is the midpoint between the contractual option life and the average vesting period for the options being granted. This resulted in an expected option life of 6.5 years for the options granted.
(b)Because the Company’s equity shares have been traded for a relatively short period of time, expected volatility assumption was based on the volatility of related industry stocks.

The following table represents the employee stock option activity during the year ended December 31, 2020:

Number of
Options
Outstanding
Weighted
Average
Exercise Price
Number of
Options Vested
Weighted
Average
Exercise Price
of Options
Vested
December 31, 20191,573 $9.71 607 $4.80 
Granted693 $30.44 
Exercised(239)$4.77 
Forfeited(36)$14.34 
Expired(9)$6.24 
December 31, 20201,982 $17.48 615 $7.52 

The aggregate intrinsic value of options outstanding, vested, unvested and exercised as of and for the period ended December 31, 2020 is as follows:
OptionsDecember 31, 2020
Outstanding$80,456 
Vested31,077 
Unvested49,379 
Exercised8,002 
The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the options. There were 1,367 unvested and outstanding options at December 31, 2020. The weighted average contractual life for options outstanding, vested and expected to vest at December 31, 2020 was 7.83 years.

75

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

Restricted Stock Awards

Under the Pennant Plans, the Company granted Restricted Stock to Pennant employees, Ensign employees, and to non-employee directors. All awards generally vest between three to five years. A summary of the status of Pennant’s non-vested Restricted Stock, and changes during the period ended December 31, 2020, is presented below:
Non-Vested Restricted AwardsWeighted Average Grant Date Fair Value
December 31, 20191,793 $14.44 
Granted29 26.84 
Vested(176)13.27 
Forfeited(11)10.92 
December 31, 20201,635 $14.80 

13. LEASES
The Company’s independent operating subsidiaries lease 54 senior living communities and its administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from five to 21 years. Most of these leases contain renewal options, most involve rent increases and none contain purchase options. The lease term excludes lease renewals because the renewal rents are not at a bargain, there are no economic penalties for the Company to renew the lease, and it is not reasonably certain that the Company will exercise the extension options. As of December 31, 2020, the Company’s independent operating subsidiaries leased 31 communities from subsidiaries of Ensign (“Ensign Leases”) under a master lease arrangement. The existing leases with subsidiaries of Ensign are for initial terms of between 14 to 20 years. In addition to rent, each of the operating companies are required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all community maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties.
Fifteen of the Company’s affiliated senior living communities, excluding the communities that are operated under the Ensign Leases (as defined herein), are operated under two separate master lease arrangements. Under these master leases, a breach at a single community could subject one or more of the other communities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company’s leases and master leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the master lease without the consent of the landlord.

The components of operating lease cost, are as follows:

Year Ended December 31,
20202019
Operating Lease Costs:
Facility Rent—cost of services$35,562 $32,011 
Office Rent—cost of services3,772 2,964 
Sublease income(143) 
Rent—cost of services$39,191 $34,975 
General and administrative expense$295 $162 
Variable lease cost(a)
$5,330 $4,608 

(a)
Represents variable lease cost for operating leases, which costs include property taxes and insurance, common area maintenance, and consumer price index increases, incurred as part of our triple net lease, and which is included in cost of services for the years ended December 31, 2020 and 2019.

Rent expense for operating leases classified under Topic 840 for the year ended December 31, 2018 was $31,199.
76

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

The following table shows the lease maturity analysis for all leases as of December 31, 2020:

YearAmount
2021$38,393 
202237,730 
202337,038 
202436,230 
202535,349 
Thereafter356,838 
Total lease payments541,578 
Less: present value adjustments(230,857)
Present value of total lease liabilities310,721 
Less: current lease liabilities(14,106)
Long-term operating lease liabilities$296,615 

Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at each lease’s commencement date to determine each lease's operating lease liability. As of December 31, 2020, the weighted average remaining lease term is 15.0 years and the weighted average discount rate is 8.2%.

14. INCOME TAXES
The provision for income taxes for the years ended December 31, 2020, 2019 and 2018 is summarized as follows:

Year Ended December 31,
202020192018
Current:
Federal$5,058 $562 $3,223 
State1,478 278 915 
Total current6,536 840 4,138 
Deferred:
Federal(3,348)1,070 226 
State(838)175 (12)
Total deferred(4,186)1,245 214 
Total income tax expense$2,350 $2,085 $4,352 

77

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

A reconciliation of the federal statutory rate to the effective tax rate for income from continuing operations for the years ended December 31, 2020, 2019 and 2018, respectively, is comprised as follows:

Year Ended December 31,
202020192018
Income tax expense at statutory rate21.0 %21.0 %21.0 %
State income taxes - net of federal benefit2.7 6.8 3.5 
Non-deductible expenses0.4 2.6 0.4 
Transaction costs(a)
 41.2  
Tax credits (1.6) 
Equity compensation(b)
(10.8)(30.0)(2.9)
Revaluation of deferred  (0.2)
Other adjustments(0.2)(0.4)(0.7)
Total income tax provision13.1 %39.6 %21.1 %

(a)
The Company's completion of the Spin-Off in the year ended December 31, 2019 resulted in the Company not being able to deduct approximately $10,300 of the related transaction costs, which increased the effective tax rate significantly and affected all items that were impacted by this exclusion.
(b)
During the year ended December 31, 2020, employees exercised stock options representing approximately 239 shares. During the year ended December 31, 2019, employees exercised stock options representing approximately 100 shares and had restricted stock awards vest representing 960 shares. These exercises and vestings resulted in tax benefits that reduced the Company's effective tax rate significantly in both years.

Prior to the date of the Spin-Off, the Company's operations were included in Ensign’s U.S. federal and state income tax returns and all income taxes were paid by subsidiaries of Ensign. Additionally, prior to the date of the Spin-Off, income tax expense and other income tax related information contained in these Consolidated and Combined Financial Statements were presented on a separate tax return approach. Under this approach, the provision for income taxes represents income tax paid or payable for the current year plus the change in deferred taxes during the year calculated as if the Company were a stand-alone taxpayer filing hypothetical income tax returns. Management believes that the assumptions and estimates used to determine these tax amounts were reasonable. However, the Company's Consolidated and Combined Financial Statements may not necessarily reflect the Company’s income tax expense or tax payments in the future, or what its tax amounts would have been if the Company had been a stand-alone company during the periods presented.

Effective January 1, 2018, the Tax Cuts and Jobs Act of 2017 (“Tax Act”) reduced the corporate rate from 35.0% to 21.0%. The Company adopted ASU 2018-05, Taxes (Topic 740): Amendments to SEC Paragraph Pursuant to SEC Staff Accounting Bulletin No. 118. As of December 31, 2018, the Company had completed its accounting for the tax effects of the enactment of the Tax Act.

The Company recorded prepaid expenses for income taxes for the year ended December 31, 2020 and for the income tax returns the Company filed for the three month period from October 1, 2019 through December 31, 2019.

78

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)


The Company’s deferred tax assets and liabilities for the years ended December 31, 2020 and 2019 are summarized below.

Year Ended December 31,
 20202019
Deferred tax assets (liabilities):
Accrued expenses$8,181 $2,670 
Allowance for doubtful accounts875 869 
State taxes147 27 
Lease liabilities80,979 83,076 
Insurance277 137 
Gross deferred tax assets90,459 86,779 
Less: valuation allowance(15) 
Net deferred tax assets90,444 86,779 
Depreciation and amortization(7,512)(6,107)
Prepaid expenses(780)(594)
Right of use asset(80,055)(82,181)
Total deferred tax liabilities(88,347)(88,882)
Net deferred tax assets (liabilities)$2,097 $(2,103)

For the year ended December 31, 2019, the Company included the net deferred tax liability in other long-term liabilities on it Consolidated Balance Sheets.

During the year ended December 31, 2020, the Company utilized all of its net operating loss ("NOL") carryforwards for federal income tax purposes. As of December 31, 2020, the Company has $500 of NOL carryforwards in various states, which are available to reduce future state taxable income, if any. Some of the state NOL carryforwards do not expire while others, if not utilized, will expire in the year ending December 31, 2039.

The Company believes that it is more likely than not that the benefit from certain state NOL carryforwards will not be realized. In recognition of this risk, as of December 31, 2020, the Company has provided a valuation allowance of $15 on the deferred tax assets related to these state NOL carryforwards.

The federal statutes of limitations on the Company’s 2016, 2015, and 2014 income tax years lapsed during the third quarter of 2020, 2019, and 2018, respectively. During the fourth quarter of each year, various state statutes of limitations also lapsed. The lapses for the years ended December 31, 2020 and 2019 had no impact on the Company’s unrecognized tax benefits.

For the years ended December 31, 2020 and 2019, the Company did not have any unrecognized tax benefits, net of their state benefits that would affect the Company’s effective tax rate. The Company classifies interest and/or penalties on income tax liabilities or refunds as additional income tax expense or income. Such amounts are not material.

15. COMMITMENTS AND CONTINGENCIES
Regulatory Matters - The Company provides services in complex and highly regulated industries. The Company’s compliance with applicable federal, state and local laws and regulations governing these industries may be subject to governmental review and adverse findings may result in significant regulatory action, which could include sanctions, damages, fines, penalties (many of which may not be covered by insurance), and even exclusion from government programs. The Company is a party to various regulatory and other governmental audits and investigations in the ordinary course of business and cannot predict the ultimate outcome of any federal or state regulatory survey, audit or investigation. While governmental audits and investigations are the subject of administrative appeals, the appeals process, even if successful, may take several years to resolve. The Department of Justice, The Centers for Medicare and Medicaid Services (“CMS”), or other federal and state enforcement and regulatory agencies may conduct additional investigations related to the Company's businesses. The Company believes that it is presently in compliance in all material respects with all applicable laws and regulations.
79

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)


Cost-Containment Measures - Government and third party payors have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect the Company.

Indemnities - From time to time, the Company enters into certain types of contracts that contingently require the Company to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which the Company may be required to indemnify property owners or prior operators for post-transfer environmental or other liabilities and other claims arising from the Company’s use of the applicable premises, (ii) operations transfer agreements, in which the Company agrees to indemnify past operators of agencies and communities the Company acquires against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer, (iii) certain Ensign lending agreements, and (iv) certain agreements with management, directors and employees, under which the subsidiaries of the Company may be required to indemnify such persons for liabilities arising out of their employment relationships. The terms of such obligations vary by contract and, in most instances, a specific or maximum dollar amount is not explicitly stated therein. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on the Company’s combined balance sheets for any of the periods presented.

Litigation - The Company’s businesses involve a significant risk of liability given the age and health of the patients and residents served by its independent operating subsidiaries. The Company, its operating companies, and others in the industry may be subject to a number of claims and lawsuits, including professional liability claims, alleging that services provided have resulted in personal injury, elder abuse, wrongful death or other related claims. Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and the Company is routinely subjected to these claims in the ordinary course of business, including potential claims related to patient care and treatment, professional negligence and class actions, as well as employment related claims. If there were a significant increase in the number of these claims or an increase in amounts owing should plaintiffs be successful in their prosecution of these claims, this could materially adversely affect the Company’s business, financial condition, results of operations and cash flows. In addition, the defense of these lawsuits may result in significant legal costs, regardless of the outcome, and can result in large settlement amounts or damage awards.

In addition to the potential lawsuits and claims described above, the Company is also subject to potential lawsuits under the False Claims Act (the “FCA”) and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare) or payor. A violation may provide the basis for exclusion from federally funded healthcare programs. Such exclusions could have a correlative negative impact on the Company’s financial performance. Some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. In addition, the Deficit Reduction Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the FCA. As such, the Company could face increased scrutiny, potential liability and legal expenses and costs based on claims under state false claims acts in markets in which it does conduct business.

In May 2009, Congress passed the Fraud Enforcement and Recovery Act ("FERA") which made significant changes to the FCA, expanding the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, healthcare providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government, including the retention of any government overpayment. The Patient Protection and Affordable Care Act of 2010 (the “ACA”) supplemented FERA by imposing an affirmative obligation on healthcare providers to return an overpayment to CMS within 60 days of “identification” or the date any corresponding cost report is due, whichever is later. According to CMS’s February 12, 2016, final rule with respect to Medicare Parts A and B, providers have an obligation to proactively exercise “reasonable diligence” to identify overpayments. The 60-day clock begins to run after the reasonable diligence period has concluded, which may take, at most, six months from the receipt of credible information. Retention of any overpayment beyond this period may create liability under the FCA. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, there is generally no need for an employment relationship in order to qualify for protection against retaliation for whistleblowing.

The Company cannot predict or provide any assurance as to the possible outcome of any litigation. If any litigation were to proceed, and the Company and its operating companies are subjected to, alleged to be liable for, or agree to a settlement of, claims or obligations under federal Medicare statutes, the FCA, or similar state and federal statutes and related regulations, the Company’s business, financial condition and results of operations and cash flows could be materially and adversely
80

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

affected. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged civil violations, and may also include the assumption of specific procedural and financial obligations by the Company or its independent operating subsidiaries going forward under a corporate integrity agreement and/or other arrangement with the government.

Medicare Revenue Recoupments - The Company is subject to probe reviews relating to Medicare services, billings and potential overpayments by Unified Program Integrity Contractors (UPIC), Recovery Audit Contractors (RAC), Zone Program Integrity Contractors (ZPIC), Program Safeguard Contractors (PSC), Supplemental Medical Review Contractors (SMRC) and Medicaid Integrity Contributors (MIC) programs, each of the foregoing collectively referred to as “Reviews.” As of December 31, 2020, seven of the Company’s independent operating subsidiaries had Reviews scheduled, on appeal or in dispute resolution process, both pre- and post-payment. The Company anticipates that these probe reviews will increase in frequency in the future. If an operation fails an initial or subsequent Review, the operation could then be subject to extended Review, suspension of payment, or extrapolation of the identified error rate to all billing in the same time period. As of December 31, 2020, and through the filing of this Annual Report on Form 10-K, the Company’s independent operating subsidiaries have responded to the Reviews that are currently ongoing, on appeal or in dispute resolution process and the Company has no probable or estimable contingencies.

Concentrations

Credit Risk - The Company has significant accounts receivable balances, the collectability of which is dependent on the availability of funds from certain governmental programs, primarily Medicare and Medicaid. These receivables represent the only significant concentration of credit risk for the Company. The Company does not believe there are significant credit risks associated with these governmental programs. The Company believes that an appropriate allowance has been recorded for the possibility of these receivables proving uncollectible, and continually monitors and adjusts these allowances as necessary. The Company’s gross receivables from the Medicare and Medicaid programs accounted for approximately 75.7% and 74.3% of its total gross accounts receivable as of December 31, 2020 and December 31, 2019, respectively. Revenue from reimbursement under the Medicare and Medicaid programs accounted for 60.1%, 55.6%, and 53.1% of the Company's revenue for the years ended December 31, 2020, 2019 and 2018, respectively.

81
EX-21.1 2 listofsubsidiariesofpntgq4.htm EX-21.1 Document

Exhibit 21.1

List of Subsidiaries of The Pennant Group, Inc.

The following is a list of subsidiaries of The Pennant Group, Inc. as of December 31, 2020:


Subsidiary  Jurisdiction
2410 Stillhouse Senior Living, Inc.  Nevada
Alpowa Healthcare, Inc.  Nevada
Arches Home Care, Inc.  Nevada
Autumn Ridge Senior Living, Inc.  Nevada
Beach City Senior Living LLC  Nevada
Bear River Healthcare LLC  Nevada
Black Mountain Healthcare LLC  Delaware
Brenwood Park Senior Living, Inc.  Nevada
Brookhollow Senior Living LLC  Nevada
Brown Road Senior Housing LLC  Nevada
Bruce Neenah Senior Living, Inc.  Nevada
Cactus Heights Healthcare LLCNevada
Canyon Healthcare, Inc.  Nevada
Capitol Healthcare, Inc.  Nevada
Casell Senior Living LLC  Nevada
Cedar Senior Living, Inc.  Nevada
Clark Fork Healthcare LLC  Nevada
Clear Creek Healthcare, Inc.  Nevada
Comfort Assisting Hospice Inc.  California
Connected Healthcare, Inc.  Nevada
Copper Basin Healthcare, Inc.  Nevada
Cornerstone Healthcare, Inc.  Nevada
Cornerstone Service Center LLC  Nevada
Cornerstone Service Center, Inc.  Nevada
Custom Care Healthcare, Inc.  Nevada
De Soto Senior Living, Inc.  Nevada
Denmark Senior Living, Inc.  Nevada
Eagle Pass Senior Living LLC  Nevada
Emblem Healthcare, Inc.Nevada
Emerald Healthcare, Inc.Nevada
Eureka Healthcare, Inc.  Nevada
Exemplar Healthcare, Inc.  Nevada
Finding Home Healthcare, Inc.  Nevada
Finding Home Management Services LLC  Nevada
Finding Home Physician Services LLC  Nevada
Gateway Cities Senior Living, Inc.  Nevada



Glacier Peak Healthcare, Inc.  Nevada
Go Assisted, Inc.  Nevada
Granite Healthcare, Inc.  Nevada
Granite Hills Senior Living, Inc.  Nevada
Great Lakes Healthcare, Inc.  Nevada
Great Plains Healthcare, Inc.  Nevada
Green Bay Senior Living, Inc.  Nevada
Heartland Healthcare, Inc.  Nevada
iCare Private Duty, Inc.  Nevada
Indigo Healthcare LLC  Nevada
Iron Bridge Healthcare, Inc.  Nevada
Jameson Senior Living, Inc.  Nevada
Jentilly Healthcare LLC  Nevada
Joshua Tree Healthcare, Inc.  Nevada
Kenosha Senior Living, Inc.  Nevada
Keystone Hospice Care, Inc.  Nevada
Laguna Healthcare, Inc.  Nevada
Lake Pointe Senior Living, Inc.  Nevada
Lemon Senior Living LLC  Nevada
Lowes Senior Living, Inc.  Nevada
Madison Senior Living, Inc.  Nevada
Manitowoc Senior Living, Inc.  Nevada
McFarland Senior Living, Inc.  Nevada
Mesa Grande Senior Living, Inc.  Nevada
Mesa Springs Senior Living LLC  Nevada
Mission Inn Senior Living LLC  Nevada
Mohave Healthcare, Inc.  Nevada
Monument Healthcare, Inc.  Nevada
Moss Bay Senior Living, Inc.  Nevada
Mountain Peak Home Care, Inc.  Nevada
Mountain Vista Senior Living, Inc.  Nevada
Oceano Senior Living, Inc.  Nevada
Oceanside Healthcare, Inc.  Nevada
Orange Senior Living, Inc.  Nevada
Orangewood Senior Living, Inc.  Nevada
Painted Sky Healthcare, Inc.  Nevada
Paragon Healthcare, Inc.  Nevada
Peaceful Heart Healthcare LLCNevada
Pearl Senior Living, Inc.  Nevada
Pecan Bayou Healthcare LLC  Nevada
Pennant Services, Inc.  Nevada
Pinnacle Senior Living LLC  Nevada
Pinnacle Service Center LLC  Nevada



Pleasant Run Senior Living, Inc.  Nevada
Prairie View Healthcare, Inc.  Nevada
Primrose Senior Living, Inc.  Nevada
Prospect Senior Living, Inc.  Nevada
Racine Senior Living, Inc.  Nevada
Rancho Bernardo Healthcare LLC  Delaware
Red Rock Healthcare, Inc.  Nevada
Riverview Village Senior Living, Inc.  Nevada
Rock Garden Healthcare LLC  Nevada
Rockbrook Senior Living, Inc.  Nevada
Rogue River Healthcare LLC  Nevada
Rolling Hills Healthcare, Inc.  Nevada
Rosenburg Senior Living, Inc.  Nevada
Saguaro Senior Living, Inc.  Nevada
San Gabriel Senior Living, Inc.  Nevada
Sand Lily Healthcare, Inc.  Nevada
Sandstone Senior Living, Inc.  Nevada
Sentinel Healthcare LLC  Nevada
Sheboygan Senior Living, Inc.  Nevada
Silver Lake Healthcare, Inc.  Nevada
Somers Kenosha Senior Living, Inc.  Nevada
South Bay Healthcare, Inc.  Nevada
South Plains Healthcare, Inc.  Nevada
Southern Pines Healthcare LLC  Nevada
Spanish Meadows Healthcare LLC  Nevada
Spokane Healthcare, Inc.  Nevada
Spring Valley Assisted Living, Inc.  Nevada
Star Valley Healthcare, Inc.  Nevada
Stevens Point Senior Living, Inc.  Nevada
Stoughton Senior Living, Inc.  Nevada
Summerlin Healthcare, Inc.  Nevada
Sun Peak Healthcare LLC  Nevada
Sycamore Senior Living, Inc.  Nevada
Symbol Healthcare, Inc.  Nevada
Terrace Court Senior Living, Inc.  Nevada
Teton Healthcare, Inc.  Nevada
The Pennant Group, Inc.  Delaware
Thomas Road Senior Housing, Inc.  Nevada
Thousand Peaks Healthcare, Inc.  Nevada
Total Healtcare Services LLCNevada
Triumph Healthcare LLCNevada
Twin Falls Senior Living LLC  Nevada
Two Rivers Senior Living, Inc.  Nevada



Vesper Healthcare, Inc.  Nevada
Victoria Ventura Assisted Living Community, Inc.  Nevada
Virgin River Healthcare, Inc.  Nevada
Whitewater Healthcare LLC  Nevada
Willow Creek Senior Living, Inc.Nevada
Wisconsin Rapids Senior Living, Inc.Nevada



EX-23.1 3 deloitteconsentq420-ex231.htm EX-23.1 Document

EXHIBIT 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in Registration Statement No. 333-233937 on Form S-8 of our report dated February 24, 2021, relating to the financial statements of The Pennant Group, Inc., appearing in this Annual Report on Form 10-K for the year ended December 31, 2020.

/s/ Deloitte & Touche LLP

Boise, Idaho
February 24, 2021

EX-31.1 4 ceocert-exhibit311q420.htm EX-31.1 Document

EXHIBIT 31.1

I, Daniel H Walker, certify that:

1.I have reviewed this annual report on Form 10-K of The Pennant Group, Inc;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 24, 2021 
     
 /s/ DANIEL H WALKER 
 Name:  Daniel H Walker 
 Title:  Chairman and Chief Executive Officer (Principal Executive Officer) 


EX-31.2 5 cfocert-exhibit312q420.htm EX-31.2 Document

EXHIBIT 31.2
I, Jennifer L. Freeman, certify that:

1.I have reviewed this annual report on Form 10-K of The Pennant Group, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: February 24, 2021
    
 /s/ JENNIFER L. FREEMAN 
 Name:  Jennifer L. Freeman 
 Title:  Chief Financial Officer (Principal Financial Officer, Principal Accounting Officer and Duly Authorized Officer) 


EX-32.1 6 ceocert-exhibit321q420.htm EX-32.1 Document

EXHIBIT 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of The Pennant Group, Inc. (the Company) on Form 10-K for the period ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Daniel H Walker, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 1 The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
 2 The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
     
 /s/ DANIEL H WALKER 
 Name:  Daniel H Walker 
 Title:  Chairman and Chief Executive Officer (Principal Executive Officer) 
 
 February 24, 2021 

A signed original of this written statement required by 18 U.S.C. Section 1350 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.


EX-32.2 7 cfocert-exhibit322q420.htm EX-32.2 Document

EXHIBIT 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of The Pennant Group, Inc. (the Company) on Form 10-K for the period ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Jennifer L. Freeman, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 1 The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
 2 The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
     
 /s/ JENNIFER L. FREEMAN 
 Name:  Jennifer L. Freeman  
 Title:  Chief Financial Officer (Principal Financial Officer, Principal Accounting Officer and Duly Authorized Officer) 
 
 February 24, 2021 

A signed original of this written statement required by 18 U.S.C. Section 1350 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.


EX-101.SCH 8 pntg-20201231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - CONSOLIDATED AND COMBINED STATEMENTS OF INCOME link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - CONSOLIDATED AND COMBINED STATEMENTS OF STOCKHOLDERS' EQUITY AND NET PARENT INVESTMENT link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - CONSOLIDATED AND COMBINED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - DESCRIPTION OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - DESCRIPTION OF BUSINESS (Details) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2205201 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - SUMMARY OF INSURANCE LIABILITY (Details) link:presentationLink link:calculationLink link:definitionLink 2108103 - Disclosure - RELATED PARTY TRANSACTIONS AND NET PARENT INVESTMENT link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - RELATED PARTY TRANSACTIONS AND NET PARENT INVESTMENT (Details) link:presentationLink link:calculationLink link:definitionLink 2110104 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 2311302 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 2412405 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE - RECONCILIATION (Details) link:presentationLink link:calculationLink link:definitionLink 2413406 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE - NARRATIVE (Details) link:presentationLink link:calculationLink link:definitionLink 2114105 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE link:presentationLink link:calculationLink link:definitionLink 2315303 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 2416407 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - NARRATIVE (Details) link:presentationLink link:calculationLink link:definitionLink 2417408 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - REVENUE BY MAJOR PAYOR (Details) link:presentationLink link:calculationLink link:definitionLink 2418409 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - ACCOUNTS RECEIVABLE (Details) link:presentationLink link:calculationLink link:definitionLink 2419410 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details) link:presentationLink link:calculationLink link:definitionLink 2120106 - Disclosure - BUSINESS SEGMENTS link:presentationLink link:calculationLink link:definitionLink 2321304 - Disclosure - BUSINESS SEGMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2422411 - Disclosure - BUSINESS SEGMENTS - NARRATIVE (Details) link:presentationLink link:calculationLink link:definitionLink 2423412 - Disclosure - BUSINESS SEGMENTS - FINANCIAL DATA (Details) link:presentationLink link:calculationLink link:definitionLink 2424413 - Disclosure - BUSINESS SEGMENTS - INCOME FROM OPERATIONS (Details) link:presentationLink link:calculationLink link:definitionLink 2125107 - Disclosure - ACQUISITIONS link:presentationLink link:calculationLink link:definitionLink 2326305 - Disclosure - ACQUISITIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 2427414 - Disclosure - ACQUISITIONS - NARRATIVE (Details) link:presentationLink link:calculationLink link:definitionLink 2428415 - Disclosure - ACQUISITIONS - OPERATIONS ACQUIRED (Details) link:presentationLink link:calculationLink link:definitionLink 2429416 - Disclosure - ACQUISITIONS - UNAUDITED PRO FORMA (Details) link:presentationLink link:calculationLink link:definitionLink 2130108 - Disclosure - PROPERTY AND EQUIPMENT—NET link:presentationLink link:calculationLink link:definitionLink 2331306 - Disclosure - PROPERTY AND EQUIPMENT—NET (Tables) link:presentationLink link:calculationLink link:definitionLink 2432417 - Disclosure - PROPERTY AND EQUIPMENT—NET (Details) link:presentationLink link:calculationLink link:definitionLink 2133109 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - NET link:presentationLink link:calculationLink link:definitionLink 2334307 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - NET (Tables) link:presentationLink link:calculationLink link:definitionLink 2435418 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - NET - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2436419 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - NET - ACTIVITY IN GOODWILL (Details) link:presentationLink link:calculationLink link:definitionLink 2437420 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - NET - INDEFINITE-LIVED INTANGIBLE ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 2138110 - Disclosure - OTHER ACCRUED LIABILITIES link:presentationLink link:calculationLink link:definitionLink 2339308 - Disclosure - OTHER ACCRUED LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2440421 - Disclosure - OTHER ACCRUED LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 2441422 - Disclosure - OTHER ACCRUED LIABILITIES - NARRATIVE (Details) link:presentationLink link:calculationLink link:definitionLink 2142111 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 2343309 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 2444423 - Disclosure - DEBT - SCHEDULE OF LONG-TERM DEBT (Details) link:presentationLink link:calculationLink link:definitionLink 2445424 - Disclosure - DEBT - NARRATIVE (Details) link:presentationLink link:calculationLink link:definitionLink 2146112 - Disclosure - OPTIONS AND AWARDS link:presentationLink link:calculationLink link:definitionLink 2347310 - Disclosure - OPTIONS AND AWARDS (Tables) link:presentationLink link:calculationLink link:definitionLink 2448425 - Disclosure - OPTIONS AND AWARDS - SHARE-BASED COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 2449426 - Disclosure - OPTIONS AND AWARDS - NARRATIVE (Details) link:presentationLink link:calculationLink link:definitionLink 2450427 - Disclosure - OPTIONS AND AWARDS - OPTIONS GRANTED (Details) link:presentationLink link:calculationLink link:definitionLink 2451428 - Disclosure - OPTIONS AND AWARDS - EMPLOYEE STOCK OPTION ACTIVITY (Details) link:presentationLink link:calculationLink link:definitionLink 2452429 - Disclosure - OPTIONS AND AWARDS - AGGREGATE INTRINSIC VALUE OF OPTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 2453430 - Disclosure - OPTIONS AND AWARDS - RESTRICTED STOCK AWARDS ACTIVITY (Details) link:presentationLink link:calculationLink link:definitionLink 2154113 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 2355311 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 2456431 - Disclosure - LEASES - NARRATIVE (Details) link:presentationLink link:calculationLink link:definitionLink 2457432 - Disclosure - LEASES - IMPACT OF NEW LEASES GUIDANCE (Details) link:presentationLink link:calculationLink link:definitionLink 2458433 - Disclosure - LEASES - FUTURE MINIMUM LEASE PAYMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 2458433 - Disclosure - LEASES - FUTURE MINIMUM LEASE PAYMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 2159114 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 2360312 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 2461434 - Disclosure - INCOME TAXES - PROVISION FOR INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 2462435 - Disclosure - INCOME TAXES - TAX RATE RECONCILIATION (Details) link:presentationLink link:calculationLink link:definitionLink 2463436 - Disclosure - INCOME TAXES - NARRATIVE (Details) link:presentationLink link:calculationLink link:definitionLink 2464437 - Disclosure - INCOME TAXES - DEFERRED TAX ASSETS AND LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 2165115 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 2466438 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 pntg-20201231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 pntg-20201231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 pntg-20201231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Revision of Prior Period [Axis] Revision of Prior Period [Axis] Document Type Document Type ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Total acquisitions Total Acquisitions Total Acquisitions Net non-cash adjustment to right-of-use assets and lease liabilities from lease modifications Adjustment Operating Lease Right-of-Use Asset And Operating Lease Liability Adjustment Operating Lease Right-of-Use Asset And Operating Lease Liability COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Options granted (in shares) Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Related Party [Axis] Related Party [Axis] Treasury Stock Treasury Stock [Member] Payables and Accruals [Abstract] Payables and Accruals [Abstract] Summary of insurance liability Summary Of Insurance Liability [Table Text Block] Summary Of Insurance Liability Segments [Axis] Segments [Axis] Medicaid Medicaid [Member] Medicaid [Member] Restricted and other assets Other Restricted Assets, Noncurrent Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Depreciation and amortization Deferred Tax Liabilities, Depreciation And Amortization Deferred Tax Liabilities, Depreciation And Amortization Expenses from transactions with related party Related Party Transaction, Expenses from Transactions with Related Party Medicare and Medicaid licenses Licensing Agreements [Member] Statistical Measurement [Domain] Statistical Measurement [Domain] Liabilities and equity Liabilities and Equity [Abstract] Line of credit Line of Credit [Member] Additional paid-in capital Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Other long-term liabilities Increase (Decrease) in Other Noncurrent Liabilities Security Exchange Name Security Exchange Name Current portion of estimated liability, included in other accrued liabilities Insurance Program Accrued Expenses, Current Insurance Program Accrued Expenses, Current Consolidated and Combined Income from operations Operating Income (Loss) State taxes Deferred Tax Assets, State Taxes Total current liabilities Liabilities, Current Accounts Receivable and Allowance for Doubtful Accounts Accounts Receivable [Policy Text Block] Scripps Health Scripps Health [Member] Scripps Health Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Beginning of period, weighted average exercise price (in dollars per share) End of period, weighted average exercise price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Variable Rate [Domain] Variable Rate [Domain] Variable Rate [Axis] Variable Rate [Axis] Real Estate, Type of Property [Axis] Real Estate, Type of Property [Axis] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Commitments and contingencies Commitments and Contingencies Revaluation of deferred Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Restricted and other assets Payments For (Proceeds From) Property Reserve Requirements Payments For (Proceeds From) Property Reserve Requirements Shares of common stock withheld to satisfy tax withholding obligations Share-based Payment Arrangement, Decrease for Tax Withholding Obligation Noncontrolling interests assumed related to acquisitions Noncontrolling Interest, Increase from Business Combination Repurchase of shares of common stock to satisfy tax withholding obligations Payments for Repurchase of Common Stock Assets Assets [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Accounting Policies [Abstract] Accounting Policies [Abstract] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Furniture and fixtures Furniture and Fixtures [Member] Number of units (in units) Number Of Units In Real Estate Property Acquired Number Of Units In Real Estate Property Acquired Revenue, Major Customer [Line Items] Revenue, Major Customer [Line Items] Issuance/ (cancellation) of restricted stock Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Entity Address, State or Province Entity Address, State or Province Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Operating lease liabilities Operating Lease, Payments Accounts payable Accounts Payable, Current Sublease income Sublease Income Retained earnings (accumulated deficit) Retained Earnings (Accumulated Deficit) General and professional liability General And Professional Insurance Liability General And Professional Insurance Liability Operating lease right-of-use assets Operating Lease, Right-of-Use Asset 2021 Lessee, Operating Lease, Liability, to be Paid, Year One Acquire interest in joint venture Payments to Acquire Interest in Joint Venture Income taxes Income Taxes Paid Beginning balance, outstanding (in shares) Ending balance, outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 2024 Lessee, Operating Lease, Liability, to be Paid, Year Four Total unrecognized share-based compensation expense Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Customer [Axis] Customer [Axis] State Current State and Local Tax Expense (Benefit) Equity, beginning balance (in shares) Equity, ending balance (in shares) Shares, Outstanding Income Taxes Income Tax, Policy [Policy Text Block] Number of operating subsidiaries with reviews scheduled Number Of Operating Subsidiaries With Reviews Scheduled Number Of Operating Subsidiaries With Reviews Scheduled Workers’ compensation Workers' Compensation Liability Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Payments for deferred financing costs Payments of Financing Costs Other long-term liabilities Other Liabilities, Noncurrent Deferred tax assets Deferred Income Tax Assets, Net Share-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Amounts of related party transaction Related Party Transaction, Amounts of Transaction Revenue Revenue from Contract with Customer, Excluding Assessed Tax Revenue % Concentration risk, percent Concentration Risk, Percentage Business Acquisition [Axis] Business Acquisition [Axis] Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items] Options, expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Business combination and asset acquisition, purchase price Business Combination and Asset Acquisition, Consideration Transferred Business Combination and Asset Acquisition, Consideration Transferred Statement [Line Items] Statement [Line Items] Weighted average interest rate Long-term Debt, Weighted Average Interest Rate, at Point in Time Earnings Per Share, Basic and Diluted [Abstract] Earnings Per Share, Basic and Diluted [Abstract] Managed care Managed Care [Member] Managed Care [Member] Proceeds from revolver agreement Proceeds from Long-term Lines of Credit Entity Voluntary Filers Entity Voluntary Filers Acquisition related costs Business combination, acquisition costs Business Combination, Acquisition Related Costs Statement [Table] Statement [Table] Write-offs of uncollectible accounts Accounts Receivable, Allowance for Credit Loss, Writeoff Statistical Measurement [Axis] Statistical Measurement [Axis] Credit Facility [Axis] Credit Facility [Axis] Deferred income taxes Deferred Income Taxes and Tax Credits Schedule of other accrued liabilities Other Current Liabilities [Table Text Block] Business acquisitions 2019 Business Acquisitions 2019 [Member] Business Acquisitions 2019 [Member] Payments on revolver agreement Repayments of Long-term Lines of Credit Contract Liabilities (CARES Act advance payments) The Coronavirus Aid, Relief, and Economic Security Act, Advance Payments Received The Coronavirus Aid, Relief, and Economic Security Act, Advance Payments Received Business Combinations [Abstract] Business Combinations [Abstract] Insurance Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Self Insurance Entity Small Business Entity Small Business Net income (loss) before taxes Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual Consolidation Consolidation, Policy [Policy Text Block] Leases, Under Adoption of ASC 842 [Abstract] Lessee, Operating Lease, Liability, Payment, Due [Abstract] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] DEBT Debt Disclosure [Text Block] Goodwill [Roll Forward] Goodwill [Roll Forward] Amendment Flag Amendment Flag Weighted average common shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Schedule of operations acquired in business combinations Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] All Other Corporate, Non-Segment [Member] Reclassification of Invested Equity Reclassification Of Invested Equity Reclassification Of Invested Equity Other accrued liabilities Other accrued liabilities Other Accrued Liabilities, Current Cash from sale of noncontrolling interest Proceeds from Divestiture of Interest in Joint Venture Recognition of tax benefits related to Tax Matters Agreement Recognition Of Tax Benefits Related To Tax Matters Agreement [Member] Recognition Of Tax Benefits Related To Tax Matters Agreement Fair Value of Financial Instruments Fair Value Measurement, Policy [Policy Text Block] Subtotal Medicare And Medicaid [Member] Medicare And Medicaid [Member] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Entity Central Index Key Entity Central Index Key Related Party [Domain] Related Party [Domain] Senior Living Services Senior Living Services Segment [Member] Senior Living Services Segment [Member] Less: Costs at start-up operations Start-Up Activities, Costs Start-Up Activities, Costs Related Party Transaction [Line Items] Related Party Transaction [Line Items] Other Accrued Liabilities, Current [Abstract] Accrued Liabilities, Current [Abstract] Payment terms Revenue, Performance Obligation, Description of Payment Terms Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Other long-term liabilities Other Noncurrent Liabilities [Member] Escrow deposits Escrow Deposit Capital expenditures Capital Expenditures Incurred but Not yet Paid Number of options vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Outstanding, Number Income tax effect Additional Paid in Capital, Before the Effect of Income Tax Additional Paid in Capital, Before the Effect of Income Tax Segments [Domain] Segments [Domain] Unvested stock options Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Medicare Medicare [Member] Medicare [Member] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Net income attributable to The Pennant Group, Inc Business Acquisition, Pro Forma Net Income (Loss) Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Plus: incremental shares from assumed conversion Weighted Average Number Diluted Shares Outstanding Adjustment Net investment from/(to) parent Distribution (To) From Parent Distribution (To) From Parent Income Statement Location [Axis] Income Statement Location [Axis] Allowance for doubtful accounts Less: allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Equity compensation(b) Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent Income Statement Location [Domain] Income Statement Location [Domain] 2022 Lessee, Operating Lease, Liability, to be Paid, Year Two Indefinite-lived Intangible Assets [Line Items] Indefinite-lived Intangible Assets [Line Items] Segment Adjusted EBITDAR from Operations Segment Adjusted EBITDAR from Operations Income (Loss) From Continuing Operations Before Interest, Taxes, Depreciation And Amortization, Rent Costs, Acquisition Costs And Stock-based Compensation Income (Loss) From Continuing Operations Before Interest, Taxes, Depreciation And Amortization, Rent Costs, Acquisition Costs And Stock-based Compensation Home Health and Hospice Services Home Health And Hospice Services Segment [Member] Home Health And Hospice Services Segment [Member] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Federal Current Federal Tax Expense (Benefit) Non-deductible expenses Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent Components of operating lease cot Lease, Cost [Table Text Block] Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table] Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table] 2023 Lessee, Operating Lease, Liability, to be Paid, Year Three Plan Name [Axis] Plan Name [Axis] Business segments Segment Reporting Disclosure [Text Block] Issuance of Common Stock after spin-off Stock Issued During Period, Value, New Issues Tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Percent Concentration Risk [Table] Concentration Risk [Table] Non-capitalizable Non-capitalizable Related to the Business Combinations Non-capitalizable Related to the Business Combinations Total assets Assets Related party transactions and net parent investment Related Party Transactions Disclosure [Text Block] Revenue Revenue from Contract with Customer Benchmark [Member] Beginning balance, outstanding (in shares) Ending balance, outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Other indefinite-lived intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Title of 12(b) Security Title of 12(b) Security Weighted average fair value of options (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Subsequent Event Type [Axis] Subsequent Event Type [Axis] Total estimated liability Insurance Program Accrued Expenses Insurance Program Accrued Expenses Cost of services Cost of Sales [Member] Interest expense, net Interest Expense Depreciation and amortization Depreciation, Depletion and Amortization Provision for income taxes on continuing operations Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Total liabilities Liabilities Unvested options and stock awards, cost net yet recognized, period for recognition Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Less: present value adjustments Lessee, Operating Lease, Liability, Undiscounted Excess Amount Weighted average contractual life for options outstanding, vested and expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Asset acquisitions 2019 Asset Acquisitions 2019 [Member] Asset Acquisitions 2019 [Member] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Rent—cost of services Rent—cost of services Operating Lease, Expense Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Accounts payable Increase (Decrease) in Accounts Payable Non-Vested Restricted Awards Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Reconciliation of total Combined Adjusted EBITDAR from Operations for our reportable segments to Combined Income from Operations Reconciliation of Adjusted EBITDAR to Income from Operations [Table Text Block] Reconciliation of Adjusted EBITDAR to Income from Operations [Table Text Block] Sale of noncontrolling interests, net of tax Noncontrolling interest Noncontrolling Interest, Increase from Sale of Parent Equity Interest Additional Paid-In Capital Additional Paid-in Capital [Member] Operating segments Operating Segments [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Accounts receivable, gross Accounts Receivable, before Allowance for Credit Loss, Current Revenue from Contract with Customer [Abstract] Share repurchase related to subsidiary equity plan Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Deferred tax assets (liabilities): Deferred Tax Assets, Net [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Less: valuation allowance Operating Loss Carryforwards, Valuation Allowance Variable lease cost Variable Lease, Cost Revolving credit facility Revolving Credit Facility [Member] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Asset Acquisition [Axis] Asset Acquisition [Axis] Asset Acquisition [Axis] Income before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Cash payments for asset acquisitions Payments for Asset Acquisitions Payments for Asset Acquisitions Equipment, furniture, and fixtures Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equipment, Furniture and Fixtures Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equipment, Furniture and Fixtures Invested Capital Invested Capital [Policy Text Block] Invested Capital [Policy Text Block] Other adjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Subsequent event Subsequent Event [Member] Beginning of period, weighted average exercise price (in dollars per share) End of period, weighted average exercise price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Federal tax authority Domestic Tax Authority [Member] Letters of credit outstanding Letters of Credit Outstanding, Amount Common stock, shares authorized (in shares) Common Stock, Shares Authorized Transaction services costs Acquisition-Related Costs, Not Capitalized Acquisition-Related Costs, Not Capitalized Concentration Risk Type [Axis] Concentration Risk Type [Axis] Property and equipment, gross Property, Plant and Equipment, Gross Issuance of common stock upon the exercise of options Proceeds from Stock Options Exercised Federal Deferred Federal Income Tax Expense (Benefit) Operating lease, rent expense Operating Lease, Rent Expense [Member] Operating Lease, Rent Expense [Member] Asset acquisitions 2018 Asset Acquisitions 2018 [Member] Asset Acquisitions 2018 [Member] Financial data combined by business segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Accrued wages and related liabilities Increase (Decrease) in Employee Related Liabilities Income Statement [Abstract] Income Statement [Abstract] Home Health Services Home Health Subsegment [Member] Home Health Subsegment [Member] Operating lease liabilities—long-term Long-term operating lease liabilities Operating Lease, Liability, Noncurrent Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Summary of non-vested restricted stock awards Nonvested Restricted Stock Shares Activity [Table Text Block] Estimates and Assumptions Use of Estimates, Policy [Policy Text Block] Current assets: Assets, Current [Abstract] Reinsurance receivables Reinsurance Recoverables, Incurred but Not Reported Claims Income Tax Authority [Domain] Income Tax Authority [Domain] Number of properties under lease Number Of Real Estate Properties Under Lease Number Of Real Estate Properties Under Lease Subsegments [Domain] Subsegments [Domain] Weighted average dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Escrow deposits Payments For Deposits On Acquisition Payments For Deposits On Acquisition Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Reconciliation of federal statutory rate to effective tax rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Allowance for doubtful accounts Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts Counterparty Name [Domain] Counterparty Name [Domain] Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment City Area Code City Area Code Revision of Prior Period, Adjustment Revision of Prior Period, Adjustment [Member] Consolidation Items [Domain] Consolidation Items [Domain] Income Tax Authority [Axis] Income Tax Authority [Axis] Document Period End Date Document Period End Date General and professional liability, retention limit General And Professional Liability Insurance, Retention Limit, Per Claim General And Professional Liability Insurance, Retention Limit, Per Claim Goodwill and intangible assets - net Goodwill and Intangible Assets Disclosure [Text Block] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Hospice Join Venture Hospice Join Venture [Member] Hospice Join Venture Non-employee director Director [Member] OTHER ACCRUED LIABILITIES Other Liabilities Disclosure [Text Block] Net income Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Lease term Lessee, Operating Lease, Term of Contract Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Total share-based compensation expense Share-based Payment Arrangement, Cost by Plan [Table Text Block] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Share-based compensation Share-based Payment Arrangement, Noncash Expense Proceeds from sale of subsidiary shares Proceeds From Sale Of Subsidiary Shares Proceeds From Sale Of Subsidiary Shares Asset Acquisitions 2020 Asset Acquisitions 2020 [Member] Asset Acquisitions 2020 Cover [Abstract] Vested Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Outstanding, Aggregate Intrinsic Value Base Rate Base Rate [Member] Additions Goodwill, Acquired During Period Spin-off related transaction costs Spinoff, Transaction Costs Spinoff, Transaction Costs Property and equipment estimated useful lives Property, Plant and Equipment, Useful Life Goodwill [Line Items] Goodwill [Line Items] Related party Affiliated Entity [Member] Long-term debt, net Long-term debt, net Long-term Debt Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Advance payments Increase (Decrease) in Contract with Customer, Liability Leases Lessee, Operating Leases [Text Block] Cost of services Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization Direct medical supplies, labor, and other expenses Direct Medical Supplies, Labor, and Other Expenses Direct Medical Supplies, Labor, and Other Expenses Spin-off transaction, distribution ratio Spin Off Transaction, Distribution Ratio Spin Off Transaction, Distribution Ratio Cost of services Related Party Costs Net deferred tax assets Deferred Tax Assets, Net Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Customer Relationships Customer Relationships [Member] Lease, Cost [Abstract] Lease, Cost [Abstract] Series of Individually Immaterial Business Acquisitions Series of Individually Immaterial Business Acquisitions [Member] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Total expenses Costs and Expenses Award Date [Domain] Award Date [Domain] Home Health Joint Venture Home Health Joint Venture [Member] Home Health Joint Venture Equity Components [Axis] Equity Components [Axis] Restricted stock awards Restricted Stock [Member] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Gross deferred tax assets Deferred Tax Assets, Gross Minimum Minimum [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss [Table Text Block] Operating lease liabilities—current Less: current lease liabilities Operating Lease, Liability, Current Award Date [Axis] Award Date [Axis] Facility Facility [Member] Facility [Member] Unvested Restricted Stock Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Less: net (loss)/ income attributable to noncontrolling interest Net income attributable to noncontrolling interest Add: Net income/ (loss) attributable to noncontrolling interest Net Income (Loss) Attributable to Noncontrolling Interest Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Stock options granted fair value assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Entity Interactive Data Current Entity Interactive Data Current Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Employee stock option activity Share-based Payment Arrangement, Option, Activity [Table Text Block] Receivables Accounts Receivable [Member] Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Amortization period Finite-Lived Intangible Assets, Remaining Amortization Period Share-Based Compensation Share-based Payment Arrangement [Policy Text Block] Customer [Domain] Customer [Domain] Statutory tax rate Effective Income Tax Rate Reconciliation, Acquisition Of Businesses, Percent Effective Income Tax Rate Reconciliation, Acquisition Of Businesses, Percent Entity Registrant Name Entity Registrant Name Subsequent Event Type [Domain] Subsequent Event Type [Domain] Options, unvested and outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares Business Acquisition [Line Items] Business Acquisition [Line Items] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Concentration Risk [Line Items] Concentration Risk [Line Items] Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Total deferred tax liabilities Deferred Tax Liabilities, Gross Impairment charges Asset Impairment Charges Accounts Receivable, Allowance for Credit Loss [Roll Forward] Accounts Receivable, Allowance for Credit Loss [Roll Forward] Less: unamortized debt issuance costs Debt Issuance Costs, Net Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Refunds payable Customer Refund Liability, Current Consolidation Items [Axis] Consolidation Items [Axis] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Accounts receivable—less allowance for doubtful accounts of $643 and $677, respectively Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Real Estate [Domain] Real Estate [Domain] Total lease payments Lessee, Operating Lease, Liability, to be Paid Ownership interest Noncontrolling Interest, Ownership Percentage by Parent Depreciation and amortization Less: Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Net deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Office Office Building [Member] 2019 Grant Year 2019 [Member] Grant Year 2019 [Member] Cash Cash Goodwill Goodwill, beginning balance Goodwill, ending balance Goodwill Revenue by major payor source Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block] Document Transition Report Document Transition Report Title of Individual [Axis] Title of Individual [Axis] Deferred: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Hospice Services Hospice Subsegment [Member] Hospice Subsegment [Member] Other income (expense): Nonoperating Income (Expense) [Abstract] Prepaid expenses Deferred Tax Liabilities, Prepaid Expenses Activity in goodwill by segment Schedule of Goodwill [Table Text Block] Current: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period General and administrative expense General and Administrative Expense [Member] General and administrative expense Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party Equity: Equity [Abstract] Deferred revenue Contract with Customer, Liability, Current Accounting Standards Update [Extensible List] Accounting Standards Update [Extensible List] Revision of Prior Period, Accounting Standards Update, Adjustment Revision of Prior Period, Accounting Standards Update, Adjustment [Member] Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Customer concentration risk Customer Concentration Risk [Member] Credit Facility [Domain] Credit Facility [Domain] Diluted (in shares) Adjusted weighted average common shares outstanding for diluted income per share (in share) Weighted Average Number of Shares Outstanding, Diluted Letters of credit Letter of Credit [Member] Basic (in dollars per share) Basic net income per share (in dollars per share) Earnings Per Share, Basic Expected life Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Entity File Number Entity File Number Lease liabilities Deferred Tax Assets, Lease Liabilities Deferred Tax Assets, Lease Liabilities Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Debt Disclosure [Abstract] Property taxes Accrual for Taxes Other than Income Taxes, Current Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Accrued expenses Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities Net cash provided by/(used in) financing activities Net Cash Provided by (Used in) Financing Activities Sale of noncontrolling interest Proceeds from Noncontrolling Interests Software expense Software Expense Software Expense Transition Services Agreement Transition Services Agreement [Member] Transition Services Agreement Share-based compensation Share-based compensation expense Share-based Payment Arrangement, Expense Balance Sheet Location [Axis] Balance Sheet Location [Axis] Counterparty Name [Axis] Counterparty Name [Axis] Common stock, $0.001 par value; 100,000 shares authorized; 28,696 and 28,243 shares issued and outstanding at December 31, 2020, respectively, and 28,435 and 27,853 shares issued and outstanding at December 31, 2019, respectively. Common Stock, Value, Issued Computation of basic and diluted net income per share Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Document Fiscal Year Focus Document Fiscal Year Focus Document Annual Report Document Annual Report Exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Aggregate intrinsic value of options outstanding, vested, expected to vest and exercisable Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block] Schedule of accounts receivable Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Entity Current Reporting Status Entity Current Reporting Status Unvested Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value Net book value Cash And Contributed Assets Net Book Value Cash And Contributed Assets Net Book Value Number of properties under lease, master lease agreement Number Of Real Estate Properties Under Lease, Master Lease Agreement Number Of Real Estate Properties Under Lease, Master Lease Agreement The Ensign Plans The Ensign Plans [Member] The Ensign Plans [Member] Related Party Transaction [Axis] Related Party Transaction [Axis] Earnings Per Share Earnings Per Share, Policy [Policy Text Block] Issuance/ (cancellation) of restricted stock (in shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Noncontrolling interest Stockholders' Equity Attributable to Noncontrolling Interest Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Other income Other income Other Income Options, vesting percent per year Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Less: long-term portion, included in other long-term liabilities Insurance Program Accrued Expenses, Noncurrent Insurance Program Accrued Expenses, Noncurrent Business Acquisition, Pro Forma Information [Abstract] Business Acquisition, Pro Forma Information [Abstract] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Schedule of Revenue by Major Customers, by Reporting Segments [Table] Schedule of Revenue by Major Customers, by Reporting Segments [Table] Number of service providers Number Of Service Providers Number Of Service Providers Present value of total lease liabilities Operating Lease, Liability Net deferred tax liabilities Deferred Tax Liabilities, Net Segment Reporting [Abstract] Segment Reporting [Abstract] Nondeductible transaction costs Effective Income Tax Rate Reconciliation, Nondeductible Expense, Transaction Costs, Amount Effective Income Tax Rate Reconciliation, Nondeductible Expense, Transaction Costs, Amount Basis of presentation and summary of significant accounting policies Basis of Presentation and Significant Accounting Policies [Text Block] Accounts receivable Increase (Decrease) in Accounts Receivable Debt Instrument [Line Items] Debt Instrument [Line Items] Description of business Nature of Operations [Text Block] Business combination, purchase price Business Combination, Consideration Transferred Concentration Risk Type [Domain] Concentration Risk Type [Domain] 2020 Grant Year 2020 [Member] Grant Year 2020 Total liabilities and equity Liabilities and Equity Number of businesses acquired Number of Businesses Acquired Income taxes Income Tax Disclosure [Text Block] AAP amount reclassified Liabilities, Noncurrent Entity Address, City or Town Entity Address, City or Town Accrued wages and related liabilities Employee-related Liabilities, Current Operating lease costs Operating Lease, Cost Net Parent Investment Parent [Member] 2025 Lessee, Operating Lease, Liability, to be Paid, Year Five Liabilities Assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Total acquisitions Total acquisitions Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Options which are anti-dilutive and not factored into the weighted average common shares amount (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Current provision for income tax, total Current Income Tax Expense (Benefit) Entity Ex Transition Period Entity Ex Transition Period Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Asset Acquisition [Domain] Asset Acquisition [Domain] [Domain] for Asset Acquisition [Axis] Noncontrolling interest to scripps Noncontrolling Interest Joint Venture Noncontrolling Interest Joint Venture Equity Component [Domain] Equity Component [Domain] Cash distribution to parent in connection with Spin-Off Payments of Dividends Right of use asset Deferred Tax Liabilities, Leasing Arrangements Less: valuation allowance Deferred Tax Assets, Valuation Allowance Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Entity Tax Identification Number Entity Tax Identification Number Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Other income (expense), net Interest Income (Expense), Nonoperating, Net Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Options and awards Share-based Payment Arrangement [Text Block] Net income and other comprehensive income attributable to The Pennant Group, Inc. Net income attributable to The Pennant Group, Inc. Net income attributable to The Pennant Group, Inc. Net Income (Loss) Attributable to Parent Change in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Number of separate master lease arrangements Number of Separate Master Lease Arrangements Number of Separate Master Lease Arrangements Repurchase of subsidiary shares Payments to Noncontrolling Interests LIBOR London Interbank Offered Rate (LIBOR) [Member] Trade name Trade Names [Member] Leases [Abstract] Leases [Abstract] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Total current assets Assets, Current Current Fiscal Year End Date Current Fiscal Year End Date Accrued insurance retention - current portion Self Insurance Reserve, Current Operating loss carryforwards Operating Loss Carryforwards Earnings per share (Note 4): Earnings Per Share [Abstract] Deferred tax assets and liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] State income taxes - net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Accrued payroll taxes employer portion Accrued Payroll Taxes Employer Portion Accrued Payroll Taxes Employer Portion Operating lease obligations Increase (Decrease) In Operating Lease Liability Increase (Decrease) In Operating Lease Liability Less: noncontrolling interest and additional paid in capital Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value Noncontrolling interest attributable to subsidiary equity plan Noncontrolling Interest, Increase from Subsidiary Equity Issuance Number of Options Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Document Fiscal Period Focus Document Fiscal Period Focus Intangible asset impairments Goodwill and Intangible Asset Impairment Number of operating facilities Number of Real Estate Properties Out-of-pocket retention Corridor as an Additional Out-of-Pocket Retention Corridor as an Additional Out-of-Pocket Retention Cash paid during the period for: Supplemental Cash Flow Information [Abstract] Net transfer from parent Stockholders' Equity, Distributions From Parent Stockholders' Equity, Distributions From Parent Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Effective Income Tax Rate Reconciliation, Percent [Abstract] Effective Income Tax Rate Reconciliation, Percent [Abstract] Number of asset acquisitions Number Of Asset Acquisitions Number Of Asset Acquisitions Incremental Costs, Direct Medical Supplies, Labor, and Other Expenses Incremental Costs, Direct Medical Supplies, Labor, and Other Expenses Incremental Costs, Direct Medical Supplies, Labor, and Other Expenses Entity Filer Category Entity Filer Category Common Stock Common stock Common Stock [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Customer Contracts Customer Contracts [Member] Weighted average volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Noncontrolling Interest Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block] Cash Dividend to Parent Dividends, Cash Schedule of property and equipment, net Property, Plant and Equipment [Table Text Block] Borrowing availability Line of Credit Facility, Remaining Borrowing Capacity Issuance of common stock after spin-off (in shares) Shares issued (in shares) Stock Issued During Period, Shares, New Issues Number of businesses acquired and assets acquisitions Number Of Businesses And Assets Acquired Number Of Businesses And Assets Acquired Leasehold improvements Leasehold Improvements [Member] Revision of Prior Period [Domain] Revision of Prior Period [Domain] Provision for doubtful accounts Additions to bad debt expense Accounts Receivable, Credit Loss Expense (Reversal) Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Non-cash investing activity: Noncash Investing and Financing Items [Abstract] Supplemental disclosures of cash flow information: Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract] Exercise of stock options, issuance of other awards after spin-off (in shares) Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Transaction costs(a) Effective Income Tax Rate Reconciliation, Transaction Costs, Percent Effective Income Tax Rate Reconciliation, Transaction Costs, Percent Related Party Transactions [Abstract] Related Party Transactions [Abstract] Net (decrease)/ increase in cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Acquisitions Business Combination Disclosure [Text Block] Future minimum lease payments Lessee, Operating Lease, Liability, Maturity [Table Text Block] Stock options Share-based Payment Arrangement, Option [Member] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Other accrued liabilities Increase (Decrease) in Other Accrued Liabilities Basic (in shares) Weighted average shares outstanding for basic net income per share (in shares) Weighted Average Number of Shares Outstanding, Basic Margin Debt Instrument, Basis Spread on Variable Rate Expense: Costs and Expenses [Abstract] Weighted average risk-free rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Forfeited (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Ownership [Axis] Ownership [Axis] Treasury stock, at cost (in shares) Treasury Stock, Shares State Deferred State and Local Income Tax Expense (Benefit) Ownership [Domain] Ownership [Domain] Home Care Home Care Subsegment [Member] Home Care Subsegment [Member] Plan Name [Domain] Plan Name [Domain] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Interest Interest Paid, Excluding Capitalized Interest, Operating Activities Total Pennant Group, Inc. stockholders' equity Net Parent Investment Net Parent Investment Total equity Equity, beginning balance Equity, ending balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Right-of-use assets obtained in exchange for new operating lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Additional paid-in capital Additional paid in capital Additional Paid in Capital Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Provision for income taxes Total income tax expense Income Tax Expense (Benefit) Cash beginning of period Cash end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Title of Individual [Domain] Title of Individual [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Diluted (in dollars per share) Diluted net income per share (in dollars per share) Earnings Per Share, Diluted Local Phone Number Local Phone Number Unaudited pro forma results of condensed combined operations Business Acquisition, Pro Forma Information [Table Text Block] Cash payments for business acquisitions Payments to Acquire Businesses, Gross Interim periods Interim Periods Interim Periods Revenue Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual Accounts Receivable [Abstract] Accounts Receivable, after Allowance for Credit Loss, Current [Abstract] Other indefinite-lived intangible assets Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Goodwill and Intangible Assets Goodwill and Intangible Assets, Policy [Policy Text Block] Revolving Credit Facility Long-term Debt, Gross Schedule of long-term debt Schedule of Long-term Debt Instruments [Table Text Block] Depreciation Depreciation Entity Address, Address Line One Entity Address, Address Line One Payables and Accruals [Line Items] Payables and Accruals [Line Items] Payables and Accruals Entity Address, Address Line Two Entity Address, Address Line Two Related Party Transaction [Domain] Related Party Transaction [Domain] Entity Emerging Growth Company Entity Emerging Growth Company Exercise of Stock Options, issuance of other awards after spin-off Stock Issued During Period, Value, Stock Options Exercised Other indefinite-lived intangibles Indefinite-lived Intangible Assets (Excluding Goodwill) Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Deferred provision for income tax, total Deferred Income Tax Expense (Benefit) Revenue Business Acquisition, Pro Forma Revenue Borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Long-term liabilities Accelerated And Advance Payment, Amount Payable Accelerated And Advance Payment, Amount Payable Award Type [Axis] Award Type [Axis] Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Noncontrolling Interest Holders Noncontrolling Interest Holders [Member] Noncontrolling Interest Holders [Member] Maximum Maximum [Member] Amortization of deferred financing fees Amortization of Debt Issuance Costs Other Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Non-Controlling Interest Noncontrolling Interest [Member] Retained Earnings/ (Accumulated Deficit) Retained Earnings [Member] Payables and Accruals [Table] Payables and Accruals [Table] Payables and Accruals [Table] Total income tax provision Effective Income Tax Rate Reconciliation, Percent Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Balance at beginning of period Balance at end of period Accounts Receivable, Allowance for Credit Loss Award Type [Domain] Award Type [Domain] Trading Symbol Trading Symbol Revenue and accounts receivable Revenue from Contract with Customer And Accounts Receivables Disclosure [Text Block] Revenue from Contract with Customer And Accounts Receivables Disclosure [Text Block] Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Workers' compensation, retention limit Workers' Compensation Insurance, Retention Limit, Per Claim Workers' Compensation Insurance, Retention Limit, Per Claim Property and equipment - net Property, Plant and Equipment Disclosure [Text Block] Commitment fee on undrawn portion Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Resident deposits Deposit Liability, Current Private and other Private And Other [Member] Private And Other [Member] Treasury stock, at cost, 3 shares at December 31, 2020 Treasury Stock, Value Other Other Sundry Liabilities, Current Computation of net income per common share Earnings Per Share [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Equipment Equipment [Member] Current liabilities: Liabilities, Current [Abstract] Income tax expense at statutory rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Entity Shell Company Entity Shell Company Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Shares of common stock withheld to satisfy tax withholding obligations (in shares) Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Weighted average exercise price of options vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Expired (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Entity Public Float Entity Public Float Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Subsegments [Axis] Subsegments [Axis] EX-101.PRE 12 pntg-20201231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 13 pntg-20201231_g1.jpg GRAPHIC begin 644 pntg-20201231_g1.jpg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end GRAPHIC 14 pntg-20201231_g2.jpg GRAPHIC begin 644 pntg-20201231_g2.jpg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pntg-20201231_g3.jpg GRAPHIC begin 644 pntg-20201231_g3.jpg M_]C_X 02D9)1@ ! @$ 8 !@ #_[@ .061O8F4 90 !_]L 0P " 0$! M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D* M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H* M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\ $0@" M6 *H P$B (1 0,1 ?_$ !\ $% 0$! 0$! ! @,$!08'" D* M"__$ +40 (! P,"! ,%!00$ !?0$" P $$042(3%!!A-180'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H MJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V M]_CY^O_$ !\! ,! 0$! 0$! 0$ ! @,$!08'" D*"__$ +41 (! M @0$ P0'!00$ $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P M%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_: P# M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "O+/C)^VU^RC^S_P"-;?X:?%KXYZ)I7B6ZL&OXO#B2 MO:RA,@C=D&O4Z_GKMO^"K?Q;_ ."%?_!;S]IJ/]NO MX"ZWXC\(?&WQLNK:7XJL%4ZE!HD,UQ_9;V3RE8[NVCM9UMW@WIY;P8#!D9& M/WB^$G[1'P%^/MO+=_ [XS>&/&$,%A;7LTWAG6X+Y([>X:9(9&:%F #M;S@9 M[Q..QKLJ^0?^"=GC'_@GA\8O%/Q8_P""DG[$7Q3\.77AWXHZ7HK_ ! CL8?L M9T_5-+74&FNKV&0*]M/)!=Q;PZKN^S^;E_,+GQC4/^#A;3YOV8M9_P""BWA3 M]E>?4/V;M ^)L/A*[\8R^*S#K]U;M-' ^L6^E&T,;6JSRQQK&]TDSY8E$V[2 M ?I+17Y_?\%*_P#@O)X9_P""=GQ?^#?@:+]FZ[^(_A[XVVD-SX2\1>%_%2QS MO&\UNA(M7M3YA9;J%HP)?WF[!V4W]GO_ (+?^-/&O_!5^X_X)2?M._L67?PN M\4:CHDFI^#]17QW:ZS]M1;)KX1W"6\*QP.;:.9CYU/]I*\_8\T_P"/'AF;XHZ?I0U*]\#1ZHAU&&V**X=HLY!\MTDV_>V.KXVD M&O1Z_*;X*?&7]B_6O^#G/QY\)]2_83;1?CYIOA-O[0^*MK\0I[VPNK;^R+.: M*5+!X(TBGDL9K>%V'W=KKELL[>PR?\%JO$_QJ^.GQ[^$O[!_[,^E?$C3?V;= M&>Y^(?B3Q!X]?18]0OD^T;M-TQ(K"Z\^3_1+I!+*T,9>$@$H5D(!]\45\1:/ M_P %NO@Y\4?^"3FN_P#!5O\ 9Y^'%QXET;PI;R-XI\%:MK2Z=?:=/ \:W-J9 M$AG1I5$L4B# 62.1&W+G%>-?!/\ X.+OBC^T_P"!/@U\2?V;?^"5_P 2_%FA M_$3QS_PCGC;6]-OWFL?!\IOC!AIH[1OM+BWVW;EEA@C21$,Q??L /TXUO6]) M\-Z1*^'O\ @IW_ ,$Z/%WC0_#?PI^W M%\*]4\1":6$Z!IWCBRGO1)%N,B>0DADW)M;<,97:_\ X)/001_\ M'=_[1*QPHH&I>.6 "@?,;Z$D_4Y/YF@#^A"O./"7[7W[+_CS]H/Q!^RAX,^. M_AG4_B1X5L%O?$/@RSU1'O[" ^7\\D8.0!YL6X#)7S4W8W#/H]?DW^PW\:/V M1?%/_!P;^T#\//!'[ 4'A;]H'2O!NHW&O^/F^)ES>:5JGE2Z ?K)7)?'+X\?!O\ 9G^%VJ?&OX_?$C2?"7A3141M4U[6 M[H0V]OOD6- 6/5F=U15&2S, 2:^-?\ @FA_P6[O?^"@_P"V!\4/V+/%'[*4 MGPQ\7_"BUN6UZQUGQLM[///!>"TE2&..T0-&DA7=+OP!)&5#!LCSW_@J3^V5 MX6^*?_!(/XC_ !Q_;._8$LO$WPLLO'[Z%:%'<032P#SY;:7[9_J9?,D%/&U]X\M)KV SBT$DK:?%"W[B-KVW;<\L< MCPRB3RU;,- 'ZAT5\9?MD_\ !7S0O@#^WI\,O^"9/P+^$*>/?B_\2%6[>WU+ MQ =*TK0-/V3R&XN;A+>XD>3RK:>00QQ$E4!++O0-S_[%W_!9+Q_^U9_P4$\= M?\$[]>_8[C\.^)/A==7<7C[7[/XCV]Y9VT,7F+%=VL,MM!<74,LOV9.$5H_M M<9=0 : /M3X@?$3P)\*?"EWXZ^)7B[3]"T6PC+WNJZI=+#!;H!DL[L0% )) M/ Q7F_P:_P""A'["O[17B?\ X0KX _M?_#CQMJX4,VF>%?&%IJ$Z@G )2"1B MH)XR>,UZAXO57\)ZHCJ"#ITX((X(\MJ_!#_@QDAA:;]J&X:)3(J^"E5RO(!. MO$@'T.!^0]* /VWU[]L?]E'PM\7K?]G_ ,2?M%^#;'QU=C-IX/N_$$":G.,D M;DMBWF.N0>0I'!]*])KYK^(%C92?\%@/A->O9Q-,O[.'Q VRF,%AC7O!P&#U MX#N/^!-ZFO _%'_!=OQQI/\ P5&\9?\ !*#PA^P5JWBGQ_X=L3<:1>Z)X\MU ML]1#Z?;ZA TSW%M$MG%Y%RAED9G,;*R(L[E%< _1"O./V??VOOV7OVK9?$D' M[-OQX\,>-G\(:M_9OB5?#NJI?$[X/:NMAK'A2]\7B^L;IW>YBC*WL=JK(%FM9 M8Y,0N%&QU+[]J_+G_!#?]K+]E#3_ -G#]K7XW?\ !.C_ ()NS^!?$WA'4+?4 M/$?AG4_B8]['KMRL=\\<2W,T8%I;6X6Y8(JL2)7"@DJ* /V+#HS%58$J?F / M2EK\;?\ @W+_ ."EO[67[0?P9^._[7_[3?P]M=8\)7_Q/UGQ%XZ^(D/B98O^ M$>BL_#UBZ:?:Z5Y322PQPP0HA64$!\G M?LF>';KX;^./B5;^$KFZT;XJ?;=<\'F:_P#LD5QK-A_9Z);^9F-U2*>4C[1 M"=K^8 #[^HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OSQ\%_M0?\$\_P#@ MJ#HWQ5_8M_X*0^&?!TVN> _C%XRT#3=+^($4>FC4M-LM;O+:UU#2+IS$Q:.V M2*WEDMI!*DD+%R!(I;]#JQ_$?P^\ ^,=&/ASQ=X(T?5=.:X:=K#4M,BGA,K, M6,FQU*[BS,2V,DL3WH _"K_@E9_P2Y\0>#_VJ_V\?AS^P;\1M0US]GOQ)\'- M6\!> _%]Q?![/5?$=Y:Q-%'!$?&EAX^\.^.KA;7X::GK'B;R?$ :2)X[.'2;&?R9+Z.\C M?]T80[%HG4N0Q3^C[3M-T[1["'2M(L(;6UMXQ';VUM$$CB0,;/-QOVX)&,XH _ ?_@Y+N?A7\+OVQ_^ M"?\ \-M!M+'PCI_@:*Q2Y\+7FLQS2^&=/COM(2"*YD,KX6..!T\UG8-Y+MO; M!-=9\7?BO\,;K_@]4^&&O6_Q!T9["S\*OI=U?+J47DQWLWA75$BMR^[;YCO/ M"BIG):55 R0*_=ZB@#\(O@S\5/AFW_!ZS\2M73X@:,UIJGAF+1].NUU*,Q7. MH)X7TN)[1'#8:82PRQF,'=OC9<;ABL3_ ((\VND?\$IOB9_P44_9_P#VS_%. MG>$?$::#%K7AZ?Q'J*VO_"4:9 FNE;NS\TC[0K_:K-(W&0PK] O^#4/7O"NI?\$4?AOHVAZSI]Q?Z;K'B!-:M;6X1IK65]9O'C$Z MJ=R,T1C8;L$H5(XQ7Z/T4 5]5U;2M!TV?6M/C+\0_CWX/T'P?K&M>-+;2_%FL^(K: MUTRYE>\0QA+J1UB.\1OL.[#X&TG(S_2310!\7_&+_@L9^ROXB_:;^#?[&'[( M?[1?A'Q[XY^)/CN"+56\%ZQ;:O!I&B6D,M]?232PF2)'EBM_(5"?,"SO(NWR MPU?GE_P36^*GPROO^#O']I+6;'X@Z+-9Z[X2U33M$NXM3B:*_NUET7=!"X;$ MD@\B;Y5)/[I_[IK]W:* /Q+_ ."L7[&/[4G[.7_!?/X(_MD?L#EM*U/]H>*Z M\&^)+^*W9X-/U$6+V]S?3(N 533]EZJ]Y=+D<\U[Q_PN[&X9YG_ (+3?%WX M5ZM\!/\ @E(-*^(VB77]A> K&\UHVVJ12"P@\GPS$9)BK'RU$EG=(2V,-;2@ M\HP'])]% 'X[?\%;-=_8E^$?_!YD"@^2@" M(2V[1_X*6?\ !*[Q'^V;^WIX?^/7[0/[,'AKX[_!W1OAV^C:/X&L_%'_ CN MN:)J[W0EDO3_P#!"+X0?!'_ (*)_#O] MN#X%?LMQ?L_>'_A[H>LPWOA=/B)".6=\QSR-,[ M(&C01AF /TTU.Q34]-N--E2L6WB;X?_ Y^$NK^%3X]TF7SM+U;5M6U32[J6ULK ME28[P6\6CQF66(M&CW21[RZR*OYE_"/XL?#*U_X/5?B?KL_Q T9;"]\*II=M M?'4XA"][#X5TQ);^$_A3Q M!877B'Q(D'Y=6\9:=XR\0:SKOPWO+"5)CID.@VJ2B\W1E;6&2 M2UFM2TH_UC!-I)Q7C'PR_9VT3]@O_@I)^SQ^TG_P0T_:]3Q=X$^/WC6TT_6O M@]_:PGU32-/,D.<\<5!:^$O"MCKT_BJR\,Z?#JES"(KG4HK)%N)8QC"- M(!N91@<$XX% &A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 5^=7_ <+_P#!:>__ ."5/[/MIH7P*LK35/BUXJN8(])6 M]M#<6>@6CF4_;+M1@;I1;W$<$3%?-:*9QN6WD4_9?[8_[2F@?L<_LK?$#]J7 MQ1H-SJMCX#\*W>LS:99N%DNS#&66(,W"[FVKNYV@DX.,'^:O_@M5_P %-?V% MOVQ/V!/#OP\^#?Q;U7QI\:-=^+]MXS^*WB"]\*75A!I^,?A5X9\7:TZ->:KX>LKR[:--JF66!'8@= MAECQ7SI_P5[_ &__ (V?\$X?V1O$O[3'PE_9=_X3^'PY:03:I?7_ (E@L++3 MEFN4MD=T!:XN"LDL;-&B*"K9\T8./1/^"=G[1/PP_:M_8A^&GQV^#>I7-YX= MU?PS%;V5Q=V;V\C/:,UG,"C\C$UO* >X (X->$?\'(7_ "A*^/G_ &+^G_\ MIVLJ .Y_X)$?MJ?$?]M/_@F#X _;5_:!ATRWU[Q)8:S?ZW%X>TZ1+:&.VU2] M@1(8=TDA"PP(,;G9B.I)K\\/^"EG_!7_ /X.$/V'O[-_;/\ $'[&_@#PG\"- M0UR*UT_PSK)%_JT%O+EK==6>"Y#VES*@/^K'EPN1&^YL;_L;_@V7_P"4'/P( M_P"P?K?_ *?]1KG_ /@MK\-_%?\ P4PO?"O_ 1]^!M\\W/P4_:1 M_P""7O[.*>-?B9\;Y=.N]$\%:UIDMZNG::]A)=7LT_E36X58'$,!F9UCW3H? MX@*^0O#W_!5__@YL\)?M1?!W]G_]IW]BWX1^!;?XM^.[?0=-OKC19;B0Q!ED MO9T2#69&Q!;;Y6)7 "@=2 ?V0^"'P^^%OPH^%'ASX3?!NULXO#?@O2(O#NBV M]G.LHM(+)5MOLY<$_,AA".#SN0[N0:^+?!X;]LC_ (.!_$GC)P;GPI^R-\+8 M=#TLGE%\6^(U\ZZEC;H2FFQK ZCE689(SB@#[^HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@"*_L+'5+.33M3LH;FWF0K-!/&'1U/8J>"/K7Q3_ ,%E/^",'@S_ (*P M_L[>'/@/X<^*.F?"J;0/&D6OOKECX%CU)KI4M+JW^S&-;FV*@FY#[MY_U>-O M.1]MT4 ?EE_P7^_X)H^./C+^R9\++SX*_M>ZYX$U_P"#]G/;>"?!7AG3G63Q MSX@DMX5T^"UB@N8FANS/;X$H\WR8YYY3A8W+?4/[>O[!WQ\_;]_X)\2_L4Z_ M^TAHGA"[\3^&M*L_'7B67P/)J\\]S;RV]Q.]N%O[5(Q)+!@[E?Y6; !(*_4D M^DZ5@JQ0!\P?\$R/V#/ MB_\ \$Y/V(](_8Q'[1V@>,X?"MIJ,?A+Q%)\/)M/>W>ZNI[M6NH1J3W$MS:5R#(YRW+,>:Y/_ ()Q M?L1>(?V+? _Q G^)'C^S\5^-_BC\5=:\<>,-?LK)X(I)[V11%;QJ[,PBA@CB MC5$_#WQI^SZ?I?B>_M+&W_X1S37\J&. MXD1%W-;%FPJ@9))..2:YC_AZ;^WA_P!%U_\ +8TO_P"1J\Q_:0_Y.(\>_P#8 MZ:I_Z5RUQ=?+SQ%=3?OO[V?R7C>).(H8RI&.,JI*3_Y>3[OS/H+_ (>F_MX? M]%U_\MC2_P#Y&H_X>F_MX?\ 1=?_ "V-+_\ D:OGVBI^L8C^=_>SF_UEXC_Z M#:O_ (,G_F?07_#TW]O#_HNO_EL:7_\ (U'_ ]-_;P_Z+K_ .6QI?\ \C5\ M^T4?6,1_._O8?ZR\1_\ 0;5_\&3_ ,SZ"_X>F_MX?]%U_P#+8TO_ .1J/^'I MO[>'_1=?_+8TO_Y&KY]HH^L8C^=_>P_UEXC_ .@VK_X,G_F?07_#TW]O#_HN MO_EL:7_\C4?\/3?V\/\ HNO_ );&E_\ R-7S[11]8Q'\[^]A_K+Q'_T&U?\ MP9/_ #/H+_AZ;^WA_P!%U_\ +8TO_P"1J/\ AZ;^WA_T77_RV-+_ /D:OGVB MCZQB/YW][#_67B/_ *#:O_@R?^9]!?\ #TW]O#_HNO\ Y;&E_P#R-1_P]-_; MP_Z+K_Y;&E__ "-7S[11]8Q'\[^]A_K+Q'_T&U?_ 9/_,^@O^'IO[>'_1=? M_+8TO_Y&H_X>F_MX?]%U_P#+8TO_ .1J^?:*/K&(_G?WL/\ 67B/_H-J_P#@ MR?\ F?07_#TW]O#_ *+K_P"6QI?_ ,C4?\/3?V\/^BZ_^6QI?_R-7S[11]8Q M'\[^]A_K+Q'_ -!M7_P9/_,^@O\ AZ;^WA_T77_RV-+_ /D:C_AZ;^WA_P!% MU_\ +8TO_P"1J^?:*/K&(_G?WL/]9>(_^@VK_P"#)_YGT%_P]-_;P_Z+K_Y; M&E__ "-1_P /3?V\/^BZ_P#EL:7_ /(U?/M%'UC$?SO[V'^LO$?_ $&U?_!D M_P#,^@O^'IO[>'_1=?\ RV-+_P#D:C_AZ;^WA_T77_RV-+_^1J^?:*/K&(_G M?WL/]9>(_P#H-J_^#)_YGT%_P]-_;P_Z+K_Y;&E__(U'_#TW]O#_ *+K_P"6 MQI?_ ,C5\^T4?6,1_._O8?ZR\1_]!M7_ ,&3_P SZ"_X>F_MX?\ 1=?_ "V- M+_\ D:C_ (>F_MX?]%U_\MC2_P#Y&KY]HH^L8C^=_>P_UEXC_P"@VK_X,G_F M?07_ ]-_;P_Z+K_ .6QI?\ \C4?\/3?V\/^BZ_^6QI?_P C5\^T4?6,1_._ MO8?ZR\1_]!M7_P &3_S/H+_AZ;^WA_T77_RV-+_^1J/^'IO[>'_1=?\ RV-+ M_P#D:OGVBCZQB/YW][#_ %EXC_Z#:O\ X,G_ )GU3\$_^"EG[;'B[XS>$?"? MB'XT_:-/U3Q/86E];_\ ".::GFPR7$:.NY;8,N58C(((SP17ZOU^%?[-_P#R M<1X"_P"QTTO_ -*XJ_=2O7RVI4J0ES-OU/VCPLS',,PP6)EBJTJC4HVYI.5M M'M=NP4445Z9^JA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110!^%?[2'_)Q'CW_ +'35/\ TKEKBZ[3]I#_ M ).(\>_]CIJG_I7+7%U\C4^-^I_&./\ ]^J_XI?FPHHHJ3E"BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH [3]F__ ).(\!?]CII?_I7%7[J5^%?[-_\ R<1X"_['32__ $KBK]U*]K*O M@EZG[OX0?[CBO\4?R84445ZQ^PA1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110!^%?[2'_)Q'CW_L=-4_\ M2N6N+KM/VD/^3B/'O_8Z:I_Z5RUQ=?(U/C?J?QCC_P#?JO\ BE^;"BBBI.4* M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@#M/V;_^3B/ 7_8Z:7_Z5Q5^ZE?A7^S?_P G$> O^QTTO_TK MBK]U*]K*O@EZG[OX0?[CBO\ %'\F%%%%>L?L(4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?A7^TA_P G M$>/?^QTU3_TKEKBZ[3]I#_DXCQ[_ -CIJG_I7+7%U\C4^-^I_&./_P!^J_XI M?FPHHHJ3E"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH [3]F_P#Y.(\!?]CII?\ Z5Q5^ZE?A7^S?_R< M1X"_['32_P#TKBK]U*]K*O@EZG[OX0?[CBO\4?R84445ZQ^PA1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0!^%?[2'_)Q'CW_L=-4_]*Y:XNNT_:0_Y.(\>_\ 8Z:I_P"EI^[^$'^XXK_%'\F%%%%>L M?L(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 ?A7^TA_R<1X]_P"QTU3_ -*Y:XNNT_:0_P"3B/'O_8Z: MI_Z5RUQ=?(U/C?J?QCC_ /?JO^*7YL****DY0HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .T_9O_P"3 MB/ 7_8Z:7_Z5Q5^ZE?A7^S?_ ,G$> O^QTTO_P!*XJ_=2O:RKX)>I^[^$'^X MXK_%'\F%%%%>L?L(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 ?A7^TA_R<1X]_['35/_ $KEKBZ[3]I# M_DXCQ[_V.FJ?^EI^[^$'^XXK_ !1_)A1117K'["%%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% 'X5_M(?\ )Q'CW_L=-4_] M*Y:XNNT_:0_Y.(\>_P#8Z:I_Z5RUQ=?(U/C?J?QCC_\ ?JO^*7YL****DY0H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** .T_9O\ ^3B/ 7_8Z:7_ .E<5?NI7X5_LW_\G$> O^QTTO\ M]*XJ_=2O:RKX)>I^[^$'^XXK_%'\F%%%%>L?L(4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?A7^TA_R< M1X]_['35/_2N6N+KM/VD/^3B/'O_ &.FJ?\ I7+7%U\C4^-^I_&./_WZK_BE M^;"BBBI.4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@#M/V;_P#DXCP%_P!CII?_ *5Q5^ZE?A7^S?\ M\G$> O\ L=-+_P#2N*OW4KVLJ^"7J?N_A!_N.*_Q1_)A1117K'["%%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% 'X5_M(?\G$>/?\ L=-4_P#2N6N+KM/VD/\ DXCQ[_V.FJ?^E/?^QTU3_P!*Y:XNNT_:0_Y.(\>_]CIJ MG_I7+7%U\C4^-^I_&./_ -^J_P"*7YL****DY0HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .T_9O_Y. M(\!?]CII?_I7%7[J5^%?[-__ "<1X"_['32__2N*OW4KVLJ^"7J?N_A!_N.* M_P 4?R84445ZQ^PA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110!^%?[2'_ "<1X]_['35/_2N6N+KM/VD/ M^3B/'O\ V.FJ?^E/?^QTU3_T MKEKBZ[3]I#_DXCQ[_P!CIJG_ *5RUQ=?(U/C?J?QCC_]^J_XI?FPHHHJ3E"B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH [3]F_\ Y.(\!?\ 8Z:7_P"E<5?NI7X5_LW_ /)Q'@+_ +'3 M2_\ TKBK]U*]K*O@EZG[OX0?[CBO\4?R84445ZQ^PA1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^%?[2 M'_)Q'CW_ +'35/\ TKEKBZ[3]I#_ ).(\>_]CIJG_I7+7%U\C4^-^I_&./\ M]^J_XI?FPHHHJ3E"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH [3]F__ ).(\!?]CII?_I7%7[J5^%?[ M-_\ R<1X"_['32__ $KBK]U*]K*O@EZG[OX0?[CBO\4?R84445ZQ^PA1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<=XY_: M$^!?PS\?>&_A3X_^+GA[2/%'C&[-MX5\.7VK1)?ZK(%9B(+VU2%YGEN9))&9D@CSECD@GJ30!^_M>>?M(_M:_LR M_L>^"HOB)^U%\=/#/@31KBX\BTO/$FJQV_VJ;&?+A5CNF?')5 Q !.,#->AU M\V?M5?\ !)O]B;]N?XE7GQ-_;(^&+_$&<: FC>'M/U?4[B*U\/VGS-,UHD$B M>7<32/N>X.9"(H5!58P" >P? 3]HOX#_ +4OPZM_BW^SE\7?#_C;PU=2O%%K M/AO4X[J 2KC?$Q0G9(N1N1L,N1D#-<5\8O\ @HY^P!^SUX_N_A5\=_VU/A;X M.\3:?'$]]X?\2^.;&RO+=9(UDC+PRRJZAD97&1RK C@U^5'_ :-?!7Q-\#K MS]JOXN:)XEU&;X(0^,AI'@K4+H%TUM+?1JH^8K;26P9D&':3;R8\#X, MUS]OO_@E%\9?VJ/%7Q)_X*X_\$H/B9=^)/&WC+4-3U#Q[;_$?5;2\2PENG%C M -(W6L:1VMF+:WRLS,P@W(/#.JQ7MG<-&YCD"31,R,5=64X/!4@\BL?QE^U7^SGX"^)MG\$O$GQAT1 M?&U_&LEIX,LKK[7J\D1( E^Q0!YQ%R/WA0(,\FOSE_X*7?\ !1[]GG_@E;_P M0I\#^(_^"5>H:;!H?CJ"+P[\%]1L)I+A=,@G6>XNM0/V@M(\\028$39=;J5? M,4E76LW_ ((Y?MI_L,?L'/\ #G]@3XV> /B7X'^._P 8-)L_$'B#XB?%3PF; M?_A86N7V6+)?O-)-*OG-);P"=8\E I ED(8 _6RBBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@#\*_VD/\ DXCQ[_V.FJ?^E/?^QTU3_TKEKBZ^1J?&_4_C''_P"_5?\ %+\V%%%%2 O^QTTO\ ]*XJ_=2OPK_9O_Y.(\!?]CII?_I7%7[J5[65 M?!+U/W?P@_W'%?XH_DPHHHKUC]A"BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH 1F5%+NP R23P!7\_W_!0+]HOX#3?\'%+R 2;H//=(X;^[B81Q%SF".1[@J2(5D_0S]L+]G74 M_P!K+X1WG[/-]XAM-*\)^*K>;3_'-V+0RZA/I4L9BN+.S8D+;R7$+RPM<'<8 MXW<(A9P\?IVBZ-I7AW1[3P_H6GQ6EC86T=O9VL"!4AB10J(H'0!0 !Z"@#\R M/^"*?_!9C]EG]K"UU']FC]A_]D'Q+X"^$WP0^%LVHZA%J%O%->&83QBVM;6& MUDD,TDJ"^ED=V,DLH7@EF8[^A?\ !6#_ ((<_P#!:/\ 9P\3_!SXU^(=/M$> M*>VO/AU\4=-ALO$<,Q!5)=-A1YFGNMW^K%D\LX?:NT,0I_2&LBR^'_@/3/$< MWC'3O!.D6^KW&[[1JL&FQ)C_@H!_P $9?VM?AU_P;<_ M!?P^_A#5]4\7?"GQCJGBKQ3X1@MVDN],T?59)W8&%"Q,L -J\R+GRS)<'.(V M8]W_ ,%2+;1_^"N7[07_ 3ALOV*M;M/$7B*[T1M<\97/A^X6=_"NEB719#< M7QC)-L()(+]=LFTF6)HP"Y /[YUFZ!X-\(>%)KJX\+>%--TV2^E\V]?3[&.$ MW#\_,Y0#>>3R_P#8Z:I_Z5RU MQ=?(U/C?J?QCC_\ ?JO^*7YL****DY0HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .T_9O\ ^3B/ 7_8 MZ:7_ .E<5?NI7X5_LW_\G$> O^QTTO\ ]*XJ_=2O:RKX)>I^[^$'^XXK_%'\ MF%%%%>L?L(4444 %%%% !1110 4444 %%%% 'A7B3_@I9^Q/X1\17_A/Q#\: M?L^H:7>RVE];_P#".:D_E31N4==RVQ5L,I&02#C@FJ7_ ]-_8/_ .BZ_P#E ML:I_\C5^5O[2'_)Q'CW_ +'35/\ TKEKBZ\.69UU)JR_'_,_G_$^*W$5'$SI MQI4K)M?#/H_\9^PW_#TW]@__ *+K_P"6QJG_ ,C4?\/3?V#_ /HNO_EL:I_\ MC5^/-%3_ &IB.R_'_,P_XBUQ'_SZI?\ @,__ )8?L-_P]-_8/_Z+K_Y;&J?_ M "-1_P /3?V#_P#HNO\ Y;&J?_(U?CS11_:F([+\?\P_XBUQ'_SZI?\ @,__ M )8?L-_P]-_8/_Z+K_Y;&J?_ "-1_P /3?V#_P#HNO\ Y;&J?_(U?CS11_:F M([+\?\P_XBUQ'_SZI?\ @,__ )8?L-_P]-_8/_Z+K_Y;&J?_ "-1_P /3?V# M_P#HNO\ Y;&J?_(U?CS11_:F([+\?\P_XBUQ'_SZI?\ @,__ )8?L-_P]-_8 M/_Z+K_Y;&J?_ "-1_P /3?V#_P#HNO\ Y;&J?_(U?CS11_:F([+\?\P_XBUQ M'_SZI?\ @,__ )8?L-_P]-_8/_Z+K_Y;&J?_ "-1_P /3?V#_P#HNO\ Y;&J M?_(U?CS11_:F([+\?\P_XBUQ'_SZI?\ @,__ )8?L-_P]-_8/_Z+K_Y;&J?_ M "-1_P /3?V#_P#HNO\ Y;&J?_(U?CS11_:F([+\?\P_XBUQ'_SZI?\ @,__ M )8?L-_P]-_8/_Z+K_Y;&J?_ "-1_P /3?V#_P#HNO\ Y;&J?_(U?CS11_:F M([+\?\P_XBUQ'_SZI?\ @,__ )8?L-_P]-_8/_Z+K_Y;&J?_ "-1_P /3?V# M_P#HNO\ Y;&J?_(U?CS11_:F([+\?\P_XBUQ'_SZI?\ @,__ )8?L-_P]-_8 M/_Z+K_Y;&J?_ "-1_P /3?V#_P#HNO\ Y;&J?_(U?CS11_:F([+\?\P_XBUQ M'_SZI?\ @,__ )8?L-_P]-_8/_Z+K_Y;&J?_ "-1_P /3?V#_P#HNO\ Y;&J M?_(U?CS11_:F([+\?\P_XBUQ'_SZI?\ @,__ )8?L-_P]-_8/_Z+K_Y;&J?_ M "-1_P /3?V#_P#HNO\ Y;&J?_(U?CS11_:F([+\?\P_XBUQ'_SZI?\ @,__ M )8?L-_P]-_8/_Z+K_Y;&J?_ "-1_P /3?V#_P#HNO\ Y;&J?_(U?CS11_:F M([+\?\P_XBUQ'_SZI?\ @,__ )8?L-_P]-_8/_Z+K_Y;&J?_ "-1_P /3?V# M_P#HNO\ Y;&J?_(U?CS11_:F([+\?\P_XBUQ'_SZI?\ @,__ )8?L-_P]-_8 M/_Z+K_Y;&J?_ "-1_P /3?V#_P#HNO\ Y;&J?_(U?CS11_:F([+\?\P_XBUQ M'_SZI?\ @,__ )8?LGX;_P""EG[$_B[Q%8>$_#WQI^T:AJE[%:6-O_PCFI)Y MLTCA$74@HHHKM/O0HHHH **** /PK_:0_Y. M(\>_]CIJG_I7+7%UVG[2'_)Q'CW_ +'35/\ TKEKBZ^1J?&_4_C''_[]5_Q2 M_-A1114G*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110!VG[-_P#R<1X"_P"QTTO_ -*XJ_=2OPK_ &;_ M /DXCP%_V.FE_P#I7%7[J5[65?!+U/W?P@_W'%?XH_DPHHHKUC]A"BBB@ HH MHH **** "BBB@ HHHH _"O\ :0_Y.(\>_P#8Z:I_Z5RUQ==I^TA_R<1X]_[' M35/_ $KEKBZ^1J?&_4_C''_[]5_Q2_-A1114G*%%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!VG[-_\ MR<1X"_['32__ $KBK]U*_"O]F_\ Y.(\!?\ 8Z:7_P"E<5?NI7M95\$O4_=_ M"#_<<5_BC^3"BBBO6/V$**** "BBB@#\*_VD/^3B/'O_ &.FJ?\ I7+7%UVG M[2'_ "<1X]_['35/_2N6N+KY&I\;]3^,_]CIJG_I7+7%UVG[2'_)Q'CW_L=-4_]*Y:XNOD:GQOU/XQQ_\ MOU7_ !2_-A1114G*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110!VG[-__)Q'@+_L=-+_ /2N*OW4K\*_ MV;_^3B/ 7_8Z:7_Z5Q5^ZE>UE7P2]3]W\(/]QQ7^*/Y,****]8_80HHHH ** M** /PK_:0_Y.(\>_]CIJG_I7+7%UVG[2'_)Q'CW_ +'35/\ TKEKBZ^1J?&_ M4_C''_[]5_Q2_-A1114G*%%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110!VG[-_P#R<1X"_P"QTTO_ -*X MJ_=2OPK_ &;_ /DXCP%_V.FE_P#I7%7[J5[65?!+U/W?P@_W'%?XH_DPHHHK MUC]A"BBB@ HHHH **** "BBB@ HHHH _"O\ :0_Y.(\>_P#8Z:I_Z5RUQ==I M^TA_R<1X]_['35/_ $KEKBZ^1J?&_4_C''_[]5_Q2_-A1114G*%%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110!VG[-_\ R<1X"_['32__ $KBK]U*_"O]F_\ Y.(\!?\ 8Z:7_P"E<5?N MI7M95\$O4_=_"#_<<5_BC^3"BBBO6/V$**** "BBB@#\*_VD/^3B/'O_ &.F MJ?\ I7+7%UVG[2'_ "<1X]_['35/_2N6N+KY&I\;]3^,_]CIJG_I7+7%UVG[2'_)Q'CW_L=-4_]*Y:XNOD M:GQOU/XQQ_\ OU7_ !2_-A1114G*%%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!VG[-__)Q'@+_L=-+_ M /2N*OW4K\*_V;_^3B/ 7_8Z:7_Z5Q5^ZE>UE7P2]3]W\(/]QQ7^*/Y,**** M]8_80HHHH **** /PK_:0_Y.(\>_]CIJG_I7+7%UVG[2'_)Q'CW_ +'35/\ MTKEKBZ^1J?&_4_C''_[]5_Q2_-A1114G*%%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!VG[-_P#R<1X" M_P"QTTO_ -*XJ_=2OPK_ &;_ /DXCP%_V.FE_P#I7%7[J5[65?!+U/W?P@_W M'%?XH_DPHHHKUC]A"BBB@ HHHH **** "BBB@ HHHH _"O\ :0_Y.(\>_P#8 MZ:I_Z5RUQ==I^TA_R<1X]_['35/_ $KEKBZ^1J?&_4_C''_[]5_Q2_-A1114 MG*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110!VG[-_\ R<1X"_['32__ $KBK]U*_"O]F_\ Y.(\!?\ M8Z:7_P"E<5?NI7M95\$O4_=_"#_<<5_BC^3"BBBO6/V$**** "BBB@#\*_VD M/^3B/'O_ &.FJ?\ I7+7%UVG[2'_ "<1X]_['35/_2N6N+KY&I\;]3^,_]CIJG_I7+7%UVG[2'_)Q'CW_L M=-4_]*Y:XNOD:GQOU/XQQ_\ OU7_ !2_-A1114G*%%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!VG[-_ M_)Q'@+_L=-+_ /2N*OW4K\*_V;_^3B/ 7_8Z:7_Z5Q5^ZE>UE7P2]3]W\(/] MQQ7^*/Y,****]8_80HHHH **** /PK_:0_Y.(\>_]CIJG_I7+7%UVG[2'_)Q M'CW_ +'35/\ TKEKBZ^1J?&_4_C''_[]5_Q2_-A1114G*%%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110! MVG[-_P#R<1X"_P"QTTO_ -*XJ_=2OPK_ &;_ /DXCP%_V.FE_P#I7%7[J5[6 M5?!+U/W?P@_W'%?XH_DPHHHKUC]A"BBB@ HHHH **** . ^/?[4OP _9?T[3 MM6^/7Q,LO#=OJTTD6G27D4K^>Z %P!&C'@,.OK7F?_#VK_@G3_T=)HG_ (!W M?_QFO!-&UV*VU?\$Z?^CI- M$_\ .[_ /C->I_\,R?LV_\ 1O?@?_PD[/\ ^-T?\,R?LV_]&]^!_P#PD[/_ M .-T ?B;\;/'W@+Q=\9O%WBSP]X[T2XT_5/$]_=V-Q_:\">;#)<2.C;6<,N5 M8'! (SR!7,?V[X:_Z&_1/_!W;?\ Q=?NS_PS)^S;_P!&]^!__"3L_P#XW1_P MS)^S;_T;WX'_ /"3L_\ XW7G/+*#=[O\/\C\RK>%/#M:K*I*K5NVW\4.O_;A M^$W]N^&O^AOT3_P=VW_Q=']N^&O^AOT3_P '=M_\77[L_P##,G[-O_1O?@?_ M ,).S_\ C='_ S)^S;_ -&]^!__ D[/_XW2_LO#]W^'^1G_P 0EX<_Y^U? M_ H?_*S\)O[=\-?]#?HG_@[MO_BZ/[=\-?\ 0WZ)_P"#NV_^+K]V?^&9/V;? M^C>_ _\ X2=G_P#&Z/\ AF3]FW_HWOP/_P"$G9__ !NC^R\/W?X?Y!_Q"7AS M_G[5_P# H?\ RL_";^W?#7_0WZ)_X.[;_P"+H_MWPU_T-^B?^#NV_P#BZ_=G M_AF3]FW_ *-[\#_^$G9__&Z/^&9/V;?^C>_ _P#X2=G_ /&Z/[+P_=_A_D'_ M !"7AS_G[5_\"A_\K/PF_MWPU_T-^B?^#NV_^+H_MWPU_P!#?HG_ (.[;_XN MOW9_X9D_9M_Z-[\#_P#A)V?_ ,;H_P"&9/V;?^C>_ __ (2=G_\ &Z/[+P_= M_A_D'_$)>'/^?M7_ ,"A_P#*S\)O[=\-?]#?HG_@[MO_ (NC^W?#7_0WZ)_X M.[;_ .+K]V?^&9/V;?\ HWOP/_X2=G_\;H_X9D_9M_Z-[\#_ /A)V?\ \;H_ MLO#]W^'^0?\ $)>'/^?M7_P*'_RL_";^W?#7_0WZ)_X.[;_XNC^W?#7_ $-^ MB?\ @[MO_BZ_=G_AF3]FW_HWOP/_ .$G9_\ QNC_ (9D_9M_Z-[\#_\ A)V? M_P ;H_LO#]W^'^0?\0EX<_Y^U?\ P*'_ ,K/PF_MWPU_T-^B?^#NV_\ BZ/[ M=\-?]#?HG_@[MO\ XNOW9_X9D_9M_P"C>_ __A)V?_QNC_AF3]FW_HWOP/\ M^$G9_P#QNC^R\/W?X?Y!_P 0EX<_Y^U?_ H?_*S\)O[=\-?]#?HG_@[MO_BZ M/[=\-?\ 0WZ)_P"#NV_^+K]V?^&9/V;?^C>_ _\ X2=G_P#&Z/\ AF3]FW_H MWOP/_P"$G9__ !NC^R\/W?X?Y!_Q"7AS_G[5_P# H?\ RL_";^W?#7_0WZ)_ MX.[;_P"+H_MWPU_T-^B?^#NV_P#BZ_=G_AF3]FW_ *-[\#_^$G9__&Z/^&9/ MV;?^C>_ _P#X2=G_ /&Z/[+P_=_A_D'_ !"7AS_G[5_\"A_\K/PF_MWPU_T- M^B?^#NV_^+H_MWPU_P!#?HG_ (.[;_XNOW9_X9D_9M_Z-[\#_P#A)V?_ ,;H M_P"&9/V;?^C>_ __ (2=G_\ &Z/[+P_=_A_D'_$)>'/^?M7_ ,"A_P#*S\)O M[=\-?]#?HG_@[MO_ (NC^W?#7_0WZ)_X.[;_ .+K]V?^&9/V;?\ HWOP/_X2 M=G_\;H_X9D_9M_Z-[\#_ /A)V?\ \;H_LO#]W^'^0?\ $)>'/^?M7_P*'_RL M_";^W?#7_0WZ)_X.[;_XNC^W?#7_ $-^B?\ @[MO_BZ_=G_AF3]FW_HWOP/_ M .$G9_\ QNC_ (9D_9M_Z-[\#_\ A)V?_P ;H_LO#]W^'^0?\0EX<_Y^U?\ MP*'_ ,K/PF_MWPU_T-^B?^#NV_\ BZ/[=\-?]#?HG_@[MO\ XNOW9_X9D_9M M_P"C>_ __A)V?_QNC_AF3]FW_HWOP/\ ^$G9_P#QNC^R\/W?X?Y!_P 0EX<_ MY^U?_ H?_*S\)O[=\-?]#?HG_@[MO_BZ/[=\-?\ 0WZ)_P"#NV_^+K]V?^&9 M/V;?^C>_ _\ X2=G_P#&Z/\ AF3]FW_HWOP/_P"$G9__ !NC^R\/W?X?Y!_Q M"7AS_G[5_P# H?\ RL_";^W?#7_0WZ)_X.[;_P"+H_MWPU_T-^B?^#NV_P#B MZ_=G_AF3]FW_ *-[\#_^$G9__&Z/^&9/V;?^C>_ _P#X2=G_ /&Z/[+P_=_A M_D'_ !"7AS_G[5_\"A_\K/Q-^"?C[P%X1^,WA'Q9XA\=Z);Z?I?B>PN[ZX_M M>!_*ACN(W=MJN6;"J3@ DXX!K]7_ /A[5_P3I_Z.DT3_ , [O_XS7J?_ S) M^S;_ -&]^!__ D[/_XW1_PS)^S;_P!&]^!__"3L_P#XW75A\-3PR:BWKW/K M>&^%LOX7I5*>%E*2FTWS-/;32T8GEG_#VK_@G3_T=)HG_@'=_P#QFC_A[5_P M3I_Z.DT3_P [O\ ^,UZG_PS)^S;_P!&]^!__"3L_P#XW1_PS)^S;_T;WX'_ M /"3L_\ XW70?2'EG_#VK_@G3_T=)HG_ (!W?_QFC_A[5_P3I_Z.DT3_ , [ MO_XS7J?_ S)^S;_ -&]^!__ D[/_XW1_PS)^S;_P!&]^!__"3L_P#XW0!Y M9_P]J_X)T_\ 1TFB?^ =W_\ &:/^'M7_ 3I_P"CI-$_\ [O_P",UZG_ ,,R M?LV_]&]^!_\ PD[/_P"-T?\ #,G[-O\ T;WX'_\ "3L__C= 'XF_&SQ]X"\7 M?&;Q=XL\/>.]$N-/U3Q/?W=C%/#M:K*I*K5NVW\4.O_ &X?A-_;OAK_ *&_ M1/\ P=VW_P 71_;OAK_H;]$_\'=M_P#%U^[/_#,G[-O_ $;WX'_\).S_ /C= M'_#,G[-O_1O?@?\ \).S_P#C=+^R\/W?X?Y&?_$)>'/^?M7_ ,"A_P#*S\)O M[=\-?]#?HG_@[MO_ (NC^W?#7_0WZ)_X.[;_ .+K]V?^&9/V;?\ HWOP/_X2 M=G_\;H_X9D_9M_Z-[\#_ /A)V?\ \;H_LO#]W^'^0?\ $)>'/^?M7_P*'_RL M_";^W?#7_0WZ)_X.[;_XNC^W?#7_ $-^B?\ @[MO_BZ_=G_AF3]FW_HWOP/_ M .$G9_\ QNC_ (9D_9M_Z-[\#_\ A)V?_P ;H_LO#]W^'^0?\0EX<_Y^U?\ MP*'_ ,K/PF_MWPU_T-^B?^#NV_\ BZ/[=\-?]#?HG_@[MO\ XNOW9_X9D_9M M_P"C>_ __A)V?_QNC_AF3]FW_HWOP/\ ^$G9_P#QNC^R\/W?X?Y!_P 0EX<_ MY^U?_ H?_*S\)O[=\-?]#?HG_@[MO_BZ/[=\-?\ 0WZ)_P"#NV_^+K]V?^&9 M/V;?^C>_ _\ X2=G_P#&Z/\ AF3]FW_HWOP/_P"$G9__ !NC^R\/W?X?Y!_Q M"7AS_G[5_P# H?\ RL_";^W?#7_0WZ)_X.[;_P"+H_MWPU_T-^B?^#NV_P#B MZ_=G_AF3]FW_ *-[\#_^$G9__&Z/^&9/V;?^C>_ _P#X2=G_ /&Z/[+P_=_A M_D'_ !"7AS_G[5_\"A_\K/PF_MWPU_T-^B?^#NV_^+H_MWPU_P!#?HG_ (.[ M;_XNOW9_X9D_9M_Z-[\#_P#A)V?_ ,;H_P"&9/V;?^C>_ __ (2=G_\ &Z/[ M+P_=_A_D'_$)>'/^?M7_ ,"A_P#*S\)O[=\-?]#?HG_@[MO_ (NC^W?#7_0W MZ)_X.[;_ .+K]V?^&9/V;?\ HWOP/_X2=G_\;H_X9D_9M_Z-[\#_ /A)V?\ M\;H_LO#]W^'^0?\ $)>'/^?M7_P*'_RL_";^W?#7_0WZ)_X.[;_XNC^W?#7_ M $-^B?\ @[MO_BZ_=G_AF3]FW_HWOP/_ .$G9_\ QNC_ (9D_9M_Z-[\#_\ MA)V?_P ;H_LO#]W^'^0?\0EX<_Y^U?\ P*'_ ,K/PF_MWPU_T-^B?^#NV_\ MBZ/[=\-?]#?HG_@[MO\ XNOW9_X9D_9M_P"C>_ __A)V?_QNC_AF3]FW_HWO MP/\ ^$G9_P#QNC^R\/W?X?Y!_P 0EX<_Y^U?_ H?_*S\)O[=\-?]#?HG_@[M MO_BZ/[=\-?\ 0WZ)_P"#NV_^+K]V?^&9/V;?^C>_ _\ X2=G_P#&Z/\ AF3] MFW_HWOP/_P"$G9__ !NC^R\/W?X?Y!_Q"7AS_G[5_P# H?\ RL_";^W?#7_0 MWZ)_X.[;_P"+H_MWPU_T-^B?^#NV_P#BZ_=G_AF3]FW_ *-[\#_^$G9__&Z/ M^&9/V;?^C>_ _P#X2=G_ /&Z/[+P_=_A_D'_ !"7AS_G[5_\"A_\K/PF_MWP MU_T-^B?^#NV_^+H_MWPU_P!#?HG_ (.[;_XNOW9_X9D_9M_Z-[\#_P#A)V?_ M ,;H_P"&9/V;?^C>_ __ (2=G_\ &Z/[+P_=_A_D'_$)>'/^?M7_ ,"A_P#* MS\)O[=\-?]#?HG_@[MO_ (NC^W?#7_0WZ)_X.[;_ .+K]V?^&9/V;?\ HWOP M/_X2=G_\;H_X9D_9M_Z-[\#_ /A)V?\ \;H_LO#]W^'^0?\ $)>'/^?M7_P* M'_RL_";^W?#7_0WZ)_X.[;_XNC^W?#7_ $-^B?\ @[MO_BZ_=G_AF3]FW_HW MOP/_ .$G9_\ QNC_ (9D_9M_Z-[\#_\ A)V?_P ;H_LO#]W^'^0?\0EX<_Y^ MU?\ P*'_ ,K/Q-^"?C[P%X1^,WA'Q9XA\=Z);Z?I?B>PN[ZX_M>!_*ACN(W= MMJN6;"J3@ DXX!K]7_\ A[5_P3I_Z.DT3_P#N_\ XS7J?_#,G[-O_1O?@?\ M\).S_P#C='_#,G[-O_1O?@?_ ,).S_\ C==6'PU/#)J+>O<^MX;X6R_A>E4I MX64I*;3?,T]M-+1B>6?\/:O^"=/_ $=)HG_@'=__ !FC_A[5_P $Z?\ HZ31 M/_ .[_\ C->I_P##,G[-O_1O?@?_ ,).S_\ C='_ S)^S;_ -&]^!__ D[ M/_XW70?2&/\ ?\ ;2_9>_:XC$=Q-H^C06KRH#D*QC0%AGG! MKH* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MKB/V@?VEOV?OV4OA]+\5OVD_C)X=\$>'8IEA.K>)-4CM8I)F!*Q)O(,DA )" M("Q .!P: .WHK@/V8 M$Q2JIW0R8(.QPK8(.,$&L?XR?MT_L>_L]^,?^%?_ !K_ &C?"GAO64M8KJ\L M-3U5$>PMI7$<=Q=D9%G"[D*LLY1&.0&.#0!ZO14=G>6FH6D5_874<\$\:R0S M0N&21&&0RD<$$$$$=:Y+PM^T)\"_'/Q4UWX'>"OBYX>UCQ?X8M(KGQ)X&-1+"SUSP[J4=U;R,IPZ;T)"NIX9#AE/! - '6T444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%<1^T#^TM^S]^RE\/I?BM^TG\9/#O@CP[%,L)U;Q)JD=K M%),P)6)-Y!DD(!(1 6(!P.#0!V]%6&IZJB/86TKB..XNR,BSA=R%66%;CQWK_BC3K'0[2Q:]N]9O+V.*TAME3>T[S,0BQA?F+D[0.,-1^'W[,?[6?@;QMKNEQ-+>:1H.O137(B4@-,D>0TL0) ,B!D! M8<\C(![517%?&W]H[X%_LX:/8:Y\*O#U^7%KK&A7Z7,# MLC%70LA.UT8%60X96!5@""* .FHHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH *^??VK_\ @F-^R'^W7\1;#QQ^V!\.SX^LM$T%M-\-^&-8OIDT[2GE MD=[J\BCA=";F9?L\9D8DHMJ@CV%G+?05?F__ ,' _P#P6Q^%_P#P39^&NG?L M^>&_&.I0?$OXA1!'G\,PPW&H>%M#=C'<:JD(O@IK.H_P#"@_"/B/4/!VB7-S,TD&HWEKJDCVY5 M^1_[(_B;P9X(\#>"+_6O$^J^-9;9Y9HDDAAS_H\C^?=W-U=K++-(1D+)A#N M!C^/_P!AKX8:?_P2F_9F_P""G?[#7[0_B6U\*^(6^']VOPW36;M8)/%5C_MJ?#CP;8&UT?P_K3Z;I5J96^,?$5IXBG6S.EK="&"V2X,I412&VMK9 MF1\,C2;& 92*^&/^#8#XY_!R;_@KK^V&3\3M"3_A./$=U=^#_-U2)/[9B.NW MC!K;+?O\K/$0$R2'!% 'Z6_\%2O@G_P28\#?#3QE^UQ_P4_\ :!XCT^YT5=( MMK[Q99F^NM/A$+;+#1D WVDTDGF2>9#ME:64EI0BH$^0_P#@S)\(?#WP[^P9 MX_UWPI\>;#Q#JFN^/Q=ZUX*M))?-\*A8!% +A)$3,MPD;/YD8:)EB10Y:.14 M^O[S_@M/_P $U?$_[6_Q&_X)R_'KQO#X,\2>%0;'58/BO8V^G:)XBBDA5I$M MI[B0QS)LD V3",R@DQK(F6KYR_X-[?\ @GM8?LT?M8?M5_M,?!_2I=,^"OCG MQE%IGP;A*NL6J:;;3W,TEY;[N9+)7G$-M-R)45V5BN&8 _5:BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ KY]_:O_ ."8W[(?[=?Q%L/''[8'P[/CZRT306TWPWX8UB^F M33M*>61WNKR*.%T)N9E^SQF1B2BVJ"/86&_&.I0?$OXA1!'G\,PPW&H>%M#=C'<:JD4_\ !'#XL:U^VC^PQ_P50_:6^*_[(_B;P9X(\#>"+_6O$^J^-9;9Y9HDDAAS_H\C^?=W-U=K++-(1D+) MA#N!C^/_ -AKX8:?_P $IOV9O^"G?[#7[0_B6U\*^(6^']VOPW36;M8)/%5C M%)?"=C9>'+'QO\ $?2=&N)7M-$L MX[B\AO 69F,$=U;1QP>43C?=KC E 'O7_!,+QSX8_P"#>3_@W[MOCG^V9HEQ MI/BCQ;KM]XDL? 5P?(U'4-3O8XXK#3MC#='*UM:02R[ES GF%US&5KY__P"" M:G_!P_\ LQQ?%]] \"?LX>._&'[3?[1_CS2K'Q5X_P#$L%E;Z:+RYN(K2UM( MEBN9)H=*L(G"Q0#YF6,L[JSEU /5O%/Q\\0?'3_@\U\)?"CQ!?2W&B_!_P " M7NF^&K*1CY-O/<^&9;ZYN$0\"1FO?+9\9(@C&2$6H_\ @W\^.GB/P=_P75_; MN_8NM=2F/AC4?'OB7QAI^F$_N+*ZM?$)M)&C3HA>._A1B/O"VCS]T5M?M$?L M\7'[''_!UO\ #?\ ;N^),D&C?#+XQ>&;NR_X3+4)E@TVPUV#P]-8_89YG(2& M25;:W=-Q7S6G(7<5?$G_ ;O_LM>*_%G_!3_ /;+_P""G[VDDG@;QG\2/$N@ M_#/Q"5/D^(;*?Q!->3W5JQ_UENJV]FJRKE&+,H),; '[(4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !6?JWA/PMK^H66JZ[X:T^]NM.D,F MGW-W9I)):N<9:-F!*'@ XML 16 pntg-20201231_htm.xml IDEA: XBRL DOCUMENT 0001766400 2020-01-01 2020-12-31 0001766400 2021-02-24 0001766400 2020-06-30 0001766400 2020-12-31 0001766400 2019-12-31 0001766400 2019-01-01 2019-12-31 0001766400 2018-01-01 2018-12-31 0001766400 us-gaap:CommonStockMember 2017-12-31 0001766400 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001766400 us-gaap:RetainedEarningsMember 2017-12-31 0001766400 us-gaap:TreasuryStockMember 2017-12-31 0001766400 us-gaap:ParentMember 2017-12-31 0001766400 us-gaap:NoncontrollingInterestMember 2017-12-31 0001766400 2017-12-31 0001766400 us-gaap:ParentMember 2018-01-01 2018-12-31 0001766400 us-gaap:NoncontrollingInterestMember 2018-01-01 2018-12-31 0001766400 us-gaap:CommonStockMember 2018-12-31 0001766400 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001766400 us-gaap:RetainedEarningsMember 2018-12-31 0001766400 us-gaap:TreasuryStockMember 2018-12-31 0001766400 us-gaap:ParentMember 2018-12-31 0001766400 us-gaap:NoncontrollingInterestMember 2018-12-31 0001766400 2018-12-31 0001766400 us-gaap:ParentMember 2019-01-01 2019-12-31 0001766400 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-12-31 0001766400 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001766400 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001766400 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001766400 us-gaap:CommonStockMember 2019-12-31 0001766400 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001766400 us-gaap:RetainedEarningsMember 2019-12-31 0001766400 us-gaap:TreasuryStockMember 2019-12-31 0001766400 us-gaap:ParentMember 2019-12-31 0001766400 us-gaap:NoncontrollingInterestMember 2019-12-31 0001766400 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-12-31 0001766400 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001766400 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001766400 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001766400 us-gaap:TreasuryStockMember 2020-01-01 2020-12-31 0001766400 us-gaap:CommonStockMember 2020-12-31 0001766400 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001766400 us-gaap:RetainedEarningsMember 2020-12-31 0001766400 us-gaap:TreasuryStockMember 2020-12-31 0001766400 us-gaap:ParentMember 2020-12-31 0001766400 us-gaap:NoncontrollingInterestMember 2020-12-31 0001766400 pntg:HomeHealthAndHospiceServicesSegmentMember 2020-12-31 0001766400 pntg:SeniorLivingServicesSegmentMember 2020-12-31 0001766400 2019-10-01 0001766400 us-gaap:OtherNoncurrentLiabilitiesMember 2020-12-31 0001766400 srt:MinimumMember 2020-01-01 2020-12-31 0001766400 srt:MaximumMember 2020-01-01 2020-12-31 0001766400 srt:MinimumMember us-gaap:CustomerContractsMember 2020-01-01 2020-12-31 0001766400 srt:MaximumMember us-gaap:CustomerContractsMember 2020-01-01 2020-12-31 0001766400 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2020-01-01 2020-12-31 0001766400 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2020-01-01 2020-12-31 0001766400 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001766400 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0001766400 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-12-31 0001766400 2019-01-01 2019-10-01 0001766400 us-gaap:CommonStockMember 2019-10-01 2019-10-01 0001766400 srt:AffiliatedEntityMember pntg:SeniorLivingServicesSegmentMember 2020-12-31 0001766400 srt:MinimumMember srt:AffiliatedEntityMember pntg:SeniorLivingServicesSegmentMember 2020-12-31 0001766400 srt:MaximumMember srt:AffiliatedEntityMember pntg:SeniorLivingServicesSegmentMember 2020-12-31 0001766400 pntg:OperatingLeaseRentExpenseMember srt:AffiliatedEntityMember 2020-01-01 2020-12-31 0001766400 pntg:OperatingLeaseRentExpenseMember srt:AffiliatedEntityMember 2019-01-01 2019-12-31 0001766400 pntg:OperatingLeaseRentExpenseMember srt:AffiliatedEntityMember 2018-01-01 2018-12-31 0001766400 srt:AffiliatedEntityMember 2020-01-01 2020-12-31 0001766400 srt:AffiliatedEntityMember 2019-01-01 2019-12-31 0001766400 srt:AffiliatedEntityMember 2018-01-01 2018-12-31 0001766400 pntg:TransitionServicesAgreementMember srt:AffiliatedEntityMember 2020-01-01 2020-12-31 0001766400 pntg:TransitionServicesAgreementMember srt:AffiliatedEntityMember 2019-01-01 2019-12-31 0001766400 pntg:RecognitionOfTaxBenefitsRelatedToTaxMattersAgreementMember 2020-01-01 2020-12-31 0001766400 pntg:RecognitionOfTaxBenefitsRelatedToTaxMattersAgreementMember 2019-01-01 2019-12-31 0001766400 pntg:NoncontrollingInterestHoldersMember us-gaap:CommonStockMember 2019-10-01 2019-10-01 0001766400 pntg:MedicareAndMedicaidMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001766400 pntg:MedicareAndMedicaidMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001766400 pntg:MedicareAndMedicaidMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001766400 pntg:SeniorLivingServicesSegmentMember 2020-01-01 2020-12-31 0001766400 pntg:MedicareMember pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HomeHealthSubsegmentMember 2020-01-01 2020-12-31 0001766400 pntg:MedicareMember pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HospiceSubsegmentMember 2020-01-01 2020-12-31 0001766400 pntg:MedicareMember pntg:SeniorLivingServicesSegmentMember 2020-01-01 2020-12-31 0001766400 pntg:MedicareMember 2020-01-01 2020-12-31 0001766400 pntg:MedicareMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001766400 pntg:MedicaidMember pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HomeHealthSubsegmentMember 2020-01-01 2020-12-31 0001766400 pntg:MedicaidMember pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HospiceSubsegmentMember 2020-01-01 2020-12-31 0001766400 pntg:MedicaidMember pntg:SeniorLivingServicesSegmentMember 2020-01-01 2020-12-31 0001766400 pntg:MedicaidMember 2020-01-01 2020-12-31 0001766400 pntg:MedicaidMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001766400 pntg:MedicareAndMedicaidMember pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HomeHealthSubsegmentMember 2020-01-01 2020-12-31 0001766400 pntg:MedicareAndMedicaidMember pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HospiceSubsegmentMember 2020-01-01 2020-12-31 0001766400 pntg:MedicareAndMedicaidMember pntg:SeniorLivingServicesSegmentMember 2020-01-01 2020-12-31 0001766400 pntg:MedicareAndMedicaidMember 2020-01-01 2020-12-31 0001766400 pntg:ManagedCareMember pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HomeHealthSubsegmentMember 2020-01-01 2020-12-31 0001766400 pntg:ManagedCareMember pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HospiceSubsegmentMember 2020-01-01 2020-12-31 0001766400 pntg:ManagedCareMember pntg:SeniorLivingServicesSegmentMember 2020-01-01 2020-12-31 0001766400 pntg:ManagedCareMember 2020-01-01 2020-12-31 0001766400 pntg:ManagedCareMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001766400 pntg:PrivateAndOtherMember pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HomeHealthSubsegmentMember 2020-01-01 2020-12-31 0001766400 pntg:PrivateAndOtherMember pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HospiceSubsegmentMember 2020-01-01 2020-12-31 0001766400 pntg:PrivateAndOtherMember pntg:SeniorLivingServicesSegmentMember 2020-01-01 2020-12-31 0001766400 pntg:PrivateAndOtherMember 2020-01-01 2020-12-31 0001766400 pntg:PrivateAndOtherMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001766400 pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HomeHealthSubsegmentMember 2020-01-01 2020-12-31 0001766400 pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HospiceSubsegmentMember 2020-01-01 2020-12-31 0001766400 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001766400 pntg:MedicareMember pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HomeHealthSubsegmentMember 2019-01-01 2019-12-31 0001766400 pntg:MedicareMember pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HospiceSubsegmentMember 2019-01-01 2019-12-31 0001766400 pntg:MedicareMember pntg:SeniorLivingServicesSegmentMember 2019-01-01 2019-12-31 0001766400 pntg:MedicareMember 2019-01-01 2019-12-31 0001766400 pntg:MedicareMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001766400 pntg:MedicaidMember pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HomeHealthSubsegmentMember 2019-01-01 2019-12-31 0001766400 pntg:MedicaidMember pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HospiceSubsegmentMember 2019-01-01 2019-12-31 0001766400 pntg:MedicaidMember pntg:SeniorLivingServicesSegmentMember 2019-01-01 2019-12-31 0001766400 pntg:MedicaidMember 2019-01-01 2019-12-31 0001766400 pntg:MedicaidMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001766400 pntg:MedicareAndMedicaidMember pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HomeHealthSubsegmentMember 2019-01-01 2019-12-31 0001766400 pntg:MedicareAndMedicaidMember pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HospiceSubsegmentMember 2019-01-01 2019-12-31 0001766400 pntg:MedicareAndMedicaidMember pntg:SeniorLivingServicesSegmentMember 2019-01-01 2019-12-31 0001766400 pntg:MedicareAndMedicaidMember 2019-01-01 2019-12-31 0001766400 pntg:ManagedCareMember pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HomeHealthSubsegmentMember 2019-01-01 2019-12-31 0001766400 pntg:ManagedCareMember pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HospiceSubsegmentMember 2019-01-01 2019-12-31 0001766400 pntg:ManagedCareMember pntg:SeniorLivingServicesSegmentMember 2019-01-01 2019-12-31 0001766400 pntg:ManagedCareMember 2019-01-01 2019-12-31 0001766400 pntg:ManagedCareMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001766400 pntg:PrivateAndOtherMember pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HomeHealthSubsegmentMember 2019-01-01 2019-12-31 0001766400 pntg:PrivateAndOtherMember pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HospiceSubsegmentMember 2019-01-01 2019-12-31 0001766400 pntg:PrivateAndOtherMember pntg:SeniorLivingServicesSegmentMember 2019-01-01 2019-12-31 0001766400 pntg:PrivateAndOtherMember 2019-01-01 2019-12-31 0001766400 pntg:PrivateAndOtherMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001766400 pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HomeHealthSubsegmentMember 2019-01-01 2019-12-31 0001766400 pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HospiceSubsegmentMember 2019-01-01 2019-12-31 0001766400 pntg:SeniorLivingServicesSegmentMember 2019-01-01 2019-12-31 0001766400 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001766400 pntg:MedicareMember pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HomeHealthSubsegmentMember 2018-01-01 2018-12-31 0001766400 pntg:MedicareMember pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HospiceSubsegmentMember 2018-01-01 2018-12-31 0001766400 pntg:MedicareMember pntg:SeniorLivingServicesSegmentMember 2018-01-01 2018-12-31 0001766400 pntg:MedicareMember 2018-01-01 2018-12-31 0001766400 pntg:MedicareMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001766400 pntg:MedicaidMember pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HomeHealthSubsegmentMember 2018-01-01 2018-12-31 0001766400 pntg:MedicaidMember pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HospiceSubsegmentMember 2018-01-01 2018-12-31 0001766400 pntg:MedicaidMember pntg:SeniorLivingServicesSegmentMember 2018-01-01 2018-12-31 0001766400 pntg:MedicaidMember 2018-01-01 2018-12-31 0001766400 pntg:MedicaidMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001766400 pntg:MedicareAndMedicaidMember pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HomeHealthSubsegmentMember 2018-01-01 2018-12-31 0001766400 pntg:MedicareAndMedicaidMember pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HospiceSubsegmentMember 2018-01-01 2018-12-31 0001766400 pntg:MedicareAndMedicaidMember pntg:SeniorLivingServicesSegmentMember 2018-01-01 2018-12-31 0001766400 pntg:MedicareAndMedicaidMember 2018-01-01 2018-12-31 0001766400 pntg:ManagedCareMember pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HomeHealthSubsegmentMember 2018-01-01 2018-12-31 0001766400 pntg:ManagedCareMember pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HospiceSubsegmentMember 2018-01-01 2018-12-31 0001766400 pntg:ManagedCareMember pntg:SeniorLivingServicesSegmentMember 2018-01-01 2018-12-31 0001766400 pntg:ManagedCareMember 2018-01-01 2018-12-31 0001766400 pntg:ManagedCareMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001766400 pntg:PrivateAndOtherMember pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HomeHealthSubsegmentMember 2018-01-01 2018-12-31 0001766400 pntg:PrivateAndOtherMember pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HospiceSubsegmentMember 2018-01-01 2018-12-31 0001766400 pntg:PrivateAndOtherMember pntg:SeniorLivingServicesSegmentMember 2018-01-01 2018-12-31 0001766400 pntg:PrivateAndOtherMember 2018-01-01 2018-12-31 0001766400 pntg:PrivateAndOtherMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001766400 pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HomeHealthSubsegmentMember 2018-01-01 2018-12-31 0001766400 pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HospiceSubsegmentMember 2018-01-01 2018-12-31 0001766400 pntg:SeniorLivingServicesSegmentMember 2018-01-01 2018-12-31 0001766400 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001766400 pntg:MedicareMember 2020-12-31 0001766400 pntg:MedicareMember 2019-12-31 0001766400 pntg:MedicaidMember 2020-12-31 0001766400 pntg:MedicaidMember 2019-12-31 0001766400 pntg:ManagedCareMember 2020-12-31 0001766400 pntg:ManagedCareMember 2019-12-31 0001766400 pntg:PrivateAndOtherMember 2020-12-31 0001766400 pntg:PrivateAndOtherMember 2019-12-31 0001766400 srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember 2019-12-31 0001766400 srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember 2018-12-31 0001766400 srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember 2017-12-31 0001766400 us-gaap:OperatingSegmentsMember pntg:HomeHealthAndHospiceServicesSegmentMember 2020-01-01 2020-12-31 0001766400 us-gaap:OperatingSegmentsMember pntg:SeniorLivingServicesSegmentMember 2020-01-01 2020-12-31 0001766400 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-12-31 0001766400 us-gaap:OperatingSegmentsMember pntg:HomeHealthAndHospiceServicesSegmentMember 2019-01-01 2019-12-31 0001766400 us-gaap:OperatingSegmentsMember pntg:SeniorLivingServicesSegmentMember 2019-01-01 2019-12-31 0001766400 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-12-31 0001766400 us-gaap:OperatingSegmentsMember pntg:HomeHealthAndHospiceServicesSegmentMember 2018-01-01 2018-12-31 0001766400 us-gaap:OperatingSegmentsMember pntg:SeniorLivingServicesSegmentMember 2018-01-01 2018-12-31 0001766400 us-gaap:CorporateNonSegmentMember 2018-01-01 2018-12-31 0001766400 2020-03-31 0001766400 2020-09-30 0001766400 pntg:SeniorLivingServicesSegmentMember pntg:AssetAcquisitions2020Member 2020-01-01 2020-12-31 0001766400 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2020-12-31 0001766400 pntg:ScrippsHealthMember 2020-10-01 2020-10-31 0001766400 pntg:ScrippsHealthMember pntg:HomeHealthJointVentureMember 2020-10-31 0001766400 pntg:ScrippsHealthMember pntg:HospiceJoinVentureMember 2020-10-31 0001766400 pntg:ScrippsHealthMember 2020-10-31 0001766400 pntg:BusinessAcquisitions2019Member pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HomeHealthSubsegmentMember 2019-01-01 2019-12-31 0001766400 pntg:BusinessAcquisitions2019Member pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HospiceSubsegmentMember 2019-01-01 2019-12-31 0001766400 pntg:BusinessAcquisitions2019Member pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HomeCareSubsegmentMember 2019-01-01 2019-12-31 0001766400 pntg:SeniorLivingServicesSegmentMember pntg:AssetAcquisitions2019Member 2019-01-01 2019-12-31 0001766400 pntg:SeniorLivingServicesSegmentMember 2019-12-31 0001766400 pntg:BusinessAcquisitions2019Member 2019-01-01 2019-12-31 0001766400 pntg:HomeHealthAndHospiceServicesSegmentMember pntg:HomeCareSubsegmentMember pntg:AssetAcquisitions2018Member 2018-01-01 2018-12-31 0001766400 pntg:SeniorLivingServicesSegmentMember 2018-12-31 0001766400 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2019-12-31 0001766400 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2018-12-31 0001766400 pntg:HomeHealthSubsegmentMember us-gaap:SubsequentEventMember 2021-01-01 2021-02-23 0001766400 pntg:HospiceSubsegmentMember us-gaap:SubsequentEventMember 2021-01-01 2021-02-23 0001766400 us-gaap:SubsequentEventMember 2021-01-01 2021-02-23 0001766400 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001766400 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001766400 us-gaap:EquipmentMember 2020-12-31 0001766400 us-gaap:EquipmentMember 2019-12-31 0001766400 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001766400 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001766400 pntg:HomeHealthAndHospiceServicesSegmentMember 2018-12-31 0001766400 pntg:HomeHealthAndHospiceServicesSegmentMember 2019-01-01 2019-12-31 0001766400 pntg:HomeHealthAndHospiceServicesSegmentMember 2019-12-31 0001766400 pntg:HomeHealthAndHospiceServicesSegmentMember 2020-01-01 2020-12-31 0001766400 us-gaap:TradeNamesMember 2020-12-31 0001766400 us-gaap:TradeNamesMember 2019-12-31 0001766400 us-gaap:LicensingAgreementsMember 2020-12-31 0001766400 us-gaap:LicensingAgreementsMember 2019-12-31 0001766400 srt:RestatementAdjustmentMember 2020-10-31 0001766400 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2020-12-31 0001766400 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2019-12-31 0001766400 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2019-10-01 0001766400 srt:MinimumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-10-01 2019-10-01 0001766400 srt:MaximumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-10-01 2019-10-01 0001766400 srt:MinimumMember us-gaap:BaseRateMember 2019-10-01 2019-10-01 0001766400 srt:MaximumMember us-gaap:BaseRateMember 2019-10-01 2019-10-01 0001766400 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2019-01-01 2019-10-01 0001766400 us-gaap:LetterOfCreditMember us-gaap:LineOfCreditMember 2020-12-31 0001766400 us-gaap:SubsequentEventMember 2021-02-23 0001766400 srt:MinimumMember us-gaap:SubsequentEventMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-02-23 2021-02-23 0001766400 srt:MaximumMember us-gaap:SubsequentEventMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-02-23 2021-02-23 0001766400 srt:MinimumMember us-gaap:SubsequentEventMember us-gaap:BaseRateMember 2021-02-23 2021-02-23 0001766400 srt:MaximumMember us-gaap:SubsequentEventMember us-gaap:BaseRateMember 2021-02-23 2021-02-23 0001766400 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001766400 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001766400 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001766400 us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0001766400 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0001766400 us-gaap:RestrictedStockMember 2018-01-01 2018-12-31 0001766400 srt:DirectorMember us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0001766400 srt:DirectorMember us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0001766400 srt:DirectorMember us-gaap:RestrictedStockMember 2018-01-01 2018-12-31 0001766400 us-gaap:EmployeeStockOptionMember pntg:TheEnsignPlansMember 2020-12-31 0001766400 us-gaap:EmployeeStockOptionMember pntg:TheEnsignPlansMember 2020-01-01 2020-12-31 0001766400 us-gaap:RestrictedStockMember pntg:TheEnsignPlansMember 2020-12-31 0001766400 us-gaap:RestrictedStockMember pntg:TheEnsignPlansMember 2020-01-01 2020-12-31 0001766400 pntg:TheEnsignPlansMember 2020-12-31 0001766400 pntg:GrantYear2020Member pntg:TheEnsignPlansMember 2020-01-01 2020-12-31 0001766400 pntg:GrantYear2020Member us-gaap:EmployeeStockOptionMember pntg:TheEnsignPlansMember 2020-01-01 2020-12-31 0001766400 pntg:GrantYear2019Member pntg:TheEnsignPlansMember 2019-01-01 2019-12-31 0001766400 pntg:GrantYear2019Member us-gaap:EmployeeStockOptionMember pntg:TheEnsignPlansMember 2019-01-01 2019-12-31 0001766400 pntg:TheEnsignPlansMember 2019-12-31 0001766400 pntg:TheEnsignPlansMember 2020-01-01 2020-12-31 0001766400 srt:MinimumMember us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0001766400 srt:MaximumMember us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0001766400 us-gaap:RestrictedStockMember pntg:TheEnsignPlansMember 2019-12-31 0001766400 srt:MinimumMember pntg:SeniorLivingServicesSegmentMember 2020-12-31 0001766400 srt:MaximumMember pntg:SeniorLivingServicesSegmentMember 2020-12-31 0001766400 pntg:FacilityMember us-gaap:CostOfSalesMember 2020-01-01 2020-12-31 0001766400 pntg:FacilityMember us-gaap:CostOfSalesMember 2019-01-01 2019-12-31 0001766400 srt:OfficeBuildingMember us-gaap:CostOfSalesMember 2020-01-01 2020-12-31 0001766400 srt:OfficeBuildingMember us-gaap:CostOfSalesMember 2019-01-01 2019-12-31 0001766400 us-gaap:CostOfSalesMember 2020-01-01 2020-12-31 0001766400 us-gaap:CostOfSalesMember 2019-01-01 2019-12-31 0001766400 us-gaap:CostOfSalesMember 2018-01-01 2018-12-31 0001766400 2019-10-01 2019-10-01 0001766400 us-gaap:DomesticCountryMember 2020-12-31 0001766400 pntg:MedicareAndMedicaidMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001766400 pntg:MedicareAndMedicaidMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 shares iso4217:USD iso4217:USD shares pntg:agency pntg:facility pure pntg:property pntg:home_health_agency pntg:hospice_agency pntg:stand-alone_senior_living_operation pntg:senior_living_unit pntg:home_care_agency pntg:arrangement pntg:review 0001766400 2020 FY false 0.50 P3Y0M0D P1Y0M0D 0.50 us-gaap:AccountingStandardsUpdate201409Member P3Y P5Y 10-K true 2020-12-31 --12-31 false 001-38900 THE PENNANT GROUP, INC. DE 83-3349931 1675 East Riverside Drive Suite 150 Eagle ID 83616 (208) 506-6100 Common Stock, par value $0.001 per share PNTG NASDAQ No No Yes Yes Accelerated Filer false true true false false 28262407 603746000 Part III of this Form 10-K incorporates information by reference from the Registrant's definitive proxy statement on Schedule 14A for the Registrant's 2021 Annual Meeting of Stockholders to be filed within 120 days after the close of the fiscal year covered by this annual report. 43000 402000 643000 677000 47221000 32183000 12335000 6098000 59599000 38683000 17884000 14644000 308650000 316328000 525000 1400000 2097000 0 4289000 2000000 66444000 41233000 47488000 33462000 506976000 447750000 9761000 8653000 26873000 16343000 14106000 12285000 38275000 13911000 89015000 51192000 296615000 304044000 11897000 2877000 8277000 18526000 405804000 376639000 0.001 0.001 100000000 100000000 28696000 28243000 28435000 27853000 28000 28000 84671000 74882000 11945000 -3799000 3000 65000 0 96579000 71111000 4593000 0 101172000 71111000 506976000 447750000 390953000 338531000 286058000 296874000 258941000 212421000 39191000 34975000 31199000 31296000 35135000 18843000 4675000 3810000 2964000 372036000 332861000 265427000 18917000 5670000 20631000 225000 0 0 1239000 410000 0 -1014000 -410000 0 17903000 5260000 20631000 2350000 2085000 4352000 15553000 3175000 16279000 -191000 629000 595000 15744000 2546000 15684000 0.56 0.11 0.58 0.52 0.11 0.58 28029000 27838000 27834000 30228000 29586000 27834000 0 0 0 0 0 0 54996000 4920000 59916000 -2539000 3917000 1378000 595000 595000 -12285000 -12285000 15684000 15684000 0 0 0 0 0 0 55856000 9432000 65288000 -2991000 3585000 594000 394000 394000 629000 629000 11894000 11894000 -3799000 6345000 2546000 11600000 11600000 72893000 -59504000 -13252000 137000 27834000 28000 -28000 0 1987000 1987000 601000 30000 30000 28435000 28000 74882000 -3799000 0 0 0 0 71111000 4646000 4646000 313000 138000 451000 -191000 -191000 15744000 15744000 8335000 8335000 238000 1141000 1141000 26000 0 3000 3000 65000 65000 28696000 28000 84671000 11945000 -3000 -65000 0 4593000 101172000 15553000 3175000 16279000 4675000 3810000 2964000 330000 78000 0 560000 858000 346000 8335000 3382000 2382000 -2201000 79000 0 15712000 8571000 2569000 7435000 2746000 210000 2068000 -1861000 0 993000 4069000 1373000 10538000 3376000 1583000 2427000 1720000 398000 27997000 0 0 2076000 2185000 729000 50204000 9554000 23275000 7253000 6714000 3603000 33193000 18760000 4725000 0 20000 593000 525000 1400000 0 645000 -429000 556000 -41616000 -26465000 -9477000 0 2293000 1972000 0 2687000 1972000 0 10788000 -13793000 0 11600000 0 555000 0 0 52700000 42500000 0 63200000 22500000 0 65000 0 0 78000 1552000 0 1141000 30000 0 -8947000 17272000 -13793000 -359000 361000 5000 402000 41000 36000 43000 402000 41000 1116000 156000 0 7865000 120000 0 35853000 37088000 0 5451000 9059000 0 1939000 77462000 0 560000 946000 717000 DESCRIPTION OF BUSINESS<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pennant Group, Inc. (herein referred to as “Pennant,” the “Company,” “it,” or “its”), is a holding company with no direct operating assets, employees or revenue. The Company, through its independent operating subsidiaries, provides healthcare services across the post-acute care continuum. As of December 31, 2020, the Company’s subsidiaries operated 76 home health, hospice and home care agencies and 54 senior living communities located in Arizona, California, Colorado, Idaho, Iowa, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin and Wyoming. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 1, 2019, The Ensign Group, Inc. (NASDAQ: ENSG) (“Ensign” or the “Parent”) completed the separation of Pennant from Ensign through a tax-free distribution (except as to cash received in lieu of fractional shares) of substantially all of Pennant’s issued and outstanding common stock to the stockholders of Ensign (the “Spin-Off”). To accomplish the Spin-Off, Ensign contributed the Company’s assets and liabilities into Pennant and each Ensign stockholder received a distribution of one share of Pennant common stock for every two shares of Ensign’s common stock, plus cash in lieu of fractional shares. Additionally, the noncontrolling interest was converted into shares of Pennant at the established conversion ratio. As a result of the Spin-Off on October 1, 2019, Pennant began trading as an independent company on the NASDAQ under the symbol “PNTG.”</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company’s subsidiaries, collectively referred to as the Service Center, provide accounting, payroll, human resources, information technology, legal, risk management, and other services to the operations through contractual relationships. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the Company’s affiliated operations are operated by separate, independent subsidiaries that have their own management, employees and assets. References herein to the consolidated “Company” and “its” assets and activities is not meant to imply, nor should it be construed as meaning, that Pennant has direct operating assets, employees or revenue, or that any of the subsidiaries, are operated by Pennant.</span></div> 76 54 BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated and combined financial statements of the Company (the “Financial Statements”) reflect the Company’s financial position, results of operations and cash flows as the business was operated as part of Ensign prior to the Spin-Off, and have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and pursuant to the regulations of the Securities and Exchange Commission (“SEC”). Prior to the Spin-Off, the combined financial statements were prepared on a stand-alone basis and derived from the consolidated financial statements and accounting records of Ensign. Management believes that the Financial Statements reflect, in all material respects, all adjustments which are of a normal and recurring nature necessary to present fairly the Company’s financial position, results of operations, and cash flows for the periods presented in conformity with GAAP applicable to the annual period. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All intercompany transactions and balances between the various legal entities comprising the Company have been eliminated in consolidation. The consolidated and combined statements of income reflect income that is attributable to the Company and the noncontrolling interest. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company consists of various limited liability companies and corporations established to operate home health, hospice, home care, and senior living operations. The Financial Statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest. Revenue was derived from transactional information specific to the Company’s services provided. The costs in the consolidated and combined statements of income reflect direct costs and allocated costs prior to the Spin-Off. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimates and Assumptions -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of the Financial Statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Financial Statements relate to revenue, cost allocations from prior to the Spin-Off, intangible assets and goodwill, right-of-use assets and lease liabilities for leases greater than 12 months, self-insurance reserves, and income taxes. Actual results could differ from those estimates.</span></div><div style="text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Revenues are recognized when services are provided to the patients at the amount that reflects the consideration to which the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net service revenue in the period such variances become known. See Note 5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Revenue and Accounts Receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify;text-indent:40.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CARES Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted on March 27, 2020 in the United States. During the second quarter of 2020 the Company applied for and received $27,997 in funds under the Accelerated and Advance Payment (“AAP”) Program. The CARES Act allows for deferred payment of the employer-paid portion of social security taxes through the end of 2020, with 50% due on December 31, 2021 and the remainder due on December 31, 2022. For the year ended December 31, 2020, the Company deferred approximately $8,358 of the employer-paid portion of social security taxes, of which $4,179 is included in other long-term liabilities and the current portion of $4,179 in accrued wages and related liabilities. The CARES Act temporarily suspended the automatic 2% reduction of Medicare claim reimbursements for the period of May 1, 2020 through March 31, 2021. The suspension of the Medicare sequestration increased our revenue by approximately $2,765 for the year ended December 31, 2020. The Company will continue to assess the effect of the CARES Act and ongoing other government legislation related to the COVID-19 pandemic that may be issued.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Cash consists of petty cash and bank term deposits and therefore approximates fair value. The Company places its cash with high credit quality financial institutions. Prior to the Spin-off the Company participated in a cash management program with Ensign where net cash activity was included in the net parent investment. </span></div><div style="text-align:justify;text-indent:40.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable and Allowance for Doubtful Accounts -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration. Subsequent to our adoption of ASU 2016-13, as noted below, the allowance for doubtful accounts is the Company’s best estimate of current expected credit losses in the accounts receivable balance. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI0MTRiODhmMTM1YzQ4M2Y4ZTJkMWNiYzJkMGY0NTNhL3NlYzpiNDE0Yjg4ZjEzNWM0ODNmOGUyZDFjYmMyZDBmNDUzYV8xMjcvZnJhZzoyOTljZWUyYTViYjY0OTM2ODgwNDRkZWQ2ZmI1N2YwOS90ZXh0cmVnaW9uOjI5OWNlZTJhNWJiNjQ5MzY4ODA0NGRlZDZmYjU3ZjA5XzE2NDkyNjc0Njg2MzU_a2eb0bdf-294f-47ad-bb3e-fae47da20484">three</span> to 15 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Long-Lived Assets -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company reviews the carrying value of long-lived assets that are held and used in the independent operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiary to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. Management has evaluated its long-lived assets and the Company did not identify any asset impairment during the years ended December 31, 2020, 2019 and 2018.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets and Goodwill -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Definite-lived intangible assets consist primarily of patient base and customer relationships. Patient base is amortized over a period of four months to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition when acquired. Customer relationships are amortized between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI0MTRiODhmMTM1YzQ4M2Y4ZTJkMWNiYzJkMGY0NTNhL3NlYzpiNDE0Yjg4ZjEzNWM0ODNmOGUyZDFjYmMyZDBmNDUzYV8xMjcvZnJhZzoyOTljZWUyYTViYjY0OTM2ODgwNDRkZWQ2ZmI1N2YwOS90ZXh0cmVnaW9uOjI5OWNlZTJhNWJiNjQ5MzY4ODA0NGRlZDZmYjU3ZjA5XzE2NDkyNjc0Njg2NjI_1856b25a-97dc-47dc-8c7c-e42c4a4b1555">one</span> to seven years depending on the significance of the relationships. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s indefinite-lived intangible assets consist of trade names and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable. The Company did not identify any asset impairment during the years ended December 31, 2020, 2019 and 2018.</span></div><div style="text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to annual test for impairment as of the beginning of the fourth quarter or more frequently if events or changes indicate that the Company's goodwill might be impaired. The Company assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company determines it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then it is required to perform a quantitative impairment test by comparing the fair value with the carrying amount of the reporting unit. If the carrying amount of a reporting unit exceeds its fair value, then the Company records an impairment of goodwill equal to the amount that the carrying amount of a reporting unit exceeds its fair value.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we evaluated potential triggering events that might be indicators that our goodwill and indefinite lived intangibles were impaired. No goodwill or intangible asset impairments were recorded during the years ended December 31, 2020, 2019 and 2018. See further discussion at Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Intangible Assets, Net.</span></div><div style="text-align:justify;text-indent:40.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company retains risk for a substantial portion of potential claims for general and professional liability and workers’ compensation. The Company does not retain risk related to its employee health plans. </span></div><div style="text-align:justify;text-indent:40.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes obligations associated with these costs, up to specified deductible limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. As of December 31, 2020 the general and professional liability insurance has a retention limit of $150 per claim with a $500 corridor as an additional out-of-pocket retention we must satisfy for claims within the policy year before the carrier will reimburse losses. The workers’ compensation insurance has a retention limit of $250 per claim, except for policies held in Texas and Washington which are subject to state insurance and possess their own limits. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis. Additionally, the Company has partially indemnified Ensign for general and professional liabilities incurred prior to the Spin-off but not reported until after that date and included that amount in its accrual below. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents details of the Company's insurance programs, including amounts accrued for the periods indicated in other accrued liabilities and other long-term liabilities in our accompanying balance sheets. The amounts accrued below represent the total estimated liability for individual claims that are less than our noted insurance coverage amounts, which includes outstanding claims and claims incurred but not reported. The amounts are reported gross of reinsurance receivable of $704 and zero included in restricted and other assets for the years ended December 31, 2020 and 2019, respectively. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:62.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.627%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Type of Insurance</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and professional liability </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,063 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers’ compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,783 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total estimated liability</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,846 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: long-term portion, included in other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,492)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(774)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of estimated liability, included in other accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,354 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s financial instruments consist principally of cash, accounts receivable, accounts payable and accrued liabilities. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations. The Company determines fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling Interest </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income/ (loss) attributable to The Pennant Group, Inc. in its consolidated and combined statements of income. Net income per share is calculated based on net income/ (loss) attributable to The Pennant Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Compensation -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and recognizes compensation expense for all share-based payment awards, including employee stock options, made to employees and Pennant’s directors based on estimated fair values, ratably over the requisite service period of the award. The Company accounts for forfeitures as they occur. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables. The total amount of share-based compensation was $8,335, $3,382, and $2,382 for the years ended December 31, 2020, 2019 and 2018, respectively, of which $7,222, $2,769 and $1,900, respectively, was recorded in general and administrative expense. For further discussion see Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Options and Awards.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prior to Spin-Off</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost Allocation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Financial Statements include allocations of costs for certain shared services provided to the Company by Ensign subsidiaries prior to the Spin-Off on October 1, 2019. Such allocations include, but are not limited to, executive management, accounting, human resources, information technology, compliance, legal, payroll, insurance, tax, treasury, and other general and administrative items. These costs were allocated to the Company on a basis of revenue, location, employee count, or other measures. These cost allocations are reflected within general and administrative expense in the consolidated and combined statements of income, including for share-based compensation expenses disclosed in Note 12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Options and Awards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amount of general and administrative costs allocated from January 1, 2019 to October 1, 2019, the date of the Spin-Off, inclusive of share-based compensation expense, was $23,710. Management believes the basis on which the expenses were allocated to be a reasonable reflection of the services provided to the Company during the periods. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Prior to the Spin-Off Ensign was partially self-insured for healthcare, general and professional liability, and workers’ compensation, and historically allocated premium expense to all subsidiaries of Ensign in its accounting records. To reflect all of the insurance costs, quarterly actuary determined adjustments were allocated to the Company based on the proportional historical premium expense. No self-insurance accruals were allocated to the Company as these accruals represent the obligations of Ensign. In connection with the Spin-Off, the Company purchased insurance through a third-party to replace the coverage provided by Ensign’s self-insured policies. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Ensign’s external debt and related interest expense were not allocated to the Company for any of the periods presented as no portion of the borrowings were assumed by the Company as part of the Spin-Off. All interest incurred by the Company was subsequent to the Spin-Off.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Prior to the date of the Spin-off, the Company’s operations have been included in Ensign’s U.S. federal and state income tax returns and all income taxes have been paid by subsidiaries of Ensign. Also prior to the date of the Spin-off, income tax expense and other income tax related information contained in these Financial Statements were presented using a separate tax return approach. Under this approach, the provision for income taxes represents income tax paid or payable for the current year plus the change in deferred taxes during the year calculated as if the Company was a stand-alone taxpayer filing hypothetical income tax returns. Management believes that the assumptions and estimates used to determine these tax amounts are reasonable. However, the Company’s Financial Statements may not necessarily reflect its income tax expense or tax </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payments in the future, or what tax amounts would have been if the Company had been a stand-alone company for the entire period presented.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Invested Capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The net parent investment on the consolidated balance sheets represents Ensign’s historical investment in the Company, the net effect of transactions with, and allocations from, Ensign and the Company’s accumulated earnings. Invested capital was reclassified into additional paid-in-capital at the date of the Spin-Off.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling Interest </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Prior to the Spin-Off, the Company presented the noncontrolling interest and the amount of consolidated net income/ (loss) attributable to the Company in its Financial Statements. The carrying amount of the noncontrolling interest was adjusted by an allocation of subsidiary earnings based on ownership interest prior to the Spin-Off. The noncontrolling subsidiary interest included in the Financial Statements was converted into common shares of Pennant concurrent with the distribution to Ensign stockholders at the date of the Spin-Off and thus, will no longer be allocated a portion of earnings</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-based compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Prior to the Spin-Off, employees of the Company’s subsidiaries participated in Ensign’s equity-based incentive plans (the “Ensign Plans”) and the Cornerstone Subsidiary Equity plan (the “Subsidiary Equity Plan”). Share-based compensation includes the expense attributable to employees of the Company’s subsidiaries who participated in the Ensign Plans, as well as the allocated cost related to Ensign subsidiaries’ employees that participated in the Ensign Plans. Share-based compensation related to Ensign subsidiaries’ employees that participated in the Ensign Plans were allocated on the basis of revenue. All share-based compensation related to the Subsidiary Equity Plan was recognized in the Financial Statements and, therefore, no cost allocation was necessary. </span></div><div style="text-align:justify;text-indent:40.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Spin-Off, share-based compensation costs associated with the Subsidiary Equity Plan awards was initially measured at fair value at the grant date and was expensed as non-cash compensation over the vesting term.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, these awards were granted once per year and the fair value has been determined by an independent valuation of the subsidiary shares. The valuation incorporated a discounted cash flow analysis combined with a market-based approach to determine the fair value of the subsidiary equity. </span></div><div style="text-align:justify;text-indent:40.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- For the year ended December 31, 2018, the earnings per share included on the accompanying Consolidated and Combined Statements of Income was calculated based on the 27,834 shares of Pennant common stock distributed on October 1, 2019 in conjunction with the Spin-Off, including shares related to the conversion of the noncontrolling interest. Prior to October 1, 2019, Pennant did not have any issued and outstanding common stock. The same number of shares was used to calculate basic and diluted earnings per share since no Pennant employee equity awards were outstanding prior to the Spin-Off. In connection with the Spin-Off, shares of existing equity awards were replaced with shares under the new Pennant awards and are reflected in basic and diluted net income per share for the years ended December 31, 2020 and 2019, respectively. For further discussion see Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Computation of Net Income Per Common Share</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Standards Adopted by the Company</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for rules and interpretive releases of the SEC under authority of federal securities laws and a limited number of grandfathered standards, the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management and certain standards are under consideration.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FASB Accounting Standards Update, or ASU, ASU 2020-04 “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” or ASU 2020-4 -</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In March 2020, the FASB concluded its reference rate reform project and issued this ASU. The amendments in this ASU provide optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in this ASU apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The optional expedients and exceptions are available for all entities as of March 12, 2020, through December 31, 2022. The Company has adopted ASU 2020-04, effective March 12, 2020. The impact of this ASU will be determined based on terms of any future contract modification related to a change in reference rate, including future modifications to the Company’s </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revolving Credit Facility described in further detail in Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt.</span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FASB ASU, 2018-15, “Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract” or ASU 2018-15.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The update helps entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement (hosting arrangement), by providing guidance in determining when the arrangement includes a software license. It requires entities to account for such costs consistent with the guidance on capitalizing costs associated with developing or obtaining internal-use software. The Company has adopted ASU 2018-15, effective January 1, 2020. There was no material impact to the Company’s Financial Statements or disclosures. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FASB ASU, 2018-13 “Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement” or ASU 2018-13</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In August 2018, the FASB issued amended guidance to simplify fair value measurement disclosure requirements. The new provisions eliminate the requirements to disclose (1) transfers between Level 1 and Level 2 of the fair value hierarchy, (2) policies related to valuation processes and the timing of transfers between levels of the fair value hierarchy, and (3) net asset value disclosure of estimates of timing of future liquidity events. The FASB also modified disclosure requirements of Level 3 fair value measurements. The Company adopted ASU 2018-13 as of January 1, 2020. There was no material impact to the Company’s Financial Statements or disclosures. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FASB ASU, 2017-04 “Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” or ASU 2017-04 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In January 2017, the FASB issued amended authoritative guidance to simplify and reduce the cost and complexity of the goodwill impairment test. The new guidance eliminates “Step 2” from the traditional two-step goodwill impairment test and redefines the concept of impairment from a measure of loss when comparing the implied fair value of goodwill to its carrying amount, to a measure comparing the fair value of a reporting unit with its carrying amount. The FASB also eliminated the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment or “Step 2” of the goodwill impairment test. The new guidance does not amend the optional qualitative assessment of goodwill impairment. The Company adopted ASU 2017-04 as of January 1, 2020. There was no material impact to the Company’s Financial Statements or disclosures.</span></div>FASB ASU 2016-13 “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” or ASU 2016-13 - In June 2016, the FASB issued ASU 2016-13, which replaced the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected to be collected. The Company adopted ASU 2016-13 as of January 1, 2020. There was no material impact to the Company’s Financial Statements or related disclosures. Basis of Presentation - The accompanying consolidated and combined financial statements of the Company (the “Financial Statements”) reflect the Company’s financial position, results of operations and cash flows as the business was operated as part of Ensign prior to the Spin-Off, and have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and pursuant to the regulations of the Securities and Exchange Commission (“SEC”). Prior to the Spin-Off, the combined financial statements were prepared on a stand-alone basis and derived from the consolidated financial statements and accounting records of Ensign. Management believes that the Financial Statements reflect, in all material respects, all adjustments which are of a normal and recurring nature necessary to present fairly the Company’s financial position, results of operations, and cash flows for the periods presented in conformity with GAAP applicable to the annual period. All intercompany transactions and balances between the various legal entities comprising the Company have been eliminated in consolidation. The consolidated and combined statements of income reflect income that is attributable to the Company and the noncontrolling interest. The Company consists of various limited liability companies and corporations established to operate home health, hospice, home care, and senior living operations. The Financial Statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest. Revenue was derived from transactional information specific to the Company’s services provided. The costs in the consolidated and combined statements of income reflect direct costs and allocated costs prior to the Spin-Off. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimates and Assumptions -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of the Financial Statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Financial Statements relate to revenue, cost allocations from prior to the Spin-Off, intangible assets and goodwill, right-of-use assets and lease liabilities for leases greater than 12 months, self-insurance reserves, and income taxes. Actual results could differ from those estimates.</span> Revenue Recognition - Revenues are recognized when services are provided to the patients at the amount that reflects the consideration to which the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net service revenue in the period such variances become known.Revenues are recognized when services are provided to the patients or residents at the amount that reflects the consideration to which the Company expects to be entitled from patients, residents and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care or senior living residence. The healthcare services in home health and hospice patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct within the context of the contract. Additionally, there may be ancillary services which are not included in the rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net service revenue in the period such variances become known. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from the Medicare and Medicaid programs accounted for 60.1%, 55.6%, and 53.1% of the Company’s revenue for the years ended December 31, 2020, 2019 and 2018, respectively. The Company records revenue from these governmental and managed care programs as services are performed at their expected net realizable amounts under these programs. The Company’s revenue from governmental and managed care programs is subject to audit and retroactive adjustment by governmental and third-party agencies. Consistent with healthcare industry accounting practices, any changes to these governmental revenue estimates are recorded in the period the change or adjustment becomes known based on final settlement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates revenue from contracts with its patients or residents by reportable operating segments and payors. The Company has determined that disaggregating revenue into these categories achieves the disclosure objectives to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. A reconciliation of disaggregated revenue to segment revenue as well as revenue by payor is provided in below. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s service specific revenue recognition policies are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Home Health Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicare Revenue</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For Medicare episodes that began after January 1, 2020, net service revenue is recognized in accordance with the Patient Driven Groupings Model (“PDGM”). This new reimbursement structure involves case mix calculation methodology refinements, changes to low-utilization payment adjustment (“LUPA”) thresholds, the elimination of therapy thresholds, a change to the unit of payment from a 60-day episode to a 30-day payment period, and reduction of requests for anticipated payments (“RAPs”) to 20% of the estimated payment for a patient’s initial or subsequent period of care up-front (after the initial assessment is completed and upon initial billing). The RAPs will be completely phased out effective January 1, 2021. Under PDGM, Medicare provides agencies with payments for each 30-day payment period provided to beneficiaries. If a beneficiary is still eligible for care after the end of the first 30-day payment period, a second 30-day payment period can begin. There are no limits to the number of periods of care a beneficiary who remains eligible for the home health benefit can receive. While payment for each 30-day payment period is adjusted to reflect the beneficiary’s health condition and needs, a special outlier provision exists to ensure appropriate payment for those beneficiaries that have the most expensive care needs. The payment under the Medicare program is also adjusted for certain variables including, but not limited to: (a) a LUPA if the number of visits is below an established threshold that varies based on the diagnosis of a beneficiary; (b) a partial payment if the patient transferred to another provider or the Company received a patient from another provider before completing the period of care; (c) adjustment to the admission source of claim if it is determined that the patient had a qualifying stay in a post-acute care setting within 14 days prior to the start of a 30-day payment period; (d) the timing of the 30-day payment period provided to a patient in relation to the admission date, regardless of whether the same home health provider provided care for the entire series of episodes; (e) changes to the acuity of the patient during the previous 30-day payment period; (f) changes in the base payments established by the Medicare program; (g) adjustments to the base payments for case mix and geographic wages; and (h) recoveries of overpayments. </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all episodes that began prior to January 1, 2020, net service revenue was recorded under the Medicare prospective payment system based on a 60-day episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a) an outlier payment if the patient’s care was unusually costly; (b) a LUPA if the number of visits was fewer than five; (c) a partial payment if the patient transferred to another provider or transferred from another provider before completing the episode; (d) a payment adjustment based upon the level of covered therapy services; (e) the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (f) changes in the base episode payments established by the Medicare program; (g) adjustments to the base episode payments for case mix and geographic wages; and (h) recoveries of overpayments.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adjusts Medicare revenue on completed episodes to reflect differences between estimated and actual payment amounts, an inability to obtain appropriate billing documentation and other reasons unrelated to credit risk. Therefore, the Company believes that its reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to revenue recognized on completed episodes and periods, the Company also recognizes a portion of revenue associated with episodes and periods in progress. Episodes in progress are 30-day payment periods, if the episode started after January 1, 2020, or 60-day episodes of care, if the episode started prior to January 1, 2020, that begin during the reporting period but were not completed as of the end of the period. As such, the Company estimates revenue and recognizes it on a daily basis. The primary factors underlying this estimate are the number of episodes in progress at the end of the reporting period, expected Medicare revenue per period of care or episode of care and the Company’s estimate of the average percentage complete based on the scheduled end of period and end of episode dates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Medicare Revenue</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Episodic Based Revenue -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company recognizes revenue in a similar manner as it recognizes Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-episodic Based Revenue -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Revenue is recognized on an accrual basis based upon the date of service at amounts equal to its established or estimated per visit rates, as applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hospice Revenue</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are calculated as daily rates for each of the levels of care the Company delivers. Revenue is adjusted for an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. Additionally, as Medicare hospice revenue is subject to an inpatient cap and an overall payment cap, the Company monitors its provider numbers and estimates amounts due back to Medicare if a cap has been exceeded. The Company regularly evaluates and records these adjustments as a reduction to revenue and an increase to other accrued liabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Living Revenue</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected the lessor practical expedient within ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 842”) and therefore recognizes, measures, presents, and discloses the revenue for services rendered under the Company’s senior living residency agreements based upon the predominant component, either the lease or non-lease component, of the contracts. The Company has determined that the services included under the Company’s senior living residency agreements each have the same timing and pattern of transfer. The Company recognizes revenue under ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for its senior residency agreements, for which it has determined that the non-lease components of such residency agreements are the predominant component of each such contract.</span></div>The Company’s senior living revenue consists of fees for basic housing and assisted living care. Accordingly, we record revenue when services are rendered on the date services are provided at amounts billable to individual residents. Residency agreements are generally for a term of 30 days, with resident fees billed monthly in advance. For residents under reimbursement arrangements with Medicaid, revenue is recorded based on contractually agreed-upon amounts or rates on a per resident, daily basis or as services are rendered.<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Practical Expedients and Exemptions</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company’s contracts have an original duration of one year or less, the Company uses the practical expedient applicable to its contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of the end of each reporting period or when the Company expects to recognize this revenue. In addition, the Company has applied the practical expedient provided by ASC 340, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 340”), and all incremental customer contract acquisition costs are expensed as they are incurred because the amortization period would have been one year or less.</span></div> 27997000 8358000 4179000 4179000 2765000 Cash - Cash consists of petty cash and bank term deposits and therefore approximates fair value. The Company places its cash with high credit quality financial institutions. Prior to the Spin-off the Company participated in a cash management program with Ensign where net cash activity was included in the net parent investment. Accounts Receivable and Allowance for Doubtful Accounts - Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration. Subsequent to our adoption of ASU 2016-13, as noted below, the allowance for doubtful accounts is the Company’s best estimate of current expected credit losses in the accounts receivable balance. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI0MTRiODhmMTM1YzQ4M2Y4ZTJkMWNiYzJkMGY0NTNhL3NlYzpiNDE0Yjg4ZjEzNWM0ODNmOGUyZDFjYmMyZDBmNDUzYV8xMjcvZnJhZzoyOTljZWUyYTViYjY0OTM2ODgwNDRkZWQ2ZmI1N2YwOS90ZXh0cmVnaW9uOjI5OWNlZTJhNWJiNjQ5MzY4ODA0NGRlZDZmYjU3ZjA5XzE2NDkyNjc0Njg2MzU_a2eb0bdf-294f-47ad-bb3e-fae47da20484">three</span> to 15 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.</span> P15Y Impairment of Long-Lived Assets - The Company reviews the carrying value of long-lived assets that are held and used in the independent operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiary to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets and Goodwill -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Definite-lived intangible assets consist primarily of patient base and customer relationships. Patient base is amortized over a period of four months to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition when acquired. Customer relationships are amortized between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI0MTRiODhmMTM1YzQ4M2Y4ZTJkMWNiYzJkMGY0NTNhL3NlYzpiNDE0Yjg4ZjEzNWM0ODNmOGUyZDFjYmMyZDBmNDUzYV8xMjcvZnJhZzoyOTljZWUyYTViYjY0OTM2ODgwNDRkZWQ2ZmI1N2YwOS90ZXh0cmVnaW9uOjI5OWNlZTJhNWJiNjQ5MzY4ODA0NGRlZDZmYjU3ZjA5XzE2NDkyNjc0Njg2NjI_1856b25a-97dc-47dc-8c7c-e42c4a4b1555">one</span> to seven years depending on the significance of the relationships. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s indefinite-lived intangible assets consist of trade names and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable. The Company did not identify any asset impairment during the years ended December 31, 2020, 2019 and 2018.</span></div><div style="text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to annual test for impairment as of the beginning of the fourth quarter or more frequently if events or changes indicate that the Company's goodwill might be impaired. The Company assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company determines it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then it is required to perform a quantitative impairment test by comparing the fair value with the carrying amount of the reporting unit. If the carrying amount of a reporting unit exceeds its fair value, then the Company records an impairment of goodwill equal to the amount that the carrying amount of a reporting unit exceeds its fair value.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we evaluated potential triggering events that might be indicators that our goodwill and indefinite lived intangibles were impaired. No goodwill or intangible asset impairments were recorded during the years ended December 31, 2020, 2019 and 2018. See further discussion at Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Intangible Assets, Net.</span></div> P4M P8M P7Y 0 0 0 150000 500000 250000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents details of the Company's insurance programs, including amounts accrued for the periods indicated in other accrued liabilities and other long-term liabilities in our accompanying balance sheets. The amounts accrued below represent the total estimated liability for individual claims that are less than our noted insurance coverage amounts, which includes outstanding claims and claims incurred but not reported. The amounts are reported gross of reinsurance receivable of $704 and zero included in restricted and other assets for the years ended December 31, 2020 and 2019, respectively. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:62.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.627%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Type of Insurance</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and professional liability </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,063 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers’ compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,783 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total estimated liability</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,846 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: long-term portion, included in other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,492)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(774)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of estimated liability, included in other accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,354 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 704000 0 1063000 521000 2783000 433000 3846000 954000 2492000 774000 1354000 180000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s financial instruments consist principally of cash, accounts receivable, accounts payable and accrued liabilities. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations. The Company determines fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences </span><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling Interest </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income/ (loss) attributable to The Pennant Group, Inc. in its consolidated and combined statements of income. Net income per share is calculated based on net income/ (loss) attributable to The Pennant Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest.</span> Share-Based Compensation -The Company measures and recognizes compensation expense for all share-based payment awards, including employee stock options, made to employees and Pennant’s directors based on estimated fair values, ratably over the requisite service period of the award. The Company accounts for forfeitures as they occur. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables. 8335000 3382000 2382000 7222000 2769000 1900000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prior to Spin-Off</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost Allocation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Financial Statements include allocations of costs for certain shared services provided to the Company by Ensign subsidiaries prior to the Spin-Off on October 1, 2019. Such allocations include, but are not limited to, executive management, accounting, human resources, information technology, compliance, legal, payroll, insurance, tax, treasury, and other general and administrative items. These costs were allocated to the Company on a basis of revenue, location, employee count, or other measures. These cost allocations are reflected within general and administrative expense in the consolidated and combined statements of income, including for share-based compensation expenses disclosed in Note 12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Options and Awards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amount of general and administrative costs allocated from January 1, 2019 to October 1, 2019, the date of the Spin-Off, inclusive of share-based compensation expense, was $23,710. Management believes the basis on which the expenses were allocated to be a reasonable reflection of the services provided to the Company during the periods. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Prior to the Spin-Off Ensign was partially self-insured for healthcare, general and professional liability, and workers’ compensation, and historically allocated premium expense to all subsidiaries of Ensign in its accounting records. To reflect all of the insurance costs, quarterly actuary determined adjustments were allocated to the Company based on the proportional historical premium expense. No self-insurance accruals were allocated to the Company as these accruals represent the obligations of Ensign. In connection with the Spin-Off, the Company purchased insurance through a third-party to replace the coverage provided by Ensign’s self-insured policies. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Ensign’s external debt and related interest expense were not allocated to the Company for any of the periods presented as no portion of the borrowings were assumed by the Company as part of the Spin-Off. All interest incurred by the Company was subsequent to the Spin-Off.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Prior to the date of the Spin-off, the Company’s operations have been included in Ensign’s U.S. federal and state income tax returns and all income taxes have been paid by subsidiaries of Ensign. Also prior to the date of the Spin-off, income tax expense and other income tax related information contained in these Financial Statements were presented using a separate tax return approach. Under this approach, the provision for income taxes represents income tax paid or payable for the current year plus the change in deferred taxes during the year calculated as if the Company was a stand-alone taxpayer filing hypothetical income tax returns. Management believes that the assumptions and estimates used to determine these tax amounts are reasonable. However, the Company’s Financial Statements may not necessarily reflect its income tax expense or tax </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payments in the future, or what tax amounts would have been if the Company had been a stand-alone company for the entire period presented.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Invested Capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The net parent investment on the consolidated balance sheets represents Ensign’s historical investment in the Company, the net effect of transactions with, and allocations from, Ensign and the Company’s accumulated earnings. Invested capital was reclassified into additional paid-in-capital at the date of the Spin-Off.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling Interest </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Prior to the Spin-Off, the Company presented the noncontrolling interest and the amount of consolidated net income/ (loss) attributable to the Company in its Financial Statements. The carrying amount of the noncontrolling interest was adjusted by an allocation of subsidiary earnings based on ownership interest prior to the Spin-Off. The noncontrolling subsidiary interest included in the Financial Statements was converted into common shares of Pennant concurrent with the distribution to Ensign stockholders at the date of the Spin-Off and thus, will no longer be allocated a portion of earnings</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-based compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Prior to the Spin-Off, employees of the Company’s subsidiaries participated in Ensign’s equity-based incentive plans (the “Ensign Plans”) and the Cornerstone Subsidiary Equity plan (the “Subsidiary Equity Plan”). Share-based compensation includes the expense attributable to employees of the Company’s subsidiaries who participated in the Ensign Plans, as well as the allocated cost related to Ensign subsidiaries’ employees that participated in the Ensign Plans. Share-based compensation related to Ensign subsidiaries’ employees that participated in the Ensign Plans were allocated on the basis of revenue. All share-based compensation related to the Subsidiary Equity Plan was recognized in the Financial Statements and, therefore, no cost allocation was necessary. </span></div><div style="text-align:justify;text-indent:40.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Spin-Off, share-based compensation costs associated with the Subsidiary Equity Plan awards was initially measured at fair value at the grant date and was expensed as non-cash compensation over the vesting term.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, these awards were granted once per year and the fair value has been determined by an independent valuation of the subsidiary shares. The valuation incorporated a discounted cash flow analysis combined with a market-based approach to determine the fair value of the subsidiary equity. </span></div><div style="text-align:justify;text-indent:40.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- For the year ended December 31, 2018, the earnings per share included on the accompanying Consolidated and Combined Statements of Income was calculated based on the 27,834 shares of Pennant common stock distributed on October 1, 2019 in conjunction with the Spin-Off, including shares related to the conversion of the noncontrolling interest. Prior to October 1, 2019, Pennant did not have any issued and outstanding common stock. The same number of shares was used to calculate basic and diluted earnings per share since no Pennant employee equity awards were outstanding prior to the Spin-Off. In connection with the Spin-Off, shares of existing equity awards were replaced with shares under the new Pennant awards and are reflected in basic and diluted net income per share for the years ended December 31, 2020 and 2019, respectively. For further discussion see Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Computation of Net Income Per Common Share</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Standards Adopted by the Company</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for rules and interpretive releases of the SEC under authority of federal securities laws and a limited number of grandfathered standards, the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management and certain standards are under consideration.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FASB Accounting Standards Update, or ASU, ASU 2020-04 “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” or ASU 2020-4 -</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In March 2020, the FASB concluded its reference rate reform project and issued this ASU. The amendments in this ASU provide optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in this ASU apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The optional expedients and exceptions are available for all entities as of March 12, 2020, through December 31, 2022. The Company has adopted ASU 2020-04, effective March 12, 2020. The impact of this ASU will be determined based on terms of any future contract modification related to a change in reference rate, including future modifications to the Company’s </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revolving Credit Facility described in further detail in Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt.</span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FASB ASU, 2018-15, “Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract” or ASU 2018-15.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The update helps entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement (hosting arrangement), by providing guidance in determining when the arrangement includes a software license. It requires entities to account for such costs consistent with the guidance on capitalizing costs associated with developing or obtaining internal-use software. The Company has adopted ASU 2018-15, effective January 1, 2020. There was no material impact to the Company’s Financial Statements or disclosures. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FASB ASU, 2018-13 “Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement” or ASU 2018-13</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In August 2018, the FASB issued amended guidance to simplify fair value measurement disclosure requirements. The new provisions eliminate the requirements to disclose (1) transfers between Level 1 and Level 2 of the fair value hierarchy, (2) policies related to valuation processes and the timing of transfers between levels of the fair value hierarchy, and (3) net asset value disclosure of estimates of timing of future liquidity events. The FASB also modified disclosure requirements of Level 3 fair value measurements. The Company adopted ASU 2018-13 as of January 1, 2020. There was no material impact to the Company’s Financial Statements or disclosures. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FASB ASU, 2017-04 “Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” or ASU 2017-04 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In January 2017, the FASB issued amended authoritative guidance to simplify and reduce the cost and complexity of the goodwill impairment test. The new guidance eliminates “Step 2” from the traditional two-step goodwill impairment test and redefines the concept of impairment from a measure of loss when comparing the implied fair value of goodwill to its carrying amount, to a measure comparing the fair value of a reporting unit with its carrying amount. The FASB also eliminated the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment or “Step 2” of the goodwill impairment test. The new guidance does not amend the optional qualitative assessment of goodwill impairment. The Company adopted ASU 2017-04 as of January 1, 2020. There was no material impact to the Company’s Financial Statements or disclosures.</span></div>FASB ASU 2016-13 “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” or ASU 2016-13 - In June 2016, the FASB issued ASU 2016-13, which replaced the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected to be collected. The Company adopted ASU 2016-13 as of January 1, 2020. There was no material impact to the Company’s Financial Statements or related disclosures. 23710000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Invested Capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The net parent investment on the consolidated balance sheets represents Ensign’s historical investment in the Company, the net effect of transactions with, and allocations from, Ensign and the Company’s accumulated earnings. Invested capital was reclassified into additional paid-in-capital at the date of the Spin-Off.</span> 27834000 RELATED PARTY TRANSACTIONS AND NET PARENT INVESTMENT<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Financial Statements include a combination of stand-alone and combined business functions between Ensign and the Company’s subsidiaries prior to the Spin-Off. The Company leases 31 of its senior living communities from subsidiaries of Ensign, each of the leases have a term of between 14 and 20 years from the lease commencement date. The total amount of rent expense included in Rent - cost of services paid to subsidiaries of Ensign was $12,536, $11,292, and $10,363 for the years ended December 31, 2020, 2019 and 2018, respectively. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain related party activity occurred as the Company’s subsidiaries received services from Ensign’s subsidiaries. Services included in cost of services were $4,205, $3,166, and $2,996 for the years ended December 31, 2020, 2019 and 2018, respectively.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated balance sheets of the Company include Ensign assets and liabilities that are specifically identifiable or otherwise attributable to the Company and were transferred to the Company in connection with the Spin-Off. Transactions that have occurred between subsidiaries of the Company and subsidiaries of Ensign are considered to be effectively settled at the time the transaction is recorded. The net effect of these transactions, including the cash management, is included in the consolidated and combined statements of cash flows as “Net investment from/(to) Parent”.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other related party activity with Ensign</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2019, in connection with the Spin-Off, Pennant entered into several agreements with Ensign that set forth the principal actions taken or to be taken in connection with the Spin-Off and govern the relationship of the parties following the Spin-Off. </span></div>The Company has incurred $5,536 and $2,982 in costs related to the Transitions Services Agreement for the years ended December 31, 2020 and 2019, respectively. Additionally, the Company has recognized $578 and $291 in tax benefits related to the Tax Matters Agreement for the years ended December 31, 2020 and 2019, respectively, and has recorded a payable to Ensign in connection with any unpaid portion of these amounts. See “Certain Relationships and Related Party Transactions—Agreements with Ensign Related to the Spin-Off,” contained within the Information Statement as well as the Form 8-K filed with the SEC on October 3, 2019 for further discussion of the agreements entered into in connection with the Spin-Off. 31 P14Y P20Y 12536000 11292000 10363000 4205000 3166000 2996000 5536000 2982000 578000 291000 COMPUTATION OF NET INCOME PER COMMON SHARE<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net income per share are computed by dividing net income by the weighted average number of outstanding common shares during the period. In the basic and diluted earnings per share calculations, net income is equal to net income attributable to The Pennant Group, Inc. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prior to Spin-Off</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to the noncontrolling interest has been included in the numerator for the years ended December 31, 2019 and 2018, respectively, as the non-controlling subsidiary interest that existed prior to the Spin-Off was converted into common shares of Pennant concurrent with the distribution to Ensign stockholders at the date of the Spin-Off</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-align:justify;text-indent:72pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:80%">The following table sets forth the computation of basic and diluted net income per share for the periods presented: </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.699%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,553 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,175 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: net (loss)/ income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to The Pennant Group, Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,744 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,546 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,684 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding for basic net income per share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,029 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,838 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,834 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: incremental shares from assumed conversion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted weighted average common shares outstanding for diluted income per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,228 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,586 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,834 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings Per Share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income per common share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income per common share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">C</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">oncurrent with the Spin-Off the noncontrolling subsidiary interest converted into 1,160 shares of Pennant. The total number of common shares distributed on October 1, 2019 of 27,834 was utilized in the denominator for the calculation of basic and diluted earnings per share for the year ended December 31, 2018 , as no common stock was outstanding prior to the date of the Spin-Off.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The calculation of dilutive shares outstanding excludes out-of-the-money stock options (i.e., such options’ exercise prices were greater than the average market price of our common shares for the period) because their inclusion would have been antidilutive. Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were 93 and 15 for the years ended December 31, 2020 and 2019, respectively.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the years ended December 31, 2019 and 2018 basic and diluted earnings per share were calculated based on net income as the numerator, which included the conversion of the noncontrolling interest in connection with the Spin-Off. For the year ended December 31, 2020, basic and diluted earnings per share was calculated based on net income attributable to The Pennant Group, Inc. as the numerator, . See Note 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">, for further information on our acquisitions for the year ended December 31, 2020. </span></div></td></tr></table></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net income per share are computed by dividing net income by the weighted average number of outstanding common shares during the period. In the basic and diluted earnings per share calculations, net income is equal to net income attributable to The Pennant Group, Inc. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prior to Spin-Off</span></div>Net income attributable to the noncontrolling interest has been included in the numerator for the years ended December 31, 2019 and 2018, respectively, as the non-controlling subsidiary interest that existed prior to the Spin-Off was converted into common shares of Pennant concurrent with the distribution to Ensign stockholders at the date of the Spin-Off. <div style="text-align:justify;text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:80%">The following table sets forth the computation of basic and diluted net income per share for the periods presented: </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.699%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,553 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,175 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: net (loss)/ income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to The Pennant Group, Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,744 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,546 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,684 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding for basic net income per share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,029 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,838 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,834 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: incremental shares from assumed conversion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted weighted average common shares outstanding for diluted income per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,228 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,586 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,834 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings Per Share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income per common share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income per common share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">C</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">oncurrent with the Spin-Off the noncontrolling subsidiary interest converted into 1,160 shares of Pennant. The total number of common shares distributed on October 1, 2019 of 27,834 was utilized in the denominator for the calculation of basic and diluted earnings per share for the year ended December 31, 2018 , as no common stock was outstanding prior to the date of the Spin-Off.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The calculation of dilutive shares outstanding excludes out-of-the-money stock options (i.e., such options’ exercise prices were greater than the average market price of our common shares for the period) because their inclusion would have been antidilutive. Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were 93 and 15 for the years ended December 31, 2020 and 2019, respectively.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the years ended December 31, 2019 and 2018 basic and diluted earnings per share were calculated based on net income as the numerator, which included the conversion of the noncontrolling interest in connection with the Spin-Off. For the year ended December 31, 2020, basic and diluted earnings per share was calculated based on net income attributable to The Pennant Group, Inc. as the numerator, . See Note 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">, for further information on our acquisitions for the year ended December 31, 2020. </span></div></td></tr></table></div> 15553000 3175000 16279000 -191000 629000 595000 15744000 2546000 15684000 28029000 27838000 27834000 2199000 1748000 0 30228000 29586000 27834000 0.56 0.11 0.58 0.52 0.11 0.58 1160000 27834000 93000 15000 REVENUE AND ACCOUNTS RECEIVABLERevenues are recognized when services are provided to the patients or residents at the amount that reflects the consideration to which the Company expects to be entitled from patients, residents and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care or senior living residence. The healthcare services in home health and hospice patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct within the context of the contract. Additionally, there may be ancillary services which are not included in the rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net service revenue in the period such variances become known. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from the Medicare and Medicaid programs accounted for 60.1%, 55.6%, and 53.1% of the Company’s revenue for the years ended December 31, 2020, 2019 and 2018, respectively. The Company records revenue from these governmental and managed care programs as services are performed at their expected net realizable amounts under these programs. The Company’s revenue from governmental and managed care programs is subject to audit and retroactive adjustment by governmental and third-party agencies. Consistent with healthcare industry accounting practices, any changes to these governmental revenue estimates are recorded in the period the change or adjustment becomes known based on final settlement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates revenue from contracts with its patients or residents by reportable operating segments and payors. The Company has determined that disaggregating revenue into these categories achieves the disclosure objectives to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. A reconciliation of disaggregated revenue to segment revenue as well as revenue by payor is provided in below. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s service specific revenue recognition policies are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Home Health Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicare Revenue</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For Medicare episodes that began after January 1, 2020, net service revenue is recognized in accordance with the Patient Driven Groupings Model (“PDGM”). This new reimbursement structure involves case mix calculation methodology refinements, changes to low-utilization payment adjustment (“LUPA”) thresholds, the elimination of therapy thresholds, a change to the unit of payment from a 60-day episode to a 30-day payment period, and reduction of requests for anticipated payments (“RAPs”) to 20% of the estimated payment for a patient’s initial or subsequent period of care up-front (after the initial assessment is completed and upon initial billing). The RAPs will be completely phased out effective January 1, 2021. Under PDGM, Medicare provides agencies with payments for each 30-day payment period provided to beneficiaries. If a beneficiary is still eligible for care after the end of the first 30-day payment period, a second 30-day payment period can begin. There are no limits to the number of periods of care a beneficiary who remains eligible for the home health benefit can receive. While payment for each 30-day payment period is adjusted to reflect the beneficiary’s health condition and needs, a special outlier provision exists to ensure appropriate payment for those beneficiaries that have the most expensive care needs. The payment under the Medicare program is also adjusted for certain variables including, but not limited to: (a) a LUPA if the number of visits is below an established threshold that varies based on the diagnosis of a beneficiary; (b) a partial payment if the patient transferred to another provider or the Company received a patient from another provider before completing the period of care; (c) adjustment to the admission source of claim if it is determined that the patient had a qualifying stay in a post-acute care setting within 14 days prior to the start of a 30-day payment period; (d) the timing of the 30-day payment period provided to a patient in relation to the admission date, regardless of whether the same home health provider provided care for the entire series of episodes; (e) changes to the acuity of the patient during the previous 30-day payment period; (f) changes in the base payments established by the Medicare program; (g) adjustments to the base payments for case mix and geographic wages; and (h) recoveries of overpayments. </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all episodes that began prior to January 1, 2020, net service revenue was recorded under the Medicare prospective payment system based on a 60-day episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a) an outlier payment if the patient’s care was unusually costly; (b) a LUPA if the number of visits was fewer than five; (c) a partial payment if the patient transferred to another provider or transferred from another provider before completing the episode; (d) a payment adjustment based upon the level of covered therapy services; (e) the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (f) changes in the base episode payments established by the Medicare program; (g) adjustments to the base episode payments for case mix and geographic wages; and (h) recoveries of overpayments.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adjusts Medicare revenue on completed episodes to reflect differences between estimated and actual payment amounts, an inability to obtain appropriate billing documentation and other reasons unrelated to credit risk. Therefore, the Company believes that its reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to revenue recognized on completed episodes and periods, the Company also recognizes a portion of revenue associated with episodes and periods in progress. Episodes in progress are 30-day payment periods, if the episode started after January 1, 2020, or 60-day episodes of care, if the episode started prior to January 1, 2020, that begin during the reporting period but were not completed as of the end of the period. As such, the Company estimates revenue and recognizes it on a daily basis. The primary factors underlying this estimate are the number of episodes in progress at the end of the reporting period, expected Medicare revenue per period of care or episode of care and the Company’s estimate of the average percentage complete based on the scheduled end of period and end of episode dates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Medicare Revenue</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Episodic Based Revenue -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company recognizes revenue in a similar manner as it recognizes Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-episodic Based Revenue -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Revenue is recognized on an accrual basis based upon the date of service at amounts equal to its established or estimated per visit rates, as applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hospice Revenue</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are calculated as daily rates for each of the levels of care the Company delivers. Revenue is adjusted for an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. Additionally, as Medicare hospice revenue is subject to an inpatient cap and an overall payment cap, the Company monitors its provider numbers and estimates amounts due back to Medicare if a cap has been exceeded. The Company regularly evaluates and records these adjustments as a reduction to revenue and an increase to other accrued liabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Living Revenue</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected the lessor practical expedient within ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 842”) and therefore recognizes, measures, presents, and discloses the revenue for services rendered under the Company’s senior living residency agreements based upon the predominant component, either the lease or non-lease component, of the contracts. The Company has determined that the services included under the Company’s senior living residency agreements each have the same timing and pattern of transfer. The Company recognizes revenue under ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for its senior residency agreements, for which it has determined that the non-lease components of such residency agreements are the predominant component of each such contract.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s senior living revenue consists of fees for basic housing and assisted living care. Accordingly, we record revenue when services are rendered on the date services are provided at amounts billable to individual residents. Residency agreements are generally for a term of 30 days, with resident fees billed monthly in advance. For residents under reimbursement arrangements with Medicaid, revenue is recorded based on contractually agreed-upon amounts or rates on a per resident, daily basis or as services are rendered. </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by payor for the years ended December 31, 2020, 2019 and 2018, is summarized in the following tables:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.113%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice Services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health Services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hospice Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Senior Living Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,399 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,873 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,272 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,645 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,780 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,887 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,044 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,335 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,780 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,159 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,572 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,546 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,118 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,968 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,514 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,676 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,584 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,075 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,294 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390,953 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Private and other payors in our home health and hospice services segment includes revenue from all payors generated in our home care operations.</span></td></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:18.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.176%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice Services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health Services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hospice Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Senior Living Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,819 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,933 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,752 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,575 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,061 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,819 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,455 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,394 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,994 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,819 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,207 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,711 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,536 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,247 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,837 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,088 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,077 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,942 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,682 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,907 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,531 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Private and other payors in our home health and hospice services segment includes revenue from all payors generated in our home care operations.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:80%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:18.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.149%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.149%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.149%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.149%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice Services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health Services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hospice Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Senior Living Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,091 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,906 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,997 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,680 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,729 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,624 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,033 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,771 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,635 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,624 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,030 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,541 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">918 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,459 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,067 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,397 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,569 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,379 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,658 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,021 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,058 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Private and other payors in our home health and hospice services segment includes revenue from all payors generated in our home care operations.</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Balance Sheet Impact</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the Company’s consolidated balance sheets are contract assets, comprised of billed accounts receivable and unbilled receivables, which are the result of the timing of revenue recognition, billings and cash collections, as well as, contract liabilities, which primarily represent payments the Company receives in advance of services provided. As of December 31, 2020, the Company had contract liabilities in the amount of $27,997 related to Advance Payments received in connection with the CARES Act. As further discussed in Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Accrued Liabilities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the repayment terms for Medicare advance payments were modified through the passage of the Continuing Appropriations Act, 2021 and Other Extensions Act on October 1, 2020.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable as of December 31, 2020 and December 31, 2019 is summarized in the following table: </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.391%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.393%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,569 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,822 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,579 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,590 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,380 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,036 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,079 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,864 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,860 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(643)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(677)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,221 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,183 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity for our allowance for doubtful accounts for the years ended years ended December 31, 2020, 2019 and 2018:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,058 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI0MTRiODhmMTM1YzQ4M2Y4ZTJkMWNiYzJkMGY0NTNhL3NlYzpiNDE0Yjg4ZjEzNWM0ODNmOGUyZDFjYmMyZDBmNDUzYV8xMzkvZnJhZzphNjcwOTJmYTYyZGM0M2YxOTk4YjkzM2UxNjA2YTBhYy90YWJsZTplYzUyMzcxODA1NTE0ZGMzOWExMzVlNDcwMDVmMTZkMy90YWJsZXJhbmdlOmVjNTIzNzE4MDU1MTRkYzM5YTEzNWU0NzAwNWYxNmQzXzMtMC0xLTEtNjE2Nw_4fa756dd-2269-46d1-ad85-c5ac97da33ef"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of ASC 606 Adoption</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,590)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to bad debt expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs of uncollectible accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(594)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(797)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subsequent to the adoption of ASC 606, the majority of what was previously presented as allowance for doubtful accounts related to bad debt expense has been incorporated as an implicit price concession factored into net revenue and accounts receivable. Allowance for doubtful accounts as of December 31, 2020 represents the Company’s best estimate of probable losses inherent in the accounts receivable balance based on known troubled accounts and other currently available evidence.</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Practical Expedients and Exemptions</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company’s contracts have an original duration of one year or less, the Company uses the practical expedient applicable to its contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of the end of each reporting period or when the Company expects to recognize this revenue. In addition, the Company has applied the practical expedient provided by ASC 340, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 340”), and all incremental customer contract acquisition costs are expensed as they are incurred because the amortization period would have been one year or less.</span></div> 0.601 0.556 0.531 Residency agreements are generally for a term of 30 days, with resident fees billed monthly in advance. For residents under reimbursement arrangements with Medicaid, revenue is recorded based on contractually agreed-upon amounts or rates on a per resident, daily basis or as services are rendered. <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by payor for the years ended December 31, 2020, 2019 and 2018, is summarized in the following tables:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.113%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice Services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health Services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hospice Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Senior Living Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,399 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,873 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,272 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,645 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,780 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,887 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,044 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,335 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,780 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,159 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,572 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,546 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,118 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,968 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,514 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,676 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,584 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,075 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,294 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390,953 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Private and other payors in our home health and hospice services segment includes revenue from all payors generated in our home care operations.</span></td></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:18.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.176%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice Services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health Services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hospice Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Senior Living Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,819 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,933 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,752 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,575 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,061 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,819 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,455 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,394 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,994 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,819 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,207 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,711 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,536 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,247 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,837 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,088 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,077 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,942 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,682 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,907 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,531 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Private and other payors in our home health and hospice services segment includes revenue from all payors generated in our home care operations.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:80%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:18.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.149%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.149%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.149%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.149%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice Services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health Services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hospice Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Senior Living Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,091 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,906 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,997 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,680 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,729 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,624 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,033 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,771 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,635 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,624 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,030 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,541 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">918 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,459 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,067 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,397 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,569 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,379 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,658 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,021 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,058 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Private and other payors in our home health and hospice services segment includes revenue from all payors generated in our home care operations.</span></td></tr></table></div> 58399000 119873000 0 178272000 0.456 7645000 12462000 36780000 56887000 0.145 66044000 132335000 36780000 235159000 0.601 31572000 1546000 0 33118000 0.085 21968000 194000 100514000 122676000 0.314 119584000 134075000 137294000 390953000 1.000 47819000 93933000 0 141752000 0.419 6575000 10061000 29819000 46455000 0.137 54394000 103994000 29819000 188207000 27711000 1536000 0 29247000 0.086 18837000 152000 102088000 121077000 0.358 100942000 105682000 131907000 338531000 1.000 42091000 73906000 0 115997000 0.405 4680000 7729000 23624000 36033000 0.126 46771000 81635000 23624000 152030000 0.531 23541000 918000 0 24459000 0.086 16067000 105000 93397000 109569000 0.383 86379000 82658000 117021000 286058000 1.000 27997000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable as of December 31, 2020 and December 31, 2019 is summarized in the following table: </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.391%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.393%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,569 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,822 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,579 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,590 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,380 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,036 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,079 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,864 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,860 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(643)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(677)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,221 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,183 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 28569000 17822000 7669000 6579000 7590000 4380000 4036000 4079000 47864000 32860000 643000 677000 47221000 32183000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity for our allowance for doubtful accounts for the years ended years ended December 31, 2020, 2019 and 2018:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,058 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI0MTRiODhmMTM1YzQ4M2Y4ZTJkMWNiYzJkMGY0NTNhL3NlYzpiNDE0Yjg4ZjEzNWM0ODNmOGUyZDFjYmMyZDBmNDUzYV8xMzkvZnJhZzphNjcwOTJmYTYyZGM0M2YxOTk4YjkzM2UxNjA2YTBhYy90YWJsZTplYzUyMzcxODA1NTE0ZGMzOWExMzVlNDcwMDVmMTZkMy90YWJsZXJhbmdlOmVjNTIzNzE4MDU1MTRkYzM5YTEzNWU0NzAwNWYxNmQzXzMtMC0xLTEtNjE2Nw_4fa756dd-2269-46d1-ad85-c5ac97da33ef"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of ASC 606 Adoption</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,590)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to bad debt expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs of uncollectible accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(594)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(797)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subsequent to the adoption of ASC 606, the majority of what was previously presented as allowance for doubtful accounts related to bad debt expense has been incorporated as an implicit price concession factored into net revenue and accounts receivable. Allowance for doubtful accounts as of December 31, 2020 represents the Company’s best estimate of probable losses inherent in the accounts receivable balance based on known troubled accounts and other currently available evidence.</span></div></td></tr></table></div> 677000 616000 5058000 0 0 -4590000 560000 858000 346000 594000 797000 198000 643000 677000 616000 BUSINESS SEGMENTS<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company classifies its operations into the following reportable operating segments: (1) home health and hospice services, which includes the Company’s home health, hospice and home care businesses; and (2) senior living services, which includes the operation of assisted living, independent living and memory care communities. The reporting segments are business units that offer different services and are managed separately to provide greater visibility into those operations. Our Chief Executive Officer and President, who is our Chief Operating Decision Maker “CODM”, reviews financial information at the operating segment level. We also report an “all other” category that includes general and administrative expense from our Service Center.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company provided services through 76 affiliated home health, hospice and home care agencies, and 54 affiliated senior living operations. The Company evaluates performance and allocates capital resources to each segment based on an operating model that is designed to maximize the quality of care provided and profitability. The Company’s Service Center provides various services to all lines of business. The Company does not review assets by segment and therefore assets by segment are not disclosed below.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the third quarter of 2019, in anticipation of the Spin-Off, the GAAP segment measure of profit and loss was changed from Segment Income (Loss) Before Provision for Income Taxes to Adjusted Segment EBITDAR from Operations. Prior period presentation has been revised to reflect the new measurement. </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CODM uses Segment Adjusted EBITDAR from Operations as the primary measure of profit and loss for the Company's reportable segments and to compare the performance of its operations with those of its competitors. Segment Adjusted EBITDAR from Operations is net income/ (loss) attributable to the Company's reportable segments excluding interest expense, provision for income taxes, depreciation and amortization expense, rent, and, in order to view the operations performance on a comparable basis from period to period, certain adjustments including: (1) costs at start-up operations, (2) share-based compensation, (3) acquisition related costs, (4) Spin-Off transaction costs, (5) redundant and nonrecurring costs associated with the transition services agreement, (6) net income/ (loss) attributable to noncontrolling interest, and (7) net COVID-19 related costs. General and administrative expenses are not allocated to the reportable segments, and are included as “All Other”, accordingly the segment earnings measure reported is before allocation of corporate general and administrative expenses. The Company's segment measures may be different from the calculation methods used by other companies and, therefore, comparability may be limited.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents certain financial information regarding our reportable segments, general and administrative expenses are not allocated to the reportable segments and are included in “All Other” for the years ended December 31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Senior Living Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390,953 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment Adjusted EBITDAR from Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,501 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,309 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,762)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,048 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,624 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,907 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,531 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment Adjusted EBITDAR from Operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,591)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,058 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment Adjusted EBITDAR from Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,427 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,230 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,466 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides a reconciliation of Segment Adjusted EBITDAR from Operations above to income from operations:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.806%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment Adjusted EBITDAR from Operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,048 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,107 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,466 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,810 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,964 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent—cost of services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,975 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to Segment EBITDAR from Operations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Costs at start-up operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,787 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,335 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,382 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,382 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition related costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spin-off related transaction costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transition services costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 Related costs and supplies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Net income/ (loss) attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated and Combined Income from operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,917 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,670 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,631 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Represents results related to start-up operations. This amount excludes rent and depreciation and amortization expense related to such operations.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense incurred which is included in cost of services and general and administrative expense. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition related costs that are not capitalizable.</span></td></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(d)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs incurred related to the Spin-Off are included in general and administrative expense.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(e)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">A portion of the costs incurred under the Transition Services Agreement (as defined in Note 3,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Related Party Transactions and Net Parent Investment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">) identified as redundant or nonrecurring that are included in general and administrative expense. Transition service costs includes $446 of duplicative software expense for the year ended December 31, 2020, of which $333 pertains to the first three quarters of the fiscal year and were not included as adjustments in previous interim periods. Fees incurred under the Transition Services agreement, net of the Company’s payroll reimbursement, were $5,536, $2,982, and zero for the years ended December 31, 2020, 2019 and 2018, respectively.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(f)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Represents incremental costs incurred as part of the Company's response to COVID-19 including direct medical supplies, labor, and other expenses, net of $2,765 in increased revenue related to the 2% payment increase in Medicare reimbursements for sequestration relief for the year ended December 31, 2020. </span></div></td></tr></table> 76 54 <div style="margin-bottom:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents certain financial information regarding our reportable segments, general and administrative expenses are not allocated to the reportable segments and are included in “All Other” for the years ended December 31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Senior Living Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390,953 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment Adjusted EBITDAR from Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,501 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,309 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,762)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,048 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,624 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,907 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,531 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment Adjusted EBITDAR from Operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,591)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,058 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment Adjusted EBITDAR from Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,427 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,230 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,466 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 253659000 137294000 0 390953000 49501000 48309000 -22762000 75048000 206624000 131907000 0 338531000 33354000 47344000 -18591000 62107000 169037000 117021000 0 286058000 26427000 47230000 -16191000 57466000 <div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.806%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment Adjusted EBITDAR from Operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,048 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,107 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,466 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,810 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,964 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent—cost of services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,975 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to Segment EBITDAR from Operations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Costs at start-up operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,787 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,335 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,382 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,382 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition related costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spin-off related transaction costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transition services costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 Related costs and supplies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Net income/ (loss) attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated and Combined Income from operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,917 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,670 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,631 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Represents results related to start-up operations. This amount excludes rent and depreciation and amortization expense related to such operations.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense incurred which is included in cost of services and general and administrative expense. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition related costs that are not capitalizable.</span></td></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(d)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs incurred related to the Spin-Off are included in general and administrative expense.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(e)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">A portion of the costs incurred under the Transition Services Agreement (as defined in Note 3,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Related Party Transactions and Net Parent Investment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">) identified as redundant or nonrecurring that are included in general and administrative expense. Transition service costs includes $446 of duplicative software expense for the year ended December 31, 2020, of which $333 pertains to the first three quarters of the fiscal year and were not included as adjustments in previous interim periods. Fees incurred under the Transition Services agreement, net of the Company’s payroll reimbursement, were $5,536, $2,982, and zero for the years ended December 31, 2020, 2019 and 2018, respectively.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(f)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Represents incremental costs incurred as part of the Company's response to COVID-19 including direct medical supplies, labor, and other expenses, net of $2,765 in increased revenue related to the 2% payment increase in Medicare reimbursements for sequestration relief for the year ended December 31, 2020. </span></div></td></tr></table> 75048000 62107000 57466000 4675000 3810000 2964000 39191000 34975000 31199000 225000 0 0 1787000 483000 129000 8335000 3382000 2382000 99000 665000 0 0 13219000 756000 1181000 532000 0 447000 0 0 -191000 629000 595000 18917000 5670000 20631000 446000 333000 333000 333000 5536000 2982000 0 2765000 ACQUISITIONS<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s acquisition focus is to purchase or lease operations that are complementary to the Company’s current businesses, accretive to the Company’s business or otherwise advance the Company’s strategy. The results of all the Company’s independent operating subsidiaries are included in the Financial Statements subsequent to the date of acquisition. Acquisitions are accounted for using the acquisition method of accounting. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Acquisitions</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, the Company expanded its operations with the addition of six home health agency, six hospice agencies, and two senior living communities. The aggregate purchase price for these acquisitions was $39,239. In connection with the addition of the senior living communities, the Company entered into a new long-term “triple-net” lease with a subsidiary of Ensign. The addition of these operations added a total of 164 operational senior living units to be operated by the Company’s independent operating subsidiaries. A subsidiary of the Company entered into a separate operations transfer agreement with the prior operator of each acquired operation as part of each transaction. The goodwill was primarily attributable intangible assets that do not qualify for separate recognition and to synergies the Company expects to achieve related to the acquisition and was allocated to the Company's operating segments which are its reporting units. The Company anticipates that the total goodwill recognized will be fully deductible for tax purposes. Acquisition costs related to the business combinations of home health, hospice, and home care acquisitions of $99 were expensed related to the business combinations during the year ended December 31, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, the Company announced it closed on a home health joint venture and hospice joint venture with Scripps Health (“Scripps”), a leading nonprofit integrated health system based in San Diego, California. The closing was effective October 1, 2020. The resulting joint ventures, which combined certain assets and the operations of Scripps’ home health business and the assets and operations of the local Pennant-affiliated home health and hospice agencies, are majority-owned and managed by an independent operating subsidiary of the Company and provide home health and hospice services to patients throughout San Diego County. The fair value of assets contributed by Scripps to the home health joint venture were included in the total value of assets acquired as described above and in the summary table below. The Company paid Scripps $6,200 in cash and contributed assets from the local Pennant-affiliated home health agency with a net book value of $614. The Company acquired 60.0% ownership interest in the joint venture. The contributions of assets by Scripps to the joint venture, resulted in the Company recording a noncontrolling interest with a fair value of $4,646. The fair value of the noncontrolling interest was determined using discounted cash flow models. As part of the transaction with Scripps, the Company contributed the assets of the local Pennant-affiliated hospice agency to another joint venture. The Company sold Scripps a noncontrolling interest in the hospice joint venture for $555 in cash. The company retained an 80.0% ownership interest in the hospice joint venture. The transaction resulted in the Company recognizing a noncontrolling interest of $138 and a contribution to additional paid in capital of $313, net of $104 of the income tax effect.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Acquisitions</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, the Company expanded its operations with the addition of two home health agencies, five hospice agencies, two home care agencies and two senior living operations. In connection with the acquisitions of one of the senior living communities, the Company entered into a new long-term “triple-net” lease with a subsidiary of Ensign. The Company did not acquire any material assets or assume any liabilities. A subsidiary of the Company entered into a separate operations transfer agreement with the prior operator of each acquired operation as part of each transaction. The addition of these operations added a total of 143 operational senior living units to be operated by the Company’s independent operating subsidiaries. The aggregate purchase price for these acquisitions was $18,780. Acquisition costs related to the business combinations of home health, hospice, and home care was $611 during the year ended December 31, 2019.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Acquisitions</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2018, the Company expanded its operations with the addition of four home health agencies, two hospice agencies, two home care agencies and seven senior living operations. The Company did not acquire any material assets or assume any liabilities other than the tenant’s post-assumption rights and obligations under the senior living long-term leases. The aggregate purchase price for these acquisitions during the year ended December 31, 2018 was $5,318. The addition of these operations added a total of 386 operational senior living units to be operated by the Company’s independent operating subsidiaries. Typically, subsidiaries of the Company entered into a separate operations transfer agreement with the prior operator as part of each transaction. The Company did not incur acquisition costs related to business combinations during the year ended December 31, 2018.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of assets for home health and hospice acquisitions was mostly concentrated in goodwill and as such, these transactions were classified as business combinations in accordance with ASC Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 805”). The table below presents the allocation of the purchase price for the operations acquired in business combinations during the years ended December 31, 2020, 2019 and 2018 as noted above:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment, furniture, and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,211 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,341 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,872 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other indefinite-lived intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,026 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,838 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities Assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Total acquisitions</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,239 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,760 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,725 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: noncontrolling interest and additional paid in capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,646)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash paid for acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,593 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,760 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,725 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consists of the of noncontrolling interest related to Scripps contribution of assets to the joint venture. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash paid for acquisitions for the year ended December 31, 2020 includes $1,400 that was recorded as an escrow deposit at December 31, 2019. </span></div></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Pro Forma Financial Information</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s acquisition strategy has been focused on identifying both opportunistic and strategic acquisitions within its target markets that offer strong opportunities for return. The independent operating subsidiaries acquired by the Company are frequently underperforming financially and can have regulatory and clinical challenges to overcome. From time to time, these acquisitions are more strategic in nature that may or may not have positive operational results. Financial information, especially with underperforming independent operating subsidiaries, is often inadequate, inaccurate or unavailable. Consequently, the Company believes that prior operating results are not a meaningful representation of the Company’s current operating results or indicative of the integration potential of its newly acquired independent operating subsidiaries. Revenue and income before tax included in the consolidated and combined statement of income relating to the business combinations was $17,676 and $750, respectively, during the year ended December 31, 2020. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables represent unaudited pro forma results of consolidated and combined operations as if the business combinations in fiscal year 2020 had occurred at the beginning of 2019, after giving effect to certain adjustments. The unaudited pro forma information is not indicative of what the results of operations would have been if the acquisitions had actually occurred at the beginning of the periods presented and is not intended as a projection of future results or trends. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Pro Forma Data</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.592%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424,805 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396,468 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to The Pennant Group, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,784 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to The Pennant Group, Inc. for the year ended December 31, 2020 and 2019 includes a tax impact of 25.0% and 25.2%, which are the respective statutory tax rates. </span></div></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma financial information has been included for the businesses combinations during the year ended December 31, 2020. The acquisitions during the year ended December 31, 2020 have been included in the December 31, 2020 consolidated balance sheets of the Company, and the operating results have been included in the consolidated and combined statements of income of the Company since the dates the Company gained effective control. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues and operating costs were based on actual results from the prior operator or from regulatory filings where available. If actual results were not available, revenues and operating costs were estimated based on available partial operating results of the prior operator of the operation, or if no information was available, estimates were derived from the Company’s post-acquisition operating results for that particular operation. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma information is not indicative of what the results of operations would have been if the business combinations had actually occurred at the beginning of the periods presented and is not intended as a projection of future results or trends. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Subsequent Events</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December 31, 2020, the Company acquired two home health agencies and two hospice agencies. The aggregate purchase price for these acquisitions was $3,625. As of the date of this report, the preliminary allocation of the purchase price for the acquisitions acquired subsequent to December 31, 2020 were not completed as necessary valuation information was not yet available. As such, the determination whether these acquisitions should be classified as business combinations or asset acquisitions under ASC 805 will be determined upon completion of the allocation of the purchase price.</span></div> 6 6 2 39239000 164 99000 6200000 614000 0.600 4646000 555000 0.800 138000 313000 104000 2 5 2 2 143 18780000 611000 4 2 2 7 5318000 386 The table below presents the allocation of the purchase price for the operations acquired in business combinations during the years ended December 31, 2020, 2019 and 2018 as noted above:<div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment, furniture, and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,211 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,341 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,872 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other indefinite-lived intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,026 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,838 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities Assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Total acquisitions</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,239 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,760 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,725 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: noncontrolling interest and additional paid in capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,646)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash paid for acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,593 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,760 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,725 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consists of the of noncontrolling interest related to Scripps contribution of assets to the joint venture. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash paid for acquisitions for the year ended December 31, 2020 includes $1,400 that was recorded as an escrow deposit at December 31, 2019. </span></div></td></tr></table></div> 174000 91000 15000 25211000 10341000 2872000 14026000 8326000 1838000 0 2000 0 172000 0 0 39239000 18760000 4725000 4646000 0 0 34593000 18760000 4725000 1400000 17676000 750000 <div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.592%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424,805 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396,468 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to The Pennant Group, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,784 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to The Pennant Group, Inc. for the year ended December 31, 2020 and 2019 includes a tax impact of 25.0% and 25.2%, which are the respective statutory tax rates. </span></div></td></tr></table></div> 424805000 396468000 13784000 1277000 0.250 0.252 2 2 3625000 PROPERTY AND EQUIPMENT—NET<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,984 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,621 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,420 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,930 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,186 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,590 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,428 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,706)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,784)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,884 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,644 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Depreciation expense was $4,661, $3,757 and $2,863 for the years ended December 31, 2020, 2019 and 2018, respectively. <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,984 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,621 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,420 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,930 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,186 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,590 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,428 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,706)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,784)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,884 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,644 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 9984000 6621000 22420000 18930000 1186000 877000 33590000 26428000 15706000 11784000 17884000 14644000 4661000 3757000 2863000 GOODWILL AND INTANGIBLE ASSETS—NET <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests goodwill during the fourth quarter of each year and also if events or changes in circumstances indicate the occurrence of a triggering event which might indicate there may be impairment. The Company performs its goodwill impairment analysis for each reporting unit that constitutes a component for which (1) discrete financial information is available and (2) segment management regularly reviews the operating results of that component, in accordance with the provisions of ASC Topic 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles-Goodwill and Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASC 350”).</span><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews goodwill for impairment by initially considering qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill, as a basis for determining whether it is necessary to perform a quantitative analysis. If it is determined that it is more likely than not that the fair value of reporting unit is less than its carrying amount, a quantitative analysis is performed to identify goodwill impairment. If it is determined that it is not more likely than not that the fair value of the reporting unit is less than its carrying amount, it is unnecessary to perform a quantitative analysis. The Company may elect to bypass the qualitative assessment and proceed directly to performing a quantitative analysis. Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value. An impairment loss is recognized for the amount that the carrying amount of the reporting unit, including goodwill, exceeds its fair value, limited to the total amount of goodwill allocated to that reporting unit. The Company did not identify any impairment charge during the years ended December 31, 2020, 2019 and 2018.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents activity in goodwill by segment as of and for the year ended December 31, 2020:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.008%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Senior Living Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2018</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,250 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,642 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,892 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,341 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,341 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,591 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,642 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,233 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,802 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,642 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,444 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other indefinite-lived intangible assets consist of the following:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicaid licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,488 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,462 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 0 0 <div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents activity in goodwill by segment as of and for the year ended December 31, 2020:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.008%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Senior Living Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2018</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,250 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,642 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,892 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,341 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,341 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,591 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,642 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,233 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,802 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,642 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,444 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 27250000 3642000 30892000 10341000 0 10341000 37591000 3642000 41233000 25211000 0 25211000 62802000 3642000 66444000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other indefinite-lived intangible assets consist of the following:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicaid licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,488 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,462 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1355000 355000 46133000 33107000 47488000 33462000 OTHER ACCRUED LIABILITIES<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities consist of the following:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Refunds payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,664 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,152 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,937 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Resident deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,647 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Liabilities (CARES Act advance payments)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,771 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">982 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued insurance retention - current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,586 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,275 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,911 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Refunds payable includes payables related to overpayments, duplicate payments and credit balances from various payor sources. Deferred revenue occurs when the Company receives payments in advance of services provided. Resident deposits include refundable deposits to residents and a small portion consists of non-refundable deposits recognized into revenue over a period of time. The CARES Act also expanded the Centers for Medicare &amp; Medicaid Services’ (“CMS”) ability to provide accelerated/advance payments intended to increase the cash flow of healthcare providers and suppliers impacted by COVID-19. During the second quarter the Company applied for and received $27,997 in funds under the AAP Program. On October 1, 2020, the Continuing Appropriations Act, 2021 and Other Extensions Act (the “CA Act”) was signed into law. </span></div>Among other things, the CA Act significantly changed the repayment terms for AAP. These funds are subject to automatic recoupment through offsets to new claims beginning one year after funds were issued beginning in April 2021, at which time, Medicare will automatically recoup 25 percent of Medicare payments for 11 months. At the end of the 11 months and assuming full repayment has not occurred, recoupment will increase to 50 percent for another six months. Any balance outstanding after these two recoupment periods will be subject to repayment at a four percent interest rate. The Company anticipates completing repayment of the AAP within the allotted recoupment periods. As a result of the recoupment guidance, the Company reclassified $5,226 of the AAP to other long-term liabilities. <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities consist of the following:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Refunds payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,664 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,152 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,937 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Resident deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,647 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Liabilities (CARES Act advance payments)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,771 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">982 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued insurance retention - current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,586 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,275 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,911 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2664000 2152000 1271000 1937000 5647000 6292000 22771000 0 982000 1130000 1354000 0 3586000 2400000 38275000 13911000 27997000 -5226000 5226000 DEBT<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt, net consists of the following:</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving Credit Facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,474)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,277 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,526 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 1, 2019, Pennant entered into a credit agreement (the “Credit Agreement”), which provided for a revolving credit facility (the “2019 Revolving Credit Facility”) with a syndicate of banks with a borrowing capacity of $75,000. The interest rates applicable to loans under the 2019 Revolving Credit Facility were, at the Company’s election, either (i) Adjusted LIBOR (as defined in the Credit Agreement) plus a margin ranging from 2.5% to 3.5% per annum or (ii) Base Rate plus a margin ranging from 1.5% to 2.5% per annum, in each case based on the ratio of Consolidated Total Net Debt to Consolidated EBITDA (each, as defined in the Credit Agreement). In addition, Pennant paid a commitment fee on the undrawn portion of the commitments under the 2019 Revolving Credit Facility that of approximately 0.6% per annum. The Company is not required to repay any loans under the Credit Agreement prior to maturity in 2024, other than to the extent the outstanding borrowings exceed the aggregate commitments under the Credit Agreement. As of December 31, 2020, the Company’s weighted average interest rate on its outstanding debt was 4.75%. As of December 31, 2020, we had availability on the 2019 Revolving Credit Facility of $62,164, which is net of outstanding letters of credit of $3,336. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the 2019 Revolving Credit Facility approximates carrying value, due to the short-term nature and variable interest rates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of this debt is categorized within Level 2 of the fair value hierarchy based on the observable market borrowing rates.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Credit Agreement is guaranteed, jointly and severally, by certain of the Company’s wholly owned subsidiaries, and is secured by a pledge of stock of the Company's material independent operating subsidiaries as well as a first lien on substantially all of each material operating subsidiary's personal property. The Credit Agreement contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its independent operating subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend certain material agreements and pay certain dividends and other restricted payments. Financial covenants require compliance with certain levels of leverage ratios that impact the amount of interest. As of December 31, 2020, the Company was compliant with all covenants.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Subsequent Events</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February 23, 2021, Pennant entered into an amendment to the Credit Agreement (the “Amended Credit Agreement”), which provides for a revolving credit facility (the “2021 Revolving Credit Facility”) with a syndicate of banks with a borrowing capacity of $150,000. The interest rates applicable to loans under the 2021 Revolving Credit Facility are, at the Company’s election, either (i) Adjusted LIBOR (as defined in the Amended Credit Agreement) plus a margin ranging from 2.3% to 3.3% per annum or (ii) Base Rate plus a margin ranging from 1.3% to 2.3% per annum, in each case based on the ratio of Consolidated Total Net Debt to Consolidated EBITDA (each, as defined in the Amended Credit Agreement). In addition, Pennant will pay a commitment fee on the undrawn portion of the commitments under the Revolving Credit Facility that will range from 0.35% to 0.50% per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio of the Company and its subsidiaries. The Company is not required to repay any loans under the Amended Credit Agreement prior to maturity in 2026.</span></div> <div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt, net consists of the following:</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving Credit Facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,474)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,277 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,526 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 9500000 20000000 1223000 1474000 8277000 18526000 75000000 0.025 0.035 0.015 0.025 0.006 0.0475 62164000 3336000 150000000 0.023 0.033 0.013 0.023 OPTIONS AND AWARDS<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all periods prior to the Spin-Off, employees of the Company participated in Ensign's share-based compensation plans. The compensation expense recorded by the Company included the expense associated with these employees, as well as an allocation of share-based compensation of certain Ensign employees who provided general and administrative services on our behalf.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding options held by employees of the Company under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensign stock plans (collectively the “Ensign Plans”) and outstanding options and restricted stock awards under the Company Subsidiary Equity Plan (together with the Ensign Plans the “Pre-Spin Plans”) </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were modified and replaced with Pennant awards under the Pennant Plans at the Spin-Off date. Additionally, in connection with the Spin-Off, the Company issued new options and restricted stock awards to Pennant and Ensign employees under the 2019 Omnibus Incentive Plan (the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OIP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and Long-Term Incentive Plan (the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LTIP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”, together referred to as the “Pennant Plans”</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Ensign Plans and the Pennant Plans, share-based payment awards, including employee stock options, restricted stock awards (“RSA”), and restricted stock units (“RSU” and together with RSA, “Restricted Stock”) are issued based on estimated fair value. The following disclosures represent share-based compensation expense relating to the Ensign and Pennant Plans, including awards to employees of the Company’s subsidiaries and an allocation of costs from employees in the Service Center prior to the Spin-Off, and total share-based compensation after the Spin-Off. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense for all of the Plans for the years ended December 31, 2020, 2019 and 2018:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prior to the Spin-Off:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,382 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Following the Spin-Off:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense related to stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,660 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense related to Restricted Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense related to Restricted Stock to non-employee directors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,335 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,382 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,382 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In future periods, the Company estimates it will recognize the following share-based compensation expense for unvested stock options and unvested Restricted Stock, which were unvested as of December 31, 2020: </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecognized Compensation Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Recognition Period (in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,055 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested Restricted Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unrecognized share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,011 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pennant Plans, options granted to employees of the subsidiaries of Pennant generally vest over five years at 20% per year on the anniversary of the grant date. Options expire ten years after the date of grant. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option-pricing model to recognize the value of share-based compensation expense for share-based payment awards under the Plans. Determining the appropriate fair-value model and calculating the fair value of share-based awards at the grant date requires considerable judgment, including estimating stock price volatility and </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expected option life. The Company develops estimates based on historical data and market information, which can change significantly over time. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option is estimated on the grant date using a Black-Scholes option-pricing model with the following weighted average assumptions for stock options granted after the Spin-Off:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.338%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Risk-Free Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expected Life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dividend Yield</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Fair Value of Options</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.05 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Under the midpoint method, the expected option life is the midpoint between the contractual option life and the average vesting period for the options being granted. This resulted in an expected option life of 6.5 years for the options granted.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Because the Company’s equity shares have been traded for a relatively short period of time, expected volatility assumption was based on the volatility of related industry stocks.</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the employee stock option activity during the year ended December 31, 2020:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:46.694%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outstanding</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Vested</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">of Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Vested</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,573 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.71 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,982 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options outstanding, vested, unvested and exercised as of and for the period ended December 31, 2020 is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.444%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,456 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,077 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,379 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,002 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the options. There were 1,367 unvested and outstanding options at December 31, 2020. The weighted average contractual life for options outstanding, vested and expected to vest at December 31, 2020 was 7.83 years.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pennant Plans, the Company granted Restricted Stock to Pennant employees, Ensign employees, and to non-employee directors. All awards generally vest between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI0MTRiODhmMTM1YzQ4M2Y4ZTJkMWNiYzJkMGY0NTNhL3NlYzpiNDE0Yjg4ZjEzNWM0ODNmOGUyZDFjYmMyZDBmNDUzYV8xNjAvZnJhZzpkNDQ1NWYwNGIwODU0ODU3YWZjNzc3ZDU5NjgxZmVmNy90ZXh0cmVnaW9uOmQ0NDU1ZjA0YjA4NTQ4NTdhZmM3NzdkNTk2ODFmZWY3XzE2NDkyNjc0NDc2Nzc_b667dab9-a1a4-4798-a1e1-5e33a6535378">three</span> to five years. A summary of the status of Pennant’s non-vested Restricted Stock, and changes during the period ended December 31, 2020, is presented below: </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.668%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Vested Restricted Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,793 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.44 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,635 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense for all of the Plans for the years ended December 31, 2020, 2019 and 2018:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prior to the Spin-Off:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,382 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Following the Spin-Off:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense related to stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,660 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense related to Restricted Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense related to Restricted Stock to non-employee directors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,335 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,382 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,382 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In future periods, the Company estimates it will recognize the following share-based compensation expense for unvested stock options and unvested Restricted Stock, which were unvested as of December 31, 2020: </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecognized Compensation Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Recognition Period (in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,055 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested Restricted Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unrecognized share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,011 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div> 1395000 2382000 1660000 315000 0 6200000 1589000 0 475000 83000 0 8335000 3382000 2382000 10055000 P4Y3M18D 10956000 P1Y9M18D 21011000 P5Y 0.20 P10Y <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option is estimated on the grant date using a Black-Scholes option-pricing model with the following weighted average assumptions for stock options granted after the Spin-Off:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.338%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Risk-Free Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expected Life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dividend Yield</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Fair Value of Options</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.05 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Under the midpoint method, the expected option life is the midpoint between the contractual option life and the average vesting period for the options being granted. This resulted in an expected option life of 6.5 years for the options granted.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Because the Company’s equity shares have been traded for a relatively short period of time, expected volatility assumption was based on the volatility of related industry stocks.</span></td></tr></table></div> 693000 0.005 P6Y6M 0.359 0 11.05 667000 0.016 P6Y6M 0.346 0 5.70 P6Y6M <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the employee stock option activity during the year ended December 31, 2020:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:46.694%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outstanding</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Vested</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">of Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Vested</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,573 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.71 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,982 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1573000 9.71 607000 4.80 693000 30.44 239000 4.77 36000 14.34 9000 6.24 1982000 17.48 615000 7.52 <div style="margin-bottom:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options outstanding, vested, unvested and exercised as of and for the period ended December 31, 2020 is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.444%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,456 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,077 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,379 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,002 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 80456000 31077000 49379000 8002000 1367000 P7Y9M29D P5Y A summary of the status of Pennant’s non-vested Restricted Stock, and changes during the period ended December 31, 2020, is presented below: <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.668%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Vested Restricted Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,793 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.44 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,635 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1793000 14.44 29000 26.84 176000 13.27 11000 10.92 1635000 14.80 LEASES<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s independent operating subsidiaries lease 54 senior living communities and its administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI0MTRiODhmMTM1YzQ4M2Y4ZTJkMWNiYzJkMGY0NTNhL3NlYzpiNDE0Yjg4ZjEzNWM0ODNmOGUyZDFjYmMyZDBmNDUzYV8xNjMvZnJhZzoxODYwNGQ4NGMyODY0MzViYWE0OGQ3YzA0ZDYwOTM0Yy90ZXh0cmVnaW9uOjE4NjA0ZDg0YzI4NjQzNWJhYTQ4ZDdjMDRkNjA5MzRjXzE2NDkyNjc0NDYyOTQ_87ec6b0f-47b7-4805-b286-b6c3d8454428">five</span> to 21 years. Most of these leases contain renewal options, most involve rent increases and none contain purchase options. The lease term excludes lease renewals because the renewal rents are not at a bargain, there are no economic penalties for the Company to renew the lease, and it is not reasonably certain that the Company will exercise the extension options. As of December 31, 2020, the Company’s independent operating subsidiaries leased 31 communities from subsidiaries of Ensign (“Ensign Leases”) under a master lease arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The existing leases with subsidiaries of Ensign are for initial terms of between 14 to 20 years. In addition to rent, each of the operating companies are required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all community maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fifteen of the Company’s affiliated senior living communities, excluding the communities that are operated under the Ensign Leases (as defined herein), are operated under two separate master lease arrangements. Under these master leases, a breach at a single community could subject one or more of the other communities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company’s leases and master leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the master lease without the consent of the landlord.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease cost, are as follows:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Costs:</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility Rent—cost of services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,011 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office Rent—cost of services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,772 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,964 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent—cost of services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,191 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,975 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,608 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Represents variable lease cost for operating leases, which costs include property taxes and insurance, common area maintenance, and consumer price index increases, incurred as part of our triple net lease, and which is included in cost of services for the years ended December 31, 2020 and 2019.</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:80%">Rent expense for operating leases classified under Topic 840 for the year ended December 31, 2018 was $31,199.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:80%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the lease maturity analysis for all leases as of December 31, 2020:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,393 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,730 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,230 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,349 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,838 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,578 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(230,857)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of total lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,721 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,106)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,615 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at each lease’s commencement date to determine each lease's operating lease liability. As of December 31, 2020, the weighted average remaining lease term is 15.0 years and the weighted average discount rate is 8.2%.</span></div> 54 P21Y 31 P14Y P20Y 15 2 <div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease cost, are as follows:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Costs:</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility Rent—cost of services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,011 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office Rent—cost of services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,772 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,964 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent—cost of services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,191 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,975 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,608 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Represents variable lease cost for operating leases, which costs include property taxes and insurance, common area maintenance, and consumer price index increases, incurred as part of our triple net lease, and which is included in cost of services for the years ended December 31, 2020 and 2019.</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:80%">Rent expense for operating leases classified under Topic 840 for the year ended December 31, 2018 was $31,199.</span></div> 35562000 32011000 3772000 2964000 143000 0 39191000 34975000 295000 162000 5330000 4608000 31199000 <div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the lease maturity analysis for all leases as of December 31, 2020:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,393 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,730 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,230 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,349 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,838 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,578 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(230,857)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of total lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,721 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,106)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,615 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 38393000 37730000 37038000 36230000 35349000 356838000 541578000 230857000 310721000 14106000 296615000 P15Y 0.082 INCOME TAXES<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes for the years ended December 31, 2020, 2019 and 2018 is summarized as follows:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.915%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,058 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,478 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,536 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,138 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,348)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(838)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,186)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,350 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,085 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,352 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the federal statutory rate to the effective tax rate for income from continuing operations for the years ended December 31, 2020, 2019 and 2018, respectively, is comprised as follows:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.769%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense at statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes - net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax provision</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The Company's completion of the Spin-Off in the year ended December 31, 2019 resulted in the Company not being able to deduct approximately $10,300 of the related transaction costs, which increased the effective tax rate significantly and affected all items that were impacted by this exclusion.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">During the year ended December 31, 2020, employees exercised stock options representing approximately 239 shares. During the year ended December 31, 2019, employees exercised stock options representing approximately 100 shares and had restricted stock awards vest representing 960 shares. These exercises and vestings resulted in tax benefits that reduced the Company's effective tax rate significantly in both years. </span></div></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the date of the Spin-Off, the Company's operations were included in Ensign’s U.S. federal and state income tax returns and all income taxes were paid by subsidiaries of Ensign. Additionally, prior to the date of the Spin-Off, income tax expense and other income tax related information contained in these Consolidated and Combined Financial Statements were presented on a separate tax return approach. Under this approach, the provision for income taxes represents income tax paid or payable for the current year plus the change in deferred taxes during the year calculated as if the Company were a stand-alone taxpayer filing hypothetical income tax returns. Management believes that the assumptions and estimates used to determine these tax amounts were reasonable. However, the Company's Consolidated and Combined Financial Statements may not necessarily reflect the Company’s income tax expense or tax payments in the future, or what its tax amounts would have been if the Company had been a stand-alone company during the periods presented.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2018, the Tax Cuts and Jobs Act of 2017 (“Tax Act”) reduced the corporate rate from 35.0% to 21.0%. The Company adopted ASU 2018-05,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Taxes (Topic 740): Amendments to SEC Paragraph Pursuant to SEC Staff Accounting Bulletin No. 118.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of December 31, 2018, the Company had completed its accounting for the tax effects of the enactment of the Tax Act.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded prepaid expenses for income taxes for the year ended December 31, 2020 and for the income tax returns the Company filed for the three month period from October 1, 2019 through December 31, 2019.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s deferred tax assets and liabilities for the years ended December 31, 2020 and 2019 are summarized below.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets (liabilities):</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,181 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,670 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,979 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,459 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,779 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,444 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,779 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,512)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,107)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(780)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(594)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,055)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82,181)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,347)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,882)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,103)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2019, the Company included the net deferred tax liability in other long-term liabilities on it Consolidated Balance Sheets.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, the Company utilized all of its net operating loss ("NOL") carryforwards for federal income tax purposes. As of December 31, 2020, the Company has $500 of NOL carryforwards in various states, which are available to reduce future state taxable income, if any. Some of the state NOL carryforwards do not expire while others, if not utilized, will expire in the year ending December 31, 2039.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it is more likely than not that the benefit from certain state NOL carryforwards will not be realized. In recognition of this risk, as of December 31, 2020, the Company has provided a valuation allowance of $15 on the deferred tax assets related to these state NOL carryforwards.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal statutes of limitations on the Company’s 2016, 2015, and 2014 income tax years lapsed during the third quarter of 2020, 2019, and 2018, respectively. During the fourth quarter of each year, various state statutes of limitations also lapsed. The lapses for the years ended December 31, 2020 and 2019 had no impact on the Company’s unrecognized tax benefits. </span></div>For the years ended December 31, 2020 and 2019, the Company did not have any unrecognized tax benefits, net of their state benefits that would affect the Company’s effective tax rate. The Company classifies interest and/or penalties on income tax liabilities or refunds as additional income tax expense or income. Such amounts are not material. <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes for the years ended December 31, 2020, 2019 and 2018 is summarized as follows:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.915%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,058 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,478 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,536 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,138 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,348)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(838)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,186)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,350 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,085 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,352 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5058000 562000 3223000 1478000 278000 915000 6536000 840000 4138000 -3348000 1070000 226000 -838000 175000 -12000 -4186000 1245000 214000 2350000 2085000 4352000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the federal statutory rate to the effective tax rate for income from continuing operations for the years ended December 31, 2020, 2019 and 2018, respectively, is comprised as follows:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.769%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense at statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes - net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax provision</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The Company's completion of the Spin-Off in the year ended December 31, 2019 resulted in the Company not being able to deduct approximately $10,300 of the related transaction costs, which increased the effective tax rate significantly and affected all items that were impacted by this exclusion.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">During the year ended December 31, 2020, employees exercised stock options representing approximately 239 shares. During the year ended December 31, 2019, employees exercised stock options representing approximately 100 shares and had restricted stock awards vest representing 960 shares. These exercises and vestings resulted in tax benefits that reduced the Company's effective tax rate significantly in both years. </span></div></td></tr></table></div> 0.210 0.210 0.210 0.027 0.068 0.035 0.004 0.026 0.004 0 0.412 0 0 0.016 0 -0.108 -0.300 -0.029 0 0 -0.002 -0.002 -0.004 -0.007 0.131 0.396 0.211 10300000 239000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s deferred tax assets and liabilities for the years ended December 31, 2020 and 2019 are summarized below.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets (liabilities):</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,181 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,670 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,979 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,459 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,779 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,444 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,779 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,512)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,107)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(780)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(594)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,055)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82,181)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,347)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,882)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,103)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>For the 8181000 2670000 875000 869000 147000 27000 80979000 83076000 277000 137000 90459000 86779000 15000 0 90444000 86779000 7512000 6107000 780000 594000 80055000 82181000 88347000 88882000 2097000 2103000 500000 15 COMMITMENTS AND CONTINGENCIES<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Matters - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides services in complex and highly regulated industries. The Company’s compliance with applicable federal, state and local laws and regulations governing these industries may be subject to governmental review and adverse findings may result in significant regulatory action, which could include sanctions, damages, fines, penalties (many of which may not be covered by insurance), and even exclusion from government programs. The Company is a party to various regulatory and other governmental audits and investigations in the ordinary course of business and cannot predict the ultimate outcome of any federal or state regulatory survey, audit or investigation. While governmental audits and investigations are the subject of administrative appeals, the appeals process, even if successful, may take several years to resolve. The Department of Justice, The Centers for Medicare and Medicaid Services (“CMS”), or other federal and state enforcement and regulatory agencies may conduct additional investigations related to the Company's businesses. The Company believes that it is presently in compliance in all material respects with all applicable laws and regulations.</span><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost-Containment Measures - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government and third party payors have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect the Company.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnities - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company enters into certain types of contracts that contingently require the Company to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which the Company may be required to indemnify property owners or prior operators for post-transfer environmental or other liabilities and other claims arising from the Company’s use of the applicable premises, (ii) operations transfer agreements, in which the Company agrees to indemnify past operators of agencies and communities the Company acquires against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer, (iii) certain Ensign lending agreements, and (iv) certain agreements with management, directors and employees, under which the subsidiaries of the Company may be required to indemnify such persons for liabilities arising out of their employment relationships. The terms of such obligations vary by contract and, in most instances, a specific or maximum dollar amount is not explicitly stated therein. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on the Company’s combined balance sheets for any of the periods presented.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s businesses involve a significant risk of liability given the age and health of the patients and residents served by its independent operating subsidiaries. The Company, its operating companies, and others in the industry may be subject to a number of claims and lawsuits, including professional liability claims, alleging that services provided have resulted in personal injury, elder abuse, wrongful death or other related claims. Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and the Company is routinely subjected to these claims in the ordinary course of business, including potential claims related to patient care and treatment, professional negligence and class actions, as well as employment related claims. If there were a significant increase in the number of these claims or an increase in amounts owing should plaintiffs be successful in their prosecution of these claims, this could materially adversely affect the Company’s business, financial condition, results of operations and cash flows. In addition, the defense of these lawsuits may result in significant legal costs, regardless of the outcome, and can result in large settlement amounts or damage awards.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the potential lawsuits and claims described above, the Company is also subject to potential lawsuits under the False Claims Act (the “FCA”) and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare) or payor. A violation may provide the basis for exclusion from federally funded healthcare programs. Such exclusions could have a correlative negative impact on the Company’s financial performance. Some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. In addition, the Deficit Reduction Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the FCA. As such, the Company could face increased scrutiny, potential liability and legal expenses and costs based on claims under state false claims acts in markets in which it does conduct business.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2009, Congress passed the Fraud Enforcement and Recovery Act ("FERA") which made significant changes to the FCA, expanding the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, healthcare providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government, including the retention of any government overpayment. The Patient Protection and Affordable Care Act of 2010 (the “ACA”) supplemented FERA by imposing an affirmative obligation on healthcare providers to return an overpayment to CMS within 60 days of “identification” or the date any corresponding cost report is due, whichever is later. According to CMS’s February 12, 2016, final rule with respect to Medicare Parts A and B, providers have an obligation to proactively exercise “reasonable diligence” to identify overpayments. The 60-day clock begins to run after the reasonable diligence period has concluded, which may take, at most, six months from the receipt of credible information. Retention of any overpayment beyond this period may create liability under the FCA. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, there is generally no need for an employment relationship in order to qualify for protection against retaliation for whistleblowing.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company cannot predict or provide any assurance as to the possible outcome of any litigation. If any litigation were to proceed, and the Company and its operating companies are subjected to, alleged to be liable for, or agree to a settlement of, claims or obligations under federal Medicare statutes, the FCA, or similar state and federal statutes and related regulations, the Company’s business, financial condition and results of operations and cash flows could be materially and adversely </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">affected. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged civil violations, and may also include the assumption of specific procedural and financial obligations by the Company or its independent operating subsidiaries going forward under a corporate integrity agreement and/or other arrangement with the government. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Revenue Recoupments - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to probe reviews relating to Medicare services, billings and potential overpayments by Unified Program Integrity Contractors (UPIC), Recovery Audit Contractors (RAC), Zone Program Integrity Contractors (ZPIC), Program Safeguard Contractors (PSC), Supplemental Medical Review Contractors (SMRC) and Medicaid Integrity Contributors (MIC) programs, each of the foregoing collectively referred to as “Reviews.” As of December 31, 2020, seven of the Company’s independent operating subsidiaries had Reviews scheduled, on appeal or in dispute resolution process, both pre- and post-payment. The Company anticipates that these probe reviews will increase in frequency in the future. If an operation fails an initial or subsequent Review, the operation could then be subject to extended Review, suspension of payment, or extrapolation of the identified error rate to all billing in the same time period. As of December 31, 2020, and through the filing of this Annual Report on Form 10-K, the Company’s independent operating subsidiaries have responded to the Reviews that are currently ongoing, on appeal or in dispute resolution process and the Company has no probable or estimable contingencies. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Risk - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has significant accounts receivable balances, the collectability of which is dependent on the availability of funds from certain governmental programs, primarily Medicare and Medicaid. These receivables represent the only significant concentration of credit risk for the Company. The Company does not believe there are significant credit risks associated with these governmental programs. The Company believes that an appropriate allowance has been recorded for the possibility of these receivables proving uncollectible, and continually monitors and adjusts these allowances as necessary. The Company’s gross receivables from the Medicare and Medicaid programs accounted for approximately 75.7% and 74.3% of its total gross accounts receivable as of December 31, 2020 and December 31, 2019, respectively. Revenue from reimbursement under the Medicare and Medicaid programs accounted for 60.1%, 55.6%, and 53.1% of the Company's revenue for the years ended December 31, 2020, 2019 and 2018, respectively.</span></div> 7 0.757 0.743 0.601 0.556 0.531 XML 17 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Cover Page - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Feb. 24, 2021
Jun. 30, 2020
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2020    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 001-38900    
Entity Registrant Name THE PENNANT GROUP, INC.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 83-3349931    
Entity Address, Address Line One 1675 East Riverside Drive    
Entity Address, Address Line Two Suite 150    
Entity Address, City or Town Eagle    
Entity Address, State or Province ID    
Entity Address, Postal Zip Code 83616    
City Area Code (208)    
Local Phone Number 506-6100    
Title of 12(b) Security Common Stock, par value $0.001 per share    
Trading Symbol PNTG    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company true    
ICFR Auditor Attestation Flag false    
Entity Ex Transition Period true    
Entity Shell Company false    
Entity Common Stock, Shares Outstanding   28,262,407  
Entity Public Float     $ 603,746
Entity Central Index Key 0001766400    
Document Fiscal Year Focus 2020    
Document Fiscal Period Focus FY    
Amendment Flag false    
Documents Incorporated by Reference Part III of this Form 10-K incorporates information by reference from the Registrant's definitive proxy statement on Schedule 14A for the Registrant's 2021 Annual Meeting of Stockholders to be filed within 120 days after the close of the fiscal year covered by this annual report.    
XML 18 R2.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Current assets:    
Cash $ 43 $ 402
Accounts receivable—less allowance for doubtful accounts of $643 and $677, respectively 47,221 32,183
Prepaid expenses and other current assets 12,335 6,098
Total current assets 59,599 38,683
Property and equipment, net 17,884 14,644
Operating lease right-of-use assets 308,650 316,328
Escrow deposits 525 1,400
Deferred tax assets 2,097 0
Restricted and other assets 4,289 2,000
Goodwill 66,444 41,233
Other indefinite-lived intangibles 47,488 33,462
Total assets 506,976 447,750
Current liabilities:    
Accounts payable 9,761 8,653
Accrued wages and related liabilities 26,873 16,343
Operating lease liabilities—current 14,106 12,285
Other accrued liabilities 38,275 13,911
Total current liabilities 89,015 51,192
Operating lease liabilities—long-term 296,615 304,044
Other long-term liabilities 11,897 2,877
Long-term debt, net 8,277 18,526
Total liabilities 405,804 376,639
Commitments and contingencies
Equity:    
Common stock, $0.001 par value; 100,000 shares authorized; 28,696 and 28,243 shares issued and outstanding at December 31, 2020, respectively, and 28,435 and 27,853 shares issued and outstanding at December 31, 2019, respectively. 28 28
Additional paid-in capital 84,671 74,882
Retained earnings (accumulated deficit) 11,945 (3,799)
Treasury stock, at cost, 3 shares at December 31, 2020 (65) 0
Total Pennant Group, Inc. stockholders' equity 96,579 71,111
Noncontrolling interest 4,593 0
Total equity 101,172 71,111
Total liabilities and equity $ 506,976 $ 447,750
XML 19 R3.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 643 $ 677
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 100,000,000 100,000,000
Common stock, shares issued (in shares) 28,696,000 28,435,000
Common stock, shares outstanding (in shares) 28,243,000 27,853,000
Treasury stock, at cost (in shares) 3,000  
XML 20 R4.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED AND COMBINED STATEMENTS OF INCOME - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Income Statement [Abstract]      
Revenue $ 390,953 $ 338,531 $ 286,058
Expense:      
Cost of services 296,874 258,941 212,421
Rent—cost of services 39,191 34,975 31,199
General and administrative expense 31,296 35,135 18,843
Depreciation and amortization 4,675 3,810 2,964
Total expenses 372,036 332,861 265,427
Consolidated and Combined Income from operations 18,917 5,670 20,631
Other income (expense):      
Other income 225 0 0
Interest expense, net (1,239) (410) 0
Other income (expense), net (1,014) (410) 0
Income before provision for income taxes 17,903 5,260 20,631
Provision for income taxes 2,350 2,085 4,352
Net income 15,553 3,175 16,279
Less: net (loss)/ income attributable to noncontrolling interest (191) 629 595
Net income and other comprehensive income attributable to The Pennant Group, Inc. $ 15,744 $ 2,546 $ 15,684
Earnings per share (Note 4):      
Basic (in dollars per share) $ 0.56 $ 0.11 $ 0.58
Diluted (in dollars per share) $ 0.52 $ 0.11 $ 0.58
Weighted average common shares outstanding:      
Basic (in shares) 28,029 27,838 27,834
Diluted (in shares) 30,228 29,586 27,834
XML 21 R5.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED AND COMBINED STATEMENTS OF STOCKHOLDERS' EQUITY AND NET PARENT INVESTMENT - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-In Capital
Retained Earnings/ (Accumulated Deficit)
Treasury Stock
Net Parent Investment
Non-Controlling Interest
Equity, beginning balance (in shares) at Dec. 31, 2017   0     0    
Equity, beginning balance at Dec. 31, 2017 $ 59,916 $ 0 $ 0 $ 0 $ 0 $ 54,996 $ 4,920
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Noncontrolling interest attributable to subsidiary equity plan 1,378         (2,539) 3,917
Net income attributable to noncontrolling interest 595           595
Net transfer from parent (12,285)         (12,285)  
Net income attributable to The Pennant Group, Inc. 15,684         15,684  
Equity, ending balance (in shares) at Dec. 31, 2018   0     0    
Equity, ending balance at Dec. 31, 2018 65,288 $ 0 0 0 $ 0 55,856 9,432
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Noncontrolling interest attributable to subsidiary equity plan 594         (2,991) 3,585
Share repurchase related to subsidiary equity plan (394)           (394)
Net income attributable to noncontrolling interest 629           629
Net transfer from parent 11,894         11,894  
Net income attributable to The Pennant Group, Inc. 2,546     (3,799)   6,345  
Cash Dividend to Parent (11,600)         (11,600)  
Reclassification of Invested Equity 137   72,893     (59,504) (13,252)
Issuance of common stock after spin-off (in shares)   27,834          
Issuance of Common Stock after spin-off 0 $ 28 (28)        
Share-based compensation 1,987   1,987        
Exercise of stock options, issuance of other awards after spin-off (in shares)   601          
Exercise of Stock Options, issuance of other awards after spin-off 30   30        
Equity, ending balance (in shares) at Dec. 31, 2019   28,435     0    
Equity, ending balance at Dec. 31, 2019 71,111 $ 28 74,882 (3,799) $ 0 0 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Noncontrolling interests assumed related to acquisitions 4,646           4,646
Sale of noncontrolling interests, net of tax 451   313       138
Net income attributable to noncontrolling interest (191)           (191)
Net income attributable to The Pennant Group, Inc. 15,744     15,744      
Share-based compensation 8,335   8,335        
Exercise of stock options, issuance of other awards after spin-off (in shares)   238          
Exercise of Stock Options, issuance of other awards after spin-off 1,141   1,141        
Issuance/ (cancellation) of restricted stock (in shares)   26          
Issuance/ (cancellation) of restricted stock 0            
Shares of common stock withheld to satisfy tax withholding obligations (in shares)   3     3    
Shares of common stock withheld to satisfy tax withholding obligations (65)       $ (65)    
Equity, ending balance (in shares) at Dec. 31, 2020   28,696     (3)    
Equity, ending balance at Dec. 31, 2020 $ 101,172 $ 28 $ 84,671 $ 11,945 $ (65) $ 0 $ 4,593
XML 22 R6.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED AND COMBINED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Cash flows from operating activities:      
Net income $ 15,553 $ 3,175 $ 16,279
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization 4,675 3,810 2,964
Amortization of deferred financing fees 330 78 0
Provision for doubtful accounts 560 858 346
Share-based compensation 8,335 3,382 2,382
Deferred income taxes (2,201) 79 0
Change in operating assets and liabilities:      
Accounts receivable (15,712) (8,571) (2,569)
Prepaid expenses and other assets (7,435) (2,746) (210)
Operating lease obligations 2,068 (1,861) 0
Accounts payable 993 4,069 1,373
Accrued wages and related liabilities 10,538 3,376 1,583
Other accrued liabilities 2,427 1,720 398
Advance payments 27,997 0 0
Other long-term liabilities 2,076 2,185 729
Net cash provided by operating activities 50,204 9,554 23,275
Cash flows from investing activities:      
Purchase of property and equipment (7,253) (6,714) (3,603)
Cash payments for business acquisitions (33,193) (18,760) (4,725)
Cash payments for asset acquisitions 0 (20) (593)
Escrow deposits (525) (1,400) 0
Restricted and other assets (645) 429 (556)
Net cash used in investing activities (41,616) (26,465) (9,477)
Cash flows from financing activities:      
Proceeds from sale of subsidiary shares 0 2,293 1,972
Repurchase of subsidiary shares 0 (2,687) (1,972)
Net investment from/(to) parent 0 10,788 (13,793)
Cash distribution to parent in connection with Spin-Off 0 (11,600) 0
Sale of noncontrolling interest 555 0 0
Proceeds from revolver agreement 52,700 42,500 0
Payments on revolver agreement (63,200) (22,500) 0
Repurchase of shares of common stock to satisfy tax withholding obligations (65) 0 0
Payments for deferred financing costs (78) (1,552) 0
Issuance of common stock upon the exercise of options 1,141 30 0
Net cash provided by/(used in) financing activities (8,947) 17,272 (13,793)
Net (decrease)/ increase in cash (359) 361 5
Cash beginning of period 402 41 36
Cash end of period 43 402 41
Cash paid during the period for:      
Interest 1,116 156 0
Income taxes 7,865 120 0
Operating lease liabilities 35,853 37,088 0
Right-of-use assets obtained in exchange for new operating lease obligations 5,451 9,059 0
Net non-cash adjustment to right-of-use assets and lease liabilities from lease modifications 1,939 77,462 0
Non-cash investing activity:      
Capital expenditures $ 560 $ 946 $ 717
XML 23 R7.htm IDEA: XBRL DOCUMENT v3.20.4
DESCRIPTION OF BUSINESS
12 Months Ended
Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Description of business DESCRIPTION OF BUSINESS
The Pennant Group, Inc. (herein referred to as “Pennant,” the “Company,” “it,” or “its”), is a holding company with no direct operating assets, employees or revenue. The Company, through its independent operating subsidiaries, provides healthcare services across the post-acute care continuum. As of December 31, 2020, the Company’s subsidiaries operated 76 home health, hospice and home care agencies and 54 senior living communities located in Arizona, California, Colorado, Idaho, Iowa, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin and Wyoming.

On October 1, 2019, The Ensign Group, Inc. (NASDAQ: ENSG) (“Ensign” or the “Parent”) completed the separation of Pennant from Ensign through a tax-free distribution (except as to cash received in lieu of fractional shares) of substantially all of Pennant’s issued and outstanding common stock to the stockholders of Ensign (the “Spin-Off”). To accomplish the Spin-Off, Ensign contributed the Company’s assets and liabilities into Pennant and each Ensign stockholder received a distribution of one share of Pennant common stock for every two shares of Ensign’s common stock, plus cash in lieu of fractional shares. Additionally, the noncontrolling interest was converted into shares of Pennant at the established conversion ratio. As a result of the Spin-Off on October 1, 2019, Pennant began trading as an independent company on the NASDAQ under the symbol “PNTG.”
Certain of the Company’s subsidiaries, collectively referred to as the Service Center, provide accounting, payroll, human resources, information technology, legal, risk management, and other services to the operations through contractual relationships.
Each of the Company’s affiliated operations are operated by separate, independent subsidiaries that have their own management, employees and assets. References herein to the consolidated “Company” and “its” assets and activities is not meant to imply, nor should it be construed as meaning, that Pennant has direct operating assets, employees or revenue, or that any of the subsidiaries, are operated by Pennant.
XML 24 R8.htm IDEA: XBRL DOCUMENT v3.20.4
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
Basis of presentation and summary of significant accounting policies BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation - The accompanying consolidated and combined financial statements of the Company (the “Financial Statements”) reflect the Company’s financial position, results of operations and cash flows as the business was operated as part of Ensign prior to the Spin-Off, and have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and pursuant to the regulations of the Securities and Exchange Commission (“SEC”). Prior to the Spin-Off, the combined financial statements were prepared on a stand-alone basis and derived from the consolidated financial statements and accounting records of Ensign. Management believes that the Financial Statements reflect, in all material respects, all adjustments which are of a normal and recurring nature necessary to present fairly the Company’s financial position, results of operations, and cash flows for the periods presented in conformity with GAAP applicable to the annual period.

All intercompany transactions and balances between the various legal entities comprising the Company have been eliminated in consolidation. The consolidated and combined statements of income reflect income that is attributable to the Company and the noncontrolling interest.

The Company consists of various limited liability companies and corporations established to operate home health, hospice, home care, and senior living operations. The Financial Statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest. Revenue was derived from transactional information specific to the Company’s services provided. The costs in the consolidated and combined statements of income reflect direct costs and allocated costs prior to the Spin-Off.

Estimates and Assumptions - The preparation of the Financial Statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Financial Statements relate to revenue, cost allocations from prior to the Spin-Off, intangible assets and goodwill, right-of-use assets and lease liabilities for leases greater than 12 months, self-insurance reserves, and income taxes. Actual results could differ from those estimates.
Revenue Recognition - Revenues are recognized when services are provided to the patients at the amount that reflects the consideration to which the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net service revenue in the period such variances become known. See Note 5, Revenue and Accounts Receivable.

CARES Act: The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted on March 27, 2020 in the United States. During the second quarter of 2020 the Company applied for and received $27,997 in funds under the Accelerated and Advance Payment (“AAP”) Program. The CARES Act allows for deferred payment of the employer-paid portion of social security taxes through the end of 2020, with 50% due on December 31, 2021 and the remainder due on December 31, 2022. For the year ended December 31, 2020, the Company deferred approximately $8,358 of the employer-paid portion of social security taxes, of which $4,179 is included in other long-term liabilities and the current portion of $4,179 in accrued wages and related liabilities. The CARES Act temporarily suspended the automatic 2% reduction of Medicare claim reimbursements for the period of May 1, 2020 through March 31, 2021. The suspension of the Medicare sequestration increased our revenue by approximately $2,765 for the year ended December 31, 2020. The Company will continue to assess the effect of the CARES Act and ongoing other government legislation related to the COVID-19 pandemic that may be issued.

Cash - Cash consists of petty cash and bank term deposits and therefore approximates fair value. The Company places its cash with high credit quality financial institutions. Prior to the Spin-off the Company participated in a cash management program with Ensign where net cash activity was included in the net parent investment.

Accounts Receivable and Allowance for Doubtful Accounts - Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration. Subsequent to our adoption of ASU 2016-13, as noted below, the allowance for doubtful accounts is the Company’s best estimate of current expected credit losses in the accounts receivable balance.

Property and Equipment - Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three to 15 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.

Impairment of Long-Lived Assets - The Company reviews the carrying value of long-lived assets that are held and used in the independent operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiary to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. Management has evaluated its long-lived assets and the Company did not identify any asset impairment during the years ended December 31, 2020, 2019 and 2018.

Intangible Assets and Goodwill - Definite-lived intangible assets consist primarily of patient base and customer relationships. Patient base is amortized over a period of four months to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition when acquired. Customer relationships are amortized between one to seven years depending on the significance of the relationships.

The Company’s indefinite-lived intangible assets consist of trade names and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable. The Company did not identify any asset impairment during the years ended December 31, 2020, 2019 and 2018.
Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to annual test for impairment as of the beginning of the fourth quarter or more frequently if events or changes indicate that the Company's goodwill might be impaired. The Company assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company determines it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then it is required to perform a quantitative impairment test by comparing the fair value with the carrying amount of the reporting unit. If the carrying amount of a reporting unit exceeds its fair value, then the Company records an impairment of goodwill equal to the amount that the carrying amount of a reporting unit exceeds its fair value.

As of December 31, 2020, we evaluated potential triggering events that might be indicators that our goodwill and indefinite lived intangibles were impaired. No goodwill or intangible asset impairments were recorded during the years ended December 31, 2020, 2019 and 2018. See further discussion at Note 9, Goodwill and Intangible Assets, Net.

Insurance - The Company retains risk for a substantial portion of potential claims for general and professional liability and workers’ compensation. The Company does not retain risk related to its employee health plans.

The Company recognizes obligations associated with these costs, up to specified deductible limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. As of December 31, 2020 the general and professional liability insurance has a retention limit of $150 per claim with a $500 corridor as an additional out-of-pocket retention we must satisfy for claims within the policy year before the carrier will reimburse losses. The workers’ compensation insurance has a retention limit of $250 per claim, except for policies held in Texas and Washington which are subject to state insurance and possess their own limits.

These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis. Additionally, the Company has partially indemnified Ensign for general and professional liabilities incurred prior to the Spin-off but not reported until after that date and included that amount in its accrual below.

The following table presents details of the Company's insurance programs, including amounts accrued for the periods indicated in other accrued liabilities and other long-term liabilities in our accompanying balance sheets. The amounts accrued below represent the total estimated liability for individual claims that are less than our noted insurance coverage amounts, which includes outstanding claims and claims incurred but not reported. The amounts are reported gross of reinsurance receivable of $704 and zero included in restricted and other assets for the years ended December 31, 2020 and 2019, respectively.

Year Ended December 31,
20202019
Type of Insurance
General and professional liability $1,063 $521 
Workers’ compensation2,783 433 
Total estimated liability3,846 954 
Less: long-term portion, included in other long-term liabilities(2,492)(774)
Current portion of estimated liability, included in other accrued liabilities$1,354 $180 

Fair Value of Financial Instruments - The Company’s financial instruments consist principally of cash, accounts receivable, accounts payable and accrued liabilities. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations. The Company determines fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.

Income Taxes - Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences
are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized.

In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.

Noncontrolling Interest - The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income/ (loss) attributable to The Pennant Group, Inc. in its consolidated and combined statements of income. Net income per share is calculated based on net income/ (loss) attributable to The Pennant Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest.

Share-Based Compensation -The Company measures and recognizes compensation expense for all share-based payment awards, including employee stock options, made to employees and Pennant’s directors based on estimated fair values, ratably over the requisite service period of the award. The Company accounts for forfeitures as they occur. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables. The total amount of share-based compensation was $8,335, $3,382, and $2,382 for the years ended December 31, 2020, 2019 and 2018, respectively, of which $7,222, $2,769 and $1,900, respectively, was recorded in general and administrative expense. For further discussion see Note 12, Options and Awards.

Prior to Spin-Off

Cost Allocation - The Financial Statements include allocations of costs for certain shared services provided to the Company by Ensign subsidiaries prior to the Spin-Off on October 1, 2019. Such allocations include, but are not limited to, executive management, accounting, human resources, information technology, compliance, legal, payroll, insurance, tax, treasury, and other general and administrative items. These costs were allocated to the Company on a basis of revenue, location, employee count, or other measures. These cost allocations are reflected within general and administrative expense in the consolidated and combined statements of income, including for share-based compensation expenses disclosed in Note 12, Options and Awards. The amount of general and administrative costs allocated from January 1, 2019 to October 1, 2019, the date of the Spin-Off, inclusive of share-based compensation expense, was $23,710. Management believes the basis on which the expenses were allocated to be a reasonable reflection of the services provided to the Company during the periods.

Insurance - Prior to the Spin-Off Ensign was partially self-insured for healthcare, general and professional liability, and workers’ compensation, and historically allocated premium expense to all subsidiaries of Ensign in its accounting records. To reflect all of the insurance costs, quarterly actuary determined adjustments were allocated to the Company based on the proportional historical premium expense. No self-insurance accruals were allocated to the Company as these accruals represent the obligations of Ensign. In connection with the Spin-Off, the Company purchased insurance through a third-party to replace the coverage provided by Ensign’s self-insured policies.

Debt - Ensign’s external debt and related interest expense were not allocated to the Company for any of the periods presented as no portion of the borrowings were assumed by the Company as part of the Spin-Off. All interest incurred by the Company was subsequent to the Spin-Off.

Income Taxes - Prior to the date of the Spin-off, the Company’s operations have been included in Ensign’s U.S. federal and state income tax returns and all income taxes have been paid by subsidiaries of Ensign. Also prior to the date of the Spin-off, income tax expense and other income tax related information contained in these Financial Statements were presented using a separate tax return approach. Under this approach, the provision for income taxes represents income tax paid or payable for the current year plus the change in deferred taxes during the year calculated as if the Company was a stand-alone taxpayer filing hypothetical income tax returns. Management believes that the assumptions and estimates used to determine these tax amounts are reasonable. However, the Company’s Financial Statements may not necessarily reflect its income tax expense or tax
payments in the future, or what tax amounts would have been if the Company had been a stand-alone company for the entire period presented.

Invested Capital - The net parent investment on the consolidated balance sheets represents Ensign’s historical investment in the Company, the net effect of transactions with, and allocations from, Ensign and the Company’s accumulated earnings. Invested capital was reclassified into additional paid-in-capital at the date of the Spin-Off.

Noncontrolling Interest - Prior to the Spin-Off, the Company presented the noncontrolling interest and the amount of consolidated net income/ (loss) attributable to the Company in its Financial Statements. The carrying amount of the noncontrolling interest was adjusted by an allocation of subsidiary earnings based on ownership interest prior to the Spin-Off. The noncontrolling subsidiary interest included in the Financial Statements was converted into common shares of Pennant concurrent with the distribution to Ensign stockholders at the date of the Spin-Off and thus, will no longer be allocated a portion of earnings.

Share-based compensation - Prior to the Spin-Off, employees of the Company’s subsidiaries participated in Ensign’s equity-based incentive plans (the “Ensign Plans”) and the Cornerstone Subsidiary Equity plan (the “Subsidiary Equity Plan”). Share-based compensation includes the expense attributable to employees of the Company’s subsidiaries who participated in the Ensign Plans, as well as the allocated cost related to Ensign subsidiaries’ employees that participated in the Ensign Plans. Share-based compensation related to Ensign subsidiaries’ employees that participated in the Ensign Plans were allocated on the basis of revenue. All share-based compensation related to the Subsidiary Equity Plan was recognized in the Financial Statements and, therefore, no cost allocation was necessary.

Prior to the Spin-Off, share-based compensation costs associated with the Subsidiary Equity Plan awards was initially measured at fair value at the grant date and was expensed as non-cash compensation over the vesting term. Historically, these awards were granted once per year and the fair value has been determined by an independent valuation of the subsidiary shares. The valuation incorporated a discounted cash flow analysis combined with a market-based approach to determine the fair value of the subsidiary equity.

Earnings Per Share - For the year ended December 31, 2018, the earnings per share included on the accompanying Consolidated and Combined Statements of Income was calculated based on the 27,834 shares of Pennant common stock distributed on October 1, 2019 in conjunction with the Spin-Off, including shares related to the conversion of the noncontrolling interest. Prior to October 1, 2019, Pennant did not have any issued and outstanding common stock. The same number of shares was used to calculate basic and diluted earnings per share since no Pennant employee equity awards were outstanding prior to the Spin-Off. In connection with the Spin-Off, shares of existing equity awards were replaced with shares under the new Pennant awards and are reflected in basic and diluted net income per share for the years ended December 31, 2020 and 2019, respectively. For further discussion see Note 4, Computation of Net Income Per Common Share

Recent Accounting Standards Adopted by the Company

Except for rules and interpretive releases of the SEC under authority of federal securities laws and a limited number of grandfathered standards, the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management and certain standards are under consideration.

FASB Accounting Standards Update, or ASU, ASU 2020-04 “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” or ASU 2020-4 - In March 2020, the FASB concluded its reference rate reform project and issued this ASU. The amendments in this ASU provide optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in this ASU apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The optional expedients and exceptions are available for all entities as of March 12, 2020, through December 31, 2022. The Company has adopted ASU 2020-04, effective March 12, 2020. The impact of this ASU will be determined based on terms of any future contract modification related to a change in reference rate, including future modifications to the Company’s Revolving Credit Facility described in further detail in Note 11, Debt.
FASB ASU, 2018-15, “Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract” or ASU 2018-15. The update helps entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement (hosting arrangement), by providing guidance in determining when the arrangement includes a software license. It requires entities to account for such costs consistent with the guidance on capitalizing costs associated with developing or obtaining internal-use software. The Company has adopted ASU 2018-15, effective January 1, 2020. There was no material impact to the Company’s Financial Statements or disclosures.

FASB ASU, 2018-13 “Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement” or ASU 2018-13 - In August 2018, the FASB issued amended guidance to simplify fair value measurement disclosure requirements. The new provisions eliminate the requirements to disclose (1) transfers between Level 1 and Level 2 of the fair value hierarchy, (2) policies related to valuation processes and the timing of transfers between levels of the fair value hierarchy, and (3) net asset value disclosure of estimates of timing of future liquidity events. The FASB also modified disclosure requirements of Level 3 fair value measurements. The Company adopted ASU 2018-13 as of January 1, 2020. There was no material impact to the Company’s Financial Statements or disclosures.

FASB ASU, 2017-04 “Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” or ASU 2017-04 - In January 2017, the FASB issued amended authoritative guidance to simplify and reduce the cost and complexity of the goodwill impairment test. The new guidance eliminates “Step 2” from the traditional two-step goodwill impairment test and redefines the concept of impairment from a measure of loss when comparing the implied fair value of goodwill to its carrying amount, to a measure comparing the fair value of a reporting unit with its carrying amount. The FASB also eliminated the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment or “Step 2” of the goodwill impairment test. The new guidance does not amend the optional qualitative assessment of goodwill impairment. The Company adopted ASU 2017-04 as of January 1, 2020. There was no material impact to the Company’s Financial Statements or disclosures.
FASB ASU 2016-13 “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” or ASU 2016-13 - In June 2016, the FASB issued ASU 2016-13, which replaced the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected to be collected. The Company adopted ASU 2016-13 as of January 1, 2020. There was no material impact to the Company’s Financial Statements or related disclosures.
XML 25 R9.htm IDEA: XBRL DOCUMENT v3.20.4
RELATED PARTY TRANSACTIONS AND NET PARENT INVESTMENT
12 Months Ended
Dec. 31, 2020
Related Party Transactions [Abstract]  
Related party transactions and net parent investment RELATED PARTY TRANSACTIONS AND NET PARENT INVESTMENT
The Financial Statements include a combination of stand-alone and combined business functions between Ensign and the Company’s subsidiaries prior to the Spin-Off. The Company leases 31 of its senior living communities from subsidiaries of Ensign, each of the leases have a term of between 14 and 20 years from the lease commencement date. The total amount of rent expense included in Rent - cost of services paid to subsidiaries of Ensign was $12,536, $11,292, and $10,363 for the years ended December 31, 2020, 2019 and 2018, respectively.

Certain related party activity occurred as the Company’s subsidiaries received services from Ensign’s subsidiaries. Services included in cost of services were $4,205, $3,166, and $2,996 for the years ended December 31, 2020, 2019 and 2018, respectively.

The consolidated balance sheets of the Company include Ensign assets and liabilities that are specifically identifiable or otherwise attributable to the Company and were transferred to the Company in connection with the Spin-Off. Transactions that have occurred between subsidiaries of the Company and subsidiaries of Ensign are considered to be effectively settled at the time the transaction is recorded. The net effect of these transactions, including the cash management, is included in the consolidated and combined statements of cash flows as “Net investment from/(to) Parent”.

Other related party activity with Ensign
On October 1, 2019, in connection with the Spin-Off, Pennant entered into several agreements with Ensign that set forth the principal actions taken or to be taken in connection with the Spin-Off and govern the relationship of the parties following the Spin-Off.
The Company has incurred $5,536 and $2,982 in costs related to the Transitions Services Agreement for the years ended December 31, 2020 and 2019, respectively. Additionally, the Company has recognized $578 and $291 in tax benefits related to the Tax Matters Agreement for the years ended December 31, 2020 and 2019, respectively, and has recorded a payable to Ensign in connection with any unpaid portion of these amounts. See “Certain Relationships and Related Party Transactions—Agreements with Ensign Related to the Spin-Off,” contained within the Information Statement as well as the Form 8-K filed with the SEC on October 3, 2019 for further discussion of the agreements entered into in connection with the Spin-Off.
XML 26 R10.htm IDEA: XBRL DOCUMENT v3.20.4
COMPUTATION OF NET INCOME PER COMMON SHARE
12 Months Ended
Dec. 31, 2020
Earnings Per Share [Abstract]  
Computation of net income per common share COMPUTATION OF NET INCOME PER COMMON SHARE
Basic and diluted net income per share are computed by dividing net income by the weighted average number of outstanding common shares during the period. In the basic and diluted earnings per share calculations, net income is equal to net income attributable to The Pennant Group, Inc.

Prior to Spin-Off

Net income attributable to the noncontrolling interest has been included in the numerator for the years ended December 31, 2019 and 2018, respectively, as the non-controlling subsidiary interest that existed prior to the Spin-Off was converted into common shares of Pennant concurrent with the distribution to Ensign stockholders at the date of the Spin-Off.

The following table sets forth the computation of basic and diluted net income per share for the periods presented:


Year Ended December 31,
 202020192018
Numerator:
Net income$15,553 $3,175 $16,279 
Add: net (loss)/ income attributable to noncontrolling interests(191)629 595 
Net income attributable to The Pennant Group, Inc.$15,744 $2,546 $15,684 
Denominator:
Weighted average shares outstanding for basic net income per share(a)
28,029 27,838 27,834 
Plus: incremental shares from assumed conversion(b)
2,199 1,748 — 
Adjusted weighted average common shares outstanding for diluted income per share30,228 29,586 27,834 
Earnings Per Share:
Basic net income per common share(c)
$0.56 $0.11 $0.58 
Diluted net income per common share(c)
$0.52 $0.11 $0.58 

(a)
Concurrent with the Spin-Off the noncontrolling subsidiary interest converted into 1,160 shares of Pennant. The total number of common shares distributed on October 1, 2019 of 27,834 was utilized in the denominator for the calculation of basic and diluted earnings per share for the year ended December 31, 2018 , as no common stock was outstanding prior to the date of the Spin-Off.
(b)
The calculation of dilutive shares outstanding excludes out-of-the-money stock options (i.e., such options’ exercise prices were greater than the average market price of our common shares for the period) because their inclusion would have been antidilutive. Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were 93 and 15 for the years ended December 31, 2020 and 2019, respectively.
(c)
For the years ended December 31, 2019 and 2018 basic and diluted earnings per share were calculated based on net income as the numerator, which included the conversion of the noncontrolling interest in connection with the Spin-Off. For the year ended December 31, 2020, basic and diluted earnings per share was calculated based on net income attributable to The Pennant Group, Inc. as the numerator, . See Note 7, Acquisitions, for further information on our acquisitions for the year ended December 31, 2020.
XML 27 R11.htm IDEA: XBRL DOCUMENT v3.20.4
REVENUE AND ACCOUNTS RECEIVABLE
12 Months Ended
Dec. 31, 2020
Revenue from Contract with Customer [Abstract]  
Revenue and accounts receivable REVENUE AND ACCOUNTS RECEIVABLERevenues are recognized when services are provided to the patients or residents at the amount that reflects the consideration to which the Company expects to be entitled from patients, residents and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care or senior living residence. The healthcare services in home health and hospice patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as
services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct within the context of the contract. Additionally, there may be ancillary services which are not included in the rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered.

Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net service revenue in the period such variances become known.

Revenue from the Medicare and Medicaid programs accounted for 60.1%, 55.6%, and 53.1% of the Company’s revenue for the years ended December 31, 2020, 2019 and 2018, respectively. The Company records revenue from these governmental and managed care programs as services are performed at their expected net realizable amounts under these programs. The Company’s revenue from governmental and managed care programs is subject to audit and retroactive adjustment by governmental and third-party agencies. Consistent with healthcare industry accounting practices, any changes to these governmental revenue estimates are recorded in the period the change or adjustment becomes known based on final settlement.

Disaggregation of Revenue

The Company disaggregates revenue from contracts with its patients or residents by reportable operating segments and payors. The Company has determined that disaggregating revenue into these categories achieves the disclosure objectives to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. A reconciliation of disaggregated revenue to segment revenue as well as revenue by payor is provided in below.

The Company’s service specific revenue recognition policies are as follows:

Home Health Revenue

Medicare Revenue

For Medicare episodes that began after January 1, 2020, net service revenue is recognized in accordance with the Patient Driven Groupings Model (“PDGM”). This new reimbursement structure involves case mix calculation methodology refinements, changes to low-utilization payment adjustment (“LUPA”) thresholds, the elimination of therapy thresholds, a change to the unit of payment from a 60-day episode to a 30-day payment period, and reduction of requests for anticipated payments (“RAPs”) to 20% of the estimated payment for a patient’s initial or subsequent period of care up-front (after the initial assessment is completed and upon initial billing). The RAPs will be completely phased out effective January 1, 2021. Under PDGM, Medicare provides agencies with payments for each 30-day payment period provided to beneficiaries. If a beneficiary is still eligible for care after the end of the first 30-day payment period, a second 30-day payment period can begin. There are no limits to the number of periods of care a beneficiary who remains eligible for the home health benefit can receive. While payment for each 30-day payment period is adjusted to reflect the beneficiary’s health condition and needs, a special outlier provision exists to ensure appropriate payment for those beneficiaries that have the most expensive care needs. The payment under the Medicare program is also adjusted for certain variables including, but not limited to: (a) a LUPA if the number of visits is below an established threshold that varies based on the diagnosis of a beneficiary; (b) a partial payment if the patient transferred to another provider or the Company received a patient from another provider before completing the period of care; (c) adjustment to the admission source of claim if it is determined that the patient had a qualifying stay in a post-acute care setting within 14 days prior to the start of a 30-day payment period; (d) the timing of the 30-day payment period provided to a patient in relation to the admission date, regardless of whether the same home health provider provided care for the entire series of episodes; (e) changes to the acuity of the patient during the previous 30-day payment period; (f) changes in the base payments established by the Medicare program; (g) adjustments to the base payments for case mix and geographic wages; and (h) recoveries of overpayments.
For all episodes that began prior to January 1, 2020, net service revenue was recorded under the Medicare prospective payment system based on a 60-day episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a) an outlier payment if the patient’s care was unusually costly; (b) a LUPA if the number of visits was fewer than five; (c) a partial payment if the patient transferred to another provider or transferred from another provider before completing the episode; (d) a payment adjustment based upon the level of covered therapy services; (e) the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (f) changes in the base episode payments established by the Medicare program; (g) adjustments to the base episode payments for case mix and geographic wages; and (h) recoveries of overpayments.

The Company adjusts Medicare revenue on completed episodes to reflect differences between estimated and actual payment amounts, an inability to obtain appropriate billing documentation and other reasons unrelated to credit risk. Therefore, the Company believes that its reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered.

In addition to revenue recognized on completed episodes and periods, the Company also recognizes a portion of revenue associated with episodes and periods in progress. Episodes in progress are 30-day payment periods, if the episode started after January 1, 2020, or 60-day episodes of care, if the episode started prior to January 1, 2020, that begin during the reporting period but were not completed as of the end of the period. As such, the Company estimates revenue and recognizes it on a daily basis. The primary factors underlying this estimate are the number of episodes in progress at the end of the reporting period, expected Medicare revenue per period of care or episode of care and the Company’s estimate of the average percentage complete based on the scheduled end of period and end of episode dates.

Non-Medicare Revenue

Episodic Based Revenue - The Company recognizes revenue in a similar manner as it recognizes Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms.

Non-episodic Based Revenue - Revenue is recognized on an accrual basis based upon the date of service at amounts equal to its established or estimated per visit rates, as applicable.

Hospice Revenue

Revenue is recognized on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are calculated as daily rates for each of the levels of care the Company delivers. Revenue is adjusted for an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. Additionally, as Medicare hospice revenue is subject to an inpatient cap and an overall payment cap, the Company monitors its provider numbers and estimates amounts due back to Medicare if a cap has been exceeded. The Company regularly evaluates and records these adjustments as a reduction to revenue and an increase to other accrued liabilities.

Senior Living Revenue

The Company has elected the lessor practical expedient within ASC Topic 842, Leases (“ASC 842”) and therefore recognizes, measures, presents, and discloses the revenue for services rendered under the Company’s senior living residency agreements based upon the predominant component, either the lease or non-lease component, of the contracts. The Company has determined that the services included under the Company’s senior living residency agreements each have the same timing and pattern of transfer. The Company recognizes revenue under ASC Topic 606, Revenue from Contracts with Customers for its senior residency agreements, for which it has determined that the non-lease components of such residency agreements are the predominant component of each such contract.

The Company’s senior living revenue consists of fees for basic housing and assisted living care. Accordingly, we record revenue when services are rendered on the date services are provided at amounts billable to individual residents. Residency agreements are generally for a term of 30 days, with resident fees billed monthly in advance. For residents under reimbursement arrangements with Medicaid, revenue is recorded based on contractually agreed-upon amounts or rates on a per resident, daily basis or as services are rendered.
Revenue by payor for the years ended December 31, 2020, 2019 and 2018, is summarized in the following tables:

Year Ended December 31, 2020
Home Health and Hospice Services
Home Health ServicesHospice ServicesSenior Living ServicesTotal RevenueRevenue %
Medicare$58,399 $119,873 $— $178,272 45.6 %
Medicaid7,645 12,462 36,780 56,887 14.5 
Subtotal66,044 132,335 36,780 235,159 60.1 
Managed care31,572 1,546 — 33,118 8.5 
Private and other(a)
21,968 194 100,514 122,676 31.4 
Total revenue$119,584 $134,075 $137,294 $390,953 100.0 %

(a)Private and other payors in our home health and hospice services segment includes revenue from all payors generated in our home care operations.


Year Ended December 31, 2019
Home Health and Hospice Services
Home Health ServicesHospice ServicesSenior Living ServicesTotal RevenueRevenue %
Medicare$47,819 $93,933 $— $141,752 41.9 %
Medicaid6,575 10,061 29,819 46,455 13.7 
Subtotal54,394 103,994 29,819 188,207 55.6 
Managed care27,711 1,536 — 29,247 8.6 
Private and other(a)
18,837 152 102,088 121,077 35.8 
Total revenue$100,942 $105,682 $131,907 $338,531 100.0 %

(a)Private and other payors in our home health and hospice services segment includes revenue from all payors generated in our home care operations.

Year Ended December 31, 2018
Home Health and Hospice Services
Home Health ServicesHospice ServicesSenior Living ServicesTotal RevenueRevenue %
Medicare$42,091 $73,906 $— $115,997 40.5 %
Medicaid4,680 7,729 23,624 36,033 12.6 
Subtotal46,771 81,635 23,624 152,030 53.1 
Managed care23,541 918 — 24,459 8.6 
Private and other(a)
16,067 105 93,397 109,569 38.3 
Total revenue$86,379 $82,658 $117,021 $286,058 100.0 %

(a)Private and other payors in our home health and hospice services segment includes revenue from all payors generated in our home care operations.

Balance Sheet Impact

Included in the Company’s consolidated balance sheets are contract assets, comprised of billed accounts receivable and unbilled receivables, which are the result of the timing of revenue recognition, billings and cash collections, as well as, contract liabilities, which primarily represent payments the Company receives in advance of services provided. As of December 31, 2020, the Company had contract liabilities in the amount of $27,997 related to Advance Payments received in connection with the CARES Act. As further discussed in Note 10, Other Accrued Liabilities, the repayment terms for Medicare advance payments were modified through the passage of the Continuing Appropriations Act, 2021 and Other Extensions Act on October 1, 2020.
Accounts receivable as of December 31, 2020 and December 31, 2019 is summarized in the following table:

December 31, 2020December 31, 2019
Medicare$28,569 $17,822 
Medicaid7,669 6,579 
Managed care7,590 4,380 
Private and other4,036 4,079 
Accounts receivable, gross47,864 32,860 
Less: allowance for doubtful accounts(643)(677)
Accounts receivable, net$47,221 $32,183 

The following table summarizes the activity for our allowance for doubtful accounts for the years ended years ended December 31, 2020, 2019 and 2018:

Year Ended December 31,
202020192018
Balance at beginning of period$677 $616 $5,058 
Impact of ASC 606 Adoption(a)
— — (4,590)
Additions to bad debt expense560 858 346 
Write-offs of uncollectible accounts(594)(797)(198)
Balance at end of period$643 $677 $616 

(a)
Subsequent to the adoption of ASC 606, the majority of what was previously presented as allowance for doubtful accounts related to bad debt expense has been incorporated as an implicit price concession factored into net revenue and accounts receivable. Allowance for doubtful accounts as of December 31, 2020 represents the Company’s best estimate of probable losses inherent in the accounts receivable balance based on known troubled accounts and other currently available evidence.


Practical Expedients and Exemptions

As the Company’s contracts have an original duration of one year or less, the Company uses the practical expedient applicable to its contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of the end of each reporting period or when the Company expects to recognize this revenue. In addition, the Company has applied the practical expedient provided by ASC 340, Other Assets and Deferred Costs (“ASC 340”), and all incremental customer contract acquisition costs are expensed as they are incurred because the amortization period would have been one year or less.
XML 28 R12.htm IDEA: XBRL DOCUMENT v3.20.4
BUSINESS SEGMENTS
12 Months Ended
Dec. 31, 2020
Segment Reporting [Abstract]  
Business segments BUSINESS SEGMENTS
The Company classifies its operations into the following reportable operating segments: (1) home health and hospice services, which includes the Company’s home health, hospice and home care businesses; and (2) senior living services, which includes the operation of assisted living, independent living and memory care communities. The reporting segments are business units that offer different services and are managed separately to provide greater visibility into those operations. Our Chief Executive Officer and President, who is our Chief Operating Decision Maker “CODM”, reviews financial information at the operating segment level. We also report an “all other” category that includes general and administrative expense from our Service Center.

As of December 31, 2020, the Company provided services through 76 affiliated home health, hospice and home care agencies, and 54 affiliated senior living operations. The Company evaluates performance and allocates capital resources to each segment based on an operating model that is designed to maximize the quality of care provided and profitability. The Company’s Service Center provides various services to all lines of business. The Company does not review assets by segment and therefore assets by segment are not disclosed below.

Beginning in the third quarter of 2019, in anticipation of the Spin-Off, the GAAP segment measure of profit and loss was changed from Segment Income (Loss) Before Provision for Income Taxes to Adjusted Segment EBITDAR from Operations. Prior period presentation has been revised to reflect the new measurement.
The CODM uses Segment Adjusted EBITDAR from Operations as the primary measure of profit and loss for the Company's reportable segments and to compare the performance of its operations with those of its competitors. Segment Adjusted EBITDAR from Operations is net income/ (loss) attributable to the Company's reportable segments excluding interest expense, provision for income taxes, depreciation and amortization expense, rent, and, in order to view the operations performance on a comparable basis from period to period, certain adjustments including: (1) costs at start-up operations, (2) share-based compensation, (3) acquisition related costs, (4) Spin-Off transaction costs, (5) redundant and nonrecurring costs associated with the transition services agreement, (6) net income/ (loss) attributable to noncontrolling interest, and (7) net COVID-19 related costs. General and administrative expenses are not allocated to the reportable segments, and are included as “All Other”, accordingly the segment earnings measure reported is before allocation of corporate general and administrative expenses. The Company's segment measures may be different from the calculation methods used by other companies and, therefore, comparability may be limited.

The following table presents certain financial information regarding our reportable segments, general and administrative expenses are not allocated to the reportable segments and are included in “All Other” for the years ended December 31, 2020, 2019 and 2018:
Home Health and Hospice ServicesSenior Living ServicesAll OtherTotal
Year Ended December 31, 2020
Revenue$253,659 $137,294 $— $390,953 
Segment Adjusted EBITDAR from Operations$49,501 $48,309 $(22,762)$75,048 
Year Ended December 31, 2019
Revenue$206,624 $131,907 $— $338,531 
Segment Adjusted EBITDAR from Operations$33,354 $47,344 $(18,591)$62,107 
Year Ended December 31, 2018
Revenue$169,037 $117,021 $— $286,058 
Segment Adjusted EBITDAR from Operations$26,427 $47,230 $(16,191)$57,466 

The table below provides a reconciliation of Segment Adjusted EBITDAR from Operations above to income from operations:

Year Ended December 31,
202020192018
Segment Adjusted EBITDAR from Operations$75,048 $62,107 $57,466 
Less: Depreciation and amortization4,675 3,810 2,964 
Rent—cost of services39,191 34,975 31,199 
Other income225 — — 
Adjustments to Segment EBITDAR from Operations:
Less: Costs at start-up operations(a)
1,787 483 129 
Share-based compensation expense(b)
8,335 3,382 2,382 
Acquisition related costs(c)
99 665 — 
Spin-off related transaction costs(d)
— 13,219 756 
Transition services costs(e)
1,181 532 — 
COVID-19 Related costs and supplies(f)
447 — — 
Add: Net income/ (loss) attributable to noncontrolling interest(191)629 595 
Consolidated and Combined Income from operations$18,917 $5,670 $20,631 

(a)Represents results related to start-up operations. This amount excludes rent and depreciation and amortization expense related to such operations.
(b)Share-based compensation expense incurred which is included in cost of services and general and administrative expense.
(c)Acquisition related costs that are not capitalizable.
(d)Costs incurred related to the Spin-Off are included in general and administrative expense.
(e)
A portion of the costs incurred under the Transition Services Agreement (as defined in Note 3, Related Party Transactions and Net Parent Investment) identified as redundant or nonrecurring that are included in general and administrative expense. Transition service costs includes $446 of duplicative software expense for the year ended December 31, 2020, of which $333 pertains to the first three quarters of the fiscal year and were not included as adjustments in previous interim periods. Fees incurred under the Transition Services agreement, net of the Company’s payroll reimbursement, were $5,536, $2,982, and zero for the years ended December 31, 2020, 2019 and 2018, respectively.
(f)
Represents incremental costs incurred as part of the Company's response to COVID-19 including direct medical supplies, labor, and other expenses, net of $2,765 in increased revenue related to the 2% payment increase in Medicare reimbursements for sequestration relief for the year ended December 31, 2020.
XML 29 R13.htm IDEA: XBRL DOCUMENT v3.20.4
ACQUISITIONS
12 Months Ended
Dec. 31, 2020
Business Combinations [Abstract]  
Acquisitions ACQUISITIONS
The Company’s acquisition focus is to purchase or lease operations that are complementary to the Company’s current businesses, accretive to the Company’s business or otherwise advance the Company’s strategy. The results of all the Company’s independent operating subsidiaries are included in the Financial Statements subsequent to the date of acquisition. Acquisitions are accounted for using the acquisition method of accounting.

2020 Acquisitions

During the year ended December 31, 2020, the Company expanded its operations with the addition of six home health agency, six hospice agencies, and two senior living communities. The aggregate purchase price for these acquisitions was $39,239. In connection with the addition of the senior living communities, the Company entered into a new long-term “triple-net” lease with a subsidiary of Ensign. The addition of these operations added a total of 164 operational senior living units to be operated by the Company’s independent operating subsidiaries. A subsidiary of the Company entered into a separate operations transfer agreement with the prior operator of each acquired operation as part of each transaction. The goodwill was primarily attributable intangible assets that do not qualify for separate recognition and to synergies the Company expects to achieve related to the acquisition and was allocated to the Company's operating segments which are its reporting units. The Company anticipates that the total goodwill recognized will be fully deductible for tax purposes. Acquisition costs related to the business combinations of home health, hospice, and home care acquisitions of $99 were expensed related to the business combinations during the year ended December 31, 2020.

In October 2020, the Company announced it closed on a home health joint venture and hospice joint venture with Scripps Health (“Scripps”), a leading nonprofit integrated health system based in San Diego, California. The closing was effective October 1, 2020. The resulting joint ventures, which combined certain assets and the operations of Scripps’ home health business and the assets and operations of the local Pennant-affiliated home health and hospice agencies, are majority-owned and managed by an independent operating subsidiary of the Company and provide home health and hospice services to patients throughout San Diego County. The fair value of assets contributed by Scripps to the home health joint venture were included in the total value of assets acquired as described above and in the summary table below. The Company paid Scripps $6,200 in cash and contributed assets from the local Pennant-affiliated home health agency with a net book value of $614. The Company acquired 60.0% ownership interest in the joint venture. The contributions of assets by Scripps to the joint venture, resulted in the Company recording a noncontrolling interest with a fair value of $4,646. The fair value of the noncontrolling interest was determined using discounted cash flow models. As part of the transaction with Scripps, the Company contributed the assets of the local Pennant-affiliated hospice agency to another joint venture. The Company sold Scripps a noncontrolling interest in the hospice joint venture for $555 in cash. The company retained an 80.0% ownership interest in the hospice joint venture. The transaction resulted in the Company recognizing a noncontrolling interest of $138 and a contribution to additional paid in capital of $313, net of $104 of the income tax effect.

2019 Acquisitions

During the year ended December 31, 2019, the Company expanded its operations with the addition of two home health agencies, five hospice agencies, two home care agencies and two senior living operations. In connection with the acquisitions of one of the senior living communities, the Company entered into a new long-term “triple-net” lease with a subsidiary of Ensign. The Company did not acquire any material assets or assume any liabilities. A subsidiary of the Company entered into a separate operations transfer agreement with the prior operator of each acquired operation as part of each transaction. The addition of these operations added a total of 143 operational senior living units to be operated by the Company’s independent operating subsidiaries. The aggregate purchase price for these acquisitions was $18,780. Acquisition costs related to the business combinations of home health, hospice, and home care was $611 during the year ended December 31, 2019.
2018 Acquisitions

During the year ended December 31, 2018, the Company expanded its operations with the addition of four home health agencies, two hospice agencies, two home care agencies and seven senior living operations. The Company did not acquire any material assets or assume any liabilities other than the tenant’s post-assumption rights and obligations under the senior living long-term leases. The aggregate purchase price for these acquisitions during the year ended December 31, 2018 was $5,318. The addition of these operations added a total of 386 operational senior living units to be operated by the Company’s independent operating subsidiaries. Typically, subsidiaries of the Company entered into a separate operations transfer agreement with the prior operator as part of each transaction. The Company did not incur acquisition costs related to business combinations during the year ended December 31, 2018.

The fair value of assets for home health and hospice acquisitions was mostly concentrated in goodwill and as such, these transactions were classified as business combinations in accordance with ASC Topic 805, Business Combinations (“ASC 805”). The table below presents the allocation of the purchase price for the operations acquired in business combinations during the years ended December 31, 2020, 2019 and 2018 as noted above:

Year Ended December 31,
202020192018
Equipment, furniture, and fixtures$174 $91 $15 
Goodwill25,211 10,341 2,872 
Other indefinite-lived intangible assets14,026 8,326 1,838 
Other Assets— — 
Liabilities Assumed(172)— — 
    Total acquisitions$39,239 $18,760 $4,725 
Less: noncontrolling interest and additional paid in capital(a)
(4,646)— — 
Total cash paid for acquisitions(b)
$34,593 $18,760 $4,725 

(a)Consists of the of noncontrolling interest related to Scripps contribution of assets to the joint venture.
(b)
Total cash paid for acquisitions for the year ended December 31, 2020 includes $1,400 that was recorded as an escrow deposit at December 31, 2019.

Unaudited Pro Forma Financial Information

The Company’s acquisition strategy has been focused on identifying both opportunistic and strategic acquisitions within its target markets that offer strong opportunities for return. The independent operating subsidiaries acquired by the Company are frequently underperforming financially and can have regulatory and clinical challenges to overcome. From time to time, these acquisitions are more strategic in nature that may or may not have positive operational results. Financial information, especially with underperforming independent operating subsidiaries, is often inadequate, inaccurate or unavailable. Consequently, the Company believes that prior operating results are not a meaningful representation of the Company’s current operating results or indicative of the integration potential of its newly acquired independent operating subsidiaries. Revenue and income before tax included in the consolidated and combined statement of income relating to the business combinations was $17,676 and $750, respectively, during the year ended December 31, 2020.

The following tables represent unaudited pro forma results of consolidated and combined operations as if the business combinations in fiscal year 2020 had occurred at the beginning of 2019, after giving effect to certain adjustments. The unaudited pro forma information is not indicative of what the results of operations would have been if the acquisitions had actually occurred at the beginning of the periods presented and is not intended as a projection of future results or trends.
Unaudited Pro Forma Data

Years Ended December 31,
20202019
Revenue$424,805 $396,468 
Net income attributable to The Pennant Group, Inc.(a)
13,784 1,277 

(a)
Net income attributable to The Pennant Group, Inc. for the year ended December 31, 2020 and 2019 includes a tax impact of 25.0% and 25.2%, which are the respective statutory tax rates.

The unaudited pro forma financial information has been included for the businesses combinations during the year ended December 31, 2020. The acquisitions during the year ended December 31, 2020 have been included in the December 31, 2020 consolidated balance sheets of the Company, and the operating results have been included in the consolidated and combined statements of income of the Company since the dates the Company gained effective control.

Revenues and operating costs were based on actual results from the prior operator or from regulatory filings where available. If actual results were not available, revenues and operating costs were estimated based on available partial operating results of the prior operator of the operation, or if no information was available, estimates were derived from the Company’s post-acquisition operating results for that particular operation.

The unaudited pro forma information is not indicative of what the results of operations would have been if the business combinations had actually occurred at the beginning of the periods presented and is not intended as a projection of future results or trends.

Subsequent Events

Subsequent to December 31, 2020, the Company acquired two home health agencies and two hospice agencies. The aggregate purchase price for these acquisitions was $3,625. As of the date of this report, the preliminary allocation of the purchase price for the acquisitions acquired subsequent to December 31, 2020 were not completed as necessary valuation information was not yet available. As such, the determination whether these acquisitions should be classified as business combinations or asset acquisitions under ASC 805 will be determined upon completion of the allocation of the purchase price.
XML 30 R14.htm IDEA: XBRL DOCUMENT v3.20.4
PROPERTY AND EQUIPMENT—NET
12 Months Ended
Dec. 31, 2020
Property, Plant and Equipment [Abstract]  
Property and equipment - net PROPERTY AND EQUIPMENT—NET
Property and equipment, net consist of the following:

Year Ended December 31,
20202019
Leasehold improvements$9,984 $6,621 
Equipment22,420 18,930 
Furniture and fixtures1,186 877 
33,590 26,428 
Less: accumulated depreciation(15,706)(11,784)
Property and equipment, net$17,884 $14,644 
Depreciation expense was $4,661, $3,757 and $2,863 for the years ended December 31, 2020, 2019 and 2018, respectively.
XML 31 R15.htm IDEA: XBRL DOCUMENT v3.20.4
GOODWILL AND INTANGIBLE ASSETS - NET
12 Months Ended
Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and intangible assets - net GOODWILL AND INTANGIBLE ASSETS—NET The Company tests goodwill during the fourth quarter of each year and also if events or changes in circumstances indicate the occurrence of a triggering event which might indicate there may be impairment. The Company performs its goodwill impairment analysis for each reporting unit that constitutes a component for which (1) discrete financial information is available and (2) segment management regularly reviews the operating results of that component, in accordance with the provisions of ASC Topic 350, Intangibles-Goodwill and Other (“ASC 350”).
The Company reviews goodwill for impairment by initially considering qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill, as a basis for determining whether it is necessary to perform a quantitative analysis. If it is determined that it is more likely than not that the fair value of reporting unit is less than its carrying amount, a quantitative analysis is performed to identify goodwill impairment. If it is determined that it is not more likely than not that the fair value of the reporting unit is less than its carrying amount, it is unnecessary to perform a quantitative analysis. The Company may elect to bypass the qualitative assessment and proceed directly to performing a quantitative analysis. Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value. An impairment loss is recognized for the amount that the carrying amount of the reporting unit, including goodwill, exceeds its fair value, limited to the total amount of goodwill allocated to that reporting unit. The Company did not identify any impairment charge during the years ended December 31, 2020, 2019 and 2018.

The following table represents activity in goodwill by segment as of and for the year ended December 31, 2020:

Home Health and Hospice ServicesSenior Living ServicesTotal
December 31, 2018$27,250 $3,642 $30,892 
Additions10,341 — 10,341 
December 31, 201937,591 3,642 41,233 
Additions25,211 — 25,211 
December 31, 2020$62,802 $3,642 $66,444 

Other indefinite-lived intangible assets consist of the following:

Year Ended December 31,
20202019
Trade name$1,355 $355 
Medicare and Medicaid licenses46,133 33,107 
Total$47,488 $33,462 
XML 32 R16.htm IDEA: XBRL DOCUMENT v3.20.4
OTHER ACCRUED LIABILITIES
12 Months Ended
Dec. 31, 2020
Payables and Accruals [Abstract]  
OTHER ACCRUED LIABILITIES OTHER ACCRUED LIABILITIES
Other accrued liabilities consist of the following:

December 31, 2020December 31, 2019
Refunds payable$2,664 $2,152 
Deferred revenue1,271 1,937 
Resident deposits5,647 6,292 
Contract Liabilities (CARES Act advance payments)22,771 — 
Property taxes982 1,130 
Accrued insurance retention - current portion1,354 — 
Other3,586 2,400 
Other accrued liabilities$38,275 $13,911 

Refunds payable includes payables related to overpayments, duplicate payments and credit balances from various payor sources. Deferred revenue occurs when the Company receives payments in advance of services provided. Resident deposits include refundable deposits to residents and a small portion consists of non-refundable deposits recognized into revenue over a period of time. The CARES Act also expanded the Centers for Medicare & Medicaid Services’ (“CMS”) ability to provide accelerated/advance payments intended to increase the cash flow of healthcare providers and suppliers impacted by COVID-19. During the second quarter the Company applied for and received $27,997 in funds under the AAP Program. On October 1, 2020, the Continuing Appropriations Act, 2021 and Other Extensions Act (the “CA Act”) was signed into law.
Among other things, the CA Act significantly changed the repayment terms for AAP. These funds are subject to automatic recoupment through offsets to new claims beginning one year after funds were issued beginning in April 2021, at which time, Medicare will automatically recoup 25 percent of Medicare payments for 11 months. At the end of the 11 months and assuming full repayment has not occurred, recoupment will increase to 50 percent for another six months. Any balance outstanding after these two recoupment periods will be subject to repayment at a four percent interest rate. The Company anticipates completing repayment of the AAP within the allotted recoupment periods. As a result of the recoupment guidance, the Company reclassified $5,226 of the AAP to other long-term liabilities.
XML 33 R17.htm IDEA: XBRL DOCUMENT v3.20.4
DEBT
12 Months Ended
Dec. 31, 2020
Debt Disclosure [Abstract]  
DEBT DEBT
Long-term debt, net consists of the following:
Year Ended December 31,
20202019
Revolving Credit Facility$9,500 $20,000 
Less: unamortized debt issuance costs(1,223)(1,474)
Long-term debt, net$8,277 $18,526 

On October 1, 2019, Pennant entered into a credit agreement (the “Credit Agreement”), which provided for a revolving credit facility (the “2019 Revolving Credit Facility”) with a syndicate of banks with a borrowing capacity of $75,000. The interest rates applicable to loans under the 2019 Revolving Credit Facility were, at the Company’s election, either (i) Adjusted LIBOR (as defined in the Credit Agreement) plus a margin ranging from 2.5% to 3.5% per annum or (ii) Base Rate plus a margin ranging from 1.5% to 2.5% per annum, in each case based on the ratio of Consolidated Total Net Debt to Consolidated EBITDA (each, as defined in the Credit Agreement). In addition, Pennant paid a commitment fee on the undrawn portion of the commitments under the 2019 Revolving Credit Facility that of approximately 0.6% per annum. The Company is not required to repay any loans under the Credit Agreement prior to maturity in 2024, other than to the extent the outstanding borrowings exceed the aggregate commitments under the Credit Agreement. As of December 31, 2020, the Company’s weighted average interest rate on its outstanding debt was 4.75%. As of December 31, 2020, we had availability on the 2019 Revolving Credit Facility of $62,164, which is net of outstanding letters of credit of $3,336.

The fair value of the 2019 Revolving Credit Facility approximates carrying value, due to the short-term nature and variable interest rates. The fair value of this debt is categorized within Level 2 of the fair value hierarchy based on the observable market borrowing rates.

The Credit Agreement is guaranteed, jointly and severally, by certain of the Company’s wholly owned subsidiaries, and is secured by a pledge of stock of the Company's material independent operating subsidiaries as well as a first lien on substantially all of each material operating subsidiary's personal property. The Credit Agreement contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its independent operating subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend certain material agreements and pay certain dividends and other restricted payments. Financial covenants require compliance with certain levels of leverage ratios that impact the amount of interest. As of December 31, 2020, the Company was compliant with all covenants.

Subsequent Events

On February 23, 2021, Pennant entered into an amendment to the Credit Agreement (the “Amended Credit Agreement”), which provides for a revolving credit facility (the “2021 Revolving Credit Facility”) with a syndicate of banks with a borrowing capacity of $150,000. The interest rates applicable to loans under the 2021 Revolving Credit Facility are, at the Company’s election, either (i) Adjusted LIBOR (as defined in the Amended Credit Agreement) plus a margin ranging from 2.3% to 3.3% per annum or (ii) Base Rate plus a margin ranging from 1.3% to 2.3% per annum, in each case based on the ratio of Consolidated Total Net Debt to Consolidated EBITDA (each, as defined in the Amended Credit Agreement). In addition, Pennant will pay a commitment fee on the undrawn portion of the commitments under the Revolving Credit Facility that will range from 0.35% to 0.50% per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio of the Company and its subsidiaries. The Company is not required to repay any loans under the Amended Credit Agreement prior to maturity in 2026.
XML 34 R18.htm IDEA: XBRL DOCUMENT v3.20.4
OPTIONS AND AWARDS
12 Months Ended
Dec. 31, 2020
Share-based Payment Arrangement [Abstract]  
Options and awards OPTIONS AND AWARDS
For all periods prior to the Spin-Off, employees of the Company participated in Ensign's share-based compensation plans. The compensation expense recorded by the Company included the expense associated with these employees, as well as an allocation of share-based compensation of certain Ensign employees who provided general and administrative services on our behalf.

Outstanding options held by employees of the Company under the Ensign stock plans (collectively the “Ensign Plans”) and outstanding options and restricted stock awards under the Company Subsidiary Equity Plan (together with the Ensign Plans the “Pre-Spin Plans”) were modified and replaced with Pennant awards under the Pennant Plans at the Spin-Off date. Additionally, in connection with the Spin-Off, the Company issued new options and restricted stock awards to Pennant and Ensign employees under the 2019 Omnibus Incentive Plan (the OIP) and Long-Term Incentive Plan (the LTIP”, together referred to as the “Pennant Plans”).

Under the Ensign Plans and the Pennant Plans, share-based payment awards, including employee stock options, restricted stock awards (“RSA”), and restricted stock units (“RSU” and together with RSA, “Restricted Stock”) are issued based on estimated fair value. The following disclosures represent share-based compensation expense relating to the Ensign and Pennant Plans, including awards to employees of the Company’s subsidiaries and an allocation of costs from employees in the Service Center prior to the Spin-Off, and total share-based compensation after the Spin-Off.

Total share-based compensation expense for all of the Plans for the years ended December 31, 2020, 2019 and 2018:

Year Ended December 31,
202020192018
Prior to the Spin-Off:
Total share-based compensation$— $1,395 $2,382 
Following the Spin-Off:
Share-based compensation expense related to stock options1,660 315 — 
Share-based compensation expense related to Restricted Stock6,200 1,589 — 
Share-based compensation expense related to Restricted Stock to non-employee directors475 83 — 
Total share-based compensation$8,335 $3,382 $2,382 

In future periods, the Company estimates it will recognize the following share-based compensation expense for unvested stock options and unvested Restricted Stock, which were unvested as of December 31, 2020:

Unrecognized Compensation ExpenseWeighted Average Recognition Period (in years)
Unvested stock options$10,055 4.3
Unvested Restricted Stock10,956 1.8
Total unrecognized share-based compensation expense$21,011 

Stock Options

Under the Pennant Plans, options granted to employees of the subsidiaries of Pennant generally vest over five years at 20% per year on the anniversary of the grant date. Options expire ten years after the date of grant.

The Company uses the Black-Scholes option-pricing model to recognize the value of share-based compensation expense for share-based payment awards under the Plans. Determining the appropriate fair-value model and calculating the fair value of share-based awards at the grant date requires considerable judgment, including estimating stock price volatility and
expected option life. The Company develops estimates based on historical data and market information, which can change significantly over time.

The fair value of each option is estimated on the grant date using a Black-Scholes option-pricing model with the following weighted average assumptions for stock options granted after the Spin-Off:

Grant YearOptions GrantedRisk-Free Interest Rate
Expected Life(a)
Expected Volatility(b)
Dividend YieldWeighted Average Fair Value of Options
2020693 0.5 %6.535.9 %— %$11.05 
2019667 1.6 %6.534.6 %— %$5.70 

(a)
Under the midpoint method, the expected option life is the midpoint between the contractual option life and the average vesting period for the options being granted. This resulted in an expected option life of 6.5 years for the options granted.
(b)Because the Company’s equity shares have been traded for a relatively short period of time, expected volatility assumption was based on the volatility of related industry stocks.

The following table represents the employee stock option activity during the year ended December 31, 2020:

Number of
Options
Outstanding
Weighted
Average
Exercise Price
Number of
Options Vested
Weighted
Average
Exercise Price
of Options
Vested
December 31, 20191,573 $9.71 607 $4.80 
Granted693 $30.44 
Exercised(239)$4.77 
Forfeited(36)$14.34 
Expired(9)$6.24 
December 31, 20201,982 $17.48 615 $7.52 

The aggregate intrinsic value of options outstanding, vested, unvested and exercised as of and for the period ended December 31, 2020 is as follows:
OptionsDecember 31, 2020
Outstanding$80,456 
Vested31,077 
Unvested49,379 
Exercised8,002 
The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the options. There were 1,367 unvested and outstanding options at December 31, 2020. The weighted average contractual life for options outstanding, vested and expected to vest at December 31, 2020 was 7.83 years.
Restricted Stock Awards

Under the Pennant Plans, the Company granted Restricted Stock to Pennant employees, Ensign employees, and to non-employee directors. All awards generally vest between three to five years. A summary of the status of Pennant’s non-vested Restricted Stock, and changes during the period ended December 31, 2020, is presented below:
Non-Vested Restricted AwardsWeighted Average Grant Date Fair Value
December 31, 20191,793 $14.44 
Granted29 26.84 
Vested(176)13.27 
Forfeited(11)10.92 
December 31, 20201,635 $14.80 
XML 35 R19.htm IDEA: XBRL DOCUMENT v3.20.4
LEASES
12 Months Ended
Dec. 31, 2020
Leases [Abstract]  
Leases LEASES
The Company’s independent operating subsidiaries lease 54 senior living communities and its administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from five to 21 years. Most of these leases contain renewal options, most involve rent increases and none contain purchase options. The lease term excludes lease renewals because the renewal rents are not at a bargain, there are no economic penalties for the Company to renew the lease, and it is not reasonably certain that the Company will exercise the extension options. As of December 31, 2020, the Company’s independent operating subsidiaries leased 31 communities from subsidiaries of Ensign (“Ensign Leases”) under a master lease arrangement. The existing leases with subsidiaries of Ensign are for initial terms of between 14 to 20 years. In addition to rent, each of the operating companies are required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all community maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties.
Fifteen of the Company’s affiliated senior living communities, excluding the communities that are operated under the Ensign Leases (as defined herein), are operated under two separate master lease arrangements. Under these master leases, a breach at a single community could subject one or more of the other communities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company’s leases and master leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the master lease without the consent of the landlord.

The components of operating lease cost, are as follows:

Year Ended December 31,
20202019
Operating Lease Costs:
Facility Rent—cost of services$35,562 $32,011 
Office Rent—cost of services3,772 2,964 
Sublease income(143)— 
Rent—cost of services$39,191 $34,975 
General and administrative expense$295 $162 
Variable lease cost(a)
$5,330 $4,608 

(a)
Represents variable lease cost for operating leases, which costs include property taxes and insurance, common area maintenance, and consumer price index increases, incurred as part of our triple net lease, and which is included in cost of services for the years ended December 31, 2020 and 2019.

Rent expense for operating leases classified under Topic 840 for the year ended December 31, 2018 was $31,199.
The following table shows the lease maturity analysis for all leases as of December 31, 2020:

YearAmount
2021$38,393 
202237,730 
202337,038 
202436,230 
202535,349 
Thereafter356,838 
Total lease payments541,578 
Less: present value adjustments(230,857)
Present value of total lease liabilities310,721 
Less: current lease liabilities(14,106)
Long-term operating lease liabilities$296,615 

Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at each lease’s commencement date to determine each lease's operating lease liability. As of December 31, 2020, the weighted average remaining lease term is 15.0 years and the weighted average discount rate is 8.2%.
XML 36 R20.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES
12 Months Ended
Dec. 31, 2020
Income Tax Disclosure [Abstract]  
Income taxes INCOME TAXES
The provision for income taxes for the years ended December 31, 2020, 2019 and 2018 is summarized as follows:

Year Ended December 31,
202020192018
Current:
Federal$5,058 $562 $3,223 
State1,478 278 915 
Total current6,536 840 4,138 
Deferred:
Federal(3,348)1,070 226 
State(838)175 (12)
Total deferred(4,186)1,245 214 
Total income tax expense$2,350 $2,085 $4,352 
A reconciliation of the federal statutory rate to the effective tax rate for income from continuing operations for the years ended December 31, 2020, 2019 and 2018, respectively, is comprised as follows:

Year Ended December 31,
202020192018
Income tax expense at statutory rate21.0 %21.0 %21.0 %
State income taxes - net of federal benefit2.7 6.8 3.5 
Non-deductible expenses0.4 2.6 0.4 
Transaction costs(a)
— 41.2 — 
Tax credits— (1.6)— 
Equity compensation(b)
(10.8)(30.0)(2.9)
Revaluation of deferred— — (0.2)
Other adjustments(0.2)(0.4)(0.7)
Total income tax provision13.1 %39.6 %21.1 %

(a)
The Company's completion of the Spin-Off in the year ended December 31, 2019 resulted in the Company not being able to deduct approximately $10,300 of the related transaction costs, which increased the effective tax rate significantly and affected all items that were impacted by this exclusion.
(b)
During the year ended December 31, 2020, employees exercised stock options representing approximately 239 shares. During the year ended December 31, 2019, employees exercised stock options representing approximately 100 shares and had restricted stock awards vest representing 960 shares. These exercises and vestings resulted in tax benefits that reduced the Company's effective tax rate significantly in both years.

Prior to the date of the Spin-Off, the Company's operations were included in Ensign’s U.S. federal and state income tax returns and all income taxes were paid by subsidiaries of Ensign. Additionally, prior to the date of the Spin-Off, income tax expense and other income tax related information contained in these Consolidated and Combined Financial Statements were presented on a separate tax return approach. Under this approach, the provision for income taxes represents income tax paid or payable for the current year plus the change in deferred taxes during the year calculated as if the Company were a stand-alone taxpayer filing hypothetical income tax returns. Management believes that the assumptions and estimates used to determine these tax amounts were reasonable. However, the Company's Consolidated and Combined Financial Statements may not necessarily reflect the Company’s income tax expense or tax payments in the future, or what its tax amounts would have been if the Company had been a stand-alone company during the periods presented.

Effective January 1, 2018, the Tax Cuts and Jobs Act of 2017 (“Tax Act”) reduced the corporate rate from 35.0% to 21.0%. The Company adopted ASU 2018-05, Taxes (Topic 740): Amendments to SEC Paragraph Pursuant to SEC Staff Accounting Bulletin No. 118. As of December 31, 2018, the Company had completed its accounting for the tax effects of the enactment of the Tax Act.

The Company recorded prepaid expenses for income taxes for the year ended December 31, 2020 and for the income tax returns the Company filed for the three month period from October 1, 2019 through December 31, 2019.
The Company’s deferred tax assets and liabilities for the years ended December 31, 2020 and 2019 are summarized below.

Year Ended December 31,
 20202019
Deferred tax assets (liabilities):
Accrued expenses$8,181 $2,670 
Allowance for doubtful accounts875 869 
State taxes147 27 
Lease liabilities80,979 83,076 
Insurance277 137 
Gross deferred tax assets90,459 86,779 
Less: valuation allowance(15)— 
Net deferred tax assets90,444 86,779 
Depreciation and amortization(7,512)(6,107)
Prepaid expenses(780)(594)
Right of use asset(80,055)(82,181)
Total deferred tax liabilities(88,347)(88,882)
Net deferred tax assets (liabilities)$2,097 $(2,103)

For the year ended December 31, 2019, the Company included the net deferred tax liability in other long-term liabilities on it Consolidated Balance Sheets.

During the year ended December 31, 2020, the Company utilized all of its net operating loss ("NOL") carryforwards for federal income tax purposes. As of December 31, 2020, the Company has $500 of NOL carryforwards in various states, which are available to reduce future state taxable income, if any. Some of the state NOL carryforwards do not expire while others, if not utilized, will expire in the year ending December 31, 2039.

The Company believes that it is more likely than not that the benefit from certain state NOL carryforwards will not be realized. In recognition of this risk, as of December 31, 2020, the Company has provided a valuation allowance of $15 on the deferred tax assets related to these state NOL carryforwards.

The federal statutes of limitations on the Company’s 2016, 2015, and 2014 income tax years lapsed during the third quarter of 2020, 2019, and 2018, respectively. During the fourth quarter of each year, various state statutes of limitations also lapsed. The lapses for the years ended December 31, 2020 and 2019 had no impact on the Company’s unrecognized tax benefits.
For the years ended December 31, 2020 and 2019, the Company did not have any unrecognized tax benefits, net of their state benefits that would affect the Company’s effective tax rate. The Company classifies interest and/or penalties on income tax liabilities or refunds as additional income tax expense or income. Such amounts are not material.
XML 37 R21.htm IDEA: XBRL DOCUMENT v3.20.4
COMMITMENTS AND CONTINGENCIES
12 Months Ended
Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIESRegulatory Matters - The Company provides services in complex and highly regulated industries. The Company’s compliance with applicable federal, state and local laws and regulations governing these industries may be subject to governmental review and adverse findings may result in significant regulatory action, which could include sanctions, damages, fines, penalties (many of which may not be covered by insurance), and even exclusion from government programs. The Company is a party to various regulatory and other governmental audits and investigations in the ordinary course of business and cannot predict the ultimate outcome of any federal or state regulatory survey, audit or investigation. While governmental audits and investigations are the subject of administrative appeals, the appeals process, even if successful, may take several years to resolve. The Department of Justice, The Centers for Medicare and Medicaid Services (“CMS”), or other federal and state enforcement and regulatory agencies may conduct additional investigations related to the Company's businesses. The Company believes that it is presently in compliance in all material respects with all applicable laws and regulations.
Cost-Containment Measures - Government and third party payors have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect the Company.

Indemnities - From time to time, the Company enters into certain types of contracts that contingently require the Company to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which the Company may be required to indemnify property owners or prior operators for post-transfer environmental or other liabilities and other claims arising from the Company’s use of the applicable premises, (ii) operations transfer agreements, in which the Company agrees to indemnify past operators of agencies and communities the Company acquires against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer, (iii) certain Ensign lending agreements, and (iv) certain agreements with management, directors and employees, under which the subsidiaries of the Company may be required to indemnify such persons for liabilities arising out of their employment relationships. The terms of such obligations vary by contract and, in most instances, a specific or maximum dollar amount is not explicitly stated therein. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on the Company’s combined balance sheets for any of the periods presented.

Litigation - The Company’s businesses involve a significant risk of liability given the age and health of the patients and residents served by its independent operating subsidiaries. The Company, its operating companies, and others in the industry may be subject to a number of claims and lawsuits, including professional liability claims, alleging that services provided have resulted in personal injury, elder abuse, wrongful death or other related claims. Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and the Company is routinely subjected to these claims in the ordinary course of business, including potential claims related to patient care and treatment, professional negligence and class actions, as well as employment related claims. If there were a significant increase in the number of these claims or an increase in amounts owing should plaintiffs be successful in their prosecution of these claims, this could materially adversely affect the Company’s business, financial condition, results of operations and cash flows. In addition, the defense of these lawsuits may result in significant legal costs, regardless of the outcome, and can result in large settlement amounts or damage awards.

In addition to the potential lawsuits and claims described above, the Company is also subject to potential lawsuits under the False Claims Act (the “FCA”) and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare) or payor. A violation may provide the basis for exclusion from federally funded healthcare programs. Such exclusions could have a correlative negative impact on the Company’s financial performance. Some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. In addition, the Deficit Reduction Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the FCA. As such, the Company could face increased scrutiny, potential liability and legal expenses and costs based on claims under state false claims acts in markets in which it does conduct business.

In May 2009, Congress passed the Fraud Enforcement and Recovery Act ("FERA") which made significant changes to the FCA, expanding the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, healthcare providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government, including the retention of any government overpayment. The Patient Protection and Affordable Care Act of 2010 (the “ACA”) supplemented FERA by imposing an affirmative obligation on healthcare providers to return an overpayment to CMS within 60 days of “identification” or the date any corresponding cost report is due, whichever is later. According to CMS’s February 12, 2016, final rule with respect to Medicare Parts A and B, providers have an obligation to proactively exercise “reasonable diligence” to identify overpayments. The 60-day clock begins to run after the reasonable diligence period has concluded, which may take, at most, six months from the receipt of credible information. Retention of any overpayment beyond this period may create liability under the FCA. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, there is generally no need for an employment relationship in order to qualify for protection against retaliation for whistleblowing.

The Company cannot predict or provide any assurance as to the possible outcome of any litigation. If any litigation were to proceed, and the Company and its operating companies are subjected to, alleged to be liable for, or agree to a settlement of, claims or obligations under federal Medicare statutes, the FCA, or similar state and federal statutes and related regulations, the Company’s business, financial condition and results of operations and cash flows could be materially and adversely
affected. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged civil violations, and may also include the assumption of specific procedural and financial obligations by the Company or its independent operating subsidiaries going forward under a corporate integrity agreement and/or other arrangement with the government.

Medicare Revenue Recoupments - The Company is subject to probe reviews relating to Medicare services, billings and potential overpayments by Unified Program Integrity Contractors (UPIC), Recovery Audit Contractors (RAC), Zone Program Integrity Contractors (ZPIC), Program Safeguard Contractors (PSC), Supplemental Medical Review Contractors (SMRC) and Medicaid Integrity Contributors (MIC) programs, each of the foregoing collectively referred to as “Reviews.” As of December 31, 2020, seven of the Company’s independent operating subsidiaries had Reviews scheduled, on appeal or in dispute resolution process, both pre- and post-payment. The Company anticipates that these probe reviews will increase in frequency in the future. If an operation fails an initial or subsequent Review, the operation could then be subject to extended Review, suspension of payment, or extrapolation of the identified error rate to all billing in the same time period. As of December 31, 2020, and through the filing of this Annual Report on Form 10-K, the Company’s independent operating subsidiaries have responded to the Reviews that are currently ongoing, on appeal or in dispute resolution process and the Company has no probable or estimable contingencies.

Concentrations

Credit Risk - The Company has significant accounts receivable balances, the collectability of which is dependent on the availability of funds from certain governmental programs, primarily Medicare and Medicaid. These receivables represent the only significant concentration of credit risk for the Company. The Company does not believe there are significant credit risks associated with these governmental programs. The Company believes that an appropriate allowance has been recorded for the possibility of these receivables proving uncollectible, and continually monitors and adjusts these allowances as necessary. The Company’s gross receivables from the Medicare and Medicaid programs accounted for approximately 75.7% and 74.3% of its total gross accounts receivable as of December 31, 2020 and December 31, 2019, respectively. Revenue from reimbursement under the Medicare and Medicaid programs accounted for 60.1%, 55.6%, and 53.1% of the Company's revenue for the years ended December 31, 2020, 2019 and 2018, respectively.
XML 38 R22.htm IDEA: XBRL DOCUMENT v3.20.4
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
Basis of Presentation Basis of Presentation - The accompanying consolidated and combined financial statements of the Company (the “Financial Statements”) reflect the Company’s financial position, results of operations and cash flows as the business was operated as part of Ensign prior to the Spin-Off, and have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and pursuant to the regulations of the Securities and Exchange Commission (“SEC”). Prior to the Spin-Off, the combined financial statements were prepared on a stand-alone basis and derived from the consolidated financial statements and accounting records of Ensign. Management believes that the Financial Statements reflect, in all material respects, all adjustments which are of a normal and recurring nature necessary to present fairly the Company’s financial position, results of operations, and cash flows for the periods presented in conformity with GAAP applicable to the annual period.
Consolidation All intercompany transactions and balances between the various legal entities comprising the Company have been eliminated in consolidation. The consolidated and combined statements of income reflect income that is attributable to the Company and the noncontrolling interest. The Company consists of various limited liability companies and corporations established to operate home health, hospice, home care, and senior living operations. The Financial Statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest. Revenue was derived from transactional information specific to the Company’s services provided. The costs in the consolidated and combined statements of income reflect direct costs and allocated costs prior to the Spin-Off.
Estimates and Assumptions Estimates and Assumptions - The preparation of the Financial Statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Financial Statements relate to revenue, cost allocations from prior to the Spin-Off, intangible assets and goodwill, right-of-use assets and lease liabilities for leases greater than 12 months, self-insurance reserves, and income taxes. Actual results could differ from those estimates.
Revenue Recognition Revenue Recognition - Revenues are recognized when services are provided to the patients at the amount that reflects the consideration to which the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net service revenue in the period such variances become known.Revenues are recognized when services are provided to the patients or residents at the amount that reflects the consideration to which the Company expects to be entitled from patients, residents and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care or senior living residence. The healthcare services in home health and hospice patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as
services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct within the context of the contract. Additionally, there may be ancillary services which are not included in the rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered.

Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net service revenue in the period such variances become known.

Revenue from the Medicare and Medicaid programs accounted for 60.1%, 55.6%, and 53.1% of the Company’s revenue for the years ended December 31, 2020, 2019 and 2018, respectively. The Company records revenue from these governmental and managed care programs as services are performed at their expected net realizable amounts under these programs. The Company’s revenue from governmental and managed care programs is subject to audit and retroactive adjustment by governmental and third-party agencies. Consistent with healthcare industry accounting practices, any changes to these governmental revenue estimates are recorded in the period the change or adjustment becomes known based on final settlement.

Disaggregation of Revenue

The Company disaggregates revenue from contracts with its patients or residents by reportable operating segments and payors. The Company has determined that disaggregating revenue into these categories achieves the disclosure objectives to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. A reconciliation of disaggregated revenue to segment revenue as well as revenue by payor is provided in below.

The Company’s service specific revenue recognition policies are as follows:

Home Health Revenue

Medicare Revenue

For Medicare episodes that began after January 1, 2020, net service revenue is recognized in accordance with the Patient Driven Groupings Model (“PDGM”). This new reimbursement structure involves case mix calculation methodology refinements, changes to low-utilization payment adjustment (“LUPA”) thresholds, the elimination of therapy thresholds, a change to the unit of payment from a 60-day episode to a 30-day payment period, and reduction of requests for anticipated payments (“RAPs”) to 20% of the estimated payment for a patient’s initial or subsequent period of care up-front (after the initial assessment is completed and upon initial billing). The RAPs will be completely phased out effective January 1, 2021. Under PDGM, Medicare provides agencies with payments for each 30-day payment period provided to beneficiaries. If a beneficiary is still eligible for care after the end of the first 30-day payment period, a second 30-day payment period can begin. There are no limits to the number of periods of care a beneficiary who remains eligible for the home health benefit can receive. While payment for each 30-day payment period is adjusted to reflect the beneficiary’s health condition and needs, a special outlier provision exists to ensure appropriate payment for those beneficiaries that have the most expensive care needs. The payment under the Medicare program is also adjusted for certain variables including, but not limited to: (a) a LUPA if the number of visits is below an established threshold that varies based on the diagnosis of a beneficiary; (b) a partial payment if the patient transferred to another provider or the Company received a patient from another provider before completing the period of care; (c) adjustment to the admission source of claim if it is determined that the patient had a qualifying stay in a post-acute care setting within 14 days prior to the start of a 30-day payment period; (d) the timing of the 30-day payment period provided to a patient in relation to the admission date, regardless of whether the same home health provider provided care for the entire series of episodes; (e) changes to the acuity of the patient during the previous 30-day payment period; (f) changes in the base payments established by the Medicare program; (g) adjustments to the base payments for case mix and geographic wages; and (h) recoveries of overpayments.
For all episodes that began prior to January 1, 2020, net service revenue was recorded under the Medicare prospective payment system based on a 60-day episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a) an outlier payment if the patient’s care was unusually costly; (b) a LUPA if the number of visits was fewer than five; (c) a partial payment if the patient transferred to another provider or transferred from another provider before completing the episode; (d) a payment adjustment based upon the level of covered therapy services; (e) the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (f) changes in the base episode payments established by the Medicare program; (g) adjustments to the base episode payments for case mix and geographic wages; and (h) recoveries of overpayments.

The Company adjusts Medicare revenue on completed episodes to reflect differences between estimated and actual payment amounts, an inability to obtain appropriate billing documentation and other reasons unrelated to credit risk. Therefore, the Company believes that its reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered.

In addition to revenue recognized on completed episodes and periods, the Company also recognizes a portion of revenue associated with episodes and periods in progress. Episodes in progress are 30-day payment periods, if the episode started after January 1, 2020, or 60-day episodes of care, if the episode started prior to January 1, 2020, that begin during the reporting period but were not completed as of the end of the period. As such, the Company estimates revenue and recognizes it on a daily basis. The primary factors underlying this estimate are the number of episodes in progress at the end of the reporting period, expected Medicare revenue per period of care or episode of care and the Company’s estimate of the average percentage complete based on the scheduled end of period and end of episode dates.

Non-Medicare Revenue

Episodic Based Revenue - The Company recognizes revenue in a similar manner as it recognizes Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms.

Non-episodic Based Revenue - Revenue is recognized on an accrual basis based upon the date of service at amounts equal to its established or estimated per visit rates, as applicable.

Hospice Revenue

Revenue is recognized on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are calculated as daily rates for each of the levels of care the Company delivers. Revenue is adjusted for an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. Additionally, as Medicare hospice revenue is subject to an inpatient cap and an overall payment cap, the Company monitors its provider numbers and estimates amounts due back to Medicare if a cap has been exceeded. The Company regularly evaluates and records these adjustments as a reduction to revenue and an increase to other accrued liabilities.

Senior Living Revenue

The Company has elected the lessor practical expedient within ASC Topic 842, Leases (“ASC 842”) and therefore recognizes, measures, presents, and discloses the revenue for services rendered under the Company’s senior living residency agreements based upon the predominant component, either the lease or non-lease component, of the contracts. The Company has determined that the services included under the Company’s senior living residency agreements each have the same timing and pattern of transfer. The Company recognizes revenue under ASC Topic 606, Revenue from Contracts with Customers for its senior residency agreements, for which it has determined that the non-lease components of such residency agreements are the predominant component of each such contract.
The Company’s senior living revenue consists of fees for basic housing and assisted living care. Accordingly, we record revenue when services are rendered on the date services are provided at amounts billable to individual residents. Residency agreements are generally for a term of 30 days, with resident fees billed monthly in advance. For residents under reimbursement arrangements with Medicaid, revenue is recorded based on contractually agreed-upon amounts or rates on a per resident, daily basis or as services are rendered.
Practical Expedients and Exemptions

As the Company’s contracts have an original duration of one year or less, the Company uses the practical expedient applicable to its contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of the end of each reporting period or when the Company expects to recognize this revenue. In addition, the Company has applied the practical expedient provided by ASC 340, Other Assets and Deferred Costs (“ASC 340”), and all incremental customer contract acquisition costs are expensed as they are incurred because the amortization period would have been one year or less.
Cash and Cash Equivalents Cash - Cash consists of petty cash and bank term deposits and therefore approximates fair value. The Company places its cash with high credit quality financial institutions. Prior to the Spin-off the Company participated in a cash management program with Ensign where net cash activity was included in the net parent investment.
Accounts Receivable and Allowance for Doubtful Accounts Accounts Receivable and Allowance for Doubtful Accounts - Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration. Subsequent to our adoption of ASU 2016-13, as noted below, the allowance for doubtful accounts is the Company’s best estimate of current expected credit losses in the accounts receivable balance.
Property and Equipment Property and Equipment - Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three to 15 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.
Impairment of Long-Lived Assets Impairment of Long-Lived Assets - The Company reviews the carrying value of long-lived assets that are held and used in the independent operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiary to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset.
Goodwill and Intangible Assets
Intangible Assets and Goodwill - Definite-lived intangible assets consist primarily of patient base and customer relationships. Patient base is amortized over a period of four months to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition when acquired. Customer relationships are amortized between one to seven years depending on the significance of the relationships.

The Company’s indefinite-lived intangible assets consist of trade names and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable. The Company did not identify any asset impairment during the years ended December 31, 2020, 2019 and 2018.
Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to annual test for impairment as of the beginning of the fourth quarter or more frequently if events or changes indicate that the Company's goodwill might be impaired. The Company assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company determines it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then it is required to perform a quantitative impairment test by comparing the fair value with the carrying amount of the reporting unit. If the carrying amount of a reporting unit exceeds its fair value, then the Company records an impairment of goodwill equal to the amount that the carrying amount of a reporting unit exceeds its fair value.

As of December 31, 2020, we evaluated potential triggering events that might be indicators that our goodwill and indefinite lived intangibles were impaired. No goodwill or intangible asset impairments were recorded during the years ended December 31, 2020, 2019 and 2018. See further discussion at Note 9, Goodwill and Intangible Assets, Net.
Fair Value of Financial Instruments Fair Value of Financial Instruments - The Company’s financial instruments consist principally of cash, accounts receivable, accounts payable and accrued liabilities. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations. The Company determines fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.
Income Taxes Income Taxes - Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences
are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized.

In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.
Noncontrolling Interest Noncontrolling Interest - The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income/ (loss) attributable to The Pennant Group, Inc. in its consolidated and combined statements of income. Net income per share is calculated based on net income/ (loss) attributable to The Pennant Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest.
Share-Based Compensation Share-Based Compensation -The Company measures and recognizes compensation expense for all share-based payment awards, including employee stock options, made to employees and Pennant’s directors based on estimated fair values, ratably over the requisite service period of the award. The Company accounts for forfeitures as they occur. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables.
Recent Accounting Pronouncements
Prior to Spin-Off

Cost Allocation - The Financial Statements include allocations of costs for certain shared services provided to the Company by Ensign subsidiaries prior to the Spin-Off on October 1, 2019. Such allocations include, but are not limited to, executive management, accounting, human resources, information technology, compliance, legal, payroll, insurance, tax, treasury, and other general and administrative items. These costs were allocated to the Company on a basis of revenue, location, employee count, or other measures. These cost allocations are reflected within general and administrative expense in the consolidated and combined statements of income, including for share-based compensation expenses disclosed in Note 12, Options and Awards. The amount of general and administrative costs allocated from January 1, 2019 to October 1, 2019, the date of the Spin-Off, inclusive of share-based compensation expense, was $23,710. Management believes the basis on which the expenses were allocated to be a reasonable reflection of the services provided to the Company during the periods.

Insurance - Prior to the Spin-Off Ensign was partially self-insured for healthcare, general and professional liability, and workers’ compensation, and historically allocated premium expense to all subsidiaries of Ensign in its accounting records. To reflect all of the insurance costs, quarterly actuary determined adjustments were allocated to the Company based on the proportional historical premium expense. No self-insurance accruals were allocated to the Company as these accruals represent the obligations of Ensign. In connection with the Spin-Off, the Company purchased insurance through a third-party to replace the coverage provided by Ensign’s self-insured policies.

Debt - Ensign’s external debt and related interest expense were not allocated to the Company for any of the periods presented as no portion of the borrowings were assumed by the Company as part of the Spin-Off. All interest incurred by the Company was subsequent to the Spin-Off.

Income Taxes - Prior to the date of the Spin-off, the Company’s operations have been included in Ensign’s U.S. federal and state income tax returns and all income taxes have been paid by subsidiaries of Ensign. Also prior to the date of the Spin-off, income tax expense and other income tax related information contained in these Financial Statements were presented using a separate tax return approach. Under this approach, the provision for income taxes represents income tax paid or payable for the current year plus the change in deferred taxes during the year calculated as if the Company was a stand-alone taxpayer filing hypothetical income tax returns. Management believes that the assumptions and estimates used to determine these tax amounts are reasonable. However, the Company’s Financial Statements may not necessarily reflect its income tax expense or tax
payments in the future, or what tax amounts would have been if the Company had been a stand-alone company for the entire period presented.

Invested Capital - The net parent investment on the consolidated balance sheets represents Ensign’s historical investment in the Company, the net effect of transactions with, and allocations from, Ensign and the Company’s accumulated earnings. Invested capital was reclassified into additional paid-in-capital at the date of the Spin-Off.

Noncontrolling Interest - Prior to the Spin-Off, the Company presented the noncontrolling interest and the amount of consolidated net income/ (loss) attributable to the Company in its Financial Statements. The carrying amount of the noncontrolling interest was adjusted by an allocation of subsidiary earnings based on ownership interest prior to the Spin-Off. The noncontrolling subsidiary interest included in the Financial Statements was converted into common shares of Pennant concurrent with the distribution to Ensign stockholders at the date of the Spin-Off and thus, will no longer be allocated a portion of earnings.

Share-based compensation - Prior to the Spin-Off, employees of the Company’s subsidiaries participated in Ensign’s equity-based incentive plans (the “Ensign Plans”) and the Cornerstone Subsidiary Equity plan (the “Subsidiary Equity Plan”). Share-based compensation includes the expense attributable to employees of the Company’s subsidiaries who participated in the Ensign Plans, as well as the allocated cost related to Ensign subsidiaries’ employees that participated in the Ensign Plans. Share-based compensation related to Ensign subsidiaries’ employees that participated in the Ensign Plans were allocated on the basis of revenue. All share-based compensation related to the Subsidiary Equity Plan was recognized in the Financial Statements and, therefore, no cost allocation was necessary.

Prior to the Spin-Off, share-based compensation costs associated with the Subsidiary Equity Plan awards was initially measured at fair value at the grant date and was expensed as non-cash compensation over the vesting term. Historically, these awards were granted once per year and the fair value has been determined by an independent valuation of the subsidiary shares. The valuation incorporated a discounted cash flow analysis combined with a market-based approach to determine the fair value of the subsidiary equity.

Earnings Per Share - For the year ended December 31, 2018, the earnings per share included on the accompanying Consolidated and Combined Statements of Income was calculated based on the 27,834 shares of Pennant common stock distributed on October 1, 2019 in conjunction with the Spin-Off, including shares related to the conversion of the noncontrolling interest. Prior to October 1, 2019, Pennant did not have any issued and outstanding common stock. The same number of shares was used to calculate basic and diluted earnings per share since no Pennant employee equity awards were outstanding prior to the Spin-Off. In connection with the Spin-Off, shares of existing equity awards were replaced with shares under the new Pennant awards and are reflected in basic and diluted net income per share for the years ended December 31, 2020 and 2019, respectively. For further discussion see Note 4, Computation of Net Income Per Common Share

Recent Accounting Standards Adopted by the Company

Except for rules and interpretive releases of the SEC under authority of federal securities laws and a limited number of grandfathered standards, the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management and certain standards are under consideration.

FASB Accounting Standards Update, or ASU, ASU 2020-04 “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” or ASU 2020-4 - In March 2020, the FASB concluded its reference rate reform project and issued this ASU. The amendments in this ASU provide optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in this ASU apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The optional expedients and exceptions are available for all entities as of March 12, 2020, through December 31, 2022. The Company has adopted ASU 2020-04, effective March 12, 2020. The impact of this ASU will be determined based on terms of any future contract modification related to a change in reference rate, including future modifications to the Company’s Revolving Credit Facility described in further detail in Note 11, Debt.
FASB ASU, 2018-15, “Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract” or ASU 2018-15. The update helps entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement (hosting arrangement), by providing guidance in determining when the arrangement includes a software license. It requires entities to account for such costs consistent with the guidance on capitalizing costs associated with developing or obtaining internal-use software. The Company has adopted ASU 2018-15, effective January 1, 2020. There was no material impact to the Company’s Financial Statements or disclosures.

FASB ASU, 2018-13 “Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement” or ASU 2018-13 - In August 2018, the FASB issued amended guidance to simplify fair value measurement disclosure requirements. The new provisions eliminate the requirements to disclose (1) transfers between Level 1 and Level 2 of the fair value hierarchy, (2) policies related to valuation processes and the timing of transfers between levels of the fair value hierarchy, and (3) net asset value disclosure of estimates of timing of future liquidity events. The FASB also modified disclosure requirements of Level 3 fair value measurements. The Company adopted ASU 2018-13 as of January 1, 2020. There was no material impact to the Company’s Financial Statements or disclosures.

FASB ASU, 2017-04 “Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” or ASU 2017-04 - In January 2017, the FASB issued amended authoritative guidance to simplify and reduce the cost and complexity of the goodwill impairment test. The new guidance eliminates “Step 2” from the traditional two-step goodwill impairment test and redefines the concept of impairment from a measure of loss when comparing the implied fair value of goodwill to its carrying amount, to a measure comparing the fair value of a reporting unit with its carrying amount. The FASB also eliminated the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment or “Step 2” of the goodwill impairment test. The new guidance does not amend the optional qualitative assessment of goodwill impairment. The Company adopted ASU 2017-04 as of January 1, 2020. There was no material impact to the Company’s Financial Statements or disclosures.
FASB ASU 2016-13 “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” or ASU 2016-13 - In June 2016, the FASB issued ASU 2016-13, which replaced the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected to be collected. The Company adopted ASU 2016-13 as of January 1, 2020. There was no material impact to the Company’s Financial Statements or related disclosures.
Invested Capital Invested Capital - The net parent investment on the consolidated balance sheets represents Ensign’s historical investment in the Company, the net effect of transactions with, and allocations from, Ensign and the Company’s accumulated earnings. Invested capital was reclassified into additional paid-in-capital at the date of the Spin-Off.
Earnings Per Share
Basic and diluted net income per share are computed by dividing net income by the weighted average number of outstanding common shares during the period. In the basic and diluted earnings per share calculations, net income is equal to net income attributable to The Pennant Group, Inc.

Prior to Spin-Off
Net income attributable to the noncontrolling interest has been included in the numerator for the years ended December 31, 2019 and 2018, respectively, as the non-controlling subsidiary interest that existed prior to the Spin-Off was converted into common shares of Pennant concurrent with the distribution to Ensign stockholders at the date of the Spin-Off.
XML 39 R23.htm IDEA: XBRL DOCUMENT v3.20.4
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
Summary of insurance liability
The following table presents details of the Company's insurance programs, including amounts accrued for the periods indicated in other accrued liabilities and other long-term liabilities in our accompanying balance sheets. The amounts accrued below represent the total estimated liability for individual claims that are less than our noted insurance coverage amounts, which includes outstanding claims and claims incurred but not reported. The amounts are reported gross of reinsurance receivable of $704 and zero included in restricted and other assets for the years ended December 31, 2020 and 2019, respectively.

Year Ended December 31,
20202019
Type of Insurance
General and professional liability $1,063 $521 
Workers’ compensation2,783 433 
Total estimated liability3,846 954 
Less: long-term portion, included in other long-term liabilities(2,492)(774)
Current portion of estimated liability, included in other accrued liabilities$1,354 $180 
XML 40 R24.htm IDEA: XBRL DOCUMENT v3.20.4
COMPUTATION OF NET INCOME PER COMMON SHARE (Tables)
12 Months Ended
Dec. 31, 2020
Earnings Per Share [Abstract]  
Computation of basic and diluted net income per share
The following table sets forth the computation of basic and diluted net income per share for the periods presented:


Year Ended December 31,
 202020192018
Numerator:
Net income$15,553 $3,175 $16,279 
Add: net (loss)/ income attributable to noncontrolling interests(191)629 595 
Net income attributable to The Pennant Group, Inc.$15,744 $2,546 $15,684 
Denominator:
Weighted average shares outstanding for basic net income per share(a)
28,029 27,838 27,834 
Plus: incremental shares from assumed conversion(b)
2,199 1,748 — 
Adjusted weighted average common shares outstanding for diluted income per share30,228 29,586 27,834 
Earnings Per Share:
Basic net income per common share(c)
$0.56 $0.11 $0.58 
Diluted net income per common share(c)
$0.52 $0.11 $0.58 

(a)
Concurrent with the Spin-Off the noncontrolling subsidiary interest converted into 1,160 shares of Pennant. The total number of common shares distributed on October 1, 2019 of 27,834 was utilized in the denominator for the calculation of basic and diluted earnings per share for the year ended December 31, 2018 , as no common stock was outstanding prior to the date of the Spin-Off.
(b)
The calculation of dilutive shares outstanding excludes out-of-the-money stock options (i.e., such options’ exercise prices were greater than the average market price of our common shares for the period) because their inclusion would have been antidilutive. Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were 93 and 15 for the years ended December 31, 2020 and 2019, respectively.
(c)
For the years ended December 31, 2019 and 2018 basic and diluted earnings per share were calculated based on net income as the numerator, which included the conversion of the noncontrolling interest in connection with the Spin-Off. For the year ended December 31, 2020, basic and diluted earnings per share was calculated based on net income attributable to The Pennant Group, Inc. as the numerator, . See Note 7, Acquisitions, for further information on our acquisitions for the year ended December 31, 2020.
XML 41 R25.htm IDEA: XBRL DOCUMENT v3.20.4
REVENUE AND ACCOUNTS RECEIVABLE (Tables)
12 Months Ended
Dec. 31, 2020
Revenue from Contract with Customer [Abstract]  
Revenue by major payor source
Revenue by payor for the years ended December 31, 2020, 2019 and 2018, is summarized in the following tables:

Year Ended December 31, 2020
Home Health and Hospice Services
Home Health ServicesHospice ServicesSenior Living ServicesTotal RevenueRevenue %
Medicare$58,399 $119,873 $— $178,272 45.6 %
Medicaid7,645 12,462 36,780 56,887 14.5 
Subtotal66,044 132,335 36,780 235,159 60.1 
Managed care31,572 1,546 — 33,118 8.5 
Private and other(a)
21,968 194 100,514 122,676 31.4 
Total revenue$119,584 $134,075 $137,294 $390,953 100.0 %

(a)Private and other payors in our home health and hospice services segment includes revenue from all payors generated in our home care operations.


Year Ended December 31, 2019
Home Health and Hospice Services
Home Health ServicesHospice ServicesSenior Living ServicesTotal RevenueRevenue %
Medicare$47,819 $93,933 $— $141,752 41.9 %
Medicaid6,575 10,061 29,819 46,455 13.7 
Subtotal54,394 103,994 29,819 188,207 55.6 
Managed care27,711 1,536 — 29,247 8.6 
Private and other(a)
18,837 152 102,088 121,077 35.8 
Total revenue$100,942 $105,682 $131,907 $338,531 100.0 %

(a)Private and other payors in our home health and hospice services segment includes revenue from all payors generated in our home care operations.

Year Ended December 31, 2018
Home Health and Hospice Services
Home Health ServicesHospice ServicesSenior Living ServicesTotal RevenueRevenue %
Medicare$42,091 $73,906 $— $115,997 40.5 %
Medicaid4,680 7,729 23,624 36,033 12.6 
Subtotal46,771 81,635 23,624 152,030 53.1 
Managed care23,541 918 — 24,459 8.6 
Private and other(a)
16,067 105 93,397 109,569 38.3 
Total revenue$86,379 $82,658 $117,021 $286,058 100.0 %

(a)Private and other payors in our home health and hospice services segment includes revenue from all payors generated in our home care operations.
Schedule of accounts receivable
Accounts receivable as of December 31, 2020 and December 31, 2019 is summarized in the following table:

December 31, 2020December 31, 2019
Medicare$28,569 $17,822 
Medicaid7,669 6,579 
Managed care7,590 4,380 
Private and other4,036 4,079 
Accounts receivable, gross47,864 32,860 
Less: allowance for doubtful accounts(643)(677)
Accounts receivable, net$47,221 $32,183 
Allowance for doubtful accounts
The following table summarizes the activity for our allowance for doubtful accounts for the years ended years ended December 31, 2020, 2019 and 2018:

Year Ended December 31,
202020192018
Balance at beginning of period$677 $616 $5,058 
Impact of ASC 606 Adoption(a)
— — (4,590)
Additions to bad debt expense560 858 346 
Write-offs of uncollectible accounts(594)(797)(198)
Balance at end of period$643 $677 $616 

(a)
Subsequent to the adoption of ASC 606, the majority of what was previously presented as allowance for doubtful accounts related to bad debt expense has been incorporated as an implicit price concession factored into net revenue and accounts receivable. Allowance for doubtful accounts as of December 31, 2020 represents the Company’s best estimate of probable losses inherent in the accounts receivable balance based on known troubled accounts and other currently available evidence.
XML 42 R26.htm IDEA: XBRL DOCUMENT v3.20.4
BUSINESS SEGMENTS (Tables)
12 Months Ended
Dec. 31, 2020
Segment Reporting [Abstract]  
Financial data combined by business segment
The following table presents certain financial information regarding our reportable segments, general and administrative expenses are not allocated to the reportable segments and are included in “All Other” for the years ended December 31, 2020, 2019 and 2018:
Home Health and Hospice ServicesSenior Living ServicesAll OtherTotal
Year Ended December 31, 2020
Revenue$253,659 $137,294 $— $390,953 
Segment Adjusted EBITDAR from Operations$49,501 $48,309 $(22,762)$75,048 
Year Ended December 31, 2019
Revenue$206,624 $131,907 $— $338,531 
Segment Adjusted EBITDAR from Operations$33,354 $47,344 $(18,591)$62,107 
Year Ended December 31, 2018
Revenue$169,037 $117,021 $— $286,058 
Segment Adjusted EBITDAR from Operations$26,427 $47,230 $(16,191)$57,466 
Reconciliation of total Combined Adjusted EBITDAR from Operations for our reportable segments to Combined Income from Operations
Year Ended December 31,
202020192018
Segment Adjusted EBITDAR from Operations$75,048 $62,107 $57,466 
Less: Depreciation and amortization4,675 3,810 2,964 
Rent—cost of services39,191 34,975 31,199 
Other income225 — — 
Adjustments to Segment EBITDAR from Operations:
Less: Costs at start-up operations(a)
1,787 483 129 
Share-based compensation expense(b)
8,335 3,382 2,382 
Acquisition related costs(c)
99 665 — 
Spin-off related transaction costs(d)
— 13,219 756 
Transition services costs(e)
1,181 532 — 
COVID-19 Related costs and supplies(f)
447 — — 
Add: Net income/ (loss) attributable to noncontrolling interest(191)629 595 
Consolidated and Combined Income from operations$18,917 $5,670 $20,631 

(a)Represents results related to start-up operations. This amount excludes rent and depreciation and amortization expense related to such operations.
(b)Share-based compensation expense incurred which is included in cost of services and general and administrative expense.
(c)Acquisition related costs that are not capitalizable.
(d)Costs incurred related to the Spin-Off are included in general and administrative expense.
(e)
A portion of the costs incurred under the Transition Services Agreement (as defined in Note 3, Related Party Transactions and Net Parent Investment) identified as redundant or nonrecurring that are included in general and administrative expense. Transition service costs includes $446 of duplicative software expense for the year ended December 31, 2020, of which $333 pertains to the first three quarters of the fiscal year and were not included as adjustments in previous interim periods. Fees incurred under the Transition Services agreement, net of the Company’s payroll reimbursement, were $5,536, $2,982, and zero for the years ended December 31, 2020, 2019 and 2018, respectively.
(f)
Represents incremental costs incurred as part of the Company's response to COVID-19 including direct medical supplies, labor, and other expenses, net of $2,765 in increased revenue related to the 2% payment increase in Medicare reimbursements for sequestration relief for the year ended December 31, 2020.
XML 43 R27.htm IDEA: XBRL DOCUMENT v3.20.4
ACQUISITIONS (Tables)
12 Months Ended
Dec. 31, 2020
Business Combinations [Abstract]  
Schedule of operations acquired in business combinations The table below presents the allocation of the purchase price for the operations acquired in business combinations during the years ended December 31, 2020, 2019 and 2018 as noted above:
Year Ended December 31,
202020192018
Equipment, furniture, and fixtures$174 $91 $15 
Goodwill25,211 10,341 2,872 
Other indefinite-lived intangible assets14,026 8,326 1,838 
Other Assets— — 
Liabilities Assumed(172)— — 
    Total acquisitions$39,239 $18,760 $4,725 
Less: noncontrolling interest and additional paid in capital(a)
(4,646)— — 
Total cash paid for acquisitions(b)
$34,593 $18,760 $4,725 

(a)Consists of the of noncontrolling interest related to Scripps contribution of assets to the joint venture.
(b)
Total cash paid for acquisitions for the year ended December 31, 2020 includes $1,400 that was recorded as an escrow deposit at December 31, 2019.
Unaudited pro forma results of condensed combined operations
Years Ended December 31,
20202019
Revenue$424,805 $396,468 
Net income attributable to The Pennant Group, Inc.(a)
13,784 1,277 

(a)
Net income attributable to The Pennant Group, Inc. for the year ended December 31, 2020 and 2019 includes a tax impact of 25.0% and 25.2%, which are the respective statutory tax rates.
XML 44 R28.htm IDEA: XBRL DOCUMENT v3.20.4
PROPERTY AND EQUIPMENT—NET (Tables)
12 Months Ended
Dec. 31, 2020
Property, Plant and Equipment [Abstract]  
Schedule of property and equipment, net
Property and equipment, net consist of the following:

Year Ended December 31,
20202019
Leasehold improvements$9,984 $6,621 
Equipment22,420 18,930 
Furniture and fixtures1,186 877 
33,590 26,428 
Less: accumulated depreciation(15,706)(11,784)
Property and equipment, net$17,884 $14,644 
XML 45 R29.htm IDEA: XBRL DOCUMENT v3.20.4
GOODWILL AND INTANGIBLE ASSETS - NET (Tables)
12 Months Ended
Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
Activity in goodwill by segment
The following table represents activity in goodwill by segment as of and for the year ended December 31, 2020:

Home Health and Hospice ServicesSenior Living ServicesTotal
December 31, 2018$27,250 $3,642 $30,892 
Additions10,341 — 10,341 
December 31, 201937,591 3,642 41,233 
Additions25,211 — 25,211 
December 31, 2020$62,802 $3,642 $66,444 
Other indefinite-lived intangible assets
Other indefinite-lived intangible assets consist of the following:

Year Ended December 31,
20202019
Trade name$1,355 $355 
Medicare and Medicaid licenses46,133 33,107 
Total$47,488 $33,462 
XML 46 R30.htm IDEA: XBRL DOCUMENT v3.20.4
OTHER ACCRUED LIABILITIES (Tables)
12 Months Ended
Dec. 31, 2020
Payables and Accruals [Abstract]  
Schedule of other accrued liabilities
Other accrued liabilities consist of the following:

December 31, 2020December 31, 2019
Refunds payable$2,664 $2,152 
Deferred revenue1,271 1,937 
Resident deposits5,647 6,292 
Contract Liabilities (CARES Act advance payments)22,771 — 
Property taxes982 1,130 
Accrued insurance retention - current portion1,354 — 
Other3,586 2,400 
Other accrued liabilities$38,275 $13,911 
XML 47 R31.htm IDEA: XBRL DOCUMENT v3.20.4
DEBT (Tables)
12 Months Ended
Dec. 31, 2020
Debt Disclosure [Abstract]  
Schedule of long-term debt
Long-term debt, net consists of the following:
Year Ended December 31,
20202019
Revolving Credit Facility$9,500 $20,000 
Less: unamortized debt issuance costs(1,223)(1,474)
Long-term debt, net$8,277 $18,526 
XML 48 R32.htm IDEA: XBRL DOCUMENT v3.20.4
OPTIONS AND AWARDS (Tables)
12 Months Ended
Dec. 31, 2020
Share-based Payment Arrangement [Abstract]  
Total share-based compensation expense
Total share-based compensation expense for all of the Plans for the years ended December 31, 2020, 2019 and 2018:

Year Ended December 31,
202020192018
Prior to the Spin-Off:
Total share-based compensation$— $1,395 $2,382 
Following the Spin-Off:
Share-based compensation expense related to stock options1,660 315 — 
Share-based compensation expense related to Restricted Stock6,200 1,589 — 
Share-based compensation expense related to Restricted Stock to non-employee directors475 83 — 
Total share-based compensation$8,335 $3,382 $2,382 

In future periods, the Company estimates it will recognize the following share-based compensation expense for unvested stock options and unvested Restricted Stock, which were unvested as of December 31, 2020:

Unrecognized Compensation ExpenseWeighted Average Recognition Period (in years)
Unvested stock options$10,055 4.3
Unvested Restricted Stock10,956 1.8
Total unrecognized share-based compensation expense$21,011 
Stock options granted fair value assumptions
The fair value of each option is estimated on the grant date using a Black-Scholes option-pricing model with the following weighted average assumptions for stock options granted after the Spin-Off:

Grant YearOptions GrantedRisk-Free Interest Rate
Expected Life(a)
Expected Volatility(b)
Dividend YieldWeighted Average Fair Value of Options
2020693 0.5 %6.535.9 %— %$11.05 
2019667 1.6 %6.534.6 %— %$5.70 

(a)
Under the midpoint method, the expected option life is the midpoint between the contractual option life and the average vesting period for the options being granted. This resulted in an expected option life of 6.5 years for the options granted.
(b)Because the Company’s equity shares have been traded for a relatively short period of time, expected volatility assumption was based on the volatility of related industry stocks.
Employee stock option activity
The following table represents the employee stock option activity during the year ended December 31, 2020:

Number of
Options
Outstanding
Weighted
Average
Exercise Price
Number of
Options Vested
Weighted
Average
Exercise Price
of Options
Vested
December 31, 20191,573 $9.71 607 $4.80 
Granted693 $30.44 
Exercised(239)$4.77 
Forfeited(36)$14.34 
Expired(9)$6.24 
December 31, 20201,982 $17.48 615 $7.52 
Aggregate intrinsic value of options outstanding, vested, expected to vest and exercisable
The aggregate intrinsic value of options outstanding, vested, unvested and exercised as of and for the period ended December 31, 2020 is as follows:
OptionsDecember 31, 2020
Outstanding$80,456 
Vested31,077 
Unvested49,379 
Exercised8,002 
Summary of non-vested restricted stock awards A summary of the status of Pennant’s non-vested Restricted Stock, and changes during the period ended December 31, 2020, is presented below:
Non-Vested Restricted AwardsWeighted Average Grant Date Fair Value
December 31, 20191,793 $14.44 
Granted29 26.84 
Vested(176)13.27 
Forfeited(11)10.92 
December 31, 20201,635 $14.80 
XML 49 R33.htm IDEA: XBRL DOCUMENT v3.20.4
LEASES (Tables)
12 Months Ended
Dec. 31, 2020
Leases [Abstract]  
Components of operating lease cot
The components of operating lease cost, are as follows:

Year Ended December 31,
20202019
Operating Lease Costs:
Facility Rent—cost of services$35,562 $32,011 
Office Rent—cost of services3,772 2,964 
Sublease income(143)— 
Rent—cost of services$39,191 $34,975 
General and administrative expense$295 $162 
Variable lease cost(a)
$5,330 $4,608 

(a)
Represents variable lease cost for operating leases, which costs include property taxes and insurance, common area maintenance, and consumer price index increases, incurred as part of our triple net lease, and which is included in cost of services for the years ended December 31, 2020 and 2019.

Rent expense for operating leases classified under Topic 840 for the year ended December 31, 2018 was $31,199.
Future minimum lease payments
The following table shows the lease maturity analysis for all leases as of December 31, 2020:

YearAmount
2021$38,393 
202237,730 
202337,038 
202436,230 
202535,349 
Thereafter356,838 
Total lease payments541,578 
Less: present value adjustments(230,857)
Present value of total lease liabilities310,721 
Less: current lease liabilities(14,106)
Long-term operating lease liabilities$296,615 
XML 50 R34.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES (Tables)
12 Months Ended
Dec. 31, 2020
Income Tax Disclosure [Abstract]  
Provision for income taxes on continuing operations
The provision for income taxes for the years ended December 31, 2020, 2019 and 2018 is summarized as follows:

Year Ended December 31,
202020192018
Current:
Federal$5,058 $562 $3,223 
State1,478 278 915 
Total current6,536 840 4,138 
Deferred:
Federal(3,348)1,070 226 
State(838)175 (12)
Total deferred(4,186)1,245 214 
Total income tax expense$2,350 $2,085 $4,352 
Reconciliation of federal statutory rate to effective tax rate
A reconciliation of the federal statutory rate to the effective tax rate for income from continuing operations for the years ended December 31, 2020, 2019 and 2018, respectively, is comprised as follows:

Year Ended December 31,
202020192018
Income tax expense at statutory rate21.0 %21.0 %21.0 %
State income taxes - net of federal benefit2.7 6.8 3.5 
Non-deductible expenses0.4 2.6 0.4 
Transaction costs(a)
— 41.2 — 
Tax credits— (1.6)— 
Equity compensation(b)
(10.8)(30.0)(2.9)
Revaluation of deferred— — (0.2)
Other adjustments(0.2)(0.4)(0.7)
Total income tax provision13.1 %39.6 %21.1 %

(a)
The Company's completion of the Spin-Off in the year ended December 31, 2019 resulted in the Company not being able to deduct approximately $10,300 of the related transaction costs, which increased the effective tax rate significantly and affected all items that were impacted by this exclusion.
(b)
During the year ended December 31, 2020, employees exercised stock options representing approximately 239 shares. During the year ended December 31, 2019, employees exercised stock options representing approximately 100 shares and had restricted stock awards vest representing 960 shares. These exercises and vestings resulted in tax benefits that reduced the Company's effective tax rate significantly in both years.
Deferred tax assets and liabilities
The Company’s deferred tax assets and liabilities for the years ended December 31, 2020 and 2019 are summarized below.

Year Ended December 31,
 20202019
Deferred tax assets (liabilities):
Accrued expenses$8,181 $2,670 
Allowance for doubtful accounts875 869 
State taxes147 27 
Lease liabilities80,979 83,076 
Insurance277 137 
Gross deferred tax assets90,459 86,779 
Less: valuation allowance(15)— 
Net deferred tax assets90,444 86,779 
Depreciation and amortization(7,512)(6,107)
Prepaid expenses(780)(594)
Right of use asset(80,055)(82,181)
Total deferred tax liabilities(88,347)(88,882)
Net deferred tax assets (liabilities)$2,097 $(2,103)
For the
XML 51 R35.htm IDEA: XBRL DOCUMENT v3.20.4
DESCRIPTION OF BUSINESS (Details)
Dec. 31, 2020
agency
facility
Oct. 01, 2019
Segment Reporting Information [Line Items]    
Spin-off transaction, distribution ratio   0.50
Home Health and Hospice Services    
Segment Reporting Information [Line Items]    
Number of service providers | agency 76  
Senior Living Services    
Segment Reporting Information [Line Items]    
Number of properties under lease | facility 54  
XML 52 R36.htm IDEA: XBRL DOCUMENT v3.20.4
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)
shares in Thousands
9 Months Ended 12 Months Ended
Oct. 01, 2019
Oct. 01, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Jun. 30, 2020
Property, Plant and Equipment [Line Items]            
Contract Liabilities (CARES Act advance payments)     $ 22,771,000 $ 0   $ 27,997,000
Accrued payroll taxes employer portion     8,358,000      
Direct medical supplies, labor, and other expenses     2,765,000      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]            
Intangible asset impairments     0 0 $ 0  
General and professional liability, retention limit     150,000      
Out-of-pocket retention     500,000      
Workers' compensation, retention limit     250,000      
Share-based compensation   $ 1,395,000 8,335,000 3,382,000 2,382,000  
General and administrative expense   $ 23,710,000 $ 31,296,000 35,135,000 18,843,000  
Minimum            
Property, Plant and Equipment [Line Items]            
Property and equipment estimated useful lives     3 years      
Maximum            
Property, Plant and Equipment [Line Items]            
Property and equipment estimated useful lives     15 years      
General and administrative expense            
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]            
Share-based compensation     $ 7,222,000 $ 2,769,000 $ 1,900,000  
Customer Contracts | Minimum            
Finite-Lived Intangible Assets [Line Items]            
Amortization period     4 months      
Customer Contracts | Maximum            
Finite-Lived Intangible Assets [Line Items]            
Amortization period     8 months      
Customer Relationships | Minimum            
Finite-Lived Intangible Assets [Line Items]            
Amortization period     1 year      
Customer Relationships | Maximum            
Finite-Lived Intangible Assets [Line Items]            
Amortization period     7 years      
Common stock            
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]            
Shares issued (in shares) 27,834     27,834    
Other long-term liabilities            
Property, Plant and Equipment [Line Items]            
Accrued payroll taxes employer portion     $ 4,179,000      
XML 53 R37.htm IDEA: XBRL DOCUMENT v3.20.4
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - SUMMARY OF INSURANCE LIABILITY (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Accounting Policies [Abstract]    
Reinsurance receivables $ 704 $ 0
General and professional liability 1,063 521
Workers’ compensation 2,783 433
Total estimated liability 3,846 954
Less: long-term portion, included in other long-term liabilities (2,492) (774)
Current portion of estimated liability, included in other accrued liabilities $ 1,354 $ 180
XML 54 R38.htm IDEA: XBRL DOCUMENT v3.20.4
RELATED PARTY TRANSACTIONS AND NET PARENT INVESTMENT (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2020
USD ($)
property
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Recognition of tax benefits related to Tax Matters Agreement      
Related Party Transaction [Line Items]      
Amounts of related party transaction $ 578 $ 291  
Senior Living Services | Minimum      
Related Party Transaction [Line Items]      
Lease term 5 years    
Senior Living Services | Maximum      
Related Party Transaction [Line Items]      
Lease term 21 years    
Related party      
Related Party Transaction [Line Items]      
Cost of services $ 4,205 3,166 $ 2,996
Related party | Operating lease, rent expense      
Related Party Transaction [Line Items]      
Expenses from transactions with related party 12,536 11,292 $ 10,363
Related party | Transition Services Agreement      
Related Party Transaction [Line Items]      
Expenses from transactions with related party $ 5,536 $ 2,982  
Related party | Senior Living Services      
Related Party Transaction [Line Items]      
Number of operating facilities | property 31    
Related party | Senior Living Services | Minimum      
Related Party Transaction [Line Items]      
Lease term 14 years    
Related party | Senior Living Services | Maximum      
Related Party Transaction [Line Items]      
Lease term 20 years    
XML 55 R39.htm IDEA: XBRL DOCUMENT v3.20.4
COMPUTATION OF NET INCOME PER COMMON SHARE - RECONCILIATION (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]      
Net income $ 15,553 $ 3,175 $ 16,279
Add: Net income/ (loss) attributable to noncontrolling interest (191) 629 595
Net income attributable to The Pennant Group, Inc. $ 15,744 $ 2,546 $ 15,684
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]      
Weighted average shares outstanding for basic net income per share (in shares) 28,029 27,838 27,834
Plus: incremental shares from assumed conversion 2,199 1,748 0
Adjusted weighted average common shares outstanding for diluted income per share (in share) 30,228 29,586 27,834
Earnings Per Share, Basic and Diluted [Abstract]      
Basic net income per share (in dollars per share) $ 0.56 $ 0.11 $ 0.58
Diluted net income per share (in dollars per share) $ 0.52 $ 0.11 $ 0.58
XML 56 R40.htm IDEA: XBRL DOCUMENT v3.20.4
COMPUTATION OF NET INCOME PER COMMON SHARE - NARRATIVE (Details) - shares
12 Months Ended
Oct. 01, 2019
Dec. 31, 2020
Dec. 31, 2019
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]      
Options which are anti-dilutive and not factored into the weighted average common shares amount (in shares)   93,000 15,000
Common stock      
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]      
Shares issued (in shares) 27,834,000   27,834,000
Noncontrolling Interest Holders | Common stock      
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]      
Shares issued (in shares) 1,160,000    
XML 57 R41.htm IDEA: XBRL DOCUMENT v3.20.4
REVENUE AND ACCOUNTS RECEIVABLE - NARRATIVE (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Jun. 30, 2020
Disaggregation of Revenue [Line Items]        
Contract Liabilities (CARES Act advance payments) $ 22,771 $ 0   $ 27,997
Senior Living Services        
Disaggregation of Revenue [Line Items]        
Payment terms Residency agreements are generally for a term of 30 days, with resident fees billed monthly in advance. For residents under reimbursement arrangements with Medicaid, revenue is recorded based on contractually agreed-upon amounts or rates on a per resident, daily basis or as services are rendered.      
Customer concentration risk | Revenue        
Disaggregation of Revenue [Line Items]        
Revenue % 100.00% 100.00% 100.00%  
Customer concentration risk | Revenue | Subtotal        
Disaggregation of Revenue [Line Items]        
Revenue % 60.10% 55.60% 53.10%  
XML 58 R42.htm IDEA: XBRL DOCUMENT v3.20.4
REVENUE AND ACCOUNTS RECEIVABLE - REVENUE BY MAJOR PAYOR (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Disaggregation of Revenue [Line Items]      
Revenue $ 390,953 $ 338,531 $ 286,058
Revenue | Customer concentration risk      
Disaggregation of Revenue [Line Items]      
Revenue % 100.00% 100.00% 100.00%
Medicare      
Disaggregation of Revenue [Line Items]      
Revenue $ 178,272 $ 141,752 $ 115,997
Medicare | Revenue | Customer concentration risk      
Disaggregation of Revenue [Line Items]      
Revenue % 45.60% 41.90% 40.50%
Medicaid      
Disaggregation of Revenue [Line Items]      
Revenue $ 56,887 $ 46,455 $ 36,033
Medicaid | Revenue | Customer concentration risk      
Disaggregation of Revenue [Line Items]      
Revenue % 14.50% 13.70% 12.60%
Subtotal      
Disaggregation of Revenue [Line Items]      
Revenue $ 235,159 $ 188,207 $ 152,030
Subtotal | Revenue | Customer concentration risk      
Disaggregation of Revenue [Line Items]      
Revenue % 60.10% 55.60% 53.10%
Managed care      
Disaggregation of Revenue [Line Items]      
Revenue $ 33,118 $ 29,247 $ 24,459
Managed care | Revenue | Customer concentration risk      
Disaggregation of Revenue [Line Items]      
Revenue % 8.50% 8.60% 8.60%
Private and other      
Disaggregation of Revenue [Line Items]      
Revenue $ 122,676 $ 121,077 $ 109,569
Private and other | Revenue | Customer concentration risk      
Disaggregation of Revenue [Line Items]      
Revenue % 31.40% 35.80% 38.30%
Home Health and Hospice Services | Home Health Services      
Disaggregation of Revenue [Line Items]      
Revenue $ 119,584 $ 100,942 $ 86,379
Home Health and Hospice Services | Home Health Services | Medicare      
Disaggregation of Revenue [Line Items]      
Revenue 58,399 47,819 42,091
Home Health and Hospice Services | Home Health Services | Medicaid      
Disaggregation of Revenue [Line Items]      
Revenue 7,645 6,575 4,680
Home Health and Hospice Services | Home Health Services | Subtotal      
Disaggregation of Revenue [Line Items]      
Revenue 66,044 54,394 46,771
Home Health and Hospice Services | Home Health Services | Managed care      
Disaggregation of Revenue [Line Items]      
Revenue 31,572 27,711 23,541
Home Health and Hospice Services | Home Health Services | Private and other      
Disaggregation of Revenue [Line Items]      
Revenue 21,968 18,837 16,067
Home Health and Hospice Services | Hospice Services      
Disaggregation of Revenue [Line Items]      
Revenue 134,075 105,682 82,658
Home Health and Hospice Services | Hospice Services | Medicare      
Disaggregation of Revenue [Line Items]      
Revenue 119,873 93,933 73,906
Home Health and Hospice Services | Hospice Services | Medicaid      
Disaggregation of Revenue [Line Items]      
Revenue 12,462 10,061 7,729
Home Health and Hospice Services | Hospice Services | Subtotal      
Disaggregation of Revenue [Line Items]      
Revenue 132,335 103,994 81,635
Home Health and Hospice Services | Hospice Services | Managed care      
Disaggregation of Revenue [Line Items]      
Revenue 1,546 1,536 918
Home Health and Hospice Services | Hospice Services | Private and other      
Disaggregation of Revenue [Line Items]      
Revenue 194 152 105
Senior Living Services      
Disaggregation of Revenue [Line Items]      
Revenue 137,294 131,907 117,021
Senior Living Services | Medicare      
Disaggregation of Revenue [Line Items]      
Revenue 0 0 0
Senior Living Services | Medicaid      
Disaggregation of Revenue [Line Items]      
Revenue 36,780 29,819 23,624
Senior Living Services | Subtotal      
Disaggregation of Revenue [Line Items]      
Revenue 36,780 29,819 23,624
Senior Living Services | Managed care      
Disaggregation of Revenue [Line Items]      
Revenue 0 0 0
Senior Living Services | Private and other      
Disaggregation of Revenue [Line Items]      
Revenue $ 100,514 $ 102,088 $ 93,397
XML 59 R43.htm IDEA: XBRL DOCUMENT v3.20.4
REVENUE AND ACCOUNTS RECEIVABLE - ACCOUNTS RECEIVABLE (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Accounts Receivable [Abstract]    
Accounts receivable, gross $ 47,864 $ 32,860
Less: allowance for doubtful accounts (643) (677)
Accounts receivable, net 47,221 32,183
Medicare    
Accounts Receivable [Abstract]    
Accounts receivable, gross 28,569 17,822
Medicaid    
Accounts Receivable [Abstract]    
Accounts receivable, gross 7,669 6,579
Managed care    
Accounts Receivable [Abstract]    
Accounts receivable, gross 7,590 4,380
Private and other    
Accounts Receivable [Abstract]    
Accounts receivable, gross $ 4,036 $ 4,079
XML 60 R44.htm IDEA: XBRL DOCUMENT v3.20.4
REVENUE AND ACCOUNTS RECEIVABLE - ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Accounts, Notes, Loans and Financing Receivable [Line Items]      
Accounting Standards Update [Extensible List] us-gaap:AccountingStandardsUpdate201409Member    
Accounts Receivable, Allowance for Credit Loss [Roll Forward]      
Balance at beginning of period $ 677 $ 616 $ 5,058
Additions to bad debt expense 560 858 346
Write-offs of uncollectible accounts (594) (797) (198)
Balance at end of period 643 677 616
Revision of Prior Period, Accounting Standards Update, Adjustment      
Accounts Receivable, Allowance for Credit Loss [Roll Forward]      
Balance at beginning of period $ 0 0 (4,590)
Balance at end of period   $ 0 $ 0
XML 61 R45.htm IDEA: XBRL DOCUMENT v3.20.4
BUSINESS SEGMENTS - NARRATIVE (Details)
Dec. 31, 2020
agency
facility
Home Health and Hospice Services  
Segment Reporting Information [Line Items]  
Number of service providers | agency 76
Senior Living Services  
Segment Reporting Information [Line Items]  
Number of properties under lease | facility 54
XML 62 R46.htm IDEA: XBRL DOCUMENT v3.20.4
BUSINESS SEGMENTS - FINANCIAL DATA (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Segment Reporting Information [Line Items]      
Revenue $ 390,953 $ 338,531 $ 286,058
Segment Adjusted EBITDAR from Operations 75,048 62,107 57,466
Senior Living Services      
Segment Reporting Information [Line Items]      
Revenue 137,294 131,907 117,021
Operating segments | Home Health and Hospice Services      
Segment Reporting Information [Line Items]      
Revenue 253,659 206,624 169,037
Segment Adjusted EBITDAR from Operations 49,501 33,354 26,427
Operating segments | Senior Living Services      
Segment Reporting Information [Line Items]      
Revenue 137,294 131,907 117,021
Segment Adjusted EBITDAR from Operations 48,309 47,344 47,230
All Other      
Segment Reporting Information [Line Items]      
Revenue 0 0 0
Segment Adjusted EBITDAR from Operations $ (22,762) $ (18,591) $ (16,191)
XML 63 R47.htm IDEA: XBRL DOCUMENT v3.20.4
BUSINESS SEGMENTS - INCOME FROM OPERATIONS (Details) - USD ($)
$ in Thousands
9 Months Ended 12 Months Ended
Oct. 01, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Revenue, Major Customer [Line Items]              
Segment Adjusted EBITDAR from Operations   $ 75,048 $ 62,107 $ 57,466      
Less: Depreciation and amortization   4,675 3,810 2,964      
Rent—cost of services   39,191 34,975 31,199      
Other income   225 0 0      
Less: Costs at start-up operations   1,787 483 129      
Share-based compensation expense $ 1,395 8,335 3,382 2,382      
Acquisition related costs   99 665 0      
Spin-off related transaction costs   0 13,219 756      
Transaction services costs   1,181 532 0      
Incremental Costs, Direct Medical Supplies, Labor, and Other Expenses   447 0 0      
Add: Net income/ (loss) attributable to noncontrolling interest   (191) 629 595      
Consolidated and Combined Income from operations   18,917 5,670 $ 20,631      
Software expense   446          
Interim periods         $ 333 $ 333 $ 333
Direct medical supplies, labor, and other expenses   2,765          
Transition Services Agreement | Related party              
Revenue, Major Customer [Line Items]              
Expenses from transactions with related party   $ 5,536 $ 2,982        
XML 64 R48.htm IDEA: XBRL DOCUMENT v3.20.4
ACQUISITIONS - NARRATIVE (Details)
$ in Thousands
1 Months Ended 2 Months Ended 12 Months Ended
Oct. 31, 2020
USD ($)
Feb. 23, 2021
USD ($)
agency
Dec. 31, 2020
USD ($)
home_health_agency
senior_living_unit
stand-alone_senior_living_operation
hospice_agency
Dec. 31, 2019
USD ($)
senior_living_unit
home_health_agency
hospice_agency
home_care_agency
stand-alone_senior_living_operation
Dec. 31, 2018
USD ($)
hospice_agency
home_health_agency
senior_living_unit
home_care_agency
stand-alone_senior_living_operation
Business Acquisition [Line Items]          
Non-capitalizable     $ 99    
Noncontrolling interest     451    
Additional paid in capital     84,671 $ 74,882  
Business combination and asset acquisition, purchase price       18,780 $ 5,318
Business combination, acquisition costs     99 665 0
Revenue     17,676    
Net income (loss) before taxes     750    
Subsequent event          
Business Acquisition [Line Items]          
Business combination, purchase price   $ 3,625      
Scripps Health          
Business Acquisition [Line Items]          
Acquire interest in joint venture $ 6,200        
Net book value 614        
Noncontrolling interest 4,646        
Cash from sale of noncontrolling interest 555        
Noncontrolling interest to scripps 138        
Additional paid in capital 313        
Income tax effect $ 104        
Scripps Health | Home Health Joint Venture          
Business Acquisition [Line Items]          
Ownership interest 60.00%        
Scripps Health | Hospice Join Venture          
Business Acquisition [Line Items]          
Ownership interest 80.00%        
Series of Individually Immaterial Business Acquisitions          
Business Acquisition [Line Items]          
Total acquisitions     $ 39,239 18,760 $ 4,725
Business acquisitions 2019          
Business Acquisition [Line Items]          
Business combination, acquisition costs       $ 611  
Home Health Services | Subsequent event          
Business Acquisition [Line Items]          
Number of businesses acquired | agency   2      
Hospice Services | Subsequent event          
Business Acquisition [Line Items]          
Number of businesses acquired | agency   2      
Home Health and Hospice Services | Home Health Services          
Business Acquisition [Line Items]          
Number of businesses acquired and assets acquisitions | home_health_agency     6   4
Home Health and Hospice Services | Home Health Services | Business acquisitions 2019          
Business Acquisition [Line Items]          
Number of businesses acquired | home_health_agency       2  
Home Health and Hospice Services | Hospice Services          
Business Acquisition [Line Items]          
Number of businesses acquired and assets acquisitions | hospice_agency     6   2
Home Health and Hospice Services | Hospice Services | Business acquisitions 2019          
Business Acquisition [Line Items]          
Number of businesses acquired | hospice_agency       5  
Home Health and Hospice Services | Home Care | Asset acquisitions 2018          
Business Acquisition [Line Items]          
Number of businesses acquired and assets acquisitions | home_care_agency         2
Home Health and Hospice Services | Home Care | Business acquisitions 2019          
Business Acquisition [Line Items]          
Number of businesses acquired | home_care_agency       2  
Senior Living Services          
Business Acquisition [Line Items]          
Number of businesses acquired and assets acquisitions | stand-alone_senior_living_operation         7
Number of units (in units) | senior_living_unit     164 143 386
Senior Living Services | Asset Acquisitions 2020          
Business Acquisition [Line Items]          
Number of businesses acquired and assets acquisitions | stand-alone_senior_living_operation     2    
Senior Living Services | Asset acquisitions 2019          
Business Acquisition [Line Items]          
Number of asset acquisitions | stand-alone_senior_living_operation       2  
XML 65 R49.htm IDEA: XBRL DOCUMENT v3.20.4
ACQUISITIONS - OPERATIONS ACQUIRED (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2020
Dec. 31, 2018
Business Acquisition [Line Items]      
Goodwill $ 41,233 $ 66,444 $ 30,892
Total acquisitions 1,400    
Series of Individually Immaterial Business Acquisitions      
Business Acquisition [Line Items]      
Equipment, furniture, and fixtures 91 174 15
Goodwill 10,341 25,211 2,872
Other indefinite-lived intangible assets 8,326 14,026 1,838
Other Assets 2 0 0
Liabilities Assumed 0 (172) 0
Total acquisitions 18,760 39,239 4,725
Less: noncontrolling interest and additional paid in capital 0 (4,646) 0
Additional paid-in capital $ 18,760 $ 34,593 $ 4,725
XML 66 R50.htm IDEA: XBRL DOCUMENT v3.20.4
ACQUISITIONS - UNAUDITED PRO FORMA (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Business Acquisition, Pro Forma Information [Abstract]    
Revenue $ 424,805 $ 396,468
Net income attributable to The Pennant Group, Inc $ 13,784 $ 1,277
Statutory tax rate 25.00% 25.20%
XML 67 R51.htm IDEA: XBRL DOCUMENT v3.20.4
PROPERTY AND EQUIPMENT—NET (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Property, Plant and Equipment [Line Items]      
Property and equipment, gross $ 33,590 $ 26,428  
Less: accumulated depreciation (15,706) (11,784)  
Property and equipment, net 17,884 14,644  
Depreciation 4,661 3,757 $ 2,863
Leasehold improvements      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross 9,984 6,621  
Equipment      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross 22,420 18,930  
Furniture and fixtures      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross $ 1,186 $ 877  
XML 68 R52.htm IDEA: XBRL DOCUMENT v3.20.4
GOODWILL AND INTANGIBLE ASSETS - NET - Narrative (Details) - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]      
Impairment charges $ 0 $ 0 $ 0
XML 69 R53.htm IDEA: XBRL DOCUMENT v3.20.4
GOODWILL AND INTANGIBLE ASSETS - NET - ACTIVITY IN GOODWILL (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Goodwill [Roll Forward]    
Goodwill, beginning balance $ 41,233 $ 30,892
Additions 25,211 10,341
Goodwill, ending balance 66,444 41,233
Home Health and Hospice Services    
Goodwill [Roll Forward]    
Goodwill, beginning balance 37,591 27,250
Additions 25,211 10,341
Goodwill, ending balance 62,802 37,591
Senior Living Services    
Goodwill [Roll Forward]    
Goodwill, beginning balance 3,642 3,642
Additions 0 0
Goodwill, ending balance $ 3,642 $ 3,642
XML 70 R54.htm IDEA: XBRL DOCUMENT v3.20.4
GOODWILL AND INTANGIBLE ASSETS - NET - INDEFINITE-LIVED INTANGIBLE ASSETS (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Indefinite-lived Intangible Assets [Line Items]    
Other indefinite-lived intangibles $ 47,488 $ 33,462
Trade name    
Indefinite-lived Intangible Assets [Line Items]    
Other indefinite-lived intangibles 1,355 355
Medicare and Medicaid licenses    
Indefinite-lived Intangible Assets [Line Items]    
Other indefinite-lived intangibles $ 46,133 $ 33,107
XML 71 R55.htm IDEA: XBRL DOCUMENT v3.20.4
OTHER ACCRUED LIABILITIES (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Jun. 30, 2020
Dec. 31, 2019
Other Accrued Liabilities, Current [Abstract]      
Refunds payable $ 2,664   $ 2,152
Deferred revenue 1,271   1,937
Resident deposits 5,647   6,292
Contract Liabilities (CARES Act advance payments) 22,771 $ 27,997 0
Property taxes 982   1,130
Accrued insurance retention - current portion 1,354   0
Other 3,586   2,400
Other accrued liabilities $ 38,275   $ 13,911
XML 72 R56.htm IDEA: XBRL DOCUMENT v3.20.4
OTHER ACCRUED LIABILITIES - NARRATIVE (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Oct. 31, 2020
Jun. 30, 2020
Dec. 31, 2019
Payables and Accruals [Line Items]        
Contract Liabilities (CARES Act advance payments) $ 22,771   $ 27,997 $ 0
Revision of Prior Period, Adjustment        
Payables and Accruals [Line Items]        
AAP amount reclassified   $ 5,226    
Long-term liabilities   $ 5,226    
XML 73 R57.htm IDEA: XBRL DOCUMENT v3.20.4
DEBT - SCHEDULE OF LONG-TERM DEBT (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Debt Instrument [Line Items]    
Less: unamortized debt issuance costs $ (1,223) $ (1,474)
Long-term debt, net 8,277 18,526
Revolving credit facility | Line of credit    
Debt Instrument [Line Items]    
Revolving Credit Facility $ 9,500 $ 20,000
XML 74 R58.htm IDEA: XBRL DOCUMENT v3.20.4
DEBT - NARRATIVE (Details) - USD ($)
9 Months Ended
Feb. 23, 2021
Oct. 01, 2019
Oct. 01, 2019
Dec. 31, 2020
Subsequent event        
Debt Instrument [Line Items]        
Borrowing capacity $ 150,000,000      
Minimum | LIBOR        
Debt Instrument [Line Items]        
Margin   2.50%    
Minimum | LIBOR | Subsequent event        
Debt Instrument [Line Items]        
Margin 2.30%      
Minimum | Base Rate        
Debt Instrument [Line Items]        
Margin   1.50%    
Minimum | Base Rate | Subsequent event        
Debt Instrument [Line Items]        
Margin 1.30%      
Maximum | LIBOR        
Debt Instrument [Line Items]        
Margin   3.50%    
Maximum | LIBOR | Subsequent event        
Debt Instrument [Line Items]        
Margin 3.30%      
Maximum | Base Rate        
Debt Instrument [Line Items]        
Margin   2.50%    
Maximum | Base Rate | Subsequent event        
Debt Instrument [Line Items]        
Margin 2.30%      
Revolving credit facility | Line of credit        
Debt Instrument [Line Items]        
Borrowing capacity   $ 75,000,000 $ 75,000,000  
Commitment fee on undrawn portion     0.60%  
Weighted average interest rate       4.75%
Borrowing availability       $ 62,164,000
Letters of credit | Line of credit        
Debt Instrument [Line Items]        
Letters of credit outstanding       $ 3,336,000
XML 75 R59.htm IDEA: XBRL DOCUMENT v3.20.4
OPTIONS AND AWARDS - SHARE-BASED COMPENSATION (Details) - USD ($)
$ in Thousands
9 Months Ended 12 Months Ended
Oct. 01, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation $ 1,395 $ 8,335 $ 3,382 $ 2,382
Stock options        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation   1,660 315 0
Restricted stock awards        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation   6,200 1,589 0
Restricted stock awards | Non-employee director        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation   $ 475 $ 83 $ 0
XML 76 R60.htm IDEA: XBRL DOCUMENT v3.20.4
OPTIONS AND AWARDS - NARRATIVE (Details)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2020
USD ($)
shares
Restricted stock awards | Minimum  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Vesting period 3 years
Restricted stock awards | Maximum  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Vesting period 5 years
The Ensign Plans  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Total unrecognized share-based compensation expense $ 21,011
Options, unvested and outstanding (in shares) | shares 1,367
Weighted average contractual life for options outstanding, vested and expected to vest 7 years 9 months 29 days
The Ensign Plans | Stock options  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Unvested stock options $ 10,055
Unvested options and stock awards, cost net yet recognized, period for recognition 4 years 3 months 18 days
Options, vesting percent per year 20.00%
Options, expiration period 10 years
The Ensign Plans | Restricted stock awards  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Unvested Restricted Stock $ 10,956
Unvested options and stock awards, cost net yet recognized, period for recognition 1 year 9 months 18 days
Vesting period 5 years
XML 77 R61.htm IDEA: XBRL DOCUMENT v3.20.4
OPTIONS AND AWARDS - OPTIONS GRANTED (Details) - The Ensign Plans - $ / shares
shares in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Options granted (in shares) 693  
2020    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Options granted (in shares) 693  
Weighted average fair value of options (in dollars per share) $ 11.05  
2020 | Stock options    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Weighted average risk-free rate 0.50%  
Expected life 6 years 6 months  
Weighted average volatility 35.90%  
Weighted average dividend yield 0.00%  
2019    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Options granted (in shares)   667
Weighted average fair value of options (in dollars per share)   $ 5.70
2019 | Stock options    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Weighted average risk-free rate   1.60%
Expected life   6 years 6 months
Weighted average volatility   34.60%
Weighted average dividend yield   0.00%
XML 78 R62.htm IDEA: XBRL DOCUMENT v3.20.4
OPTIONS AND AWARDS - EMPLOYEE STOCK OPTION ACTIVITY (Details) - The Ensign Plans - $ / shares
shares in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Number of Options Outstanding    
Beginning balance, outstanding (in shares) 1,573  
Granted (in shares) 693  
Exercised (in shares) (239)  
Forfeited (in shares) (36)  
Expired (in shares) (9)  
Ending balance, outstanding (in shares) 1,982 1,573
Weighted Average Exercise Price    
Beginning of period, weighted average exercise price (in dollars per share) $ 9.71  
Granted (in dollars per share) 30.44  
Exercised (in dollars per share) 4.77  
Forfeited (in dollars per share) 14.34  
Expired (in dollars per share) 6.24  
End of period, weighted average exercise price (in dollars per share) $ 17.48 $ 9.71
Number of options vested (in shares) 615 607
Weighted average exercise price of options vested (in dollars per share) $ 7.52 $ 4.80
XML 79 R63.htm IDEA: XBRL DOCUMENT v3.20.4
OPTIONS AND AWARDS - AGGREGATE INTRINSIC VALUE OF OPTIONS (Details) - The Ensign Plans
$ in Thousands
Dec. 31, 2020
USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Outstanding $ 80,456
Vested 31,077
Unvested 49,379
Exercised $ 8,002
XML 80 R64.htm IDEA: XBRL DOCUMENT v3.20.4
OPTIONS AND AWARDS - RESTRICTED STOCK AWARDS ACTIVITY (Details) - The Ensign Plans - Restricted stock awards
shares in Thousands
12 Months Ended
Dec. 31, 2020
$ / shares
shares
Non-Vested Restricted Awards  
Beginning balance, outstanding (in shares) | shares 1,793
Granted (in shares) | shares 29
Vested (in shares) | shares (176)
Forfeited (in shares) | shares (11)
Ending balance, outstanding (in shares) | shares 1,635
Weighted Average Grant Date Fair Value  
Beginning of period, weighted average exercise price (in dollars per share) | $ / shares $ 14.44
Granted (in dollars per share) | $ / shares 26.84
Vested (in dollars per share) | $ / shares 13.27
Forfeited (in dollars per share) | $ / shares 10.92
End of period, weighted average exercise price (in dollars per share) | $ / shares $ 14.80
XML 81 R65.htm IDEA: XBRL DOCUMENT v3.20.4
LEASES - NARRATIVE (Details)
Dec. 31, 2020
facility
property
arrangement
Lessee, Lease, Description [Line Items]  
Weighted average remaining lease term 15 years
Weighted average discount rate 8.20%
Senior Living Services  
Lessee, Lease, Description [Line Items]  
Number of properties under lease 54
Senior Living Services | Related party  
Lessee, Lease, Description [Line Items]  
Number of operating facilities | property 31
Number of properties under lease, master lease agreement 15
Number of separate master lease arrangements | arrangement 2
Senior Living Services | Minimum  
Lessee, Lease, Description [Line Items]  
Lease term 5 years
Senior Living Services | Minimum | Related party  
Lessee, Lease, Description [Line Items]  
Lease term 14 years
Senior Living Services | Maximum  
Lessee, Lease, Description [Line Items]  
Lease term 21 years
Senior Living Services | Maximum | Related party  
Lessee, Lease, Description [Line Items]  
Lease term 20 years
XML 82 R66.htm IDEA: XBRL DOCUMENT v3.20.4
LEASES - IMPACT OF NEW LEASES GUIDANCE (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Lease, Cost [Abstract]      
Sublease income $ (143) $ 0  
Variable lease cost 5,330 4,608  
Cost of services      
Lease, Cost [Abstract]      
Operating lease costs 39,191 34,975 $ 31,199
Cost of services | Facility      
Lease, Cost [Abstract]      
Operating lease costs 35,562 32,011  
Cost of services | Office      
Lease, Cost [Abstract]      
Operating lease costs 3,772 2,964  
General and administrative expense      
Lease, Cost [Abstract]      
Operating lease costs $ 295 $ 162  
XML 83 R67.htm IDEA: XBRL DOCUMENT v3.20.4
LEASES - FUTURE MINIMUM LEASE PAYMENTS (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Leases, Under Adoption of ASC 842 [Abstract]    
2021 $ 38,393  
2022 37,730  
2023 37,038  
2024 36,230  
2025 35,349  
Thereafter 356,838  
Total lease payments 541,578  
Less: present value adjustments (230,857)  
Present value of total lease liabilities 310,721  
Less: current lease liabilities (14,106) $ (12,285)
Long-term operating lease liabilities $ 296,615 $ 304,044
XML 84 R68.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES - PROVISION FOR INCOME TAXES (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Current:      
Federal $ 5,058 $ 562 $ 3,223
State 1,478 278 915
Current provision for income tax, total 6,536 840 4,138
Deferred:      
Federal (3,348) 1,070 226
State (838) 175 (12)
Deferred provision for income tax, total (4,186) 1,245 214
Total income tax expense $ 2,350 $ 2,085 $ 4,352
XML 85 R69.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES - TAX RATE RECONCILIATION (Details)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Effective Income Tax Rate Reconciliation, Percent [Abstract]      
Income tax expense at statutory rate 21.00% 21.00% 21.00%
State income taxes - net of federal benefit 2.70% 6.80% 3.50%
Non-deductible expenses 0.40% 2.60% 0.40%
Transaction costs(a) 0.00% 41.20% 0.00%
Tax credits 0.00% (1.60%) 0.00%
Equity compensation(b) (10.80%) (30.00%) (2.90%)
Revaluation of deferred 0.00% 0.00% (0.20%)
Other adjustments (0.20%) (0.40%) (0.70%)
Total income tax provision 13.10% 39.60% 21.10%
XML 86 R70.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES - NARRATIVE (Details) - USD ($)
shares in Thousands
12 Months Ended
Oct. 01, 2019
Dec. 31, 2020
Income Tax Disclosure [Abstract]    
Nondeductible transaction costs $ 10,300,000  
The Ensign Plans    
Operating Loss Carryforwards [Line Items]    
Exercised (in shares)   (239)
Federal tax authority    
Operating Loss Carryforwards [Line Items]    
Operating loss carryforwards   $ 500,000
Less: valuation allowance   $ 15
XML 87 R71.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES - DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Deferred tax assets (liabilities):    
Accrued expenses $ 8,181 $ 2,670
Allowance for doubtful accounts 875 869
State taxes 147 27
Lease liabilities 80,979 83,076
Insurance 277 137
Gross deferred tax assets 90,459 86,779
Less: valuation allowance (15) 0
Net deferred tax assets 90,444 86,779
Depreciation and amortization (7,512) (6,107)
Prepaid expenses (780) (594)
Right of use asset (80,055) (82,181)
Total deferred tax liabilities (88,347) (88,882)
Net deferred tax assets $ 2,097  
Net deferred tax liabilities   $ (2,103)
XML 88 R72.htm IDEA: XBRL DOCUMENT v3.20.4
COMMITMENTS AND CONTINGENCIES (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2020
USD ($)
review
Dec. 31, 2019
USD ($)
Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]      
Number of operating subsidiaries with reviews scheduled | review 7    
Reinsurance receivables | $ $ 704 $ 0  
Revenue | Customer concentration risk      
Concentration Risk [Line Items]      
Concentration risk, percent 100.00% 100.00% 100.00%
Subtotal | Receivables | Customer concentration risk      
Concentration Risk [Line Items]      
Concentration risk, percent 75.70% 74.30%  
Subtotal | Revenue | Customer concentration risk      
Concentration Risk [Line Items]      
Concentration risk, percent 60.10% 55.60% 53.10%
EXCEL 89 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 91 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 92 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 267 435 1 false 63 0 false 14 false false R1.htm 0001001 - Document - Cover Page Sheet http://pennantgroup.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETSParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - CONSOLIDATED AND COMBINED STATEMENTS OF INCOME Sheet http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME CONSOLIDATED AND COMBINED STATEMENTS OF INCOME Statements 4 false false R5.htm 1004005 - Statement - CONSOLIDATED AND COMBINED STATEMENTS OF STOCKHOLDERS' EQUITY AND NET PARENT INVESTMENT Sheet http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFSTOCKHOLDERSEQUITYANDNETPARENTINVESTMENT CONSOLIDATED AND COMBINED STATEMENTS OF STOCKHOLDERS' EQUITY AND NET PARENT INVESTMENT Statements 5 false false R6.htm 1005006 - Statement - CONSOLIDATED AND COMBINED STATEMENTS OF CASH FLOWS Sheet http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS CONSOLIDATED AND COMBINED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 2101101 - Disclosure - DESCRIPTION OF BUSINESS Sheet http://pennantgroup.com/role/DESCRIPTIONOFBUSINESS DESCRIPTION OF BUSINESS Notes 7 false false R8.htm 2103102 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 2108103 - Disclosure - RELATED PARTY TRANSACTIONS AND NET PARENT INVESTMENT Sheet http://pennantgroup.com/role/RELATEDPARTYTRANSACTIONSANDNETPARENTINVESTMENT RELATED PARTY TRANSACTIONS AND NET PARENT INVESTMENT Notes 9 false false R10.htm 2110104 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE Sheet http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARE COMPUTATION OF NET INCOME PER COMMON SHARE Notes 10 false false R11.htm 2114105 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE Sheet http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLE REVENUE AND ACCOUNTS RECEIVABLE Notes 11 false false R12.htm 2120106 - Disclosure - BUSINESS SEGMENTS Sheet http://pennantgroup.com/role/BUSINESSSEGMENTS BUSINESS SEGMENTS Notes 12 false false R13.htm 2125107 - Disclosure - ACQUISITIONS Sheet http://pennantgroup.com/role/ACQUISITIONS ACQUISITIONS Notes 13 false false R14.htm 2130108 - Disclosure - PROPERTY AND EQUIPMENT???NET Sheet http://pennantgroup.com/role/PROPERTYANDEQUIPMENTNET PROPERTY AND EQUIPMENT???NET Notes 14 false false R15.htm 2133109 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - NET Sheet http://pennantgroup.com/role/GOODWILLANDINTANGIBLEASSETSNET GOODWILL AND INTANGIBLE ASSETS - NET Notes 15 false false R16.htm 2138110 - Disclosure - OTHER ACCRUED LIABILITIES Sheet http://pennantgroup.com/role/OTHERACCRUEDLIABILITIES OTHER ACCRUED LIABILITIES Notes 16 false false R17.htm 2142111 - Disclosure - DEBT Sheet http://pennantgroup.com/role/DEBT DEBT Notes 17 false false R18.htm 2146112 - Disclosure - OPTIONS AND AWARDS Sheet http://pennantgroup.com/role/OPTIONSANDAWARDS OPTIONS AND AWARDS Notes 18 false false R19.htm 2154113 - Disclosure - LEASES Sheet http://pennantgroup.com/role/LEASES LEASES Notes 19 false false R20.htm 2159114 - Disclosure - INCOME TAXES Sheet http://pennantgroup.com/role/INCOMETAXES INCOME TAXES Notes 20 false false R21.htm 2165115 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://pennantgroup.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 21 false false R22.htm 2205201 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 22 false false R23.htm 2304301 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES 23 false false R24.htm 2311302 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE (Tables) Sheet http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARETables COMPUTATION OF NET INCOME PER COMMON SHARE (Tables) Tables http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARE 24 false false R25.htm 2315303 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE (Tables) Sheet http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLETables REVENUE AND ACCOUNTS RECEIVABLE (Tables) Tables http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLE 25 false false R26.htm 2321304 - Disclosure - BUSINESS SEGMENTS (Tables) Sheet http://pennantgroup.com/role/BUSINESSSEGMENTSTables BUSINESS SEGMENTS (Tables) Tables http://pennantgroup.com/role/BUSINESSSEGMENTS 26 false false R27.htm 2326305 - Disclosure - ACQUISITIONS (Tables) Sheet http://pennantgroup.com/role/ACQUISITIONSTables ACQUISITIONS (Tables) Tables http://pennantgroup.com/role/ACQUISITIONS 27 false false R28.htm 2331306 - Disclosure - PROPERTY AND EQUIPMENT???NET (Tables) Sheet http://pennantgroup.com/role/PROPERTYANDEQUIPMENTNETTables PROPERTY AND EQUIPMENT???NET (Tables) Tables http://pennantgroup.com/role/PROPERTYANDEQUIPMENTNET 28 false false R29.htm 2334307 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - NET (Tables) Sheet http://pennantgroup.com/role/GOODWILLANDINTANGIBLEASSETSNETTables GOODWILL AND INTANGIBLE ASSETS - NET (Tables) Tables http://pennantgroup.com/role/GOODWILLANDINTANGIBLEASSETSNET 29 false false R30.htm 2339308 - Disclosure - OTHER ACCRUED LIABILITIES (Tables) Sheet http://pennantgroup.com/role/OTHERACCRUEDLIABILITIESTables OTHER ACCRUED LIABILITIES (Tables) Tables http://pennantgroup.com/role/OTHERACCRUEDLIABILITIES 30 false false R31.htm 2343309 - Disclosure - DEBT (Tables) Sheet http://pennantgroup.com/role/DEBTTables DEBT (Tables) Tables http://pennantgroup.com/role/DEBT 31 false false R32.htm 2347310 - Disclosure - OPTIONS AND AWARDS (Tables) Sheet http://pennantgroup.com/role/OPTIONSANDAWARDSTables OPTIONS AND AWARDS (Tables) Tables http://pennantgroup.com/role/OPTIONSANDAWARDS 32 false false R33.htm 2355311 - Disclosure - LEASES (Tables) Sheet http://pennantgroup.com/role/LEASESTables LEASES (Tables) Tables http://pennantgroup.com/role/LEASES 33 false false R34.htm 2360312 - Disclosure - INCOME TAXES (Tables) Sheet http://pennantgroup.com/role/INCOMETAXESTables INCOME TAXES (Tables) Tables http://pennantgroup.com/role/INCOMETAXES 34 false false R35.htm 2402401 - Disclosure - DESCRIPTION OF BUSINESS (Details) Sheet http://pennantgroup.com/role/DESCRIPTIONOFBUSINESSDetails DESCRIPTION OF BUSINESS (Details) Details http://pennantgroup.com/role/DESCRIPTIONOFBUSINESS 35 false false R36.htm 2406402 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables 36 false false R37.htm 2407403 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - SUMMARY OF INSURANCE LIABILITY (Details) Sheet http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSUMMARYOFINSURANCELIABILITYDetails BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - SUMMARY OF INSURANCE LIABILITY (Details) Details 37 false false R38.htm 2409404 - Disclosure - RELATED PARTY TRANSACTIONS AND NET PARENT INVESTMENT (Details) Sheet http://pennantgroup.com/role/RELATEDPARTYTRANSACTIONSANDNETPARENTINVESTMENTDetails RELATED PARTY TRANSACTIONS AND NET PARENT INVESTMENT (Details) Details http://pennantgroup.com/role/RELATEDPARTYTRANSACTIONSANDNETPARENTINVESTMENT 38 false false R39.htm 2412405 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE - RECONCILIATION (Details) Sheet http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARERECONCILIATIONDetails COMPUTATION OF NET INCOME PER COMMON SHARE - RECONCILIATION (Details) Details 39 false false R40.htm 2413406 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE - NARRATIVE (Details) Sheet http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARENARRATIVEDetails COMPUTATION OF NET INCOME PER COMMON SHARE - NARRATIVE (Details) Details 40 false false R41.htm 2416407 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - NARRATIVE (Details) Sheet http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLENARRATIVEDetails REVENUE AND ACCOUNTS RECEIVABLE - NARRATIVE (Details) Details 41 false false R42.htm 2417408 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - REVENUE BY MAJOR PAYOR (Details) Sheet http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEREVENUEBYMAJORPAYORDetails REVENUE AND ACCOUNTS RECEIVABLE - REVENUE BY MAJOR PAYOR (Details) Details 42 false false R43.htm 2418409 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - ACCOUNTS RECEIVABLE (Details) Sheet http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEACCOUNTSRECEIVABLEDetails REVENUE AND ACCOUNTS RECEIVABLE - ACCOUNTS RECEIVABLE (Details) Details 43 false false R44.htm 2419410 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details) Sheet http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEALLOWANCEFORDOUBTFULACCOUNTSDetails REVENUE AND ACCOUNTS RECEIVABLE - ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details) Details 44 false false R45.htm 2422411 - Disclosure - BUSINESS SEGMENTS - NARRATIVE (Details) Sheet http://pennantgroup.com/role/BUSINESSSEGMENTSNARRATIVEDetails BUSINESS SEGMENTS - NARRATIVE (Details) Details 45 false false R46.htm 2423412 - Disclosure - BUSINESS SEGMENTS - FINANCIAL DATA (Details) Sheet http://pennantgroup.com/role/BUSINESSSEGMENTSFINANCIALDATADetails BUSINESS SEGMENTS - FINANCIAL DATA (Details) Details 46 false false R47.htm 2424413 - Disclosure - BUSINESS SEGMENTS - INCOME FROM OPERATIONS (Details) Sheet http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails BUSINESS SEGMENTS - INCOME FROM OPERATIONS (Details) Details 47 false false R48.htm 2427414 - Disclosure - ACQUISITIONS - NARRATIVE (Details) Sheet http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails ACQUISITIONS - NARRATIVE (Details) Details 48 false false R49.htm 2428415 - Disclosure - ACQUISITIONS - OPERATIONS ACQUIRED (Details) Sheet http://pennantgroup.com/role/ACQUISITIONSOPERATIONSACQUIREDDetails ACQUISITIONS - OPERATIONS ACQUIRED (Details) Details 49 false false R50.htm 2429416 - Disclosure - ACQUISITIONS - UNAUDITED PRO FORMA (Details) Sheet http://pennantgroup.com/role/ACQUISITIONSUNAUDITEDPROFORMADetails ACQUISITIONS - UNAUDITED PRO FORMA (Details) Details 50 false false R51.htm 2432417 - Disclosure - PROPERTY AND EQUIPMENT???NET (Details) Sheet http://pennantgroup.com/role/PROPERTYANDEQUIPMENTNETDetails PROPERTY AND EQUIPMENT???NET (Details) Details http://pennantgroup.com/role/PROPERTYANDEQUIPMENTNETTables 51 false false R52.htm 2435418 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - NET - Narrative (Details) Sheet http://pennantgroup.com/role/GOODWILLANDINTANGIBLEASSETSNETNarrativeDetails GOODWILL AND INTANGIBLE ASSETS - NET - Narrative (Details) Details 52 false false R53.htm 2436419 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - NET - ACTIVITY IN GOODWILL (Details) Sheet http://pennantgroup.com/role/GOODWILLANDINTANGIBLEASSETSNETACTIVITYINGOODWILLDetails GOODWILL AND INTANGIBLE ASSETS - NET - ACTIVITY IN GOODWILL (Details) Details 53 false false R54.htm 2437420 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - NET - INDEFINITE-LIVED INTANGIBLE ASSETS (Details) Sheet http://pennantgroup.com/role/GOODWILLANDINTANGIBLEASSETSNETINDEFINITELIVEDINTANGIBLEASSETSDetails GOODWILL AND INTANGIBLE ASSETS - NET - INDEFINITE-LIVED INTANGIBLE ASSETS (Details) Details 54 false false R55.htm 2440421 - Disclosure - OTHER ACCRUED LIABILITIES (Details) Sheet http://pennantgroup.com/role/OTHERACCRUEDLIABILITIESDetails OTHER ACCRUED LIABILITIES (Details) Details http://pennantgroup.com/role/OTHERACCRUEDLIABILITIESTables 55 false false R56.htm 2441422 - Disclosure - OTHER ACCRUED LIABILITIES - NARRATIVE (Details) Sheet http://pennantgroup.com/role/OTHERACCRUEDLIABILITIESNARRATIVEDetails OTHER ACCRUED LIABILITIES - NARRATIVE (Details) Details 56 false false R57.htm 2444423 - Disclosure - DEBT - SCHEDULE OF LONG-TERM DEBT (Details) Sheet http://pennantgroup.com/role/DEBTSCHEDULEOFLONGTERMDEBTDetails DEBT - SCHEDULE OF LONG-TERM DEBT (Details) Details 57 false false R58.htm 2445424 - Disclosure - DEBT - NARRATIVE (Details) Sheet http://pennantgroup.com/role/DEBTNARRATIVEDetails DEBT - NARRATIVE (Details) Details 58 false false R59.htm 2448425 - Disclosure - OPTIONS AND AWARDS - SHARE-BASED COMPENSATION (Details) Sheet http://pennantgroup.com/role/OPTIONSANDAWARDSSHAREBASEDCOMPENSATIONDetails OPTIONS AND AWARDS - SHARE-BASED COMPENSATION (Details) Details 59 false false R60.htm 2449426 - Disclosure - OPTIONS AND AWARDS - NARRATIVE (Details) Sheet http://pennantgroup.com/role/OPTIONSANDAWARDSNARRATIVEDetails OPTIONS AND AWARDS - NARRATIVE (Details) Details 60 false false R61.htm 2450427 - Disclosure - OPTIONS AND AWARDS - OPTIONS GRANTED (Details) Sheet http://pennantgroup.com/role/OPTIONSANDAWARDSOPTIONSGRANTEDDetails OPTIONS AND AWARDS - OPTIONS GRANTED (Details) Details 61 false false R62.htm 2451428 - Disclosure - OPTIONS AND AWARDS - EMPLOYEE STOCK OPTION ACTIVITY (Details) Sheet http://pennantgroup.com/role/OPTIONSANDAWARDSEMPLOYEESTOCKOPTIONACTIVITYDetails OPTIONS AND AWARDS - EMPLOYEE STOCK OPTION ACTIVITY (Details) Details 62 false false R63.htm 2452429 - Disclosure - OPTIONS AND AWARDS - AGGREGATE INTRINSIC VALUE OF OPTIONS (Details) Sheet http://pennantgroup.com/role/OPTIONSANDAWARDSAGGREGATEINTRINSICVALUEOFOPTIONSDetails OPTIONS AND AWARDS - AGGREGATE INTRINSIC VALUE OF OPTIONS (Details) Details 63 false false R64.htm 2453430 - Disclosure - OPTIONS AND AWARDS - RESTRICTED STOCK AWARDS ACTIVITY (Details) Sheet http://pennantgroup.com/role/OPTIONSANDAWARDSRESTRICTEDSTOCKAWARDSACTIVITYDetails OPTIONS AND AWARDS - RESTRICTED STOCK AWARDS ACTIVITY (Details) Details 64 false false R65.htm 2456431 - Disclosure - LEASES - NARRATIVE (Details) Sheet http://pennantgroup.com/role/LEASESNARRATIVEDetails LEASES - NARRATIVE (Details) Details 65 false false R66.htm 2457432 - Disclosure - LEASES - IMPACT OF NEW LEASES GUIDANCE (Details) Sheet http://pennantgroup.com/role/LEASESIMPACTOFNEWLEASESGUIDANCEDetails LEASES - IMPACT OF NEW LEASES GUIDANCE (Details) Details 66 false false R67.htm 2458433 - Disclosure - LEASES - FUTURE MINIMUM LEASE PAYMENTS (Details) Sheet http://pennantgroup.com/role/LEASESFUTUREMINIMUMLEASEPAYMENTSDetails LEASES - FUTURE MINIMUM LEASE PAYMENTS (Details) Details 67 false false R68.htm 2461434 - Disclosure - INCOME TAXES - PROVISION FOR INCOME TAXES (Details) Sheet http://pennantgroup.com/role/INCOMETAXESPROVISIONFORINCOMETAXESDetails INCOME TAXES - PROVISION FOR INCOME TAXES (Details) Details 68 false false R69.htm 2462435 - Disclosure - INCOME TAXES - TAX RATE RECONCILIATION (Details) Sheet http://pennantgroup.com/role/INCOMETAXESTAXRATERECONCILIATIONDetails INCOME TAXES - TAX RATE RECONCILIATION (Details) Details 69 false false R70.htm 2463436 - Disclosure - INCOME TAXES - NARRATIVE (Details) Sheet http://pennantgroup.com/role/INCOMETAXESNARRATIVEDetails INCOME TAXES - NARRATIVE (Details) Details 70 false false R71.htm 2464437 - Disclosure - INCOME TAXES - DEFERRED TAX ASSETS AND LIABILITIES (Details) Sheet http://pennantgroup.com/role/INCOMETAXESDEFERREDTAXASSETSANDLIABILITIESDetails INCOME TAXES - DEFERRED TAX ASSETS AND LIABILITIES (Details) Details 71 false false R72.htm 2466438 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://pennantgroup.com/role/COMMITMENTSANDCONTINGENCIESDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://pennantgroup.com/role/COMMITMENTSANDCONTINGENCIES 72 false false All Reports Book All Reports pntg-20201231.htm ceocert-exhibit311q420.htm ceocert-exhibit321q420.htm cfocert-exhibit312q420.htm cfocert-exhibit322q420.htm deloitteconsentq420-ex231.htm listofsubsidiariesofpntgq4.htm pntg-20201231.xsd pntg-20201231_cal.xml pntg-20201231_def.xml pntg-20201231_lab.xml pntg-20201231_pre.xml pntg-20201231_g1.jpg pntg-20201231_g2.jpg pntg-20201231_g3.jpg http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/us-gaap/2020-01-31 true true JSON 95 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "pntg-20201231.htm": { "axisCustom": 1, "axisStandard": 29, "contextCount": 267, "dts": { "calculationLink": { "local": [ "pntg-20201231_cal.xml" ] }, "definitionLink": { "local": [ "pntg-20201231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "pntg-20201231.htm" ] }, "labelLink": { "local": [ "pntg-20201231_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "pntg-20201231_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml" ] }, "schema": { "local": [ "pntg-20201231.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 591, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 5, "http://pennantgroup.com/20201231": 2, "http://xbrl.sec.gov/dei/2020-01-31": 4, "total": 11 }, "keyCustom": 56, "keyStandard": 379, "memberCustom": 25, "memberStandard": 38, "nsprefix": "pntg", "nsuri": "http://pennantgroup.com/20201231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://pennantgroup.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110104 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE", "role": "http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARE", "shortName": "COMPUTATION OF NET INCOME PER COMMON SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "pntg:RevenuefromContractwithCustomerAndAccountsReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114105 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE", "role": "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLE", "shortName": "REVENUE AND ACCOUNTS RECEIVABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "pntg:RevenuefromContractwithCustomerAndAccountsReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120106 - Disclosure - BUSINESS SEGMENTS", "role": "http://pennantgroup.com/role/BUSINESSSEGMENTS", "shortName": "BUSINESS SEGMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2125107 - Disclosure - ACQUISITIONS", "role": "http://pennantgroup.com/role/ACQUISITIONS", "shortName": "ACQUISITIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2130108 - Disclosure - PROPERTY AND EQUIPMENT\u2014NET", "role": "http://pennantgroup.com/role/PROPERTYANDEQUIPMENTNET", "shortName": "PROPERTY AND EQUIPMENT\u2014NET", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2133109 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - NET", "role": "http://pennantgroup.com/role/GOODWILLANDINTANGIBLEASSETSNET", "shortName": "GOODWILL AND INTANGIBLE ASSETS - NET", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2138110 - Disclosure - OTHER ACCRUED LIABILITIES", "role": "http://pennantgroup.com/role/OTHERACCRUEDLIABILITIES", "shortName": "OTHER ACCRUED LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2142111 - Disclosure - DEBT", "role": "http://pennantgroup.com/role/DEBT", "shortName": "DEBT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2146112 - Disclosure - OPTIONS AND AWARDS", "role": "http://pennantgroup.com/role/OPTIONSANDAWARDS", "shortName": "OPTIONS AND AWARDS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2154113 - Disclosure - LEASES", "role": "http://pennantgroup.com/role/LEASES", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "idfce51e6cb5d45cc83386b544fe71b37_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "idfce51e6cb5d45cc83386b544fe71b37_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2159114 - Disclosure - INCOME TAXES", "role": "http://pennantgroup.com/role/INCOMETAXES", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2165115 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://pennantgroup.com/role/COMMITMENTSANDCONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2205201 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "pntg:SummaryOfInsuranceLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables", "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "pntg:SummaryOfInsuranceLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311302 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE (Tables)", "role": "http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARETables", "shortName": "COMPUTATION OF NET INCOME PER COMMON SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315303 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE (Tables)", "role": "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLETables", "shortName": "REVENUE AND ACCOUNTS RECEIVABLE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2321304 - Disclosure - BUSINESS SEGMENTS (Tables)", "role": "http://pennantgroup.com/role/BUSINESSSEGMENTSTables", "shortName": "BUSINESS SEGMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2326305 - Disclosure - ACQUISITIONS (Tables)", "role": "http://pennantgroup.com/role/ACQUISITIONSTables", "shortName": "ACQUISITIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2331306 - Disclosure - PROPERTY AND EQUIPMENT\u2014NET (Tables)", "role": "http://pennantgroup.com/role/PROPERTYANDEQUIPMENTNETTables", "shortName": "PROPERTY AND EQUIPMENT\u2014NET (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2334307 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - NET (Tables)", "role": "http://pennantgroup.com/role/GOODWILLANDINTANGIBLEASSETSNETTables", "shortName": "GOODWILL AND INTANGIBLE ASSETS - NET (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "idfce51e6cb5d45cc83386b544fe71b37_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "idfce51e6cb5d45cc83386b544fe71b37_I20201231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2339308 - Disclosure - OTHER ACCRUED LIABILITIES (Tables)", "role": "http://pennantgroup.com/role/OTHERACCRUEDLIABILITIESTables", "shortName": "OTHER ACCRUED LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2343309 - Disclosure - DEBT (Tables)", "role": "http://pennantgroup.com/role/DEBTTables", "shortName": "DEBT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2347310 - Disclosure - OPTIONS AND AWARDS (Tables)", "role": "http://pennantgroup.com/role/OPTIONSANDAWARDSTables", "shortName": "OPTIONS AND AWARDS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2355311 - Disclosure - LEASES (Tables)", "role": "http://pennantgroup.com/role/LEASESTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2360312 - Disclosure - INCOME TAXES (Tables)", "role": "http://pennantgroup.com/role/INCOMETAXESTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i21fb1bfde1644a5e948465eba318333e_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "pntg:NumberOfServiceProviders", "reportCount": 1, "unitRef": "agency", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - DESCRIPTION OF BUSINESS (Details)", "role": "http://pennantgroup.com/role/DESCRIPTIONOFBUSINESSDetails", "shortName": "DESCRIPTION OF BUSINESS (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "idfce51e6cb5d45cc83386b544fe71b37_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "pntg:TheCoronavirusAidReliefAndEconomicSecurityActAdvancePaymentsReceived", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "role": "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "idfce51e6cb5d45cc83386b544fe71b37_I20201231", "decimals": "-3", "lang": "en-US", "name": "pntg:AccruedPayrollTaxesEmployerPortion", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "pntg:SummaryOfInsuranceLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "idfce51e6cb5d45cc83386b544fe71b37_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ReinsuranceReceivablesIncurredButNotReportedClaims", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - SUMMARY OF INSURANCE LIABILITY (Details)", "role": "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSUMMARYOFINSURANCELIABILITYDetails", "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - SUMMARY OF INSURANCE LIABILITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "pntg:SummaryOfInsuranceLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "idfce51e6cb5d45cc83386b544fe71b37_I20201231", "decimals": "-3", "lang": "en-US", "name": "pntg:GeneralAndProfessionalInsuranceLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i34534c20b1da45f597485856f34fd71a_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409404 - Disclosure - RELATED PARTY TRANSACTIONS AND NET PARENT INVESTMENT (Details)", "role": "http://pennantgroup.com/role/RELATEDPARTYTRANSACTIONSANDNETPARENTINVESTMENTDetails", "shortName": "RELATED PARTY TRANSACTIONS AND NET PARENT INVESTMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i34534c20b1da45f597485856f34fd71a_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412405 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE - RECONCILIATION (Details)", "role": "http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARERECONCILIATIONDetails", "shortName": "COMPUTATION OF NET INCOME PER COMMON SHARE - RECONCILIATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - CONSOLIDATED AND COMBINED STATEMENTS OF INCOME", "role": "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME", "shortName": "CONSOLIDATED AND COMBINED STATEMENTS OF INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413406 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE - NARRATIVE (Details)", "role": "http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARENARRATIVEDetails", "shortName": "COMPUTATION OF NET INCOME PER COMMON SHARE - NARRATIVE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "idfce51e6cb5d45cc83386b544fe71b37_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "pntg:TheCoronavirusAidReliefAndEconomicSecurityActAdvancePaymentsReceived", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416407 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - NARRATIVE (Details)", "role": "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLENARRATIVEDetails", "shortName": "REVENUE AND ACCOUNTS RECEIVABLE - NARRATIVE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "ib103ebda54b74980ac38079de8e90b20_D20200101-20201231", "decimals": null, "lang": "en-US", "name": "us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417408 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - REVENUE BY MAJOR PAYOR (Details)", "role": "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEREVENUEBYMAJORPAYORDetails", "shortName": "REVENUE AND ACCOUNTS RECEIVABLE - REVENUE BY MAJOR PAYOR (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "id8e665661e8d47ab8d14e672816263da_D20200101-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "idfce51e6cb5d45cc83386b544fe71b37_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418409 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - ACCOUNTS RECEIVABLE (Details)", "role": "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEACCOUNTSRECEIVABLEDetails", "shortName": "REVENUE AND ACCOUNTS RECEIVABLE - ACCOUNTS RECEIVABLE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "idfce51e6cb5d45cc83386b544fe71b37_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i57caed2175e0425291ba8ca1484ff2dc_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419410 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details)", "role": "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEALLOWANCEFORDOUBTFULACCOUNTSDetails", "shortName": "REVENUE AND ACCOUNTS RECEIVABLE - ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i3e3bc3b63f994468b2af58bff3e0546d_I20171231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i21fb1bfde1644a5e948465eba318333e_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "pntg:NumberOfServiceProviders", "reportCount": 1, "unitRef": "agency", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422411 - Disclosure - BUSINESS SEGMENTS - NARRATIVE (Details)", "role": "http://pennantgroup.com/role/BUSINESSSEGMENTSNARRATIVEDetails", "shortName": "BUSINESS SEGMENTS - NARRATIVE (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423412 - Disclosure - BUSINESS SEGMENTS - FINANCIAL DATA (Details)", "role": "http://pennantgroup.com/role/BUSINESSSEGMENTSFINANCIALDATADetails", "shortName": "BUSINESS SEGMENTS - FINANCIAL DATA (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i3f04d8170d814eb8a24e3798ec9cd108_D20200101-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "pntg:IncomeLossFromContinuingOperationsBeforeInterestTaxesDepreciationAndAmortizationRentCostsAcquisitionCostsAndStockBasedCompensation", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424413 - Disclosure - BUSINESS SEGMENTS - INCOME FROM OPERATIONS (Details)", "role": "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails", "shortName": "BUSINESS SEGMENTS - INCOME FROM OPERATIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "pntg:ReconciliationofAdjustedEBITDARtoIncomefromOperationsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": "-3", "lang": "en-US", "name": "pntg:StartUpActivitiesCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "pntg:NonCapitalizableRelatedToTheBusinessCombinations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427414 - Disclosure - ACQUISITIONS - NARRATIVE (Details)", "role": "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails", "shortName": "ACQUISITIONS - NARRATIVE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "pntg:NonCapitalizableRelatedToTheBusinessCombinations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i57caed2175e0425291ba8ca1484ff2dc_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428415 - Disclosure - ACQUISITIONS - OPERATIONS ACQUIRED (Details)", "role": "http://pennantgroup.com/role/ACQUISITIONSOPERATIONSACQUIREDDetails", "shortName": "ACQUISITIONS - OPERATIONS ACQUIRED (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i1e1ce177c97644868375b02a61fcecca_D20190101-20191231", "decimals": "-3", "lang": "en-US", "name": "pntg:TotalAcquisitions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i0f85d05cd91b496ebf76f9ba78fd784f_I20171231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - CONSOLIDATED AND COMBINED STATEMENTS OF STOCKHOLDERS' EQUITY AND NET PARENT INVESTMENT", "role": "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFSTOCKHOLDERSEQUITYANDNETPARENTINVESTMENT", "shortName": "CONSOLIDATED AND COMBINED STATEMENTS OF STOCKHOLDERS' EQUITY AND NET PARENT INVESTMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i0f85d05cd91b496ebf76f9ba78fd784f_I20171231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429416 - Disclosure - ACQUISITIONS - UNAUDITED PRO FORMA (Details)", "role": "http://pennantgroup.com/role/ACQUISITIONSUNAUDITEDPROFORMADetails", "shortName": "ACQUISITIONS - UNAUDITED PRO FORMA (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "idfce51e6cb5d45cc83386b544fe71b37_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432417 - Disclosure - PROPERTY AND EQUIPMENT\u2014NET (Details)", "role": "http://pennantgroup.com/role/PROPERTYANDEQUIPMENTNETDetails", "shortName": "PROPERTY AND EQUIPMENT\u2014NET (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "idfce51e6cb5d45cc83386b544fe71b37_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:AssetImpairmentCharges", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435418 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - NET - Narrative (Details)", "role": "http://pennantgroup.com/role/GOODWILLANDINTANGIBLEASSETSNETNarrativeDetails", "shortName": "GOODWILL AND INTANGIBLE ASSETS - NET - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:AssetImpairmentCharges", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i57caed2175e0425291ba8ca1484ff2dc_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436419 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - NET - ACTIVITY IN GOODWILL (Details)", "role": "http://pennantgroup.com/role/GOODWILLANDINTANGIBLEASSETSNETACTIVITYINGOODWILLDetails", "shortName": "GOODWILL AND INTANGIBLE ASSETS - NET - ACTIVITY IN GOODWILL (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "idfce51e6cb5d45cc83386b544fe71b37_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437420 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - NET - INDEFINITE-LIVED INTANGIBLE ASSETS (Details)", "role": "http://pennantgroup.com/role/GOODWILLANDINTANGIBLEASSETSNETINDEFINITELIVEDINTANGIBLEASSETSDetails", "shortName": "GOODWILL AND INTANGIBLE ASSETS - NET - INDEFINITE-LIVED INTANGIBLE ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i8ed05918f4c4443ea73ca7df67ed7bb1_I20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "idfce51e6cb5d45cc83386b544fe71b37_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CustomerRefundLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440421 - Disclosure - OTHER ACCRUED LIABILITIES (Details)", "role": "http://pennantgroup.com/role/OTHERACCRUEDLIABILITIESDetails", "shortName": "OTHER ACCRUED LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "idfce51e6cb5d45cc83386b544fe71b37_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CustomerRefundLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "idfce51e6cb5d45cc83386b544fe71b37_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "pntg:TheCoronavirusAidReliefAndEconomicSecurityActAdvancePaymentsReceived", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441422 - Disclosure - OTHER ACCRUED LIABILITIES - NARRATIVE (Details)", "role": "http://pennantgroup.com/role/OTHERACCRUEDLIABILITIESNARRATIVEDetails", "shortName": "OTHER ACCRUED LIABILITIES - NARRATIVE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "pntg:AcceleratedAndAdvancePaymentAmountPayable", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i6667a0cef12a4496a81c7a88734d93e9_I20201031", "decimals": "-3", "lang": "en-US", "name": "us-gaap:LiabilitiesNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "idfce51e6cb5d45cc83386b544fe71b37_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2444423 - Disclosure - DEBT - SCHEDULE OF LONG-TERM DEBT (Details)", "role": "http://pennantgroup.com/role/DEBTSCHEDULEOFLONGTERMDEBTDetails", "shortName": "DEBT - SCHEDULE OF LONG-TERM DEBT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "idfce51e6cb5d45cc83386b544fe71b37_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "idd48ca79f1cd4c5fb7ac162c8229b3b7_I20210223", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445424 - Disclosure - DEBT - NARRATIVE (Details)", "role": "http://pennantgroup.com/role/DEBTNARRATIVEDetails", "shortName": "DEBT - NARRATIVE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "idd48ca79f1cd4c5fb7ac162c8229b3b7_I20210223", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i7fe80b8fb4b54c779344732e638356d2_D20190101-20191001", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448425 - Disclosure - OPTIONS AND AWARDS - SHARE-BASED COMPENSATION (Details)", "role": "http://pennantgroup.com/role/OPTIONSANDAWARDSSHAREBASEDCOMPENSATIONDetails", "shortName": "OPTIONS AND AWARDS - SHARE-BASED COMPENSATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i533f874fe7ed4a6e80ded10992660b59_D20200101-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - CONSOLIDATED AND COMBINED STATEMENTS OF CASH FLOWS", "role": "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS", "shortName": "CONSOLIDATED AND COMBINED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i0943e16f09434aba99606fa0a75f02ed_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2449426 - Disclosure - OPTIONS AND AWARDS - NARRATIVE (Details)", "role": "http://pennantgroup.com/role/OPTIONSANDAWARDSNARRATIVEDetails", "shortName": "OPTIONS AND AWARDS - NARRATIVE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i0943e16f09434aba99606fa0a75f02ed_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i8298f7e426a14a20bddaeccf2e2d00be_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2450427 - Disclosure - OPTIONS AND AWARDS - OPTIONS GRANTED (Details)", "role": "http://pennantgroup.com/role/OPTIONSANDAWARDSOPTIONSGRANTEDDetails", "shortName": "OPTIONS AND AWARDS - OPTIONS GRANTED (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "ib718fbd34c1d42da903bc1a00e92efc3_D20200101-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i236479aaaffd4178b9952dbb90e06332_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2451428 - Disclosure - OPTIONS AND AWARDS - EMPLOYEE STOCK OPTION ACTIVITY (Details)", "role": "http://pennantgroup.com/role/OPTIONSANDAWARDSEMPLOYEESTOCKOPTIONACTIVITYDetails", "shortName": "OPTIONS AND AWARDS - EMPLOYEE STOCK OPTION ACTIVITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i8298f7e426a14a20bddaeccf2e2d00be_D20200101-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i65f9a2b3971b4e7ba5c8622e124929fe_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2452429 - Disclosure - OPTIONS AND AWARDS - AGGREGATE INTRINSIC VALUE OF OPTIONS (Details)", "role": "http://pennantgroup.com/role/OPTIONSANDAWARDSAGGREGATEINTRINSICVALUEOFOPTIONSDetails", "shortName": "OPTIONS AND AWARDS - AGGREGATE INTRINSIC VALUE OF OPTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i65f9a2b3971b4e7ba5c8622e124929fe_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "ic623bbbf99cc4f5db27f7d34f68dda1a_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2453430 - Disclosure - OPTIONS AND AWARDS - RESTRICTED STOCK AWARDS ACTIVITY (Details)", "role": "http://pennantgroup.com/role/OPTIONSANDAWARDSRESTRICTEDSTOCKAWARDSACTIVITYDetails", "shortName": "OPTIONS AND AWARDS - RESTRICTED STOCK AWARDS ACTIVITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "ic623bbbf99cc4f5db27f7d34f68dda1a_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "idfce51e6cb5d45cc83386b544fe71b37_I20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2456431 - Disclosure - LEASES - NARRATIVE (Details)", "role": "http://pennantgroup.com/role/LEASESNARRATIVEDetails", "shortName": "LEASES - NARRATIVE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "idfce51e6cb5d45cc83386b544fe71b37_I20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SubleaseIncome", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2457432 - Disclosure - LEASES - IMPACT OF NEW LEASES GUIDANCE (Details)", "role": "http://pennantgroup.com/role/LEASESIMPACTOFNEWLEASESGUIDANCEDetails", "shortName": "LEASES - IMPACT OF NEW LEASES GUIDANCE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SubleaseIncome", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "idfce51e6cb5d45cc83386b544fe71b37_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2458433 - Disclosure - LEASES - FUTURE MINIMUM LEASE PAYMENTS (Details)", "role": "http://pennantgroup.com/role/LEASESFUTUREMINIMUMLEASEPAYMENTSDetails", "shortName": "LEASES - FUTURE MINIMUM LEASE PAYMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "idfce51e6cb5d45cc83386b544fe71b37_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2461434 - Disclosure - INCOME TAXES - PROVISION FOR INCOME TAXES (Details)", "role": "http://pennantgroup.com/role/INCOMETAXESPROVISIONFORINCOMETAXESDetails", "shortName": "INCOME TAXES - PROVISION FOR INCOME TAXES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2462435 - Disclosure - INCOME TAXES - TAX RATE RECONCILIATION (Details)", "role": "http://pennantgroup.com/role/INCOMETAXESTAXRATERECONCILIATIONDetails", "shortName": "INCOME TAXES - TAX RATE RECONCILIATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - DESCRIPTION OF BUSINESS", "role": "http://pennantgroup.com/role/DESCRIPTIONOFBUSINESS", "shortName": "DESCRIPTION OF BUSINESS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i72ed24709c504ab8b5ffe97d91024569_D20191001-20191001", "decimals": "-3", "first": true, "lang": "en-US", "name": "pntg:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostsAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2463436 - Disclosure - INCOME TAXES - NARRATIVE (Details)", "role": "http://pennantgroup.com/role/INCOMETAXESNARRATIVEDetails", "shortName": "INCOME TAXES - NARRATIVE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i72ed24709c504ab8b5ffe97d91024569_D20191001-20191001", "decimals": "-3", "first": true, "lang": "en-US", "name": "pntg:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostsAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "idfce51e6cb5d45cc83386b544fe71b37_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2464437 - Disclosure - INCOME TAXES - DEFERRED TAX ASSETS AND LIABILITIES (Details)", "role": "http://pennantgroup.com/role/INCOMETAXESDEFERREDTAXASSETSANDLIABILITIESDetails", "shortName": "INCOME TAXES - DEFERRED TAX ASSETS AND LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "idfce51e6cb5d45cc83386b544fe71b37_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "idfce51e6cb5d45cc83386b544fe71b37_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "pntg:NumberOfOperatingSubsidiariesWithReviewsScheduled", "reportCount": 1, "unique": true, "unitRef": "review", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2466438 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "role": "http://pennantgroup.com/role/COMMITMENTSANDCONTINGENCIESDetails", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "idfce51e6cb5d45cc83386b544fe71b37_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "pntg:NumberOfOperatingSubsidiariesWithReviewsScheduled", "reportCount": 1, "unique": true, "unitRef": "review", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108103 - Disclosure - RELATED PARTY TRANSACTIONS AND NET PARENT INVESTMENT", "role": "http://pennantgroup.com/role/RELATEDPARTYTRANSACTIONSANDNETPARENTINVESTMENT", "shortName": "RELATED PARTY TRANSACTIONS AND NET PARENT INVESTMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pntg-20201231.htm", "contextRef": "i76149c649334415c96d65efc5b2c44f5_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 63, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r532", "r533", "r534" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r530" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r536" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r536" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r536" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r536" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r536" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r536" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r536" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r532", "r533", "r534" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r529" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "pntg_AcceleratedAndAdvancePaymentAmountPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accelerated And Advance Payment, Amount Payable", "label": "Accelerated And Advance Payment, Amount Payable", "negatedTerseLabel": "Long-term liabilities" } } }, "localname": "AcceleratedAndAdvancePaymentAmountPayable", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/OTHERACCRUEDLIABILITIESNARRATIVEDetails" ], "xbrltype": "monetaryItemType" }, "pntg_AccruedPayrollTaxesEmployerPortion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Payroll Taxes Employer Portion", "label": "Accrued Payroll Taxes Employer Portion", "terseLabel": "Accrued payroll taxes employer portion" } } }, "localname": "AccruedPayrollTaxesEmployerPortion", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "monetaryItemType" }, "pntg_AcquisitionRelatedCostsNotCapitalized": { "auth_ref": [], "calculation": { "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails": { "order": 6.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Acquisition-Related Costs, Not Capitalized", "label": "Acquisition-Related Costs, Not Capitalized", "terseLabel": "Transaction services costs" } } }, "localname": "AcquisitionRelatedCostsNotCapitalized", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails" ], "xbrltype": "monetaryItemType" }, "pntg_AdditionalPaidInCapitalBeforeTheEffectOfIncomeTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Additional Paid in Capital, Before the Effect of Income Tax", "label": "Additional Paid in Capital, Before the Effect of Income Tax", "terseLabel": "Income tax effect" } } }, "localname": "AdditionalPaidInCapitalBeforeTheEffectOfIncomeTax", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails" ], "xbrltype": "monetaryItemType" }, "pntg_AdjustmentOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustment Operating Lease Right-of-Use Asset And Operating Lease Liability", "label": "Adjustment Operating Lease Right-of-Use Asset And Operating Lease Liability", "terseLabel": "Net non-cash adjustment to right-of-use assets and lease liabilities from lease modifications" } } }, "localname": "AdjustmentOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "pntg_AssetAcquisitionAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition [Axis]", "label": "Asset Acquisition [Axis]", "terseLabel": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails" ], "xbrltype": "stringItemType" }, "pntg_AssetAcquisitionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Domain] for Asset Acquisition [Axis]", "label": "Asset Acquisition [Domain]", "terseLabel": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails" ], "xbrltype": "domainItemType" }, "pntg_AssetAcquisitions2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Acquisitions 2018 [Member]", "label": "Asset Acquisitions 2018 [Member]", "terseLabel": "Asset acquisitions 2018" } } }, "localname": "AssetAcquisitions2018Member", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails" ], "xbrltype": "domainItemType" }, "pntg_AssetAcquisitions2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Acquisitions 2019 [Member]", "label": "Asset Acquisitions 2019 [Member]", "terseLabel": "Asset acquisitions 2019" } } }, "localname": "AssetAcquisitions2019Member", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails" ], "xbrltype": "domainItemType" }, "pntg_AssetAcquisitions2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Acquisitions 2020", "label": "Asset Acquisitions 2020 [Member]", "terseLabel": "Asset Acquisitions 2020" } } }, "localname": "AssetAcquisitions2020Member", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails" ], "xbrltype": "domainItemType" }, "pntg_BusinessAcquisitions2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Acquisitions 2019 [Member]", "label": "Business Acquisitions 2019 [Member]", "terseLabel": "Business acquisitions 2019" } } }, "localname": "BusinessAcquisitions2019Member", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails" ], "xbrltype": "domainItemType" }, "pntg_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipmentFurnitureAndFixtures": { "auth_ref": [], "calculation": { "http://pennantgroup.com/role/ACQUISITIONSOPERATIONSACQUIREDDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equipment, Furniture and Fixtures", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equipment, Furniture and Fixtures", "terseLabel": "Equipment, furniture, and fixtures" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipmentFurnitureAndFixtures", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSOPERATIONSACQUIREDDetails" ], "xbrltype": "monetaryItemType" }, "pntg_BusinessCombinationandAssetAcquisitionConsiderationTransferred": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination and Asset Acquisition, Consideration Transferred", "label": "Business Combination and Asset Acquisition, Consideration Transferred", "terseLabel": "Business combination and asset acquisition, purchase price" } } }, "localname": "BusinessCombinationandAssetAcquisitionConsiderationTransferred", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails" ], "xbrltype": "monetaryItemType" }, "pntg_CashAndContributedAssetsNetBookValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash And Contributed Assets Net Book Value", "label": "Cash And Contributed Assets Net Book Value", "terseLabel": "Net book value" } } }, "localname": "CashAndContributedAssetsNetBookValue", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails" ], "xbrltype": "monetaryItemType" }, "pntg_CorridorAsAnAdditionalOutOfPocketRetention": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Corridor as an Additional Out-of-Pocket Retention", "label": "Corridor as an Additional Out-of-Pocket Retention", "terseLabel": "Out-of-pocket retention" } } }, "localname": "CorridorAsAnAdditionalOutOfPocketRetention", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "monetaryItemType" }, "pntg_DeferredTaxAssetsLeaseLiabilities": { "auth_ref": [], "calculation": { "http://pennantgroup.com/role/INCOMETAXESDEFERREDTAXASSETSANDLIABILITIESDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets, Lease Liabilities", "label": "Deferred Tax Assets, Lease Liabilities", "terseLabel": "Lease liabilities" } } }, "localname": "DeferredTaxAssetsLeaseLiabilities", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESDEFERREDTAXASSETSANDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "pntg_DeferredTaxLiabilitiesDepreciationAndAmortization": { "auth_ref": [], "calculation": { "http://pennantgroup.com/role/INCOMETAXESDEFERREDTAXASSETSANDLIABILITIESDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Liabilities, Depreciation And Amortization", "label": "Deferred Tax Liabilities, Depreciation And Amortization", "negatedTerseLabel": "Depreciation and amortization" } } }, "localname": "DeferredTaxLiabilitiesDepreciationAndAmortization", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESDEFERREDTAXASSETSANDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "pntg_DirectMedicalSuppliesLaborAndOtherExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Direct Medical Supplies, Labor, and Other Expenses", "label": "Direct Medical Supplies, Labor, and Other Expenses", "terseLabel": "Direct medical supplies, labor, and other expenses" } } }, "localname": "DirectMedicalSuppliesLaborAndOtherExpenses", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails" ], "xbrltype": "monetaryItemType" }, "pntg_DistributionToFromParent": { "auth_ref": [], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Distribution (To) From Parent", "label": "Distribution (To) From Parent", "terseLabel": "Net investment from/(to) parent" } } }, "localname": "DistributionToFromParent", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "pntg_EffectiveIncomeTaxRateReconciliationAcquisitionOfBusinessesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Acquisition Of Businesses, Percent", "label": "Effective Income Tax Rate Reconciliation, Acquisition Of Businesses, Percent", "terseLabel": "Statutory tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAcquisitionOfBusinessesPercent", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSUNAUDITEDPROFORMADetails" ], "xbrltype": "percentItemType" }, "pntg_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostsAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Transaction Costs, Amount", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Transaction Costs, Amount", "terseLabel": "Nondeductible transaction costs" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostsAmount", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESNARRATIVEDetails" ], "xbrltype": "monetaryItemType" }, "pntg_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent": { "auth_ref": [], "calculation": { "http://pennantgroup.com/role/INCOMETAXESTAXRATERECONCILIATIONDetails": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Transaction Costs, Percent", "label": "Effective Income Tax Rate Reconciliation, Transaction Costs, Percent", "terseLabel": "Transaction costs(a)" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTransactionCostsPercent", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESTAXRATERECONCILIATIONDetails" ], "xbrltype": "percentItemType" }, "pntg_FacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facility [Member]", "label": "Facility [Member]", "terseLabel": "Facility" } } }, "localname": "FacilityMember", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/LEASESIMPACTOFNEWLEASESGUIDANCEDetails" ], "xbrltype": "domainItemType" }, "pntg_GeneralAndProfessionalInsuranceLiability": { "auth_ref": [], "calculation": { "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSUMMARYOFINSURANCELIABILITYDetails": { "order": 1.0, "parentTag": "pntg_InsuranceProgramAccruedExpenses", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "General And Professional Insurance Liability", "label": "General And Professional Insurance Liability", "terseLabel": "General and professional liability" } } }, "localname": "GeneralAndProfessionalInsuranceLiability", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSUMMARYOFINSURANCELIABILITYDetails" ], "xbrltype": "monetaryItemType" }, "pntg_GeneralAndProfessionalLiabilityInsuranceRetentionLimitPerClaim": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "General And Professional Liability Insurance, Retention Limit, Per Claim", "label": "General And Professional Liability Insurance, Retention Limit, Per Claim", "terseLabel": "General and professional liability, retention limit" } } }, "localname": "GeneralAndProfessionalLiabilityInsuranceRetentionLimitPerClaim", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "monetaryItemType" }, "pntg_GrantYear2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Grant Year 2019 [Member]", "label": "Grant Year 2019 [Member]", "terseLabel": "2019" } } }, "localname": "GrantYear2019Member", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSOPTIONSGRANTEDDetails" ], "xbrltype": "domainItemType" }, "pntg_GrantYear2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Grant Year 2020", "label": "Grant Year 2020 [Member]", "terseLabel": "2020" } } }, "localname": "GrantYear2020Member", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSOPTIONSGRANTEDDetails" ], "xbrltype": "domainItemType" }, "pntg_HomeCareSubsegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Home Care Subsegment [Member]", "label": "Home Care Subsegment [Member]", "terseLabel": "Home Care" } } }, "localname": "HomeCareSubsegmentMember", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails" ], "xbrltype": "domainItemType" }, "pntg_HomeHealthAndHospiceServicesSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Home Health And Hospice Services Segment [Member]", "label": "Home Health And Hospice Services Segment [Member]", "terseLabel": "Home Health and Hospice Services" } } }, "localname": "HomeHealthAndHospiceServicesSegmentMember", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails", "http://pennantgroup.com/role/BUSINESSSEGMENTSFINANCIALDATADetails", "http://pennantgroup.com/role/BUSINESSSEGMENTSNARRATIVEDetails", "http://pennantgroup.com/role/DESCRIPTIONOFBUSINESSDetails", "http://pennantgroup.com/role/GOODWILLANDINTANGIBLEASSETSNETACTIVITYINGOODWILLDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEREVENUEBYMAJORPAYORDetails" ], "xbrltype": "domainItemType" }, "pntg_HomeHealthJointVentureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Home Health Joint Venture", "label": "Home Health Joint Venture [Member]", "terseLabel": "Home Health Joint Venture" } } }, "localname": "HomeHealthJointVentureMember", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails" ], "xbrltype": "domainItemType" }, "pntg_HomeHealthSubsegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Home Health Subsegment [Member]", "label": "Home Health Subsegment [Member]", "terseLabel": "Home Health Services" } } }, "localname": "HomeHealthSubsegmentMember", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEREVENUEBYMAJORPAYORDetails" ], "xbrltype": "domainItemType" }, "pntg_HospiceJoinVentureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hospice Join Venture", "label": "Hospice Join Venture [Member]", "terseLabel": "Hospice Join Venture" } } }, "localname": "HospiceJoinVentureMember", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails" ], "xbrltype": "domainItemType" }, "pntg_HospiceSubsegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hospice Subsegment [Member]", "label": "Hospice Subsegment [Member]", "terseLabel": "Hospice Services" } } }, "localname": "HospiceSubsegmentMember", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEREVENUEBYMAJORPAYORDetails" ], "xbrltype": "domainItemType" }, "pntg_IncomeLossFromContinuingOperationsBeforeInterestTaxesDepreciationAndAmortizationRentCostsAcquisitionCostsAndStockBasedCompensation": { "auth_ref": [], "calculation": { "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income (Loss) From Continuing Operations Before Interest, Taxes, Depreciation And Amortization, Rent Costs, Acquisition Costs And Stock-based Compensation", "label": "Income (Loss) From Continuing Operations Before Interest, Taxes, Depreciation And Amortization, Rent Costs, Acquisition Costs And Stock-based Compensation", "terseLabel": "Segment Adjusted EBITDAR from Operations", "verboseLabel": "Segment Adjusted EBITDAR from Operations" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeInterestTaxesDepreciationAndAmortizationRentCostsAcquisitionCostsAndStockBasedCompensation", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/BUSINESSSEGMENTSFINANCIALDATADetails", "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails" ], "xbrltype": "monetaryItemType" }, "pntg_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Operating Lease Liability", "label": "Increase (Decrease) In Operating Lease Liability", "terseLabel": "Operating lease obligations" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "pntg_IncrementalCostsDirectMedicalSuppliesLaborAndOtherExpenses": { "auth_ref": [], "calculation": { "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails": { "order": 11.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Incremental Costs, Direct Medical Supplies, Labor, and Other Expenses", "label": "Incremental Costs, Direct Medical Supplies, Labor, and Other Expenses", "terseLabel": "Incremental Costs, Direct Medical Supplies, Labor, and Other Expenses" } } }, "localname": "IncrementalCostsDirectMedicalSuppliesLaborAndOtherExpenses", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails" ], "xbrltype": "monetaryItemType" }, "pntg_InsuranceProgramAccruedExpenses": { "auth_ref": [], "calculation": { "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSUMMARYOFINSURANCELIABILITYDetails": { "order": 1.0, "parentTag": "pntg_InsuranceProgramAccruedExpensesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Insurance Program Accrued Expenses", "label": "Insurance Program Accrued Expenses", "totalLabel": "Total estimated liability" } } }, "localname": "InsuranceProgramAccruedExpenses", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSUMMARYOFINSURANCELIABILITYDetails" ], "xbrltype": "monetaryItemType" }, "pntg_InsuranceProgramAccruedExpensesCurrent": { "auth_ref": [], "calculation": { "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSUMMARYOFINSURANCELIABILITYDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Insurance Program Accrued Expenses, Current", "label": "Insurance Program Accrued Expenses, Current", "totalLabel": "Current portion of estimated liability, included in other accrued liabilities" } } }, "localname": "InsuranceProgramAccruedExpensesCurrent", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSUMMARYOFINSURANCELIABILITYDetails" ], "xbrltype": "monetaryItemType" }, "pntg_InsuranceProgramAccruedExpensesNoncurrent": { "auth_ref": [], "calculation": { "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSUMMARYOFINSURANCELIABILITYDetails": { "order": 2.0, "parentTag": "pntg_InsuranceProgramAccruedExpensesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Insurance Program Accrued Expenses, Noncurrent", "label": "Insurance Program Accrued Expenses, Noncurrent", "negatedTerseLabel": "Less: long-term portion, included in other long-term liabilities" } } }, "localname": "InsuranceProgramAccruedExpensesNoncurrent", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSUMMARYOFINSURANCELIABILITYDetails" ], "xbrltype": "monetaryItemType" }, "pntg_InterimPeriods": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interim Periods", "label": "Interim Periods", "terseLabel": "Interim periods" } } }, "localname": "InterimPeriods", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails" ], "xbrltype": "monetaryItemType" }, "pntg_InvestedCapitalPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Invested Capital [Policy Text Block]", "label": "Invested Capital [Policy Text Block]", "terseLabel": "Invested Capital" } } }, "localname": "InvestedCapitalPolicyTextBlock", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "pntg_ManagedCareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Managed Care [Member]", "label": "Managed Care [Member]", "terseLabel": "Managed care" } } }, "localname": "ManagedCareMember", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEACCOUNTSRECEIVABLEDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEREVENUEBYMAJORPAYORDetails" ], "xbrltype": "domainItemType" }, "pntg_MedicaidMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medicaid [Member]", "label": "Medicaid [Member]", "terseLabel": "Medicaid" } } }, "localname": "MedicaidMember", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEACCOUNTSRECEIVABLEDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEREVENUEBYMAJORPAYORDetails" ], "xbrltype": "domainItemType" }, "pntg_MedicareAndMedicaidMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medicare And Medicaid [Member]", "label": "Medicare And Medicaid [Member]", "verboseLabel": "Subtotal" } } }, "localname": "MedicareAndMedicaidMember", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLENARRATIVEDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEREVENUEBYMAJORPAYORDetails" ], "xbrltype": "domainItemType" }, "pntg_MedicareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medicare [Member]", "label": "Medicare [Member]", "terseLabel": "Medicare" } } }, "localname": "MedicareMember", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEACCOUNTSRECEIVABLEDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEREVENUEBYMAJORPAYORDetails" ], "xbrltype": "domainItemType" }, "pntg_NetParentInvestment": { "auth_ref": [], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net Parent Investment", "label": "Net Parent Investment", "totalLabel": "Total Pennant Group, Inc. stockholders' equity" } } }, "localname": "NetParentInvestment", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "pntg_NonCapitalizableRelatedToTheBusinessCombinations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non-capitalizable Related to the Business Combinations", "label": "Non-capitalizable Related to the Business Combinations", "terseLabel": "Non-capitalizable" } } }, "localname": "NonCapitalizableRelatedToTheBusinessCombinations", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails" ], "xbrltype": "monetaryItemType" }, "pntg_NoncontrollingInterestHoldersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Noncontrolling Interest Holders [Member]", "label": "Noncontrolling Interest Holders [Member]", "terseLabel": "Noncontrolling Interest Holders" } } }, "localname": "NoncontrollingInterestHoldersMember", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARENARRATIVEDetails" ], "xbrltype": "domainItemType" }, "pntg_NoncontrollingInterestJointVenture": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncontrolling Interest Joint Venture", "label": "Noncontrolling Interest Joint Venture", "terseLabel": "Noncontrolling interest to scripps" } } }, "localname": "NoncontrollingInterestJointVenture", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails" ], "xbrltype": "monetaryItemType" }, "pntg_NumberOfAssetAcquisitions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Asset Acquisitions", "label": "Number Of Asset Acquisitions", "terseLabel": "Number of asset acquisitions" } } }, "localname": "NumberOfAssetAcquisitions", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails" ], "xbrltype": "integerItemType" }, "pntg_NumberOfBusinessesAndAssetsAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Businesses And Assets Acquired", "label": "Number Of Businesses And Assets Acquired", "terseLabel": "Number of businesses acquired and assets acquisitions" } } }, "localname": "NumberOfBusinessesAndAssetsAcquired", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails" ], "xbrltype": "integerItemType" }, "pntg_NumberOfOperatingSubsidiariesWithReviewsScheduled": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Operating Subsidiaries With Reviews Scheduled", "label": "Number Of Operating Subsidiaries With Reviews Scheduled", "terseLabel": "Number of operating subsidiaries with reviews scheduled" } } }, "localname": "NumberOfOperatingSubsidiariesWithReviewsScheduled", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "integerItemType" }, "pntg_NumberOfRealEstatePropertiesUnderLease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Real Estate Properties Under Lease", "label": "Number Of Real Estate Properties Under Lease", "terseLabel": "Number of properties under lease" } } }, "localname": "NumberOfRealEstatePropertiesUnderLease", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/BUSINESSSEGMENTSNARRATIVEDetails", "http://pennantgroup.com/role/DESCRIPTIONOFBUSINESSDetails", "http://pennantgroup.com/role/LEASESNARRATIVEDetails" ], "xbrltype": "integerItemType" }, "pntg_NumberOfRealEstatePropertiesUnderLeaseMasterLeaseAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Real Estate Properties Under Lease, Master Lease Agreement", "label": "Number Of Real Estate Properties Under Lease, Master Lease Agreement", "terseLabel": "Number of properties under lease, master lease agreement" } } }, "localname": "NumberOfRealEstatePropertiesUnderLeaseMasterLeaseAgreement", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/LEASESNARRATIVEDetails" ], "xbrltype": "integerItemType" }, "pntg_NumberOfSeparateMasterLeaseArrangements": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Separate Master Lease Arrangements", "label": "Number of Separate Master Lease Arrangements", "terseLabel": "Number of separate master lease arrangements" } } }, "localname": "NumberOfSeparateMasterLeaseArrangements", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/LEASESNARRATIVEDetails" ], "xbrltype": "integerItemType" }, "pntg_NumberOfServiceProviders": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Service Providers", "label": "Number Of Service Providers", "terseLabel": "Number of service providers" } } }, "localname": "NumberOfServiceProviders", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/BUSINESSSEGMENTSNARRATIVEDetails", "http://pennantgroup.com/role/DESCRIPTIONOFBUSINESSDetails" ], "xbrltype": "integerItemType" }, "pntg_NumberOfUnitsInRealEstatePropertyAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Units In Real Estate Property Acquired", "label": "Number Of Units In Real Estate Property Acquired", "terseLabel": "Number of units (in units)" } } }, "localname": "NumberOfUnitsInRealEstatePropertyAcquired", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails" ], "xbrltype": "integerItemType" }, "pntg_OperatingLeaseRentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Lease, Rent Expense [Member]", "label": "Operating Lease, Rent Expense [Member]", "terseLabel": "Operating lease, rent expense" } } }, "localname": "OperatingLeaseRentExpenseMember", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/RELATEDPARTYTRANSACTIONSANDNETPARENTINVESTMENTDetails" ], "xbrltype": "domainItemType" }, "pntg_PayablesAndAccrualsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payables and Accruals", "label": "Payables and Accruals [Line Items]", "terseLabel": "Payables and Accruals [Line Items]" } } }, "localname": "PayablesAndAccrualsLineItems", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/OTHERACCRUEDLIABILITIESNARRATIVEDetails" ], "xbrltype": "stringItemType" }, "pntg_PayablesAndAccrualsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payables and Accruals [Table]", "label": "Payables and Accruals [Table]", "terseLabel": "Payables and Accruals [Table]" } } }, "localname": "PayablesAndAccrualsTable", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/OTHERACCRUEDLIABILITIESNARRATIVEDetails" ], "xbrltype": "stringItemType" }, "pntg_PaymentsForDepositsOnAcquisition": { "auth_ref": [], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Deposits On Acquisition", "label": "Payments For Deposits On Acquisition", "negatedTerseLabel": "Escrow deposits" } } }, "localname": "PaymentsForDepositsOnAcquisition", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "pntg_PaymentsForProceedsFromPropertyReserveRequirements": { "auth_ref": [], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For (Proceeds From) Property Reserve Requirements", "label": "Payments For (Proceeds From) Property Reserve Requirements", "negatedTerseLabel": "Restricted and other assets" } } }, "localname": "PaymentsForProceedsFromPropertyReserveRequirements", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "pntg_PaymentsforAssetAcquisitions": { "auth_ref": [], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments for Asset Acquisitions", "label": "Payments for Asset Acquisitions", "negatedTerseLabel": "Cash payments for asset acquisitions" } } }, "localname": "PaymentsforAssetAcquisitions", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "pntg_PrivateAndOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private And Other [Member]", "label": "Private And Other [Member]", "terseLabel": "Private and other" } } }, "localname": "PrivateAndOtherMember", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEACCOUNTSRECEIVABLEDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEREVENUEBYMAJORPAYORDetails" ], "xbrltype": "domainItemType" }, "pntg_ProceedsFromSaleOfSubsidiaryShares": { "auth_ref": [], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Sale Of Subsidiary Shares", "label": "Proceeds From Sale Of Subsidiary Shares", "terseLabel": "Proceeds from sale of subsidiary shares" } } }, "localname": "ProceedsFromSaleOfSubsidiaryShares", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "pntg_ReclassificationOfInvestedEquity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reclassification Of Invested Equity", "label": "Reclassification Of Invested Equity", "terseLabel": "Reclassification of Invested Equity" } } }, "localname": "ReclassificationOfInvestedEquity", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFSTOCKHOLDERSEQUITYANDNETPARENTINVESTMENT" ], "xbrltype": "monetaryItemType" }, "pntg_RecognitionOfTaxBenefitsRelatedToTaxMattersAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Recognition Of Tax Benefits Related To Tax Matters Agreement", "label": "Recognition Of Tax Benefits Related To Tax Matters Agreement [Member]", "terseLabel": "Recognition of tax benefits related to Tax Matters Agreement" } } }, "localname": "RecognitionOfTaxBenefitsRelatedToTaxMattersAgreementMember", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/RELATEDPARTYTRANSACTIONSANDNETPARENTINVESTMENTDetails" ], "xbrltype": "domainItemType" }, "pntg_ReconciliationofAdjustedEBITDARtoIncomefromOperationsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reconciliation of Adjusted EBITDAR to Income from Operations [Table Text Block]", "label": "Reconciliation of Adjusted EBITDAR to Income from Operations [Table Text Block]", "terseLabel": "Reconciliation of total Combined Adjusted EBITDAR from Operations for our reportable segments to Combined Income from Operations" } } }, "localname": "ReconciliationofAdjustedEBITDARtoIncomefromOperationsTableTextBlock", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/BUSINESSSEGMENTSTables" ], "xbrltype": "textBlockItemType" }, "pntg_RevenuefromContractwithCustomerAndAccountsReceivablesDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue from Contract with Customer And Accounts Receivables Disclosure [Text Block]", "label": "Revenue from Contract with Customer And Accounts Receivables Disclosure [Text Block]", "terseLabel": "Revenue and accounts receivable" } } }, "localname": "RevenuefromContractwithCustomerAndAccountsReceivablesDisclosureTextBlock", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLE" ], "xbrltype": "textBlockItemType" }, "pntg_ScrippsHealthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Scripps Health", "label": "Scripps Health [Member]", "terseLabel": "Scripps Health" } } }, "localname": "ScrippsHealthMember", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails" ], "xbrltype": "domainItemType" }, "pntg_SeniorLivingServicesSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Living Services Segment [Member]", "label": "Senior Living Services Segment [Member]", "terseLabel": "Senior Living Services" } } }, "localname": "SeniorLivingServicesSegmentMember", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails", "http://pennantgroup.com/role/BUSINESSSEGMENTSFINANCIALDATADetails", "http://pennantgroup.com/role/BUSINESSSEGMENTSNARRATIVEDetails", "http://pennantgroup.com/role/DESCRIPTIONOFBUSINESSDetails", "http://pennantgroup.com/role/GOODWILLANDINTANGIBLEASSETSNETACTIVITYINGOODWILLDetails", "http://pennantgroup.com/role/LEASESNARRATIVEDetails", "http://pennantgroup.com/role/RELATEDPARTYTRANSACTIONSANDNETPARENTINVESTMENTDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLENARRATIVEDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEREVENUEBYMAJORPAYORDetails" ], "xbrltype": "domainItemType" }, "pntg_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Unvested" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSAGGREGATEINTRINSICVALUEOFOPTIONSDetails" ], "xbrltype": "monetaryItemType" }, "pntg_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Outstanding, Aggregate Intrinsic Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Vested" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSAGGREGATEINTRINSICVALUEOFOPTIONSDetails" ], "xbrltype": "monetaryItemType" }, "pntg_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedOutstandingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Outstanding, Number", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Outstanding, Number", "terseLabel": "Number of options vested (in shares)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedOutstandingNumber", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSEMPLOYEESTOCKOPTIONACTIVITYDetails" ], "xbrltype": "sharesItemType" }, "pntg_SoftwareExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Software Expense", "label": "Software Expense", "terseLabel": "Software expense" } } }, "localname": "SoftwareExpense", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails" ], "xbrltype": "monetaryItemType" }, "pntg_SpinOffTransactionDistributionRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Spin Off Transaction, Distribution Ratio", "label": "Spin Off Transaction, Distribution Ratio", "terseLabel": "Spin-off transaction, distribution ratio" } } }, "localname": "SpinOffTransactionDistributionRatio", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/DESCRIPTIONOFBUSINESSDetails" ], "xbrltype": "pureItemType" }, "pntg_SpinoffTransactionCosts": { "auth_ref": [], "calculation": { "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails": { "order": 7.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Spinoff, Transaction Costs", "label": "Spinoff, Transaction Costs", "terseLabel": "Spin-off related transaction costs" } } }, "localname": "SpinoffTransactionCosts", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails" ], "xbrltype": "monetaryItemType" }, "pntg_StartUpActivitiesCosts": { "auth_ref": [], "calculation": { "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Start-Up Activities, Costs", "label": "Start-Up Activities, Costs", "terseLabel": "Less: Costs at start-up operations" } } }, "localname": "StartUpActivitiesCosts", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails" ], "xbrltype": "monetaryItemType" }, "pntg_StockholdersEquityDistributionsFromParent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stockholders' Equity, Distributions From Parent", "label": "Stockholders' Equity, Distributions From Parent", "terseLabel": "Net transfer from parent" } } }, "localname": "StockholdersEquityDistributionsFromParent", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFSTOCKHOLDERSEQUITYANDNETPARENTINVESTMENT" ], "xbrltype": "monetaryItemType" }, "pntg_SummaryOfInsuranceLiabilityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary Of Insurance Liability", "label": "Summary Of Insurance Liability [Table Text Block]", "terseLabel": "Summary of insurance liability" } } }, "localname": "SummaryOfInsuranceLiabilityTableTextBlock", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "pntg_TheCoronavirusAidReliefAndEconomicSecurityActAdvancePaymentsReceived": { "auth_ref": [], "calculation": { "http://pennantgroup.com/role/OTHERACCRUEDLIABILITIESDetails": { "order": 6.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The Coronavirus Aid, Relief, and Economic Security Act, Advance Payments Received", "label": "The Coronavirus Aid, Relief, and Economic Security Act, Advance Payments Received", "terseLabel": "Contract Liabilities (CARES Act advance payments)" } } }, "localname": "TheCoronavirusAidReliefAndEconomicSecurityActAdvancePaymentsReceived", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://pennantgroup.com/role/OTHERACCRUEDLIABILITIESDetails", "http://pennantgroup.com/role/OTHERACCRUEDLIABILITIESNARRATIVEDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLENARRATIVEDetails" ], "xbrltype": "monetaryItemType" }, "pntg_TheEnsignPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Ensign Plans [Member]", "label": "The Ensign Plans [Member]", "terseLabel": "The Ensign Plans" } } }, "localname": "TheEnsignPlansMember", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESNARRATIVEDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSAGGREGATEINTRINSICVALUEOFOPTIONSDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSEMPLOYEESTOCKOPTIONACTIVITYDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSNARRATIVEDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSOPTIONSGRANTEDDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSRESTRICTEDSTOCKAWARDSACTIVITYDetails" ], "xbrltype": "domainItemType" }, "pntg_TotalAcquisitions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total Acquisitions", "label": "Total Acquisitions", "terseLabel": "Total acquisitions" } } }, "localname": "TotalAcquisitions", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSOPERATIONSACQUIREDDetails" ], "xbrltype": "monetaryItemType" }, "pntg_TransitionServicesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transition Services Agreement", "label": "Transition Services Agreement [Member]", "terseLabel": "Transition Services Agreement" } } }, "localname": "TransitionServicesAgreementMember", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails", "http://pennantgroup.com/role/RELATEDPARTYTRANSACTIONSANDNETPARENTINVESTMENTDetails" ], "xbrltype": "domainItemType" }, "pntg_WorkersCompensationInsuranceRetentionLimitPerClaim": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Workers' Compensation Insurance, Retention Limit, Per Claim", "label": "Workers' Compensation Insurance, Retention Limit, Per Claim", "terseLabel": "Workers' compensation, retention limit" } } }, "localname": "WorkersCompensationInsuranceRetentionLimitPerClaim", "nsuri": "http://pennantgroup.com/20201231", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "monetaryItemType" }, "srt_AffiliatedEntityMember": { "auth_ref": [ "r269", "r431", "r432", "r435", "r528" ], "lang": { "en-us": { "role": { "label": "Affiliated Entity [Member]", "terseLabel": "Related party" } } }, "localname": "AffiliatedEntityMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails", "http://pennantgroup.com/role/LEASESNARRATIVEDetails", "http://pennantgroup.com/role/RELATEDPARTYTRANSACTIONSANDNETPARENTINVESTMENTDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r147", "r160", "r161", "r162", "r163", "r165", "r167", "r171" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BUSINESSSEGMENTSFINANCIALDATADetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r147", "r160", "r161", "r162", "r163", "r165", "r167", "r171" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BUSINESSSEGMENTSFINANCIALDATADetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r48", "r93" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails", "http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARENARRATIVEDetails" ], "xbrltype": "stringItemType" }, "srt_DirectorMember": { "auth_ref": [ "r179" ], "lang": { "en-us": { "role": { "label": "Director [Member]", "terseLabel": "Non-employee director" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSSHAREBASEDCOMPENSATIONDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r177", "r258", "r262", "r497" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://pennantgroup.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEACCOUNTSRECEIVABLEDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLENARRATIVEDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEREVENUEBYMAJORPAYORDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r271", "r273", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r496", "r498" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://pennantgroup.com/role/DEBTNARRATIVEDetails", "http://pennantgroup.com/role/LEASESNARRATIVEDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSNARRATIVEDetails", "http://pennantgroup.com/role/RELATEDPARTYTRANSACTIONSANDNETPARENTINVESTMENTDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r271", "r273", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r496", "r498" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://pennantgroup.com/role/DEBTNARRATIVEDetails", "http://pennantgroup.com/role/LEASESNARRATIVEDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSNARRATIVEDetails", "http://pennantgroup.com/role/RELATEDPARTYTRANSACTIONSANDNETPARENTINVESTMENTDetails" ], "xbrltype": "domainItemType" }, "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": { "auth_ref": [ "r514", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527" ], "lang": { "en-us": { "role": { "label": "Real Estate, Type of Property [Axis]", "terseLabel": "Real Estate, Type of Property [Axis]" } } }, "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://pennantgroup.com/role/LEASESIMPACTOFNEWLEASESGUIDANCEDetails" ], "xbrltype": "stringItemType" }, "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": { "auth_ref": [ "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526" ], "lang": { "en-us": { "role": { "label": "Real Estate [Domain]", "terseLabel": "Real Estate [Domain]" } } }, "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://pennantgroup.com/role/LEASESIMPACTOFNEWLEASESGUIDANCEDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r177", "r258", "r262", "r497" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://pennantgroup.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEACCOUNTSRECEIVABLEDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLENARRATIVEDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEREVENUEBYMAJORPAYORDetails" ], "xbrltype": "domainItemType" }, "srt_OfficeBuildingMember": { "auth_ref": [ "r514", "r527" ], "lang": { "en-us": { "role": { "label": "Office Building [Member]", "terseLabel": "Office" } } }, "localname": "OfficeBuildingMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://pennantgroup.com/role/LEASESIMPACTOFNEWLEASESGUIDANCEDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r268", "r271", "r273", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r496", "r498" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://pennantgroup.com/role/DEBTNARRATIVEDetails", "http://pennantgroup.com/role/LEASESNARRATIVEDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSNARRATIVEDetails", "http://pennantgroup.com/role/RELATEDPARTYTRANSACTIONSANDNETPARENTINVESTMENTDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r268", "r271", "r273", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r496", "r498" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://pennantgroup.com/role/DEBTNARRATIVEDetails", "http://pennantgroup.com/role/LEASESNARRATIVEDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSNARRATIVEDetails", "http://pennantgroup.com/role/RELATEDPARTYTRANSACTIONSANDNETPARENTINVESTMENTDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails", "http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARENARRATIVEDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAdjustmentMember": { "auth_ref": [ "r97", "r98", "r99", "r100", "r101", "r102", "r105", "r106", "r107", "r109", "r110", "r112", "r113", "r125" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period, Adjustment [Member]", "terseLabel": "Revision of Prior Period, Adjustment" } } }, "localname": "RestatementAdjustmentMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OTHERACCRUEDLIABILITIESNARRATIVEDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r97", "r98", "r99", "r100", "r101", "r102", "r105", "r106", "r107", "r109", "r110", "r111", "r112", "r113", "r125", "r194", "r195", "r316", "r347", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]", "terseLabel": "Revision of Prior Period [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OTHERACCRUEDLIABILITIESNARRATIVEDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEALLOWANCEFORDOUBTFULACCOUNTSDetails" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r97", "r98", "r99", "r100", "r101", "r102", "r105", "r106", "r107", "r109", "r110", "r111", "r112", "r113", "r125", "r194", "r195", "r316", "r347", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]", "terseLabel": "Revision of Prior Period [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OTHERACCRUEDLIABILITIESNARRATIVEDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEALLOWANCEFORDOUBTFULACCOUNTSDetails" ], "xbrltype": "domainItemType" }, "srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember": { "auth_ref": [ "r101", "r102", "r107", "r194", "r195", "r316", "r347", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period, Accounting Standards Update, Adjustment [Member]", "terseLabel": "Revision of Prior Period, Accounting Standards Update, Adjustment" } } }, "localname": "RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEALLOWANCEFORDOUBTFULACCOUNTSDetails" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r179", "r434" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSSHAREBASEDCOMPENSATIONDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSSHAREBASEDCOMPENSATIONDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r101", "r102", "r103", "r104", "r190", "r191", "r192", "r193", "r194", "r195", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r346", "r347", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510" ], "lang": { "en-us": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update [Extensible List]", "terseLabel": "Accounting Standards Update [Extensible List]" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEALLOWANCEFORDOUBTFULACCOUNTSDetails" ], "xbrltype": "extensibleListItemType" }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]" } } }, "localname": "AccountsNotesAndLoansReceivableLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEACCOUNTSRECEIVABLEDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEALLOWANCEFORDOUBTFULACCOUNTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "auth_ref": [ "r201" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsReceivableGrossCurrent": { "auth_ref": [ "r180", "r181" ], "calculation": { "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEACCOUNTSRECEIVABLEDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, before Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, gross" } } }, "localname": "AccountsReceivableGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEACCOUNTSRECEIVABLEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Receivables" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r2", "r22", "r180", "r181" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEACCOUNTSRECEIVABLEDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable\u2014less allowance for doubtful accounts of $643 and $677, respectively", "totalLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEACCOUNTSRECEIVABLEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]", "terseLabel": "Accounts Receivable [Abstract]" } } }, "localname": "AccountsReceivableNetCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEACCOUNTSRECEIVABLEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent": { "auth_ref": [ "r6", "r37", "r322" ], "calculation": { "http://pennantgroup.com/role/OTHERACCRUEDLIABILITIESDetails": { "order": 4.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrual for Taxes Other than Income Taxes, Current", "terseLabel": "Property taxes" } } }, "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OTHERACCRUEDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]", "terseLabel": "Other Accrued Liabilities, Current [Abstract]" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OTHERACCRUEDLIABILITIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r32", "r220" ], "calculation": { "http://pennantgroup.com/role/PROPERTYANDEQUIPMENTNETDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/PROPERTYANDEQUIPMENTNETDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosures of cash flow information:" } } }, "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r23", "r316" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "pntg_NetParentInvestment", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "verboseLabel": "Additional paid in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails", "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r97", "r98", "r100", "r313", "r314", "r315" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFSTOCKHOLDERSEQUITYANDNETPARENTINVESTMENT" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Shares of common stock withheld to satisfy tax withholding obligations" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFSTOCKHOLDERSEQUITYANDNETPARENTINVESTMENT" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r274", "r276", "r319", "r320" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFSTOCKHOLDERSEQUITYANDNETPARENTINVESTMENT" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r276", "r305", "r318" ], "calculation": { "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails": { "order": 5.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Share-based compensation", "verboseLabel": "Share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSSHAREBASEDCOMPENSATIONDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r186", "r196", "r197", "r200" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEALLOWANCEFORDOUBTFULACCOUNTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r26", "r186", "r196" ], "calculation": { "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEACCOUNTSRECEIVABLEDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "negatedTerseLabel": "Less: allowance for doubtful accounts", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEACCOUNTSRECEIVABLEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]", "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableRollforward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEALLOWANCEFORDOUBTFULACCOUNTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "auth_ref": [ "r199" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "negatedTerseLabel": "Write-offs of uncollectible accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEALLOWANCEFORDOUBTFULACCOUNTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r60", "r79", "r410" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of deferred financing fees" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Options which are anti-dilutive and not factored into the weighted average common shares amount (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARENARRATIVEDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r79", "r217" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Impairment charges" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/GOODWILLANDINTANGIBLEASSETSNETNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r90", "r155", "r162", "r169", "r189", "r381", "r388", "r398", "r463", "r480" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r3", "r4", "r47", "r90", "r189", "r381", "r388", "r398" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r278", "r307" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date [Axis]", "terseLabel": "Award Date [Axis]" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSOPTIONSGRANTEDDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted.", "label": "Award Date [Domain]", "terseLabel": "Award Date [Domain]" } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSOPTIONSGRANTEDDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r278", "r307" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSNARRATIVEDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSOPTIONSGRANTEDDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSRESTRICTEDSTOCKAWARDSACTIVITYDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSSHAREBASEDCOMPENSATIONDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r393", "r394" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/DEBTNARRATIVEDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Basis of presentation and summary of significant accounting policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r270", "r272" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails", "http://pennantgroup.com/role/ACQUISITIONSOPERATIONSACQUIREDDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r270", "r272", "r363", "r364" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails", "http://pennantgroup.com/role/ACQUISITIONSOPERATIONSACQUIREDDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails", "http://pennantgroup.com/role/ACQUISITIONSOPERATIONSACQUIREDDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Acquisition, Pro Forma Information [Abstract]", "terseLabel": "Business Acquisition, Pro Forma Information [Abstract]" } } }, "localname": "BusinessAcquisitionProFormaInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSUNAUDITEDPROFORMADetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r361", "r362" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Unaudited pro forma results of condensed combined operations" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r361", "r362" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Net income attributable to The Pennant Group, Inc" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSUNAUDITEDPROFORMADetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r361", "r362" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Revenue" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSUNAUDITEDPROFORMADetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": { "auth_ref": [ "r366" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.", "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value", "negatedTerseLabel": "Less: noncontrolling interest and additional paid in capital" } } }, "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSOPERATIONSACQUIREDDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r359" ], "calculation": { "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "terseLabel": "Business combination, acquisition costs", "verboseLabel": "Acquisition related costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails", "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r371", "r372", "r373" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Business combination, purchase price" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisitions" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONS" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": { "auth_ref": [ "r360" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.", "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual", "terseLabel": "Net income (loss) before taxes" } } }, "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": { "auth_ref": [ "r360" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.", "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual", "terseLabel": "Revenue" } } }, "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": { "auth_ref": [ "r365" ], "calculation": { "http://pennantgroup.com/role/ACQUISITIONSOPERATIONSACQUIREDDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets", "terseLabel": "Other indefinite-lived intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSOPERATIONSACQUIREDDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r365" ], "calculation": { "http://pennantgroup.com/role/ACQUISITIONSOPERATIONSACQUIREDDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "negatedTerseLabel": "Liabilities Assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSOPERATIONSACQUIREDDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r365" ], "calculation": { "http://pennantgroup.com/role/ACQUISITIONSOPERATIONSACQUIREDDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Other Assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSOPERATIONSACQUIREDDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest": { "auth_ref": [ "r365" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the assets, including goodwill, in excess of (less than) the aggregate liabilities assumed, less the noncontrolling interest in the acquiree.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest", "terseLabel": "Additional paid-in capital" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSOPERATIONSACQUIREDDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r365" ], "calculation": { "http://pennantgroup.com/role/ACQUISITIONSOPERATIONSACQUIREDDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "terseLabel": "Total acquisitions", "totalLabel": "Total acquisitions" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails", "http://pennantgroup.com/role/ACQUISITIONSOPERATIONSACQUIREDDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]", "terseLabel": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r84", "r85", "r86" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Capital expenditures" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r29", "r512", "r513" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r11", "r82", "r88" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r74", "r81", "r87" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash end of period", "periodStartLabel": "Cash beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r74", "r399" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease)/ increase in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r42", "r230", "r470", "r487" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r227", "r228", "r229", "r231" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/COMMITMENTSANDCONTINGENCIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r97", "r98" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common stock", "verboseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARENARRATIVEDetails", "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFSTOCKHOLDERSEQUITYANDNETPARENTINVESTMENT" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r21", "r237" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r21" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "pntg_NetParentInvestment", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value; 100,000 shares authorized; 28,696 and 28,243 shares issued and outstanding at December\u00a031, 2020, respectively, and 28,435 and 27,853 shares issued and outstanding at December 31, 2019, respectively." } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r136", "r137", "r177", "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLENARRATIVEDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEREVENUEBYMAJORPAYORDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r136", "r137", "r177", "r395", "r396", "r511" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLENARRATIVEDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEREVENUEBYMAJORPAYORDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r136", "r137", "r177", "r395", "r396", "r511" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLENARRATIVEDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEREVENUEBYMAJORPAYORDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r136", "r137", "r177", "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Revenue %", "verboseLabel": "Concentration risk, percent" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLENARRATIVEDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEREVENUEBYMAJORPAYORDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r134", "r136", "r137", "r138", "r395", "r397" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r136", "r137", "r177", "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLENARRATIVEDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEREVENUEBYMAJORPAYORDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r88", "r383" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": { "auth_ref": [ "r88", "r383" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.", "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]", "terseLabel": "Noncontrolling Interest" } } }, "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r246", "r247", "r259" ], "calculation": { "http://pennantgroup.com/role/OTHERACCRUEDLIABILITIESDetails": { "order": 2.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OTHERACCRUEDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r160", "r161", "r162", "r163", "r165", "r171", "r173" ], "lang": { "en-us": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "All Other" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BUSINESSSEGMENTSFINANCIALDATADetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": { "auth_ref": [ "r54", "r55" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.", "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization", "terseLabel": "Cost of services" } } }, "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of services" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/LEASESIMPACTOFNEWLEASESGUIDANCEDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r61" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Expense:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/DEBTNARRATIVEDetails", "http://pennantgroup.com/role/DEBTSCHEDULEOFLONGTERMDEBTDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/DEBTNARRATIVEDetails", "http://pennantgroup.com/role/DEBTSCHEDULEOFLONGTERMDEBTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r91", "r343", "r350" ], "calculation": { "http://pennantgroup.com/role/INCOMETAXESPROVISIONFORINCOMETAXESDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESPROVISIONFORINCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r91", "r343", "r350", "r352" ], "calculation": { "http://pennantgroup.com/role/INCOMETAXESPROVISIONFORINCOMETAXESDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Current provision for income tax, total" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESPROVISIONFORINCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Current:" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESPROVISIONFORINCOMETAXESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r91", "r343", "r350" ], "calculation": { "http://pennantgroup.com/role/INCOMETAXESPROVISIONFORINCOMETAXESDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESPROVISIONFORINCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r135", "r177" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer concentration risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLENARRATIVEDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEREVENUEBYMAJORPAYORDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerContractsMember": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Entity's established relationships with its customers through contracts.", "label": "Customer Contracts [Member]", "terseLabel": "Customer Contracts" } } }, "localname": "CustomerContractsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRefundLiabilityCurrent": { "auth_ref": [], "calculation": { "http://pennantgroup.com/role/OTHERACCRUEDLIABILITIESDetails": { "order": 1.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.", "label": "Customer Refund Liability, Current", "terseLabel": "Refunds payable" } } }, "localname": "CustomerRefundLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OTHERACCRUEDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer Relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "DEBT" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/DEBT" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Margin" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/DEBTNARRATIVEDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r15", "r234", "r466", "r479" ], "calculation": { "http://pennantgroup.com/role/DEBTSCHEDULEOFLONGTERMDEBTDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Revolving Credit Facility" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/DEBTSCHEDULEOFLONGTERMDEBTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/DEBTNARRATIVEDetails", "http://pennantgroup.com/role/DEBTSCHEDULEOFLONGTERMDEBTDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r40", "r94", "r238", "r239", "r240", "r241", "r408", "r409", "r411", "r477" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/DEBTNARRATIVEDetails", "http://pennantgroup.com/role/DEBTSCHEDULEOFLONGTERMDEBTDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r91", "r344", "r350" ], "calculation": { "http://pennantgroup.com/role/INCOMETAXESPROVISIONFORINCOMETAXESDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESPROVISIONFORINCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r33", "r410" ], "calculation": { "http://pennantgroup.com/role/DEBTSCHEDULEOFLONGTERMDEBTDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedLabel": "Less: unamortized debt issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/DEBTSCHEDULEOFLONGTERMDEBTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r325", "r326" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r79", "r91", "r344", "r350", "r351", "r352" ], "calculation": { "http://pennantgroup.com/role/INCOMETAXESPROVISIONFORINCOMETAXESDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "totalLabel": "Deferred provision for income tax, total" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESPROVISIONFORINCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Deferred:" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESPROVISIONFORINCOMETAXESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r18", "r19", "r333", "r464", "r478" ], "calculation": { "http://pennantgroup.com/role/INCOMETAXESDEFERREDTAXASSETSANDLIABILITIESDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESDEFERREDTAXASSETSANDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "auth_ref": [ "r80" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.", "label": "Deferred Income Taxes and Tax Credits", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxesAndTaxCredits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r91", "r344", "r350" ], "calculation": { "http://pennantgroup.com/role/INCOMETAXESPROVISIONFORINCOMETAXESDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESPROVISIONFORINCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r334" ], "calculation": { "http://pennantgroup.com/role/INCOMETAXESDEFERREDTAXASSETSANDLIABILITIESDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Gross deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESDEFERREDTAXASSETSANDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r336" ], "calculation": { "http://pennantgroup.com/role/INCOMETAXESDEFERREDTAXASSETSANDLIABILITIESDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESDEFERREDTAXASSETSANDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r336" ], "calculation": { "http://pennantgroup.com/role/INCOMETAXESDEFERREDTAXASSETSANDLIABILITIESDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESDEFERREDTAXASSETSANDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net [Abstract]", "terseLabel": "Deferred tax assets (liabilities):" } } }, "localname": "DeferredTaxAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESDEFERREDTAXASSETSANDLIABILITIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsStateTaxes": { "auth_ref": [], "calculation": { "http://pennantgroup.com/role/INCOMETAXESDEFERREDTAXASSETSANDLIABILITIESDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from state taxes.", "label": "Deferred Tax Assets, State Taxes", "terseLabel": "State taxes" } } }, "localname": "DeferredTaxAssetsStateTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESDEFERREDTAXASSETSANDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r341", "r342" ], "calculation": { "http://pennantgroup.com/role/INCOMETAXESDEFERREDTAXASSETSANDLIABILITIESDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESDEFERREDTAXASSETSANDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": { "auth_ref": [ "r341", "r342" ], "calculation": { "http://pennantgroup.com/role/INCOMETAXESDEFERREDTAXASSETSANDLIABILITIESDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the allowance for doubtful accounts.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESDEFERREDTAXASSETSANDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance": { "auth_ref": [ "r341", "r342" ], "calculation": { "http://pennantgroup.com/role/INCOMETAXESDEFERREDTAXASSETSANDLIABILITIESDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated losses under self insurance.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Self Insurance", "terseLabel": "Insurance" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESDEFERREDTAXASSETSANDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r335" ], "calculation": { "http://pennantgroup.com/role/INCOMETAXESDEFERREDTAXASSETSANDLIABILITIESDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedTerseLabel": "Less: valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESDEFERREDTAXASSETSANDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r326", "r336" ], "calculation": { "http://pennantgroup.com/role/INCOMETAXESDEFERREDTAXASSETSANDLIABILITIESDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Net deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESDEFERREDTAXASSETSANDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "auth_ref": [ "r341", "r342" ], "calculation": { "http://pennantgroup.com/role/INCOMETAXESDEFERREDTAXASSETSANDLIABILITIESDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.", "label": "Deferred Tax Liabilities, Leasing Arrangements", "negatedLabel": "Right of use asset" } } }, "localname": "DeferredTaxLiabilitiesLeasingArrangements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESDEFERREDTAXASSETSANDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": { "auth_ref": [], "calculation": { "http://pennantgroup.com/role/INCOMETAXESDEFERREDTAXASSETSANDLIABILITIESDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.", "label": "Deferred Tax Liabilities, Prepaid Expenses", "negatedLabel": "Prepaid expenses" } } }, "localname": "DeferredTaxLiabilitiesPrepaidExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESDEFERREDTAXASSETSANDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositLiabilityCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://pennantgroup.com/role/OTHERACCRUEDLIABILITIESDetails": { "order": 3.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The current portion, due within one year or one operating cycle, if longer, of deposits held other than customer deposits.", "label": "Deposit Liability, Current", "terseLabel": "Resident deposits" } } }, "localname": "DepositLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OTHERACCRUEDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r79", "r218" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/PROPERTYANDEQUIPMENTNETDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r79", "r218" ], "calculation": { "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails": { "order": 8.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 }, "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Less: Depreciation and amortization", "verboseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails", "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r79", "r150" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLENARRATIVEDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEREVENUEBYMAJORPAYORDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r258", "r260", "r261", "r262", "r263", "r264", "r265", "r266" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLENARRATIVEDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEREVENUEBYMAJORPAYORDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Options and awards" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDS" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DividendsCash": { "auth_ref": [ "r242", "r476" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.", "label": "Dividends, Cash", "negatedTerseLabel": "Cash Dividend to Parent" } } }, "localname": "DividendsCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFSTOCKHOLDERSEQUITYANDNETPARENTINVESTMENT" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Federal tax authority" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESNARRATIVEDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings per share (Note 4):" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r57", "r105", "r106", "r107", "r108", "r109", "r114", "r116", "r119", "r120", "r121", "r125", "r126", "r473", "r489" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Basic net income per share (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARERECONCILIATIONDetails", "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Earnings Per Share, Basic and Diluted [Abstract]" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARERECONCILIATIONDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r57", "r105", "r106", "r107", "r108", "r109", "r116", "r119", "r120", "r121", "r125", "r126", "r473", "r489" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Diluted net income per share (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARERECONCILIATIONDetails", "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]", "terseLabel": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]" } } }, "localname": "EarningsPerShareDilutedLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARENARRATIVEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r88", "r122", "r123" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r122", "r123", "r124", "r127" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Computation of net income per common share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARE" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r328" ], "calculation": { "http://pennantgroup.com/role/INCOMETAXESTAXRATERECONCILIATIONDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Total income tax provision" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESTAXRATERECONCILIATIONDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]", "terseLabel": "Effective Income Tax Rate Reconciliation, Percent [Abstract]" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESTAXRATERECONCILIATIONDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r328", "r353" ], "calculation": { "http://pennantgroup.com/role/INCOMETAXESTAXRATERECONCILIATIONDetails": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Income tax expense at statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESTAXRATERECONCILIATIONDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r328", "r353" ], "calculation": { "http://pennantgroup.com/role/INCOMETAXESTAXRATERECONCILIATIONDetails": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Revaluation of deferred" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESTAXRATERECONCILIATIONDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": { "auth_ref": [ "r328", "r353" ], "calculation": { "http://pennantgroup.com/role/INCOMETAXESTAXRATERECONCILIATIONDetails": { "order": 8.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent", "terseLabel": "Non-deductible expenses" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESTAXRATERECONCILIATIONDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r328", "r353" ], "calculation": { "http://pennantgroup.com/role/INCOMETAXESTAXRATERECONCILIATIONDetails": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent", "terseLabel": "Equity compensation(b)" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESTAXRATERECONCILIATIONDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r328", "r353" ], "calculation": { "http://pennantgroup.com/role/INCOMETAXESTAXRATERECONCILIATIONDetails": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Other adjustments" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESTAXRATERECONCILIATIONDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r328", "r353" ], "calculation": { "http://pennantgroup.com/role/INCOMETAXESTAXRATERECONCILIATIONDetails": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State income taxes - net of federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESTAXRATERECONCILIATIONDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": { "auth_ref": [ "r328", "r353" ], "calculation": { "http://pennantgroup.com/role/INCOMETAXESTAXRATERECONCILIATIONDetails": { "order": 7.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent", "negatedLabel": "Tax credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESTAXRATERECONCILIATIONDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued wages and related liabilities" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r306" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Total unrecognized share-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSNARRATIVEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unvested options and stock awards, cost net yet recognized, period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSNARRATIVEDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r306" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unvested Restricted Stock" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSNARRATIVEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r306" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unvested stock options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSNARRATIVEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSNARRATIVEDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSOPTIONSGRANTEDDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSSHAREBASEDCOMPENSATIONDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EntityWideRevenueMajorCustomerLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Major Customer [Line Items]", "terseLabel": "Revenue, Major Customer [Line Items]" } } }, "localname": "EntityWideRevenueMajorCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/PROPERTYANDEQUIPMENTNETDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity:" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r97", "r98", "r100", "r102", "r110", "r113", "r128", "r193", "r237", "r242", "r313", "r314", "r315", "r346", "r347", "r400", "r401", "r402", "r403", "r404", "r405", "r501", "r502", "r503" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARENARRATIVEDetails", "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFSTOCKHOLDERSEQUITYANDNETPARENTINVESTMENT" ], "xbrltype": "domainItemType" }, "us-gaap_EscrowDeposit": { "auth_ref": [ "r469" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.", "label": "Escrow Deposit", "terseLabel": "Escrow deposits" } } }, "localname": "EscrowDeposit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r207", "r209", "r212", "r214", "r447", "r448" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r207", "r211" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Amortization period" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/PROPERTYANDEQUIPMENTNETDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative expense" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://pennantgroup.com/role/LEASESIMPACTOFNEWLEASESGUIDANCEDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r202", "r203", "r462" ], "calculation": { "http://pennantgroup.com/role/ACQUISITIONSOPERATIONSACQUIREDDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill, ending balance", "periodStartLabel": "Goodwill, beginning balance", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSOPERATIONSACQUIREDDetails", "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS", "http://pennantgroup.com/role/GOODWILLANDINTANGIBLEASSETSNETACTIVITYINGOODWILLDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r204" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Additions" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/GOODWILLANDINTANGIBLEASSETSNETACTIVITYINGOODWILLDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetImpairment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.", "label": "Goodwill and Intangible Asset Impairment", "terseLabel": "Intangible asset impairments" } } }, "localname": "GoodwillAndIntangibleAssetImpairment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and intangible assets - net" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/GOODWILLANDINTANGIBLEASSETSNET" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r88", "r205", "r210" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/GOODWILLANDINTANGIBLEASSETSNETACTIVITYINGOODWILLDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/GOODWILLANDINTANGIBLEASSETSNETACTIVITYINGOODWILLDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r53", "r155", "r161", "r165", "r168", "r171", "r461", "r471", "r475", "r490" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r222" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://pennantgroup.com/role/LEASESIMPACTOFNEWLEASESGUIDANCEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://pennantgroup.com/role/LEASESIMPACTOFNEWLEASESGUIDANCEDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESNARRATIVEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESNARRATIVEDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r329", "r331", "r338", "r348", "r354", "r356", "r357", "r358" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXES" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r91", "r112", "r113", "r153", "r327", "r349", "r355", "r491" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 }, "http://pennantgroup.com/role/INCOMETAXESPROVISIONFORINCOMETAXESDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision for income taxes", "totalLabel": "Total income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME", "http://pennantgroup.com/role/INCOMETAXESPROVISIONFORINCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r51", "r88", "r323", "r324", "r331", "r332", "r337", "r345", "r515" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r76", "r83" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r78" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r78" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r78" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Advance payments" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r78" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Accrued wages and related liabilities" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Change in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": { "auth_ref": [ "r78" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.", "label": "Increase (Decrease) in Other Accrued Liabilities", "terseLabel": "Other accrued liabilities" } } }, "localname": "IncreaseDecreaseInOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "terseLabel": "Other long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r78" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFSTOCKHOLDERSEQUITYANDNETPARENTINVESTMENT" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r208", "r213" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/GOODWILLANDINTANGIBLEASSETSNETINDEFINITELIVEDINTANGIBLEASSETSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Indefinite-lived Intangible Assets [Line Items]", "terseLabel": "Indefinite-lived Intangible Assets [Line Items]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/GOODWILLANDINTANGIBLEASSETSNETINDEFINITELIVEDINTANGIBLEASSETSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r213" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Other indefinite-lived intangibles" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS", "http://pennantgroup.com/role/GOODWILLANDINTANGIBLEASSETSNETINDEFINITELIVEDINTANGIBLEASSETSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r208", "r213" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/GOODWILLANDINTANGIBLEASSETSNETINDEFINITELIVEDINTANGIBLEASSETSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r52", "r149", "r407", "r410", "r474" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense, net" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income (Expense), Nonoperating, Net", "totalLabel": "Other income (expense), net" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r72", "r75", "r83" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Lease, Cost [Abstract]" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/LEASESIMPACTOFNEWLEASESGUIDANCEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Components of operating lease cot" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/PROPERTYANDEQUIPMENTNETDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/LEASESIMPACTOFNEWLEASESGUIDANCEDetails", "http://pennantgroup.com/role/LEASESNARRATIVEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/LEASESIMPACTOFNEWLEASESGUIDANCEDetails", "http://pennantgroup.com/role/LEASESNARRATIVEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Future minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r426" ], "calculation": { "http://pennantgroup.com/role/LEASESFUTUREMINIMUMLEASEPAYMENTSDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://pennantgroup.com/role/LEASESFUTUREMINIMUMLEASEPAYMENTSDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/LEASESFUTUREMINIMUMLEASEPAYMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r426" ], "calculation": { "http://pennantgroup.com/role/LEASESFUTUREMINIMUMLEASEPAYMENTSDetails_1": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/LEASESFUTUREMINIMUMLEASEPAYMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r426" ], "calculation": { "http://pennantgroup.com/role/LEASESFUTUREMINIMUMLEASEPAYMENTSDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/LEASESFUTUREMINIMUMLEASEPAYMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r426" ], "calculation": { "http://pennantgroup.com/role/LEASESFUTUREMINIMUMLEASEPAYMENTSDetails_1": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/LEASESFUTUREMINIMUMLEASEPAYMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r426" ], "calculation": { "http://pennantgroup.com/role/LEASESFUTUREMINIMUMLEASEPAYMENTSDetails_1": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/LEASESFUTUREMINIMUMLEASEPAYMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r426" ], "calculation": { "http://pennantgroup.com/role/LEASESFUTUREMINIMUMLEASEPAYMENTSDetails_1": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/LEASESFUTUREMINIMUMLEASEPAYMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r426" ], "calculation": { "http://pennantgroup.com/role/LEASESFUTUREMINIMUMLEASEPAYMENTSDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/LEASESFUTUREMINIMUMLEASEPAYMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r426" ], "calculation": { "http://pennantgroup.com/role/LEASESFUTUREMINIMUMLEASEPAYMENTSDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: present value adjustments" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/LEASESFUTUREMINIMUMLEASEPAYMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/LEASESNARRATIVEDetails", "http://pennantgroup.com/role/RELATEDPARTYTRANSACTIONSANDNETPARENTINVESTMENTDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/LEASES" ], "xbrltype": "textBlockItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letters of credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/DEBTNARRATIVEDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letters of credit outstanding" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/DEBTNARRATIVEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r36", "r90", "r163", "r189", "r382", "r388", "r389", "r398" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r25", "r90", "r189", "r398", "r468", "r485" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r39", "r90", "r189", "r382", "r388", "r389", "r398" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r8", "r9", "r10", "r15", "r16", "r90", "r189", "r382", "r388", "r389", "r398" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "terseLabel": "AAP amount reclassified" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OTHERACCRUEDLIABILITIESNARRATIVEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "Medicare and Medicaid licenses" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/GOODWILLANDINTANGIBLEASSETSNETINDEFINITELIVEDINTANGIBLEASSETSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r35" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/DEBTNARRATIVEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r35" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Borrowing availability" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/DEBTNARRATIVEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "terseLabel": "Commitment fee on undrawn portion" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/DEBTNARRATIVEDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/DEBTNARRATIVEDetails", "http://pennantgroup.com/role/DEBTSCHEDULEOFLONGTERMDEBTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "LIBOR" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/DEBTNARRATIVEDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r15", "r235", "r466", "r482" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://pennantgroup.com/role/DEBTSCHEDULEOFLONGTERMDEBTDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Long-term debt, net", "totalLabel": "Long-term debt, net" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS", "http://pennantgroup.com/role/DEBTSCHEDULEOFLONGTERMDEBTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/DEBTNARRATIVEDetails", "http://pennantgroup.com/role/DEBTSCHEDULEOFLONGTERMDEBTDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r40", "r233" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/DEBTNARRATIVEDetails", "http://pennantgroup.com/role/DEBTSCHEDULEOFLONGTERMDEBTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongtermDebtWeightedAverageInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average interest rate of long-term debt outstanding calculated at point in time.", "label": "Long-term Debt, Weighted Average Interest Rate, at Point in Time", "terseLabel": "Weighted average interest rate" } } }, "localname": "LongtermDebtWeightedAverageInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/DEBTNARRATIVEDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r46", "r90", "r189", "r398", "r467", "r484" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromRedemptions": { "auth_ref": [ "r242", "r379", "r380" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).", "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests", "negatedTerseLabel": "Share repurchase related to subsidiary equity plan" } } }, "localname": "MinorityInterestDecreaseFromRedemptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFSTOCKHOLDERSEQUITYANDNETPARENTINVESTMENT" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Noncontrolling Interest, Ownership Percentage by Parent", "terseLabel": "Ownership interest" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails" ], "xbrltype": "percentItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r129", "r142" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Description of business" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/DESCRIPTIONOFBUSINESS" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r74" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by/(used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r74" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r74", "r77", "r80" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r49", "r50", "r56", "r80", "r90", "r101", "r105", "r106", "r107", "r108", "r112", "r113", "r118", "r155", "r161", "r165", "r168", "r171", "r189", "r398", "r472", "r488" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income attributable to The Pennant Group, Inc.", "totalLabel": "Net income and other comprehensive income attributable to The Pennant Group, Inc.", "verboseLabel": "Net income attributable to The Pennant Group, Inc." } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARERECONCILIATIONDetails", "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME", "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFSTOCKHOLDERSEQUITYANDNETPARENTINVESTMENT" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r49", "r50", "r112", "r113", "r385", "r391" ], "calculation": { "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails": { "order": 9.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 }, "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "netLabel": "Net income attributable to noncontrolling interest", "terseLabel": "Less: net (loss)/ income attributable to noncontrolling interest", "verboseLabel": "Add: Net income/ (loss) attributable to noncontrolling interest" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails", "http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARERECONCILIATIONDetails", "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME", "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFSTOCKHOLDERSEQUITYANDNETPARENTINVESTMENT" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]", "terseLabel": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARERECONCILIATIONDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash investing activity:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination": { "auth_ref": [ "r243", "r366", "r387" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in noncontrolling interest from a business combination.", "label": "Noncontrolling Interest, Increase from Business Combination", "terseLabel": "Noncontrolling interests assumed related to acquisitions" } } }, "localname": "NoncontrollingInterestIncreaseFromBusinessCombination", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFSTOCKHOLDERSEQUITYANDNETPARENTINVESTMENT" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest": { "auth_ref": [ "r243", "r379", "r387" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest.", "label": "Noncontrolling Interest, Increase from Sale of Parent Equity Interest", "terseLabel": "Sale of noncontrolling interests, net of tax", "verboseLabel": "Noncontrolling interest" } } }, "localname": "NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails", "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFSTOCKHOLDERSEQUITYANDNETPARENTINVESTMENT" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": { "auth_ref": [ "r243", "r379", "r387" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.", "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance", "terseLabel": "Noncontrolling interest attributable to subsidiary equity plan" } } }, "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFSTOCKHOLDERSEQUITYANDNETPARENTINVESTMENT" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r97", "r98", "r100", "r242", "r376" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Non-Controlling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFSTOCKHOLDERSEQUITYANDNETPARENTINVESTMENT" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "terseLabel": "Summary of non-vested restricted stock awards" } } }, "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_NumberOfBusinessesAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of businesses acquired by the entity during the period.", "label": "Number of Businesses Acquired", "terseLabel": "Number of businesses acquired" } } }, "localname": "NumberOfBusinessesAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfRealEstateProperties": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of real estate properties owned as of the balance sheet date.", "label": "Number of Real Estate Properties", "terseLabel": "Number of operating facilities" } } }, "localname": "NumberOfRealEstateProperties", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/LEASESNARRATIVEDetails", "http://pennantgroup.com/role/RELATEDPARTYTRANSACTIONSANDNETPARENTINVESTMENTDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r155", "r161", "r165", "r168", "r171" ], "calculation": { "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Consolidated and Combined Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails", "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r418", "r427" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease costs" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/LEASESIMPACTOFNEWLEASESGUIDANCEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r414" ], "calculation": { "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 }, "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Rent\u2014cost of services", "verboseLabel": "Rent\u2014cost of services" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails", "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Leases, Under Adoption of ASC 842 [Abstract]" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/LEASESFUTUREMINIMUMLEASEPAYMENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r413" ], "calculation": { "http://pennantgroup.com/role/LEASESFUTUREMINIMUMLEASEPAYMENTSDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "Present value of total lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/LEASESFUTUREMINIMUMLEASEPAYMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r413" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://pennantgroup.com/role/LEASESFUTUREMINIMUMLEASEPAYMENTSDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "negatedLabel": "Less: current lease liabilities", "terseLabel": "Operating lease liabilities\u2014current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS", "http://pennantgroup.com/role/LEASESFUTUREMINIMUMLEASEPAYMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r413" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://pennantgroup.com/role/LEASESFUTUREMINIMUMLEASEPAYMENTSDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities\u2014long-term", "verboseLabel": "Long-term operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS", "http://pennantgroup.com/role/LEASESFUTUREMINIMUMLEASEPAYMENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r415", "r421" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r412" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r424", "r427" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/LEASESNARRATIVEDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r423", "r427" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/LEASESNARRATIVEDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r339" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESNARRATIVEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESNARRATIVEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESNARRATIVEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsValuationAllowance": { "auth_ref": [ "r335" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.", "label": "Operating Loss Carryforwards, Valuation Allowance", "terseLabel": "Less: valuation allowance" } } }, "localname": "OperatingLossCarryforwardsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESNARRATIVEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r160", "r161", "r162", "r163", "r165", "r171" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BUSINESSSEGMENTSFINANCIALDATADetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r5", "r6", "r7", "r37" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://pennantgroup.com/role/OTHERACCRUEDLIABILITIESDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued liabilities", "totalLabel": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS", "http://pennantgroup.com/role/OTHERACCRUEDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of other current liabilities.", "label": "Other Current Liabilities [Table Text Block]", "terseLabel": "Schedule of other accrued liabilities" } } }, "localname": "OtherCurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OTHERACCRUEDLIABILITIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r492" ], "calculation": { "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails": { "order": 10.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 }, "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "Other Income", "terseLabel": "Other income", "verboseLabel": "Other income" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails", "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other liabilities.", "label": "Other Liabilities Disclosure [Text Block]", "terseLabel": "OTHER ACCRUED LIABILITIES" } } }, "localname": "OtherLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OTHERACCRUEDLIABILITIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r41" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherRestrictedAssetsNoncurrent": { "auth_ref": [], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets that are pledged or subject to withdrawal restrictions, classified as other.", "label": "Other Restricted Assets, Noncurrent", "terseLabel": "Restricted and other assets" } } }, "localname": "OtherRestrictedAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherSundryLiabilitiesCurrent": { "auth_ref": [ "r37", "r232" ], "calculation": { "http://pennantgroup.com/role/OTHERACCRUEDLIABILITIESDetails": { "order": 5.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.", "label": "Other Sundry Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherSundryLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OTHERACCRUEDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ParentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.", "label": "Parent [Member]", "terseLabel": "Net Parent Investment" } } }, "localname": "ParentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFSTOCKHOLDERSEQUITYANDNETPARENTINVESTMENT" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]", "terseLabel": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r69" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Repurchase of shares of common stock to satisfy tax withholding obligations" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r69" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "negatedLabel": "Cash distribution to parent in connection with Spin-Off" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r71" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "negatedLabel": "Payments for deferred financing costs" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r64", "r374" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "negatedLabel": "Cash payments for business acquisitions" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInterestInJointVenture": { "auth_ref": [ "r64" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.", "label": "Payments to Acquire Interest in Joint Venture", "terseLabel": "Acquire interest in joint venture" } } }, "localname": "PaymentsToAcquireInterestInJointVenture", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r65" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToMinorityShareholders": { "auth_ref": [ "r71" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.", "label": "Payments to Noncontrolling Interests", "negatedTerseLabel": "Repurchase of subsidiary shares" } } }, "localname": "PaymentsToMinorityShareholders", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r278", "r307" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESNARRATIVEDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSAGGREGATEINTRINSICVALUEOFOPTIONSDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSEMPLOYEESTOCKOPTIONACTIVITYDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSNARRATIVEDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSOPTIONSGRANTEDDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSRESTRICTEDSTOCKAWARDSACTIVITYDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESNARRATIVEDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSAGGREGATEINTRINSICVALUEOFOPTIONSDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSEMPLOYEESTOCKOPTIONACTIVITYDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSNARRATIVEDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSOPTIONSGRANTEDDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSRESTRICTEDSTOCKAWARDSACTIVITYDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r3", "r27", "r28" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfInterestInJointVenture": { "auth_ref": [ "r63" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of an investment interest in a joint venture that the reporting entity has not previously accounted for using consolidation or the equity method of accounting.", "label": "Proceeds from Divestiture of Interest in Joint Venture", "terseLabel": "Cash from sale of noncontrolling interest" } } }, "localname": "ProceedsFromDivestitureOfInterestInJointVenture", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "auth_ref": [ "r67" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Proceeds from Long-term Lines of Credit", "terseLabel": "Proceeds from revolver agreement" } } }, "localname": "ProceedsFromLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMinorityShareholders": { "auth_ref": [ "r68" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.", "label": "Proceeds from Noncontrolling Interests", "terseLabel": "Sale of noncontrolling interest" } } }, "localname": "ProceedsFromMinorityShareholders", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r66", "r308" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Issuance of common stock upon the exercise of options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r49", "r50", "r73", "r90", "r101", "r112", "r113", "r155", "r161", "r165", "r168", "r171", "r189", "r378", "r384", "r386", "r391", "r392", "r398", "r475" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Net income", "verboseLabel": "Net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARERECONCILIATIONDetails", "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS", "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r32", "r221" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/PROPERTYANDEQUIPMENTNETDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r224", "r516", "r517", "r518" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and equipment - net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/PROPERTYANDEQUIPMENTNET" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r31", "r219" ], "calculation": { "http://pennantgroup.com/role/PROPERTYANDEQUIPMENTNETDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/PROPERTYANDEQUIPMENTNETDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://pennantgroup.com/role/PROPERTYANDEQUIPMENTNETDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r12", "r13", "r221", "r486" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://pennantgroup.com/role/PROPERTYANDEQUIPMENTNETDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS", "http://pennantgroup.com/role/PROPERTYANDEQUIPMENTNETDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r30", "r88", "r221", "r516", "r517" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r12", "r221" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/PROPERTYANDEQUIPMENTNETTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r12", "r219" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/PROPERTYANDEQUIPMENTNETDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property and equipment estimated useful lives" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r59", "r198" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Provision for doubtful accounts", "verboseLabel": "Additions to bad debt expense" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEALLOWANCEFORDOUBTFULACCOUNTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReinsuranceReceivablesIncurredButNotReportedClaims": { "auth_ref": [ "r493", "r494" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Estimated amount after valuation allowance of reinsurance recoverables, due from reinsurers for incurred claims not yet reported, and claims settlement expenses.", "label": "Reinsurance Recoverables, Incurred but Not Reported Claims", "terseLabel": "Reinsurance receivables" } } }, "localname": "ReinsuranceReceivablesIncurredButNotReportedClaims", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSUMMARYOFINSURANCELIABILITYDetails", "http://pennantgroup.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyCosts": { "auth_ref": [ "r62", "r95" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Direct costs arising from transactions with related parties who are not affiliates or joint Ventures. These costs are categorized as cost of goods sold.", "label": "Related Party Costs", "terseLabel": "Cost of services" } } }, "localname": "RelatedPartyCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/RELATEDPARTYTRANSACTIONSANDNETPARENTINVESTMENTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r269", "r431", "r432" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails", "http://pennantgroup.com/role/LEASESNARRATIVEDetails", "http://pennantgroup.com/role/RELATEDPARTYTRANSACTIONSANDNETPARENTINVESTMENTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r431", "r435" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related Party Transaction, Amounts of Transaction", "terseLabel": "Amounts of related party transaction" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/RELATEDPARTYTRANSACTIONSANDNETPARENTINVESTMENTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r269", "r431", "r432", "r435" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails", "http://pennantgroup.com/role/RELATEDPARTYTRANSACTIONSANDNETPARENTINVESTMENTDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails", "http://pennantgroup.com/role/RELATEDPARTYTRANSACTIONSANDNETPARENTINVESTMENTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r431" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Expenses from Transactions with Related Party", "verboseLabel": "Expenses from transactions with related party" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails", "http://pennantgroup.com/role/RELATEDPARTYTRANSACTIONSANDNETPARENTINVESTMENTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/RELATEDPARTYTRANSACTIONSANDNETPARENTINVESTMENTDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty": { "auth_ref": [], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.", "label": "Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party", "terseLabel": "General and administrative expense" } } }, "localname": "RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r269", "r431", "r435", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails", "http://pennantgroup.com/role/LEASESNARRATIVEDetails", "http://pennantgroup.com/role/RELATEDPARTYTRANSACTIONSANDNETPARENTINVESTMENTDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r429", "r430", "r432", "r436", "r437" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related party transactions and net parent investment" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/RELATEDPARTYTRANSACTIONSANDNETPARENTINVESTMENT" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "auth_ref": [ "r70" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Repayments of Long-term Lines of Credit", "negatedLabel": "Payments on revolver agreement" } } }, "localname": "RepaymentsOfLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted stock awards" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSNARRATIVEDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSRESTRICTEDSTOCKAWARDSACTIVITYDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSSHAREBASEDCOMPENSATIONDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r24", "r242", "r316", "r483", "r505", "r510" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "pntg_NetParentInvestment", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings (accumulated deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r97", "r98", "r100", "r102", "r110", "r113", "r193", "r313", "r314", "r315", "r346", "r347", "r501", "r503" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings/ (Accumulated Deficit)" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFSTOCKHOLDERSEQUITYANDNETPARENTINVESTMENT" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r146", "r147", "r160", "r166", "r167", "r174", "r175", "r177", "r257", "r258", "r446" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BUSINESSSEGMENTSFINANCIALDATADetails", "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEREVENUEBYMAJORPAYORDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerMember": { "auth_ref": [ "r136", "r177" ], "lang": { "en-us": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue from Contract with Customer Benchmark [Member]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLENARRATIVEDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEREVENUEBYMAJORPAYORDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r89", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r267" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration.", "label": "Revenue, Performance Obligation, Description of Payment Terms", "terseLabel": "Payment terms" } } }, "localname": "RevenuePerformanceObligationDescriptionOfPaymentTerms", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLENARRATIVEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving credit facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/DEBTNARRATIVEDetails", "http://pennantgroup.com/role/DEBTSCHEDULEOFLONGTERMDEBTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r422", "r427" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for new operating lease obligations" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEACCOUNTSRECEIVABLEDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEALLOWANCEFORDOUBTFULACCOUNTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Schedule of accounts receivable" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r363", "r364" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails", "http://pennantgroup.com/role/ACQUISITIONSOPERATIONSACQUIREDDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Total share-based compensation expense" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Provision for income taxes on continuing operations" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r40", "r94", "r238", "r239", "r240", "r241", "r408", "r409", "r411", "r477" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of long-term debt" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/DEBTTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Deferred tax assets and liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": { "auth_ref": [ "r116", "r117", "r119", "r121", "r126" ], "lang": { "en-us": { "role": { "documentation": "Complete disclosure pertaining to an entity's diluted earnings per share.", "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]", "terseLabel": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]" } } }, "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARENARRATIVEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock": { "auth_ref": [ "r117", "r121", "r126" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share.", "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]", "terseLabel": "Computation of basic and diluted net income per share" } } }, "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Reconciliation of federal statutory rate to effective tax rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r276", "r304", "r318" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": { "auth_ref": [ "r177" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.", "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]", "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]" } } }, "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BUSINESSSEGMENTSINCOMEFROMOPERATIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r207", "r211", "r447" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r205", "r206" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/GOODWILLANDINTANGIBLEASSETSNETACTIVITYINGOODWILLDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r205", "r206" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Activity in goodwill by segment" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/GOODWILLANDINTANGIBLEASSETSNETTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r213", "r215" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/GOODWILLANDINTANGIBLEASSETSNETINDEFINITELIVEDINTANGIBLEASSETSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r213", "r215" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Other indefinite-lived intangible assets" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/GOODWILLANDINTANGIBLEASSETSNETTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r32", "r221" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://pennantgroup.com/role/PROPERTYANDEQUIPMENTNETDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of operations acquired in business combinations" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r92", "r433", "r435" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/RELATEDPARTYTRANSACTIONSANDNETPARENTINVESTMENTDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.", "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]", "verboseLabel": "Revenue by major payor source" } } }, "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r155", "r158", "r164", "r205" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BUSINESSSEGMENTSFINANCIALDATADetails", "http://pennantgroup.com/role/BUSINESSSEGMENTSNARRATIVEDetails", "http://pennantgroup.com/role/DESCRIPTIONOFBUSINESSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r155", "r158", "r164", "r205" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Financial data combined by business segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BUSINESSSEGMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]", "terseLabel": "Aggregate intrinsic value of options outstanding, vested, expected to vest and exercisable" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r278", "r307" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSAGGREGATEINTRINSICVALUEOFOPTIONSDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSEMPLOYEESTOCKOPTIONACTIVITYDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSNARRATIVEDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSOPTIONSGRANTEDDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSRESTRICTEDSTOCKAWARDSACTIVITYDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSSHAREBASEDCOMPENSATIONDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r284", "r294", "r296" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Employee stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Stock options granted fair value assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r143", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r160", "r161", "r162", "r163", "r165", "r166", "r167", "r168", "r169", "r171", "r177", "r495" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails", "http://pennantgroup.com/role/BUSINESSSEGMENTSFINANCIALDATADetails", "http://pennantgroup.com/role/BUSINESSSEGMENTSNARRATIVEDetails", "http://pennantgroup.com/role/DESCRIPTIONOFBUSINESSDetails", "http://pennantgroup.com/role/GOODWILLANDINTANGIBLEASSETSNETACTIVITYINGOODWILLDetails", "http://pennantgroup.com/role/LEASESNARRATIVEDetails", "http://pennantgroup.com/role/RELATEDPARTYTRANSACTIONSANDNETPARENTINVESTMENTDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLENARRATIVEDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEREVENUEBYMAJORPAYORDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r143", "r144", "r145", "r155", "r159", "r165", "r169", "r170", "r171", "r172", "r174", "r176", "r177", "r178" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Business segments" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BUSINESSSEGMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BUSINESSSEGMENTSFINANCIALDATADetails", "http://pennantgroup.com/role/BUSINESSSEGMENTSNARRATIVEDetails", "http://pennantgroup.com/role/DESCRIPTIONOFBUSINESSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SelfInsuranceReserveCurrent": { "auth_ref": [], "calculation": { "http://pennantgroup.com/role/OTHERACCRUEDLIABILITIESDetails": { "order": 7.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid within one year (or the normal operating cycle, if longer).", "label": "Self Insurance Reserve, Current", "terseLabel": "Accrued insurance retention - current portion" } } }, "localname": "SelfInsuranceReserveCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OTHERACCRUEDLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.", "label": "Series of Individually Immaterial Business Acquisitions [Member]", "terseLabel": "Series of Individually Immaterial Business Acquisitions" } } }, "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails", "http://pennantgroup.com/role/ACQUISITIONSOPERATIONSACQUIREDDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r78" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSNARRATIVEDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSRESTRICTEDSTOCKAWARDSACTIVITYDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSRESTRICTEDSTOCKAWARDSACTIVITYDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSRESTRICTEDSTOCKAWARDSACTIVITYDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSRESTRICTEDSTOCKAWARDSACTIVITYDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Ending balance, outstanding (in shares)", "periodStartLabel": "Beginning balance, outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSRESTRICTEDSTOCKAWARDSACTIVITYDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "verboseLabel": "Non-Vested Restricted Awards" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSRESTRICTEDSTOCKAWARDSACTIVITYDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "End of period, weighted average exercise price (in dollars per share)", "periodStartLabel": "Beginning of period, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSRESTRICTEDSTOCKAWARDSACTIVITYDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSRESTRICTEDSTOCKAWARDSACTIVITYDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSRESTRICTEDSTOCKAWARDSACTIVITYDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSRESTRICTEDSTOCKAWARDSACTIVITYDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Weighted average dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSOPTIONSGRANTEDDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Weighted average risk-free rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSOPTIONSGRANTEDDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "terseLabel": "Weighted average volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSOPTIONSGRANTEDDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSAGGREGATEINTRINSICVALUEOFOPTIONSDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSEMPLOYEESTOCKOPTIONACTIVITYDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSNARRATIVEDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSOPTIONSGRANTEDDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSRESTRICTEDSTOCKAWARDSACTIVITYDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSSHAREBASEDCOMPENSATIONDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedTerseLabel": "Expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSEMPLOYEESTOCKOPTIONACTIVITYDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSEMPLOYEESTOCKOPTIONACTIVITYDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Options granted (in shares)", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSEMPLOYEESTOCKOPTIONACTIVITYDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSOPTIONSGRANTEDDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average fair value of options (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSOPTIONSGRANTEDDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r307" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSAGGREGATEINTRINSICVALUEOFOPTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r286", "r307" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending balance, outstanding (in shares)", "periodStartLabel": "Beginning balance, outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSEMPLOYEESTOCKOPTIONACTIVITYDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Options Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSEMPLOYEESTOCKOPTIONACTIVITYDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "End of period, weighted average exercise price (in dollars per share)", "periodStartLabel": "Beginning of period, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSEMPLOYEESTOCKOPTIONACTIVITYDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSEMPLOYEESTOCKOPTIONACTIVITYDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price of options vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSEMPLOYEESTOCKOPTIONACTIVITYDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r275", "r281" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSNARRATIVEDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSOPTIONSGRANTEDDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSRESTRICTEDSTOCKAWARDSACTIVITYDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSSHAREBASEDCOMPENSATIONDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSEMPLOYEESTOCKOPTIONACTIVITYDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Expired (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSEMPLOYEESTOCKOPTIONACTIVITYDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSEMPLOYEESTOCKOPTIONACTIVITYDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSEMPLOYEESTOCKOPTIONACTIVITYDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r88", "r278", "r282" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Options, vesting percent per year" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSNARRATIVEDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Options, expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSNARRATIVEDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r299", "r317" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSNARRATIVEDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSOPTIONSGRANTEDDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r307" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Exercised" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSAGGREGATEINTRINSICVALUEOFOPTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares", "terseLabel": "Options, unvested and outstanding (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSNARRATIVEDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average contractual life for options outstanding, vested and expected to vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/OPTIONSANDAWARDSNARRATIVEDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Equity, ending balance (in shares)", "periodStartLabel": "Equity, beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFSTOCKHOLDERSEQUITYANDNETPARENTINVESTMENT" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "terseLabel": "Shares of common stock withheld to satisfy tax withholding obligations (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFSTOCKHOLDERSEQUITYANDNETPARENTINVESTMENT" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r0", "r143", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r160", "r161", "r162", "r163", "r165", "r166", "r167", "r168", "r169", "r171", "r177", "r205", "r223", "r225", "r226", "r495" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails", "http://pennantgroup.com/role/BUSINESSSEGMENTSFINANCIALDATADetails", "http://pennantgroup.com/role/BUSINESSSEGMENTSNARRATIVEDetails", "http://pennantgroup.com/role/DESCRIPTIONOFBUSINESSDetails", "http://pennantgroup.com/role/GOODWILLANDINTANGIBLEASSETSNETACTIVITYINGOODWILLDetails", "http://pennantgroup.com/role/LEASESNARRATIVEDetails", "http://pennantgroup.com/role/RELATEDPARTYTRANSACTIONSANDNETPARENTINVESTMENTDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLENARRATIVEDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEREVENUEBYMAJORPAYORDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r44", "r97", "r98", "r100", "r102", "r110", "r113", "r128", "r193", "r237", "r242", "r313", "r314", "r315", "r346", "r347", "r400", "r401", "r402", "r403", "r404", "r405", "r501", "r502", "r503" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARENARRATIVEDetails", "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFSTOCKHOLDERSEQUITYANDNETPARENTINVESTMENT" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFSTOCKHOLDERSEQUITYANDNETPARENTINVESTMENT" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r97", "r98", "r100", "r128", "r446" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFSTOCKHOLDERSEQUITYANDNETPARENTINVESTMENT" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r20", "r21", "r237", "r242" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Shares issued (in shares)", "verboseLabel": "Issuance of common stock after spin-off (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARENARRATIVEDetails", "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFSTOCKHOLDERSEQUITYANDNETPARENTINVESTMENT" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r20", "r21", "r237", "r242" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance/ (cancellation) of restricted stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFSTOCKHOLDERSEQUITYANDNETPARENTINVESTMENT" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r20", "r21", "r237", "r242", "r287" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (in shares)", "terseLabel": "Exercise of stock options, issuance of other awards after spin-off (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFSTOCKHOLDERSEQUITYANDNETPARENTINVESTMENT", "http://pennantgroup.com/role/INCOMETAXESNARRATIVEDetails", "http://pennantgroup.com/role/OPTIONSANDAWARDSEMPLOYEESTOCKOPTIONACTIVITYDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r20", "r21", "r237", "r242" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of Common Stock after spin-off" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFSTOCKHOLDERSEQUITYANDNETPARENTINVESTMENT" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r20", "r21", "r242", "r277", "r295" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance/ (cancellation) of restricted stock" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFSTOCKHOLDERSEQUITYANDNETPARENTINVESTMENT" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r44", "r237", "r242" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of Stock Options, issuance of other awards after spin-off" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFSTOCKHOLDERSEQUITYANDNETPARENTINVESTMENT" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r90", "r97", "r98", "r100", "r102", "r110", "r189", "r193", "r242", "r313", "r314", "r315", "r346", "r347", "r376", "r377", "r390", "r398", "r400", "r401", "r405", "r502", "r503" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Equity, ending balance", "periodStartLabel": "Equity, beginning balance", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFSTOCKHOLDERSEQUITYANDNETPARENTINVESTMENT", "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r420", "r427" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "negatedTerseLabel": "Sublease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/LEASESIMPACTOFNEWLEASESGUIDANCEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsegmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by business subsegments.", "label": "Subsegments [Axis]", "terseLabel": "Subsegments [Axis]" } } }, "localname": "SubsegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEREVENUEBYMAJORPAYORDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Subsegments [Domain]", "terseLabel": "Subsegments [Domain]" } } }, "localname": "SubsegmentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails", "http://pennantgroup.com/role/REVENUEANDACCOUNTSRECEIVABLEREVENUEBYMAJORPAYORDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r406", "r438" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails", "http://pennantgroup.com/role/DEBTNARRATIVEDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r406", "r438" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails", "http://pennantgroup.com/role/DEBTNARRATIVEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r406", "r438" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/ACQUISITIONSNARRATIVEDetails", "http://pennantgroup.com/role/DEBTNARRATIVEDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Cash paid during the period for:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r182", "r183", "r184", "r185", "r187", "r188" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable and Allowance for Doubtful Accounts" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Trade name" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/GOODWILLANDINTANGIBLEASSETSNETINDEFINITELIVEDINTANGIBLEASSETSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r43", "r244" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFSTOCKHOLDERSEQUITYANDNETPARENTINVESTMENT" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r43", "r244" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury stock, at cost (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r43", "r244", "r245" ], "calculation": { "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "pntg_NetParentInvestment", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Treasury stock, at cost, 3 shares at December 31, 2020" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r130", "r131", "r132", "r133", "r139", "r140", "r141" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Estimates and Assumptions" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r419", "r427" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/LEASESIMPACTOFNEWLEASESGUIDANCEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/DEBTNARRATIVEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/DEBTNARRATIVEDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r121" ], "calculation": { "http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARERECONCILIATIONDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Plus: incremental shares from assumed conversion" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARERECONCILIATIONDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r115", "r121" ], "calculation": { "http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARERECONCILIATIONDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Adjusted weighted average common shares outstanding for diluted income per share (in share)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARERECONCILIATIONDetails", "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average common shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r114", "r121" ], "calculation": { "http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARERECONCILIATIONDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted average shares outstanding for basic net income per share (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARERECONCILIATIONDetails", "http://pennantgroup.com/role/CONSOLIDATEDANDCOMBINEDSTATEMENTSOFINCOME" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARERECONCILIATIONDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WorkersCompensationLiabilityCurrentAndNoncurrent": { "auth_ref": [ "r14", "r17", "r465", "r481" ], "calculation": { "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSUMMARYOFINSURANCELIABILITYDetails": { "order": 2.0, "parentTag": "pntg_InsuranceProgramAccruedExpenses", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature.", "label": "Workers' Compensation Liability", "terseLabel": "Workers\u2019 compensation" } } }, "localname": "WorkersCompensationLiabilityCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://pennantgroup.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSUMMARYOFINSURANCELIABILITYDetails" ], "xbrltype": "monetaryItemType" } }, "unitCount": 14 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r127": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r142": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8475-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r178": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e4975-111524" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5212-111524" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5093-111524" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r216": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r224": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r229": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r231": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r236": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r267": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r321": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6419918&loc=d3e35281-107843" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r358": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5333-128473" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r375": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4616395-111683" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r428": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r437": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.4)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99404803&loc=d3e21409-158489" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99404803&loc=d3e21412-158489" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r529": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r530": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r531": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r532": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r533": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r534": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r535": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r536": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r537": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r538": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(2)(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(2)(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r96": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e22044-107793" } }, "version": "2.1" } ZIP 96 0001766400-21-000037-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001766400-21-000037-xbrl.zip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®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�>(@\!"&6)&7*L4^C2$Z_W%KU"Q^Y,M &T M\\ &O8UH=S/]XNWA+QLU UG^W0!W0'??OW+!8TC6(0G'R'=1CO' BO5:>A-R M,I&YR2HE_?G?_ KXQE\/)(L.E[N^!"%CB5%[KC+G+A:F9&%%D6=XOK'SJ0%'M0?D]< KFTCGM4R+V3 M-EH;(R-'6J1T";?''[]M0^1X?G2V(+O\=IM7S]"ID!PD35Z$0-F7B-0MP@3- 1-J2 M0]'.-TDU>XRHW0=&AT#"W6;0 XF]P67A6RPXGV-^-SVK%QEO9HOS1>U03OL_ MTE87B:RB0/GJ)(G(P;"(="Y$97F3L>(/T/-<@+"]L%MTO9R=?3G%^??*\L1' MLK68X,!H"R8+S"FRN5V"G"(31BHZ6)KTXKA)Q//0]L9B;=+Q_R9_5ZVD%<_6 M)%$GR:?:EMY D#)6U"F1O5)![6##WVE*>_O=O;]H]WUA>,W'&]J8IN?O0JH! MC7\NQV!ZHU-1";AG#)2RY(U9):"HXKW64C#;)%'J+BG[2C#?6KFS087<8/._ M3=%UP\X.-+7,!+^/J/VD>F^KL$?UOX6T=X4$Z;,E?Y>(T;;4(%8!CSJ!X*)D M&^K04O>T$; FX7H7 .@CY :*/\&_9M]JH?5MXJZNSQB+.F%04)!,4F70@9.) M=!8]TX[5;BU-IL(\2M7N+<3M%3=K)?46.21DNYY?V:X_FO\7JV.05D'BB;@- M&B&8.M,L:^>D%&ARD]N0^XAY+@;!UH)NX"RLTO2SE\-:JEH:!?>3M1^S8'NU MK<'!%C)O=$-P#W6LIM8 D3-V^N'38[*Y@5TA88Q[L"@A] M1-T" .0J'Y?+D^KJA,J"&1N+@I@+@LHL05Q&V;C35A8>2Z.+HCND[-X8&$)) M=U()MY+P[@*70^2[W_N<@<)0O3+9L[%%1:FXP*ABQI 8D\D&H56, M7DWB>V M"3998:3U&4&0ELFMR Q"XIY\"ZFS]XY T*0Y9*-@TTU _S!NP]_3[Q???YG- MY[/_J:9O^),^.?]GHH6L79L$($9/)I2+X$D=X(L4F0QA[VR3SAM]B!S/K70? MI#RVSPRJEB;!J9O\_Q(6T\7G/^<8\O'9[V$^K<;W23A'/K&,)P-J-PAI[ MRO_"Z9>OM2K@+YP3:4=G] $NSNN*F*#+WDKI()>:DBY9!F<,!Z&3\):SP&*3 M4%M'^IX)BAHHXRYFMA['?1_83[!*C4[>>XY@'X427H'+G! >48(3GL1BBBC! M<1]9FTNW7F0^$P2U4\U=(*GMAY6>$ZH7UP0?7YPOSL-9_IE:Y$SM_I(LI.70 MA2@]^(0,$@L2F45R4IO$;M81]DS ,J3X[\)#MTCYR,8%IY!#/3=!!9O .YE! M9ZZYMBJ+L ,7@CY%T%^KO0]&)3/GHIK$O$?Q-I[PH)*G$EE7(@G:X9R71X M>:\4%.U8*CI;)IHX*V-.^1@< 'V$O/.4#S29&1,4".Z(VR(4;7RBD%<=O1=% M<2>;-,U["BD?O137*^6CC]1;I'PL[=F5$)3.2I-++$ G;4%9:<$7I"^L8'1> M$H%-D' ?,<\ %O+>.B*U'#VY3)D[6IHNI#SBLD+4)AS';H5P6O'2R$MA=!E MT^]6?WK]UJ=NXFTNP@'O(G\0<06G+F0,W@[@Y_OWT A@,PVLZG +\;58E5?D MA&)40L5I7Q":#(_@"*!!@//&:H?9Y=0ERV(<6GRLX']0)?:1VL#*^T"2^G[Q M_8H0VK\#.D4^FZ]><>%_)O*?C:$X 8TAI:$ M7$;#K_<#SPV+1 @+O!!/P8+#FNPM(A-<&+2=DEZ[:?#FFY^@!C<67 ,/YV9$ M>KFO2!$\[28.BJ]=V7+29&%E!)J-^FY3L_O M0%'+.ZV[).WG1FL[53VB]RWDW'C)7Y=6F9AKC [8T% MUZ3KY:XTO^8FJ[7B^XBW35IZGITM@_LQG/UQ7 J28UWI>W_TR_')#_^:/.DB M$EBB"A1+9%2XXL $9Z66+/C8I)5!)^IV?ZFQK1KO9ET,K(,&=UN_A,62WVL# M1ZID4SWQEE/I%)?@.$HHTFN3N.2F-*EKODW&DU?]%E+=08W*B2M5YJZU:IM(G, M=U>RQFPM^*A;7;8!E+ (K@[%PMIU)Y._RVR7/HNC1L(F)6L-@-!'U+LI6?.1 M9:N]@Z1N5MZ>EH$L$VLX2))T< M"RZ$J.0S0,4:\V"WH.@C\_9@N/9D S(3F:VC.@P=BCF24YP8Y**8,$'0>=EF M#OQ]U.S>5!A(6X]C8 -1[Z;&_?C3Z='QQ\\'']\>_.O@Y.UFO+68[WO^D!K+K,LW1.D^F MK"MD%RD?N/>Y-@0@ RGK0C"](\&MQSBN/._S?QR<'/YR\/GP[9OC#Y\.Z9/Z M^39#!GN]H('4>W"TH@QG..>H1.(YJYQ4-"ZJY#F7*CL9]!UE//ZJ+<^,KV&. M]>XSOYE])\X7X7([GM<0^K(R^I^?OW(]&>I_PCR__U%\(I7FQ7():+6J.2X" M@LOD=5DL6@D14#8)26Q/^K8'[L&WY>]@OI^4P[_KMSCQ1G(G>(9DJF_*B17/ MI((24_&!>5U\DT+L;N3MX4C>+>96S^X&6FOA_:>OF"^^X7%9*Z[%0_*Z=(J1 M:V5XXA X(SM'6C)SK96@>0[*ELPQM_$$AN)@5]5U>\;E?C0^EO*]2_*O_3-E MLHRU,"4Q5GM8NSHBR=>F"*[^Q#K3ID_G+2KV=;.U)R"L;I,;*Z2%:[NQ('ZR M<98_?0MG'\/W:P>P"T]-+] :,+6?N[87/ %H:N/[H='I> MS>"CLSS]:YHOPK?+X UC,I!A"\*HRF+6X 5'$+DX;9+FW'3)@^Y4Q7(O!2_3 M,1A&(0,7B]XAZ%_3\Z\G^&TIC\77Z9^GL\.S\QN]*CJ0.G1!:4\:=U]T.H!6 M'\-( Y6TWF?6D$QG*)IB:0^TR8#2+D/,M<9,>X4J"?#GH>*7;=+WCZ M:&)@T+R=SC'1Q]5GJ6./L:Y8DZB30WPE> M#MQO?H [>LV-1D,+BAE),$0K:NZ/)T7P[)EW3LLF=\O[CU?^< ]Q_M97/ZJ_QR>((>AL$!RSZ;+=7N": 7)N$[-&A?RTCH][V7Q='N-!48-F M-QL+>_GE=Y+!].S+)6=\XKUF1M#Z-Q)I_0<9P5L2>W#!&2DE-VUJ8H=DXL7A M?6\(:%"]OR0TKN>2C OWC_+PB?@^XN MW MMV^X_W[I:)_E'XMX5G]T8T[:RI#&'Y/VWLS.SNDJM6 M&Z(GJ\U%$*4XB0*-R:-<(<.)X'51/0WTW5V'?CQ5C28ZETCNM(V$5$?>20C1 M7!_2\A6S; M:]QPFW/)!H+.RTH-#E$K!%7(,';26,N:7.F.H.:NE:+[B'1 !=<\SLGI5SPD M[K^<59H65UFKN3*&R4!BT=%F)3($F1$B?SMZ&W'/ MAI15@QRPVW6@S@29+(^@M:=3QB."\S*#S\%X'I*6H%I]<&!/T;$/3"RBZ*N#=1]%-I0! ]>F<%^842+2UQ#!"4U! MYIAH MTV:V37NA)P/>7@T(1H?=/OK=:0."B"Q4$D"28$"Y)"!XLA=,]DIYZX0-31J@ M/_<&!+T4WKD!01]M[:X!@>/!)BL!4V7596+5.0M,6N&-M&ATDU*@Y]R 8!OX M;*^E@6L\?TYR-<$H50*#@H&\D\@2>%E<'3!0$OFO]?.ARCOW/E-ZOP[ YH(? M,#EU=8YH%S*>Z23J7AIX8(CQ)N)KL9:O1WMXSHKWN18((*BL+#CA/=B4:FMD M FNG^:GCT&*G2=1#*+&/U 96WNV!RJZDA(EI,"E)4#8[B%YGX))9SG,6Q0^F MOI%,HNXE^P!5@,*%+\(R&8=;@".9 M1+VQ!C<6W(-KL&D?A*M__WIR\/'T\.V S1#N?W"#C@@=.%@=46"B,8(5HU"K ME),7FDEM"E=,!\/NCBBX_Q5[[XT@LA0ZISK! @E=,2H(L@Z_RE8*G[@/LLDP MT?WW1MB8@JL&C14GY3EN[+9CZ9+OYX-T=<#DLFM[W.SJ7# M*7N/Y-ZY@.3M24*GBPG!!A8,>LO([!P5X+MR]@K_O6*E52RD36J_]D%A)OLZ M,TM&MG#D:@4FB#V)/CL?&XUE?2W\&!;^^T?'/@+9?1;V2MKQ[[/:!>[;]/R? MY0K7/"7+98"0,BG ,@,Q<@.2"5VDS*Z$=F5].V'Q9:Z+\:%G3$T)'ML!WM:6 MB>0W+AG,=,[YFBXEK*YY;XF!]Y(1FF-F:GD&CG]YW,?9ZZK8*U9:]308S!E: M6??+#]\2ES^D,6$8?/!< ,I2IS#8"+[V_A0J$YQ223:-ZQIB,SY?%\J(<-2B M0\)@850AN%6&%GP*G(,RB@[#0'RE0#Z3D&A3FW34EUCMM!7 ]Z+Q458[:>>$ ME8'DIIRIE881HBP9I'=:)&^UVFE0&#Q6[=1''>UK7[I0\Z*JG7JIY_$B MF$UDVU[C,:C(LW$0G50$Y)S!:4='<1#:AA*8=$WJ=4>0X-M*T7U$NI-JIYB, MS 4S!,,R*,$3^&P,<,9+\<5ZO7KA\Y2JG7J)>VVU4Q]9M:IVJL;RY=0[H=!Z M)\%%XO988[29AA[2]1;B;7!BKY(547R;PSS*OFK@RBE[ ,O&K*O3FY1GHXD'V@],*L+ZD)D M=3JT[WGX[L_LK:0]&U!4 Y[9J_1P?SW4DQG#T&&]I)"@@N(0K9$@I'0QNUI0 M'?NJ[OKAST-U&XFJU=;ZH\:OZ&A=R80C2Y:_(DB!USJ!5BTN[U]>%'H/6K ZF4 [ M\$4+R,&8%#1#%9K,MW@ZX.U57#XZ[/;1[TZ+RSEBDA81>"[57N!DAB3TX(TM M)4:&WKY.MV^M\,[%Y7VTM9_AH(?3XS?_[_+#@S>G1[\?G?Y[ MP J9#F]I4"[3E[>5VAE>E#3.26&X5SGP6 IY60F5X627([]3.]/A?7LOI'$, MDQ)%@Z9#1;7,\;G2U/9E]^_9N-J\?3K@.WM;* MQ<(M&?O*)@A(4K62!:F%5=DWV9#;L#/"W7Q83 ^=^3, *L9447.7J\M^Z1.> MM,?B.3!=6,T.9Q"E\6!L*F3"!^%]ERGB^X3Y)2=/".$#0JP=ZC? QSZR #*%$65C0MHAVHZU>;)7D>$&_+49:%,U4C^-HL;C M_/9B_F/6W)*-Q7Q!_UVMM$H+Q!JT%KVL+7J]KR(7<:HD2M<_6 M*M%FJ,+PO+RB>@08&6$IRL\!=#]9*IFQI)>]<&IPL+HXSBL!B8N2>78ZZC;9 M]Y5 MM"L52=>VPJ?Y-&$%=[D"MZJ5),62)6NY E4BTAYJ'9@DM+T$K9 M$53WL[)ZX6Q4>11=BF176"W611LYH*O%*)HCF3=D$F34(BB!)8;]+*GA>'Q= M5MLNJSWA;51#7%8N?[IQ&[3@S$@R(R+M)BJ9ZC,+#=(Q'SB73'@_RM75B\W7 M!=9Z@;5#W:AR61^^&)%-[",K$)+ESFDMO=C/K<7 MC+ZNM/8G6CODC?OR]5$V92HR*4X<.N9 298A+B>F,(M)&&\9&_N5;/=UU;/^ M;4E ?(3&^$!'SBL:?\<%D77W&ARU9"B*!ZMUI,4@'7A!WQ'B,)$IY4Q4]/56VP=G.4?K61G]4==]Q4K3%!,%7"RQM)D[3:; M0P3:]%56(@41V^2B[)7M%[-RQB'N7BAKX7@.5U>*1G,49,TG7T>LY B1LUC= M:!^R0,]+FU3S%]AL;RN\[T7CHVRV)YDWV6XYSY("URT,G5UAE6 MD+]<1A! 7/K13=1Z0[:;;'),]6, VG/OC@UU]/#G\].#T\^GAZ M_W9X_.[J%P2@>2-&EUB+1=C:O$]?T(:X:/SL[G4]H TF4' M>,5\Q4HA?S224QJ3)?^"2<"2I Y>)H_[:2"R*4=/\E:C#[(;IGUM@8VAV[D- M?M%Y\.7+'+^$4!F.49E _D8-D1O DS%D-:3BS6Z".GTI M?P7_:'#1*@ST&+\/316\G0A6[ZIN,\8G5JO"Z \A\!HA5X)T(")"5K$72>MB3*-(Y@L,S6R% MY;UH?)2AF<2=0.L3U#85M5[:0XQ.$,*T%*@=G4=-!Y\\C]!,+Q@\%IKIHX[V M%_5=J'E1H9E>ZGG\QGX3V;;7..'71H\1M*0-56&P$(2R((R-HG!F);Z(T,R MBNXCTIV$9IRO@YS00#&AYJS2MA5JMZ+H'GTY.C-Z>';Y<-1Z^""L,W;^WTG@9!F?[\K41D)"DLA!R9]ZB8%M$+ MJ2H,C"=F4=Z)R'1ZX_[#,3('PW4 R^O<"&HG&"Z68@YP=KYU( MZE T$K1.S&/65O$VR4N[9?-IWF?T6 .#!6[:HVA,K6"[>BU-:(NF6G/ZCR;I[IPB*Y#.&TU,RNS'U?VM)X.ORVDORVD+E(VI FDMGY<1Z!]\1BNB M]LB >U8KK8H!K[P!5,)KG9D7\8F=3K<9?%U->UE-6Z!L3+UWU_)YU8/@!JM6 M66+)>1 Z%-)'[;=J8@)64S881H9V7&YH?QY?U]1>UM1V6!M3;]_>MFV6CADL MF11B$_FUR8##E$$((74PPKN1-3_=SH<:I2I6BDF7]E(=__HN3.?+O(6;*RA) MYK5T 7BMRE(B9HA1)Y!%D MA+I;8JECL+61X)F.P&/D-@OE\,ENGFN9?T(+< PK8(2KN1=\G]02?K01YSV" ML$D1PT63U:,5.5%>@),Q0D)&%_,37YXIN">2G>+]7>XRNEP+I*X40 M/.10$J@D'#E.VM>T?2]S]IZ/;"[1H.R_KN5QKN5F$'Z:-XH=-C,T*06I !E: M4 5I,Y,\073>!1N-XWQ-#[*TB')/=J4$I0@8\T9J T*,($UTD1?>"Y1OI8.#0J# M1[NZ]5#'#KJZ=:#F194.]5+/FJYN&\BVO<:]%>0$<0:$8X*OY 3DVLJJ)&^, M*Q*E:6)'C*UT:$!%]Q'I3DJ'Z*PDT]Y9HD#4XAHEP"4Z2'722I=2F--/N'2H ME[C7E@[UD56#C._+(X9^>0G*$&.1T47(BLO:3$@#N3A$5C'H,'"E5).ZOEM4 MO.S#>G.%C&K6V$\VSO+*^NG"4\LSOP53^[$ZJK&PUXUQA#(\=N'_TVP.P)+L[GT]H6ZO/Y M+/UQ92M8R[C"4B!S68>Z9@8Q8H1B4LC6L^1RD]Z:]U(SPIOMYHJ>#:VEW12# MOS\\^'SX>9/R[JN_'*!@^SX:5DJP,;"@F?#%,U,K\GWF)2 J:X24ON3)76HV MD> MN=T6_AX7"\3W2'O16URD^?3/*V:OAX8DYC!'!\K$VCM$<=HFZ#OR)ZW+66=4 M36J,UM"UU6W 9=KV<3G!\.UP<1[.\=-\1B[8^107OY%&YLO73HP(R6!M4AL9 M@M+1@-REQR5*LSA1^X'^CVOMV?5$/J_M850@,!-[A4N&3_F.BB$_KL MRY*F4YQ_/RYO9F?G\Y#.)PFYTJ+.)HF\YD:( L$FA,(BB])Q9K')&,[UI#T/ MM#1210-3]S%(3^C<8[+.N)-+UJ4EZXQGA*"M,#:8DMJX68\1];P ,ICX![Q^ MZK'5?0B+\ZMO#[[,<>D&3$QTTC%AP8A"B Y&@?-9 _.$\Y(D\L0'/%_NH^%Y M@&27BA@P ^X6V9_QST";WRT";[B,DVQ"TKCL*9[(7:O)M\M!.\5:,K-9TDG9 M7F!9\\)GB(PA1=P@?^KVZ;>2[7."588WCT8^(3*+P<"!,ZX)MN2\!^L2I"@$ M<]JQ7)J<.GT)?1Y0VHF:&@S4?I3>M]-%FEV?JY&V3'*\6)" %HO/E\]=+&,M M.0ONE5#$C&7UBZM-?&@7):?/Y;*TS9J$KAZC:E]!_\%4OQJ4&DP%+2*BE[1< M14"Z$-,T'G^3FOT$T@?4UBH.MA9U<_VC=ADS%R!++=# :D9Q+,!SM('^8W9U MN-:3T?N:&/2NU-Y'PH./K<*SZ6S^?OH764"?',]S)H)<< ;]\7\?')2'>TE8BUJ M@3K4#DV:'"*>),3$,F3FZN0<([GH% M)')RU#);%[!+*>PXM/C V3J\$OM(;6#E?2!)?;_X?HVFD)76Y%-J76^SG>1$ MB)?U8H )D[QW?##UW7KS[L[-K60_&T)P Q^.'\+?-PAQKKAH'%ESUL3:,8_8 M2;) ]MEQKK'XU.5BMYL&;[[Y"6IP8\$U28?\1I9Z_A3FY_^\O M_]S\Y+*N)A)% LG&BZR2ZSB$:"585RMN=#7HF_38ZT[B,F_1< M%\EUH*CEY<==DO9S ])*B8]@90L---YBKF]KBJ3W\GIL:=HZ-9$796VYIFS& MJ+U5KLG%R*XPL>9V9'^0Z"/X@2V^@U*FWZ:5H,.S\^GY/U?G'[>%UX)-<%97 M"Z84^BX[T$I(&XA**;LD:W8R'.XG8?=W)]LJ9C:H5'>9*7_TX=/!F]/C=Q\/ M_W7Y@U]_.WI[\/'-]AG1:Y\\6(9T/QY6,J:%E4[9(HO.0N6D?+#,Z.R4=X7G MS"<=W]$V@YH%1B8+,^!"KCTPE2'G,AI()17#M929-3'U&F50_WP\/?C-;'%^ M$!>7&9H*HRA8+.10:U2$]! MTHHI.=$66V(130ZB.Y2,+S.@#P;NAGVW$72# MO.G;J0J5L@D*)&.<'"_:7=-ECHL/)H!0S"0K/7W>9%;X75+VH?NM]/-H'DAO MX;8(PUV0ZT6T')W1WHV3Y&Q(1D807&=07#D(@6N(02;+4Y(L-RF^OTW&4U?S M%D)M4$#_>YA/JX/]$W,20T ?"A O')3A!4+F9$*YD)@OGMSN)MD7=RAYZHK> M3K0-;A<>NU\)DAE9<\J"D@3#[#UX8Q0=6-:Y4JLL?!.M/X'$K>U.\&%$/I;$ MK9@NNR&D2T4L7.T8(Y68*$C4M:@ M;*1%YTH(X&T.7K#L: D]$Y2LN>+<#TCZR+\!.*JM=%P^AV]XW8.,6 HA9P^: MUQYD+A6(W%EPWAHON$N!-TDKOT/)[FW2 34U&U+,#6X7?L4S\H"_'9SE@_R= M!%MM\//I7WCX=^VE^MBD77LGZIX3 M/H97Q]#)+[/Y^9?P!=_/PMGB^.QG^>=-FXN> M!@A<$NT,#3?11>V&RY+9B,3G8K;N2$D#IS<^2'%MRG1-9"7YNMUF!U*'3H'L M2>/NTR1WH?8N*!M09[O:O1X@.2HFM,J6Y(ZTE6>3("9N(1IGG8J,S,$N?8F? M#KP>R=\<.;KZJ&KHX,.D@9DTF^<".[#![KM 7<1\#ST_H@HGYP"3?(_'CWV^EO)X??CM MP_)'GP[^_>'PX^GGK5,_UC]ZL-R/GERL)'_0\I-,>1.Y)>=#6.]8UM8+:6.R MD>G)!OSTT\71QS?''PY/#_YSLZ:5-_]\ )D^2,V*W*(/VI>4-.-<:RO/N08>74H:4ED[PD;1@= EE%&4-4W 7EF% IAY F MC]*XL8G5W?_BP,N[#R6JC587!6&0H?2!7TP6; MN<')X=OCC^^.7I_='!*KQM&(X\^>F#,=^9B M11M2N!!E4@H]4ZIPSX2SL23G=4@LL,D&_&RLBR&:OS[VN&%EWJL-K-1"E,PR MUU;4>2O>EHIZ9VEWYDKER6,/'BJQ:[98O GS^3_EH+GMU+Y8? M7HWD._P;YVFZP#PA0Y-\ M\CY$OB3P;*FB!NF<#]-Z&<5)R")75D.T48!R6D,MFX4MXP$2;IU>9T*[(;5-& M^L*:)(S>3\Z^(J:#*OS>')VM!-\L<^LF55?7KUWH:I_B=Y>P?6;W;:>\M7C8 M0O*[1$;46-!$#LE?[J@,G% >LE,1O>7"FH;I?+M"1*=,OMT HH_ &P"!J,#% M^32]J8UKYS^":8;V/$M$^;STP)@"7_.&"H\*+6?6M'&8[Z5F7WE:VRIK-K2D M&_BZMZ8("^>%92A),:ZZ5]Q!U(&XXR:CS+'D3AW?>FM]#,/56QH'&PNY@=.Q M,K"N"S4O:F1Z+_4\/DE[$]DVV.%7![G32554CI!L(*J<9U#GOH&FG48'+2WZ M]%0UW6=D^H"*[B/2H5.([AT#CD'Y+#$"<^0,*V*U#D 5H#F1Z4W,I72;0C+* MD>F]Q+UV9'H?6>VF;>QQ ^BA,[6K22E6.1NL\R6CTD*ZF(0* MB"Y8*='D24>Z!Y/M%@N@PU/;2KI3]I063.J$FKFL= J.!ZLE9\D9S)CD8P(? M)MC\9G96YYC,EU?G)]/%'S\O7WD=9&)J<(ZSVIL:,[DNED/.44J!DK;51H5> M#Y&T?3';RI.OIKB$+\@GBI40E")O FM3;EZ6=\T6T 0>4XU2AB8ETX\1M?NS M>" \W*UO&TCR#7SD.[1=>H2%MCV5#1&D:@IK"?QJ,G<115K9-<=_>SSL-"JS M*_WWE_&^8S"7?6[_:S9_<[$XGWW'^>7@A^!E\L5)" 5K,]2B(7@EP A>R(*Q M(HHN*0,=NP2OOGY?URE#Z',VF%P'K@:JOLAQN473E6O2A:BAR\L>I&8/A61; MJFG62L8[ X WI61MR3?ERM=Y';4)F"Z !66BXRME-MC0C!TK_K$2KUWHO8]H MA[YE^8!YFL(<#\[RY;?3?#VJI3#IA,J5SPA*^ RQ2$$G7^"IWE,H[#9]_L%7 M[+:09R#YSP87WBX,NU_^^07/TM?O8?['5<#/*I6T AE" :4=T28B@$=PX;:6Z M60.Y-S!-3O O/+O =R0-XG_9W_1?T_.OUR;9CXEDMH3 #7!)&J0CN$"PGKY( MG74P,EK=9 9X)^J>&5*&U\A.3IQET?WE]FE*)NLZ@=>,F%?606"> 6J;,'HE MI=G-?>5/FIZW';N1Y!NT$K[+[<\^#%U(VZGUNJ\^2(/K<>T%]W9*V,7F<8-$ M%#ZH4!1HK'-HE;2T<^J:"9N8-S)87&U-\T3QT=](;0Z//K)O 8NK$^X.B5=' MGHXV12&(O&SH*'4N0 Q9@C3&H9-<&-_$0EU#UPC,CTUUN(J- 170-X/IZL?U M2PP+_+__YW\!4$L#!!0 ( ,*#6%+'6 VP'TT! )>_ 0 4 <&YT9RTR M,#(P,3(S,5]G,2YJ<&?LO =4$V_7+SHTZ41ZE2B@@#0+B%(2RY\F8@1%!(2H M@)2(V!"0D"A*;X)_0$6)"(B*&!$P"D@(54%$BE0A34&:3%##0-H=OWO/O>>> M]7YK?>>L>]?[G7/>R=JSPIJ99_9^=OG]]C,31",B!K!VO[.;,R F+@:<@#^ MZ >@M"1E9N3\;_$U!7D[ASQ]_!OD_+Q67DI"0DI->(RWWW[V)F@%E&8GU M4OH28@: N+*8A+*8J U PCI*_9MZ8L#_M8F)2TA*K9&&U9"'3ZA;"ZLO(0$K M+05K#!]-@(\#DLI2*ANV[EFCZGE2VN"\VK9KN24RAGNK:>I>?:#1]E,7$F7E M-#2UM'4V;C(V,=UL;;/#=NMZMO_,+"F_?N?NPM*S\4<7C)T]?UM36O:*\?E/? MTMK6WM'Y[GU7_\#@YZ'AD=$Q)HO]]=O4]/>96<[2SU^_NG863-W,CY8]J_6?8?,RSQ?\BR_]NP_\>N,4!!0@QVGH0R@ 8$ M_(?I)L"_Y#^]2+03-A%IKN@3B$2A72&3V"X"QOFBUU=>W\FB@5 (6* "E D-2T'?J&TL)O$E0+-:&3B*W8Z!=]*-]^%WP-9."FWPWEN+!H9:.CN'6PW3ZY(%J MIRA)@LF=8K=UJ3+I);>KUXOE10SSUWER]C%<%MYPW+E$R%<$2/[F6!9R]K&K MDBGQYC%(V2C5P]07-5'KQ\LH.PY,'DYX(!NDT-RF_G5%XNP)!'W6[!MR7%,H M9UA"I)E33_9*\;T$3Q?.\GTYTH=K^_'V(4PRHA%WGH55=3OS\!CK](I!ZKN\ MAOV$(X'7[N3JVC(I?+7EC@S>1:P(H.U A]&OV2&N"RWH?%N,%M\QPY7SH;X@ MB[53[H-1+8[R(M$_O+1@\APF=W/MN?<&2Y)GQ+A2ZJ /7X4ME+]X$3;:4%#> MM)G0-38\3S9N16C@-R4[#5^Z']-1&1=M\R$F"F=^OGW=PQQ+TT/F>5$K!ZHC M?;ZXSJ(,B+13>%T>/&DT-'X?/,H:P3.4"CG)6A>K$A@FE/_T"ZE"C/@"/7=] M7O&*4C!1/#81E/UU_+V#4XTP4[*'\N.0]&BM3P=1"^HD?-M935K/9]>>,9M;&^T\2EVS24H-5G#9L\&Y5 M5_P:*"D"$GE\?XC"NXP_!G^_P->']^=GBTV@?/!CY^$"J_G>M,O5,Y0EWPG_ M%C__C*)C'F4*QI*N1YTG@W*Z[9=-I&<\U$$J7R5'*.]Y$K;DD"!7N!X? T;- M\R3CZ';]L:=K0J;.GLH9XF0SN[ M/0055$:1"-"B,AZB$(*;EL^>"15GJ_UGA6I43I=LU,*825E)FUG M;D=63$L#5PFW^[!:>#-8XV&^&$>3KZ+1*903 9P<6GW*=0?C&!R!W<*9+!?\ M*EP;,6P7O.-%TTB!;V@!X+/!^Z\[I]2UYPR;D>"Q7N7OQ'5",3Q20*:>[K9* M.4JLI2>3O""?RAG"CLB DD9YR;1'$9XV^:\I]]GU=6(/PV_UW':YA]AV%35% MMA.4B <>93(=>^S<-C#<\?C07)BY&]9?-56_+YG[5$V_#L2W92TG#OG^#D% M-D&]^V=0EGS7/H(BWX2#;E]4<5ZLB/5I':YO7_W+>2IQ3/I."S3S&-'-^U'?M M1.+ ^[U;+G]Q=0N-B0 $5\%%OAJ%*\/93J?A>#ZQ.SZR#_1_&R2;1_<<"J>8 MA:H4YGT[T:#\WFC_4W>[)Y[9'O'1;]ML+W,F_%WU=QUR.&NW+?3Q M;O2H0>-%H;PT' MG"X4R/6!4,UVUT8WG8)OS"[-V]OK>F!><$P,_+*)4)KYA M)]X^*V$'IV.*8M=?W?'S+L [FPY=Y\;#'FWBNT ]'#E4!A#N>6!(=/"0"("NK).(ITJ@\,V5A$:SA7G@#58%%K"M["P(W M##@2SI*N*SS[+=O;F.!U+'#'HO:]*YW M -IUL^*^PP.U1;I9&*^WV?+QKCJX.\%GS#T?&]5< <1V<+S\:7&Y' MIA$5FW0)/74+.(719D1=1@QL&M(UJQN5-:@I\C7[JGMFV MFZE=KIS3BX%V! GE%'E1A$E]*ZB',\X:;JE$K TG;(/NY<6FM-^$JBP,P%K/ M<%>+2SR/7>R8N^KR*N(;#]_1'FF(.@T(]D&RO%.$+F2=XU1UA; '6YN3Z)" M3N&3%T;P&UBXR#V_1(#UZYR/:^VU*%IE$I>W?WMEI_,K77B>RD@CU85V8$>6 MN4FPAV_@/2!5GC$=[_FVSV;%ILKYO8-+9&GXZF722>+S;ON>Z,T-<>6ZRX=< M5&N+C]][L!?'S1'*VL!A90+:\M5#N78#Z(C>-;%*BRT#J,J+97-"O8:W_N1Y M'K1#,\O8&V.W+>^O6=Y:)GAD;9C$=Z0N-$W#*O -'_-W0SFLA>V[/UV*=ZG_ M7%<5(;3W=S=9&U)>X"OC^DGI69M8H!LS"C)UF==EJY_NHT:09#8(>Q+VCMJL M]^0="M^!E1.:1[ST=V/:8U5;*#H78A,U?&KK!ZP(Q]'WU.)4 MM()S QX<-KG@*CV+[N@=$P'< $%18Q 3F4+5;W*(#6KQH^=$&YYD+&P/^.PE M6X>[^B[)X*@#O[_CS4[=,J>/QR2^_U[9 ]]P!IKC:>*W"]Y20WKE"2/8%]>@ M_*<1*&-G*(KU%LU26(T/KRGBF7QS[[:Y'M)F9EW0_]0Z6S=(7&V[&<]E003 M0]#>"!+1C =8)>+)=?Y7*&YO\&X]RS+VT+$ON7+ZCEC6[_V56'YX !Q)]]@HF"QV6 MHR#L@*?>@]3&LQK%MG8_P0<.U6%UFG(UQRYN+3PX,&1F]NCU7:.ZAFT.Q?L- M_>H51Q5W(XE]6&FH0BB_R-L>2Q3*EH)LF%B$@(MM/A2D1MV>$DB:^;3Q_*Q= MP6O+TW5Y SU1$V6FUBH_WAB>;;YA&GJL-P&T%\J%/HT0 11N.-*V= M(:R![N(142RZG >S5_W]LW _83'O!J?3^E5!GM-Y^;('):F599;,Y!V?I(?^ M2I*Z?17X>ALQ2N'%QHF^TW>V M-YFX1M:\>WVF+.1VY)EL)4=--LPB[NMR4Z!=9+PRQRK5)L#6C6/SH'JHHB]* M9W(*IQG-\WC9]3KLQJ>T]:%[UQT]:M+5O(6O)0*N)Q(9.?2:BF;B6 /W,&C% M5YECAH'(=JO4)HOZ%[7]?*MH^\T9N\S+4KPW_^B0.-O?T-A\U5/[MO#[33'> M-">*C6S)N=HDV0B1.)4LRRPF%G'LC.:5CH;'+I'BVU\<\?BXV_+#WJ<*-5OE M'N1)A>*5!64H26&_SL&29WQ%J+PL-L]1GS\R=VAF&3FC$_E)>\GRQ(F-E%OA MBB^=CJZ_GKD6MV0KA*> ,]V&,H>]/$5H059'#I5;\0TUD&L=;-F*[OL5'(K& M*TEKY5W]CNQ"5)N?]G['.+Y?>M(&D0PG00;#A:]_GD5**M:ISZ,[051&O*-M M&]>S>NGY)@K8%O-J6>&^0CIW_[75I+L'S_7<1 PO9I)J-9OIH]-.-1Q$)R:C M>!V87UR:L*Z@R)):Z13)'7^B[;T^*>#:W:.G#RF+!17G#\Y>*2YZ&$[1^5CS M>$]X:+A$3TQ,].9.M:T&!:&73XD_!O+%@G0XNGB&>"^P M."=&_RW;2BL@1SE"\V[/Y_'C&0F']X>I_[7T.FWMQ %U0[FGS]0 ]=V"=Q"/ MA\9;"QX)D926J,R[Q\[Q+[4P)@; M_L@JM@68*#$BS1U] CE&8@5,TWI'![A44#JST3-$+\_M81C*(#GN6Q:*?_,J ML5_Y2D'&A6OO=Y+/D:=3#O6A&7\WV<*Q\1"EY"ML(:KPM4'R;O#&CEX6 G*N M';466+6A3-)Q20'&&-?28RINK#R9XU,[@]M2B[Z=>$G<-RAVG6/(RFDE7Y_4 M).KP/3F/[I>$ASN-T>0<;\O@6_RS50$Y[?OF7X'L*[>;I;,?7TW5X;YX: MH8]"!0]'05:83H1R;/K\)!XEN'5I$7)&Z859QO@[D;]\\<#%5ZE_7Y;TP_IW M&CLE[J%(W2EB1T$[$[R)C&GD"/_I58^45I;K.@Q_TY5\@,#DJPAJJ4&+8S[> MKS^A0TEC)"8]VT;7Z73# -Z8;6^Q=TKJ<&)PNJSO)XF)JW.!=["91#!F>9Y3 MBD=!BN"X4,X']'+#FW*PS:2U"]9DZ >-=6_ZJ^;$9^2V=C'G"@IEFE\B>FJ MV6^W5?W'*H:O*0*8O30D9-!+HT,FE 5E9F45L8.D;#WR*\N*-J;L'E MKJL/?F<6=3;X5<'1A&>&/DYB=W*/2?PJ:*2V8%_USB>PZ9FPLVJ&$XGAB^(1 M30[]0Y<'&[4KH(=# 5Z#>\7^?A_Q/,3C:N)HH)CZSZEK\#R'#Q,TA/1 !7BZ MHPD3:/%+Q)3)K5 A,[:.F+*ZF.1P9G4JE[C=^MWJF26/D-"-;]_%&GEOT-\E MNUO;]S.FA;C&^[ 0$0:]5-^-!*_ZWQ.C"Y4==:ZBCS^)BXNK>+C?X/)=K7N->X)/I)S3.B4V]78'%4%E MI'9,#@B5@@1OOI[*[2C%QCC"H)*>.)A'],)-.IR',\?8/X+Z4K,- 9E@YCMY M6[Y/VD![P%Z6%#798=^F:HY&I'&;K7AX)"M[51164B*%L!WT236W+IKNL[+I*X_0 M^!2!T#NO$*=:^B[OG?+P.0G)RIT=>!A;__#1&;R/X+'0@B_5AU*$"^YVE%$$ M4HFP=>8)K(+_@M(8-N7'C8T_-ASU]Z(HC[LJ>'D8CB=?R@]2B<-?):3V8>]1 M8;,8C00S015!'^)Q;P@*B"&1")A-.TBP_B'+F\R?4F[N7,IN;. M=6F^1K>$J,RB]3<7[(];??\,Q'7>(.(61XF=]%K-5&*(E10_!OQ8P4&V%)C% ML:S6^,ZF+G/7(JVF8VD?I8LTYH/)MXNJ7X?VS2VE<"6@'IYN+%FHI TM@^.M M]!>N8%1G@FU+X4^(S#)"*H<.UBXX[YP>R&W,<*%D14XR0U_%W%Q_(NAD9D/! M=Y0V;&\K45.X2_B)N X=3$U$@AZ._FVDM03I^Z<CP+?EK?6 M#7*KK5U[]0WD]?+>?2SM]E9QTY*>^7T!"0\2AH CL(:4A,DF./+]P.7KE[QW M)F#;ZI\=/?KN@G2/^3/UN!"]XF?25U;80ID!.%@#02Q?_2?7NT%0@G<$6^9H M5YZGL7QKK92AL^S#FD^B+MQLM7NOV)R-WF&4?#ZPNJ>=L( MGYKDH6NXTEX]N[K.ZXUND8_+[V7+&W2=N#QRS&RMTO9:=LD3 HHP2*WQF:\J M.0:5<@NA%3B>@/"Q^Z-U ^3&DRRS!#NS)RV%6SL&ZE-./,A;?9 MYU3)X 9TI D[T*D^\#P(;V([]X9-:\2D&JNH#=1^3=F!6.[-]"@]:#.#[ MBS_/8L'H8")(18?T(O'XUZC+U\ &EE(6N$P[$.=FH[UO$C<V+-\S1L(*+F4JW'F@K4(D+\H BXT?OZ- MY&O@V,;S)\'Q-F*U2PHQ,F=D)]]+9_!H*9.>>DD$I%Z<(5<^8=JE7:)3;\%R6A&91-2 M\ )ERP\49#E@P'J$%/\<9!/G8+=\8R-'NW$@VE4#L]E^SIYY-L^QQGY?X]N7 M;EJO,[Y>.+\;&="'O45?@V9\@XLLL9;J*8]_S4/>?Q"K9_[K+YH4N>(YUAJ[[V.Z3]?6NYL]T\>HWIXK^ M+@<2F,]Q?E')O]Q[E7&V:W3MY7TMSWY3KOD[3:UFQV>I(D#UJJQCTE$P*LMA M'4>S94A_%Y3 >FL;T&?C'O)ZP"9!?]6^R/]U45FNN[;);+RZD<\'.HP[*YQ> M;B)GN'7"L)-84Y%DSM_(L6)^6TQWL.7H,A?;*!R-O.!KSZX-;+2H&*OUV1VP M_^"%&_Y;CIY6,<)NXYL)'MH@1A!"I:T<8[YJU^1,"13"ZKW.IB/?1ZF^P%'/%*;]&5;_; ==T#WR'&[^W"6EPR,YSAOG*)"Y3 M\ "E+QS"OD1)G,QV!;E6Z=6IQ1Y>H^ZRU?6KC+RN:Y[\H#UEW0TI=9_UO=I350!21?M_Y9 M!J%;[0CY8<';="-WO%^?^:;#/P+8=FX7]P&B/0HR+9QWXWD1/I+ 4LJ:^Q=/U6RV='-U M>+=/;UUUX86]I3J",\4=7;.Q9Y^?8>7YAUI%&7;(_]6^/Z],T.^=^F[>=='K MI@Q-36S%'9Z=08@,[W%_%EJ@ZPQJ!ST)B7# L*-R4+HOZM[4OQS">[,\O*:; M55WTSTX7Q_,J*,F#^[6#: ;,LBQ/6:N:*1)DY-.^>&,5RU_GP0N$V(>A^\RY M!(UEFM"JJ:*0(T\*J")RB= M&91A=23NR-"9'Q;64V\\MX^_CXQ9>V^#?6;\Z)%76^2!\[G8#42:'3H,D8P5 MHS*21,"KSOEHSCZOMP--IK-^E>;Z$G;>K1%;._4.[3OO4'U#\.&0@Y=L\,W' MF8\/_[0S(Q[QWMO:,JG=_SN#NG:F>-V+5X,VBM2HIL0>%=S]4OFIG;HDB4=N M[0#1096OQAE>"!(!:T[C46!GL^+DAJ$F;8CN-8SW82ZHWU@.QVE0G]WQ9!U_ M82HU;QMRGF1AJY!-]8#1WE0(ET2:'IKQ@*I #(U?:91FD=<)/Y$0 VY;8[%' M.5%I-KHY,K.7LW#V7[P\5%"PIRKHC8*V9\L^X&A1L W/V+=>^KH#DNGV M_+F#!=/#UB-O%;N#ZX'JV.G'7%FY]T"WU_C6K?L++=:_JSP[L M\J.GC"TRE2PW%$2P3"3!(J/1,4(%/0+33 MK]F%\E4QW%I.5F<&WP>1JMI>+TW+2;=+:J.X:W*Q(PH%=M'=F[?^M&S9DG7@ M-L$_M)L*UX(4WUA=)EQ#]\8_<1,4)KWUK?P>-V$A,CB$&.L4RN)8.8DB0,+!^Y&;"(#QKKE;(-&R^KPH7GM,\)P([22U:!F\(R>QE?6L6)_$+'[D M:3-*?A[UZY;>^5';Q> O&9;:1S+W;)#^NE.86VDY34,I-'*,4-L:P.Q"2_+9 MHO6?@U]D/0\ZKEP78O9:"0,L6XNM%('^0MFMG.V=1/",4B&9G4@'<*UT&':D$FOF^;K M]"5P6MD651TE'&G:*]EG_&WN&4?=B]!RL0260*7];W[;[2B;M+6 [9-:+91? MM3!]MM'N8&'4(S@*:(_&RTD%0;S->Q\ZICQ=D-#:Y7!(&N8FH(L(2"+I'!;* M8I@D;?SEI@07%K8=+4FK@M)_1(\LW;&NC+>PT=/W'CY8]\)73 04-.%.:!A0 M451&CPC(1$E 5F E6W.^@;//D^3$6<4[XQI@ D4?<5_W\4YX9$5D\=3\MFLX MA0N[.=N[CLCZ[>SM,9#@54BN]6LN&/I4=K[C6E"6FI2W! #8 9O-$K9[U#84 M"PCJVT^>X( /.[.-03NLR"71? MU([U&SA>4WBX&NI[@HFO<+GP*-:@T&- TLOAQ _OBWK7CF5NS6K^.) S7&\B M 9,FR(2^\#N4)PY1&!5I^)"*64U]>4Y%FVX. AH*V.X6__Z,A:Y[0[']@%Y8 M?]RA'LE(T\!<;5W%6HF5/ZTLW';3;/\L:MJIJ<(*1[6&S:?V;8A/;G1RTI7)OUV?+V 7='V,3WT^79OV M[2HEUZQ#WB7W>NUO;3V]HP=30#J3GFPSUZL&X9K]+.\_F36ZO\^KNI^9')]W M$'/'P"3TJU(9/&7-.=#.1=_7H/0"# V2*Z!+!S;M;L!R!EX35X%,]>F/2.W0 M'OKIHAKPT4U*Q24Y1HFQ1JZS^GFW4)[(P3'/H,$+U'G_*G>.[CX-/_- W<)C MC<+!C/?5;G7=:0;AI,LCK<[?&=5 :65"OZR _O J>@TQ%)%*$"L2(MRABB=. M[,B-5>1:M]INLZ3!(%/'V5CBP;2%7,K)>9TTW5V:=?$92^ M=R<> G=I.<@!?&>X-)8[H%F]V=CJQ?E%'I[0@Y7'.XD N45F:);5#\N%-3FH M?(.1XW5W:@;;3%3B[7UP*D^VFQ]\.+NI97$OH1H&V,NQG7##R@L3?A+*"*J( MI^")A4@=)+5+)*6N:(3Z7),!1ZDDAA&_*S(TZ]EBQ>#SX%1[Q[87Y?7629EY M/5JFNEUHIQ\6C(9K"V2E #*==A,,5A M^I_Q6T1 \,"9?IEE_:HZ0'NG'N^0M!G/G="/EB8&8ZX%;A24"E%0BR*BA: V M$/CS*+7HUK6KNS@<785M=XT7K-A6XS5LXOQ; MCED[7>-WAFDM6GRL9*"TG[^!^35WC'Z@]O+],I6#G1_KZ[?^B#/:G%K]X*@P M/0RF0(N09>C\..?P'D$3]209VDQO0RO2(A]"F':"6A_*>E8C8B:4F7"W31-W MT?1"AYGGQL^S*]GGR@V/GGE7A^/&"8I_B( S49#=3Y;MPF=PI!4N7Y CL](= M#1WX-5J0L(-WO*CUQ3%!LG:AJ7EUU>?6G7LG?2FZZ06'B,'D,\]^F^VZM.#< M;Y81QPZ;3@QK+4MUEGM9+&.8J+BO)):X!VPJU$AAWE<9./CR*G+3QX[1D^D. M>0<'=P/OC4"[NP!?&7;\:^%._H9;W%%![KPYRBBLL) @Q]&HB&-UVSMZF6[L M/V67G7?DBTG4E^GY 1 2 4IO%@BS8\8C(:,22V(-7P"U%N)\QN^[H!C MQ?[R1ZA J@<]CG[LN[.NY\.2RWI/N=1Q@6^>\_H;6>#(:L0?(,V @312M%-JI2PYZCA)SUB!K*EL?R&L"E3\QSSW,X@=F@N/G#KO.X1Z-ERLF.!P>!X-7/JP _'+;_@H-\%:&7 M"!XE0B;&\\OLQP[W@Z'9UB,UFJ9I9\V52IZYJ[=,W\_;1\09'\0/\@DGX&M2 MA39\?0RT"\D-YKR#RIG+?8W:)QG1G,M/-,CRM%(;:H:-_)VAF<^I5SLERI[I M)3[NZ@32!?DKVG>LRM?; MC1_O4;$?#]AC=/Z]8G^GL7)JF?/>1^A')A*<*+@]@Q9$ "( PH$B0"A;!6?9 MVRW\<,ZF2G9WPL4.N\6K9P\?ZKLD[QYKG&ST=O"D!4XLSA+?6G_@ :45"-X] M"0._U!*7 MFKO&,RK#.UC;$F>W7+F%I?[*<\XK==J\YJCDMA?O##]]DF89\]5*6V$N(64, M3TLZ,3B5&$35"!=NZVO2#:LWSH0C@BH781H?5#H#XK;1<^Q8*GWM1KF[,W2J MNVT^'#^9'$>_3M(@:)+Y^D\XVP/0RM:8%[,HK0S7ZK?"@8SWQ4*T_,QYQZ=- M"X]""K2#3._3V"$=S'3!![ 7YH>,2E_S1EV8'[HEASN\+QDP#[H63"A*W2V& MFJI]+ &&"F5*.87,-B)XP6JAFA6 ;*\G5.I7XUB^^%U*142UG"IKNXG&K'6/ M=#65O+6NWO@J?D4<]W4QBT[9<0V.\058Z%^1"Y M%2$1$"[4!J?N1ML;1C^+&/#=?3,0^\8GZ1OU0E=? XB!-/NG/[Y)T.U"D7KRN?I!E6"T$P:+]Z"^-P6"QB]PM. GG\ M+[\U.8IU'[\'3G'I/MF^S*NNF@OZ?L$U+F]\@A(O9$K/QO#7%@: @138[4D" M4B'-;NA^O&)AJ\>.X4,ZT?W[+1:/JMLJN]7>STO3IIC2))?,YN3=W=WEC\T_ MBRQ-UCID=*CMFK>: @ PQ&:\X,YW \\7KP3%\QSY'B":KUXHE,'RW,@I#A?9 MZ-0M8?7+\]-KGK[$Z5Q^<]',>@Q_-'W?Q+'&ZIM#2R[?;D\8966>243//*4M M!E^R78;T.._+%1?7'$;QBL\J:W;MHS3V>.;1 Q0S?5QR]0)4!3<^:5SS' M\M41YTV)>D'=+N-O#DMF/6#?'7B :$% FRCMY"0*%8S!+IBQ=#&I8WH%.L,W M; +0+DT>7H:*O_O='RXF:DZD&>G_1=^<1[PD B9LVF$BH8G:CC?H(S)JT:"G ME>ZL"%!S0$>61H2S[[L<^!PZM,$_OF$/2_O;]O8-D2]=OKUL^F84N?Z7C4"V M;SDW.1QIE[%5FYA^,6M6E JDM08D'WJ/WK=N=]FC8[=U^0 M9*G20^I>*J,&J]FDP=\ !P8.[S^(,L'OZ;>6J;.2#A@-K_"FNOHM33G)W&Q[ M=M&LX(3X8^/B_-_J<)O?!X/,/F%+?>'" !C*Z%SXR9.?O5QLPHE);@RH@*[T M^H')#PK%5SN]WF;;RY:^OO$"Y?R0([7Y'#4R-VT%AQ8JQ8"4UM[1>*%,.&-Q M%.,%D2HB4%88O>_+MO2PQC0;Q2O"/?$7GT14 1MR2)>651N2QO1/[7RGSL,X M 7^6V=F:+1[N0H6>G+T#0I/8*_'?4;HS=@>XGK@MUGUT$1#91NAZIWNN2/D= M_J7M22TV<'=EFIL(Y8.SBT*%+LB%,1>E']8?P>Z,C+A4-LBR-8C]+=@?;K!$ MB9JL=M-+.G\SS^S2" N(,.'H]*PRHUPE5F#9/0&J@-+N98XP3[+="[ M?U[B.1XT#<74Q%XY9KDMO3TE?ZMRDTO75U,:JX$([4*SK5K0:^>HX,'[[JUT MU5K%O?3]V9$8K[N=1Y-#ZFKR,$IG7M\L79=+&9UNU4?E MOJ\7Y2L^2%0Q-A\!D!LDRK#2[RS=X/3*MUMW#N>N$ MPYS]7,A=TRT7; T3$>OUG=!N_=;W)3Q2G#_5-L2;V5\:C0H/%^_4<__^](&4 M?LM5]%TJM('/>!A^?Z WPNZ+&0%UR^V:JDR*_K[&'<-3L:=2;X_(IX;ZRF5N;I]!4Z2OUI&S MJ7\>#K(?01M"\O%28 3]",>IS3!#ZP0ID#1M^/#-F[J,N7.E;PE4I[ M?=5P:Y3$C'*$IJQ%UVC+DY!UOR?[?3X6[!QY/M6\[0_.@"IXUII9EVT4+G/+^ M&7#X:_861*G)PW3@7_(O^5]!IE [\,=!8C/B.LH2XG"4PMF?'%29&0+B\;PQ MJVU.-364/-:IC-PW-\Z_6N.,45_IX]G!*8VA,AZB*5G3+>0,],OB)Z#/_KZF M39!T9[TP"V1C^Q?K9$]&(@[WF3-K!FV.6;*W!'39:. [<=^:=177??R59]6/ M3!.J@8ALH4YL1K,(4*_EF5'EY^S4)W+2+*)-Q?U[*GKD.\_E51LJW[[3JI;2YG'A/!,>MR?2<-^EL:3VQKVX9-^_7=8UNAK=+#BKHJV% MSX>/PN4R$:9.M ,.[C"_\^%0^2I!0KEPL)?V$R+M[3,>7'!P8^!VI)L=RMUS M7ON"7MFK&O]>7>=O0;GK\O54VER6D?.RO# 7^-K-\$C$6!NC6D]U]NJGLU\E[&SN"=Y>9XM#@H5YH4PQ? MKPF>#"(.HP81642^C52#6S1G#;WUT/CQP)%]D;OJXD^)Y;7YO[V[;^/-W(=+ M?;K3!MJ[I8<#5>";E@@_$\%#Z/%.;JK@)AIN151B0VGU/O.\!U_\:>2Y8CV[ MJLYT!P^]1>G1";^P_LEF#P6.RK7RR(=[#))''.6%,EFP]MDB(*5:V'F%WO[6 MG7GA&-X5M! !W)C,1B23EZ0<<* OKF!9(WG62;E]I]+3E^__C@WVF@W"+(>^K_CW4Q%K+-B)H-WO?;OU%WF&1%H$$8<>\Q'*I["BH$V% M;=31@581H.1@S\A1G"W4R4_]3*V+MN^^73"Z\ U7-BKGW'=0SSDWSY;Q;H0\ M,,;?*LBB?KN(S4%RC2=$P S9E?QE%H ,6<-\M586N0,-F4MB0=>GQ,/Q7>N#7,W.$;/6BIO*I&\L-W!U)3R M^K#J]OPP_ZD-5Y%B1-I.:[IJ.!:,=5DPP[%HZ^NC%'$7G:9ND6IX:='WW1B]D>,JQ ^?I'\L MJ'GNEOJ7_'>)7D4G,:F N XE#74S"N!.OV()4W4>YM MM&:SD;F80RY6$N\%9V 4D>9%,(,J:%@9@J'PLU!LF&\? J([X*[\-S6C&UP] M]OOPR5I(L9O^ MJ=&]FA\WJ8IIHR; 3JX*1^,M[V@8EA*SD,0F(6*IK*@DAXVV*7S-2*:58L^C ML$F]1.;MB5Z%&$W;[3W16X)T#RP]?88U:"MKH/9?.B3=37_E,X_DQ CE9"MZ MP5#V\H(*?CL8\6/!_SB(:.W9Q1AL=!??&4UI^CQU\^]7%YX&RL?'WEYZ=%E] M$:V$4H[5942U>%@Q.INQG\D7 MW"Q>%SR'$8O_%;*!B_!.Z">8(90;8.5 9MN$$X$Z@_@]K-_UE,]\ W@R*M(_ M^+E+'C+W[+)IF7WW8F_,S='-%UZ?49H3RLG#%]^"JGCA<$;L)D@(1YN4!+7P MB.(S2!FRQ;?!1MV3D6:/2KX%ZA;&KCOME.Y^ WWZ[_J=6S>?:U:+>AWV )$C M="32MD3C>B$30@9#+GLX5QJVLQ)R<:[VZ82 M-L1^9-$BE2H?N[J-J\GU?O7OT+YQ/NJ"?(/&QIX$M!.@YODO^8\+%LT_!*=; MJ;"%N 9/?(JWA/(YO3S;@+ZSA-XG(R*@9?M3CZ_OKUY>3!_-?6V8?\K,[XB9 M3_Z3]O2ZOF]3NH6'"'AY=L&A\.;6/1FW2RUN9BU?S+R8GG[; M(43KXL%[>3\&7/L+[*4"(]1F.S O\Z+ T+(^)_4/T?]L7/I/+P2 2,.(@*\B M@ #[=:2+OKK93B "R,T(R%0$\$F+[4B>MK\(<'+!8EKHB[?@7)O-R64CEG6( M+($V8]#3*>']RG=/)S7@'XG/+(FO2Q(!!L;M:)[\#'%U\Q35S.PW1JC8*P)R M55DD0=(OJD#]8J#M6N*[IQ7=/UW>MJ*7=E6(@"CBC+E@X\-TLY_7?Z__3_#3 MTW^RK-AS\^ 2]X:O!UG O9(:?Q?D#A9V(#5^BP QZ%;K%>,<"[[:F9.UGZRB MWWJ-8U[6WOTAG)(IGIG\=E[2>6^%^&6*1_]ZZ2%KGVM\#7B@7&$/6DNHQW>" M4A+.LY"2E!:SSEJ(] !:;OT9OIJ2]X:TY5]LJHFO6]NFS<_)K&T M(T<$2.\E=-?'+&0\('0AUU&#Z5E8N4B^?T(4CDE2Y[N"M_O[OV*,\Z4&"UZ^ MN&OFBTRZ+=VQ)WJWUF/IF2KUG_2%GS!=%Z*D7]"PF_ZXQW'G]8T:/)\Y]*%,/.7WTZ'K]-TZQ)+Z:&7<)LH)U'Q'D_UX< M&V"W/W\24_(]1J.@NQS.FHV_!>UM,PKGFO/>ZVS'MW\,.)?[9B%]Q5 HNP#/ M] [A.RKH11PC[17<0DD0/J(U(Z-[SD[^^/;;X^*! 95.#(5R;2HO?-)L9MWA M;T>T]A7F:D*/)7YEIYL\$/\O0@70##B=EHA4->)\2)1 ?1U!! PSI/EJ(D"( M66;E"#*K1,##4G(%,VKY/=Q._G9YQTGA9:$YA$PPPN1ATU?^KW]OY>(?)#(V M/W\5OMV::1@,TC@88%W:L_ M,[-^-.2)'Y0W[O>JKE'*=UX$#)2N=8K1"@Z;/D:?#MDGT!R>BEGHXU1P.T Z MC:B'EQ54H(-RM''U*L(!_;6#3?JQRZT4O]/E%7.!^E&I=H[?WF9]<)XY_>K- MD9ZG+D9[=XBO_]A8!\23^"J57%"00F54(N7Q>WB'^0#H%RXTHC;U+P@W05'^ M28%+K9XOL=O>EQ^__4T^ZU/ >JD;[O?)2N]$P#8T@VTU]G*YA0X>08YVMM$I M%?,(5@/Z&EJ^T24^KCPVL=N_-@^KZ68T1#9*!U<>Y^Z-7']SI*'3^NE'[8=* MSQSI7#LXRPE$FA.548B4HH;GC$MS306W&HWH:X5;\0=J!ALU0?GCPQO"\+N8 MN/CN40W-O*$I^\N-2^3C,@:OMW94/_:Y.64XBWX514.,V0OEJW@;(4/N<:B/ MIPBU,N)ANGF^? Z[EK^''8!QO[M.1]Z[<$%Y9M,8R^W'CTV^.B:3KANRO-QT MG"4ESR$:4<:Q[*-@9TO6879%,RGQ)=Z)H_[QNF0]*J.4/CJS;/?5\-+-?=S* M5UDJ6Z??L>-/XCM;\MJ0'41HAQ4W%XJJ)-(.B( (-,!/$-RO(P.$/NS:1K>G ML87>KQH+-2[O<'^L_=PZM6K,.CXNZ.YWUX",E>]7A8O=XIA/F!QZG2U?K8+K M(ZBQMDHF*1 9]S <*^X9E&;MJY2V0. S7""8!OV+A]3/?0J8:-?+77_$4_O( MEXK8>S=/:1-KI/FJ VWZ,*(G5O!A%1)?XWV@F&B&V:)ZK$YO"T$1C/X\\:R^ M[+S1(8N/E82A/ _)&*7UZ5H/W4+&5:;VZMW8C6B#R_EA026:D4BO0R^8H!G% MPET#!$N\TF 4WF\ MW)EM-8Z ;!$T;/5R(I'Q-T&*(L@0KI\E;/I4)U]925>-N+OPSG3OBH9$?/1C/ND%U8+?_ZA EV0B0Y?A(QM.\DCE#:2 MQD+3^HC5JNEK> P3EV678-^>&QC>-^JBWOTEP'D5GPYVFEG/BL=E=WWP=/_^ MYX4 3"]D1OKSBH10)E $R(B DXYH)X[F@AC+*NUZ6]/F@:J>F?'X%?@>8>\S=\IC(*+NNHQ2 1 M=5G[VOSRI\C$1W%Y$9BPH:.5ZDUE.5&;NN.+YFNO Q_+UOK8,)"@*PFR("YT M!O'BCL%-KR6:0<;61%;<:#*<&[I%;#%F=6,0+H^ZH[\<_)O MEXN1J?QW+9&1[;=FZ&/RW$>P'[_A):!H4+,#BZ">L)+&'RL\!.97$C[9*66Q MU.H^6PN"VS7OJ%^W:4XR5 A9:3G^Y"3EZZ'G@@.D&JLT=%3.N#L#NS#!N<4] M,TS0\.,C^G\_^96@V>%S!7]WLOK)[)96.?.TBB]?G!3OORQ[:1J''[Z[A_>X M[UB7&#?Z7YSQ?S'Y1]ZB_H;$X!A'BX!; JA4! 29$;\_GIN!_ 5+1*; <\GA MI)"-X6-+'7323KQ'-?!0JRH'UDAA"V_#A6Z6(N A47!1E)9K:<3X1RA M[)^_@/%/6SC))(%8X@I*$2ULDT<(3!O(^RR:14 8*Z'0UC)KC?US.9S31T3 S++0702,2Z_"5.X@ M>BE*."@L-B%/Z:?_5V/3A+ O!W+X12*@#EV1;K:2\C '3E02\2M5\(+X_^5= MFT XH.+17Y<]T*602\*N4:P(%Z&_7:#)00RA%%@#&/XR+L."H"^CR'%P7_J(ZM$N#V"$^" MB$?P.5K$US!5U?S>NP:N*3\PO7O_:V+]_R+9L.:,+R)@11D%I]0(%C:AS\=F MQ1?[E B>)?)323#9GK5A9QO3X#(RJS&^_6BKP8J3]XB^N?,.M 1$!I=I2!F\6'EL MS/X,6K]R:+F?^?X%[I,URX9W])8O;\RYZ,%6:3MOHJP@),,XF1I,E8\M1FM$#-43TQJ= MR.%3BSX%OA-'7:ZEA3%>W=B*"FQ]>\IROCS[L^#)1D&Z4)5(\SX]9.VHU(%- M:=)MRN:U7='(#[[EAWD\WMS_/DC!93G$Z+YAVDV63>A-OE^Z"D8 -&0<&%OI-+%3T^H C?TF: "@!KZNKYO=KV[Z MVOK6YXJWO"NJF33/5J^L_=%'!HO\-KVB$ _KI*^F<.4%E7@$N+T3I09J)E-# MT(JQ YXZ5@4MS6B5]#'W3ZC[VD3K*Y\;W^,&_#FRV+?Q:Z*VEY(_>P3Q2 M?6%U^L7?.O61CG9QEY94:?MFT<>R_AH+MPD=KIF;PE?"\7NR6?T?M?9=7?\8 M[+/:D$N;GRSQ^Q;/]?*SP^&B3E]U1[N%/4SG,P2N_^R7+O[_$C-I%J8=G8Q< MTVAJFRVTXKM\PIN6C->7=]2P/$[)Z[K>>7UHX&!7.N8$QN8M-@L)GJ,L2/QY M)8*&@A&D EU#YJL5_V34];:AKZ$DP-\=]^-*MVX:=Q^V+*]/GYJ[/.3O7U%W M=^#=G0[MJOMB>I^D9ROF?_+\"!^P=15)ASM(->C.7EEH^B N=BH/JXB[.>%8 M_[HKK=1YVV[A$X-*B9N[UZ>SA3O@VWD0&<4BH":F/9YXC:J//I.34JS&B:3E M"(W\AM,>),<3MX@GG_/7H%V3U-XO+F.8#G4+94)+A#3J*P0M:I3*?0Y)<.3W MWF(--R]>OSPI!66%!)TV& S.^C42V5.WM-5-9^?Z>RE9*7-0U'DTO1^ M^9" A>T?V@PZ-*NN^.Q@0OW@->QO[2GI>'2; ,AP*7X<$#G/#P-_% M;Y_B_P(_9I7-Z5N!-S9^+$UXV&[1WA(>Z#.9YW^L_"7*Q=PCN5V!=H1?PX"# M_&FW4+Z.01QI%$4,140HC).8>,LQ!RB!S'*2+#C,/8S)X]SW9] MG^>^O]_KZKJ?[_-Z_>[GOG_W[_O'?KVTF[WVVI^UUOOS_GS6>ZT5.;>@H37N M>A8>:>_MN]AU:SRBHZO96JZ/7T;N=;O24+2S%Z-HZ33;:\+(1W0P2RM]?N];5V'Q#8$M;K?-1,!"J)"^>RYT M>V,Y?8!OHAGM.F#GJL78;[R')X9^)FH)J,^8=M<1=H)VB"Q+I*PO1WDS18E?=6J&[19=GA>[(2AKY M+YU]9RZ@H.C,=;_"5[2F<342)_4:7*I32=U%VU6AK$+S-]6WR3)TDCUX1D;J M?IN>@3WUG M:'"-&ZC?LGZ1<&-3M9Q>]61JT29&_]^O&OXSP^XOAVPW=A%$?#H5 2WZOFO MC,%P(!LW\*D5'@9>+5TW14)3(L,?GUE_%0E0[N$=_XK "ZZ&0KO[$?(2,Q[- M.&@*K'MT_QQ=9]3!W'-(@/6)ILN,DR4Q3\ZL3$VC%^5R?MPM0T-1;]<)^CHC,5CC\#N_ MI48QP_N0QJ.^]?;T;5'A+8RK;8H18IL#N#^K4K#I6,0%#ZXV#)!K*Z=F(X>KNAHG$#AKK3@&AQ4R; MVB1F=+C&*3R]/"397_!K5(_?\([.#]X>J<=%MH"F'VN03Y %9Y/V%OMH/AR[ M,L&-M>KVP8(&%$@JL^%.HE",U;[G$Q; $?U@>F5NS>;S+GCU[RDD@XK%HKZ@\AP@P2H;'.KR%LV MT7AJ,0^C6"@^>?5Z$SXG>NT5Z?YSM#/J%O.2L1).9MOU3AK%7G3YT0&>?(0& M'=&H%\#G% 4XOAG+]8,D"/F_QIUV#W?)J0.(S3AWNQZ?835N[?0/Q_U#3"W> MQ%BV1L[O2ZW*J$ /\--[F&\PSF_EQL&UB0B%79JID0DJ"F.!RB-^@L_-XNV# MAB4Y+P1'??LYZUF5]6B]C3,J\U.2ZPBE*)Z^.&_:]YY\M?Z*D5-/K)/DNUC7 M04"SL6^NCZ&%[T13#;'AY>[1<[BMZ_X]%.LR@@%-)72K0;931^R.XZTB"8H^ MTK=BCFZ=4+]70X\&C[BE48E6S R3]\V?R MT6S!"QI?2MN*KPKM2Z@>TINJ=&B C]),ZWGXK<".1GA_Q57Y/*CY$#&\1='+]=VQSVU,+"4:G6E MY RMRXX6LE"UH4@EO'$7P$\3S;WX0S\31MBH4,J>6P?0SCV6@38>WVL-WS;X MK=81^Q,G^AJ(H?C]8"%U8BPD/0?TK8U)[%NQ,,8>Z9%Q=^/:[IFU]/YT@^F. MVSN="9'P2>@,C5S'PX';T^>.8/ #H$;6GQELY^Z2=:ZP66*G[9T;FO;M MJ.KJO- Q84H<0POB O7&"?>1?E7IY\U"<8,UDI;.K7,>Y]NFM"<_=59D.3X? MW\1Q>2>JD7U[T=5\Q8G#9X>ZXE<^YKYFH;I,1VQGQYS;=V7ASS<.F*]^)26> M8+RS +EHT?109D@E\ IRH/8%8_7CKA99I"A!^F-/OCCWGENTCG6L\[^U<\>3 MXZGXE4 TTF7+:81:4OC=TIJ.2#Q?Y[YN2&L"'9K_4XSRH2FU).X=GUG8HRU> M1WX^V.&_'_5CF]\Y M4(,V!Q&51] W'2 E=#<'ICS,TC)Q5/XHQ&![G/Z@M$ M;=;AS0PK,#Y]Z1I_:=#Y\[OCXPY MW[Z\_2A[<_8ASNS-]U";"Z_I]33J(NUX:-AQU=#EQ\= [O(3/TM&DJJJCHF M=W,\BW-*B('ECK8(L/Q(O?:O+-U_G%U+ ARQ@YGT:V W$8==OA;V*A#[U= M>9H(W.-?-3#^$R'AIV2MXO/F*43O,JMIYIXWO.DY;^2\]L5>W(G"Z!NC=X$V M=?@CW18Z-&SH.Q]UY1MM3F\')#OYU/CRV#O&3J/;.Z!=!/K)?! )9K=9,%-A M%;C>2NUC#\3OP3AQ#0RFQY0%L5 =W47<)HSS*;9=TR]P069'>EOFS-5%#Z@3 M',]76TW3)Q'F'H<9344+8D9?)AR#K," "?='+!0[S/[SYM(8/7K,(D"Z&Z<_ M[KB:YI)H/^Z]9%VR+;9=ZO*;BO;/OCH1C"RJS6A'';I_>LSD/E5WM..!ZS*: MRP][(?CBE^5D!U\+%\=+DDY5.@Z>@CJ6_<_+8_7:O)Q/KLON.RE3OTMW7:Q@";1G%;A^Z;@EJ MU9A?C)Q#G7)Z4"[T^!DN):&T/R6)SM\52_?.6J,X)V%'Y M="M^/'&N>ZS+VU6-2U_?K]9BT+PVOXGO=%Q%@U[HQ)I\N7^#9 MO+O\@;2GQ-%/6_L6,B)>.::*O[>4K1M0RGV8?>+XH)G%.Z.0FV:/C%&VL7HK MDDG%_P;%!X-HZD&#!T K%$$D!?A6,[NLP/O2:= MQ%S^RZS\__3K5\P=W]8W(0T)DV'#8$.D@38C(>$%MY\_3KK .ECZ3R9/TCAI M31 8;%W1/("XI.4M2Z?_$M(K,:,C'6L:T0) __$*%JK[,0'+UO>+7J5R$O& M=EBMKY^0WNRJV\-\M.'L^%?>_VO*Y3_I$@RF28\3ZGB"K022FP!A6.*'IL 7 MRO#E"3/:P?QM46]^&SKDE&FG+?U>.FF$V!@-GK2@WV>^1486 :!>(?3WP9R& M_E3SZ7%T-6$3>'?B8F7GLSC7])^)EX>UO7PJ7.1SNP?:G"9_F]C1VW[OL>.6 ME2MT?V8NQEYAH+LV:\*PGS Q_0#RRE2J]-)3""G^Y)8Z?-WN7&>:Z#[@:HSQ M_4_[=FE[L%"[@=$,$M40Z*\8_TBJ)D>C2W3K.CC]2D:;-B(6E_HO6J=(SS9I MG92/N%$=M"-]TU;>!AP"TUM/?&&A;I 'V49+Y\@,4]PF\.$K/9K+J&]-A?MF M2*<@OY#7^;C.^BWEJ8$UD3=1XEZ#:T\N:C76M5W%').=0%-O=T"\?3#'&)4? MYC"EL=&3@VOBHB/*K7(SR<3Z7"WC5%>+^O6/\YE;377FA!>GEAXL-><;F"AIAK]B(@PDT/[0L>MDCHD\FNS[ROK2=Y#_4P"L>.DQR0G M-"B="8D-CA)"T0(:W.-$/IQ.7R6OW9AJ$;>:*@M5)"_G(VH7:V'J-Q%#L2*? M/UXM.8#+.G F\CZ6#Z@Y "-]M:8$NQMPB=X*RHZS0?S)]9BM5=+F8%Z[^S9+ M%[) L:N[=N*U$&\7QX/^&1&V4<=?7ILJ/78"%]F_[RC;LL^$@ABH,M;Q< 'G M0>-J*+U][X[G4W8@9>&3H&=5!9*#\RA MIC5L*%-"5@:5*CJ+F.!@):88/=/%2N#S&1 G"^^9$GC7IMXNVB)&^:(8*@--'L)=YM#&/G[9?A7U MZ$("M*L4YFABG,7M(ZFIA$&B'AFS=X5>.2M7JBADR@^6Z.P4N_;T_8]^U384 MH/O41*$N6K0?T@7]7T):W2\=6O/UW"'V(&2TF ME1A2)!B2VM2O) <2PC6IT81=RN^5 #"N?W@-UOU620370@PJ<#.:\R MBD8K#"!AT.;$-8+AGWZN^^VIG;F!JBY%\^=GYNR&(]=:N4UL- 052!!A.\+\;FX+A9\.]\T-_X*_5@6' MD":1CW$C?5G+DT58@2FSDG1E7 ;A::=+%H!8U!TN3 M,&^2&$I!ZR?X/))TW;^CA7V'\<6OTE[B,D'GM]L=JE6)*Y#9E:+GV6"Y)AXO M"-2/"-(P02O/*U4GT#NQ,VH/R^KI8BG)-8H.S#>W1? 'B W4TO%S9)XI,"]U M^U=@3+2T0M_,AU[@X31==:=>2L(%TX*_I"T1Y\D[T;']VG8Z:%HO8E%F1W-/OAAW;GL M $V\:>O(0.#T86UW/YXQ]_KH:POCE*5Y"31%$8S&Z*#8[\UT=2KQ1(BD])) XH5$16> M^SY&1*>*ZEPVGK1-$[>]/!U$D%^A]*1?3 L]E5*QK'KWT.NW]_[%^/[;7H)+ MAA0NAC?@4MCE>:9H0L:MSMUTUVZBH>'B^<399$( M*JTH2+'8^^%C6SZ]FFJV&>>T& 1?'$5GJRN-,^\^BN4J[SR4=T#UK M7",*'=JRUH]X"WZX20C#11K- 0K)B!?Z%M%D6DX(P=]G5H"L_KLJXG^_8]_= (^ MFCMPHJ -0P.2^:+)#HE2HZJ"Q]RY9BXY#>R-NS7_T]65D\3A?BZ41)Z.P[I>EL[J=.0H-;$0C5Y]\Q>%*TCVJ%3X]@;T$4O MVJA'[E9"0(3C@D*K@;A13K.=.E_N/:D01;[\(7@+TD,-06WD^67$"A3<<=!Z M OUM2Q.>CX9MM"#N=>PR W-J9=*,.[U/''%/[XTYV^;DOD.F:U_Y57?-DQ.A M\LI]3-\>;PK&-#]9_^N[_>4E'R+?T%=YV1YKGS*.+V#7#,GV+B@+],O]FWZA]O!_6/$BM^O.1I M)^,=,G,S"5TMMK M>VXI55_O>Z2.P-%G#];N[\#_QBRJ%/9%#(>PE" SH$:#= /3GWB]I$]SO^&^ M;DAOK(+C09_F'OW=U^;^M]P(':*K[=4'CS!L_%\-B4L]YM82WM..S3=BCO-,<:SP\F*G9J:./J1\T""FD[*MO@D_I8& 1@\"]5RKDH4&3DZ2RR4P:K24E3@GK\MY7@: MACN!P%/4-)P\[Y*(AB=,H>/0\_Y$X%-M-#BQEK::C;R@Q;!_,TD4,UJ%P!E. M#& ^$D*O7_'%%OJ S8BA5Q$,'>UFH>9.OV>ANI++UW>*(4"MJCJ8CV%V?!=0B&DD=9WY0)(VLDVP=ER KBDI--7$U M: _W(,C%#U1UZ/HLZ1;&]M#]0M)W.K8T#_ID.T%)5KJ/\)UD .-O$'3().I$OA1'&0Z0BDL?5QK2 MI&'V*]2E1LWC/=HC:5ZY9F]6-PM$WPX/^!3W_;2 -:\NRINH@C1$.V3\!:_8 M3+W)M< ]:(Z[@F5_KN'_VNEGE:N:Q<,2OUNV6^3R"IAO'CU;.",M,2TXBT'C M!2!]-/4L&@5>\N,R5A[*+ =QN$76YZ8(>3F_B4:^$JW)>;_X[>HQ(^]4$W9B"M\3B"YMY M2Z!D*AGF6&-+B#)E5YWBVC\&LAG2%_<+#= MPM_M*^SWW>/ :[9-J9(C=X.&K\5S3 ED7_X>%YD4R[CP\PY#:FBRMOSIXD#/ M3R_M"X<;2 _?](;YNF>?= M;J5H0P3K"I$(B=47K2)K7JL/<=8,,;@!?X29AW$T81*.:!@(!R_D+CKVJ^02SEKC5UJB$7%.DN-D>$M>@XWC^#$1<7$^ M-P,]!8C+H",+,QH+;_T"Z3'8\%VEJ7RE9I6N 6,!PVK[.;=_L+#O=G"4N#@K ME=@F[G.,>#E-#,VM<2(-0GA_T#;PGM^X8@)VJXNOKZ9817)B4YP^=F]OE^/8LS0] MU:G^J*=7-(+[P7(YX>*% Z^N'@YR/S8:.B(0+.D1:M9&3/ @O+IN3FW.+>^GY MG2'UG2';&-<^+)Z]O1@7US4PG[KN_;$CZ,?K\/43WX-^*33%H;%^0,U'PJ+_ MQI** CL$Y#/W:%8.3<#:\8$\IA((Z!2CK_PN-OULV%O[KS57_P5KJ*94("36 M3QN=9L#[8'-7_(N^/]P)$&6#HK*04'(YP0^'Q) 'S$GT!?AI]&>$3)/.8V3_ MDF>OJ\,<2!,?YMLX2M1Z=P=39:BO76G9%^+3A2]+43O@6A7"NGM9WG6 $86E MMBXZV"-A@00G9B)Z*GHD&RG\,,;V?U%N.B^X&BVH>0 GUW.P!T;[52WI)XVW MS").J7FQTE1HT>)S^L6K<0)YK_+C/\EHH70QVH=UCILX__!X^DJVH3]\?E'5 M]^;G)LFX6 ,I@2N\ =HT3)C&25MW'K^0]>H6U--^RTJ+ZIF4-_99K7)QG[H- M)-0KA'QM8NM7)%H%/(*2+$*?GFW#;>D%EO]9^?1D?AGVS&J M0GBQPF#3N,]*0F+589Q. [KC3,QWW6\E+N2Q.1-ACO 7.6UG3BX<3#0> MN5 MB%H\]S)E"HRN#YM;HKVFUF6]8$%2%.8'-T(L>%DHVE6@MI26R=Q$6KR)@66J M2 P':1;J93@ B@.?H3Z&_A$6BO %<7"):\^\3:8A64 ,^+*;A3J(=)?QMRS4 M0_<)P_4MP&0] !FC!U4QS*U(0%8] 2,$-1'H^ &,ZD.?U?[C=T937A#@(.1K M1SU8J*-P5RMI>AE#E8+M]P@B(1XGN9&PO!WI58^0&"@;,V8!=L/WR&O'T"R4 MH"Z]'>E59Q#,H2*&? 8XV9&7UM$@'PMU8F?XT!\J1\W=V$'UM#OT+)J%"D_[ M^^_$%!4LK#%Y( [@>:BVVS]6#C39R,>^5(%_TV6A&HR8A7$LU!=M#+03,X4> M,/.%X%!X*^ESW>O2/U3M#Y:"^Q$4_'& +.AEW@H4#T^%UG.EXOT:2;D^>8Q* MI*1=!>("\L((6K4?AO;<6GQQN"<"3P_+@(6G\)%&VH+4II_W_QL<8_'[983% MFCDE7'$VCY\TH=-IBJ7"_)]X#VB+VMMK'$+QZ8UNNMPW[0OMV4)MI>>#KQ!" M7=1S"_%73*0OF"?JT#*2<\#5NB1O0\4D4JAKUUCF_9>&2>/[;]^:BMW?>_)Z MZJ:7/+EX 9B,S6=K,GQT-[36/1@H;JHC\H/)OY4+K9H+A4UPJ4=D>'$:,#YT MG;6_%'O$ZE2+B!K?GCTF"Q1UAC.^F9 /A+ZK-&(8PU^J!*E[4C-/:&>@>9V; MMR;F?9#;'Z%I6W%F6\GAP9@7MJ:3AA"_"KU@8Z,MH,8S%Y;''0"[7<;(H6C! M2F.:5EV5(N@S%C9N^J'KB#=AIZ/07GR\+'M]Q/0,?TAI5*]AH::(C1Q&&W-+ M 928AO@1]&REF496*>('K+8 PLYB&2$)RFKM^>_:4-2$Y]M(ZQ4\\E_EJY]V M>'<=M7&35,)VL=\5;47Z>9"55LA@R\0=BS%B,MI?2'4Y^0\ MQ7[@=K6>J(3G>YD6_\OL^W9IF] Z*!Q4A3%"=*4*-;.)A1+6./7&+ZU1Q7ZP MMDJ\ZNMK?:;)Z7?U9]PL/C_9IB,51!&9#(<2$/)P#.:"+*C8.2>:S;CTHX65 M_51&H]6I*-PF[B]^VSKZK6.Y6L%$5:/#1\]>0Y/L6U^D^TU3])$7958#H ;7 MZ,$X:JM.65&H95<1$VOBTF8R1;=([BOYNM\_U>*Y9,SS6/:E!-5]J6^^L,VK M-!$&L'0_9D+E89<)TL"5B>B'&MM>DYVYK!VR09)5:3=ENMQQ1/N^9,I7\[,Q MGVK.M/-&VUBYCF% F06(']V4>K@;QS-* ^A:]JP9KT^[+>\HV0-P(A, X\ MGQ./QH,.==WL.C_?DIW-(75OR\'WF-$T#/4"X1Y O1JH6XU',[.*79U_UNQE M)UPBN7,XKB[8*QGH^ 0=.ICDK?YU?YC;Z7,#G_M0"YLX2=,+2$PGX0#Q+XSZ M0N+;J&EC"G.!U*"EWPI!=>K4ZKA"_<:N^KQ6SH>EF/6U'=I%+-3YF/K+3?L" MW@MO>WI8FBLYQLQW#EK=:CT M<8 _>??^9PF#6Z-B'CS)V5.W)<9J,+>?[*RF-$)(G^VP]CKU+F:0K,M787&^ MY>PGP?LF,N=/2K")]XU%0^((TFR]C13OCV\E40U:#2.!K54"0S,D0?ZFNU;) M&7Z/9DM-RXF1"NZV0%'Z6,P@Q:ME:ZEZT *9EZO8[.D]_-QF]D^*II% C2HL MAKL.JC"VXG:#5V@_+Z?^;,3O!5W2KOG%S]LM23Z>5S_?>_XY"_4]34"CF"F)+%3',\3[R$+1K:2B)84U%@H#<6*G D_] MXAGT'PON^ZQH]/=E!#,,CR,N#/I$^9?=?CG MZN"-YB"-$K%4(QY^W!5J1\@*:4"XHZ!'XXR=JS\/=.#NV;48/379/),OO/&2 MMKMTG=>VEQ/O8Q8M(,0KVVRDT=*/]5QMI7+RK!H-KIFN">N?^)QR+=,\@(B, MS<]PW-O7X= ')DYV:3>\4YV%,J)Z,5FH78"\,NFBRY_N?8P,AG5Z8&!=7T-3 M$B%U\E@&$D)=T)W:)F"$?8.._TM9S"]S1=-BOV+D1S#,1B)HMW:B$"%E,0_1 MM*8EW05CI/RGA(+_]MJB<3(D@(8-M<;1S-!H..("\PVQ@00>PD"IH?48!@^: M*13_?8I4$YVUAHD@+$HB#A^+H??O5=$6, T!,'^M*D+PLF8':=(0#-M8\XZT MB78'-D5P?6-#$J3_Q6#&I9D/EA>8PJ?N?&>A%CS68-UA/W<62BH$W06LGXNN M=-P(BM?]_JM7U?Q;\%L/N+D/NE2CW_L^T!"D8<<94IG!/J1')O@]M(LD&=5H MK=+RXHIC5I^N6A^P>)8;J^L>+Q'_;7%;@,_Q\1&N#WM[9[ MR%UG9MDII]%M#I!@(OTT*,C0Q@_N50 W-A]MI\W'!] FKC S(8PUE7$6M,FV M:-L&QTL'%YTZZ^HAU.U9G;">W"I76L>[\"'Y\\UJ088#O'-C7YTQN TH7'WT M#AA-@O?1>,)61"K/W")0/RYHBJ^A!Y35%&/FU31X%-\^,;S[1BY/7U&Y2UQ6 MXU/S>B*UCGX7/$S%UJ?*T'QKB2$#]L%O_0:-0R_3--:]M;=1/IOEL93^$\OAY(*7/!TD\( T)%@QZ@X)A&-X<3+,:)+]'JVQTEI2L)5@ MU[O]P>:[=%@HQP]."0,#(^K^>Q5##LE]ES-[_CS=L*SHN>;&,H_[^$Y@4P9" M74-*^U[WWHT,*;$[<;68R)+PJ=< MUC>_OB<[,+MN3(_?^]$N:[#-1NG#AQ#ZX?C7?N'S?&QLVRXLBHC;)($G8'9K M-W*1 D-C&:)%6C$XK\ 0O-]-:N7\T1 _7,*Z3-:A'+#1,\F.(T6P+=CJ=<5 M'J+1I-'TC>,Y1U/60VL4=OE=PHEU%7,QKS2M?U]VLE94YM<6["G<;\R0Q'SD MTY95EXN):K(_C4DB[-G(^W> TL3Z!?"0-R"NJ8S;#X9.=&S#B??8A8ZZA;WJ M-SN2(K^VR8&FU#(T)-'L[?%]0&*?4*?"<[C\Y@'X7FZ1/%^'<5F?JZ++-2+1 M6&AQ4=W'S.&JR.GY[=<.2>Z(BZ29O-W2"(P2T,5'2AFWX*:1';(,PAZMQ-^G_'K; $F[?2A\TLG"&N")BP4%T88 M&<],#>C17XZO[(W#G:5(-22ZT@QY_S^*O. X6*I8\2F:((4!Q^/'K3"KY M53IZO.DKNLL'0=<8=,DVO U0TP3,:NX$2.,\WS/Z9MK^>"?_"?!I@-"QL= Y MM)ZP*)7#0KDA,'D>JMY(; 0OOG\=WDU-#()L)BC.&&X__MJ[J<5O6])?=R\G M8UQ9GCA&H6*A*S52F#B@2>"R'FY- C#XAB M!XF9>IPM5T>?#8?TFS+?2/)^DC0VW 3)@S$TG=GYCK&^^\66KG/R>V<1-Z#< M_-WB&J^^8D%!I,Z]P^K/[C=Z[DQN3TGCV\>+*"7D+R"-86_)B+0YX? MZ]@V0^*MU!IU-:D[VROMYYUBOM@\'K32J:7R]#/J"4KGPJ17;U:S=(Z4SF6# M]/Q@;5\T-\D>.R [L3=8.AS/C]M!N>'G=O';I>*&<]>1I M+D&=?3ZU<0-I@T;3WZ=,*8$&IQ[B+^)-W>AW3CH?-C;[=N"PY L4FV2?^P2Z M/V=BH8[,A8G2<*5&6W8K?OKMP/S4;$/B7(C=,'L*?J7LB6?J#[,J+N^\-.FZ[D^V,W 9"FH C=^ M1,QZP>9M%J3RPTD7S%_174Y!FF52EW(?^XQ,]2"O1P<3%L#@-:?B=:\_WIFS M12\J9R+\N\MLC"8-A3FS4(.D]>8":1;T M\\'C.ZR$P+AQR\NR%0%45-*2PMY6=]XLL1IV$W]>5!\LQD M^ 28.4J %$NK(RR=-YAP7X15Z]7@NOL#J[^=V81...D/@.1BG$ MRQC'1FK8,/@A/VK"Q\ M,^L[@UBH?I->^J[J]VOE@5_BF)>/C(]"^L> 3I/)3]8PP+;CQYG-*>3'TE7Q>^_8FD>L)-PV1EMAJ"KI/?&?&P.JM"L'%A_KJU2[7O%(LN?@:-GP_'*D= MPVBWB\25,6HK.>,%?XLO:SB8+C@Y-Y&]YL@472YR4C-;CU(MTVZ\V.'C(X_N M,)Z-;@,XP4QSJE4%6QCNE!SOR$#)3W^'PG"/W7=N%.0<&>L1MQ7G#3J!30.H MYF1>YQ$%YF.20X>0R^H!%^850XN*_J!M2P?C#(M];^W8E'#S]DEBNSMX%KJ) M.X\3TY#.8J%NL7WS)K[7HS_YUJ[QSJU=M5'-=$8%$E(8(T7;,$,TM_" 6BL' M6:@'7GHAW %V<:7T@"AEU+EOZ(J:J*:V2$&EF8EA#&7'B:[5Q$F_-<^WBY^O M^Q2GK2ZA938F>8)>XKLPA9B:%.%1XAP+Y9'N**3,-S0TFUCHY&'9\7:X[41^ M3&2VL:#-8AKG=N".GLV';L-Q8I/16.FV\TU0L>2TTE+3G WU/-R)*98.PN_JV,F0OW(]:@7W M8EM^Z E+O@#\E*K::H,SC 23NQ0PMTB#7A:TO8G9 X/:XRR42$/&#U.5 O_; M%F9K84Z.UUFHS7+ZHC?91 X6)^SFS)\U"KIXN+G"Q?=U'_(_@*2#N)7\]X(' M&0-QE\*K$DS<#:%MN/X1H&9/%;\C5HCDCN48]$NJE"GL_ KP):XUO2-J;2,/"G%J,:SAYVO![4B=T9L]P:KK+L99FSN%G C=6 MKWINHCR6K<<+X&0+$0N>_7UW?^[7T&4P-\-Y_6#%J^/.Y@V5W&YR8Q5+-ZXH MWFK+O^P7$V$;=*]49%^ [QQCG!VP10:Q.CV3F:FI,%/H5"44QMT;EW.]T2;4 MV.5YTM0(EQE/JWK+J]N[4M-.$J6/O:7QOYBIR+H2K9 \;>$_0KX_]]T[04Q@ MYJN)1]810.K3ZN+&SAR+I0VIZ ]40K@/ALOR_%[+$Y>2NG2M(CO+S@+'S%9< M+'L5<-JY(W[!EV_W"?==OG[]Z/Q\PS/8]JOY>GR ,PZ7^YGRWO1/2L,J#V(: M:306LQBC$ +0>2M9J.[ -B\;%FH( 8L0;)S:XL*:B!$+)0XHXE8Y_I M+Z:*Z&Z_T$:P631!Q"&_1"?]Y?8K@4C$>C\W:3EZRMKG=C7+!152V&- M'SX ?#.\B!3NU>>&A5?1A,G OA#$,M>LF=(LU)OSC,;P0\0T3&;07^E5_O^Z M*M/HW\'X"6PPJ4 ENDH:.ME+*BQNXZ];O#Z32+9_['[P4LN66_%FN[/&GH:O MW*5V@(>CH6>B&(()'7Q+*C\9$YE_M-KVHOZ2:'_OTMH^4L#UB XE%&Q@M MRT)MDV2ATAZS4*T8I'DFU3!CBR3J9&!M%^5NA82_G=E/ &/,:8DU/-M!4GTBR:G'!\LYTY>X MNM<\,UFCI+.BJF>3J5S]*&J[W^;R; 0 [!76E$FA!+J$$V9=5]!7<"W0-MY, M:IA -'+MC A\8MJ H5HMK!U[A)GS[T9XM7%;8"X6<7/_6.LOM>@-UY)?-PE:T#RIK[$#1K1 M +EG0.1I<<23]W4^5 M LM9TVZ9K 33FY\'KVXSBL4;HW;>VW1MV4A/2M#N_="+E,$>A$W>E.XNMC34 M+6/8Q[SM<%&N374M^AQ5%,D;OV_T,?M;A.,>[%&2US4I4RE/A_I.'+_7??V" MY:,M*-L75!3ZH9YO[D]3^E$GWX&//;V]+R,L_-U$TT)/W@!=05KWLCN3PR5S&[QF".DOZ1Y19[;\'L"OK;\.EUWQHCWY#U:V;UD_S7Q& MFAR ]P+?HMX@$;>X\9 I#^,8T%P,:2!%[]9#1N_)G _$9EE S.H=,R^4*O&# MM.^?S5D5(O=BXA5H$J&JR!_&[M1"VAW$K-T=GX+"92D*W]!T!"T??F6(0!= M"K6TUEPE''_(<7WHKF^HXJF[([+/Y%UC3QY,\"YY)F*?I!U[]A1N,)7!A[;#BZ8+6!A1+#XC87)#98\5'G9G@>^>1TX^?L\S_4W&BK]5M=O?:KRY?J=GRX8@P#(/ MG=(?*!^]D( *.H/6QXF"LF/N@ZD\ \FCY' <.JW.=]35ASQF6VX5M2WGAYU4 M#Y_ZM22!*Y-'BTMU(B=WF57!(AH7;?2YC1J(#P]"92F):Z3]UI[EW[*-GEJ^ M>/'4U%?0=Z;?GY#L;?K#?2Z,(54SCL3'OH^JE. V3>%NI8Z(/O/*' \?#VON M84K4QX^U"T6%?#GL=BXX_?C-NDMW@BY6:TS#G-RCV)!UW[EHJNXX)KQ2-@,, MF-A>D?$)=R7SFE-GOT' S8H'IKXFM.P'3RG1.XWU%^)4^Q\^L[\Z>_-4+-:I MJ7W&BDZ9,OXM.U=#H<1]+LO?K,*UZ5E,4JAS1*[GBY)H6]?// MQ7D$I*;EQ?=<*)*RG&%'^A-#:B:G7VI14_8U06-I^.*JZ16-V$_?W\3J2#T/ M:Y9,?9.ZW#*KNOE/LVM]LG]R>K,R />ZF!$L%VC$E-Z 95[&C?_VPK8D9!0/ M^&G5E2]00NT"LF?@6VDURA=VM_F,&OHT;MJ;03)S62R$N1!_+.V%O.>F72(< MC91I)<'[,*U#Q^WX?++A@NYTU<'>7*T0\:SFAJ6FJW/K=,TC&PJE4=+O"B7" MWQ1*PG]3*,6Q4.&Y+;*M<'\[YL>!3)A-80F30BHJ1*\Q,1 '"_4\=$,850/\ M+HP*P_Q-%Z7PNV ( 6I!BZ=&S,(7P!=M0V@G=D.F% W!!'@K"_6Y[O_EE8?^ M[HT\%+DF&##<"(ZGK%FHVE(J]G=5E.'?5%%H8^@A1)"#<"^DXSX!_K%\:+$@*0J!U0T?&!]",R[31@ZI-S*U7D5]_WY"< M(?C?,8- E2'T&?./533Z@\&&7D=37DS 03+ J.?OJK//P/0RX@:E87OT'VM( MX0'W$QY48E["7ZLD*KJ\62@9'3# .W+$I<24TBN-/J895*5/S =&P["+WE7[ M-[@%PF_UW[DXBV8XF!=97Z[\+ESN&6?XW6OFPPGTXYP&D6OM[Y(\^YN+"Y

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